<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"><HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<A name=1></a>Table of Contents<br>
<A href="010912_0s.html#6">Rpt. 18609261</a><br>
<A href="010912_0s.html#6"><b>PERRIGO CO.</b></a><br>
<A href="010912_0s.html#6">6 - 12</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#13">Rpt. 18609533</a><br>
<A href="010912_0s.html#13"><b>ENDO PHARMACEUTICALS HOLDINGS INC</b></a><br>
<A href="010912_0s.html#13">13 - 18</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#19">Rpt. 18607860</a><br>
<A href="010912_0s.html#19"><b>SILVERBIRCH ENERGY CORP</b></a><br>
<A href="010912_0s.html#19">19 - 36</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#37">Rpt. 18607812</a><br>
<A href="010912_0s.html#37"><b>WILLIAM MORRISON</b></a><br>
<A href="010912_0s.html#37">37 - 45</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#46">Rpt. 18607813</a><br>
<A href="010912_0s.html#46"><b>WILLIAM MORRISON</b></a><br>
<A href="010912_0s.html#46">46 - 54</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#55">Rpt. 18608632</a><br>
<A href="010912_0s.html#55"><b>AUGME TECHNOLOGIES INC</b></a><br>
<A href="010912_0s.html#55">55 - 66</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#67">Rpt. 18588388</a><br>
<A href="010912_0s.html#67"><b>PIEDMONT NATURAL GAS CO.</b></a><br>
<A href="010912_0s.html#67">67 - 74</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#75">Rpt. 18590504</a><br>
<A href="010912_0s.html#75"><b>RPM INTERNATIONAL INC</b></a><br>
<A href="010912_0s.html#75">75 - 93</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#94">Rpt. 18590543</a><br>
<A href="010912_0s.html#94"><b>CONSTELLATION BRANDS INC.</b></a><br>
<A href="010912_0s.html#94">94 - 114</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#115">Rpt. 18590732</a><br>
<A href="010912_0s.html#115"><b>RPM INTERNATIONAL INC</b></a><br>
<A href="010912_0s.html#115">115 - 135</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<b>These reports were compiled using a product of Thomson Reuters           www.thomsonreuters.com</b><br>
<i>1</i><br>
<hr>
<A name=2></a>Table of Contents<br>
<A href="010912_0s.html#136">Rpt. 18590746</a><br>
<A href="010912_0s.html#136"><b>CONSTELLATION BRANDS INC.</b></a><br>
<A href="010912_0s.html#136">136 - 157</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#158">Rpt. 18590821</a><br>
<A href="010912_0s.html#158"><b>WORTHINGTON INDUSTRIES INC</b></a><br>
<A href="010912_0s.html#158">158 - 180</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#181">Rpt. 18590877</a><br>
<A href="010912_0s.html#181"><b>WORTHINGTON INDUSTRIES INC</b></a><br>
<A href="010912_0s.html#181">181 - 205</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#206">Rpt. 18593622</a><br>
<A href="010912_0s.html#206"><b>ROSS STORES, INC.</b></a><br>
<A href="010912_0s.html#206">206 - 208</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#209">Rpt. 18608914</a><br>
<A href="010912_0s.html#209"><b>MAGNUM HUNTER RESOURCES CORP</b></a><br>
<A href="010912_0s.html#209">209 - 214</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#215">Rpt. 18595662</a><br>
<A href="010912_0s.html#215"><b>DURECT CORP</b></a><br>
<A href="010912_0s.html#215">215 - 223</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#224">Rpt. 18595681</a><br>
<A href="010912_0s.html#224"><b>IHS INC</b></a><br>
<A href="010912_0s.html#224">224 - 239</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#240">Rpt. 18595853</a><br>
<A href="010912_0s.html#240"><b>ALPHATEC HOLDINGS INC</b></a><br>
<A href="010912_0s.html#240">240 - 250</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#251">Rpt. 18595943</a><br>
<A href="010912_0s.html#251"><b>INTEGRA LIFESCIENCES HOLDINGS CORP</b></a><br>
<A href="010912_0s.html#251">251 - 267</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#268">Rpt. 18595945</a><br>
<A href="010912_0s.html#268"><b>INTEGRA LIFESCIENCES HOLDINGS CORP</b></a><br>
<A href="010912_0s.html#268">268 - 283</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<b>These reports were compiled using a product of Thomson Reuters           www.thomsonreuters.com</b><br>
<i>2</i><br>
<hr>
<A name=3></a>Table of Contents<br>
<A href="010912_0s.html#284">Rpt. 18597077</a><br>
<A href="010912_0s.html#284"><b>DURECT CORP</b></a><br>
<A href="010912_0s.html#284">284 - 292</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#293">Rpt. 18597104</a><br>
<A href="010912_0s.html#293"><b>IHS INC</b></a><br>
<A href="010912_0s.html#293">293 - 310</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#311">Rpt. 18597737</a><br>
<A href="010912_0s.html#311"><b>THE ACTIVE NETWORK INC</b></a><br>
<A href="010912_0s.html#311">311 - 321</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#322">Rpt. 18607954</a><br>
<A href="010912_0s.html#322"><b>HMV GROUP</b></a><br>
<A href="010912_0s.html#322">322 - 330</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#331">Rpt. 18608549</a><br>
<A href="010912_0s.html#331"><b>PENFORD CORP.</b></a><br>
<A href="010912_0s.html#331">331 - 339</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#340">Rpt. 18608606</a><br>
<A href="010912_0s.html#340"><b>NOVARTIS AG</b></a><br>
<A href="010912_0s.html#340">340 - 345</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#346">Rpt. 18608610</a><br>
<A href="010912_0s.html#346"><b>MITCHAM INDUSTRIES INC.</b></a><br>
<A href="010912_0s.html#346">346 - 351</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#352">Rpt. 18608658</a><br>
<A href="010912_0s.html#352"><b>EVOLUTION PETROLEUM CORP</b></a><br>
<A href="010912_0s.html#352">352 - 357</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#358">Rpt. 18608673</a><br>
<A href="010912_0s.html#358"><b>ARTHROCARE CORP.</b></a><br>
<A href="010912_0s.html#358">358 - 363</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#364">Rpt. 18608689</a><br>
<A href="010912_0s.html#364"><b>THERAVANCE INC</b></a><br>
<A href="010912_0s.html#364">364 - 379</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<b>These reports were compiled using a product of Thomson Reuters           www.thomsonreuters.com</b><br>
<i>3</i><br>
<hr>
<A name=4></a>Table of Contents<br>
<A href="010912_0s.html#380">Rpt. 18608822</a><br>
<A href="010912_0s.html#380"><b>AMERICAN STANDARD ENERGY CORP</b></a><br>
<A href="010912_0s.html#380">380 - 385</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#386">Rpt. 18608833</a><br>
<A href="010912_0s.html#386"><b>HEALTH NET, INC.</b></a><br>
<A href="010912_0s.html#386">386 - 392</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#393">Rpt. 18608865</a><br>
<A href="010912_0s.html#393"><b>INCYTE CORP</b></a><br>
<A href="010912_0s.html#393">393 - 398</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#399">Rpt. 18608869</a><br>
<A href="010912_0s.html#399"><b>COVIDIEN PLC</b></a><br>
<A href="010912_0s.html#399">399 - 404</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#405">Rpt. 18608874</a><br>
<A href="010912_0s.html#405"><b>BANKERS PETROLEUM LTD</b></a><br>
<A href="010912_0s.html#405">405 - 413</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#414">Rpt. 18608896</a><br>
<A href="010912_0s.html#414"><b>UNION DRILLING INC</b></a><br>
<A href="010912_0s.html#414">414 - 419</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#420">Rpt. 18608902</a><br>
<A href="010912_0s.html#420"><b>AMGEN INC</b></a><br>
<A href="010912_0s.html#420">420 - 426</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#427">Rpt. 18608925</a><br>
<A href="010912_0s.html#427"><b>CAREFUSION CORP</b></a><br>
<A href="010912_0s.html#427">427 - 439</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#440">Rpt. 18608926</a><br>
<A href="010912_0s.html#440"><b>CAREFUSION CORP</b></a><br>
<A href="010912_0s.html#440">440 - 452</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#453">Rpt. 18608942</a><br>
<A href="010912_0s.html#453"><b>CONTANGO OIL &amp; GAS COMPANY</b></a><br>
<A href="010912_0s.html#453">453 - 458</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<b>These reports were compiled using a product of Thomson Reuters           www.thomsonreuters.com</b><br>
<i>4</i><br>
<hr>
<A name=5></a>Table of Contents<br>
<A href="010912_0s.html#459">Rpt. 18608992</a><br>
<A href="010912_0s.html#459"><b>AGILENT TECHNOLOGIES INC</b></a><br>
<A href="010912_0s.html#459">459 - 466</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#467">Rpt. 18609007</a><br>
<A href="010912_0s.html#467"><b>CELGENE CORP.</b></a><br>
<A href="010912_0s.html#467">467 - 473</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#474">Rpt. 18609051</a><br>
<A href="010912_0s.html#474"><b>ADA ES INC</b></a><br>
<A href="010912_0s.html#474">474 - 481</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#482">Rpt. 18609070</a><br>
<A href="010912_0s.html#482"><b>INFOSPACE, INC.</b></a><br>
<A href="010912_0s.html#482">482 - 498</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#499">Rpt. 18609071</a><br>
<A href="010912_0s.html#499"><b>INFOSPACE, INC.</b></a><br>
<A href="010912_0s.html#499">499 - 515</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#516">Rpt. 18609080</a><br>
<A href="010912_0s.html#516"><b>ONYX PHARMACEUTICALS</b></a><br>
<A href="010912_0s.html#516">516 - 521</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#522">Rpt. 18609117</a><br>
<A href="010912_0s.html#522"><b>TECK RESOURCES LTD</b></a><br>
<A href="010912_0s.html#522">522 - 535</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#536">Rpt. 18609118</a><br>
<A href="010912_0s.html#536"><b>TECK RESOURCES LTD</b></a><br>
<A href="010912_0s.html#536">536 - 549</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#550">Rpt. 18609123</a><br>
<A href="010912_0s.html#550"><b>ENERGY XXI BERMUDA LTD</b></a><br>
<A href="010912_0s.html#550">550 - 556</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<A href="010912_0s.html#557">Rpt. 18609130</a><br>
<A href="010912_0s.html#557"><b>GILEAD SCIENCES INC.</b></a><br>
<A href="010912_0s.html#557">557 - 563</a><br>
09-Jan-2012<br>
THOMSON REUTERS STREETEVENTS<br>
- ANON<br>
<b>These reports were compiled using a product of Thomson Reuters           www.thomsonreuters.com</b><br>
<i>5</i><br>
<hr>
<A name=6></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
PRGO - PERRIGO COMPANY AT<br>JPMORGAN GLOBAL HEALTHCARE<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 6:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>6</i><br>
<hr>
<A name=7></a>JANUARY 09, 2012 / 6:30PM, PRGO - Perrigo Company at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Joe Papa</b><i> Perrigo Company - President, CEO and Chairman</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Chris Schott</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Chris Schott</b><i> - JPMorgan - Analyst</i><br>
Good morning, everybody. I'm Chris Schott, pharmaceutical analyst at JPMorgan and very pleased to be introducing Perrigo this morning. Perrigo,<br>a very exciting story, coming off a couple strong years and from Perrigo we've got Joe Papa, the Company's Chairman, President and CEO, as well<br>as Judy Brown, Company's CFO.<br>
With that, I'm going to turn it over to Joe.<br>
<b>Joe Papa</b><i> - Perrigo Company - President, CEO and Chairman</i><br>
Thank you, Chris. It's a pleasure to be here today to talk about Perrigo. Perrigo is, this year, a 125-year-old Company. We're celebrating our 125th<br>year in business this year, but a Company that is not only 125 years old, but a Company that is poised for continued strong growth behind a couple<br>of key factors.<br>
Number one, just the move to what I would call quality, affordable healthcare and what we are doing in the store brand, private label space. Number<br>two, it is an increasing number of products that are moving from prescription to over-the-counter and our very strong position in the over-the-counter<br>store brand space, as more and more products go from prescription to OTC.<br>
Number three for us, clearly, it's going to be, in the past and certainly in the future, new products, new products, new products. We've had a great<br>success in launching new products and we expect to continue to be able to launch new products going into the future.<br>
And finally, it's also a story that is involved with mergers and acquisitions. I'm delighted to say this morning for example, we just announced an<br>acquisition of a smaller company, a bolt-on company in the diabetes space that's going to help us to continue to improve our offering in the store<br>brand private-label space for diabetes.<br>
So, let me move to the presentation. I refer you to our SEC filings for some of the risk statements that we have there relative to the Company and<br>refer you to the SEC filings.<br>
Let me move though to give you a broader sense of Perrigo. Perrigo predominantly is a Consumer Healthcare store brand private-label Company.<br>Consumer Healthcare represents approximately 60%, 61% of our business.To that, we supplement it with the nutritional store brand opportunities.<br>So, that's about another 18%. So, about 80% of our business is what I would call an over-the-counter and nutritional store brand private-label<br>business where we make products for the Walgreens, the Wal-Marts, the CVS', the Rite Aids, Targets, Costco, you name it. We make a version of a<br>product that offers the same quality, safety and effectiveness as the national brand, but a much better savings for the consumer and a much higher<br>margin for the retailers.<br>
In addition to that, we have an Rx business, generic Rx business predominantly focused on what I would call extended topicals, generic prescriptions,<br>think of things that are absorbed topically. So, dermatology, respiratory drugs absorbed topically through the lungs, nasal products absorbed<br>topically through the nasal mucosa as examples. And then finally, we have an active ingredient business that represents about 6% of the business<br>and that's where we make many of the active ingredients for other pharmaceutical companies around the world, but also for our own vertical<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>7</i><br>
<hr>
<A name=8></a>JANUARY 09, 2012 / 6:30PM, PRGO - Perrigo Company at JPMorgan Global Healthcare Conference<br>
integration. So, that gives you the sense of our 2011 sales in a relative percent. But far and away, the majority of our business is Consumer Healthcare<br>or nutritional store brand private-labels representing about 80% of our business.<br>
Well, this looks at our P&amp;L statement. You can see we've grown dramatically. 2007, we were about a $1.4 billion Company, we're really relatively<br>double that now since in the last five years. So, significant growth in the topline. Importantly, it's about a 19% topline growth. We've been able to<br>leverage the P&amp;L and show significant operating income compounded annual growth rate of about 45%, and really by leveraging what we're doing<br>and sending more products, adding more products as we send our products from Perrigo every day going to our large retailers out there.<br>
Really, the growth driver is very much what I talked about before.The growth in store brand, international, our Rx performance and clearly the new<br>products, we'll have about $190 million of new product revenue just this year -- our fiscal year 2012, representing over 45 new products.We always<br>talk about, since we launch about one new product a week at Perrigo -- really speaks to the competitive side of launching store brand private-label<br>products.<br>
One thing I talked about before was the fact that we do both organic growth and inorganic growth. This looks at our six-year compound annual<br>growth rate. Organically, it's been about 10%. The bottom line -- I'm sorry, the inorganic compound annual growth rate, it's been about 47% as<br>you can see, as we looked at from 2005 going forward to 2011. So, strong focus on organic growth, but also looking at appropriate M&amp;A activities<br>to drive the bottom line for our customers.<br>
We are one of the world's leading pharmaceutical manufacturers that may be a surprise to some of you. But when you talk about actual volume<br>out the door, we do over 45 billion tablets a year. It turns out every second, every day, somewhere in the world, approximately 1,400 people take<br>a Perrigo product. So, every second of every day, somewhere in the world, 1,400 people taking one of our products. It just really speaks to the<br>critical mass of getting tablets out the door from our facilities around the world.<br>
If I move to our largest segment, Consumer Healthcare, it has seen also a very significant growth, essentially doubling as well since 2007. Importantly,<br>we've been able to dramatically also improve our operating margin from about 7.5%somewhere to the 18%, 19% range. So, very strong growth<br>in leverage in our operating margin as well in the Consumer Healthcare, our largest business.<br>
This slide really just steps back [in terms of ] why do we exist as a Company. This looks at how we position our products relative to the national<br>brand. So, on your left hand side is Nicorette, it's a branded nicotine gum. The cost to the retailer for that is about $57. They sell it for $71, there is<br>about a $14 profit or about 20% profit for the retailer. Conversely, on your right-hand side, you see what we do with our nicotine gum, we sell it to<br>the retailer for about $23, they sell it for $53. They make significant higher absolute dollar profit, about twice the profit as the national brand, and<br>importantly, certainly a percentage of much higher profitability. Critical to this equation though, it's also the savings for the consumer. Usually<br>there is about a 25%, 30% savings for the consumer. And this is the -- in essence the reason we exist. We had same quality and effectiveness in<br>terms of our manufacturing capabilities that offer the consumer about a 25% to 30% savings and obviously, a much higher margin for the retailers.<br>And this is really what's driving the profitability for the retailers and why they continue to give us more shelf space for the products.<br>
This is the all-category review data through December 18th and this looks at the -- this year versus the previous year for the major categories in<br>which we compete. I won't go through all of them, but you can see from the dark blue on this chart that store brand clearly is driving many of these<br>categories. If you look at OTC as a total category, we are up 6.4%. The national brands are down slightly about 2.5% and the category is growing<br>about 0.3%. But the important point here is that store brand continue to drive the categories through most of these with perhaps just exceptions<br>of vitamins and infant formula and to some degree smoking. But smoking cessation, it really is just a -- there's a [branded] new launch for the<br>national brand and it's gone very well, gives us more opportunities for us to go after for the future.<br>
Talking about Perrigo, one of the things that we think we do well is launch new products. This is cetirizine, I'll just talk about quickly. We launched<br>this product in a very crowded market. There were seven total OTC approvals for cetirizine, which is the store brand of Zyrtec. We launched again<br>a total of seven, ourself plus six others. Usually, in that kind of competitive, multi-source market, you would think we get somewhere in the 15%<br>share. We have actually over 80% share of this market from the day we launched and as we sit here today, we still have over 80%. So, clearly there<br>is something here that is different from the casual multi-source market and what we do in terms of driving store brand share, but importantly<br>holding on to our share of this business represented by this 80% store brand share that Perrigo has today.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>8</i><br>
<hr>
<A name=9></a>JANUARY 09, 2012 / 6:30PM, PRGO - Perrigo Company at JPMorgan Global Healthcare Conference<br>
So, it's part of what we do is not only make the tablets, but we put together full marketing programs for the retailers to help them be successful<br>and it's successful in driving store brand volume share. In this chart you can see store brand cetirizine has moved from -- in the first 12 months<br>moved from essentially zero share up to well into the 48%, 50% range. So, in just really a year's time, we were able to move product from national<br>brand over-the-counter products to store brand. And you can see, usually ranges for these more recent launches somewhere in that 40% to 50%<br>range within the first 12 months. So, we feel very good about our capabilities to educate consumer, educate pharmacists about the importance of<br>the quality and the effectiveness of our product to allow the movement from national brand to store brand.<br>
One recent launch, just to give you some indication of what we do beyond making tablets is our Fexofenadine launch program. We put together<br>a full turnkey program for the retailers that start with direct-to-consumer marketing. We put at-launch web banners, at-shelf messaging because<br>most consumers don't know initially that Fexofenadine is comparable to the national brand, Allegra.We try to help educate the consumers so they<br>understand that and indeed they feel comfortable using a store brand version or a generic version of the national brand. But there's a lot of education<br>that goes on there, we do pharmacy marketing, we do off-shelf displays, we do the end-cap displays of the aisles, many different tools to help the<br>consumer understand that you have a quality product, but it's more affordable and better value for US consumer.<br>
This is one of the slides that actually shows what happened. Many of you would know, Allegra was a prescription-only item and just last year it<br>went from prescription to OTC. As it switched to OTC, you got a continued expansion in the category as products move from prescription to OTC,<br>the category grows. There is some cannibalization, a slight amount of cannibalization, but overall you get continued strong growth in category as<br>you move products from prescription to OTC.This is a continuing theme that we saw with Loratadine when cetirizine launch and now we see with<br>Fexofenadine launch as well. So, continued strong growth and gives us good opportunities for strong growth for the future.<br>
One of the questions we often get, well, that's great, what about the future? What does the future look like? And we've talked about -- we have<br>more than 45 new products launched and over $190 million of revenue in our fiscal year '12. But to be clear, many of these products that we plan,<br>the larger products we plan to launch are second half-weighted products. In other words, the timing on the expectations for these launch will<br>occur in the second half of our fiscal year 2012, which is between January and June of 2012.<br>
So, you can see we have a generic version of Clarinex, unclear whether that will be a prescription product or an OTC. I think it still has a very high<br>probability, it could be OTC, but unclear at this time. Prevacid, generic version, Delsym, Allegra D12, Mucinex, Claritin D and Rogaine Foam, all very<br>significant products that we expect to launch in the next six months for a store brand over-the-counter view of those products. So, we are excited<br>about what that means for the future for us. And in total, we think we'll launch over 45 new products, over $190 million of sales, which for a Company<br>our size really drives the topline and bottom line for us as a Company.<br>
Beyond that, clearly, you have to look at what's the future look like. And we are delighted that we think that over the next five years, we think there<br>are approximately over $10 billion to $15 billion of products that are prescription items today that will move over-the-counter in the next five plus<br>years. So, we're really excited what it means for the future for us. Many of the remaining non-sedating antihistamines like the Clarinex, like the<br>Allegra D12, we expect to have those over-the-counter. Also the rest of the proton pump inhibitors, we know Prilosec has switched, Prevacid has<br>switched, we'll launch our version of Prevacid later this year in May of 2012. But also then the rest of the proton pump inhibitors like Nexium,<br>Protonix, Aciphex are all examples of potential switch candidates.<br>
And then we think there are some other exciting ones like potentially Voltaren Topical Gel, diclofenac topical gel, all representing good switch<br>candidates to move from prescription status to OTC that will help drive our growth beyond just the next 12 months.<br>
On the right hand side of your page also though is your some potential switch categories.We do not include those in our numbers. Let me say that<br>again, we do not include those potential switch candidates in our numbers. If they are to switch though, they would be very important and very<br>significant products obviously led by the Statins category as potential switch candidates moving from prescription to OTC for the future.<br>
One of the other things we're focused on I told you and I mentioned was the area of adjacent categories where we can add an adjacent category<br>and bring that into our portfolio and make us more valuable to our retailers. Today, we compete in about $40 billion of categories. We think there<br>are incremental adjacent categories beyond that that we can go after, led by areas of diabetics, which is what we talked about this morning. [Also<br>we'll have] adult nutrition, wound care, ophthalmics, all areas we think would be very exciting areas for entry for Perrigo to bring a store brand<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>9</i><br>
<hr>
<A name=10></a>JANUARY 09, 2012 / 6:30PM, PRGO - Perrigo Company at JPMorgan Global Healthcare Conference<br>
private-label offering to our retailers, which would help try to offer a quality product to make it more affordable for consumers around the United<br>States and the world for that matter. So, that's what we are excited about for the future is looking at these new adjacent category for future growth.<br>
I mentioned the acquisition this morning. It was -- we acquired a business called CanAm. They're expected to generate about $40 million of sales<br>in our calendar year 2012. We paid about $36 million in cash for that opportunity. It critically gave us a position in some of the areas of diabetes<br>that we are not in today. So for hypoglycemia, it gave us both a branded product for dextrose tablets, but also gave us opportunities for glucose<br>gel, glucose tablets, other areas in the store brand space as well.<br>
Insulin delivery gave us access to syringes, pen needles, alcohol swabs, our lancing, wound care and also in the compression stocking. Importantly,<br>these opportunities represent about somewhere around $1.5 billion branded opportunity that we now have physicians with a store brand offering.<br>And indeed, we can offer the full portfolio of diabetes from the blood glucose monitors and strips that we had before, now also these new products<br>that will help us to have a full line offering for the retailer. So, we're really excited about that. We also think it gives us some interesting ways to go<br>in the future. So for example, think of sugar-free cough syrups, think of sugar-free nicotine lozenges, things that we can do that also expand this<br>portfolio as we think about the diabetes opportunity for the future.<br>
Nutritional business, it was really a business that's been a very significant grower for us, especially with the acquisition in 2010 of a business called<br>PBM. So, a very exciting business opportunity. This will be a business that has continued growth opportunity for new products and I'll talk about<br>some of those in just a second, but also increasing store brand penetration especially in the area of infant formula. This is a -- we acquired PBM, it's<br>an infant formula company.<br>
It's one of only four manufacturers that can manufacture infant formula in the United States, the other ones being Abbott, Mead Johnson and<br>Nestle. So, we are the only store brand private-label manufacturer of infant formula in the United States, so it gives us a good opportunity for<br>continued growth in that category. This just looks at some of the opportunities we see, hypoallergenic, a nice opportunity. We're not there yet, but<br>we just hope that will be something for the future.<br>
Comfort Care, we have approval now with that product. So, we are excited with that. We have some additional soy and organic opportunities,<br>Ultra-Kosher opportunity. And then we have what I would call, on the right-hand side of the page, international opportunities to bring that product,<br>which is made in USA, which has an important quality perception to other countries around the world. So, very exciting opportunity for us in the<br>nutritional space and the growth that that entails for us for the future.<br>
We did do two deals. We announced in the China market, a very large market, actually over $5 billion market, where we have a non-exclusive<br>arrangement to make product in the United States and ship it to China, which is an exciting place to be relative to having a quality product made<br>in the USA, which has a very high quality perception in China that we're excited about shipping into China. In addition, we already have been<br>shipping some product. We think this will dramatically increase the opportunities for us for the future.<br>
The Rx generics and topicals business, an important part of our business. Once again, we're not trying to be the -- [compete] on the next oral solid<br>dose in this Rx business. What we are really after is looking at the extended topical products, products that are dermatologics, respiratory nasal<br>products, opthalmic products in which we can compete against some of the other players.<br>
We are now one of the larger players in the extended topical space as a result of some of the initiatives we put in place over the last five years in<br>terms of growing this business and we feel that there is still very significant growth drivers for us in this business. One is through new products,<br>but also last year, we acquired a company called Paddock. Paddock Labs became a part of Perrigo, and it's doing very well in terms of the growth<br>for us in this business. Also because of some issues from some of our competitors, we have a very favorable pricing environment at this time. And<br>that's allowed us to continue to grow this business and be successful and also importantly, expand the margin, the operating margin of this business.<br>
Importantly, as you look to the future, we have 41 ANDAs pending, that's our largest number ever and it gives us good hope for the future in terms<br>of continued strong growth, as well as some first-to-file. And on the bottom of the page is some of the other products that have been disclosed<br>publicly that we expect over the next six to 12 months in terms of launch opportunities for Duac, Clobex and Cenestin products. So, exciting<br>opportunities in our Rx space for good, strong, continued growth of the business.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>10</i><br>
<hr>
<A name=11></a>JANUARY 09, 2012 / 6:30PM, PRGO - Perrigo Company at JPMorgan Global Healthcare Conference<br>
API, last area I'll talk about. Really, it's once again the active pharmaceutical business opportunity that -- it's not going to be the fastest growing<br>part of our business, but as you can see from the adjusted operating margin, it has had some significant improvement in adjusted operating margin<br>behind some of the things we've done. And really that is to focus in areas of this business where it is more difficult to make the API. So, think about<br>drugs that are -- have a different double bond configuration, think of steroidal products, think of cancer agents as all areas that we are focused on<br>to ensure that we're going to be adding real value to our customers.<br>
So, that's been part of what we've been able to do in terms of driving the -- mostly the operating margins of the business. The other thing this<br>business does for us, Perrigo to be clear, is that it helps us understand how much should we pay for raw material. Having that information is very<br>valuable if our chemists can start with a raw material and say, going to this final active ingredient, you should be able to buy that for $400 a kilogram.<br>And we know today, we're paying $700 a kilogram. That allows us to have a very strong negotiating position as we go out and talk to our current<br>suppliers of the product. It is not our intent to make every raw material that we have, but clearly it puts us in a very good negotiating position we<br>know and understand how much these raw materials should cost us, starting at these raw materials and ending up at a finished active ingredient.<br>So, it's very helpful for us in that sense of the business.<br>
Just to close -- in summation, where are we with our guidance? As I remind you, we are a July 1st fiscal year start.We did our initial earnings guidance<br>in August with 15% to 18% topline growth. In October, we updated that guidance. We said, we indeed we think we'll grow faster, we'll grow 17%<br>to 20%. And then you can see write-down through the adjusted consolidated gross margin of 35% to 38%, consolidated operating margin of 20%<br>to 22%, estimated worldwide tax rate of between 27% to 29%. And we increased our diluted EPS from $4.50 to $4.65 to our October guidance of<br>$4.65 to $4.80 between a 16% to 20% year-over-year growth rate and obviously, we improved our cash flow from operations.<br>
So, that's really the Perrigo story. We are excited about our future based on, as I started at the beginning, the move to store brand and continued<br>strong move to store brand. The movement [of products] from prescription to OTC, also the success we've had in launching new products and<br>finally as we've been able to look for other organic and inorganic opportunities for growth.<br>
That concludes what I wanted to say at this time. There is a couple of minutes for additional questions. If I should open it up for questions, Chris?<br>
<b>Chris Schott</b><i> - JPMorgan - Analyst</i><br>
Yes, let me open to one question, just so we could be around the corner in the Olympic Room, but can you talk a little bit about the kind of national<br>brand's environment between [Ortho-McNeil] coming back to market and some of the news out of Novartis recently with regards to Excedrin, kind<br>of what dynamic you are kind of expecting as we head into calendar 2012 on that front?<br>
<b>Joe Papa</b><i> - Perrigo Company - President, CEO and Chairman</i><br>
Sure. Well, first of all, J&amp;J has had some issues that they've been working on from the consumer products. And they have talked about re-entering<br>into the liquid market in October, November, December of 2011. And they said, they would re-enter in the -- for a solid market in January, February,<br>March of 2012 with a complete return sometime around mid-year 2012 at least is what I have heard from them [or as has been] shared with me. I<br>have no reason to doubt that. I would say that the liquids at this time, they are not fully back, but they do have some products, but it is clear that<br>they probably only have some of the products back at this time. They are not completely back at this time for example, on the Tylenol suspension.<br>
Novartis has said that they were going to stop shipping and recall some products. Those products represent somewhere around a branded<br>opportunity of about what appears to be about $200 million from the IMS data, but I don't have their internal data obviously.<br>
For us, knowing those products, knowing the discounts on those products, it probably represents somewhere in the $70 million to $100 million<br>store brand opportunity for us if it was a full-year event. I don't know at this time whether it's a three-month event, a six-month or a year event or<br>beyond. So, what we will do is clearly, we'll go out and talk to our retailers, in fact we already have.There are some opportunities for us to get some<br>incremental commitments from the retailers for additional product, but as to the duration of this at this time, it's probably too early for me to make<br>any comment on how long it would be a duration.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>11</i><br>
<hr>
<A name=12></a>JANUARY 09, 2012 / 6:30PM, PRGO - Perrigo Company at JPMorgan Global Healthcare Conference<br>
From our point of view, we'll take a quarter at a time in terms of how we look at the business opportunity, but clearly, we've got capacity, we are<br>able to ship additional products should the retailers need that product.<br>
<b>Chris Schott</b><i> - JPMorgan - Analyst</i><br>
Thanks a lot. Let's meet around the corner at the Olympic Room.<br>
<b>Joe Papa</b><i> - Perrigo Company - President, CEO and Chairman</i><br>
Thank you very much for your interest in Perrigo.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4699869-2012-01-09T22:06:07.690</b><br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>12</i><br>
<hr>
<A name=13></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
ENDP - ENDO PHARMACEUTICALS<br>HLDGS INC AT JPMORGAN GLOBAL<br>HEALTHCARE CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 9:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>13</i><br>
<hr>
<A name=14></a>JANUARY 09, 2012 / 9:30PM, ENDP - ENDO PHARMACEUTICALS HLDGS INC at JPMorgan Global Healthcare<br>Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Dave Holveck</b><i> Endo Pharmaceuticals Holdings Inc. - President, CEO and Director</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Chris Schott</b><i> JP Morgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Chris Schott</b><i> - JP Morgan - Analyst</i><br>
Good afternoon, everybody. I'm Chris Schott, pharmaceutical analyst at JPMorgan. I'm very pleased today to be introducing Endo Pharmaceuticals.<br>From Endo, we have Dave Holveck, the Company's President and CEO. Obviously the Company had pretty transformational year in 2011 and look<br>forward to hearing the presentation.<br>
So with that, I'd turn it over to Dave.<br>
<b>Dave Holveck</b><i> - Endo Pharmaceuticals Holdings Inc. - President, CEO and Director</i><br>
Okay. Quite a (inaudible) before getting up here, so. Let me go back here, if I can. Okay. Before I begin, I'll remind you of our forward-looking<br>statements and that during the course of today's presentation, I may refer to non-GAAP financial measures. You can read more about these items<br>in the 8-K that we will file in conjunction with today's presentation.<br>
Good afternoon. It is a pleasure to be here and I thank you for the opportunity to speak with you at this conference. I'm very pleased, and I believe<br>that Endo is not only achieving its corporate goals and objectives, but also redefining healthcare through a very successful diversification program.<br>I'll put that into context for you by providing you an update on our recent financial performance, our strategy for growth and value creation, our<br>commitments to R&amp;D, innovation and some keys as to why we believe 2012 will be another exciting year for Endo.<br>
Now, for our strategy for growth is based on our belief that the healthcare system is changing and that the healthcare value will exist at the<br>intersection of the [axis] of economics and outcomes, a system where all parties are working towards three common objectives; maximum access<br>of care providers and patients alike; prices that enable suppliers, payers, and providers to thrive; and lastly, success measured by patients recovery<br>rates and quality of life.<br>
At Endo, we believe we can achieve this by creating more comprehensive offerings focused in pain and urology. And in 2012, we will focus on<br>unlocking some of the value creation that a larger diversified Endo now has the opportunity to build on. We see notable opportunities in the<br>Qualitest, HealthTronics and AMS businesses. At the same time, we'll continue to evaluate the licensing and acquisitions of assets aligned with our<br>current commercial businesses.<br>
We will focus on executing in our established businesses and with the acceleration launch of our new formulation of Opana ER. Strong commercial<br>execution in our base business enhances cash flow, pays down our debt and makes strategic investments that we believe will grow. We've made<br>commitments to reduce our leverage and we will pay down our debt in a timely fashion.<br>
Now, these slides I am really getting confused with, but I think we got them right here now. This is a very exciting time for Endo, not just in terms<br>of our recent financial performance, but also because of the significant transformation of our business over the past three years. What was once a<br>Company focused solely on a single product in pain, we have diversified the Company into a diversified healthcare Company. Endo was focused<br>on multiple therapeutic products and platforms with the ability to sell both branded and generic pharmaceuticals, medical devices and healthcare<br>services to a wide array of medical specialties with particular focus in pain management and urology.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>14</i><br>
<hr>
<A name=15></a>JANUARY 09, 2012 / 9:30PM, ENDP - ENDO PHARMACEUTICALS HLDGS INC at JPMorgan Global Healthcare<br>Conference<br>
The numbers reflect the success from our diversification strategy. Endo had a strong 2011 with good performance across every segment of our<br>business, and we look forward to reporting the final results for the year to our investors in February. We have a well established track record of<br>delivering double-digit revenue growth at Endo. Acquisitions have added significantly to the performance in 2011 and more importantly, there's<br>double-digit growth in the pro forma revenues as well.<br>
Growing the topline is good, but we use the attractive financing environment to fund our diversification. And so there is an increasing focus on<br>the operating cash flow produced by our businesses.<br>
We expect 2011 to be a banner year for net cash provided by operational activities. And we expect growth in 2012, as we benefit from the full year<br>of AMS acquisition and the expansion of our generics and other businesses. We'll dedicate the majority of that cash flow to achieving our target<br>debt-to-EBITDA ratio of 2 to 2.5 times in 2013.<br>
With the acquisition of HealthTronics, Penwest, Qualitest and AMS, we believe Endo is poised for continued long-term growth. The presence we<br>have and built in urology through the recent AMS and HealthTronics acquisition includes a broad network of partnerships and relationships with<br>the majority of urologists in the United States.The addition of Qualitest to our generics business created substantial scale in generics and will help<br>us combine generic business and grow with a compounded annual growth rate of over 15% across the 2011 and 2012 time frame with strong<br>prospects beyond that.<br>
Our acquisitions of the American Medical System furthers Endo's evolution from a product-driven Company to a healthcare solutions provider and<br>strengthens Endo's leading core urology franchise while diversifying revenue, earnings and cash flow. That diversification has created multiple<br>opportunities for sustainable growth for Endo, and we believe that reflects in our plan for 2012.<br>
Today, Endo operates in three key business segments; Branded Pharmaceuticals from Endo, Generics through Qualitest, Device and Services through<br>AMS and HealthTronics, respectfully. These businesses provide therapeutic solutions primarily in the pain and urology areas with an emerging<br>presence in oncology and endocrinology.<br>
We expect double-digit growth overall from our business units. Individually, they are all strong growth businesses. Longer term, we believe their<br>growth can be accelerated through integration and the development of customer centric offerings especially such as urology and pain management.<br>
Pain products remain a significant growing and core part of our business. Importantly, pain products are an attractive business that produces<br>significant cash flows and enables our strategic diversification and now can be focused towards the repayment of debt.<br>
Branded Pharmaceuticals. Our Branded Pharmaceutical business continues to grow. In the third quarter of 2011, sales of branded drugs rose 17%<br>year-over-year. That's double-digit organic growth in our legacy businesses. We transformed our commercial business model to focus more on<br>customer-centric marketing and deployment of our sales forces. Customer-centric marketing reflects our focus on identifying customer needs and<br>matching our offers with those needs. This allows us to take advantage of the changing healthcare landscape and be more effective and efficient.<br>
We expect that model to continue to be successful in 2012. Notwithstanding the limited short-term supply disruption announced earlier today,<br>our approach has created strong prescription growth for Voltaren Gel and our model has driven attractive growth for Opana ER.<br>
The recent approval of the new formulation of Opana ER has us excited as we believe there is now an opportunity to meaningfully extend the<br>franchise with patent protection through 2023. We firmly believe the new formulation of Opana ER coupled with our long-term commitment to<br>awareness and education around appropriate use of opioids reflects our focus on safety and efficacious pain relief.<br>
We highlighted in a press release earlier today that Opana ER franchise will experience some short-term supply constraints. As a result of a Novartis<br>facility shutdown where the original formulation of Opana ER is manufactured, Endo is expediting the production of the new formulation of Opana<br>ER, designed to be crush-resistant at a third-party manufacturing facility managed by Endo's development partner, Grunenthal. We estimate that<br>facility will reach full production by the end of the first quarter or early second quarter.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>15</i><br>
<hr>
<A name=16></a>JANUARY 09, 2012 / 9:30PM, ENDP - ENDO PHARMACEUTICALS HLDGS INC at JPMorgan Global Healthcare<br>Conference<br>
We're focused on the current supply situation, and it's important to note that we believe that we have significant period of time to capture the<br>value from the new formulation. Recent DEA decisions have strengthened that belief. DEA designated a significant portion of the 2012 industry<br>quota of oxymorphone to support the manufacturer of the new formulation of Opana ER through Grunenthal's third-party partner [Pmrs].<br>
Lidoderm, for the treatment of PHN, remains a stable franchise for Endo.This past year, the product market marks its 12th year on the market, since<br>commercial launch in 1999.We continue to believe that the regulatory and litigation hurdles for the generics remains high and that Lidoderm and<br>strong operating cash flow that it provides have durability over the next few years.<br>
We understand the value of this franchise and the maximization of its value for our current and potential investors, and we believe that there is<br>value in resolving market uncertainties with respect to the anticipated cash flows from this product. If we find that there is an opportunity to fairly<br>value the interest of all parties in actively in achieving certainty, then we look to do so.<br>
The acquisition of Qualitest has delivered and diversified a robust generics business, expanding our ANDA pipeline and adding a solid portfolio of<br>manufacturing assets to build on. As a result, our generics segment had a strong third quarter with pro forma growth in net sales of 17% versus<br>previous year.That growth will continue driven by continued optimization of our current commercial portfolio and favorable economics for generic<br>products, particularly in pain products where we have a strong focus and are continuing to explore growth opportunities.<br>
In 2011, we received approval of 10 new ANDAs that will enhance the breadth of our generic offering and supplement the strong growth for the<br>established product portfolio. We believe the outlook for this business is very bright, given existing inventories that expected to restart our<br>production at Novartis and our shift of products to our Huntsville facility, we believe that supply constraints for Percocet and other generic<br>opioid-based products will be minimal. We will be investing in this segment to improve our margins and support our growth trajectory.<br>
With the combination -- with the completion of our acquisition of American Medical Systems, a leading provider of urology devices, we have a<br>unique opportunity to build our medical device business and create value for customers and shareholders. In 2012, we are planning for growth<br>from all major lines of this business.<br>
In Men's Health, there are two major product lines; erectile restoration products and male incontinency products. AMS' commitment to physician<br>training, which increases the number of skilled prostatic implanters gives us confidence in the durability of growth in this business. In BPH, we<br>believe increasing share of procedural volumes of the GreenLight XPS console and the accompanying MoXy fiber is a trend that will continue in<br>2012. This trend reflects our belief that GreenLight system allows more efficient removal of prostatic tissue than traditional procedures.<br>
In Women's Health, there are two major product lines; slings for female stress urinary incontinence and products for the repair of pelvic organ<br>prolapse. We plan for returned growth in this line of business in 2012 by emphasizing non-US markets first and engaging with US physicians to<br>address their questions about the new regulatory environment for mesh products.The international presence of AMS positions Endo for opportunities<br>outside the US. It's a foothold that will enable us to consider new investment opportunities.<br>
We expect the mobile transport infrastructure of HealthTronics to support growth by creating greater access to equipment for patients and<br>physicians. HealthTronics is a leader in the provision of urology services and we have strong expectations for top line growth for this business in<br>2012. Cryosurgery should benefit from an expanding set of partnerships and one of our pilot programs involves the sale of this device through our<br>AMS business.<br>
HealthTronics is viewed as a trusted partner of urologists focused on practice economics and improved patient outcomes. Providing this type of<br>service is a source of stable revenue that we believe has good investment potential. We believe that having good data is critical to enhancing the<br>organic growth potential of urology franchise. Data gives us unique insights into our customers. And over time, we believe this will in turn give us<br>additional insight and the kinds of solutions and outcomes that are most desirable and meaningful to patients, providers and payors.<br>
We recently made a pair of EMR strategic acquisitions of UroChart and meridian, two profitable providers of electronic medical record software<br>designed specifically for urologists. UroChart and meridianEMR will enhance HealthTronics service offering in urology practice management and<br>further solidify our relationship with approximately 1,800 practicing urologists, many of whom are new to Endo.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>16</i><br>
<hr>
<A name=17></a>JANUARY 09, 2012 / 9:30PM, ENDP - ENDO PHARMACEUTICALS HLDGS INC at JPMorgan Global Healthcare<br>Conference<br>
Within all of these business, there is an ability to build value through partnerships. We believe partnerships are a key to the future growth and a<br>part of the industry dynamics. We will always have good products, but we believe that increasing focus on economics and outcomes reduces the<br>probability that products alone will be sufficient to create value in the future. Adaptation to that new environment is evident in the virtual research<br>model that we have adopted. But we are focused on creating channels within pelvic health and pain as the next step.<br>
We believe the recent addition of the data offering to urologists that I just discussed is a critical part of creating meaningful chance. The service<br>not product orientation opens us to a wide range of partnering opportunities. Diversification enables our business development effort to evaluate<br>tuck-in products opportunities across areas such as prostate cancer, sexual function and pain.<br>
Our commitment to innovation is reflected across all three of our business segments. In Branded Pharmaceuticals, we have received approvals for<br>two new products in the past year; Fortesta Gel and a new formulation of Opana ER. Last week, we announced our latest addition, BEMA, and I'll<br>detail that more in a moment, but as results we have seen in several late-stage product candidates in development as well as early-stage research<br>collaborations in pain management and oncology.<br>
Our strong generics portfolio includes approximately 50 ANDAs currently under review by the FDA. In devices we have a number of new product<br>introductions to support the growth of this business. Some recent advances include GreenLight XPS laser systems and the MoXy fiber which were<br>recently introduced to the market. We've seen a strong pickup in BPH procedures as a result of those two new innovations and AMS recently<br>launched the AdVance XP treatment for male incontinence within Men's Health business.<br>
Devices for the delivery of drug therapies continue to be of interest, and we have multiple projects that are exploring opportunities to improve<br>outcomes through the convergence of device and drug and we look forward to updating you more on those innovative programs in this year 2012.<br>
We are excited about our partnership announced last week with BioDelivery Sciences International for BEMA.This addition reflects Endo's commitment<br>to pain therapeutics allowing us to offer an integrated suite of products that includes Opana ER, Voltaren Gel and Lidoderm, as well as a broad<br>range of generic pain products.<br>
Financial terms of the agreement include an upfront payment of $30 million to BDSI, royalties of net sales and up to approximately $150 million<br>in milestones contingent upon the achievement of predefined IP, late stage clinical and regulatory events and achievement of sales targets. We<br>expect in mid-2012 to initiate a pair of Phase III trials to study this product in the treatment of moderate-to-severe chronic pain. We look forward<br>to working closely with BDSI on the development of this important asset.<br>
Today, we are reaffirming our 2011 financial guidance of $2.72 billion to $2.80 billion in revenues and $4.55 to $4.65 in adjusted diluted earnings<br>per share. We also estimate reported GAAP diluted earnings per share to be between $1.87 and $1.97 per share. Counsel would like me to remind<br>you that these are still forward-looking statements. Our guidance reflects the flexibility that we've built into our operating model as well as the<br>recognition of synergies identified through the continued integration of Qualitest and AMS.<br>
In addition to our financial success in 2011, we had some notable commercial achievements. The recent approval of our new crush-resistant<br>formulation of Opana ER was a significant accomplishment for our R&amp;D organization and a very exciting opportunity for our pain franchise. This<br>product addresses the growth demand for improved opioid formulations, and we look forward to launching this.<br>
Our acquisitions of Qualitest and AMS were major leaps forward in our generic and urology businesses and great examples of how diversification<br>and synergies are strengthening Endo. In urology, we are now offering diagnostic products, medical devices and services, pharmaceuticals and<br>electronic data management.We are also exploring potential across opportunities plus all of our businesses such as the AMS Men's Health franchise<br>for Fortesta Gel or the Endocare cryoablation therapy and the AMS GreenLight laser through our HealthTronics franchise.These initiatives are now<br>being piloted by our commercial organization, and we expect to see the results of these pilot programs early this year at which time we will assess<br>whether these efforts should be scaled nationally.<br>
As I've given you only a few brief overviews of our recent accomplishments and business outlook, but I think you can see that our diversification<br>strategy has been successful and gives us a much stronger business platform for sustainable growth and value creation. This year we will be<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>17</i><br>
<hr>
<A name=18></a>JANUARY 09, 2012 / 9:30PM, ENDP - ENDO PHARMACEUTICALS HLDGS INC at JPMorgan Global Healthcare<br>Conference<br>
launching a number of new branded and generic products, implementing new programs across urology franchise and continuing the integration<br>of our expanded and diversified business. We are committed to the success of these initiatives and believe that we are important in creating value<br>and delivering better care to all of our customers. We will continue to invest in our business as appropriate and leverage our strong cash flow to<br>reduce our debt. Truly excited about the year ahead, and thank you for the opportunity to speak with you today. Thank you.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4695004-2012-01-10T00:36:07.413</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>18</i><br>
<hr>
<A name=19></a>THOMSON REUTERS STREETEVENTS<br>PRELIMINARY TRANSCRIPT<br>
SBE.V - TECK RESOURCES LIMITED TO<br>ACQUIRE SILVERBIRCH - CONFERENCE<br>CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 2:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>19</i><br>
<hr>
<A name=20></a><IMG src="010912_0-20_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>&gt;&gt; Re</b><br>
<b>T R A N S C R I P T</b><br>
<b>T R A N S C R I P T</b><br>
<b>Editor</b><br>
Please stand by for realtime transcript.<br>
<b>Unknown Speaker*</b><br>
Welcome to the SilverBirch energy conference call.<br>
At this time all participants are in a listen only mode.<br>
Following the presentation, we will conduct a question and answer session.<br>
Instructions will be provided at that time for you to queue up for questions.<br>
(Operator Instructions) The Company may make forward-looking statements during this call.<br>
These statements are based on SilverBirch expectations and are subject to a variety of risks and uncertainties and other factors which are inherent<br>in a pre-development stage oil sands mining and extraction enterprise that could materially affect SilverBirch is results.<br>
No representation can be or is being made with respect to the accuracy of projections -- to achieve the projected results.<br>
The Company assumes no obligation to update any forward-looking statements.<br>
I would like to remind everyone that this conference call and webcast is being recorded on Monday, January 9 on Monday, January 9, 2012 7 AM<br>mountain time and will be available for playback on the Company's website.<br>
I will now turn the conference over to Mr. Michael Stephens, head of investor relations.<br>
Please go ahead.<br>
<b>Unknown Speaker*</b><br>
Good morning everyone and thank you all for joining the call today.<br>
I am Michael Stephens, SilverBirch manager of finance and investor relations.<br>
Howard Lutley president and chief executive officer of ? energy will lead the call this morning and he will begin with some compared remarks.<br>
Also present in today call is way body president and chief financial officer and Jina Abells Morissette vice president of legal and administration.<br>
For today's conference call webcast, we will discuss the details of the agreement for text resources Ltd.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>20</i><br>
<hr>
<A name=21></a><IMG src="010912_0-21_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
the SilverBirch Energy by way of a plan of arrangement and the creation of silver will energy Corporation, a new corporation focusing on Institute<br>oil sands Institute does.<br>
I will turn the call over to Howard Lutley.<br>
<b>Unknown Speaker*</b><br>
Thanks Mike.<br>
Welcome everybody and thank you for joining us this morning.<br>
We are very pleased to tell you about our transaction and the formation of our new Company, silver will energy.<br>
Before I start I want to knowledge the tremendous work -- by our team and how very and tech team in Vancouver as well is the their most devices<br>that have assisted us in putting this deal together over the Christmas and New Year's period, a difficult time for any of us with families, which is of<br>course most of us. And the way, this will be a fairly short call covering the transaction, and a description of the new Company and what assets will<br>be in the new Company.<br>
I turn your attention to the forward-looking statements on slides two and three.<br>
I'm particularly, if you just would take a second to look at slide four, as for -- but as the resource disclosure.<br>
When we are talking about Silver Willow -- we will be talking about this governor bitumen -- in place.<br>
We talked about contingent resources I wanted to draw your attention to this distinction, we discovered bitumen initially in place.<br>
It's move on to slide five, and we will start discussing the proposed transaction.<br>
Silver Willow As Mike mentioned, is being created through a plan of arrangement.<br>
And the construction of this transaction is quite similar to the one that we did 15 months ago between UTS and total.<br>
It is familiar for us as we put this together.<br>
Teck Resources all of SilverBirch is common shares, and Silver Willow shareholders and Silver Willow pinning the share holder Company, $8.50 per<br>share in cash plus one share of Silver Willow.<br>
Additionally tech will constitute $75 million in cash and will contribute 50% working interest in the Birch Mountain's and Georgian properties which<br>we held jointly to Silver Willow.<br>
Also assets will be transferred to Silver Willow accept working interest in frontier and Equinox project and the twin Lakes leases which of course<br>tech will keep.<br>
As a result, so we're will which will be focused on Institute rather than our former the mining site will 100% of debt properties, Birch Mountain's<br>leases, and the Jordan leases and will be capitalized initially with $25 million.<br>
Let's go to slide six.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>21</i><br>
<hr>
<A name=22></a><IMG src="010912_0-22_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
To focus in a little bit on the details, the cash component that you'd shareholder, SilverBirch shareholder will receive is $8.50 and for each share of<br>SilverBirch they hold they will receive a share of silver will, which will have approximately $.50 a working capital per share plus approximately 30<br>-- discovered resource per share in the -- property.<br>
Of course at the moment we have no knowledge of resources discovered or otherwise and the Birch Mountain or Jordan properties.<br>
In addition to the lands described, we will also have 117,000 acres of exploration.<br>
As far as the headline metrics, based just on the cash component alone, and that is the cash that shareholders receive and that is the cash going<br>into Silver Willow , SilverBirch shareholders will receive a 25% premium to a closing price on January 9 and a 30% premium to the 20 day volume<br>weighted average price.<br>
As an important point here, SilverBirch board of management unanimously recommending acceptance of this offer to SilverBirch shareholders,<br>and -- agreements have been signed and the two major shareholders West face and the -- let's move to the slide seven, I will talk a bit about Silver<br>Willow.<br>
As SilverBirch announced back in October, we have confirmed a significant resource potential on the on that property northeast of Fort McMurray.<br>
We are in the field grilling as we speak, we've got started a couple of days ago and we will have additional information which by the end of this<br>year should allow us to determine contingent resources on this property.<br>
We also have the additional upside in the Birch Mountain's area, immediately west of frontier so this is the exploration lands where the oil sands<br>are a little deeper buried, and as you may have noticed in the past couple of years, this has been quite active expiration with a number of countries<br>with a number of programs going on in the Birch Mountain's.<br>
We have taken across the complete management team and the board for the previous Company from SilverBirch to Silver Willow, so you will have<br>the same experienced leadership training -- do with its proven exploration and development record working for you for the shareholders in Silver<br>Willow.<br>
We also have a work plan focused on doing what we do best, which is exploring these properties and moving them forward along the regulatory<br>path and the engineering path and determining what the value is whether it makes sense to keep advancing the project or looking for partners,<br>or looking for constructive deals once we know what we have and have the risk to the process for possible partners.<br>
And of course we will have additional working capital of approximately $25 million that will be subject to working capital corrections and adjustments<br>following closing.<br>
<b>Unknown Speaker*</b><br>
We will move on to slide eight.<br>
There's a series of slides now, which take us through the land position and we can have a better appreciation of what lands Silver Willow will own.<br>
On slide eight, you can see the current situation in which the shows the lands that we have primarily 50/50 with tech buyer to closing with the<br>exception of -- which currently SilverBirch owned 100% and -- is on the right side of the map there.<br>
If you go to slide nine in bright blue, highlighted the lands that Teck will now have 100% of. The frontier project, Equinox project, and the twin<br>Lakes leases just on the east of the Athabasca River.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>22</i><br>
<hr>
<A name=23></a><IMG src="010912_0-23_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
If you flip to slide 10, this highlights the lens that Silver Willow will own 100% of, that very large exploration block on the West side, the Birch<br>Mountain's, the Jordan lands on the middle of the map, and then the Audette leases on the east side of the map, which have the discovered<br>resources that I mentioned earlier.<br>
And we will spend a little bit of time talking about Audette, because that is the focus of our activity right now.<br>
Let's move on to slide 11. This is the summary of the discovered bitumen initially in place on the Audet Lands.<br>
This summary is from -- report that was released in October by SilverBirch, October 2011. As pointed out below that, we also have the urge mountains<br>leases, 100% working interest in non-leases, 100 or a seven sections, very extensively position and then the Jordan positions 100% working interest<br>into leases comprising Earnie six sections.<br>
We will talk to slide 12. Again, people who are familiar with SilverBirch, this will be a familiar drawing.<br>
Where moving object forward toward development, but of course we have quite a ways to go yet.<br>
The 2012 winter program as I mentioned is just underway, and in addition to additional to litigation drilling, we will be doing some 2-D seismic<br>and a key part of the program will be a -- and valuation.<br>
One of the important things about the Audette lease is that we know that the cap rock is intermittent across the least.<br>
Our focus this year is to identify an area where there is sufficient cash rock to allow us to proceed for the conventional -- project.<br>
We are quite confident that the resources that are based on last year's drilling program and we know that that is a very high-quality, quite thick<br>continuous bitumen resource.<br>
The technical issue as far as production will be this president -- presence of caprock.<br>
However having said that, we also know there are new emerging technologies that may be applicable even if the caprock is somewhat limited or<br>intermittent.<br>
We believe this whole area has tremendous potential because of the size of the resource.<br>
The drilling will continue through the first 6 to 8 weeks of this year, and then of course the analysis cycle goes through the geotechnical testing of<br>the caprock samples, the analysis of the many frac test it we will be doing, and then once that data is all assembled and analyzed and evaluating<br>by our independent assessors, we should be able to report contingent resources either by the end of this year or in 2013. The project scheduled<br>below is a notional because of course it assumes that we are successful improving our technical -- but one could conjecture that it would be viable<br>to have production from these leases by 2016 or 2017 timeframe based on normal regulatory and development cycles.<br>
<b>Unknown Speaker*</b><br>
Let's move on to slide 13. Moving towards the summary here, but that's basically provides us a platform for growth, and as we mentioned that his<br>1.6 9 billion barrels of discovered resourcing place, we will have our contingent resource by the end of this year.<br>
We will also commenced desktop assessment of the Birch Mountain's resources, which back in the UTS days we put seven -- core roles into those<br>leases on very preliminary explorations.<br>
And the balance of this year, we will be doing some desktop work to identify best locations for seismic and perhaps drilling, and it will be later in<br>the year before we can announce what we plan to do as far as an expiration program of those leases.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>23</i><br>
<hr>
<A name=24></a><IMG src="010912_0-24_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
Jordan, some interesting level patch of land, quite close to some other major projects.<br>
The eight core holes that have been drilled into date have indicated there is bitumen, but it's not very extensive.<br>
However, we believe that this might be an interesting opportunity for some shallow unconventional approaches to extraction and so we will<br>basically look at it in that light, and see how that might be taking forward.<br>
As we do this work, of course we are open-minded to consider joint venture prospects or other approaches and looking at the best way for Silver<br>Willow shareholders as to how to -- and move onto slide 14. As far as financing, the initial $25 million will be used to finance our exploration work<br>and analysis 40 balance of this year and of course G&amp;A and miscellaneous expenses as part of the transaction, tech has provided an interim $20<br>million loan facility and that is buyers in the middle of the year, but it helps tide us over and the shortfalls of cash during the closing period and<br>shortly thereafter.<br>
So we are looking to once again be successful with the drill-bit to drive the Company forward and create the financing flexibility and strategic<br>opportunities.<br>
We believe that we successfully feel, you will all is to continue us to fund our objective in the our exploration and development objectives.<br>
<b>Unknown Speaker*</b><br>
Finally, to close this part of the presentation, we believe we have completed a very successful transaction, obviously subject to closing, which<br>should be by the end of March.<br>
We believe we have provided a significant premium to our shareholders, our shareholders, Schilder birch shareholders will receive a one for one<br>share in the Silver Willow Company I'm a 10 SilverBirch shareholders will retain their resource outside through its exposure to Silver Willow, and<br>your management team is here to go to work on the Silver Willow resources.<br>
Finally, the Board of Directors has unanimously approved his plan and recommend that SilverBirch shareholders vote in favor of it. I will finish my<br>prepared comments at this point, and turn it back to Mike and the operator for the next step.<br>
<b>Unknown Speaker*</b><br>
Thank you Howard I would now like to open the floor for the question and answer session and ask the operator to come back on to explain how<br>we will proceed.<br>
+++q-and-a<br>
<b>Unknown Speaker*</b><br>
(Operator Instructions) We will now conduct the question-and-answer session.<br>
(Operator Instructions) Said Jean Shaw --<br>
<b>Unknown Speaker*</b><br>
Hi good morning thank you for taking my question.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>24</i><br>
<hr>
<A name=25></a><IMG src="010912_0-25_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
I wanted to go over the regulatory approvals.<br>
I did the that you are expecting this deal to close late April.<br>
Was wondering if you could go over that timeline.<br>
I did see here that you've got some shareholders to support this transaction, so if you can talk about the background and how you guys came to<br>this transaction.<br>
I missed the first part of the call, I apologize if you discussed this already.<br>
<b>Unknown Speaker*</b><br>
Okay.<br>
39% of the shareholders basically management in the two major shareholders have already locked up to the deal.<br>
As far as how the deal came together, I'm not quite sure on your question, but I am assuming -- are you talking about timeline or --<br>
<b>Unknown Speaker*</b><br>
Yes, when I say deal came together like were you talking to other parties, was this an option process, did Teck approach you, I want to understand<br>was this is solely one-off situation with Teck our the companies solicit other offers and this was a best situation for SilverBirch shareholders as well<br>as Teck shareholders kind of a situation.<br>
<b>Unknown Speaker*</b><br>
Okay, I understand that.<br>
No, we have been through a long strategic process, actually we are pretty well 12 months now, once SilverBirch was formed October October 2010,<br>we basically got up and running and got settled in and starting in January and starting in January 2011, we formed an informal strategic working<br>group with some of the members of the board was also our financial advisors joined the team as well.<br>
And we basically look at the strategic options for the Company, understanding the assets that we had.<br>
Of course at that time, we didn't have any results from our audit drilling program, so we did not know the scale of the opportunity.<br>
During the first three or four months of that strategic process, we were assessing our asset and then getting to understand what we had on the<br>object property.<br>
By midyear, we had some additional information.<br>
We had a pretty good industry and in -- understanding of the scale at Audette, and we'll say completion of the design basis memorandum, the<br>resource update on frontier and equinox, and probably the key factor was in end of June, we had the revised capital cost estimate for frontier and<br>equinox projects.<br>
Again, with those bits of information, we were able to get a pretty good handle on the potential economics of frontier and equinox as well as what<br>the capital on some desk want some that would be required from SilverBirch Tuesday May project at 50/50. All along we heard all is said SilverBirch<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>25</i><br>
<hr>
<A name=26></a><IMG src="010912_0-26_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
at some point we would look at our options for how great our participation in the -- will be and that we would be quite open to constructive ways<br>to reduce our interest.<br>
As long as they created value for the shareholders.<br>
The financial advisors also conducted a confidential low-key process of contacting potential participants who might be willing to either participate<br>with us , by our shares, and the number of the normal kind of things would consider and that was quite extensive, it was international, that it wasn't<br>a public process.<br>
At the same time, commencing and about Midsummer, we also started negotiations with tech -- Teck on our partnership agreement.<br>
And long-standing commitment between both ourselves and Teck was to form a partnership and properly paper it with a partnership agreement.<br>
Through that process, we had to examine value, all parties examine value and we are looking at ways to make a good agreement, having learned<br>a lot from our participation also with Teck any Fort Hills agreement and recognizing there were if you things in that agreement that hadn't worked<br>well for junior partner.<br>
Particularly junior financial crisis.<br>
We wanted to come up with a similar worship agreement but something that provided flexibility for the smaller Company, SilverBirch.<br>
We work hard with Teck to put that kind of agreement together, and actually had something that we could put in front of our boards and ultimately<br>then just two days before Christmas,Teck came back with the offer that we are looking at now rather than proceed with the partnership approach.<br>
Willie, it was quite a long process, interest our partners talk to a lot of different parties over the intervening period and family came to what we<br>believe now is the offer we have -- a good offer we have in front of us now.<br>
<b>Unknown Speaker*</b><br>
Perfect.<br>
Just as they -- regulatory approvals and then a potential timeline between now and that April, I think that's when you are expecting the deal to<br>close on or before Midshipman April ?<br>
<b>Unknown Speaker*</b><br>
Yes.<br>
I will answer the one I know, Jean our legal counsel is here as well so she can fill in. There is competition ask, is that the --<br>
<b>Unknown Speaker*</b><br>
That is the only one.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>26</i><br>
<hr>
<A name=27></a><IMG src="010912_0-27_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
And then arrangements a we'll have to get the court order and take all of those steps, so you how works once we mail the circular at the clock starts<br>ticking, but because we are starting Silver Willow -- a lot of information that the new companies that will take some time.<br>
We are still aiming for that end of March/early April closing time for.<br>
<b>Unknown Speaker*</b><br>
Okay.<br>
And as far as regulatory approval and competition, it seems but a much not an issue, but is that the case?<br>
<b>Unknown Speaker*</b><br>
We wouldn't be so presumptuous to speculate on that, however we don't foresee any issue there.<br>
<b>&gt;&gt; Re</b><br>
.<br>
It is no issue you're going to go through the process, ultimately they will make the decision?<br>
<b>Unknown Speaker*</b><br>
Right.<br>
<b>Unknown Speaker*</b><br>
Fair enough.<br>
Think you guys.<br>
<b>Unknown Speaker*</b><br>
Mark Friesen with RBC Capital Markets.<br>
<b>Unknown Speaker*</b><br>
Thank you good morning.<br>
Just have two questions for you Howard.<br>
First of all, is there any follow-up lockup to shareholders post closing of this transaction?<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>27</i><br>
<hr>
<A name=28></a><IMG src="010912_0-28_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
I will as Gina to answer that one.<br>
<b>Unknown Speaker*</b><br>
Do you mean about additional shareholders walking up?<br>
<b>Unknown Speaker*</b><br>
No, I mean following closing so once Silver Willow begins trading.<br>
<b>Unknown Speaker*</b><br>
No, it doesn't carry on into Silver Willow.<br>
<b>Unknown Speaker*</b><br>
All right so second question, perhaps as explained the context of why or how to links became part of the 100% Teck land?<br>
<b>Unknown Speaker*</b><br>
Yes, it was really just a negotiation.<br>
We as SilverBirch didn't feel strongly about keeping 20 lakes -- on the geological potential, it's probably limited and that is SilverBirch view, and<br>that is only subject to the limited drilling that has been done to date.<br>
Teck Was interested in keeping 20 lakes, so it was easy for us to make that swap of those lands.<br>
<b>Unknown Speaker*</b><br>
Is that he possibly but a mining opportunity?<br>
<b>Unknown Speaker*</b><br>
I wouldn't say it is or and isn't a mining opportunity.<br>
It's certainly if there is coin to be oilsands there, it would be that more likely a mineable prospect that an in situ prospect just because of the debt<br>of the geology in that area.<br>
<b>Unknown Speaker*</b><br>
Sure, okay.<br>
And finally if you could give a little more detail as the terms of the interim loan facility please.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>28</i><br>
<hr>
<A name=29></a><IMG src="010912_0-29_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
It is normal commercial terms. Wayne is sitting here, I will ask them to talk about that.<br>
There's not a whole lot to be said about it I don't think.<br>
<b>Unknown Speaker*</b><br>
Hello Mark, it's just a regular log.<br>
It's there somewhere to the one that we have in place now.<br>
Is put in place to provide fact flexibility.<br>
The rate is very competitive with what we have now.<br>
Related to product.<br>
And it's just been in place other we have some flexibility point forward and we hadn't done this transaction, we probably would've raised them<br>aggregate, this gives us some flexibility to move forward with our capital spending program.<br>
<b>Unknown Speaker*</b><br>
What's the duration of that facility?<br>
<b>Unknown Speaker*</b><br>
It would terminate in the middle of the year.<br>
I think August is the date on it.<br>
<b>Unknown Speaker*</b><br>
Sure.<br>
Okay, great, thanks for much.<br>
<b>Unknown Speaker*</b><br>
Thanks Mark.<br>
<b>Unknown Speaker*</b><br>
And your right not with Scotia Capital.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>29</i><br>
<hr>
<A name=30></a><IMG src="010912_0-30_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
Good morning as Katherine Sarah.<br>
Just two questions.<br>
To clarify the loan facility -- when the transaction closes, you'll use the $25 million working capital funding in part to repay that facility?<br>
<b>Unknown Speaker*</b><br>
Yes, but there is $24 million cash and SilverBirch right now.<br>
We will also have proceeds from exercise of options, which we estimate up to now will be about $22 million to SilverBirch.<br>
That actually in the time period between on closing by our calculations, gives us sufficient cash to meet current obligations and the first three<br>months of drilling and 2012. So by closing, SilverBirch as working capital will be essentially zero.<br>
And the $25 million that will be contributed by Teck will go into Silver Willow.<br>
As Wayne said, the $20 million loan provides us the flexibility because obviously the proceeds from the exercise of options will only come at closing,<br>and so if there is a shortfall on cash just due to timing reasons, because drilling programs tend to be quite financially intense and spend a lot of<br>money in a hurry, and the bills come in very quickly.<br>
We are just assuming that there may be a cash shortfall and that is really what the loan will be used for.<br>
So in theory by closing, we should have most of the $25 million in tax once we start with Silver Willow.<br>
<b>Unknown Speaker*</b><br>
That makes sense, thank you.<br>
And just a question on the timing.<br>
Silver Willow is being listed, do you expect that it's listing will be collected in with the closing of the transaction?<br>
Or is it possible we might see the arrangement close and then a few weeks later Silver Willow start to trade ?<br>
<b>Unknown Speaker*</b><br>
I will turn onto Gina.<br>
<b>Unknown Speaker*</b><br>
Sure.<br>
Our hope is that we will start listing our coins that with the closing so we would close one day and start trading at Silver Willow been asked.<br>
That is what we are working towards.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>30</i><br>
<hr>
<A name=31></a><IMG src="010912_0-31_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
Okay, and that will be on the venture exchange?<br>
<b>Unknown Speaker*</b><br>
Yes, that's where we are applying to.<br>
<b>Unknown Speaker*</b><br>
That's great, congratulations on the transaction.<br>
<b>Unknown Speaker*</b><br>
Thank you.<br>
<b>Unknown Speaker*</b><br>
(Operator Instructions) John Tumazos very independent research.<br>
<b>Unknown Speaker*</b><br>
I have three questions if you are so patient.<br>
Are the twin Lakes areas an area that was contemplated potentially as a gift to the -- for environmental Park and recreation area?<br>
<b>Unknown Speaker*</b><br>
That's an interesting idea.<br>
There's been discussion of that kind of thing from time to time, that nothing ever followed up on. I think there is actually -- if you look at it John,<br>all the SilverBirch and Teck hot on our was the oil sands leases.<br>
We don't have any of the -- but how Teck will make use of this land obviously is a question for Teck.<br>
<b>Unknown Speaker*</b><br>
Is an area I recall in the class -- past relatively close to the river that have a set a potential use, they may confuse it with another --.<br>
<b>Unknown Speaker*</b><br>
Yes, we didn't have anything else close to the river that I can recall.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>31</i><br>
<hr>
<A name=32></a><IMG src="010912_0-32_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
Could you update us on the lease for 20 one area?<br>
I didn't seem to cut which of the two companies would go to. Is it already sold to Imperial Uber<br>
<b>Unknown Speaker*</b><br>
Our interest or UTS interest was arty sold to Imperial Teck, that would be an question for Teck what's going on with their interest in 421.<br>
<b>Unknown Speaker*</b><br>
The -- a pair cash and cut the waiting as the 435 cash plus the $25 million working capital or 460 decided by 1.4 barrels or $.33 per barrel.<br>
And that is less than the two dollar apparent price at the time at a lower oil price.<br>
So at -- sold to -- admittedly it's not apples and oranges, because the degree of engineering and -- construction isn't the same.<br>
But could you talk to the sixfold difference in valuation?<br>
And why you are embracing selling frontier Equinox at 1/6 of the term or even if you made an adjustment for the difference in phase, one third of<br>the terms.<br>
<b>Unknown Speaker*</b><br>
Yes.<br>
I think that one is one we could certainly respond to. If you look, the number we use is about $.34 a barrel.<br>
I agree with your Thai collation, we come to the number slightly different see but it is $0.34 a barrel.<br>
If you think of frontier and Equinox as -- stage, we don't have any regulatory approval at this pace, at this point.<br>
We have literally just amended the application or a least Teck had at the end of the year last year.<br>
And where is Fort Hills had regulatory approval in place by the time we exited that project eight years, and two point and $2.8 billion had been<br>spent by the partners.<br>
In addition, UTS had an earnings rates, and there is additional value in Fort Hills from the earning.<br>
When you compare the metrics, it is quite a different transaction.<br>
Also keep in mind that frontier and Equinox will not commence production until about 2020 or 21. And the issue that was facing SilverBirch the<br>even prior to sanction, the partnership would have to spend $300 million-$500 million just to get to --. That's over the next three or four years.<br>
And we recognize that for us, that would be quite dilutive with the equity we would raise, the quite dilutive for SilverBirch shareholders and the<br>offer from a made by Teck seem to be quite fair and quite reasonable and that was why we made the decision to proceed.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>32</i><br>
<hr>
<A name=33></a><IMG src="010912_0-33_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
If I could be so tedious with one more question.<br>
The calculation of $0.34 per barrel is only the cash consideration.<br>
There is the much more difficult question of value in the in situ asset or in situ potential assets.<br>
That Teck is what they with you in addition to the cash consideration.<br>
Did you assess only the cat -- cash consideration and avoided a bit loose in or did you assign value to the in situ assets were the documentation<br>and the potential recovery rates, the existence of the bitumen and recover ability of the bitumen require a greater standard of documentation.<br>
They are deeper into.<br>
<b>Unknown Speaker*</b><br>
Of course the potential value of the lands played into our consideration.<br>
Because obviously we are quite optimistic about the potential of both our debt -- Audette and Birch Mountain's.<br>
As far as formally assigning value, we basically for our own the collation just use the book value which provides quite a modest amount of value.<br>
I believe by closing book value and the various properties will be about $90 million.<br>
A little over one dollar and 80 $1.80 per share for the book value going into Silver Willow.<br>
Obviously held the market values that we will get to see in the next few days, but it was in a calculation from the point of view of establishing total<br>value but as far as the metrics we have referenced, we have only referenced the cash component.<br>
<b>Unknown Speaker*</b><br>
Thank you Howard.<br>
It sounds like there were a lot of considerations that were hard to put an exact value of pod.<br>
<b>Unknown Speaker*</b><br>
Yes, thank you for your questions John.<br>
<b>Unknown Speaker*</b><br>
To give.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>33</i><br>
<hr>
<A name=34></a><IMG src="010912_0-34_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
Mike Dunn with FirstEnergy Capital.<br>
<b>Unknown Speaker*</b><br>
Good morning everyone.<br>
First question is just a follow-up on your comments about the book value of the asset and Silver Willow.<br>
Is that $90 million Howard, outside the $25 million in working capital to a<br>
<b>Unknown Speaker*</b><br>
Yes, that's right, that excludes the working capital.<br>
<b>Unknown Speaker*</b><br>
Great.<br>
<b>Unknown Speaker*</b><br>
And Mike, it's a bit approximately.<br>
Some of that working capital -- some of that book value is dependent on what we spend at our debt -- Audette in the first three months and<br>notionally cut off at the end of March what we have spent on Audette the continent book value got collation.<br>
<b>Unknown Speaker*</b><br>
I see.<br>
Great.<br>
I'm not sure what you can comment on, but you mentioned potential he other recovery techniques that Audette should the capital not prove<br>sufficient.<br>
Can you talk about what you are think there?<br>
<b>Unknown Speaker*</b><br>
The way we're looking at right now and we've got a bit of modeling work going on with an engineering Company that should be completed<br>sometime in the next two or three months.<br>
Is we are looking at it as a conventional -- and I think as we mentioned in previous calls, that we did have -- we did find some pretty extensive<br>occurrences of what we believe will be a sold will -- suitable caprock material.<br>
While we don't know is how extensive.<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>34</i><br>
<hr>
<A name=35></a><IMG src="010912_0-35_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
Our opening position is if we can -- caprock materials existence of a big enough area and the modeling and the taxpaying and the many frac test<br>showed sufficient for conventional -- I wouldn't call it will pressure, sort of a moderate pressure site B., that's basically a conventional approach,<br>and so that if we find that that would necessarily be technically feasible, we would look at other -- related approaches maybe was solid assist or<br>low pressure -- as is being dried out and the other places and then a further fallback would be some of the new techniques that some of the other<br>coming seven talking about, some of the electrical or other solid assist type tactics.<br>
But focus for Audette will be on dimensional -- as the first days.<br>
<b>Unknown Speaker*</b><br>
Great.<br>
Have you been in touch with the regulator, whether current thinking is about caprock and I'm not sure if there is any -- if they are getting any more<br>stringent with regards to testing over the past couple of years.<br>
Maybe comment on that?<br>
<b>Unknown Speaker*</b><br>
Yes, certainly the engineering consultants that we have worked with have been involved with a number of the recent applications.<br>
And of course, our other advisor has been involved in a number of applications.<br>
So are reasonably aware on the consultants of the regulatory requirements, we recognize that there is a bit of a work in progress, how that will<br>evolve over the next 12 to 24 months.<br>
But we are certainly taking an approach that is relatively conservative as we consider what the operating pressures would be as we do in the current<br>modeling.<br>
And it goes to current modeling is really just an early scope things that he does to try and understand what the potential will be, there will be<br>further rounds of engineering once we have the many frac test, the rest of the data from the geotechnical program and more resource data.<br>
<b>Unknown Speaker*</b><br>
Great, thanks Howard, thanks guys.<br>
<b>Unknown Speaker*</b><br>
Thanks Mike.<br>
<b>Unknown Speaker*</b><br>
Mr. Stevens there no further questions at this time.<br>
Please continue.<br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>35</i><br>
<hr>
<A name=36></a><IMG src="010912_0-36_1.jpg"><br>
PRELIMINARY<br>
JANUARY 09, 2012 / 2:00PM, SBE.V - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Unknown Speaker*</b><br>
This concludes the conference call for today.<br>
Thank you for participating.<br>
Please disconnect your lines.<br>
(End of Transcript)<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4703300-2012-01-09T14:43:04.847</b><br>
17<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>36</i><br>
<hr>
<A name=37></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
MRW.L - WM MORRISON<br>SUPERMARKETS P L C CHRISTMAS<br>TRADING UPDATE CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 9:00AM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>37</i><br>
<hr>
<A name=38></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Dalton Philips</b><i> Morrison Supermarkets Plc - CEO</i><br>
<b>Richard Pennycook</b><i> Morrison Supermarkets Plc - CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Jonathan Pritchard</b><i> Oriel Securities - Analyst</i><br>
<b>Jaime Vazquez</b><i> Santander - Analyst</i><br>
<b>Clive Black</b><i> Shore Capital - Analyst</i><br>
<b>Niamh McSherry</b><i> Berenberg Bank - Analyst</i><br>
<b>Sam Hart</b><i> Charles Stanley - Analyst</i><br>
<b>Matthew Truman</b><i> JPMorgan - Analyst</i><br>
<b>Alastair Johnston</b><i> Citi - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Welcome to the Morrison post-Christmas sales update conference call. (Operator Instructions). Later we will conduct a question and answer session.<br>Please note that this conference is being recorded.<br>
I will now turn the call over to your host, CEO Dalton Philips. Sir, you may begin.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Thank you and good morning, everybody. Sorry we're starting a little bit late. The lines are incredibly busy so we're just trying to get most people<br>in, although there's still a large number trying to get in; but I'm going to start anyway.<br>
So joining on this call this morning is Richard Pennycook, and we're going to be talking about the pre-close trading update for the six weeks to<br>January 1.<br>
Today we'll focus solely on our sales performance over the Christmas period, so hopefully this will be a fairly straightforward call. At our prelims in<br>March we'll update you on our progress with our various initiatives and outline our plans for the future.<br>
As you will have seen from the release, we traded well during a tough Christmas period. A record 800,000 additional customers shopped with us<br>each week this Christmas, with our sales over Christmas now over 40% higher than they were just five years ago.<br>
Before taking your questions, let me set the scene. You will recall that when we started this year, we expected 2011 to be challenging. It certainly<br>turned out that way, and Christmas has been no exception.<br>
Consumer confidence continues to be very low. For December, the GfK NOP reading dipped to minus 33. And let me remind you that in the 37<br>years the index has been running it, it has only been lower on two occasions, a single month in 1990, and eight months during the trough of the<br>2008/2009 recession.<br>
Against this backdrop, we are pleased to have delivered sales in line with the market. And most importantly, we provided our customers with the<br>high quality food at the value prices they needed this Christmas.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>38</i><br>
<hr>
<A name=39></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
There were some notable sales patterns this year which were indicative of the market conditions. We saw Christmas coming later. Clearly, it always<br>falls on the 25th, but we have seen the percentage of sales in the final seven days rise by more than one-quarter over the last two years.<br>
As customers shop later, we also saw them take advantage of our fresh offer for their traditional favorites.There was a 3% swing from frozen turkey<br>to fresh turkey, with an overall 9% growth in the number of whole fresh turkeys sold.<br>
So overall, we were pleased to achieve a good like-for-like sales uplift over the Christmas period. We've a strong program already in place for<br>January, including our free shopping campaign and the introduction of our new M Savers range. And as you will have seen, we are on track to<br>deliver our full-year profit expectations.<br>
I'm also pleased to say that we're making good progress on our strategic initiatives, and we'll be talking about that in a couple of months' time at<br>our prelims.<br>
So now let's move to your questions. Operator?<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
Thank you. We will now begin the question and answer session. (Operator Instructions). Jonathan Pritchard, Oriel Securities.<br>
<b>Jonathan Pritchard</b><i> - Oriel Securities - Analyst</i><br>
A couple from me, if I may. Firstly on inflation, could you just give us a clue as to how that moved in the period; whether that came down a little<br>bit?<br>
And secondly, not necessarily just for Morrison but for the sector, for the industry as a whole, what would a realistic level of like-for-like growth be<br>to expect for 2012 do you think?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Good morning. It's Richard. I'll take those. We don't, as you know, break out inflation specifically, but we've talked about the fact that in the run-in<br>to Christmas, it was still pretty stubborn. It was around -- what we saw though was a very promotional Christmas with some record weeks in terms<br>of promotional participation helping just to take the edge off those inflationary pressures for the customer.<br>
As far as 2012 is concerned, a bit like the conversation we had this time last year.We're expecting overall market growth levels to be pretty subdued,<br>and that's how we're planning our business.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
And Jonathan, just to add some color on that, you obviously saw the petrol prices coming down. We've started to see some movements there in<br>proteins produce. And, obviously, non-food was very deflationary over the Christmas period.<br>
<b>Jonathan Pritchard</b><i> - Oriel Securities - Analyst</i><br>
Okay. Thank you very much.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>39</i><br>
<hr>
<A name=40></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Operator</b><br>
Jaime Vazquez, Santander.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
I missed the first minute, so apologies if this has been mentioned, but can you confirm that you will reach your 600,000 square feet opening program<br>this year?<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
It's Dalton. We will. We'll confirm that.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
Okay. Secondly, can you also confirm that you will reach GBP500 million of buybacks by March?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Jaime, it's Richard.We're well on track with the program. It's GBP1 billion over the two years. And in terms of the momentum on the program, we're<br>back in the market again today with that. We remain very comfortable to get that done over the two years to March '13.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
I thought that in the third quarter trading statement call, you not only commented to GBP1 billion in two years, but to [have GBP1 billion] by March.<br>Should we forget about the second part of the commitment?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
No, we'll keep the momentum going. But precisely where we land at March obviously we'll tell you on the day. Volumes in the market have been<br>very low in our share shares. We can only go at a sensible pace to run the program, but we're committed to getting it done.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
Okay. And finally, there's an article in the FT today suggesting that you're interested in 11 Best Buy sites in retail parks. Can you make a comment,<br>or at least say whether you are looking at it?<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
I'm afraid we can't comment specifically on that speculation.What we can do, Jaime, which we said actually before Christmas, is that we're ambitious<br>for Kiddicare. We can see real growth in that business. We like it very much. And if there's an opportunity out there to accelerate that growth, we<br>will take it. But I can't comment on specific situations.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>40</i><br>
<hr>
<A name=41></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
So in principle, you are not against the idea of expanding non-food in stores, in specialized stores.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
I think I've been quite vocal on this issue that we just don't see non-food being sold in bricks and mortar, certainly not in food stores. I think Kiddicare<br>is a very different proposition, and we've got a large store down in Peterborough. It's one of the largest kids' stores in all of Europe. It's quite a tactile<br>purchase. It's an emotional purchase. [You need to think about it because this is expensive.<br>
So Kiddicare is a great example of multi-channel. People go to the store, think about it, go home, buy it online. And so it's a proposition; think IKEA,<br>think Apple; that lends itself well to having a very small number of physical outlets, but I can't comment on the Best Buy, obviously. But Scott<br>Weavers-Wright was quite vocal about it before Christmas saying this is a business that can grow. And we're very ambitious for it. We've spent<br>[GBP70 million] on it, and we're going to grow this thing.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
Okay, that's very clear. Thanks very much.<br>
<b>Operator</b><br>
Clive Black, Shore Capital.<br>
<b>Clive Black</b><i> - Shore Capital - Analyst</i><br>
A couple from me. Could you give us some color to your description of sharp prices within the industry, and how you see the pricing environment<br>year on year going into 2012, or in 2012?<br>
And could you also confirm whether you had positive or negative like-for-like volumes in the six-week period, please?<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Okay, Clive. We are very comfortable with our value proposition, and we have had very sharp pricing all year.You'll remember we started with Fuel<br>Britannia about this time last year, and then into Price Crunch, so we've always had sharp pricing. It's a market that has a lot of sharp pricing in it,<br>none more so than Christmas which was extremely competitive, and we see that competitive cut and thrust continuing into this year that's coming.<br>
So no change there, and that's why if you're not on the right price you're not going to do well. And it's also how we've seen customers shop. And<br>I'll give you a good example; people trading our champagne into sparkling wine. That's an example of people trading into joints of protein, like<br>pork, for example, out of more expensive protein. So that sort of thing.<br>
And in terms of volume, you know we don't break it out, but you've had low like for likes. And the market in general has had negative volumes, so<br>you can draw your own conclusions.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>41</i><br>
<hr>
<A name=42></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Clive Black</b><i> - Shore Capital - Analyst</i><br>
And just in terms of that trading environment, pricing environment, would you say that the Tesco Big Price Drop initiative where they're seeking<br>to seemingly lower promotional activity for price, and Asda's pricing activity has particularly led to any switching, or share loss for you? It looks like<br>Asda has had a very strong festive trading period.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Well, you've got to play tunes at Christmas, Clive, and our job, Richard and I and the rest of the team here, our job is to chart a course which is smart<br>sales. And that's what we've been focused on this Christmas.We've had a solid performance. If you look at our like for like on transactions, customer<br>count is up nearly 5%, 4.8%.<br>
So obviously, we were watching what was going on with our competitors, but we are maintaining our full-year guidance. We've had a cracking<br>year. We've been growing strongly all year, and we had to trade through Christmas and anticipate what was coming at us, and deal with that.<br>
<b>Clive Black</b><i> - Shore Capital - Analyst</i><br>
Okay. Thanks for that, and all the best for the New Year.<br>
<b>Operator</b><br>
Niamh McSherry, Berenberg Bank.<br>
<b>Niamh McSherry</b><i> - Berenberg Bank - Analyst</i><br>
Independent of Kiddicare, could you update us on your plans for launching non-food online in 2012?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Hi, it's Richard. We really would rather do that at the prelims in March. This is just a sales update, so forgive us. That said, the plans that we've talked<br>about before are very much on track, but we'll give the detail for that in March.<br>
<b>Niamh McSherry</b><i> - Berenberg Bank - Analyst</i><br>
Okay, thanks.<br>
<b>Operator</b><br>
Sam Hart, Charles Stanley.<br>
<b>Sam Hart</b><i> - Charles Stanley - Analyst</i><br>
I was wondering if you could just comment on whether or not you're seeing any major differences in trading conditions by region, please.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>42</i><br>
<hr>
<A name=43></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Sam, I think in terms of the Christmas context, we would say it's similar to what we've been talking about through the rest of the year. So for us as<br>we look at the business, we've got growth everywhere. It's a little bit stronger in the south, but not an order of magnitude different.<br>
<b>Sam Hart</b><i> - Charles Stanley - Analyst</i><br>
Is there any particular reason why you think trading is holding up in the north? A lot of the anecdotal evidence seems to suggest that the north is<br>being -- well, suffering more in the current economic environment.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
I think for us, it's about offering those great deals, that great value. It's clearly very important in areas of country that are particularly challenged in<br>terms of the household budget, and that's where through 2011 I think we've shown real success in having that very strong focus on value.<br>
<b>Sam Hart</b><i> - Charles Stanley - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
(Operator Instructions). Matthew Truman, JPMorgan.<br>
<b>Matthew Truman</b><i> - JPMorgan - Analyst</i><br>
Just two from me. Firstly, can you just give us a rough idea of the entry rate versus the exit rate for the like for like?<br>
And secondly, as fuel is now coming off, are you seeing the spend return to in-store? Clearly, one of the arguments last year was that fuel was so<br>high that the like for like in total was good and you would hope to see that return in store. But looking at the industry slowdown, it doesn't appear<br>that that's the case. Can you just give us an idea of the kind of trend you're seeing in terms of the customer? Are they just stopping the buying<br>process in total in store and not replicating that exchange back as you maybe have hoped? More of an industry question.<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Matt, let me take the entry/exit point. Forgive me, but I'm not going to get into that level of detail.This trading update is the six weeks of Christmas,<br>which is a relatively short time span anyway. But the other point I'd make, which you're well aware of, is the trading patterns change greatly because<br>of Christmas falling on the Sunday and we're, all of us, up against some weather effects from the previous year. So when you look at those individual<br>trading patterns around the period, it really is very difficult to unpick and I'd suggest that there's limited upside in trying to do that.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
And on the fuel, Matt, we would expect some of that to start coming back in. As you know, fuel is literally a fixed cost, and with prices starting to<br>drop, we'd like to see some of that coming through. Not seeing that at the moment. I think people are up to their eyes now with carrying debts<br>over from Christmas, so I don't think you're going to see much of that until February, if you do see it at all.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>43</i><br>
<hr>
<A name=44></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Matthew Truman</b><i> - JPMorgan - Analyst</i><br>
Okay. That's great. Thank you.<br>
<b>Operator</b><br>
Alastair Johnston, Citigroup.<br>
<b>Alastair Johnston</b><i> - Citi - Analyst</i><br>
Sorry, I was very late on this call, so you may have already answered this, but just a very quick question. Can you just specify if there were any specific<br>calendar effects and whether they're positive or negative during the period?<br>
You mentioned in reply to Matt's question regarding Christmas falling on the Sunday. If you could just talk through the calendar effects, that would<br>be very helpful.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Al, you certainly didn't miss that point. We just addressed it briefly in the context of Matt's question as well. Christmas came very late because of<br>that big shopping opportunity on the Saturday before Christmas, so I suspect that will be a theme of comments that you hear over the next week<br>or two. But in a way, you'd expect that because of that Saturday shopping opportunity that people had.<br>
<b>Alastair Johnston</b><i> - Citi - Analyst</i><br>
But it doesn't change the overall level of sales year on year for the Christmas period. It just shifts it around within the Christmas period. Is that<br>correct or --?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Correct.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Yes, that's the expectation. We obviously, all of us, wait to see market stats. We had some out on Friday from Nielsen, but the fact that they were<br>just up to the 24th itself, with an extra trading day in the numbers they were talking about, I don't think allows anybody really to get under the skin<br>of it. We've got Kantar tomorrow, and I guess everyone will look at that with interest.<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
I think what you might have missed on the beginning there, Al, was this point that I made that the last seven days saw a marked uplift in the amount<br>of sales falling into that seven days if you compare it to previous years. So it was up 25% on two years ago, the amount that fell in those last seven<br>days. Now clearly, part of that is Christmas on a Sunday, but not all of it, and it just shows the extent to which people were holding off, holding off,<br>holding off and then spending at the last moment.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>44</i><br>
<hr>
<A name=45></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Alastair Johnston</b><i> - Citi - Analyst</i><br>
Okay. Brilliant. Thank you very much.<br>
<b>Operator</b><br>
There are no further questions at this time.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Okay. Thank you very much for all joining the call. Sorry that we got off a little bit late. As I said, that was the quantity of calls coming in. And we<br>look forward to speaking to you in March. Thank you.<br>
<b>Operator</b><br>
I'm sorry, Dalton, there's one more question. I don't know whether you want to take it.<br>
Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4692215-2012-01-09T13:33:05.140</b><br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>45</i><br>
<hr>
<A name=46></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
MRW.L - WM MORRISON<br>SUPERMARKETS P L C CHRISTMAS<br>TRADING UPDATE CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 9:00AM GMT<br>
OVERVIEW:<br>
MRW.L provided pre-close update for the Christmas period, six weeks to 01/01/12.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>46</i><br>
<hr>
<A name=47></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Dalton Philips</b><i> Morrison Supermarkets Plc - CEO</i><br>
<b>Richard Pennycook</b><i> Morrison Supermarkets Plc - CFO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Jonathan Pritchard</b><i> Oriel Securities - Analyst</i><br>
<b>Jaime Vazquez</b><i> Santander - Analyst</i><br>
<b>Clive Black</b><i> Shore Capital - Analyst</i><br>
<b>Niamh McSherry</b><i> Berenberg Bank - Analyst</i><br>
<b>Sam Hart</b><i> Charles Stanley - Analyst</i><br>
<b>Matthew Truman</b><i> JPMorgan - Analyst</i><br>
<b>Alastair Johnston</b><i> Citi - Analyst</i><br>
<b>OVERVIEW</b><br>
MRW.L provided pre-close update for the Christmas period, six weeks to 01/01/12.<br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. PRE-CLOSE TRADING UPDATE (D.P.)</b><br>
<b>A. Highlights (Six Weeks to 01/01/12):</b><br>
<b>1. </b>Traded well during tough Christmas period.<br>
<b>a. </b>Record 800,000 additional customers shopped with Co. each week this Christmas.<br><b>b. </b>Sales [over] Christmas now 40% higher than five years ago.<br>
<b>2. </b>Expected 2011 to be challenging.<br>
<b>a. </b>It turned out that way and Christmas has been no exception.<br>
<b>3. </b>Consumer confidence continues to be low.<br>
<b>a. </b>For Dec., GfK NOP reading dipped to negative 33.<br><b>b. </b>In 37 years, index has been low on two occasions.<br>
<b>i. </b>Single month in 1990.<br>
<b>ii. </b>Eight months during trough of 2008-2009 recession.<br>
<b>c. </b>Against this backdrop, delivered sales in line with market.<br>
<b>4. </b>Some notable sales patterns this year; indicative of market conditions.<br><b>5. </b>Saw Christmas coming later.<br>
<b>a. </b>Always falls on 25th.<br><b>b. </b>Percentage of sales in final seven days rose by more than 25% over last two years.<br>
<b>c. </b>As customers shopped later, also saw them take advantage of fresh offer for their traditional favorites.<br>
<b>d. </b>3% swing from frozen turkey to fresh turkey.<br><b>e. </b>Overall 9% growth in number of whole fresh turkeys sold.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>47</i><br>
<hr>
<A name=48></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>6. </b>Achieved good like-for-like sales uplift over Christmas period.<br><b>7. </b>Has strong program already in place for Jan., including:<br>
<b>a. </b>Free shopping campaign.<br><b>b. </b>Introduction of new M Savers range.<br>
<b>8. </b>On track to deliver full-year profit expectations.<br><b>9. </b>Making good progress on strategic initiatives.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
Thank you. We will now begin the question and answer session. (Operator Instructions). Jonathan Pritchard, Oriel Securities.<br>
<b>Jonathan Pritchard</b><i> - Oriel Securities - Analyst</i><br>
A couple from me, if I may. Firstly on inflation, could you just give us a clue as to how that moved in the period; whether that came<br>down a little bit?<br>
And secondly, not necessarily just for Morrison but for the sector, for the industry as a whole, what would a realistic level of like-for-like<br>growth be to expect for 2012 do you think?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Good morning. It's Richard. I'll take those. We don't, as you know, break out inflation specifically, but we've talked about the fact that<br>in the run-in to Christmas, it was still pretty stubborn. It was around -- what we saw though was a very promotional Christmas with<br>some record weeks in terms of promotional participation helping just to take the edge off those inflationary pressures for the<br>customer.<br>
As far as 2012 is concerned, a bit like the conversation we had this time last year. We're expecting overall market growth levels to<br>be pretty subdued, and that's how we're planning our business.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
And Jonathan, just to add some color on that, you obviously saw the petrol prices coming down.We've started to see some movements<br>there in proteins produce. And, obviously, non-food was very deflationary over the Christmas period.<br>
<b>Jonathan Pritchard</b><i> - Oriel Securities - Analyst</i><br>
Okay. Thank you very much.<br>
<b>Operator</b><br>
Jaime Vazquez, Santander.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>48</i><br>
<hr>
<A name=49></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
I missed the first minute, so apologies if this has been mentioned, but can you confirm that you will reach your 600,000 square feet<br>opening program this year?<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
It's Dalton. We will. We'll confirm that.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
Okay. Secondly, can you also confirm that you will reach GBP500 million of buybacks by March?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Jaime, it's Richard. We're well on track with the program. It's GBP1 billion over the two years. And in terms of the momentum on the<br>program, we're back in the market again today with that. We remain very comfortable to get that done over the two years to March<br>'13.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
I thought that in the third quarter trading statement call, you not only commented to GBP1 billion in two years, but to [have GBP1<br>billion] by March. Should we forget about the second part of the commitment?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
No, we'll keep the momentum going. But precisely where we land at March obviously we'll tell you on the day.Volumes in the market<br>have been very low in our share shares. We can only go at a sensible pace to run the program, but we're committed to getting it<br>done.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
Okay. And finally, there's an article in the FT today suggesting that you're interested in 11 Best Buy sites in retail parks. Can you make<br>a comment, or at least say whether you are looking at it?<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
I'm afraid we can't comment specifically on that speculation.What we can do, Jaime, which we said actually before Christmas, is that<br>we're ambitious for Kiddicare. We can see real growth in that business. We like it very much. And if there's an opportunity out there<br>to accelerate that growth, we will take it. But I can't comment on specific situations.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
So in principle, you are not against the idea of expanding non-food in stores, in specialized stores.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>49</i><br>
<hr>
<A name=50></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
I think I've been quite vocal on this issue that we just don't see non-food being sold in bricks and mortar, certainly not in food stores.<br>I think Kiddicare is a very different proposition, and we've got a large store down in Peterborough. It's one of the largest kids' stores<br>in all of Europe. It's quite a tactile purchase. It's an emotional purchase. [You need to think about it because this is expensive.<br>
So Kiddicare is a great example of multi-channel. People go to the store, think about it, go home, buy it online. And so it's a proposition;<br>think IKEA, think Apple; that lends itself well to having a very small number of physical outlets, but I can't comment on the Best Buy,<br>obviously. But Scott Weavers-Wright was quite vocal about it before Christmas saying this is a business that can grow. And we're<br>very ambitious for it. We've spent [GBP70 million] on it, and we're going to grow this thing.<br>
<b>Jaime Vazquez</b><i> - Santander - Analyst</i><br>
Okay, that's very clear. Thanks very much.<br>
<b>Operator</b><br>
Clive Black, Shore Capital.<br>
<b>Clive Black</b><i> - Shore Capital - Analyst</i><br>
A couple from me. Could you give us some color to your description of sharp prices within the industry, and how you see the pricing<br>environment year on year going into 2012, or in 2012?<br>
And could you also confirm whether you had positive or negative like-for-like volumes in the six-week period, please?<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Okay, Clive. We are very comfortable with our value proposition, and we have had very sharp pricing all year. You'll remember we<br>started with Fuel Britannia about this time last year, and then into Price Crunch, so we've always had sharp pricing. It's a market that<br>has a lot of sharp pricing in it, none more so than Christmas which was extremely competitive, and we see that competitive cut and<br>thrust continuing into this year that's coming.<br>
So no change there, and that's why if you're not on the right price you're not going to do well. And it's also how we've seen customers<br>shop. And I'll give you a good example; people trading our champagne into sparkling wine. That's an example of people trading<br>into joints of protein, like pork, for example, out of more expensive protein. So that sort of thing.<br>
And in terms of volume, you know we don't break it out, but you've had low like for likes. And the market in general has had negative<br>volumes, so you can draw your own conclusions.<br>
<b>Clive Black</b><i> - Shore Capital - Analyst</i><br>
And just in terms of that trading environment, pricing environment, would you say that the Tesco Big Price Drop initiative where<br>they're seeking to seemingly lower promotional activity for price, and Asda's pricing activity has particularly led to any switching, or<br>share loss for you? It looks like Asda has had a very strong festive trading period.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>50</i><br>
<hr>
<A name=51></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Well, you've got to play tunes at Christmas, Clive, and our job, Richard and I and the rest of the team here, our job is to chart a course<br>which is smart sales. And that's what we've been focused on this Christmas. We've had a solid performance. If you look at our like<br>for like on transactions, customer count is up nearly 5%, 4.8%.<br>
So obviously, we were watching what was going on with our competitors, but we are maintaining our full-year guidance. We've had<br>a cracking year. We've been growing strongly all year, and we had to trade through Christmas and anticipate what was coming at<br>us, and deal with that.<br>
<b>Clive Black</b><i> - Shore Capital - Analyst</i><br>
Okay. Thanks for that, and all the best for the New Year.<br>
<b>Operator</b><br>
Niamh McSherry, Berenberg Bank.<br>
<b>Niamh McSherry</b><i> - Berenberg Bank - Analyst</i><br>
Independent of Kiddicare, could you update us on your plans for launching non-food online in 2012?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Hi, it's Richard. We really would rather do that at the prelims in March. This is just a sales update, so forgive us. That said, the plans<br>that we've talked about before are very much on track, but we'll give the detail for that in March.<br>
<b>Niamh McSherry</b><i> - Berenberg Bank - Analyst</i><br>
Okay, thanks.<br>
<b>Operator</b><br>
Sam Hart, Charles Stanley.<br>
<b>Sam Hart</b><i> - Charles Stanley - Analyst</i><br>
I was wondering if you could just comment on whether or not you're seeing any major differences in trading conditions by region,<br>please.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>51</i><br>
<hr>
<A name=52></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Sam, I think in terms of the Christmas context, we would say it's similar to what we've been talking about through the rest of the<br>year. So for us as we look at the business, we've got growth everywhere. It's a little bit stronger in the south, but not an order of<br>magnitude different.<br>
<b>Sam Hart</b><i> - Charles Stanley - Analyst</i><br>
Is there any particular reason why you think trading is holding up in the north? A lot of the anecdotal evidence seems to suggest<br>that the north is being -- well, suffering more in the current economic environment.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
I think for us, it's about offering those great deals, that great value. It's clearly very important in areas of country that are particularly<br>challenged in terms of the household budget, and that's where through 2011 I think we've shown real success in having that very<br>strong focus on value.<br>
<b>Sam Hart</b><i> - Charles Stanley - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
(Operator Instructions). Matthew Truman, JPMorgan.<br>
<b>Matthew Truman</b><i> - JPMorgan - Analyst</i><br>
Just two from me. Firstly, can you just give us a rough idea of the entry rate versus the exit rate for the like for like?<br>
And secondly, as fuel is now coming off, are you seeing the spend return to in-store? Clearly, one of the arguments last year was that<br>fuel was so high that the like for like in total was good and you would hope to see that return in store. But looking at the industry<br>slowdown, it doesn't appear that that's the case. Can you just give us an idea of the kind of trend you're seeing in terms of the<br>customer? Are they just stopping the buying process in total in store and not replicating that exchange back as you maybe have<br>hoped? More of an industry question.<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Matt, let me take the entry/exit point. Forgive me, but I'm not going to get into that level of detail. This trading update is the six<br>weeks of Christmas, which is a relatively short time span anyway. But the other point I'd make, which you're well aware of, is the<br>trading patterns change greatly because of Christmas falling on the Sunday and we're, all of us, up against some weather effects<br>from the previous year. So when you look at those individual trading patterns around the period, it really is very difficult to unpick<br>and I'd suggest that there's limited upside in trying to do that.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>52</i><br>
<hr>
<A name=53></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
And on the fuel, Matt, we would expect some of that to start coming back in. As you know, fuel is literally a fixed cost, and with prices<br>starting to drop, we'd like to see some of that coming through. Not seeing that at the moment. I think people are up to their eyes<br>now with carrying debts over from Christmas, so I don't think you're going to see much of that until February, if you do see it at all.<br>
<b>Matthew Truman</b><i> - JPMorgan - Analyst</i><br>
Okay. That's great. Thank you.<br>
<b>Operator</b><br>
Alastair Johnston, Citigroup.<br>
<b>Alastair Johnston</b><i> - Citi - Analyst</i><br>
Sorry, I was very late on this call, so you may have already answered this, but just a very quick question. Can you just specify if there<br>were any specific calendar effects and whether they're positive or negative during the period?<br>
You mentioned in reply to Matt's question regarding Christmas falling on the Sunday. If you could just talk through the calendar<br>effects, that would be very helpful.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Al, you certainly didn't miss that point. We just addressed it briefly in the context of Matt's question as well. Christmas came very<br>late because of that big shopping opportunity on the Saturday before Christmas, so I suspect that will be a theme of comments that<br>you hear over the next week or two. But in a way, you'd expect that because of that Saturday shopping opportunity that people had.<br>
<b>Alastair Johnston</b><i> - Citi - Analyst</i><br>
But it doesn't change the overall level of sales year on year for the Christmas period. It just shifts it around within the Christmas<br>period. Is that correct or --?<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
Correct.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Yes, that's the expectation. We obviously, all of us, wait to see market stats. We had some out on Friday from Nielsen, but the fact<br>that they were just up to the 24th itself, with an extra trading day in the numbers they were talking about, I don't think allows anybody<br>really to get under the skin of it. We've got Kantar tomorrow, and I guess everyone will look at that with interest.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>53</i><br>
<hr>
<A name=54></a>JANUARY 09, 2012 / 9:00AM, MRW.L - Wm Morrison Supermarkets P L C Christmas Trading Update Conference<br>Call<br>
<b>Richard Pennycook</b><i> - Morrison Supermarkets Plc - CFO</i><br>
I think what you might have missed on the beginning there, Al, was this point that I made that the last seven days saw a marked<br>uplift in the amount of sales falling into that seven days if you compare it to previous years. So it was up 25% on two years ago, the<br>amount that fell in those last seven days. Now clearly, part of that is Christmas on a Sunday, but not all of it, and it just shows the<br>extent to which people were holding off, holding off, holding off and then spending at the last moment.<br>
<b>Alastair Johnston</b><i> - Citi - Analyst</i><br>
Okay. Brilliant. Thank you very much.<br>
<b>Operator</b><br>
There are no further questions at this time.<br>
<b>Dalton Philips</b><i> - Morrison Supermarkets Plc - CEO</i><br>
Okay.Thank you very much for all joining the call. Sorry that we got off a little bit late. As I said, that was the quantity of calls coming<br>in. And we look forward to speaking to you in March. Thank you.<br>
<b>Operator</b><br>
I'm sorry, Dalton, there's one more question. I don't know whether you want to take it.<br>
Thank you, ladies and gentlemen. This concludes today's conference. Thank you for participating. You may now disconnect.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4692215-1-2012-01-09T14:34:24.397</b><br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>54</i><br>
<hr>
<A name=55></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
AUGT.OB - Q3 2012 AUGME<br>TECHNOLOGIES INC EARNINGS<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 4:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>55</i><br>
<hr>
<A name=56></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Stephanie Prince</b><i> Lippert/Heilshorn &amp; Associates, Inc. - IR</i><br>
<b>Paul Arena</b><i> Augme Technologies, Inc. - Chairman, CEO</i><br>
<b>Tom Virgin</b><i> Augme Technologies, Inc. - CFO</i><br>
<b>Eric Harber</b><i> Augme Technologies, Inc. - COO</i><br>
<b>Ivan Braiker</b><i> Augme Technologies, Inc. - President</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Ken Nagy</b><i> Zacks Investment Research, Inc. - Analyst</i><br>
<b>Robert Coolbrith </b><i>ThinkEquity LLC - Analyst</i><br>
<b>Todd Mitchell</b><i> Brean Murray, Carret &amp; Co. - Analyst</i><br>
<b>Darren Aftahi</b><i> Northland Securities - Analyst</i><br>
<b>Art Asad</b><i> Argasell USA - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Welcome to the Augme Technologies third-quarter fiscal 2012 earnings conference call. (Operator Instructions). As a reminder, this conference is<br>being recorded January 9, 2012. I would now like to turn the conference over to Stephanie Prince. Please go ahead.<br>
<b>Stephanie Prince</b><i> - Lippert/Heilshorn &amp; Associates, Inc. - IR</i><br>
Thank you, Christy, and welcome, everyone, to the Augme Technologies third-quarter fiscal 2012 earnings conference call for the third quarter<br>ended November 30, 2011. With me today are Paul Arena, Chief Executive Officer; Ivan Braiker, President; Eric Harber, Chief Operating Officer; and<br>Tom Virgin, Chief Financial Officer.<br>
After Paul's opening remarks and Tom's financial review, we will open the call up to your questions. In order to allow everyone the opportunity to<br>ask a question, we are asking that you limit yourself to one question and one follow-up.<br>
To access the webcast, please visit our website at www.augme.com.<br>
Please note that the information presented and discussed today includes forward-looking statements which are made under the Safe Harbor<br>provisions of the Private Securities Litigation Reform Act of 1995. Actual results in future periods may differ materially and you should not attribute<br>uncertainty to our forward-looking statements. Risks and uncertainties that could cause our actual results to differ from those expressed or implied<br>by forward-looking statements include those set forth in the Risk Factors section of the Annual Report on Form 10-K that we filed on May 13, 2011.<br>
In addition, our comments may contain certain non-GAAP financial measures, including non-GAAP operating loss per share. For additional<br>information, including the reconciliation from GAAP results to non-GAAP measures, how the non-GAAP measures provide useful information, and<br>why we use non-GAAP measures, please see the reconciliation statements section of our press release, which appears on our website at<br>www.augme.com.<br>
I would now like to urn the call over to Paul Arena. Paul?<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>56</i><br>
<hr>
<A name=57></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
Thank you, Stephanie. Good morning, everyone, and thank you for joining us on today's call.This morning I will open the call with comments about<br>our third-quarter performance and give you an update on our patent litigation cases and then turn the call over to Tom Virgin, Augme's CFO, for<br>a financial review of the quarterly results. We'll then open up the call for questions. I will ask Ivan, Eric, and Tom to address questions with me.<br>
This has been a very exciting quarter for Augme. Our combination of Augme, Hipcricket and JAGTAG has resulted in a very strong company and<br>high recognition in the mobile marketplace. We have a great team in place and that experience is drawing business to us from brands, retailers<br>and agencies.<br>
We have completed a combined industry-leading 150,000 mobile campaigns since 2004. Approximately one-third of these were done during<br>calendar 2011 alone. We signed a record $6.4 million in new contracts during November and December, over $3.7 million in December alone. We<br>have currently signed a backlog of over $15 million. That momentum has continued into the new calendar year.<br>
We began this year servicing more than 50 brands and have increased to approximately 300 brands as of last quarter. We currently service 15<br>industry verticals.<br>
Our gross margin has increased from 58% in the third quarter of 2011 to 68% in the third quarter of 2012.<br>
Our revenue per client was approximately $110,000 on an annualized basis in the third quarter versus approximately $50,000 annualized in the<br>beginning of this fiscal year. This is over 100% increase in the last nine months.<br>
We powered nearly 16,000 campaigns in the quarter. During the quarter, we executed 136 new contracts, which breaks down as follows -- 22% or<br>30 new customers, 57% or 78 up-sells to existing customers, 21% or 28 license renewals to existing customers. Our customer retention rate is<br>approximately 95%, one of the highest in the mobile marketing space.<br>
Our recurring revenues are approximately 60%. We are really excited about the Yahoo! court date coming up in the next year. We are very pleased<br>that we picked up the best IP team of Goodwin Procter. We've never deviated that our IP is a very valuable.<br>
Looking forward, we have a lot of momentum generating bigger revenues from our clients. We are really excited to have completed a successful<br>integration with Hipcricket and JAGTAG and now have a fully integrated sales team, selling exclusively under the Hipcricket brand in the marketplace.<br>
We are a premier end-to-end mobile marketing and advertising company in the United States. We have done more mobile marketing campaigns<br>than any of our competitors.We have a higher CECTM, effective cost per thousand, and produced a more robust post-click engagement with higher<br>margins to it. In the past 18 months, we have grown from 15 employees to now over 140 employees in eight locations across the United States,<br>nearly a tenfold increase.<br>
We are excited about our business and we've never been in a stronger position. We've accomplished a lot in a short period.<br>
The $20 million capital raise that we recently completed fully funds us to execute our growth plans and reach profitability. Today, the company is<br>buzzing with activity and energy. We are one company selling under the Hipcricket brand name. We are growing our business and hitting our<br>goals.<br>
We completed the combination of the sales force and client service organizations under Doug Stovall, who held that same position at Hipcricket<br>where he led the company's 225% revenue growth over an 18-month period. We have combined the customer-facing functionality of the Augme<br>and Hipcricket software as a service technology platforms into a unified horizontal platform named Hipcricket AD LIFE.This best-of-breed platform<br>currently serves 15 verticals, including CPG, pharma health, retail, automotive, quick-service restaurants, financial broadcast media and entertainment,<br>to name a few. The combination of the two platforms has resulted in a clearly differentiated offering and provides our clients with best practices<br>in the industry. This has created efficiencies for them by the platform's ability to scale with their needs and speed their time to market.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>57</i><br>
<hr>
<A name=58></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
Our platform is powered by proprietary patented technology, together with our portfolio of IP assets create significant barriers to entry.<br>
Hipcricket has received much industry recognition lately. Frost and Sullivan named Hipcricket the preferred provider of high-impact mobile<br>marketing solutions in the United States as part of its customer value enhancement award for 2011. Frost and Sullivan went on to say that the<br>combination of Augme calls us an industry powerhouse. Recently, a mobile marketer named Hipcricket the Mobile Service Provider of the Year.<br>These awards are recognition for our unmatched service offerings in the domain expertise.<br>
I want to take a moment to explain to you how our business model has changed and a result of these acquisitions. Both Augme and Hipcricket<br>sold services under SaaS licenses. Now, approximately 60% of our revenue is derived from recurring payments under contracts with a term of one<br>year or more. Augme, with its expertise in the mobile health and mobilized Web assets, tended to have more project-based revenue and paid close<br>attention to revenue per campaign.<br>
Hipcricket's revenue was more heavily weighted toward long-term recurring revenue and monitored revenue per customer. The way we're set up<br>today, some customers create and manage our campaigns autonomously, often by integrating Hipcricket AD LIFE platform into the CRM system.<br>We also provide managed services along with a SaaS license for those customers to ask our client services to collaborate with them.These services<br>could include the creation, design, execution, and measurement of the results of their mobile campaigns. As customers become more comfortable<br>with mobile marketing and the ability to create and manage their campaigns on their own AD LIFE platform, we expect the self service model to<br>account for an increasing portion of license revenue. Today, self-service is approaching 10% of revenue.<br>
With the addition of Hipcricket, we now have a larger mix of longer-term contracts ranging from 1 to 3 years. Our strategy is to drive longer-term<br>contracts for all of our products and services.<br>
Going forward, our focus will be on acquiring new customers as well as growing revenue per customer. The expectation is that we will penetrate<br>deeper into the brand portfolios of our existing customers as they use more and more of our products and services. We expect this to result in an<br>increase in the size and duration of the contracts.<br>
I'll now turn to an overview of our quarterly performance. Revenue for the third quarter was $4.4 million, an increase of 244% sequentially. The<br>gross margin was 68% compared to last year's third quarter of 58%. New order bookings or the dollar value of contracts signed during the quarter<br>totaled $5.3 million.<br>
The backlog or the dollar value of signed contracts was $13.1 million as of November 30, 2011. Backlog is over $15 million today.Tom will give you<br>more details in a few minutes.<br>
Our customer base continues to grow with customer retention around 95%. In the third quarter, we added 30 new customers in large relationships<br>with 78 existing customers. We have over 50 of the Fortune 500 companies and work with approximately 300 brands.<br>
For competitive reasons, many of our customers do not want us to disclose what we do for them. We do, however count as customers 10 of the<br>world's top 20 pharmaceutical companies, six of the largest media companies in the world, four of the largest advertising companies in the world,<br>three of the leading quick-service restaurant companies in the world, and one of the largest food companies in the world.We are very pleased that<br>our customer Macy's was awarded Mobile Marketer of the Year by Mobile Marketer.<br>
We have succeeded in cross-selling products and services to Augme and its client. Our revenue guidance for fiscal 2012 which ends February 29,<br>2012, was approximately $13 million. We are confident that we're on the cusp of rapidly scaling revenue and will achieve positive cash flow during<br>fiscal 2013. Our pro forma trailing 12 months revenues alone was over $12 million at November 30. We intend to invest a portion of the capital we<br>raise enhancing our capabilities, balancing near-term and longer-term opportunities to drive revenue growth. We are bringing on additional sales<br>people and will continue to invest in our technology platforms.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>58</i><br>
<hr>
<A name=59></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
Another priority is to build out our enterprise OEM channel to ensure that we are properly staffed in this important area.These partnerships, Oracle<br>being one example, will expand our sales reach and facilitate high margin revenue generation. And we will continue to invest in our intellectual<br>property portfolio.<br>
We view our intellectual property portfolio as a critical component of Augme's overall business model. Our IP is foundational in the area of mobile<br>and Internet marketing technology, including content targeting, device detection and advanced analytic systems. We intend to continue to<br>vigorously defend our portfolio.We're making good progress with our partners at Goodwin Procter on litigation front and ipCapital on the licensing<br>strategies.<br>
In conjunction with ipCapital Group, we've developed a data-driven strategy for further targeted invention and accelerated IP development in<br>calendar 2012. This includes a prototype database of hundreds of new Augme invention concepts.<br>
Augme's internal IP developments, the activities of which are complemented by ongoing external patent acquisitions like those we acquired with<br>JAGTAG, the JAGTAG acquisition expanded our patent portfolio to seven patents with over 150 issued claims and 21 pending applications with<br>over 1500 patents, pending claim.<br>
This includes three additional patents that have been filed in the last two weeks.<br>
Some of the recent developments on the IP front include, last Friday, Judge Spiro set the Yahoo! case to proceed to trial on January 7, 2013. This<br>was an event that we have been long awaiting. The US District Court of New York reactivated Augme's patented and trademark infringement case<br>against AOL, Time Warner and Platform A in December. The pretrial conference has been rescheduled for February 1.<br>
We're now waiting for the judge's response to our opposition brief regarding the AOL Dakota case. Last week the US patent office granted Augme's<br>request for re-examination of Yahoo!'s patent in question. This is meaningful because we believe our patent predates Yahoo!'s.<br>
We believe that our IP portfolio, which is available for licensing, is key to commercial protection of our proprietary technology and to solidifying<br>our market position. I'd now like to turn the call over to Tom Virgin for a review of the third-quarter financial results.<br>
<b>Tom Virgin</b><i> - Augme Technologies, Inc. - CFO</i><br>
Thank you, Paul. Hi, everyone.<br>
I'll start by discussing the results for third quarter of fiscal 2012.<br>
For the third quarter which ended November 30, 2011, we reported revenue of $4.4 million, an increase of approximately 418% compared to<br>revenue of $854,000 for the third fiscal quarter last year and an increase of 244% compared to revenue of $1.3 million for the second fiscal quarter<br>this year, which ended August 31, 2011.<br>
The increase in overall revenue resulted primarily from the combined revenues of Augme, Hipcricket, and JAGTAG.These acquisitions closed during<br>second quarter, Hipcricket on August 25, right at the end of the quarter, and Jagtag on July 22.<br>
Also contributing to revenue growth was increased spending by existing customers and from adding new customers.To give investors and analysts<br>insight into our revenue mix, starting this quarter, we will give you a breakdown of revenue into three components. These three are software as a<br>service revenue; mobile advertising solutions revenue; and the third category is other licensed mobile products. The third category includes<br>nonrecurring revenue, such as development work for marketing campaigns and shorter-term licenses.<br>
For the third quarter, 60% of our revenue came from SaaS licenses, followed by 20% from mobile advertising solutions and 20% in the other<br>category.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>59</i><br>
<hr>
<A name=60></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
Bookings, including new order and renewals for the quarter, totaled $5.3 million. We are defining bookings as the dollar value of contracts signed.<br>For the quarter of approximately 22% of our bookings were to new customers; 57% were new sales to existing customers; and 21% were license<br>renewals.<br>
We ended the quarter with a backlog of signed contracts of $13.2 million. $2.7 million of this $13.2 million represents revenues that we expect to<br>recognize in fourth quarter and $7 million that we expect to recognize in our fiscal 2013.<br>
Cost of sales were $1.4 million for the quarter compared to $361,000 for the same period last year and $412,000 for the second quarter of the fiscal<br>year. The increase in cost of sales reflects the higher volume of revenues.<br>
Gross profit, which is revenue minus cost of sales, increased 515% to $3 million. Gross margin of 68% of revenue for the third quarter of our fiscal<br>2012 versus gross profit of $492,000 or 58% of revenue for the third quarter of November 30, 2010. Now this compares with $875,000 or 68% of<br>revenue for the second quarter of fiscal 2012.<br>
The increased margin over the third quarter of last year reflects the current mix of business and cost efficiencies.<br>
Selling, general and administrative expenses increased 299% to $11.3 million for the third quarter versus SG&amp;A expenses of $2.8 million for the<br>third quarter of this fiscal 2011, and compared to an increase of 68% from $6.8 million for the second quarter of fiscal 2012.<br>
SG&amp;A includes expenses for payroll, accounting, professional services, consulting fees, patent research costs and the non-cash cost of stock options<br>and warrants.<br>
During the third quarter, we incurred some one-time expenses related to the acquisitions. These included nonrecurring transaction expenses,<br>primarily professional fees, and transition and consolidation expenses. As part of the integration of the three companies into one, we moved and<br>consolidated operations in both Seattle and New York and we recorded some severance expenses. We expect these integration expenses to taper<br>off during the current fourth fiscal quarter, after which we expect normalized SG&amp;A, including non-cash charges, to run around $7.5 million per<br>quarter based on current staffing levels.<br>
Having said that, we expect to continue to invest selectively in sales, OEM channel management and engineering to enhance our products and<br>services during fiscal 2013.<br>
Before turning to non-cash stock expense, I want to touch on the 8-K we filed on December 29 pertaining to restating financial statements from<br>prior periods.<br>
We're in the process of filing these restatements. One of the issues relates to accounting for stock options and warrants. We incorrectly recognized<br>warrant expense used in the contractual term of the warrant rather than the in the vesting or service period. A substantial number of warrants<br>issued were fully vested upon issuance.<br>
Also, for warrants issued in connection with equity financings or issued in connection with the issuance of common stock, the company incorrectly<br>recognized foreign expense during the period instead of classifying the amount as an adjustment to paving capital.<br>
On stock options, we used an expected life that was inconsistent with historical experience and expectations, that did not adjust to related expense<br>for expected forfeitures. As a result, we are restating fiscal years for 2011 and 2010, or as of this year. The results of the restatement overall will be<br>a reduction of non-cash G&amp;A expense.<br>
We are also correcting the accounting for the acquisitions of Hipcricket and JAGTAG. The primary result of the restatement was an increase to<br>goodwill and an increase to contingent liabilities to reflect the fair value of the contingent consideration related to the potential earn out for<br>Hipcricket's shareholders and employees. This resulted in a $23.3 million increase to assets and the same increase to liabilities.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>60</i><br>
<hr>
<A name=61></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
We also capitalized acquisition-related transaction costs for the Hipcricket and JAGTAG business acquisitions which should have been expensed<br>as incurred. These changes result in an additional transaction expense of approximately $700,000.<br>
Turning back to the third quarter income statement, non-cash stock option warrant expense which is included in SG&amp;A totaled $2.7 million for the<br>quarter compared with $615,000 in the same period last year. Last quarter, these non-cash expenses totaled $2 million.<br>
We recorded a net loss of $10.5 million or $0.12 per share for the quarter compared to a net loss of $2.6 million or $0.04 per share for the same<br>period last year, and a net loss of $6.2 million or $0.09 per share for the second quarter. Besides the non-cash charges for warrants and stock options<br>of $2.7 million for the quarter, we had approximately $1 million of non-cash expense related to the continued consideration and approximately<br>$1 million in one-time costs related to the integration of the companies.<br>
As of November 30, 2011, the company's cash balance was $16.9 million.We brought in $19.5 million from the secondary offering and from proceeds<br>from the exercise of stock options.We invested approximately $800,000 in patent defense costs.We used $1 million to pay off the note to Hipcricket<br>and spent $4.2 million on operations. All of these factors resulted in an increase in cash of approximately $14 million.<br>
I'll now turn the call back over to Paul.<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
Thanks, Tom. In closing, mobile marketing is moving up the adoption curve, as evidenced by the fact that the companies are now dedicating a<br>separate line item in the marketing advertising budgets to mobile. More customers like Miller Coors for one example are spending on and committing<br>to multi-year, multimillion dollar contracts. We believe that with our superior patented technology, industry recognition, reputation for quality,<br>reliability, and mobile marketing and advertising expertise, we are ideally suited to take full advantage of the rapid growth of the mobile marketing<br>and advertising industry. I'd now like to open up the call for questions. Operator, please?<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions). Ken Nagy, Zacks Investment.<br>
<b>Ken Nagy</b><i> - Zacks Investment Research, Inc. - Analyst</i><br>
Just curious what the goal for self-service is eventually? Will it be 50% of revenues? Did you say it was 10% now? Will it eventually be 100% or just<br>if you could speak on that?<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
Yes, thanks, Ken, for joining us. I think it's going to continue to grow as we scale the business and we open up larger multichannel forms of distribution<br>with some of the ERP companies, for example, and others that we are discussing with.<br>
<b>Ken Nagy</b><i> - Zacks Investment Research, Inc. - Analyst</i><br>
Great. So is the idea for -- it's just to be completely self-service at some point in the future?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>61</i><br>
<hr>
<A name=62></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
I don't think we'll ever be completely self-service, no. We are going to continue to build the business the way we have it today, but to the extent<br>we can shift some of our SG&amp;A away from the business and revenue share with others, that certainly is a great business model.<br>
<b>Operator</b><br>
Robert Coolbrith, ThinkEquity.<br>
<b>Robert Coolbrith</b><i> - ThinkEquity LLC - Analyst</i><br>
Good morning. Just wanted to ask a couple of quick questions.Thank you for all the segment detail that you provided. Just wondering if you might<br>be able to address growth by segment given that we didn't have the reporting previously. And, in line with that, just wondering if you could maybe<br>give some thoughts on which parts of the business are growing more rapidly, which parts of the business are relatively more profitable from a<br>gross margin perspective, and what if any movement that would imply in terms of gross margin going up or staying the same over the next few<br>quarters? Then also just wanted to make sure I heard correctly that the normalized expense levels or SG&amp;A going forward is that -- did you say $7.5<br>million per quarter? Thank you.<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
All right, thanks, Rob. I'm going to turn that over to Tom Virgin, if you would, Tom.<br>
<b>Tom Virgin</b><i> - Augme Technologies, Inc. - CFO</i><br>
Yes, thanks for the question, Rob. The margins vary a little bit by business at the gross level. It's a little more in sync when you get down to the net<br>margin I think.<br>
We've experienced, if you've looked kind of back on the Hipcricket and Augme combined, this mobile advertising network business is growing<br>pretty rapidly for us and so we're investing in that.<br>
The gross margin on that's a little bit lower, although as Paul mentioned, the ECTM on that being higher for us than some of the competitors<br>because of some of the back-end things we do with mobile marketing -- or mobile advertising and post-click engagement. So, we get a little bit<br>better margin on that, but it's not as good as the margins on the rest of the business. But at the bottom line, it is a pretty cost-effective business.<br>So that we expect to grow a little bit more rapidly. The margins for the rest of the business are pretty similar on this.<br>
<b>Robert Coolbrith</b><i> - ThinkEquity LLC - Analyst</i><br>
Okay. So just wondering maybe if you could -- just a quick follow-up in terms of maybe how many -- what percentage of the customer base you<br>think have you really sort of gone around to selling the new mobile ad network solution or the relatively new mobile ad network solution? How<br>far along do you think you are in terms of sort of the cross sell opportunity there?<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
Eric, do you want to address that? I think that's under you.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>62</i><br>
<hr>
<A name=63></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
<b>Eric Harber</b><i> - Augme Technologies, Inc. - COO</i><br>
Sure, I can do that. Thanks for the question. So we're in the early stages now. We see -- we've seen good demand by customers across the different<br>verticals for that particular product, but we are just getting started as it relates to growing that penetration through our product base.<br>
<b>Operator</b><br>
Todd Mitchell, Brean Murray Carret.<br>
<b>Todd Mitchell</b><i> - Brean Murray, Carret &amp; Co. - Analyst</i><br>
(technical difficulty) previously. Do those targets change now that -- with the Hipcricket also being part of the SaaS model? And if I look at the --<br>have you gotten any traction I guess on the AD LIFE side? And is any of your backlog included in that business?<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
Hey, Todd, thanks for joining us. You kind of cut out there in the beginning of your question. I'm not sure why. Do you remind repeating that? I'm<br>sorry.<br>
<b>Todd Mitchell</b><i> - Brean Murray, Carret &amp; Co. - Analyst</i><br>
Yes, sure. I also want to ask about the new segmentation. In terms of the SaaS licensing, it looks like you are re-segmenting because Hipcricket --<br>an element of their businesses -- is SaaS licensing. And I wanted to know, at this point are you -- do you have any -- you have not made any<br>announcements in terms of licensing the AD LIFE platform. Are the targets for that still on track, and do they change now that the merger has<br>occurred? And also do you -- would you put that business in your backlog and is there anything in your backlog really that's that?<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
Okay, so, yes; I would answer that Hipcricket was further along on some of the self-service-type SaaS revenues than what Augme has been previously.<br>However, we're in the process of discussions with a number of large companies right now for distribution. In fact, I happen to be at an Oracle<br>conference out in Scottsdale as we speak.<br>
We're going to continue to build our initiatives in that area. And we think it's a very scalable, profitable piece of the business in the future. But right<br>-- for now we're making an investment in hiring additional sales and additional client services personnel because we are seeing a dramatic growth.<br>We did $3.7 million in new contract business just in the last month alone, which I think is indicative of the strength of the revenues that are starting<br>to come in. Ivan, would you have anything to add to that?<br>
<b>Ivan Braiker</b><i> - Augme Technologies, Inc. - President</i><br>
I think that basically that we're -- mobile is in such a state of growth on all fronts and our ability to penetrate that is really better than it has ever<br>been. So I think you're going to see that as Tom and Paul have outlined already, every one of these categories are going to grow and they're going<br>to grow rapidly.<br>
And you see what's going on in the mobile ad space, and our ability to gain traction there, we are very optimistic on the kind of percentages that<br>that's going to get. The SaaS model itself is growing.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>63</i><br>
<hr>
<A name=64></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
And I don't know that you mentioned, Paul, that we literally just hired a stellar guy that is helping to lead their charge on the enterprise level of<br>what we're doing. And we feel very confident that that's going to start gaining some good traction even though it's a brand-new vertical for us.<br>With what he brings to the table along with Paul driving that, we are very optimistic of the kind of numbers we're going to hit.<br>
<b>Todd Mitchell</b><i> - Brean Murray, Carret &amp; Co. - Analyst</i><br>
Great. Thank you.<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
Thanks, Todd.<br>
<b>Operator</b><br>
Darren Aftahi, Northland Capital Management.<br>
<b>Darren Aftahi</b><i> - Northland Securities - Analyst</i><br>
Just two quick ones. Based on your OpEx number of $7.5 million kind of going forward, is there any kind of be any variation to gross margin? Or if<br>I do kind of back-of-the-envelope math, does that assume an $11 million quarterly run rate and revenue to get to break even? I guess is my math<br>right on that?<br>
And then my second question would be, on your Yahoo! trial date, I know Yahoo! had counter claimed against you. Are these two cases consolidated,<br>or is there a separate date for that case as well? Or is anything has anything been moved along on that secondary part of the case? Thanks.<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
All right; thanks, Darren. I'm going to address the cash burn and then sort of back into the first part of your question because I know that the net<br>loss of $10.5 million is a big number for last quarter. However, I want to point out that $2.7 million of that was non-cash option warrant expense<br>related, approximately $1.3 million from professional fees and about $1 million of restructure charges related to the transactions from prior quarters.<br>Did really about -- if you back out that $5 million of nonrecurring expense, approximately $5.5 million of operational net loss.<br>
We're starting to see that dissipate. We're currently at about $3.5 million, $4 million burn as we speak. The revenues are increasing faster than the<br>expenses, however. And I would say our quarterly break-even is probably closer to $8.5 million, $9 million at the moment.<br>
On the Yahoo! counterclaims that -- that is going to be tried separately. There has not yet been a scheduling order set forth that's going back<br>through review with the US PTO, patent trademark office, at the moment and, so whereas they -- US PTO had granted Yahoo!'s request to review<br>their claims, they also granted our request to review their claims. They had questioned one of our patents. I think we questioned four of theirs. So,<br>that's something that is not going to stay the case if that's the question.<br>
<b>Darren Aftahi</b><i> - Northland Securities - Analyst</i><br>
No, that's helpful. So just to be clear, the day of the 7th next year is effectively Augme versus the Yahoo!, if you will?<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>64</i><br>
<hr>
<A name=65></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
Correct. And that's a solid date.<br>
<b>Operator</b><br>
(Operator Instructions). [Art Asad], [Argasell USA].<br>
<b>Art Asad</b><i> - Argasell USA - Analyst</i><br>
Yes, this question backs up a little on that last person's question on the Yahoo! countersuit. That was the first time I had heard that and I was just<br>wondering, from Augme's perspective, is there any merit in that Yahoo! countersuit against Augme?<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
No, we don't believe so, Art. This is Paul. I've looked at it very carefully, and in fact, we believe that we have claims that predate Yahoo's claims in<br>sufficient grounds that would negate those claims altogether. We'll see how it shakes out eventually, but, we feel very confident that those are not<br>going to be a problem for us.<br>
<b>Art Asad</b><i> - Argasell USA - Analyst</i><br>
When I read that, Paul, it came to me as kind of a childish play that all of a sudden Yahoo! is getting the realization that we are -- we've set a court<br>date and it's coming to a realization that we are going to strengthen our position on the patents with them. But (multiple speakers)<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
That's exactly right, Art. In fact, we look at it at the same way is that they are going to strengthen our position, so, we welcomed it.<br>
<b>Art Asad</b><i> - Argasell USA - Analyst</i><br>
Okay. Okay, well that's all I wanted. Keep doing a great job, Paul.You're running the company very well, and I'm personally very pleased to see that.<br>And Jason and I have talked about it, we're really proud that you're at the helm of the company.<br>
<b>Paul Arena</b><i> - Augme Technologies, Inc. - Chairman, CEO</i><br>
I appreciate it, Art. And thank you for all your patience and support and confidence. We've made a lot of progress and we are going to continue to<br>make progress, and we're very excited about the prospects of the business going forward.<br>
If there's no further questions at this time, I'm going to go on ahead and conclude the call. Thank you for everyone for joining us. And we look<br>forward to future success together. Thank you.<br>
<b>Operator</b><br>
Ladies and gentlemen, that concludes your conference call for today. We thank you for your participation and ask that you please disconnect your<br>line.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>65</i><br>
<hr>
<A name=66></a>JANUARY 09, 2012 / 4:00PM, AUGT.OB - Q3 2012 Augme Technologies Inc Earnings Conference Call<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4691390-2012-01-09T17:39:57.420</b><br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>66</i><br>
<hr>
<A name=67></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
PNY - Q4 2011 PIEDMONT NATURAL<br>GAS EARNINGS CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 04, 2012 / 3:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>67</i><br>
<hr>
<A name=68></a>JANUARY 04, 2012 / 3:00PM, PNY - Q4 2011 Piedmont Natural Gas Earnings Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Nick Giaimo</b><i> Piedmont Natural Gas - IR</i><br>
<b>Tom Skains</b><i> Piedmont Natural Gas - Chairman, President, CEO</i><br>
<b>Karl Newlin</b><i> Piedmont Natural Gas - SVP, CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Dan Fidell</b><i> US Capitol Advisors - Analyst</i><br>
<b>Jim Lykins</b><i> Hilliard Lyons - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Good day, and welcome to the Piedmont Natural Gas year-end 2011 conference call. Today's conference is being recorded. At this time, I would<br>like to turn the conference over to Mr. Nick Giaimo. Please go ahead, sir.<br>
<b>Nick Giaimo</b><i> - Piedmont Natural Gas - IR</i><br>
Thank you, Jennifer. Good morning, everyone, and thank you for joining the Piedmont Natural Gas year-end 2011 earnings conference call.<br>
This call is open to the general public and is being webcast live over the Internet. If you would like to access the webcast of this call or view the<br>slides of the accompanying presentation, please visit our website at PiedmontNG.com and choose the for investors link. On the right-hand side of<br>that page, you will find the appropriate links.<br>
On the call today presenting prepared remarks, we have Tom Skains, President, Chairman, and Chief Executive Officer; and Karl Newlin, Senior Vice<br>President and Chief Financial Officer. Other officers of the Company are also in attendance to take your questions.<br>
During the prepared remarks and in the accompanying presentation, references are made to certain non-GAAP items. A reconciliation to GAAP is<br>available at the end of the presentation.<br>
And finally, this call may include forward-looking statements and our actual results may materially differ from those statements. More information<br>about the risks and uncertainties relating to these forward-looking statements may be found in Piedmont's 2011 Form 10-K filed with the SEC on<br>December 23. And with that, I will turn the call over to Tom.<br>
<b>Tom Skains</b><i> - Piedmont Natural Gas - Chairman, President, CEO</i><br>
Thanks, Nick, and good morning, everybody, and thank you for joining us for our year-end 2011 earnings conference call. I know many of you are<br>just getting back into the office after the holidays, and we appreciate you taking the time to be with us today.<br>
As you know, we filed our 2011 10-K and issued our year-end earnings release on December 23. This morning, I'm going to begin on slide two and<br>talk about our 2011 accomplishments and provide you with a general update on the Company. Then I'll turn it over to Karl to give a more detailed<br>discussion of our 2011 financial results and our 2012 guidance.<br>
I'm extremely proud of our team's accomplishments in 2011. During another year of continuing economic challenges, we were able to deliver net<br>income of $114 million and diluted earnings per share of $1.57, towards the upper end of our guidance range. While the housing market has<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>68</i><br>
<hr>
<A name=69></a>JANUARY 04, 2012 / 3:00PM, PNY - Q4 2011 Piedmont Natural Gas Earnings Conference Call<br>
remained stagnant, we added over 10,500 customers to our distribution system, more than 20% of which came from residential conversions to<br>clean, affordable, natural gas.<br>
We also completed two of our power generation delivery projects during the fiscal year at Duke's Buck's facility and Progress's Richmond facility.<br>And in early fiscal 2012, we completed a third project at Duke's Dan River facility.<br>
Our remaining two large projects are for Progress's Wayne County and Sutton plants, both of which remain on their respective June 2012 and June<br>2013 delivery schedules. I'll speak to those projects in greater detail in just a moment.<br>
Last September, we filed a general rate case in Tennessee for the first time since 2003. Our filing requested a revenue increase of $16.7 million,<br>based upon a return on equity of 11.25% and an equity capital structure component of 52.7%. In addition, we proposed to alter our rate design to<br>increase the fixed component of our cost recovery.<br>
Last month, we entered into a settlement of the case with the Attorney General's Consumer Advocate Office that would increase revenues by $11.9<br>million at an ROE of 10.2% with an equity capital component of 52.7%. Of course, this settlement is subject to approval by the Tennessee regulatory<br>authority, and we cannot predict the outcome of their deliberations. But a hearing in the case has been set for January 23, and our new rates will<br>become effective on March 1.<br>
During the year, we also refinanced $200 million of long-term debt at lower rates, which will translate to annual savings of $4.3 million.<br>
And finally, our Board once again demonstrated its confidence in the Company by raising our quarterly dividend in 2011 for the 33rd consecutive<br>year.<br>
Slide three shows our 2011 earnings of $114 million, which were 2% higher than the 2010 level when you exclude the one-time gain associated<br>with the 2010 sale of half our ownership stake in SouthStar. Higher margin was offset somewhat by increased O&amp;M expense, higher depreciation<br>expense, higher general taxes, and lower contributions from SouthStar. I will let Karl speak to these items in more detail in just a moment.<br>
On slide four, we've highlighted our gross customer additions for the year. While new customer additions were slightly lower than last year, we're<br>pleased to have added 10,522 customers in this economic environment, a gross growth rate of more than 1%.<br>
We're also encouraged by the year-over-year improvement in residential conversions and commercial additions. Interestingly, on a net basis at<br>year-end, our actual customers billed were 11,522 customers higher in 2011 than 2010. A lower and more stable wholesale commodity cost of gas<br>has benefited our customer acquisition efforts.<br>
Included in the commercial additions are 28 new industrial customers added during 2011 that contributed approximately $0.01 to earnings per<br>share. Our throughput to our industrial customers was up 10% in 2011 and our throughput to power generation customers was up 33%. We are<br>again forecasting a gross customer addition growth rate of about 1% in 2012.<br>
Moving to slide five, we continued to make good strides on our two largest projects, Progress's Wayne County and Sutton projects.We've completed<br>all design work for both. We have received all pipe deliveries for Wayne and are currently receiving pipe deliveries for Sutton.<br>
In addition, the construction bid process is complete for both projects, and construction for Wayne County is currently underway, while construction<br>for Sutton should begin in May or June.<br>
You will notice that we made a slight adjustment to our power generation CapEx schedule for 2012, compared to our guidance release in November.<br>But this is just a timing adjustment, and both projects remain well on track for their targeted completion dates by June 2012 and June 2013.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>69</i><br>
<hr>
<A name=70></a>JANUARY 04, 2012 / 3:00PM, PNY - Q4 2011 Piedmont Natural Gas Earnings Conference Call<br>
Slide six demonstrates how our consistent financial performance allows us to reward our shareholders. In 2011, our Board raised the dividend for<br>the 33rd consecutive year.We remain committed to long-term shareholder value, and our Board understands the importance of a growing dividend<br>to our shareholders.<br>
Before I turn the call over to Karl, you've probably noticed a press release we issued last month announcing that Victor Gaglio will join our executive<br>management team next month as our new Senior Vice President and Chief Utility Operations Officer. Victor is currently Senior Vice President of<br>Operations with NiSource Gas Transmission &amp; Storage.<br>
He will be replacing Michael Yount, who announced his intention to retire at the end of February. Michael has been a valued member of our team<br>over the last six years and we wish him nothing but the best in his retirement.<br>
Like Michael, Victor has a wealth of experience in utility operations, having over 30 years of experience in natural gas pipeline, compression, and<br>storage operations with NiSource and Columbia Gas Transmission. So while we will miss Michael, we are excited to have someone of Victor's caliber<br>join our team.<br>
With that, I'd now like to turn the call over to our Senior Vice President and Chief Financial Officer, Karl Newlin. Karl?<br>
<b>Karl Newlin</b><i> - Piedmont Natural Gas - SVP, CFO</i><br>
Thank you, Tom, and good morning, everyone.<br>
As Tom mentioned, we had a great year in 2011 with net income of $114 million and diluted earnings per share of $1.57.This was a 2% improvement<br>from last year when you exclude the one-time gain from our sale of a portion of SouthStar in 2010.<br>
As a reminder, a reconciliation to GAAP earnings can be found on the last slide of the presentation.<br>
As for the details of the income statement, let's start with slide seven. Margin of $574 million increased nearly 4% compared to 2010, due to increased<br>volumes and services to industrial and power generation customers, residential and commercial customer growth, net gas cost adjustments and<br>increased wholesale marketing activity.<br>
On the expense side, slide eight, O&amp;M of $225 million was 2.5% higher than last year, due to higher vehicle and transportation expense, a regulatory<br>disallowance of certain Tennessee franchise fees that led to a one-time charge, and higher materials expense.<br>
Slide nine shows depreciation expense of $103 million and general taxes of $38 million, up 4% and 13%, respectively. The increased depreciation<br>was due to growth in utility investment and plant in service. Higher general taxes were a function of the accrual for and payment of sales tax on<br>certain customer accounts, as well as higher property taxes in our jurisdictions.<br>
On slide 10, income from joint ventures was $24 million in 2011, 17% lower than in 2010, due primarily to a lower ownership percentage of SouthStar<br>during the entire fiscal year of 2011. Due to the timing of the sale, the first quarter of 2010 had a 30% ownership in SouthStar, while the first quarter<br>of 2011 represented our current 15% ownership. All other income statement categories tracked along their normal trends.<br>
Finally, on slide 11, we've outlined our 2012 earnings guidance of $1.58 to $1.68 per share that we reaffirmed in our December 23 earnings release.<br>Our guidance range assumes gross customer additions of 1%; the Wayne County project being in service on June 1, 2012; a $3.1 million margin<br>decrease under the South Carolina Rate Stabilization Act, or RSA; and a 9% increase in O&amp;M expense. Capital expenditures are expected to be<br>between $540 million and $600 million, with $240 million to $280 million associated with our power generation delivery projects. $70 million to<br>$80 million will be related to transmission and pipeline integrity expenditures.<br>
On the financing side, we anticipate issuing $300 million of long-term debt during the third quarter. We will also repurchase common shares to<br>offset issuances from our DRIP and other stock-based programs. We do not anticipate the need to issue any equity in 2012.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>70</i><br>
<hr>
<A name=71></a>JANUARY 04, 2012 / 3:00PM, PNY - Q4 2011 Piedmont Natural Gas Earnings Conference Call<br>
With that, I will turn the call back over to Nick.<br>
<b>Nick Giaimo</b><i> - Piedmont Natural Gas - IR</i><br>
Thank you, Karl. Jennifer, we are now ready to open the call to questions.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions). Dan Fidell, US Capital Advisors.<br>
<b>Dan Fidell</b><i> - US Capitol Advisors - Analyst</i><br>
Good morning and Happy New Year to all. Just a couple of questions on my side, I guess.The first, I was wondering if you could talk a little bit about<br>the trends you're seeing from the income from equity investments line, excluding SouthStar.You went into some detail in the presentation material<br>on SouthStar, but just specifically on Pine Needle and Hardy, I noticed Pine Needle's numbers fell down a bit, Hardy's numbers came up a bit. Can<br>you talk just a little bit about what's kind of moving those numbers and where you see things going into the next year?<br>
<b>Karl Newlin</b><i> - Piedmont Natural Gas - SVP, CFO</i><br>
Yes, sure, Dan. It's Karl. Overall, the joint venture has continued to perform very well. You mentioned Pine Needle specifically. It's down about $1<br>million because they had a rate case implemented that reduced their rates at Pine Needle by FERC during our fiscal 2011, and that reduced the<br>pretax net income by about $1 million. I'd expect some CapEx at Pine Needle in future periods. But all that, of course, is baked into our guidance<br>for 2012.<br>
Hardy continues to perform very well, and then I think you know, on the Cardinal side there should be some increase, just given the CapEx and the<br>expansion there to serve the Wayne plant.<br>
<b>Dan Fidell</b><i> - US Capitol Advisors - Analyst</i><br>
Okay, great. Maybe just, then, second question on the O&amp;M guidance for 2012, up 9%. Can you just discuss the drivers for the increase in O&amp;M in<br>the next year?<br>
<b>Karl Newlin</b><i> - Piedmont Natural Gas - SVP, CFO</i><br>
Yes, sure. It's -- O&amp;M is up largely, although not entirely, from nondiscretionary items -- for example, higher pension expense from a lower discount<br>rate is driving our FAS 87 expense, we have higher medical costs due to higher claims in 2011, and we're going to have higher amortization from<br>expected recovery of the deferred Tennessee pension asset. Now that has a revenue offset to it, but in the O&amp;M category, that's a higher expense<br>item.<br>
There was also some other expenses related to the implementation of systems and IT as it relates to pipeline integrity.<br>
I think one way to think about that -- I don't want to get into predicting the individual components of O&amp;M too much, but if you think about the<br>increase of 9%, I think about it as about a third from the benefits category; about 25% from an other category, which would be amortization of the<br>deferred pension expense, etc.; and then about 40% is from an increase in payroll from merit adjustments, etc.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>71</i><br>
<hr>
<A name=72></a>JANUARY 04, 2012 / 3:00PM, PNY - Q4 2011 Piedmont Natural Gas Earnings Conference Call<br>
<b>Dan Fidell</b><i> - US Capitol Advisors - Analyst</i><br>
Terrific, that's very helpful. Thank you. And then, maybe just a last question or two. On the macro level, I don't know if, Tom, this is a sort of a more<br>generalized question. But just specifically in terms of what you see on the docket beyond 2013 for additional regional build projects, if you've got<br>any in queue or anything you can share on that front?<br>
And then, maybe a follow-on question, just talking about how you feel about your current holdings in SouthStar. We've seen recently some other<br>utilities start to divest the small holdings that they have on the marketing side, refocused toward the infrastructure business. Is that something<br>that you guys would consider as well? And sort of where does that stand with AGLR? Do they have an ability to purchase the remaining 15% or is<br>it entirely yours? I guess those are my two macro questions. Thanks very much.<br>
<b>Tom Skains</b><i> - Piedmont Natural Gas - Chairman, President, CEO</i><br>
Okay, good. Good questions. Thank you, Dan. I'll start with SouthStar first.<br>
As you know, we entered into a new amended agreement with AGLR on SouthStar a little over a year ago in connection with the sale of half of our<br>then 30% ownership stake in the marketing company. We have 15% of the ownership in equity currently going forward.<br>
There is no, as you mentioned, additional buyout opportunity for our 15%, so that's a stable investment for us. It's not subject to any right of<br>purchase by our partner.<br>
We like the business. SouthStar performs well. It's a very profitable investment for our shareholders. We're comfortable with that 15% stake and<br>don't have any strategic desires at this point to change that position.<br>
On the macro level, if you look at the fundamentals of the natural gas industry in my 32 years they've never been better.You look at the enormous<br>supply -- domestic supply base in our country driving down wholesale natural gas prices to competitive levels that we haven't seen in a decade,<br>perhaps. It's positioned us very well in the marketplace compared to alternative fuels such as propane and oil.<br>
There's also upward pressure in our regional markets on electricity rates, whereas we've had rate reductions for our services. So we're positioned<br>very well in the marketplace.<br>
We will continue to pursue and exploit all opportunities we have for investment growth in our core utility, to add not only continuing additions in<br>the residential and commercial space, but looking at the larger volume market as well in the industrial sector. I mentioned the success that we had<br>in the industrial market in 2011. We will continue to seek additional opportunities to save industrial customers in our region energy costs that yet<br>provide us an opportunity to make investment and returns on investments to do so.<br>
We will continue to work with the electric utilities in the region as they continue to mature their plans for fleet modernization of power generation<br>facilities to serve their current and forecasted needs. If and to the extent that replacement of existing units or additional growth requires gas-fired<br>facilities, we want to be there to serve them and make investments to make that happen.<br>
One of the areas that we've continued to evaluate and will look at on a continuing basis this year and in the future is our supply diversity strategy<br>to feed our core utility markets.You've seen evidence of that as we have diversified our supply portfolio away from the Gulf Coast into more diverse<br>supply contracts in the -- across the geographic region that serves the East Coast.<br>
As you know, we've previously entered into contracts with Midwestern. We've partnered with NiSource to construct and build the Hardy storage<br>facility that we're also a customer of. We entered into the Pine Needle regional LNG facility many years ago.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>72</i><br>
<hr>
<A name=73></a>JANUARY 04, 2012 / 3:00PM, PNY - Q4 2011 Piedmont Natural Gas Earnings Conference Call<br>
We will continue to look at how we can bring competitive, diverse gas supplies to our markets to benefit our customers, and yet, at the same time,<br>make investments in infrastructure to do that, infrastructure such as pipeline and midstream assets to bring gas supplies into our East Coast markets.<br>So that's a strategy that we will continue to pursue. We think there's an opportunity for us to provide benefits to our customers, but also make<br>additional investment opportunities for (inaudible) benefits at the same time.<br>
<b>Dan Fidell</b><i> - US Capitol Advisors - Analyst</i><br>
I appreciate your comments very much. Thanks, and good luck as you head through -- into 2012.<br>
<b>Operator</b><br>
(Operator Instructions). Jim Lykins, Hilliard Lyons.<br>
<b>Jim Lykins</b><i> - Hilliard Lyons - Analyst</i><br>
Just a -- or first of all, another question on your guidance assumptions. I'm wondering if you can break out what you think the impact would be<br>from Wayne County if that does go into service in early June.<br>
<b>Karl Newlin</b><i> - Piedmont Natural Gas - SVP, CFO</i><br>
This is Karl. We do assume the project goes into service on June 1, and contractually we begin recovery of the cost, as well as a return on the costs<br>per the contract, beginning on June 1. And all that is baked into our guidance assumptions.<br>
<b>Jim Lykins</b><i> - Hilliard Lyons - Analyst</i><br>
But you guys aren't going to disclose what you think the EPS impact would be from Wayne County at this point?<br>
<b>Tom Skains</b><i> - Piedmont Natural Gas - Chairman, President, CEO</i><br>
This is Tom. Need to be careful here because our contract with Progress for these projects are confidential and subject to a nondisclosure agreement.<br>
We had disclosed previously, with their consent, the fact that these are long-term contracts, that they do contain fixed-cost recovery through<br>straight fixed variable rate design.They were subject to approval by the North Carolina Utilities Commission, and for purposes of your assumptions,<br>I would assume that these would be continued core utility investments that generate utility type of regulated returns.<br>
<b>Jim Lykins</b><i> - Hilliard Lyons - Analyst</i><br>
Okay, well, that's helpful. I was also wondering if you could just give us an update on the CNG initiative for fueling stations, just what the thinking<br>is right now and if there's anything that we might see on that front in 2012.<br>
<b>Karl Newlin</b><i> - Piedmont Natural Gas - SVP, CFO</i><br>
Sure, Jim. It's Karl. We continue to prosecute that market, I guess I would call it.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>73</i><br>
<hr>
<A name=74></a>JANUARY 04, 2012 / 3:00PM, PNY - Q4 2011 Piedmont Natural Gas Earnings Conference Call<br>
The way we look at it is essentially we're a fleet operator. We roll about 900 trucks every day, and we are converting a number of our vehicles to be<br>either CNG dedicated or bi-fuel vehicles. And so, we realize the benefits of operating natural gas as a fleet operator and owner ourselves.<br>
When we do that, we build refueling stations at our current resource centers. And to the extent there is excess capacity, we try and market that to<br>commercial fleets in and around our service territory.<br>
I can tell you that the team that we have dedicated to that is working diligently. A lot of it is education in the marketplace, trying to convince people<br>of the benefits of natural gas and how they can use it in their fleets on a daily basis. And so, I think they're getting some traction, but it's very small<br>[effort] at this point.<br>
And I think in terms of any benefits, the greatest benefit to us in the near term, essentially in 2012, will be as a fleet operator burning the natural<br>gas versus more expensive diesel and gasoline.<br>
<b>Operator</b><br>
It appears there are no further questions at this time.<br>
<b>Nick Giaimo</b><i> - Piedmont Natural Gas - IR</i><br>
Thank you, Jennifer. This concludes our year-end 2011 earnings conference call. Thank you all for joining us this morning and Happy New Year.<br>
<b>Operator</b><br>
That concludes today's conference. Thank you for your participation.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4689825-2012-01-09T18:47:23.487</b><br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>74</i><br>
<hr>
<A name=75></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
RPM - Q2 2012 RPM INTERNATIONAL<br>INC EARNINGS CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 3:00PM GMT<br>
OVERVIEW:<br>
RPM reported YTD consolidated net sales of $1.90b, net income attributable to<br>RPM shareholders of $126.7m and EPS of $0.97. 2Q12 consolidated net sales were<br>$916.1m, net income attributable to RPM shareholders was $49.9m and EPS was<br>$0.38. Expects full-year 2012 EPS to be $1.60-1.65.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>75</i><br>
<hr>
<A name=76></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Frank Sullivan</b><i> RPM International Inc. - Chairman and CEO</i><br>
<b>Bob Matejka</b><i> RPM International Inc. - SVP, CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Ivan Marcuse</b><i> Keybanc Capital Markets - Analyst</i><br>
<b>John McNulty</b><i> Credit Suisse - Analyst</i><br>
<b>Saul Ludwig</b><i> Northcoast Research - Analyst</i><br>
<b>Aleksey Yefremov</b><i> BofA Merrill Lynch - Analyst</i><br>
<b>Silke Kueck</b><i> JPMorgan - Analyst</i><br>
<b>Edward Yang</b><i> Oppenheimer &amp; Co. - Analyst</i><br>
<b>Rosemarie Morbelli</b><i> Gabelli &amp; Co. - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Welcome to the RPM International conference call for the fiscal 2012 second quarter. Today's call is being recorded. This call is also being webcast<br>and can be accessed live or replayed on the RPM website at www.rpminc.com. Comments made on this call may include forward-looking statements<br>based on current expectations that involve risks and uncertainties, which could cause actual results to be materially different. For more information<br>on these risks and uncertainties, please review RPM's reports filed with the SEC. During this conference call, references may be made to non-GAAP<br>financial measures. To assist you in understanding these non-GAAP terms, RPM has posted reconciliations for the most directly comparable GAAP<br>financial measures on the RPM website.<br>
Following today's presentation, there will be a question and answer session. (Operator Instructions) Please note that only financial analysts will be<br>permitted to ask questions. At this time, I would like to turn the call over to RPM's chairman and CEO, Mr. Frank Sullivan, for opening remarks. Please<br>go ahead, sir.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Thank you, Jennifer. Happy New Year, and welcome to the RPM International Inc. quarterly conference call for the second quarter ended November<br>30, 2011. As you saw from the earnings release this morning and related to our comments about our second quarter during our October conference<br>call, there are a lot of moving parts in relationship to one-time gains in last year's second quarter and a number of offsetting one-time gains and<br>one-time expenses in this year's second quarter, principally related to investment in acquisition activity. When you strip away the non-operating<br>expense from last year and the various non-operating gains and expenses in this year's second quarter, we believe the right way to look at our<br>results from an ongoing operating basis is the second quarter, where sales grew 10% and net income and earnings per share grew about 9% year<br>over year. From a segment perspective, the non-operating income and expense items principally impacted our corporate expense categories and<br>our industrial segment.<br>
If you strip these non-operating items out, our industrial segment generated a year-over-year second-quarter performance of 10% sales growth<br>and 10% earnings growth, while our consumer segment generated a year-over-year performance of 12% sales growth and a decline in EBIT of 2%.<br>Continuing raw material challenges and the balance of higher cost versus pricing actions resulted in less than desired leverage to the bottom line<br>in our industrial businesses and a decline in profit margins in our consumer businesses.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>76</i><br>
<hr>
<A name=77></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
Our goal in coming out of the recession was a focus on growth in global expansion and we have been aggressively and successfully executing on<br>this strategy. We are picking up market share in the vast majority of both our consumer and industrial businesses, in excess of underlying market<br>growth. In recent months, we are also seeing the first signs of some lessening in significant raw material categories with the sole exception of TiO2,<br>which only really impacts our consumer segment and more specifically, Rust-Oleum. It is important to note that the combination of the non-operating<br>income and non-operating expense items in this year's second quarter almost all relate to our ongoing acquisition activity.<br>
We've increased our investment in Kemrock in India to a level of 23%, allowing us to account for this investment for the first time on an equity<br>basis. With the closing of the FEMA EIFS and coatings business in Germany on January 3, 2012, we have completed more than $160 million of<br>annualized sales from acquisitions during this fiscal year. While these acquisitions have resulted in the expense of significant deal transactions,<br>including on a number of the smaller transaction's broker fees, as well as one-time hits to the cost of goods sold and the relationship to inventory<br>write-ups, all of which are in our industrial segment results, all of these acquisitions will be nicely additive to sales and earnings towards the end<br>of our 2012 fiscal year and for our full 2013 fiscal year.<br>
I would now like to turn the call over to Bob Matejka, RPM's senior vice president and chief financial officer to provide you details on the quarter,<br>after which we'll answer your questions. Bob?<br>
<b>Bob Matejka</b><i> - RPM International Inc. - SVP, CFO</i><br>
Thanks, Frank, and good morning, everyone. We thank you for joining us today. First, I'll review the results of operations and cash flow activities<br>for our fiscal 2012 second quarter, comment briefly on some year-to-date results of operations items, I'll touch upon a few November 30, 2011<br>balance sheet measures and then I'll turn it back to Frank for closing comments before we take your questions. Our fiscal 2012 second-quarter<br>results resulted in a consolidated net sales increase of 10.9% over the prior year to $916.1 million, principally due to volume improvement of 5.1%,<br>price increases of 2.9%, and acquisition growth of 3%.These all were partially offset by unfavorable forex of about 0.1%, almost nonexistent on the<br>forex side.The industrial segment net sales of $641.5 million, which accounted for 70% of net sales, increased 10.1% over last year with acquisition<br>growth of 4.2%, volume increases of 3.2%, price increases of 2.9%; all which were partially offset by unfavorable foreign exchange of about 0.2%.<br>
At the consumer segment, net sales of $274.6 million increased by 12.6% over the same quarter last year, with 9.5% attributable to unit volume<br>growth, 3.0% from positive price, and 0.1% attributable to acquisitions. Forex had no impact on the consumer segment during this quarter.<br>
Our consolidated gross profit increased to $369 million from $339 million last year, principally due to the higher sales volume, price increases, and<br>some favorable mix. As a percent of net sales, gross profit declined by 80 basis points to 40.3%, due to the persistently high cost of raw materials.<br>
Consolidated SG&amp;A increased roughly 12.5% to $281.9 million from $250.6 million last year, due to the increase in the variable costs that are<br>associated with higher sales volumes, such as compensation and benefits, distribution costs, advertising and promotional issues, as well as acquisition<br>costs associated with our increased M&amp;A activity. As a percent of net sales, SG&amp;A increased to 30.8% of sales from 30.3% a year ago.<br>
Earnings before interest and taxes, or EBIT, increased to $93 million this year from $89.4 million last year, due principally to the higher sales volumes.<br>Realized price increases were not able to offset the higher raw material costs, resulting in an EBIT margin percent that declined from 10.8% to<br>10.2%.<br>
At the industrial segment, EBIT increased 14% to $78.3 million from $68.7 million a year ago, driven by overall 10.1% increases in sales, including<br>price increase, and a favorable sales mix. These improvements were more than offset by higher raw material, resulting in an EBIT margin increase<br>to 12.2% of net sales this year compared to 11.8% last year.<br>
Our consumer segment EBIT declined 2.0% to $26.7 million from $27.3 million a year ago. The sales increase to 12.6%, including price increases of<br>3%, were not able to offset higher raw material costs and an increase in variable selling expenses that are associated with higher sales volumes.<br>
Corporate and other expenses increased by $5.4 million, primarily due to the higher acquisition costs of $3 million and insurance reimbursements<br>in last year's second quarter of approximately $2.9 million that did not repeat this year.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>77</i><br>
<hr>
<A name=78></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
Interest expense increased from $16.4 million a year ago to $17.9 million and this is primarily due to the issuance of an additional $150 million in<br>debt in May of 2011, a higher average interest rate year over year and increased borrowings associated with this year's increased acquisition activity.<br>
Investment income decreased $3.3 million year over year, primarily as a result of gains on sales of marketable securities last year of approximately<br>$3.2 million that did not recur this year.<br>
The income tax rate of 29.2% for the quarter compared to last year's rate of 30.8%, principally due to the change in the jurisdictional mix of actual<br>and forecasted earnings, the impact of certain foreign operations on our U.S. taxes, and adjustments to certain tax valuation allowances.<br>
The bottom line net income attributable to RPM shareholders increased 2.3% to $49.9 million compared to last year's $48.8 million and EPS was<br>flat to last year at $0.38 per share.<br>
As you've seen in our earnings release and Frank's comments at the beginning of this discussion, we previously reported that last year's second<br>quarter included roughly $7.5 million of nonrecurring items representing an after-tax benefit of approximately $0.04 per diluted share. This year's<br>second-quarter result of $0.38 per share include the benefit of the company's equity ownership in Kemrock Industries and Exports Ltd., totaling<br>about $0.04 a share, which was offset by $0.03 per share of costs related to higher acquisition-related expenses. Excluding one-time items in both<br>years, EPS for the second quarter of this fiscal year of $0.37 per share exceeded EPS for the same quarter last year of $0.34 a share, or an increase<br>of 8.8%.<br>
Now, a few comments on our year-to-date results -- consolidated net sales increased 10.5% to $1.9 billion from $1.72 billion last year, principally<br>due to a volume improvement of 3.6%, price increases of 2.9%, acquisition growth of 1.9%, and favorable forex, or foreign exchange, of 2.1%. EBIT<br>increased 8.6% to $229.5 million this year from $211.4 million last year, due principally to higher sales volumes. Realized price increases were not<br>able to offset higher raw material costs, resulting in an EBIT margin that declined from 12.3% to 12.1% of sales.The net income attributable to RPM<br>shareholders on a year-to-date basis increased 7.6% to $126.7 million compared to last year's $117.8 million. EPS increased 6.6% to $0.97 per share<br>this year compared to $0.91 a share last year.<br>
Looking at the balance sheet and cash flows, we find our six-month capex of [$18.4 million] (corrected by company after the call) compares to<br>$15.3 million for fiscal 2011. The depreciation and amortization expense increased slightly to $36.9 million from last year's $36.7 million.<br>
Cash from operating activities for the year to date of $110 million compares with $183 million a year ago. Increases in inventory of $24.7 million<br>attributable to higher material costs, and a reduction of $46.3 million in accounts payable due to timing differences of payments, and a negative<br>swing in other accrued liabilities were the main factors that contributed to the decrease. Our receivable days sales outstanding was 61.6 days<br>compared to 58.7 a year ago and days of inventory of 84 this year compared to 80.2 days last year.<br>
Finally, a few comments on our capital structure and overall liquidity -- as of November 30, 2011, total debt was $1.1 billion compared to $925.1<br>million last November. On May 24, 2011, we sold $150 million aggregate principal amount of 6.125% notes, which were a follow-on issuance of<br>our $300 million aggregate principal amount of notes due in 2019, which we initially issued on October 9, 2009. The follow-on offering was priced<br>at a premium with an effective yield to maturity of 4.934%.The proceeds will continue to be used for general corporate purposes. Our net-debt-to-cap<br>ratio of 38.7 at November 30, 2011 compared to 34.5 a year ago. The increase is primarily attributable to the additional $150 million of new debt<br>issued in May of 2011.The total long-term liquidity at November 30, 2011 was $803.9 million, with $301 million in cash and $502.9 million available<br>through our bank revolver in accounts receivable securitization facilities.<br>
With that, I'll turn the call back to Frank.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Thanks, Bob. For the second half of our fiscal year, we expect continued high single-digit growth in our consumer businesses and continuing low<br>double-digit growth in our industrial businesses, as a result of underlying unit volume growth, continuing price increases, market share gains, and<br>the impact of completed acquisitions. As mentioned earlier, we are seeing relief in most of our major raw materials, with the exception of TiO2. We<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>78</i><br>
<hr>
<A name=79></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
are counting on this as an important aspect of our ability to continue to deliver the full-year result targeted at $1.60 to $1.65 per share, which we<br>discussed at the beginning of this fiscal year.<br>
I'd like to remind you that RPM's third quarter, covering the months of December, January and February, are historically a seasonal low. This year<br>is obviously no exception and we will be somewhat negatively impacted by the acquisition costs and inventory write-up of the FEMA transaction<br>in our third quarter. In providing the details on that quarter, we'll call out the one-time impact of this acquisition to provide you a better understanding<br>of the expected growth in sales and earnings of the core RPM businesses in our third quarter.<br>
With hints of improving economic conditions in North America, both as it relates to consumer takeaway and in some of the construction markets<br>we serve, expectations of some raw material relief in relationship to the huge challenges we have faced over the last couple of years, and the full<br>and positive impact of the acquisitions we have completed this year, we expect a strong finish to our 2012 fiscal year and a good start to our 2013<br>fiscal year.<br>
That concludes our prepared remarks. We'd now be pleased to answer your questions.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions) Ivan Marcuse, KeyBanc Capital Markets.<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
On the consumer side, the volume is very strong. Was there any benefit from weather, or was there pre-buying activity ahead of announced price<br>increases by your customers, or could you give a little detail? How much of that percentage increase was due to new products? What new products<br>are you seeing a lot of momentum in?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
The unit volume growth there has been very good, about 9% in the quarter, and we're continuing to get raw material price increases or product<br>price increases. I'm not aware of any pre-buying, but I do know we have some additional price increases going into effect at the beginning of this<br>calendar year. A lot of it is market share gains, both at our core retail customers, as well as pickups in some new accounts and also some new<br>channels. We're continuing to gain share, for instance, in the automotive sector. Some of the gross margin issues are a mix issue, as we're picking<br>up share in lower margin categories relative to, for instance, Rust-Oleum's historic margins. Some of it relates, in particular, to TiO2 -- just significant<br>ongoing raw material cost increases that are impacting the whole industry. But the strategy that we had coming out of the recession, we're executing.<br>And it was really to focus on aggressive growth in all of our businesses, and we are executing on that.<br>
One other comment I would make in relationship to some of the new product introductions at our Rust-Oleum businesses and our DAP businesses,<br>a good example would be DAP. We just announced a whole new window, door, and sealant line into the construction markets, particularly in<br>relationship to seeing those markets bottom out. And in the process, we have incurred a significant amount of SG&amp;A expense in terms of packaging,<br>product introductions, and the expense associated with a new product line whose potential over time is tens of millions of dollars of new sales,<br>but whose P&amp;L today looks a lot like expense and not a lot of sales because it was just introduced.<br>
We are focused on growth. We are focused on market share gains. And we believe, over time, that a combination of price increases and relief in<br>raw materials will get our margins back in line.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>79</i><br>
<hr>
<A name=80></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
Great. Looking into the third quarter, are the acquisitions that you've made in the first half of the year -- I know historically the quarters were<br>breakeven, plus or minus $0.05 here or there.Would you expect, due to the acquisitions contribution, to be in the black for the quarter? Or is it still,<br>think about it breakeven, plus or minus a couple of cents?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
No, we still have a little bit of inventory write-off relative to the Legend Brands, or write-up relative to Legend Brands business that we closed in<br>September, and the FEMA transaction which we closed just this month, January 3. We'll also have some negative impact on our third quarter as it<br>relates to inventory write-up. It'll be a hit to cost of goods sold, and also the acquisition-related costs in that transaction. But we will call out those<br>separate results.<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
Historically, you've never really called out acquisition costs. Is that a change going forward that you're going to start calling that out? Or was this<br>quarter just particularly high due to all the activity that you've had in the first half, and you just want to make people aware of that?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I think the answer is yes to both. For a number of reasons, our acquisition activity kind of in the mid to late 2000s had slowed down, and we were<br>doing mostly relatively small product lines. I think the last sizable acquisition we did was illbruck in 2005, and that was in relationship to private<br>equity valuation expectations, which are down dramatically, which is a good thing. We are buying businesses at our historic valuations, not the<br>inflated valuations of 2006 to 2008. And in relation to that, changes in accounting, where five to seven years ago, all of your acquisition costs, be<br>they legal costs, due diligence costs, or on some privately negotiated deals, broker fees, were all capitalized. In today's world, all those costs are<br>period expenses.<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
Great. In the consumer segment going forward, even with the market share gains and the mix issues, you'd still expect to benefit from an improving<br>price/cost spread. I know there's a volume issue in the third quarter, but going forward you'd expect the price/cost spread to sort of improve going<br>forward, even with the lower mix?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
That's correct.You will begin to see price/cost mix improvement really in the spring, as our third quarter is so seasonally low. It's hard to really guess<br>at what that will be, but we have been experiencing some significant benefits in certain raw material categories with a FIFO accounting that will<br>start to show up here in the coming months.<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
Great. Thanks a lot for taking my questions.<br>
<b>Operator</b><br>
John McNulty, Credit Suisse.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>80</i><br>
<hr>
<A name=81></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>John McNulty</b><i> - Credit Suisse - Analyst</i><br>
With regard to the negative mix that you're talking about in the consumer business, can you flush out what product lines might be dragging that<br>mix down? Also, if they're some of the newer ones, is it an issue of you have to discount to get the initial shelf space, and then over time we can<br>see them go back, or is this something that could be a permanent drag on the margins going forward?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
In some cases, for instance, in automotive channels, a number of the product areas are lower margin, so that'll be permanently lower margin. In<br>other cases, it has been one-time lifts associated with getting into new accounts or getting new space, which won't be repeated. Then the other<br>issue is just a continuing game of catch-up on what has been an extraordinary increase in raw materials, particularly TiO2 that has hit our industry<br>broadly. The good news about TiO2 is it really does not impact RPM's industrial businesses. The only place that it really has an impact on us today<br>is in our Rust-Oleum Group, a little bit in small project paints, and principally in primers. Our primer business is a multi-$100 million business, and<br>it is white. That white comes from TiO2, and that's been the raw material that has been most frustratingly high for our Rust-Oleum Group, as well<br>as for our industry.<br>
<b>John McNulty</b><i> - Credit Suisse - Analyst</i><br>
Okay, great. One last question, you reiterated your full-year guidance that you gave back in July. And since then, you've made three acquisitions<br>that you say are going to be at least modestly accretive. I'm wondering what incrementally is getting worse than maybe what you were expecting,<br>if anything, or is it just you're taking maybe just a conservative approach?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I don't think we're taking a conservative approach. I think what's happening is two things -- number one, our sales are better a little bit than we<br>anticipated, particularly in consumer, but our raw material costs are worse, up until this point, than we anticipated. And then, the acquisitions will<br>most definitely help us in the fourth quarter. But on the full year, they're kind of a wash because, as you look at $1.60 to $1.65 target in EPS, it seems<br>like we're behind the curve. Part of that is the expensing of acquisition expenses, $3 million, $3.5 million of which hit this quarter, as well as the<br>one-time negative hit to cost of goods sold from inventory write-ups. Those acquisitions have actually hurt us now. You will see a nice benefit in<br>the fourth quarter, which will make the fourth quarter look good. But relative to our full-year targets, we'll essentially offset the negative impacts<br>of the transaction costs in the period in which the deals were done.<br>
<b>John McNulty</b><i> - Credit Suisse - Analyst</i><br>
Okay, great. Thanks for the color.<br>
<b>Operator</b><br>
Saul Ludwig, Northcoast Research.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
In the past, you used to give us gross profit margin by the segments, if you would have that information available for both the quarter and for the<br>six months?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>81</i><br>
<hr>
<A name=82></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
We do not have that, and it was brought to our attention mostly from a number of outside sources, including our businesses, that it's not required<br>by the SEC, and none of our peers provide segment gross profit information. We are advocates of providing segment gross profit information, and<br>we would encourage you and all the investors here to encourage our peer companies and all companies; you can even write a letter to the SEC<br>and suggest that companies provide gross margin information by segment. We think it would provide better information to investors. We may<br>get back to that unilaterally on our own accord, but you can only get hit over the head by so many places as to why we're the only one providing<br>it relative to our industrial peers, and so that's what's behind that. We are advocates of it. As you point out, we've done it in the past, but it has, in<br>certain instances, competitively served to hurt us in our businesses, because our peer companies do not provide it, nor does the SEC require it to<br>be provided.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Maybe just qualitatively, if your total gross profits were down 80 basis points, was it mostly in one segment or the other?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
It was entirely in our consumer segment. Our industrial segment gross margins are relatively flat, and the deterioration in the quarter was entirely<br>in consumer.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Great. That is helpful. Kemrock -- how much do you have invested in Kemrock? Where does it show up on the balance sheet? This run rate of<br>$600,000 of equity income, ex the one-time catch-up, is that what we should be looking for?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes. The investment in Kemrock's currently about $36 million. We would hope that that would go up over time. It's an extraordinary company that<br>we have partnered with in India. Seven years ago, it was a $14 million business. This year, it will do about $250 million in sales. Our ownership<br>interest over that period has gone from 5% to what is now 23%. I think that's correct, the ongoing benefit from an equity accounting is about<br>$600,000 a quarter.We would hope, over time, that that would grow with Kemrock, both in relationship to their growth and our growing investment.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
What do you think -- two balance sheet items, cash flow from operations, last year you had $238 million, and you're running way behind in the first<br>half of the year. What would you expect the full-year cash from operations to be? What do you think your full-year cap spending will be?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I think the full-year cap spending will be around $70 million, and I think free cash flow will be around $100 million. We're in generally good shape<br>on cash from operations in our industrial business. The shortfall is a combination of higher inventory and lower margin delivery in the consumer<br>segment, and that's being addressed. A lot of that is at our Rust-Oleum Group, that's, over time, one of our better businesses. I would expect us to<br>catch that up by the end of the fiscal year. We've targeted about $100 million of free cash flow for the year, and I think we'll get there.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
$100 million is after dividends or before dividends?<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>82</i><br>
<hr>
<A name=83></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
That's after capital spending and after dividends, but before acquisitions.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Got you. Cap spending, $70 million, dividends about $110 million, so that's $190 million. Sounds like you would look for about $280 million, $290<br>million cash from operations?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Correct, somewhere in that range.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Okay, good. Finally, you have this non-controlling interest that was $4 million. What are the sales that you've consolidated that reflect that<br>non-controlling interest? What was 100% of the earnings of those businesses that you took $4 million off the bottom?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I'm not sure I understand the question.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
You have $4 million of earnings that were attributed to non-controlling interest. That's the portion of --<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, those are a combination of joint ventures and other items. We haven't disclosed that. It would be business by business. Some of that is joint<br>ventures or licensees associated with our Carboline business or other joint venture activity, not any one of which is material.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
No, what I mean is, Frank, when you take off $4 million off the bottom for non-controlling interest, that's the percentage of those businesses that<br>you don't own, that are owned by somebody else. But you've consolidated 100% of their revenue and 100% of their earnings up above. So my<br>question --.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
No, that's an accounting issue that we had explained earlier. It's in relationship to SPHC, and the accounting for that situation is such that there are<br>businesses that, for instance, as I've highlighted in the past, Day-Glo is part of SPHC, but the Day-Glo subsidiaries or operations outside of the United<br>States are not. And so it is a percentage of minority ownership of SPHC companies, principally Day-Glo and Dryvit, affiliated with those two entities'<br>foreign operations or foreign subsidiaries that are not part of the SPHC/Bondex filing.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>83</i><br>
<hr>
<A name=84></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Got you. Okay. Thank you very much.<br>
<b>Operator</b><br>
Kevin McCarthy, Bank of America.<br>
<b>Aleksey Yefremov</b><i> - BofA Merrill Lynch - Analyst</i><br>
This is Aleksey Yefremov for Kevin. Frank, could you size the expected price increases in consumer pricing, maybe on a blended rate, how much it<br>would help sales in the back half of the year?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, year to date we're about 3%, and I don't know that we would guesstimate what it would be in the back half, but it'll at least be 3%. It could be<br>more, and I, at this point, don't have a good sense of what that is. We've had, in general, about 3% price increases across both of our segments on<br>average. Of course, that is a widely varying mix of some product categories where we have not gotten price increases, and other unique product<br>categories where we've had price increases in double-digit ranges. But on average, it's been 3%, and on average holds about the same for each<br>segment. There are new price increases continuing, some of which were announced in January.<br>
<b>Aleksey Yefremov</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay, thank you. Can you size, at this point, the expected cost hit from the FEMA acquisition in the third quarter?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
No, we can provide that -- we will call that out in the third quarter. We'll have some transaction expenses, as well as an inventory write-up that'll<br>one-time negatively impact cost of goods sold. When we report the third quarter, we will specifically call out those numbers.<br>
<b>Aleksey Yefremov</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay. Finally, if I may, multi-family residential construction seems to be doing better than single family. Where do you have exposure to this<br>multi-family market within your portfolio? Is it in consumer or industrial? Do you see better performance in those product lines?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
There are two areas where that will, in the future, impact us. The one area where we're currently starting to benefit is in our Building Solutions<br>Group. Our Tremco sealants, in particular, is showing modest single-digit growth in sales and earnings. That's continuing, and it's principally in<br>relationship to our broad distribution, which gets at multi-family housing, and gets at some of the small construction activity that's picking up. We<br>are benefiting from that there in our Building Solutions Group in particular, and in particular, our sealant product lines.<br>
The other area that we would expect to benefit from that in the future is this new WDS category that we have been investing forward in, in our<br>DAP business. It is a new product line that was just launched that is specifically targeted at the residential and light commercial markets. I think<br>the timing is such that we feel that the worm has turned a little bit on those markets. There's not going to be any huge rebound, but we believe<br>we've found a base at which you're starting to see modest growth. Multi-family housing in particular, in relationship to rent versus own, is an area<br>that's starting to grow pretty nicely.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>84</i><br>
<hr>
<A name=85></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Aleksey Yefremov</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay. Thank you.<br>
<b>Operator</b><br>
Jeff Zekauskas, JPMorgan.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
This is Silke Kueck for Jeff. Can you clarify how much of the 80 basis point in gross margin squeeze is due to higher raw material costs, and how<br>much may be due to the acquisition-related inventory write-ups?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
The 80 basis points in the quarter was all in our consumer segment. About two-thirds of that was cost/price, maybe 70%-plus was cost/price<br>difference, and the balance is negative mix, which is deliberate. The step-up in inventory is entirely in our industrial segment. All the acquisitions<br>that we have done this year, about $160 million on annualized sales, is in our industrial segment, and I think it's about $2.5 million in the quarter.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
From a raw material cost standpoint, it seems that going into November, raw material costs shouldn't have really increased. So, does your comment<br>on TiO2 have to do with there also being some share gains in specialty primers? How come your raw material costs still seem to be lifting rather<br>than moving lower?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
There's a couple issues -- number one is gains in our Zinsser primer areas. Number two is market share mix into some different channel areas, and<br>number three is FIFO accounting. We're on a first in/first out inventory accounting basis, where the majority of our peers are on LIFO. We would<br>pick up the benefits of improving raw materials 60, 75 days later than what you might see in somebody -- then if we had been on, for instance,<br>LIFO accounting.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
What you really hope for is a very strong fourth quarter?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
We are already seeing, in major raw material areas, improvements in costs. That is in the marketplace today, and that will show up in our results in<br>the coming months. We are also getting additional price increases across a number of our consumer industrial businesses. Unless there is a<br>resurgence in raw material price increases, which we don't see, but in certain categories like TiO2, the market dynamics are such that it's a little bit<br>unconnected to supply and demand, it's hard to predict.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>85</i><br>
<hr>
<A name=86></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
Lastly, the December retail sales number seemed reasonably strong, and supported by heavy discounting. Is that stuff representative of what's<br>happening in the consumer product side as well? Can you just talk about trends?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
We had a 9% unit volume growth in our consumer businesses in the quarter, and there was some negative impacts to some lifts, some cost of<br>lifting competitive product in some new areas, both in terms of existing customers and some new customers. But the principal -- again, as I said,<br>about 70%, two-thirds to 70% of that gross margin deterioration was associated with just the lag in cost/price. The balance was an issue of mix or<br>lift cost, things like that.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
But I guess my question was -- how sales trends look in December, both on the consumer side, maybe the industrial side?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Sales trends look good. We anticipate, for the balance of the year, that consumer sales will be up in the high single-digits, and a combination of<br>continuing unit growth, market share gains, price increases, and the benefit of these acquisitions will allow our industrial segment to finish the<br>year with low- to mid-teen sales growth.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
Okay, thanks.<br>
<b>Operator</b><br>
Edward Yang, Oppenheimer.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
On the consumer side, what do you think is a good margin long term for that business? You lost some margin this quarter, but when I look at the<br>full year margins you'll probably have for this year, which is probably going to be in the 13% range, it's not all that out of whack with the 12% to<br>14% range you've experienced in the last five to 10 years or so.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Sure.We have a couple hundred basis points of operating margin to pick up in that business.We have lost gross margin in a number of our product<br>categories significantly over the last two or three years.We have made that up through a sharper focus in SG&amp;A, the benefits of continuing to focus<br>on sales growth, which has been a very deliberate strategy that's working, and then obviously some loss in operating margin. There is absolutely<br>a couple hundred basis points of operating margin that we would expect to pick up relative to where we will be this year.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
How long do you think that will take?<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>86</i><br>
<hr>
<A name=87></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
It really depends on the trajectory of raw material costs. If raw material costs have peaked, and most analysis of the cyclical nature of raw materials<br>would suggest that in a lot of cases that they're there and passed, I think sooner rather than later. As I indicated earlier, there's some market dynamics<br>that are unconnected to supply and demand, which are challenging. The one that's the biggest challenge there is TiO2. Fortunately, that's not a<br>huge raw material for RPM on a consolidated basis, but it's a meaningful raw material to our Rust-Oleum Group.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Do you expect to see any competitive response? You've spoken a couple of times about gaining share in consumer.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
We are continuing to execute growth plans across all of our businesses, and we face competitive responses every day. And I don't mean that<br>cavalierly. Different people in our industry have approached this raw material situation and some of the economic turmoil, depending on their<br>regional focus, in different manners. Certain industry competitors have announced multi-$100 million restructurings and divestitures. We are very<br>focused on growth. We think, in the long run, that's the right strategy relative to delivering bottom-line results and utilizing the asset base that we<br>have.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay. In this quarter, you called out the acquisition costs. The increase was $0.03. But these costs are fairly recurring. How should we think about<br>these costs going forward? Do you expect them to decline, stay about where they are, or increase from where they are? I would think that you<br>would continue to pursue acquisition opportunities.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, normally we wouldn't go through the exercise of adding pluses and minuses that changed our $0.38 to $0.37. However, as we talked about<br>last year in the second quarter, and we talked about in relationship to the upcoming second quarter in our last conference call in October, it was<br>important that we got the financial community focused on the base of last year, which was more like $0.34. You can't go through that exercise of<br>identifying for people your one-time non-operating gains or expenses, and not do it equally in both quarters. I think that's a fair statement. We<br>don't try and call out every little expense item, but if you're going to do it in relationship to a prior period, I think you need to make your adjustments<br>on a consistent basis, and that's what we did.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Got it.With the acquisition of FEMA and Grupo, could you give us an update on your exposure to Europe, and maybe some qualitative or quantitative<br>comments in terms of what you're seeing in terms of demand there?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Sure. Interestingly enough, our European sales and earnings are relatively flat to last year, and we haven't lost any margin. It's a combination of the<br>fact that our exposure in Europe is principally industrial. Our Performance Coatings Group, which is our most global group and also has a big<br>presence in Europe, is serving what is an expanding industrial capital spending and industrial maintenance spending market pretty much across<br>all of our product categories and channels, whether it's in energy, oil and gas, infrastructure, a lot of areas like aerospace or food service. We have<br>a very broad presence in multiple channels, and that is the area both in North America and globally where we're seeing continued strength.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>87</i><br>
<hr>
<A name=88></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
When you look at that industrial segment growth of about 10%, and you realize that half of that is in building materials, mostly North America that<br>are growing 3% or 4%, it gives you a sense of the strong growth in the high performance coatings that serve the industrial capital spending and<br>maintenance markets in what they're doing. Secondly, our largest concentration of business in Europe is in Germany, and that's just been in part<br>strategic, but also lucky, because that's the largest market in Europe and the one that continues to show some positive momentum.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay, but even on the industrial side, there have been some press reports about refineries having issues in Europe. But you haven't seen any impact<br>on industrial demand you're seeing in Europe?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
None.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
It's slower than in North America. It's slower than what little business we do in South America or Asia, but it's still positive. Our results in Europe are<br>not in any way in relationship to the headlines that you see every day.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I think the impact is more in the consumer markets, which we don't serve, except for the UK.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay. Just final question from me on the guidance, $1.60 to $1.65, what's the level of confidence there? Year to date, you've had $0.95 in earnings.<br>The third quarter for you is usually a wash. The fourth quarter, just by subtraction, would mean $0.65 to $0.70 in earnings. That would be up 20%<br>to 30% year over year. What's your updated level of confidence in hitting that number this year?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Without getting into the expectations from one quarter to the next, as I commented earlier, I think we're still comfortable that we can get into that<br>range. It will be a combination of the raw material environment that we see today continuing. I think we're confident that the raw material<br>environment and the cost/price situation that we see today is such that we ought to have some improvement. Having been through what we've<br>been through the last two years, it does not anticipate another significant rise in major raw materials this spring. That's one factor.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>88</i><br>
<hr>
<A name=89></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
The other factor is, we have done a pretty good chunk of nice, strategic acquisitions, and year to date they have hurt our gross margin in industrial<br>because of inventory step-ups, and they have hurt our corporate/other expense to the tune of $3.5 million or $4 million. In the fourth quarter, the<br>one-time expenses will be gone.The inventory write-ups will have happened, and you're going to be looking at businesses with sales and earnings<br>that will begin to contribute nicely to the bottom line.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay. Thank you for the clarification.<br>
<b>Operator</b><br>
Rosemarie Morbelli, Gabelli &amp; Company.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Frank, when you are rather confident that raw material costs are going to stay more or less level with where they are currently. But with the outlook<br>for oil going up, and oil being already up versus the second quarter, how confident are you that actually you are not going to have any cost increases<br>announcements?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Highly confident, Rosemarie, is an overstatement. We're hopeful, and we're more hopeful than we've been for a while. There have been some<br>significant reductions in certain resin prices and certain packaging and certain solvent areas, and oil prices aren't particularly out of whack relative<br>to where they were a few years ago. Again, the raw material environment we see today makes us hopeful that we'll have a better second half as it<br>relates to the cost/price impact on our gross margins. Having experienced what we've experienced the last couple of years, I'm hopeful that we're<br>not going to jump into another environment where our raw material suppliers are increasing prices 15% or 20%. They're not signaling that, and<br>we don't see it, but it doesn't mean it couldn't happen.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Could you give us a feel for how much you spent in order to introduce the new DAP product line, and when do you think that amount is going to<br>go away?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Without being real specific, we've spent many single millions of dollars to build up an independent division of DAP, and have just introduced the<br>product. Obviously, construction, particularly -- it's a North American, basically U.S.-focused effort at this point, and the construction markets,<br>obviously, are seasonal. I would think the first impacts of that would be this spring and this summer, and depending on our distribution and<br>penetration level, it's a very exciting product line for us. It has potential to add tens of millions of dollars to DAP and RPM, but obviously we've got<br>to have the right product and get broad distribution to get going. So far, it's been an expense base as we build up this organization, develop the<br>packaging, and introduced the product. Revenues from that effort should show up late spring and in the summer.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Are they introduced to the Lowe's of the world, or are they going into industrial applications?<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>89</i><br>
<hr>
<A name=90></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
This is going into more building materials, independent distributors, and really focused on residential and light commercial construction as opposed<br>to the consumer DIY channels and presence, which is predominantly what DAP serves today.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. Talking about the DIY, what are you hearing in terms of your kind of product lines going forward? Are they seeing more maintenance, more<br>renovations, or is it flattish from where we are today?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Our unit volume growth in the quarter was 9%. As we've commented, some of that was new product and market share gains, but we are seeing<br>consumer takeaway pick up across a number of our product categories, and I think that makes sense given the relatively low price point and either<br>small project redecorating and/or home maintenance and repair nature of our products.We would expect that modest pickup in consumer takeaway<br>to continue for the balance of the year.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. You talked about Europe and the fact that you haven't seen any decline at this particular point. But if you talk about anecdotes, whatever<br>you hear in the field as well, once you may not have seen it yet in the third quarter, what do you hear going forward from your customers, for<br>example?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, again, I don't want to overstate Europe. We are generally, in sales, earnings, and margins, flat to last year. We have some areas of strength, but<br>we're not experiencing the significant deterioration that the daily headlines would suggest. Given the nature of the products that we are manufacturing<br>and selling in Europe, we don't anticipate any big deterioration there.The biggest challenge at this stage from Europe is what happens to the euro<br>versus the dollar, and the impact on revenues and through our P&amp;L of changes in relative foreign currencies, basically the dollar to the euro.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. Lastly, if I may, could you update us on the performance of Legend Brands versus what you were anticipating?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Legend Brands is brand new, and so I don't have a good sense of where they're going. Unfortunately, they add to the seasonality of RPM, and so<br>their winter months are also seasonally low. We're not getting the big boom from them relative to the seasonality of their business, but they are<br>on target in the early months of their ownership by RPM, and we're real excited about that business and its growth prospects long term.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. Thank you very much.<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>90</i><br>
<hr>
<A name=91></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Operator</b><br>
(Operator Instructions) Saul Ludwig.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
I have a couple quickie follow-ups. The $1.60 to $1.65, that's all-in with all the goodies and the baddies, right?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
That is every bit of good, bad, and help that we can get, Saul.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Okay, and then as we look to the fourth quarter, we'll recall that last year you had a $5.5 million bad debt charge, which was $0.06 a share, that we<br>hope doesn't repeat, which would give you $0.06 goodie in the fourth quarter just for showing up, right?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, we also had, I think, many millions of dollars of one-time gains from a change in insurance, as well as marketable securities. I think last year's<br>fourth quarter is essentially between the goods and the bads where it is. The Lancaster was the bankruptcy, and we highlighted that as it related<br>to the results of our consumer segment, because it hit in the last month of our fourth quarter. But on a consolidated basis, that was essentially<br>offset by marketable securities gains from our captive insurance companies and other insurance items. I don't recall what those were, but on a<br>consolidated basis, the fourth quarter is what it was.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Got it. One final thing, your corporate expense last year, third quarter, fourth quarter was $16 million and then $4 million; $16 million expense in<br>the third quarter, and only $4 million expense in the fourth quarter. Why such a divergence in numbers, and how should we think about corporate<br>expense in the back end of the year?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I'll let Bob talk about the quarterly corporate expense. But, again, without looking at the numbers, Saul, just to the comment you and I made, my<br>guess is that the one-time gains in relationship to marketable securities or a pickup in insurance recovery that I mentioned in relationship to the<br>Lancaster write-off, would have occurred in the corporate/other category as the offsets. Because, again, on a year-over-year basis, our fourth quarter<br>essentially was what it was, with the hit on Lancaster being offset by corporate non-Other in the quarter.<br>
Now, as it relates to how to think about corporate expense in the third or fourth quarter, the balance of the year, maybe Bob can add to that.<br>
<b>Bob Matejka</b><i> - RPM International Inc. - SVP, CFO</i><br>
Saul, that fourth quarter a year ago was impacted, as Frank said, a lot of insurance adjustments and prior-year stuff. You should probably look at<br>each quarter at somewhere between $11 million to $12 million. It would be a normal run rate on the corporate and other side of our P&amp;L structure.<br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>91</i><br>
<hr>
<A name=92></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Okay. Thanks very much.<br>
<b>Bob Matejka</b><i> - RPM International Inc. - SVP, CFO</i><br>
And that's assuming that everything is -- no unique items, one-timers happening in those quarters.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
You're not assuming any securities gains or losses in the back end of the year, in your outlook comments?<br>
<b>Bob Matejka</b><i> - RPM International Inc. - SVP, CFO</i><br>
No.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
That is correct.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Very good. Thank you.<br>
<b>Operator</b><br>
Rosemarie Morbelli.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Just quickly, on the pension expense, could you give us a feel for how much you spent in 2011? And given the level of the rates and the performance<br>in the market, what do you expect for 2012?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Our pension expense for 2012 should be flat to what we spent in 2011. We had a pickup in pension expense last year in relationship to a drop in<br>securities, as well as an adjustment in the discount rate, relative to interest rates. But I think year over year, we will be flat in pension expense on<br>2012 to what we spent in 2011.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Can you remind me how much that was?<br>
17<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>92</i><br>
<hr>
<A name=93></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I don't have that number handy, Rosemarie. I think it's disclosed in our 10-K, but we can get back to you on that.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. I'll check the 10-K. Thanks. Okay. That was it for me. Thank you.<br>
<b>Operator</b><br>
And there are no further questions at this time. I will now turn the call back over to Mr. Frank Sullivan, Chairman and CEO. Please proceed.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Thank you for your participation on our investor call this morning. We look forward to providing you the details of our third quarter in April of this<br>year, and also to giving you our expectations for the 2012 finish, and our outlook for our 2013 fiscal year. In the meantime, please accept our best<br>wishes for a happy, healthy, and successful new year. Thank you for your investment in RPM.<br>
<b>Operator</b><br>
Ladies and gentlemen, that concludes today's conference. Thank you for your participation. You may now disconnect. Have a great day.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4675796-2012-01-09T20:59:00.153</b><br>
18<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>93</i><br>
<hr>
<A name=94></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
STZ - Q3 2012 CONSTELLATION<br>BRANDS, INC. EARNINGS CONFERENCE<br>CALL<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 3:30PM GMT<br>
OVERVIEW:<br>
Co. reported 3Q12 consolidated reported net sales decrease of 27% and comparable<br>diluted EPS of $0.50. FY12 comparable diluted EPS is expected to be $2.00-2.10.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>94</i><br>
<hr>
<A name=95></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Patty Yahn-Urlaub</b><i> Constellation Brands Inc - VP, IR</i><br>
<b>Rob Sands</b><i> Constellation Brands Inc - President and CEO</i><br>
<b>Bob Ryder</b><i> Constellation Brands Inc - EVP and CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Kaumil Gajrawala</b><i> UBS - Analyst</i><br>
<b>Judy Hong</b><i> Goldman Sachs - Analyst</i><br>
<b>Dara Mohsenian</b><i> Morgan Stanley - Analyst</i><br>
<b>Tim Ramey</b><i> D.A. Davidson &amp; Co. - Analyst</i><br>
<b>Reza Vahabzadeh</b><i> Barclays Capital - Analyst</i><br>
<b>Vivien Azer</b><i> Citigroup - Analyst</i><br>
<b>Mark Swartzberg</b><i> Stifel Nicolaus - Analyst</i><br>
<b>Gary Albanese</b><i> Auriga, USA - Analyst</i><br>
<b>Carla Casella</b><i> JPMorgan Chase &amp; Co. - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Good morning. My name is Jackie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Constellation<br>Brands Third Quarter 2012 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers'<br>remarks, there will be a question-and-answer session. (Operator Instructions) Thank you.<br>
I would now like to turn the conference over to Patty Yahn-Urlaub, Vice President of Investor Relations. Please go ahead.<br>
<b>Patty Yahn-Urlaub</b><i> - Constellation Brands Inc - VP, IR</i><br>
Thank you, Jackie. Good morning, everyone, and welcome to Constellation's Third Quarter Fiscal 2012 Conference Call. I'm here this morning with<br>Rob Sands, our President and Chief Executive Officer, and Bob Ryder, our Chief Financial Officer. This call complements our news release, which<br>has also been furnished to the SEC.<br>
During this call, we may discuss financial information on a GAAP comparable organic and constant-currency basis. However, discussions will<br>generally focus on comparable financial results. Reconciliations between the most directly comparable GAAP measure, and these and other<br>non-GAAP financial measures are included in the news release, or otherwise available on the Company's web site at www.Cbrands.com under the<br>Investor section in Financial History.<br>
Please also be aware that we may make forward-looking statements during this call. While those statements represent our best estimates and<br>expectations, actual results could differ materially from our estimates and expectations. For a detailed list of risk factors that may impact the<br>Company's estimates, please refer to the news release and Constellation's SEC filings.<br>
Now I'd like to turn the call over to Rob.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>95</i><br>
<hr>
<A name=96></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Thanks, Patty. Good morning, and happy new year to everyone. I hope you all had a great holiday, and the opportunity to enjoy some of our fine<br>products throughout the season.<br>
Welcome to our discussion of Constellation's third quarter fiscal 2012 sales and earnings results. We continued to progress through the year with<br>results that are generally in line with our expectations for most areas of the business.<br>
I'm especially pleased with our significantly improved consolidated margin structure, and our continued progress in the area of free cash flow<br>generation, which has essentially enabled us to fund our share repurchase efforts, where we have already completed more than 50% of our current<br>authorization.<br>
Our top line performance for the quarter was not surprising, as we continued to lap last year's third-quarter US distributor inventory build. As a<br>reminder, our shipments to distributors last year exceeded distributors' sales to retail as part of our US distributor transition initiative. This had the<br>effect of benefiting our sales and profits for fiscal 2011, but created a sales and EBIT comparison challenge for fiscal 2012.<br>
Now, despite these sales trends, our US wine and spirits depletions improved sequentially during the third quarter, with the entire portfolio growing<br>almost 2%, and focus brands growing about 6%. As previously discussed, we expected our depletion trends to improve as we progressed through<br>the year due to the gating of the promotional spend for our US wine and spirits businesses.<br>
This year, we are driving enhanced promotional and merchandising activity in the second half to better align with the seasonality of our business.<br>As such, you can see in the IRI data coinciding with our third quarter, that we gained volume share for total table wine and the premium plus<br>segment, which represents the greater than $5 retail price point. This channel accounts for about 35% of our business. And our spirit sales remain<br>robust as we gained share, driven by our SVEDKA vodka brand.<br>
However, growth for our total US wine portfolio continues to lag that of the overall US wine category on a year-to-date basis through the third<br>quarter. Our US wine share loss for this time period can be primarily attributed to a decline in value brands below the $5 retail price point, as we<br>increased net prices for some of our higher volume value brands, such as Vendange and Arbor Mist. As would be expected, this action negatively<br>impacted volumes, but to a bit greater degree than we originally anticipated.<br>
So, what are we doing about this market share issue? We are in the process of revamping up innovation and new product development, where we<br>currently have more than 20 new product launches underway in fiscal 2012, many of which are included in hot categories that are experiencing<br>significant growth.<br>
We currently have strong momentum for many of our newly launched products, like Primal Roots, a sweet red blend, Rex Goliath Moscato, Ruffino<br>Prosecco, Woodbridge Malbec, and the Simply Naked unoaked line of varietals.<br>
Our most recent introduction to the new product line-up is the Dreaming Tree brand; a collaboration between Steve Reeder, our award-winning<br>winemaker at Simi, and acclaimed musician Dave Matthews, that is receiving rave reviews.<br>
This collection of new products is gaining traction, and performed very well in the marketplace during the holiday selling season. And next year,<br>in fiscal 2013, we expect to have an increasing percentage of our sales growth coming from innovation.<br>
As I mentioned earlier, from a depletion perspective, during the third quarter our focus brands grew almost 6%, with several brands growing double<br>digits, including SVEDKA vodka, Black Box, Rex-Goliath, and Kim Crawford, just to name a few.<br>
However, the previously mentioned price increase on Arbor Mist has reduced our Focus brands' growth rate somewhat. To mitigate this, we have<br>introduced Arbor Mist Pomegranate Berry Pinot Noir, which is doing very well in the marketplace, and we recently launched Arbor Mist Strawberry<br>Moscato at Walmart.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>96</i><br>
<hr>
<A name=97></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
This new flavor extension has exceeded all initial launch expectations. Next month, we're introducing Arbor Mist frozen wine cocktails at Walmart<br>in order to capitalize on one of the fastest-growing segments in beverage alcohol.<br>
We have other initiatives underway to drive some of our key focus brands. They include our recent re-launch of the Ravenswood brand with new<br>labeling and a refinement of the Ravenswood blend to produce a more fruit-forward taste profile. Ravenswood is a great turnaround story, with<br>recent symphony IRI trends showing mid-single-digit volume growth rates during the third quarter.<br>
For Blackstone, we have new packaging in the works, and two new line extensions, a red blend was introduced last Fall, and we will be rolling out<br>a Malbec in the new year.<br>
One of the things which I am particularly proud is the string of awards and accolades that we continue to receive for many of our focus brands<br>from several industry-leading publications. They include the following.<br>
In the December 31 issue of Wine Spectator, the 2008 Robert Mondavi Oakville Cabernet Sauvignon was named one of the top 100 wines of 2011.<br>Wine Spectator also awarded the 2008 Robert Mondavi Napa Valley Reserve Chardonnay 93 points, while the 2009 Robert Mondavi Napa Valley<br>Reserve Pinot Noir was awarded a 91-point score. The Franciscan Cabernet Sauvignon 2007 was named to the Wine Enthusiast Top 100 of 2011<br>list, and the Inniskillin 2007 Vidal Icewine received 92 points from the Wine Enthusiast, and 95 points from the Tasting PAL.<br>
Five of our brands made Wine.com's Top 100 list for 2011, including varietals from Franciscan, Robert Mondavi, Ravenswood, Ruffino, and Kim<br>Crawford. Finally, impact blue chip awards were given to Clos Du Bois, Estancia, Robert Mondavi Private Selection, and SVEDKA.<br>
Overall, we are catching up with industry trends, and addressing some of the short-term challenges we face within our portfolio of brands. As you<br>can see, we have several initiatives underway. And I believe we are firing on all cylinders from an innovation and new product development<br>perspective.<br>
While our recent trends are improving, we are tracking a bit short of our goal of growing in line with the US wine category growth for the year due<br>primarily to our tactical decision earlier this year to take pricing in the Valley segment. However, we remain focused on achieving this goal, and<br>we're strongly committed to this as one of our strategic objectives in driving profitable, organic growth over the long term.<br>
Moving to SVEDKA vodka. During the quarter, SVEDKA posted double-digit sales depletion and consumer take-away trends, in addition to gaining<br>share in the vodka category in the IRI channels. In advance of the holiday selling season, SVEDKA launched its first-ever limited edition party bottle<br>package in the marketplace. This was accompanied by a multi-channel marketing campaign, including mobile and social media applications.<br>
Moving to the Crown [Imports] joint venture. As expected, Crown faced a difficult third-quarter sales and earnings comparison versus last year<br>when sales increased 22%, driven by the re-build of wholesaler inventories to more optimal levels after Crown experienced supply chain disruptions<br>in the summer of calendar 2010.<br>
Despite these comparison issues, the Crown business remains very healthy with [depletions] growing mid-single digits during the third quarter,<br>driven by Modelo Especial, Victoria, and Corona Familiar.<br>
In addition, Crown continues to experience strong consumer demand resulting from the combined success of a number of promotional and<br>marketing initiatives, including the Corona Extra Find Your Beach campaign, and additional advertising investments during the NFL season.<br>
According to SymphonyIRI retail data, coinciding with the end of our third quarter, Crown continues to out-perform the total US beer industry, the<br>import category, and the other three major beer suppliers in both case and dollar sales trends in the food, drug, mass, and convenience channels.<br>And Crown is also the only major supplier to gain industry dollar share or case share.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>97</i><br>
<hr>
<A name=98></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
Throughout calendar 2011, Crown achieved several milestones, and has received recognition from some of the most notable beer and marketing<br>channels in the industry, including the following.This is the first year that Crown Imports has been named to Advertising Age's prestigious Marketer<br>A list.<br>
This is the second consecutive year that Corona Extra has been named one of the best global brands by Interbrand. Modelo Especial won an Impact<br>Hot Brands award, and an Impact Blue Chip Award, with Corona Light winning a Blue Chip Award from Impact as well. Modelo Especial and Victoria<br>each received Cheers growth brand awards, and Victoria also received a Market Watch Leader's Choice award in the best new product segment.<br>These awards highlight the continuing success of the brand portfolio, and underscore Crown's unique approach to marketing.<br>
Overall, calendar 2011 was the largest volume year for the collection of Modelo brands in the US. Throughout the remainder of the year, Crown is<br>focused on market execution, and optimizing promotional and marketing initiatives.<br>
Some examples include the continued expansion of the Corona Familiar 32-ounce bottle, primarily in Mexican and Hispanic markets throughout<br>the US. Launched in the US in calendar 2010, Corona Familiar had strong depletions in calendar 2011. Victoria will expand to select cities within<br>those states where it is already available.<br>
In addition, new packaging configurations are being introduced for the brands in existing markets. Victoria already ranks as a top import, and is<br>larger than many national distributed competitors in the import category.<br>
Crown continues to expand its draft offerings for the Pacifico, Negra Modelo, Modelo Especial, and Victoria brands, which are doing extremely well<br>in existing markets. Year to date through the third quarter, Crown's depletions for its draft offerings increased 60% versus the same period last<br>year.<br>
Now, in closing, we believe we are in good shape to deliver our financial objectives for the year. Even though we may fall a bit short of our depletion<br>goals for our US wine business, we have solid promotional programs in place designed to drive continued improvement in these trends throughout<br>the remainder of the year.<br>
I would now like to turn the call over to Bob Ryder for our financial discussion of our third quarter business results.<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Thanks, Rob. Good morning, everyone. The quarter came in essentially in line with our Q2 earnings call discussion. Our free cash flow is running<br>ahead of expectations, and we've increased our free cash flow guidance for the year.<br>
As it relates to earnings guidance for the year, we're maintaining our comparable-basis EPS goal of $2 to $2.10 provided at Q2, which is essentially<br>the guidance provided at the beginning of the year, exclusive of the benefits from reduced shares and reduced tax rates.<br>
For Q3, our comparable-basis diluted EPS came in at $0.50, versus $0.66 last year. The majority of the EPS decrease was driven by a 17% decline in<br>comparable-basis EBIT.This EBIT result was in line with the expectations we outlined last quarter, and was driven primarily by three items, all related<br>to overlaps of events which occurred in fiscal 2011.<br>
These include the overlap of the Q3 fiscal 2011 distributor inventory build from our US wine and spirits distributor consolidation initiative; the<br>overlap of the Q3 fiscal 2011 distributor inventory replenishment, combined with incremental marketing funding at Crown; and the divestiture of<br>the Australia and UK wine business.<br>
We've generated $587 million of free cash flow for the first nine months of the year, $287 million more than the same period last year. Due to this<br>excellent performance, we've increased our fiscal 2012 free cash flow target by $100 million to a range of $700 million to $750 million, an all-time<br>high at Constellation.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>98</i><br>
<hr>
<A name=99></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
Through Q3, our strong free cash flow generation has enabled us to reduce debt, re-purchase stock, and acquire the remaining 50% interest in the<br>Ruffino business. I'll outline more details on this activity in a moment.<br>
Given those brief highlights, let's look at our third quarter 2012 P&amp;L performance in more detail, where my comments will generally focus on<br>comparable-basis financial results.<br>
As you can see from our news release, consolidated reported net sales decreased 27%, primarily due to the divestiture of our Australian and UK<br>business. North America net sales on an organic constant-currency basis decreased 8%, primarily due to a decrease in volume, driven by the overlap<br>of distributor inventory build in Q3 last year. This result also reflects higher promotion costs, partially offset by positive mix.<br>
Now, let's look at our profits on a comparable basis. For the quarter, our consolidated gross margin was 40.5% versus 36.5% in the prior year. This<br>primarily reflects the benefit of divesting the lower gross margin Australian and UK business.<br>
I'd now like to discuss the segment operating income results to provide highlights of our operating income change.<br>
North America segment operating income decreased $21 million to $172 million, primarily due to the lower volume, combined with higher<br>promotional and transportation costs, partially offset by favorable product mix.<br>
Corporate costs were down $6 million, primarily related to a benefit from the early redemption of notes receivable from Accolade, our former<br>Australian and UK business, and from lower compensation costs. As a reminder, the Australia and Europe segment reported EBIT of $11 million in<br>Q3 last year.<br>
Consolidated equity earnings totaled $53 million, versus $71 million last year. Equity earnings for Crown totaled $43 million, versus $58 million for<br>the prior year. The remainder of equity earnings in Q3 of both fiscal 2012 and 2011 are primarily generated by Opus One. For the quarter, Crown<br>generated net sales of $541 million, a decrease of 12%, and operating income of $87 million, a decrease of 25%.<br>
The net sales decrease was primarily driven by lower volume due to the overlap of the prior-year quarter distributor inventory re-build following<br>the supply chain issues during the summer of 2010.<br>
As Rob mentioned, Crown depletions have been growing mid-single digits in an industry experiencing negative volume growth for the year. Lower<br>volume and higher marketing costs drove operating income decrease.<br>
Interest expense for the quarter was $46 million, down 6% versus last year. This decrease was primarily due to lower average borrowings.<br>
Let's take a look at debt. At the end of November, our debt totalled $3.1 billion. This represents a $132 million decrease from our debt level at the<br>end of fiscal 2011. Our continued strong free cash flow generation and deleveraging efforts over the past several years have enabled us to re-deploy<br>a portion of free cash flow to re-purchase stock.<br>
During Q3 2012, we re-purchased about 5 million shares at a cost of $94 million. During the first nine months of fiscal 2012, we've re-purchased 15<br>million shares at a cost of $281 million for an average cost of $18.79 a share. We expect total repurchases through Q3 to benefit diluted EPS by<br>approximately $0.06 for fiscal 2012.<br>
During the third quarter, we funded the purchase of the remaining 50% of the Ruffino business for EUR50 million, or about $69 million. We also<br>assumed debt net of cash acquired of EUR54 million, or about $73 million.<br>
Our comparable-basis effective tax rate came in at 37%, versus 29% in Q3 last year, which reflected the favorable outcome of various tax items. We<br>continue to target a full year tax rate of 27% for fiscal 2012.<br>
Several state and federal audits are still underway. The timing and resolution of these could favorably impact our tax rate for the year.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>99</i><br>
<hr>
<A name=100></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
Now, let's discuss free cash flow, which we define as net cash provided by operating activities, less CapEx. For the first nine months of fiscal 2012,<br>we generated free cash flow of $587 million, versus $299 million for the same period last year. This improvement primarily reflects a reduced use<br>of cash to fund receivables and a cash benefit for taxes.<br>
Our receivable balance increased less than the previous year due to timing of sales, and the sale of our Australia and UK business.<br>
As a reminder, in Q1 we received a net refund of taxes, primarily related to the Q4 fiscal 2011 sale of our UK business.<br>
As mentioned earlier, we're increasing our fiscal 2012 free cash flow target by $100 million, to a range of $700 million to $750 million. The increase<br>is primarily due to the expected realization of additional cash tax benefits from the sale of our UK business that were previously targeted for fiscal<br>2013.<br>
We're also reducing our CapEx estimate by $15 million to a range of $70 million to $80 million. As previously discussed, we believe our sustainable<br>free cash flow is in the $500 million-plus range.<br>
Now, let's move to our full-year fiscal 2012 P&amp;L outlook. As noted earlier, we continue to expect comparable basis diluted EPS to be in the range<br>of $2 to $2.10, versus our $1.91 result in fiscal 2011. This includes the estimated $0.06 benefit for share re-purchases, which is consistent with our<br>previous guidance.<br>
As outlined by Rob, we now expect depletions for our US wine and spirits business to come in a bit below the market trend, and our planned target<br>for the full year. We expect the corresponding shortfall in sales volume to be somewhat offset by some mix benefits and cost reductions. We've<br>also reduced our interest expense guidance.<br>
For Crown, we continue to target low- to mid-single-digit depletion growth for the year, and flat to slightly down operating earnings due to the<br>incremental marketing funding.<br>
I would also like to highlight a few Q4 fiscal 2012 comparison items for you. For our North American business, we're facing an easier shipment<br>comparison for Q4, as the inventory build during fiscal 2011 was effectively completed by the end of Q3. We are also expecting lower promotional<br>expense, and some additional mix benefit in Q4 versus Q4 last year.<br>
For Crown, in Q4 we expect an improvement in sales growth, and marketing spend to moderate, versus the higher levels experienced in Q2 and<br>Q3 of this fiscal year.<br>
Overall, the good news is that the beer business continues to drive growth in a difficult category, and we're seeing improving depletions and<br>marketplace trends for our wine and spirit business, as our focus brands are performing better, and our new product development initiatives are<br>gaining traction. Our strong free cash flow generation and deleveraging efforts have created flexibility in our capital structure management.<br>
This flexibility has enabled us to buy back a significant number of shares, as we have repurchased $281 million of stock through Q3, which is on<br>top of the $300 million we re-purchased in the last fiscal year. We expect to continue to evaluate share re-purchases as an opportunistic basis, as<br>part of our ongoing efforts to optimize the capital structure of the business.<br>
With that, we're happy to take your questions.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions) Kaumil Gajrawala, UBS.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>100</i><br>
<hr>
<A name=101></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Hi, everybody, good afternoon. If I could start maybe and see if you can quantify for us the impact that Arbor Mist and Vendage had on your overall<br>focus brand depletions.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes. It actually had quite a significant impact and if we stripped out just those two brands, we would have gained share in the overall category,<br>wine category, for the quarter. That really has been a big driver of our overall market share loss in total wine.<br>
Now if you look at just table wine, we did gain share in the quarter, and if you look at premium plus, we gained share in the quarter, too. I mention<br>that because clearly, the premium plus category above $5 is our primary focus.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Got it. And then also just a follow-up on quantification. Is there any way for you to give us some context on what growth may have been on<br>shipments, excluding the inventory build from -- at Crown last year?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes, this is Bob, Kaumil. I don't think we can get into that kind of detail.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Okay. No problem.Then just clarifying something on your guidance for Crown.You said improved sales growth and marketing spend to moderate.<br>Just want to understand, because was that from a depletions perspective, or is that from a shipments perspective. Also, was the increased volume<br>last year in 4Q also the replenishment of the supply issues?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes. So, the replenishment of the supply chain issues in the beer business was done by the end of the fourth quarter -- I mean the third quarter.<br>The fourth quarter, from a shipment-depletion perspective was pretty clean. Okay. So, we expect to -- for shipments in depletions, to continue to<br>have pretty good growth in the fourth quarter.<br>
Now this year, one of the reasons that the beer business's EBIT is down is incremental marketing spend. You'd think the majority of that is behind<br>us, as this year they spent the wide majority of that incremental monies in the peak summer season; so in Q2, Q3.<br>
That's why I said Q4, we expect continued or even slightly better sales growth, which would -- the same as depletion growth for the fourth quarter,<br>and reduced marketing, as opposed to the previous year.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Got it. And final question on prioritization of the free cash flow. You now have $100 million more than planned. Should we -- given how often you<br>talked about the buy-back in your prepared remarks -- should we assume that much of that can go toward incremental buy-back?<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>101</i><br>
<hr>
<A name=102></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes. I mean our Board authorization is still at the $500 million level, and we have a little bit over $200 left on that. We don't have any additional<br>Board authorization at this point. But as usual, we'll be looking at the market general trends to see whether we should be out there buying back<br>more of our shares.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Okay, got it. Thanks, guys.<br>
<b>Operator</b><br>
Judy Hong, Goldman Sachs.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Good morning. Rob, just on the wine business, just as you think about the payback that you've gotten in the current quarter from higher promotions.<br>Obviously depletions improved sequentially, but it seems like it sort of came at the expense of higher promos. Can you maybe help us understand,<br>do you think you've got enough payback on those spendings? What will the competitive environment look like?<br>
Then as you look out in fiscal 2013 with a lot of these new products coming in line, how should we think about the promotional spending? Then<br>is 2013 finally the year where you think you can get the wine business to grow in category growth?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes, so I think in terms of payback on promotional spending, we certainly feel that we are getting a payback, and you can sort of see it as a result<br>of the sequential improvement in growth when we increase promotional spending.<br>
Now, we do also mitigate that to a degree and fund it by taking some of the actions which we've taken, such as increasing net price on our value<br>brands, where we frankly don't care that much about share, to help fund and offset some of the costs of promoting our premium plus portfolio.<br>But in general, yes, promotional expense is up net, net, net, and yes, we think that it is paying back, given where we would otherwise be if we didn't<br>do so. What was your second question, Judy?<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
So, if that's the case--<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
As far as growing with the category next year, our plan is certainly to grow in line with the category next year, and as we build momentum this<br>year and are either -- depending on the category -- exceeding category growth rates or nearing total category growth rates, we should go into<br>next year with good momentum to achieve that.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Okay. And then Bob, just in terms of the whole shipment versus depletion delta on the wine business, are we completely now done just in terms<br>of the distortions in the fourth quarter? Are we still to start off cleanly as depletions matches shipments at your wholesaler level?<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>102</i><br>
<hr>
<A name=103></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes, I'd say the wide majority of it is done. There could still be some adjustments for the fourth quarter, because what we've said is for the full year,<br>shipments will equal depletions, right? So, you kind of adjust in the fourth quarter to get to the full-year balance.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Okay. And then on the Crown side, just any updated thinking just in terms of how you're thinking about pricing? Clearly your depletion trends<br>have been pretty healthy, but the margins have not really followed through. Just how you're thinking about pricing at this point?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes, good question. So, as we know, the beer category has been experiencing negative volumes. The larger domestic players have been taking<br>some pricing.We actually at the Crown business took some front-line pricing in October. Not as much as the domestic players, and the pricing was<br>different by brands and by geographies.<br>
But the other thing that the Crown business is doing is reducing its promotion spending, which is in essence, an increase in the net price to the<br>consumer. Now that reduced promotion spending is reinvested in marketing. So, that's why when you see the Crown income statement, you'll see<br>a pretty big increase in marketing expense, because there's two things going on there.<br>
There's money coming from promotion down into marketing, and there's the incremental funding that's occurring on the Crown P&amp;L versus the<br>prior year. So it's a pretty big increase in the marketing spend.<br>
Looking at how volumes and how dollars sales growth has been doing versus the category, it seems to be being pretty successful. And the marketing's<br>been pretty well received, Rob gave some of those awards. I think those guys are doing a great job in feeling good about their top line. I think the<br>marketing overlaps from prior year are kind of hurting the bottom line. But that should abate as we go into next year.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
So, if you take the front-line pricing and the reduced promo spending on Crown, the net price per barrel would have been up sort of 1% to 2% kind<br>of level?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
That's probably about right, maybe on the high end of that.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Okay. All right, got it.<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Judy, you can kind of look at IRI and look at the volume growth versus the net sales growth. You'll see that the net pricing to the consumer in IRI<br>is up just north of 2%, which is less than the domestic guys, but still pretty healthy, especially when you compare that to how the volumes are<br>doing to prior year.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>103</i><br>
<hr>
<A name=104></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Right. Okay. Great, thank you.<br>
<b>Operator</b><br>
Dara Mohsenian, Morgan Stanley.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
Good morning, guys.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Dara.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
You mentioned innovation is one of the primary drivers to drive, improve wine market share trends going forward. I think previously you had<br>thought that would play out this holiday season. I just want to get a sense from you on how much of an increase in innovation contribution you're<br>expecting in calendar 2012 versus 2011, or the pipeline of innovation you have planned versus this year, and if there's a significant ramp-up going<br>forward?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes, we expect pretty significant increase in the contribution of innovation to our growth in next year, whether it's calendar 2012 or fiscal 2013.<br>Almost probably double the rate of the contribution that innovation made in 2012 or calendar 2011.<br>
As I mentioned in my talk, we have very ramped up new product initiatives and expect to introduce almost 20 new products into the market place.<br>This year, it contributed roughly 200 basis points or 2% to our overall growth, and next year it should -- as I said, contribute significantly more.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
Okay. That's helpful. And can you give us an update on your thoughts for the pricing environment in the wine category as we look out to calendar<br>2012 year, and an update on the promotional environment?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes. I would say starting with the promotional environment and the holiday season, it has been fairly consistent with how things have played out<br>through the year, and basically with last year.<br>
Now, as you are aware from previous calls, this year's harvest in California was down, and in certain areas and in certain varietals, oversupply is<br>turning into under-supply, especially in the north coast.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>104</i><br>
<hr>
<A name=105></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
As a consequence of that, I would say that we probably think that you will see some pricing being taken on, especially higher-end products that<br>are suffering from some of the under-supply.<br>
Now, that said, are we seeing any widespread examples of that? No. I've put that just more in the category of what people think, as opposed to<br>what's really happening, so we're going to be watching it very carefully as we go into next year to see what's happening out there in the market<br>place.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
Okay, and are you anticipating adjusting pricing at all on the value wines given some of the demand elasticity issues, or are you more focused on<br>profitability at this point?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
We kind of pulse that activity, so we've taken some pricing up on some of the value wines, and then we've taken some of the pricing back down<br>on the value wines, depending on whether we think we're getting the benefit from the pricing or not, over an appropriate period of time. It can<br>kind of go both ways, but in general, I would say that we're going to be more inclined to price value wines than the opposite, meaning take pricing<br>down or drive for volume or share.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
Okay. Thanks so much, guys.<br>
<b>Operator</b><br>
Tim Ramey with D.A. Davidson.<br>
<b>Tim Ramey</b><i> - D.A. Davidson &amp; Co. - Analyst</i><br>
Good morning. Just Rob, wondering how you think about the dollar price point positioning of your portfolio now versus the wine category. It<br>seems to me that it skews more favorably up the price point than it did several years ago.That's been kind of where the growth is in the wine sector.<br>
Why shouldn't we think that you would out-perform the overall wine category in 2013, or fiscal 2013, I should say?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Well, again, whether we gain share or lose share in the category, it will be very dependent on sort of the decisions we make as to how do we price<br>various elements of our portfolio.<br>
Our portfolio is large, we've got a lot of wines -- and I'll say outside of mainstream categories -- whether it is beverage, dessert wines, kosher wines,<br>fruit-flavored varietal wines. We are very tactical in our decisions from a financial perspective as to whether to opt more for pricing or whether to<br>opt more for value.<br>
I would say that sort of the best measure of how we're doing overall is how we're doing on our focus brands, which is a relatively small portfolio<br>of 17 brands, and constitutes the vast majority of our profitability in the United States.There, we're particularly interested in whether we're gaining<br>or losing share.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>105</i><br>
<hr>
<A name=106></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
Now that said, one of the focus brands is the value brand. It is Arbor Mist. It's a big brand. As I have said, we have made the decision and we did so<br>last year -- this year, in actuality of the current year -- to tactically raise prices on that particular brand, and to sacrifice the volume which did impact<br>the overall growth rate of the focus brand. So, it's sum and sum.<br>
<b>Tim Ramey</b><i> - D.A. Davidson &amp; Co. - Analyst</i><br>
Got you. And just a quick one on some of the brands that you used to own over at Sentia. Any -- I hear that some of those are either on the block<br>or somewhat distressed. Any thoughts on that? You've managed those brands before. Would it make sense to look at them again?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
No. We sold them.<br>
<b>Tim Ramey</b><i> - D.A. Davidson &amp; Co. - Analyst</i><br>
Okay. That's definitive.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Nothing that we sold that we want back at the moment.<br>
<b>Tim Ramey</b><i> - D.A. Davidson &amp; Co. - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Reza Vahabzadeh, Barclays Capital.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
You talked about optimizing the cap structure as well as the share buy-back activities. Can you continue with the share repurchase activities and<br>de-lever the balance sheet and get the leverage down to perhaps below three times in the coming year, given your $600 million to $750 million<br>cash flow?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes, Reza, this is Bob. Obviously you decide how much stock to buy back, right? So, this year we've given new guidance, which is improved. And<br>we decide if we're going to buy any more stock in the fourth quarter, and we have to decide, because next year, we should have $500 million plus<br>of free cash flow. Because it will be at least a sustainable year next year. We would be able to de-lever and buy stock, depending on how much<br>stock we buy back.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
Right. You still want to de-lever, right? In the past, I think you have thrown out two and a half, three turns, as well?<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>106</i><br>
<hr>
<A name=107></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
No, I think what we've said is our ideal structure is three to four turns. You know, year-to-date, I think as of the -- if you just use our guidance, and<br>assume we don't buy back any more stock, I think we'll finish the year just under 3.4. Had we not bought any stock back, we would have been closer<br>to 3.0. We've made conscious decisions by buying back stock to stay north of 3.0, and we will assess those as we go along.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
Fair enough. Have you commented on the food service channel, the restaurant channel and how sales are progressing in that channel for your<br>products?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes, I think that we're seeing the on-premise channel up for the first time in a long time. For us, we've probably gained share on a dollar perspective<br>and lost share on a volume perspective because we've significantly changed the mix of product that we're selling in the on-premise to more<br>high-end, premium plus product from I'd say lower end.<br>
So the on-premise is rebounding, it is up a bit we believe overall and we believe we're gaining share from a dollar perspective.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
So the category itself, on-premise is up in terms of sales.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Correct.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
Thank you much.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Probably in the1% to 2% range.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
Got it. Thanks.<br>
<b>Operator</b><br>
Vivien Azer, Citigroup.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>107</i><br>
<hr>
<A name=108></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Vivien Azer</b><i> - Citigroup - Analyst</i><br>
Hi, good morning. My question has to do with the focus brand strategy. Specifically, while I recognize that the wine category is highly fragmented<br>so you need a number of offerings to compete effectively. I do wonder a little bit whether 19 focus brands is maybe too many, and could you<br>possibly better leverage your investments if you narrowed your focus a little bit? Is that under consideration at all?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
I don't think that 19 is necessarily too many, but that said, we have had, I'll say, a strategy of narrowing our focus and investment against a smaller<br>number of brands, even within our focus brands.<br>
Fundamentally, the answer to your question is no, there are not too many, but yes, we agree that in terms of investment, that probably narrowing<br>the focus and making bigger bets against a smaller number of brands is probably strategically the way to go.<br>
On the other hand, a lot of the brands are very profitable and need to be looked after appropriately. Fundamentally, we agree strategically with<br>what you just suggested.<br>
<b>Vivien Azer</b><i> - Citigroup - Analyst</i><br>
Within that subset then, of maybe like focused focus brands, where do those fall generally across the pricing spectrum?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Well when you look at this -- first of all, we don't have a subset of focused focus brands -- you made that up, not us. But going along with that<br>concept, okay, you kind of start with what is the biggest piece of the portfolio, and that's the Mondavi franchise. Robert Mondavi and Woodbridge<br>by Robert Mondavi. That, in and of itself, is a large part of -- or the most important part of the focus brand portfolio.<br>
Then you've got a few -- I'm not just talking wine here -- you've got a few other important brands, like SVEDKA vodka, like Kim Crawford. Those<br>would be examples of brands that really rise to the top in terms of their level of importance -- Clos Du Bois -- In the overall focus brand portfolio.<br>
<b>Vivien Azer</b><i> - Citigroup - Analyst</i><br>
Great. That helps a lot. Thank you.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
I guess I didn't quite answer your question. If you look at Woodbridge, that's premium. If you look at Clos Du Bois, that's super premium. If you look<br>at Kim Crawford, that's luxury. If you look at Robert Mondavi Private Selection, that's super premium, and Robert Mondavi Napa is luxury.<br>
<b>Operator</b><br>
Mark Swartzberg from Stifel Nicolaus.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Hi, Mark.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>108</i><br>
<hr>
<A name=109></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Are you there, Mark?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
We can't hear you, Mark. Are you muted?<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
I'm trying to speak. Can you hear me?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Now, we can.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
Okay. Morning, guys. So, a couple of questions on wine and then one on Crown. Rob, you gave us that 2% depletion, or that 2% contribution from<br>innovation year-to-date for the wine business. Is that a contribution to depletions?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
Got it, great. As you think about, you remarked that you think you can grow in line with the wine category still, in spite of some of these value<br>challenges this year. How do you feel about your ability to grow operating income faster than the wine category, given the experience with spending,<br>and the mix issues, and so forth?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
So, to your first question, we did not say that we would grow in line with the category this year. I would say that --<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
I'm sorry. I mean calendar 2012, fiscal 2013.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Okay. Yes. And then to your second question, we should be able to leverage the P&amp;L.<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>109</i><br>
<hr>
<A name=110></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
You do expect it, great. Then over on Crown, are we kind of done with the structural step-up in marketing spend? Do you think fiscal 2013 is more<br>of a operating income in line with revenue type type of year?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes, I mean I think we're done, Mark, with the step-up in marketing. There might still be some flux between promo spend and marketing, but they<br>kind of zero off at times, gets to the bottom line. All you'll be left with is pretty much pricing -- normal stuff, pricing and mix. Now, we do have the<br>contractual cost of goods sold increase.<br>
Okay, so just normal stuff, but I think the increased marketing and promotion spending will be behind us, and it will be [an] apples-to-apples year<br>if you look at fiscal 2013 over fiscal 2012 from a marketing and spending perspective at Crown.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
Great. And if I could build a little on the earlier question about operating income and wine growing faster than revenue. From where I sit, it's hard<br>to see why you have that view. Is that a function of your mix view? Is it simply leveraging of the fixed costs? Can you talk a little bit more about<br>that, Rob?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes. I think, Mark, most of it will come from we have some pretty robust plans in place to reduce costs of goods sold, and we've talked about these<br>a number of times, around things like reduced number of bottling lines, a higher fixed-cost leverage, some blend changes, some better warehouse<br>management, some better grape buying, things around that. I think that we will keep SG&amp;A growing below net sales, okay? I think those two areas,<br>and COGS is the big number, will be -- will help us leverage the P&amp;L.<br>
The wild card, I think will be promotion spending. Okay, because as you know, it's a pretty fractious industry. We're not the only player. We kind of<br>can't raise prices when nobody else is, which as you know, Rob mentioned some of that earlier. I think the things within our control we feel pretty<br>good about.<br>
I think that things that are a little less within our control, like pricing and promotions, well they're not within our control. That being said, we've<br>had two years in a row of short harvests, so you would hope that the industry would reduce promotion spend and maybe increase prices, but time<br>will tell.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
Got it. That's great. Thank you.<br>
<b>Operator</b><br>
Gary Albanese, Auriga USA.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
I was wondering if you could just touch on inventory levels. Seems to be -- is that roughly what you were expecting, and was that impacted from<br>the cost of the high cost from you grape harvest this year?<br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>110</i><br>
<hr>
<A name=111></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
In terms of the harvest, the harvest from a dollar perspective will be smaller this year than it was last and therefore, it sent a positive impact on our<br>inventories and our cash flow this year. And I would say that the harvest was a bit smaller than we expected.<br>
Therefore, the inventory impact and positive cash flow impact was a bit greater than we expected to have. We started the year with lower cash<br>flow guidance than we're ending the year with. We've increased our cash flow guidance, and that was one of the components of why cash flow is<br>coming in higher than our initial guidance. Is that what you were asking me about, Gary?<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
To some degree. Let me move on to, looks like double-digit growth again in the quarter. Are you guys still on pace to exceed or -- was it 4 million<br>cases, I think you said, the last quarter?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Gary, I'm sorry. We're having a tough time hearing you.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Sure. SVEDKA, are you still on pace to exceed four million cases this year?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
No. We'll be slightly under it, but fundamentally on pace to be around four million cases.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Okay.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
So, yes. It will be around -- certainly, the run rate is at that level.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Okay.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
SVEDKA is generally meeting all of our expectations, and continues to grow double digits now on a very large base. It's the third largest vodka<br>brand.<br>
17<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>111</i><br>
<hr>
<A name=112></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Yes. I mean, being that's a smaller segment, I know the question's been posed in the past about whether it fits, but is that actually an area that, the<br>spirits business, that you've contemplated actually growing?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Well, our spirits business is three brands, basically. SVEDKA, Black Velvet and Paul Masson Grand Amber Brandy, three big brands.<br>
Yes, we're certainly consciously and specifically trying to grow that business, with our primary focus being on taking advantage of our position in<br>the vodka category with basically the hottest large brand.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Okay. All right, thank you.<br>
<b>Operator</b><br>
Carla Casella, JPMorgan.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Hi, looking at your distributor markets, what percentage of your business now is in markets where it's a sole distributor, and is there still more<br>markets to go there?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
In terms of what we've consolidated, 60% of our business is -- has been consolidated in those markets where we've been able to do that in the<br>United States. So 60%.Then of the remaining 40%, there's probably about another 8%, for argument's sake, that in theory could be more consolidated<br>in the manner that we consolidated the initial 60%.<br>
The reason that there's only 8% of the remaining 40% is because you have to remember that some of the markets are control-state markets like<br>Pennsylvania, where there's really -- where the whole concept of consolidating distributors is inapplicable.<br>
And then another large percentage are what are called franchise-law states which means that we don't have the ability to necessarily terminate<br>the existing distributors pursuant to a consolidation plan, so it's difficult to change your distribution network in those franchise markets, so 8%.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay, great. And then you see -- oh, go ahead, sorry?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Sorry, I was just saying 8%.<br>
18<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>112</i><br>
<hr>
<A name=113></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay. Do you see a big difference in performance between the distributor and -- I'm sorry, the sole distributor -- and the multiple distributor markets?<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Yes. It's not so much sole distributor and multiple distributor, although that's a part of it. But what really -- yes, the answer is yes. We definitely are<br>out-performing in markets where we've implemented our distributor consolidation efforts but that -- what are some of the things that really drive<br>that, where we're able to consolidate, we're able to have exclusive sales forces within those distributors selling only our products.<br>
That gives us a lot of additional focus on our portfolio, as being -- opposed to being just part of a general sales force and selling multiple products.<br>So, the answer is yes. We're outperforming in those markets.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Great.Then just one follow-up you may have already answered and I may have missed it. Did you say whether there has been any change in terms<br>of the timing of the Crown JV decision? Is that still an end -- think it was the end of 2012 event, we should know?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
The initial term of the Crown contract was ten years, ending 2016. It cannot be terminated or altered for five more years.There are notice provisions<br>as to what they may propose that would require them to give us notice three years in advance of the termination at the end of 2016, but there's<br>five years left on the Crown contract, period, and it automatically renews for another ten years, except in the event of their giving us advanced<br>notice of non-renewal.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay, great. So, the earliest would be the notice period would be end of 2013.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
That's only notice.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Right. Only notice for the termination 2012, if that were to occur. Okay.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Notice.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
That's all I have, thank you.<br>
19<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>113</i><br>
<hr>
<A name=114></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Operator</b><br>
That was our final question. I would like to turn the floor back over to Mr. Rob Sands for any closing remarks.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Okay, well thank you all for joining our call today. I would say that overall, I'm very satisfied with our third-quarter results, and would summarize<br>the highlights as follows. We generated very strong free cash flow, and as a result, have increased our guidance for the year. Our strong free cash<br>flow results have enabled us to fund share re-purchases, and we expect to be opportunistic in this regard as part of our on-going efforts to optimize<br>the capital structure of the business.<br>
We are experienced improving depletion momentum for our US wine business and the spirits business as well, and our new product development<br>initiatives are being well received in the market place. Our Crown imports beer business continues its strong market place momentum. Our plan<br>is to continue solid execution of our initiatives throughout the final quarter of the year. Thanks again, everyone, for your participation.<br>
<b>Operator</b><br>
Thank you. This concludes today's conference call. You may now disconnect.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4687961-2012-01-09T04:58:52.310</b><br>
20<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>114</i><br>
<hr>
<A name=115></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
RPM - Q2 2012 RPM INTERNATIONAL<br>INC EARNINGS CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 3:00PM GMT<br>
OVERVIEW:<br>
RPM reported YTD consolidated net sales of $1.90b, net income attributable to<br>RPM shareholders of $126.7m and EPS of $0.97. 2Q12 consolidated net sales were<br>$916.1m, net income attributable to RPM shareholders was $49.9m and EPS was<br>$0.38. Expects full-year 2012 EPS to be $1.60-1.65.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>115</i><br>
<hr>
<A name=116></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Frank Sullivan</b><i> RPM International Inc. - Chairman and CEO</i><br>
<b>Bob Matejka</b><i> RPM International Inc. - SVP, CFO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Ivan Marcuse</b><i> Keybanc Capital Markets - Analyst</i><br>
<b>John McNulty</b><i> Credit Suisse - Analyst</i><br>
<b>Saul Ludwig</b><i> Northcoast Research - Analyst</i><br>
<b>Aleksey Yefremov</b><i> BofA Merrill Lynch - Analyst</i><br>
<b>Silke Kueck</b><i> JPMorgan - Analyst</i><br>
<b>Edward Yang</b><i> Oppenheimer &amp; Co. - Analyst</i><br>
<b>Rosemarie Morbelli</b><i> Gabelli &amp; Co. - Analyst</i><br>
<b>OVERVIEW</b><br>
RPM reported YTD consolidated net sales of $1.90b, net income attributable to RPM shareholders of $126.7m and EPS of $0.97. 2Q12<br>consolidated net sales were $916.1m, net income attributable to RPM shareholders was $49.9m and EPS was $0.38. Expects full-year<br>2012 EPS to be $1.60-1.65.<br>
<b>FINANCIAL DATA</b><br>
<b>A. YTD consolidated net sales = $1.90b.</b><br>
<b>B. 2Q12 consolidated net sales = $916.1m.</b><br>
<b>C. YTD net income attributable to RPM shareholders = $126.7m.</b><br>
<b>D. 2Q12 net income attributable to RPM shareholders = $49.9m.</b><br>
<b>E. YTD EPS = $0.97.</b><br>
<b>F. 2Q12 EPS = $0.38.</b><br>
<b>G. 2Q12 EPS (excluding one-time items in both years) = $0.37.</b><br>
<b>H. YTD YoverY consolidated net sales growth = 10.5%.</b><br>
<b>I. 2Q12 YoverY consolidated net sales growth = 10.9%.</b><br>
<b>J. 2Q12 consolidated gross profit margin = 40.3%.</b><br>
<b>K. 1H12 CapEx = $18.4m.</b><br>
<b>L. 1H12 receivable DSO = 61.6.</b><br>
<b>M. Total debt as of 11/30/11 = $1.1b.</b><br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>116</i><br>
<hr>
<A name=117></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>N. Full-year 2012 EPS guidance = $1.60-1.65.</b><br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. OPENING REMARKS (F.S.)</b><br>
<b>A. 2Q12 Highlights:</b><br>
<b>1. </b>There are lot of moving parts in relationship to one-time gains in 2Q11 and number of offsetting one-time gains and one-time<br>
expenses in 2Q12 principally related to investment and acquisition activity.<br>
<b>a. </b>Stripping away non-OpEx from last year and various non-operating gains and expenses in 2Q12, believes right way to<br>
look at results from ongoing operating basis is that 2Q sales grew 10% and net income and EPS grew about 9% YoverY.<br>
<b>2. </b>From a segment perspective, non-operating income and expense items principally impacted corporate expense categories<br>
and industrial segment.<br>
<b>a. </b>Stripping these non-operating items out:<br>
<b>i. </b>Industrial segment generated YoverY performance of 10% sales growth and 10% earnings growth.<br>
<b>ii. </b>Consumer segment generated YoverY performance of 12% sales growth and decline in EBIT of 2%.<br>
<b>3. </b>Continuing raw material challenges and balance of higher cost vs. pricing actions resulted in:<br>
<b>a. </b>Less than desired leverage to bottom line in industrial businesses.<br><b>b. </b>Decline of profit margins in consumer businesses.<br>
<b>4. </b>Goal in coming out of recession was focus on growth in global expansion.<br>
<b>a. </b>Has been aggressively and successfully executing on this strategy.<br><b>b. </b>Picking up market share in vast majority of consumer and industrial businesses in excess of underlying market growth.<br>
<b>c. </b>In recent months, seeing first signs of some lessening in significant raw material categories with sole exception of TiO2,<br>
which only really impacts consumer segment and more specifically Rust-Oleum.<br>
<b>5. </b>Combination of non-operating income and non-OpEx items in 2Q12 almost all relate to ongoing acquisition activity.<br>
<b>a. </b>Increased investment in Kemrock in India to 23% allowing Co. to account for this investment for first time in equity basis.<br><b>b. </b>With closing of FEMA [eastern] coatings business in Germany on 01/03/12, completed more than $160m of annualized<br>
sales from acquisitions during this FY.<br>
<b>c. </b>While aforementioned acquisitions resulted in expansive significant deal transactions including number of smaller<br>
transactions' broker fees and one-time hedge to COGS and relationship to inventory write-offs, all of which are in industrial<br>segment results, all of these acquisitions will be nicely added at sales and earnings towards FY12-end and for FY13.<br>
<b>II. 2Q12 FINANCIALS (B.M.)</b><br>
<b>A. Net Sales:</b><br>
<b>1. </b>Consolidated, increased 10.9% over prior-year to $916.1m.<br>
<b>a. </b>Principally due to:<br>
<b>i. </b>Volume improvement 5.1%.<br>
<b>ii. </b>Price increases 2.9%.<br>
<b>iii. </b>Acquisition growth 3%.<br>
<b>b. </b>Aforementioned partially offset by unfavorable FX of about 0.1%; almost nonexistent on FX side.<br>
<b>2. </b>Industrial segment, $641.5m.<br>
<b>a. </b>70% of net sales.<br><b>b. </b>Increased 10.1% over 2Q11 with:<br>
<b>i. </b>Acquisition growth 4.2%.<br>
<b>ii. </b>Volume increases 3.2%.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>117</i><br>
<hr>
<A name=118></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>iii. </b>Price increases 2.9%.<br>
<b>c. </b>Aforementioned partially offset by unfavorable FX of about [0.2%].<br>
<b>3. </b>Consumer segment, $274.6m.<br>
<b>a. </b>Increased 12.6% over 2Q11, with:<br>
<b>i. </b>9.5% attributable to unit volume growth.<br>
<b>ii. </b>3.0% from positive price.<br>
<b>iii. </b>0.1% attributable to acquisitions.<br>
<b>b. </b>FX had no impact on consumer segment.<br>
<b>B. Gross Profit:</b><br>
<b>1. </b>Consolidated, increased to $369m from $339m last year, principally due to:<br>
<b>a. </b>Higher sales volume.<br><b>b. </b>Price increases.<br>
<b>c. </b>Some favorable mix.<br>
<b>2. </b>Declined 80 BP to 40.3% of net sales, due to persistently high cost of raw materials.<br>
<b>C. SG&amp;A:</b><br>
<b>1. </b>Consolidated, increased 12.5% to $281.9m from $250.6m last year, due to increase in variable costs associated with higher<br>
sales volumes like compensation and benefits, distribution costs, advertising and promotional issues and acquisitions costs<br>associated with increased M&amp;A activity.<br>
<b>a. </b>As a percent of net sales, increased to 30.8% from 30.3% year-ago.<br>
<b>D. EBIT:</b><br>
<b>1. </b>Increased $93m from $89.4m last year, due principally to higher sales volumes.<br>
<b>a. </b>Realized price increases were not able to offset higher raw material cost resulting in EBIT margin percent that declined<br>
from 10.8% to 10.2%.<br>
<b>2. </b>Industrial segment, increased 14% to $78.3m from $68.7m year-ago, driven by:<br>
<b>a. </b>Overall 10.1% increases in sales.<br><b>b. </b>Price increase.<br>
<b>c. </b>Favorable sales mix.<br>
<b>i. </b>Aforementioned improvements more than offset by higher raw material cost resulting in EBIT margin increased 12.2%<br>
of net sales vs. 11.8% last year.<br>
<b>3. </b>Consumer segment, declined 2% to $26.7m from $27.3m year-ago.<br>
<b>a. </b>Sales increase of 12.6% including price increases of 3% were not able to offset higher raw material costs and increased in<br>
variable selling expenses that are associated with higher sales volumes.<br>
<b>E. Other Metrics:</b><br>
<b>1. </b>Corporate and other expenses increased $5.4m, primarily due to higher acquisition cost of $3m in insurance reimbursements<br>
in 2Q11 of approx. $2.9m that did not repeat this year.<br>
<b>2. </b>Interest expense increased from $16.4m year-ago to $17.9m; primarily due to:<br>
<b>a. </b>Issuance of additional $150m in dept in May 2011.<br><b>b. </b>Higher avg. interest rate YoverY.<br>
<b>c. </b>Increased borrowings associated with this year's increased acquisition activity.<br>
<b>3. </b>Investment income decreased $3.3m YoverY, primarily due to gains on sales of marketable securities last year of approx.<br>
$3.2m that did not reoccurred this year.<br>
<b>4. </b>Income tax rate 29.2% vs. 2Q11's 30.8%, principally due to:<br>
<b>a. </b>Change in jurisdictional mix of actual and forecasted earnings.<br><b>b. </b>Impact of certain foreign operations on US taxes.<br>
<b>c. </b>Adjustments to certain tax valuation allowances.<br>
<b>5. </b>Net income attributable to RPM shareholders increased 2.3% to $49.9m vs. 2Q11's $48.8m.<br><b>6. </b>EPS $0.38.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>118</i><br>
<hr>
<A name=119></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>a. </b>Flat to 2Q11.<br><b>b. </b>2Q11 included roughly $7.5m of non-recurring items representing after-tax benefit of approx. $0.04 per diluted share.<br>
<b>c. </b>2Q12 results of $0.38 per share include benefit of Co.'s equity ownership in Kemrock Industries and Exports Limited totaling<br>
about $0.04 a share, which was offset by $0.03 per share of costs related to higher acquisition related expenses.<br>
<b>d. </b>Excluding one-time items in both years, EPS of $0.37, exceeded 2Q11's EPS of $0.34 or an increase of 8.8%.<br>
<b>F. YTD Results:</b><br>
<b>1. </b>Consolidated net sales increased 10.5% to $1.90b from $1.72b last year, principally due to:<br>
<b>a. </b>Volume improvement 3.6%.<br><b>b. </b>Price increases 2.9%.<br>
<b>c. </b>Acquisition growth 1.9%.<br>
<b>d. </b>Favorable FX 2.1%.<br>
<b>2. </b>EBIT increased 8.6% to $229.5m from $211.4m last year, due principally to higher sales volumes.<br>
<b>a. </b>Realized price increases were not able to offset higher raw material cost resulting in EBIT margin that declined from 12.3%<br>
to 12.1% of sales.<br>
<b>3. </b>Net income attributable to RPM shareholders increased 7.6% to $126.7m vs. last year's $117.8m.<br><b>4. </b>EPS increased 6.6% to $0.97 vs. $0.91 last year.<br>
<b>G. Balance Sheet &amp; Cash Flows:</b><br>
<b>1. </b>1H12:<br>
<b>a. </b>CapEx $18.4m vs. 1H11's $15.3m.<br><b>b. </b>Depreciation and amortization expense increased slightly to $36.9m from last year's $36.7m.<br>
<b>c. </b>Cash from operating activities $110m vs. $183m year-ago; main factors that contributed to decrease:<br>
<b>i. </b>Increases in inventory of $24.7m attributable to higher material cost.<br>
<b>ii. </b>Reduction of $46.3m in AP due to timing differences of payments.<br>
<b>iii. </b>Negative swing in other accrued liabilities.<br>
<b>2. </b>Receivable DSO 61.6 vs. 58.7 year-ago.<br><b>3. </b>Days of inventory 84 vs. 80.2 last year.<br>
<b>H. Capital Structure and Overall Liquidity:</b><br>
<b>1. </b>As of 11/30/11, total debt $1.1b vs. $925.1m last Nov.<br><b>2. </b>On 05/24/11, sold $150m aggregate principal amount of 6.125% notes, which were on follow-on issuance of $300m aggregate<br>
principal amount of notes due in 2019, which Co. initially issued on 10/09/09.<br>
<b>a. </b>Follow-on offering was priced at premium with an effective yield to maturity of 4.934%.<br><b>b. </b>Proceeds will continue to be used for general corporate purposes.<br>
<b>3. </b>Net debt-to-cap ratio 38.7% at 11/30/11 vs. 34.5% year-ago.<br>
<b>a. </b>Increase primarily attributable to additional $150m of new debt issued in May 2011.<br>
<b>4. </b>Total long-term liquidity at 11/30/11, $803.9m.<br>
<b>a. </b>$301m in cash.<br><b>b. </b>$502.9m available through bank revolver and AR securitization facilities.<br>
<b>III. CLOSING COMMENTS (F.S.)</b><br>
<b>A. 2H12 Outlook:</b><br>
<b>1. </b>Expects continued high-single digit growth in consumer businesses and continuing low-double digit growth in industrial<br>
businesses due to:<br>
<b>a. </b>Underlying unit volume growth.<br><b>b. </b>Continuing price increases.<br>
<b>c. </b>Market share gains.<br>
<b>d. </b>Impact of completed acquisitions.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>119</i><br>
<hr>
<A name=120></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>2. </b>Sees relief in most of major raw materials with exception of TiO2.<br>
<b>a. </b>Counting on this as important aspect of Co.'s ability to continue deliver full-year result targeted at $1.60-1.65 per share.<br>
<b>3. </b>3Q covers Dec., Jan. and Feb.<br>
<b>a. </b>Historically seasonal low.<br>
<b>i. </b>No exception this year.<br>
<b>ii. </b>Will be somewhat negatively impacted by acquisition costs and inventory write-off of FEMA transaction in 3Q.<br>
<b>4. </b>With hints of improving economic conditions in North America both as relates to consumer takeaway and some of construction<br>
markets Co. serves, expectations of some raw material relief and relationship to huge challenges it has faced over last couple<br>of years and full and positive impact of acquisitions completed this year, expects strong finish to FY12 and good start to<br>FY13.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
(Operator Instructions) Ivan Marcuse, KeyBanc Capital Markets.<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
On the consumer side, the volume is very strong. Was there any benefit from weather, or was there pre-buying activity ahead of<br>announced price increases by your customers, or could you give a little detail? How much of that percentage increase was due to<br>new products? What new products are you seeing a lot of momentum in?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
The unit volume growth there has been very good, about 9% in the quarter, and we're continuing to get raw material price increases<br>or product price increases. I'm not aware of any pre-buying, but I do know we have some additional price increases going into effect<br>at the beginning of this calendar year. A lot of it is market share gains, both at our core retail customers, as well as pickups in some<br>new accounts and also some new channels.We're continuing to gain share, for instance, in the automotive sector. Some of the gross<br>margin issues are a mix issue, as we're picking up share in lower margin categories relative to, for instance, Rust-Oleum's historic<br>margins. Some of it relates, in particular, to TiO2 -- just significant ongoing raw material cost increases that are impacting the whole<br>industry. But the strategy that we had coming out of the recession, we're executing. And it was really to focus on aggressive growth<br>in all of our businesses, and we are executing on that.<br>
One other comment I would make in relationship to some of the new product introductions at our Rust-Oleum businesses and our<br>DAP businesses, a good example would be DAP.We just announced a whole new window, door, and sealant line into the construction<br>markets, particularly in relationship to seeing those markets bottom out. And in the process, we have incurred a significant amount<br>of SG&amp;A expense in terms of packaging, product introductions, and the expense associated with a new product line whose potential<br>over time is tens of millions of dollars of new sales, but whose P&amp;L today looks a lot like expense and not a lot of sales because it was<br>just introduced.<br>
We are focused on growth. We are focused on market share gains. And we believe, over time, that a combination of price increases<br>and relief in raw materials will get our margins back in line.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>120</i><br>
<hr>
<A name=121></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
Great. Looking into the third quarter, are the acquisitions that you've made in the first half of the year -- I know historically the quarters<br>were breakeven, plus or minus $0.05 here or there. Would you expect, due to the acquisitions contribution, to be in the black for the<br>quarter? Or is it still, think about it breakeven, plus or minus a couple of cents?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
No, we still have a little bit of inventory write-off relative to the Legend Brands, or write-up relative to Legend Brands business that<br>we closed in September, and the FEMA transaction which we closed just this month, January 3.We'll also have some negative impact<br>on our third quarter as it relates to inventory write-up. It'll be a hit to cost of goods sold, and also the acquisition-related costs in that<br>transaction. But we will call out those separate results.<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
Historically, you've never really called out acquisition costs. Is that a change going forward that you're going to start calling that out?<br>Or was this quarter just particularly high due to all the activity that you've had in the first half, and you just want to make people<br>aware of that?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I think the answer is yes to both. For a number of reasons, our acquisition activity kind of in the mid to late 2000s had slowed down,<br>and we were doing mostly relatively small product lines. I think the last sizable acquisition we did was illbruck in 2005, and that was<br>in relationship to private equity valuation expectations, which are down dramatically, which is a good thing.We are buying businesses<br>at our historic valuations, not the inflated valuations of 2006 to 2008. And in relation to that, changes in accounting, where five to<br>seven years ago, all of your acquisition costs, be they legal costs, due diligence costs, or on some privately negotiated deals, broker<br>fees, were all capitalized. In today's world, all those costs are period expenses.<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
Great. In the consumer segment going forward, even with the market share gains and the mix issues, you'd still expect to benefit<br>from an improving price/cost spread. I know there's a volume issue in the third quarter, but going forward you'd expect the price/cost<br>spread to sort of improve going forward, even with the lower mix?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
That's correct. You will begin to see price/cost mix improvement really in the spring, as our third quarter is so seasonally low. It's<br>hard to really guess at what that will be, but we have been experiencing some significant benefits in certain raw material categories<br>with a FIFO accounting that will start to show up here in the coming months.<br>
<b>Ivan Marcuse</b><i> - Keybanc Capital Markets - Analyst</i><br>
Great. Thanks a lot for taking my questions.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>121</i><br>
<hr>
<A name=122></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Operator</b><br>
John McNulty, Credit Suisse.<br>
<b>John McNulty</b><i> - Credit Suisse - Analyst</i><br>
With regard to the negative mix that you're talking about in the consumer business, can you flush out what product lines might be<br>dragging that mix down? Also, if they're some of the newer ones, is it an issue of you have to discount to get the initial shelf space,<br>and then over time we can see them go back, or is this something that could be a permanent drag on the margins going forward?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
In some cases, for instance, in automotive channels, a number of the product areas are lower margin, so that'll be permanently lower<br>margin. In other cases, it has been one-time lifts associated with getting into new accounts or getting new space, which won't be<br>repeated. Then the other issue is just a continuing game of catch-up on what has been an extraordinary increase in raw materials,<br>particularly TiO2 that has hit our industry broadly.The good news about TiO2 is it really does not impact RPM's industrial businesses.<br>The only place that it really has an impact on us today is in our Rust-Oleum Group, a little bit in small project paints, and principally<br>in primers. Our primer business is a multi-$100 million business, and it is white.That white comes from TiO2, and that's been the raw<br>material that has been most frustratingly high for our Rust-Oleum Group, as well as for our industry.<br>
<b>John McNulty</b><i> - Credit Suisse - Analyst</i><br>
Okay, great. One last question, you reiterated your full-year guidance that you gave back in July. And since then, you've made three<br>acquisitions that you say are going to be at least modestly accretive. I'm wondering what incrementally is getting worse than maybe<br>what you were expecting, if anything, or is it just you're taking maybe just a conservative approach?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I don't think we're taking a conservative approach. I think what's happening is two things -- number one, our sales are better a little<br>bit than we anticipated, particularly in consumer, but our raw material costs are worse, up until this point, than we anticipated. And<br>then, the acquisitions will most definitely help us in the fourth quarter. But on the full year, they're kind of a wash because, as you<br>look at $1.60 to $1.65 target in EPS, it seems like we're behind the curve. Part of that is the expensing of acquisition expenses, $3<br>million, $3.5 million of which hit this quarter, as well as the one-time negative hit to cost of goods sold from inventory write-ups.<br>Those acquisitions have actually hurt us now. You will see a nice benefit in the fourth quarter, which will make the fourth quarter<br>look good. But relative to our full-year targets, we'll essentially offset the negative impacts of the transaction costs in the period in<br>which the deals were done.<br>
<b>John McNulty</b><i> - Credit Suisse - Analyst</i><br>
Okay, great. Thanks for the color.<br>
<b>Operator</b><br>
Saul Ludwig, Northcoast Research.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>122</i><br>
<hr>
<A name=123></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
In the past, you used to give us gross profit margin by the segments, if you would have that information available for both the quarter<br>and for the six months?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
We do not have that, and it was brought to our attention mostly from a number of outside sources, including our businesses, that<br>it's not required by the SEC, and none of our peers provide segment gross profit information.We are advocates of providing segment<br>gross profit information, and we would encourage you and all the investors here to encourage our peer companies and all companies;<br>you can even write a letter to the SEC and suggest that companies provide gross margin information by segment.We think it would<br>provide better information to investors. We may get back to that unilaterally on our own accord, but you can only get hit over the<br>head by so many places as to why we're the only one providing it relative to our industrial peers, and so that's what's behind that.<br>We are advocates of it. As you point out, we've done it in the past, but it has, in certain instances, competitively served to hurt us in<br>our businesses, because our peer companies do not provide it, nor does the SEC require it to be provided.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Maybe just qualitatively, if your total gross profits were down 80 basis points, was it mostly in one segment or the other?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
It was entirely in our consumer segment. Our industrial segment gross margins are relatively flat, and the deterioration in the quarter<br>was entirely in consumer.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Great. That is helpful. Kemrock -- how much do you have invested in Kemrock? Where does it show up on the balance sheet? This<br>run rate of $600,000 of equity income, ex the one-time catch-up, is that what we should be looking for?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes. The investment in Kemrock's currently about $36 million. We would hope that that would go up over time. It's an extraordinary<br>company that we have partnered with in India. Seven years ago, it was a $14 million business. This year, it will do about $250 million<br>in sales. Our ownership interest over that period has gone from 5% to what is now 23%. I think that's correct, the ongoing benefit<br>from an equity accounting is about $600,000 a quarter. We would hope, over time, that that would grow with Kemrock, both in<br>relationship to their growth and our growing investment.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
What do you think -- two balance sheet items, cash flow from operations, last year you had $238 million, and you're running way<br>behind in the first half of the year.What would you expect the full-year cash from operations to be? What do you think your full-year<br>cap spending will be?<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>123</i><br>
<hr>
<A name=124></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I think the full-year cap spending will be around $70 million, and I think free cash flow will be around $100 million.We're in generally<br>good shape on cash from operations in our industrial business.The shortfall is a combination of higher inventory and lower margin<br>delivery in the consumer segment, and that's being addressed. A lot of that is at our Rust-Oleum Group, that's, over time, one of our<br>better businesses. I would expect us to catch that up by the end of the fiscal year. We've targeted about $100 million of free cash<br>flow for the year, and I think we'll get there.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
$100 million is after dividends or before dividends?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
That's after capital spending and after dividends, but before acquisitions.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Got you. Cap spending, $70 million, dividends about $110 million, so that's $190 million. Sounds like you would look for about $280<br>million, $290 million cash from operations?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Correct, somewhere in that range.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Okay, good. Finally, you have this non-controlling interest that was $4 million.What are the sales that you've consolidated that reflect<br>that non-controlling interest? What was 100% of the earnings of those businesses that you took $4 million off the bottom?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I'm not sure I understand the question.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
You have $4 million of earnings that were attributed to non-controlling interest. That's the portion of --<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, those are a combination of joint ventures and other items. We haven't disclosed that. It would be business by business. Some<br>of that is joint ventures or licensees associated with our Carboline business or other joint venture activity, not any one of which is<br>material.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>124</i><br>
<hr>
<A name=125></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
No, what I mean is, Frank, when you take off $4 million off the bottom for non-controlling interest, that's the percentage of those<br>businesses that you don't own, that are owned by somebody else. But you've consolidated 100% of their revenue and 100% of their<br>earnings up above. So my question --.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
No, that's an accounting issue that we had explained earlier. It's in relationship to SPHC, and the accounting for that situation is such<br>that there are businesses that, for instance, as I've highlighted in the past, Day-Glo is part of SPHC, but the Day-Glo subsidiaries or<br>operations outside of the United States are not. And so it is a percentage of minority ownership of SPHC companies, principally<br>Day-Glo and Dryvit, affiliated with those two entities' foreign operations or foreign subsidiaries that are not part of the SPHC/Bondex<br>filing.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Got you. Okay. Thank you very much.<br>
<b>Operator</b><br>
Kevin McCarthy, Bank of America.<br>
<b>Aleksey Yefremov</b><i> - BofA Merrill Lynch - Analyst</i><br>
This is Aleksey Yefremov for Kevin. Frank, could you size the expected price increases in consumer pricing, maybe on a blended rate,<br>how much it would help sales in the back half of the year?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, year to date we're about 3%, and I don't know that we would guesstimate what it would be in the back half, but it'll at least be<br>3%. It could be more, and I, at this point, don't have a good sense of what that is. We've had, in general, about 3% price increases<br>across both of our segments on average. Of course, that is a widely varying mix of some product categories where we have not<br>gotten price increases, and other unique product categories where we've had price increases in double-digit ranges. But on average,<br>it's been 3%, and on average holds about the same for each segment.There are new price increases continuing, some of which were<br>announced in January.<br>
<b>Aleksey Yefremov</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay, thank you. Can you size, at this point, the expected cost hit from the FEMA acquisition in the third quarter?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
No, we can provide that -- we will call that out in the third quarter. We'll have some transaction expenses, as well as an inventory<br>write-up that'll one-time negatively impact cost of goods sold. When we report the third quarter, we will specifically call out those<br>numbers.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>125</i><br>
<hr>
<A name=126></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Aleksey Yefremov</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay. Finally, if I may, multi-family residential construction seems to be doing better than single family.Where do you have exposure<br>to this multi-family market within your portfolio? Is it in consumer or industrial? Do you see better performance in those product<br>lines?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
There are two areas where that will, in the future, impact us.The one area where we're currently starting to benefit is in our Building<br>Solutions Group. Our Tremco sealants, in particular, is showing modest single-digit growth in sales and earnings. That's continuing,<br>and it's principally in relationship to our broad distribution, which gets at multi-family housing, and gets at some of the small<br>construction activity that's picking up.We are benefiting from that there in our Building Solutions Group in particular, and in particular,<br>our sealant product lines.<br>
The other area that we would expect to benefit from that in the future is this new WDS category that we have been investing forward<br>in, in our DAP business. It is a new product line that was just launched that is specifically targeted at the residential and light commercial<br>markets. I think the timing is such that we feel that the worm has turned a little bit on those markets. There's not going to be any<br>huge rebound, but we believe we've found a base at which you're starting to see modest growth. Multi-family housing in particular,<br>in relationship to rent versus own, is an area that's starting to grow pretty nicely.<br>
<b>Aleksey Yefremov</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay. Thank you.<br>
<b>Operator</b><br>
Jeff Zekauskas, JPMorgan.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
This is Silke Kueck for Jeff. Can you clarify how much of the 80 basis point in gross margin squeeze is due to higher raw material<br>costs, and how much may be due to the acquisition-related inventory write-ups?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
The 80 basis points in the quarter was all in our consumer segment. About two-thirds of that was cost/price, maybe 70%-plus was<br>cost/price difference, and the balance is negative mix, which is deliberate. The step-up in inventory is entirely in our industrial<br>segment. All the acquisitions that we have done this year, about $160 million on annualized sales, is in our industrial segment, and<br>I think it's about $2.5 million in the quarter.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
From a raw material cost standpoint, it seems that going into November, raw material costs shouldn't have really increased. So, does<br>your comment on TiO2 have to do with there also being some share gains in specialty primers? How come your raw material costs<br>still seem to be lifting rather than moving lower?<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>126</i><br>
<hr>
<A name=127></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
There's a couple issues -- number one is gains in our Zinsser primer areas. Number two is market share mix into some different<br>channel areas, and number three is FIFO accounting. We're on a first in/first out inventory accounting basis, where the majority of<br>our peers are on LIFO. We would pick up the benefits of improving raw materials 60, 75 days later than what you might see in<br>somebody -- then if we had been on, for instance, LIFO accounting.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
What you really hope for is a very strong fourth quarter?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
We are already seeing, in major raw material areas, improvements in costs. That is in the marketplace today, and that will show up<br>in our results in the coming months. We are also getting additional price increases across a number of our consumer industrial<br>businesses. Unless there is a resurgence in raw material price increases, which we don't see, but in certain categories like TiO2, the<br>market dynamics are such that it's a little bit unconnected to supply and demand, it's hard to predict.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
Lastly, the December retail sales number seemed reasonably strong, and supported by heavy discounting. Is that stuff representative<br>of what's happening in the consumer product side as well? Can you just talk about trends?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
We had a 9% unit volume growth in our consumer businesses in the quarter, and there was some negative impacts to some lifts,<br>some cost of lifting competitive product in some new areas, both in terms of existing customers and some new customers. But the<br>principal -- again, as I said, about 70%, two-thirds to 70% of that gross margin deterioration was associated with just the lag in<br>cost/price. The balance was an issue of mix or lift cost, things like that.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
But I guess my question was -- how sales trends look in December, both on the consumer side, maybe the industrial side?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Sales trends look good. We anticipate, for the balance of the year, that consumer sales will be up in the high single-digits, and a<br>combination of continuing unit growth, market share gains, price increases, and the benefit of these acquisitions will allow our<br>industrial segment to finish the year with low- to mid-teen sales growth.<br>
<b>Silke Kueck</b><i> - JPMorgan - Analyst</i><br>
Okay, thanks.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>127</i><br>
<hr>
<A name=128></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Operator</b><br>
Edward Yang, Oppenheimer.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
On the consumer side, what do you think is a good margin long term for that business? You lost some margin this quarter, but when<br>I look at the full year margins you'll probably have for this year, which is probably going to be in the 13% range, it's not all that out<br>of whack with the 12% to 14% range you've experienced in the last five to 10 years or so.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Sure.We have a couple hundred basis points of operating margin to pick up in that business.We have lost gross margin in a number<br>of our product categories significantly over the last two or three years. We have made that up through a sharper focus in SG&amp;A, the<br>benefits of continuing to focus on sales growth, which has been a very deliberate strategy that's working, and then obviously some<br>loss in operating margin. There is absolutely a couple hundred basis points of operating margin that we would expect to pick up<br>relative to where we will be this year.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
How long do you think that will take?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
It really depends on the trajectory of raw material costs. If raw material costs have peaked, and most analysis of the cyclical nature<br>of raw materials would suggest that in a lot of cases that they're there and passed, I think sooner rather than later. As I indicated<br>earlier, there's some market dynamics that are unconnected to supply and demand, which are challenging.The one that's the biggest<br>challenge there is TiO2. Fortunately, that's not a huge raw material for RPM on a consolidated basis, but it's a meaningful raw material<br>to our Rust-Oleum Group.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Do you expect to see any competitive response? You've spoken a couple of times about gaining share in consumer.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
We are continuing to execute growth plans across all of our businesses, and we face competitive responses every day. And I don't<br>mean that cavalierly. Different people in our industry have approached this raw material situation and some of the economic turmoil,<br>depending on their regional focus, in different manners. Certain industry competitors have announced multi-$100 million restructurings<br>and divestitures.We are very focused on growth.We think, in the long run, that's the right strategy relative to delivering bottom-line<br>results and utilizing the asset base that we have.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>128</i><br>
<hr>
<A name=129></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay. In this quarter, you called out the acquisition costs. The increase was $0.03. But these costs are fairly recurring. How should<br>we think about these costs going forward? Do you expect them to decline, stay about where they are, or increase from where they<br>are? I would think that you would continue to pursue acquisition opportunities.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, normally we wouldn't go through the exercise of adding pluses and minuses that changed our $0.38 to $0.37. However, as we<br>talked about last year in the second quarter, and we talked about in relationship to the upcoming second quarter in our last conference<br>call in October, it was important that we got the financial community focused on the base of last year, which was more like $0.34.<br>You can't go through that exercise of identifying for people your one-time non-operating gains or expenses, and not do it equally<br>in both quarters. I think that's a fair statement. We don't try and call out every little expense item, but if you're going to do it in<br>relationship to a prior period, I think you need to make your adjustments on a consistent basis, and that's what we did.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Got it.With the acquisition of FEMA and Grupo, could you give us an update on your exposure to Europe, and maybe some qualitative<br>or quantitative comments in terms of what you're seeing in terms of demand there?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Sure. Interestingly enough, our European sales and earnings are relatively flat to last year, and we haven't lost any margin. It's a<br>combination of the fact that our exposure in Europe is principally industrial. Our Performance Coatings Group, which is our most<br>global group and also has a big presence in Europe, is serving what is an expanding industrial capital spending and industrial<br>maintenance spending market pretty much across all of our product categories and channels, whether it's in energy, oil and gas,<br>infrastructure, a lot of areas like aerospace or food service. We have a very broad presence in multiple channels, and that is the area<br>both in North America and globally where we're seeing continued strength.<br>
When you look at that industrial segment growth of about 10%, and you realize that half of that is in building materials, mostly North<br>America that are growing 3% or 4%, it gives you a sense of the strong growth in the high performance coatings that serve the<br>industrial capital spending and maintenance markets in what they're doing. Secondly, our largest concentration of business in Europe<br>is in Germany, and that's just been in part strategic, but also lucky, because that's the largest market in Europe and the one that<br>continues to show some positive momentum.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay, but even on the industrial side, there have been some press reports about refineries having issues in Europe. But you haven't<br>seen any impact on industrial demand you're seeing in Europe?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
None.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>129</i><br>
<hr>
<A name=130></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
It's slower than in North America. It's slower than what little business we do in South America or Asia, but it's still positive. Our results<br>in Europe are not in any way in relationship to the headlines that you see every day.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I think the impact is more in the consumer markets, which we don't serve, except for the UK.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay. Just final question from me on the guidance, $1.60 to $1.65, what's the level of confidence there? Year to date, you've had<br>$0.95 in earnings. The third quarter for you is usually a wash. The fourth quarter, just by subtraction, would mean $0.65 to $0.70 in<br>earnings. That would be up 20% to 30% year over year. What's your updated level of confidence in hitting that number this year?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Without getting into the expectations from one quarter to the next, as I commented earlier, I think we're still comfortable that we<br>can get into that range. It will be a combination of the raw material environment that we see today continuing. I think we're confident<br>that the raw material environment and the cost/price situation that we see today is such that we ought to have some improvement.<br>Having been through what we've been through the last two years, it does not anticipate another significant rise in major raw materials<br>this spring. That's one factor.<br>
The other factor is, we have done a pretty good chunk of nice, strategic acquisitions, and year to date they have hurt our gross margin<br>in industrial because of inventory step-ups, and they have hurt our corporate/other expense to the tune of $3.5 million or $4 million.<br>In the fourth quarter, the one-time expenses will be gone. The inventory write-ups will have happened, and you're going to be<br>looking at businesses with sales and earnings that will begin to contribute nicely to the bottom line.<br>
<b>Edward Yang</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay. Thank you for the clarification.<br>
<b>Operator</b><br>
Rosemarie Morbelli, Gabelli &amp; Company.<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>130</i><br>
<hr>
<A name=131></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Frank, when you are rather confident that raw material costs are going to stay more or less level with where they are currently. But<br>with the outlook for oil going up, and oil being already up versus the second quarter, how confident are you that actually you are<br>not going to have any cost increases announcements?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Highly confident, Rosemarie, is an overstatement. We're hopeful, and we're more hopeful than we've been for a while. There have<br>been some significant reductions in certain resin prices and certain packaging and certain solvent areas, and oil prices aren't particularly<br>out of whack relative to where they were a few years ago. Again, the raw material environment we see today makes us hopeful that<br>we'll have a better second half as it relates to the cost/price impact on our gross margins. Having experienced what we've experienced<br>the last couple of years, I'm hopeful that we're not going to jump into another environment where our raw material suppliers are<br>increasing prices 15% or 20%. They're not signaling that, and we don't see it, but it doesn't mean it couldn't happen.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Could you give us a feel for how much you spent in order to introduce the new DAP product line, and when do you think that amount<br>is going to go away?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Without being real specific, we've spent many single millions of dollars to build up an independent division of DAP, and have just<br>introduced the product. Obviously, construction, particularly -- it's a North American, basically U.S.-focused effort at this point, and<br>the construction markets, obviously, are seasonal. I would think the first impacts of that would be this spring and this summer, and<br>depending on our distribution and penetration level, it's a very exciting product line for us. It has potential to add tens of millions<br>of dollars to DAP and RPM, but obviously we've got to have the right product and get broad distribution to get going. So far, it's<br>been an expense base as we build up this organization, develop the packaging, and introduced the product. Revenues from that<br>effort should show up late spring and in the summer.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Are they introduced to the Lowe's of the world, or are they going into industrial applications?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
This is going into more building materials, independent distributors, and really focused on residential and light commercial construction<br>as opposed to the consumer DIY channels and presence, which is predominantly what DAP serves today.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. Talking about the DIY, what are you hearing in terms of your kind of product lines going forward? Are they seeing more<br>maintenance, more renovations, or is it flattish from where we are today?<br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>131</i><br>
<hr>
<A name=132></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Our unit volume growth in the quarter was 9%. As we've commented, some of that was new product and market share gains, but<br>we are seeing consumer takeaway pick up across a number of our product categories, and I think that makes sense given the relatively<br>low price point and either small project redecorating and/or home maintenance and repair nature of our products.We would expect<br>that modest pickup in consumer takeaway to continue for the balance of the year.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay.You talked about Europe and the fact that you haven't seen any decline at this particular point. But if you talk about anecdotes,<br>whatever you hear in the field as well, once you may not have seen it yet in the third quarter, what do you hear going forward from<br>your customers, for example?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, again, I don't want to overstate Europe. We are generally, in sales, earnings, and margins, flat to last year. We have some areas<br>of strength, but we're not experiencing the significant deterioration that the daily headlines would suggest. Given the nature of the<br>products that we are manufacturing and selling in Europe, we don't anticipate any big deterioration there. The biggest challenge<br>at this stage from Europe is what happens to the euro versus the dollar, and the impact on revenues and through our P&amp;L of changes<br>in relative foreign currencies, basically the dollar to the euro.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. Lastly, if I may, could you update us on the performance of Legend Brands versus what you were anticipating?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Legend Brands is brand new, and so I don't have a good sense of where they're going. Unfortunately, they add to the seasonality of<br>RPM, and so their winter months are also seasonally low. We're not getting the big boom from them relative to the seasonality of<br>their business, but they are on target in the early months of their ownership by RPM, and we're real excited about that business and<br>its growth prospects long term.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. Thank you very much.<br>
<b>Operator</b><br>
(Operator Instructions) Saul Ludwig.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
I have a couple quickie follow-ups. The $1.60 to $1.65, that's all-in with all the goodies and the baddies, right?<br>
17<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>132</i><br>
<hr>
<A name=133></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
That is every bit of good, bad, and help that we can get, Saul.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Okay, and then as we look to the fourth quarter, we'll recall that last year you had a $5.5 million bad debt charge, which was $0.06<br>a share, that we hope doesn't repeat, which would give you $0.06 goodie in the fourth quarter just for showing up, right?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Yes, we also had, I think, many millions of dollars of one-time gains from a change in insurance, as well as marketable securities. I<br>think last year's fourth quarter is essentially between the goods and the bads where it is. The Lancaster was the bankruptcy, and we<br>highlighted that as it related to the results of our consumer segment, because it hit in the last month of our fourth quarter. But on<br>a consolidated basis, that was essentially offset by marketable securities gains from our captive insurance companies and other<br>insurance items. I don't recall what those were, but on a consolidated basis, the fourth quarter is what it was.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Got it. One final thing, your corporate expense last year, third quarter, fourth quarter was $16 million and then $4 million; $16 million<br>expense in the third quarter, and only $4 million expense in the fourth quarter. Why such a divergence in numbers, and how should<br>we think about corporate expense in the back end of the year?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I'll let Bob talk about the quarterly corporate expense. But, again, without looking at the numbers, Saul, just to the comment you<br>and I made, my guess is that the one-time gains in relationship to marketable securities or a pickup in insurance recovery that I<br>mentioned in relationship to the Lancaster write-off, would have occurred in the corporate/other category as the offsets. Because,<br>again, on a year-over-year basis, our fourth quarter essentially was what it was, with the hit on Lancaster being offset by corporate<br>non-Other in the quarter.<br>
Now, as it relates to how to think about corporate expense in the third or fourth quarter, the balance of the year, maybe Bob can<br>add to that.<br>
<b>Bob Matejka</b><i> - RPM International Inc. - SVP, CFO</i><br>
Saul, that fourth quarter a year ago was impacted, as Frank said, a lot of insurance adjustments and prior-year stuff. You should<br>probably look at each quarter at somewhere between $11 million to $12 million. It would be a normal run rate on the corporate and<br>other side of our P&amp;L structure.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Okay. Thanks very much.<br>
18<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>133</i><br>
<hr>
<A name=134></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Bob Matejka</b><i> - RPM International Inc. - SVP, CFO</i><br>
And that's assuming that everything is -- no unique items, one-timers happening in those quarters.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
You're not assuming any securities gains or losses in the back end of the year, in your outlook comments?<br>
<b>Bob Matejka</b><i> - RPM International Inc. - SVP, CFO</i><br>
No.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
That is correct.<br>
<b>Saul Ludwig</b><i> - Northcoast Research - Analyst</i><br>
Very good. Thank you.<br>
<b>Operator</b><br>
Rosemarie Morbelli.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Just quickly, on the pension expense, could you give us a feel for how much you spent in 2011? And given the level of the rates and<br>the performance in the market, what do you expect for 2012?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Our pension expense for 2012 should be flat to what we spent in 2011.We had a pickup in pension expense last year in relationship<br>to a drop in securities, as well as an adjustment in the discount rate, relative to interest rates. But I think year over year, we will be<br>flat in pension expense on 2012 to what we spent in 2011.<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Can you remind me how much that was?<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
I don't have that number handy, Rosemarie. I think it's disclosed in our 10-K, but we can get back to you on that.<br>
19<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>134</i><br>
<hr>
<A name=135></a>JANUARY 05, 2012 / 3:00PM, RPM - Q2 2012 RPM International Inc Earnings Conference Call<br>
<b>Rosemarie Morbelli</b><i> - Gabelli &amp; Co. - Analyst</i><br>
Okay. I'll check the 10-K. Thanks. Okay. That was it for me. Thank you.<br>
<b>Operator</b><br>
And there are no further questions at this time. I will now turn the call back over to Mr. Frank Sullivan, Chairman and CEO. Please<br>proceed.<br>
<b>Frank Sullivan</b><i> - RPM International Inc. - Chairman and CEO</i><br>
Thank you for your participation on our investor call this morning. We look forward to providing you the details of our third quarter<br>in April of this year, and also to giving you our expectations for the 2012 finish, and our outlook for our 2013 fiscal year. In the<br>meantime, please accept our best wishes for a happy, healthy, and successful new year. Thank you for your investment in RPM.<br>
<b>Operator</b><br>
Ladies and gentlemen, that concludes today's conference. Thank you for your participation. You may now disconnect. Have a great<br>day.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4675796-6-2012-01-09T20:59:00.153</b><br>
20<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>135</i><br>
<hr>
<A name=136></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
STZ - Q3 2012 CONSTELLATION<br>BRANDS, INC. EARNINGS<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 3:30PM GMT<br>
OVERVIEW:<br>
Co. reported 3Q12 consolidated reported net sales decrease of 27% and comparable<br>diluted EPS of $0.50. FY12 comparable diluted EPS is expected to be $2.00-2.10.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>136</i><br>
<hr>
<A name=137></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Patty Yahn-Urlaub</b><i> Constellation Brands Inc - VP, IR</i><br>
<b>Rob Sands</b><i> Constellation Brands Inc - President and CEO</i><br>
<b>Bob Ryder</b><i> Constellation Brands Inc - EVP and CFO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Kaumil Gajrawala</b><i> UBS - Analyst</i><br>
<b>Judy Hong</b><i> Goldman Sachs - Analyst</i><br>
<b>Dara Mohsenian</b><i> Morgan Stanley - Analyst</i><br>
<b>Tim Ramey</b><i> D.A. Davidson &amp; Co. - Analyst</i><br>
<b>Reza Vahabzadeh</b><i> Barclays Capital - Analyst</i><br>
<b>Vivien Azer</b><i> Citigroup - Analyst</i><br>
<b>Mark Swartzberg</b><i> Stifel Nicolaus - Analyst</i><br>
<b>Gary Albanese</b><i> Auriga, USA - Analyst</i><br>
<b>Carla Casella</b><i> JPMorgan Chase &amp; Co. - Analyst</i><br>
<b>OVERVIEW</b><br>
Co. reported 3Q12 consolidated reported net sales decrease of 27% and comparable diluted EPS of $0.50. FY12 comparable diluted<br>EPS is expected to be $2.00-2.10.<br>
<b>FINANCIAL DATA</b><br>
<b>A. 3Q12 consolidated reported net sales decreased 27%.</b><br>
<b>B. 3Q12 comparable diluted EPS = $0.50.</b><br>
<b>C. 3Q12 consolidated GM = 40.5%.</b><br>
<b>D. Nov.-end debt = $3.1b.</b><br>
<b>E. YTD share repurchase = 15m shares at a cost of $281m for an avg. cost of $18.79 a share.</b><br>
<b>F. 3Q12 share repurchase = about 5m shares at a cost of $94m.</b><br>
<b>G. FY12 expected comparable diluted EPS = $2.00-2.10.</b><br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. 3Q12 BUSINESS REVIEW (R.S.)</b><br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>137</i><br>
<hr>
<A name=138></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>A. Highlights:</b><br>
<b>1. </b>Progressed through year with results generally in line with expectations for most areas of business.<br><b>2. </b>Significantly improved consolidated margin structure.<br><b>3. </b>Progress in free cash flow generation enabled to fund share repurchase efforts where Co. has already completed more than<br>
50% of current authorization.<br>
<b>4. </b>Topline performance not surprising as Co. continued to lap 3Q11 US distributor inventory build.<br><b>5. </b>Shipments to distributors last year exceeded distributors' sales to retail as part of US distributor transition initiative.<br>
<b>a. </b>Benefitted FY11 sales and profits but created sales and EBIT comparison challenge for FY12.<br>
<b>B. Wine &amp; Spirits:</b><br>
<b>1. </b>US wine and spirits depletions improved sequentially.<br>
<b>a. </b>Entire portfolio grew almost 2%.<br><b>b. </b>Focus brands grew about 6%.<br>
<b>c. </b>Expected depletion trends to improve progressing through the year due to gating of promotional spend for US wine and<br>
spirits businesses.<br>
<b>2. </b>This year, driving enhanced promotional and merchandising activity in 2H12 to better align with business seasonality.<br><b>3. </b>In the IRI data coinciding with 3Q, Co. gained volume share for total table wine and premium plus segment which represents<br>
greater than $5 retail price point.<br>
<b>a. </b>This channel accounts for about 35% of Co.'s business.<br><b>b. </b>Spirits sales remain robust as it gains share driven by SVEDKA Vodka brand.<br>
<b>4. </b>Growth for total US wine portfolio continues to lag that of overall US wine category on YTD basis through 3Q12.<br>
<b>a. </b>US wine share loss for this time period primarily attributed to decline in value brands below the $5 retail price point as<br>
Co. increased net prices for some of its higher volume value brands such as Vendange and Arbor Mist.<br>
<b>i. </b>As expected, this action negatively impacted volumes but to a bit greater degree than originally anticipated.<br>
<b>5. </b>In process of revamping up innovation and new product development where Co. currently has more than 20 new product<br>
launches underway in FY12, many of which are included in hot categories that are experiencing significant growth.<br>
<b>a. </b>Has strong momentum for many newly launched products like:<br>
<b>i. </b>Primal Roots; sweet bread blend.<br>
<b>ii. </b>Rex Goliath Moscato.<br>
<b>iii. </b>Ruffino Prosecco.<br>
<b>iv. </b>Woodbridge Malbec.<br>
<b>v. </b>Simply Naked unoaked line of varietals.<br>
<b>b. </b>Dreaming Tree brand:<br>
<b>i. </b>Most recent introduction to new product line-up.<br>
<b>ii. </b>Collaboration between Steve Reeder (award-winning winemaker at Simi) and acclaimed musician Dave Matthews.<br>
<b>c. </b>Collection of new products gaining traction and performed well in marketplace during holiday selling season.<br>
<b>d. </b>In FY13, expects to have increasing percentage of sales growth coming from innovation.<br>
<b>6. </b>Focus brands grew almost 6% with several brands growing double digits including:<br>
<b>a. </b>SVEDKA Vodka.<br><b>b. </b>Black Box.<br>
<b>c. </b>Rex Goliath.<br>
<b>d. </b>Kim Crawford.<br>
<b>7. </b>Aforementioned price increase on Arbor Mist reduced focus brand's growth rates.<br>
<b>a. </b>To mitigate this, introduced Arbor Mist Pomegranate Berry Pinot Noir which is doing well in marketplace.<br><b>b. </b>Recently launched Arbor Mist Strawberry Moscato at Walmart.<br>
<b>i. </b>This new flavor extension exceeded all initial launch expectations.<br>
<b>c. </b>In Feb., introducing Arbor Mist Frozen Wine Cocktails at Walmart in order to capitalize on one of the fastest growing<br>
segments in beverage alcohol.<br>
<b>8. </b>Has other initiatives underway to drive some key focus brands including:<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>138</i><br>
<hr>
<A name=139></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>a. </b>Recent relaunch of Ravenswood with new labeling and refinement of Ravenswood blend to produce a more forward taste<br>
profile.<br>
<b>i. </b>Ravenswood, great turnaround with recent SymphonyIRI trends showing mid single digit volume growth rates.<br>
<b>b. </b>For Blackstone, has new packaging in the works and two line extensions.<br>
<b>i. </b>A red blend was introduced last fall.<br>
<b>ii. </b>Will be rolling out Malbec in the New Year.<br>
<b>9. </b>Awards &amp; Accolades:<br>
<b>a. </b>In the Dec. 31 issue of Wine Spectator, the 2008 Robert Mondavi Oakville Cabernet Sauvignon was named one of the top<br>
100 wines of 2011.<br>
<b>b. </b>Wine Spectator awarded the 2008 Robert Mondavi Napa Valley Reserve Chardonnay 93 points and the 2009 Robert<br>
Mondavi Napa Valley Reserve Pinet Noir 91 points.<br>
<b>c. </b>The Franciscan Cabernet Sauvignon 2007 was named to the Wine Enthusiast's Top 100 of 2011 list.<br>
<b>d. </b>The Inniskillin 2007 Vidal Icewine received 92 points from the Wine Enthusiast and 95 points from the tasting panel.<br><b>e. </b>Five of Co.'s brands made Wine.com's Top 100 list for 2011 including varietals from:<br>
<b>i. </b>Franciscan.<br>
<b>ii. </b>Robert Mondavi.<br>
<b>iii. </b>Ravenswood.<br>
<b>iv. </b>Ruffino.<br>
<b>v. </b>Kim Crawford.<br>
<b>f. </b>IMPACT Blue Chip awards were given to:<br>
<b>i. </b>Clos du Bois.<br>
<b>ii. </b>Estancia.<br>
<b>iii. </b>Robert Mondavi Private Selection.<br>
<b>iv. </b>SVEDKA.<br>
<b>10. </b>Overall, catching up with industry trends and addressing some short-term challenges within brand portfolio.<br>
<b>a. </b>Has several initiatives underway.<br><b>b. </b>Doing well in innovation and new product development.<br>
<b>c. </b>Recent trends improving; tracking a bit short of goal of growing in line with US wine category growth for the year due<br>
primarily to tactical decision to take pricing in value segment.<br>
<b>i. </b>Remains focused on achieving this goal.<br>
<b>ii. </b>Strongly committed to this as one of the strategic objectives in driving profitable organic growth over long-term.<br>
<b>C. SVEDKA Vodka:</b><br>
<b>1. </b>Posted double digit sales depletion and consumer takeaway trends in addition to gaining share in the (indiscernible) IRI<br>
channels.<br>
<b>2. </b>In advance of holiday selling season, launched first-ever limited-edition party bottle package in marketplace.<br>
<b>a. </b>Accompanied by multi-channel marketing campaign including mobile and social media applications.<br>
<b>D. Crown Imports JV:</b><br>
<b>1. </b>As expected, Crown faced difficult 3Q sales and earnings comparison vs. last year when sales increased 22% driven by rebuild<br>
of wholesaler inventories to more optimal levels after Crown experienced supply chain disruptions in the summer of calendar<br>2010.<br>
<b>a. </b>Despite these comparison issues, business remains healthy with depletions growing mid single digits driven by Modelo<br>
Especial, Victoria and Corona Familiar.<br>
<b>2. </b>Experienced strong consumer demand resulting from combined success of number of promotional and marketing initiatives<br>
including the Corona Extra's &quot;Find Your Beach&quot; campaign and additional advertising investments during the NFL season.<br>
<b>3. </b>According to SymphonyIRI retail data coinciding with 3Q12-end, Crown continues to outperform the total US beer industry,<br>
the import category and the other three major beer suppliers in both case and dollar sales trends in the food, drug, mass<br>and convenience channels.<br>
<b>4. </b>Only major supplier to gain industry dollar share or (K) share.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>139</i><br>
<hr>
<A name=140></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>5. </b>Throughout calendar 2011, achieved several milestones and received recognition from some of the most notable beer and<br>
marketing channels in the industry.<br>
<b>a. </b>First year that Crown Imports has been named to Advertising Age's prestigious Marketer A-list.<br><b>b. </b>Second year that Corona Extra has been named one of the best global brands by Interbrand.<br>
<b>c. </b>Modelo Especial won an IMPACT Hot Brands Award and an IMPACT Blue Chip Award with Corona Light winning a Blue<br>
Chip award from IMPACT as well.<br>
<b>d. </b>Modelo Especial and Victoria each received Cheers growth brand awards.<br><b>e. </b>Victoria received a Marketwatch Leaders Choice award in the best new product segment.<br>
<b>6. </b>These awards highlight continuing success of brand portfolio and underscore Crown's unique approach to marketing.<br><b>7. </b>Overall, calendar 2011 was the largest volume year for the collection of Modelo brands in US.<br><b>8. </b>Throughout remainder of year, focused on market execution and optimizing promotional and marketing initiatives.<br>
<b>a. </b>Continued expansion of Corona Familiar 32-ounce bottle primarily in Mexican and Hispanic markets throughout US.<br>
<b>i. </b>Launched in US in calendar 2010, Corona Familiar had strong depletions in calendar 2011.<br>
<b>b. </b>Victoria will expand to select cities within those states where it is already available.<br>
<b>i. </b>New packaging configurations are being introduced for the brand in existing markets.<br>
<b>ii. </b>Ranks as top import and is larger than many national distributed competitors in import category.<br>
<b>c. </b>Expanding draft offerings for Pacifico, Negra Modelo, Modelo Especial, and Victoria brands which are doing well in existing<br>
markets.<br>
<b>i. </b>YTD, through 3Q12, depletions for draft offerings increased 60% vs. same period last year.<br>
<b>E. Conclusion:</b><br>
<b>1. </b>Believes is in good shape to deliver financial objectives for the year.<br><b>2. </b>Even though Co. may fall a bit short of depletion goals for US wine business, it has solid promotional programs in place<br>
designed to drive continued improvement in these trends throughout remainder of year.<br>
<b>II. 3Q12 FINANCIAL REVIEW (B.R.)</b><br>
<b>A. Results:</b><br>
<b>1. </b>3Q12 in line with 2Q12 earnings call discussion.<br><b>2. </b>Free cash flow, ahead of expectations.<br>
<b>a. </b>Increased free cash flow guidance for the year.<br>
<b>3. </b>Relating to earnings guidance for the year, maintaining comparable basis EPS goal of $2.00-2.10 provided at 2Q12, which<br>
is essentially the guidance provided at beginning of the year exclusive of the benefits from reduced shares and reduced<br>tax rate.<br>
<b>4. </b>3Q12 comparable diluted EPS came in at $0.50 vs. $0.66 last year.<br>
<b>a. </b>Majority of EPS decrease driven by 17% decline in comparable basis EBIT.<br><b>b. </b>This EBIT result was in line with expectations outlined last qtr. and was driven primarily by three items all related to overlap<br>
of events which occurred in FY11 including:<br>
<b>i. </b>Overlap of 3Q11 distributor inventory build from US wine and spirits distributor consolidation initiative.<br>
<b>ii. </b>Overlap of 3Q11 distributor inventory replenishment combined with incremental marketing funding at Crown and<br>
divestiture of Australia and UK wine business.<br>
<b>5. </b>Generated $587m of free cash flow for first nine months of year.<br>
<b>a. </b>$287m more than same period last year.<br><b>b. </b>Increased FY12 free cash flow target by $100m to $700-750m; an all-time high.<br>
<b>c. </b>Through 3Q12, strong free cash flow generation enabled to reduce debt, repurchase stock and acquire remaining 50%<br>
interest in the Ruffino business.<br>
<b>B. P&amp;L (On Comparable Basis):</b><br>
<b>1. </b>Consolidated reported net sales decreased 27% primarily due to divestiture of Australian and UK business.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>140</i><br>
<hr>
<A name=141></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>2. </b>North American net sales on an organic constant currency basis decreased 8% primarily due to decrease in volume driven<br>
by overlap of distributor inventory build in 3Q11.<br>
<b>a. </b>Reflects higher promotion costs partially offset by positive mix.<br>
<b>3. </b>3Q12 consolidated GM 40.5% vs. 36.5% in prior year.<br>
<b>a. </b>Primarily reflects the benefit of divesting the lower GM Australian and UK business.<br>
<b>C. Segment Operating Income:</b><br>
<b>1. </b>North American decreased $21m to $172m.<br>
<b>a. </b>Primarily due to lower volume combined with higher promotional and transportation costs partially offset by favorable<br>
product mix.<br>
<b>2. </b>Corporate costs down $6m.<br>
<b>a. </b>Primarily related to benefit from early redemption of notes receivable from Accolade, the former Australian and UK business<br>
and from lower compensation costs.<br>
<b>3. </b>Australia and Europe reported EBIT of $11m in 3Q11.<br><b>4. </b>Consolidated equity earnings totaled $53m vs. $71m last year.<br>
<b>a. </b>Equity earnings for Crown totaled $43m vs. $58m for prior year.<br><b>b. </b>Remainder of equity earnings in 3Q12 and 3Q11 are primarily generated by Opus One.<br>
<b>5. </b>Crown:<br>
<b>a. </b>Net sales $541m.<br>
<b>i. </b>Decrease of 12%.<br>
<b>b. </b>Operating income $87m.<br>
<b>i. </b>Decrease of 25%.<br>
<b>c. </b>Net sales decrease primarily driven by lower volumes due to overlap of 3Q11 distributor inventory built, following supply<br>
chain issues during summer of 2010.<br>
<b>d. </b>Depletions have been growing mid single-digits in an industry experiencing negative volume growth for the year.<br><b>e. </b>Lower volume and higher marketing costs drove operating income decrease.<br>
<b>D. Other Metrics:</b><br>
<b>1. </b>3Q12 interest expense $46m.<br>
<b>a. </b>Down 6% vs. last year.<br><b>b. </b>Decrease primarily due to lower avg. borrowings.<br>
<b>2. </b>Debt:<br>
<b>a. </b>At Nov.-end, debt totaled $3.1b.<br>
<b>i. </b>Represents $132m decrease from FY11-end debt level.<br>
<b>3. </b>Continued strong free cash flow generation and deleveraging efforts over past several years have enabled to redeploy<br>
portion of free cash flow to repurchase stock.<br>
<b>a. </b>During 3Q12, repurchased about 5m shares at a cost of $94m.<br><b>b. </b>During first nine months of FY12, repurchased 15m shares at a cost of $281m for an avg. cost of $18.79 a share.<br>
<b>c. </b>Expects total repurchases through 3Q to benefit diluted EPS by approx. $0.06 for FY12.<br>
<b>4. </b>During 3Q12, funded purchase of remaining 50% of Ruffino business for EUR50m or about $69m.<br><b>5. </b>Assumes debt net of cash acquired of EUR54m or about $73m.<br><b>6. </b>Tax Rate:<br>
<b>a. </b>Comparable basis effective tax rate 37% vs. 29% in 3Q11, which reflected the favorable outcome of various tax items.<br>
<b>i. </b>Targeting full year tax rate of 27% for FY12.<br>
<b>b. </b>Several state and federal audits are still underway.<br>
<b>i. </b>Timing and resolution of these could favorably impact tax rate for the year.<br>
<b>7. </b>Free Cash Flow:<br>
<b>a. </b>Defined as net cash provided by operating activities less CapEx.<br><b>b. </b>For first nine months of FY12, generated free cash flow of $587m vs. $299m for same period last year.<br>
<b>i. </b>Improvement primarily reflects reduced use of cash to fund receivables and cash benefit for taxes.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>141</i><br>
<hr>
<A name=142></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>c. </b>Receivable balance increased less than previous year due to timing of sales and sale of Australia and UK business.<br>
<b>d. </b>In 1Q12, received a net refund of taxes primarily related to the 4Q11 sale of UK business.<br><b>e. </b>Increasing FY12 free cash flow target by $100m to $700-750m.<br>
<b>i. </b>Increase primarily due to expected realization of additional cash tax benefits from sale of UK business previously targeted<br>
for FY13.<br>
<b>f. </b>Reducing CapEx estimate by $15m to $70-80m.<br>
<b>g. </b>Believes sustainable free cash flow is in the $500m plus range.<br>
<b>E. FY12 P&amp;L Outlook:</b><br>
<b>1. </b>Expects comparable diluted EPS to be $2.00-2.10 vs. $1.91 result in FY11.<br>
<b>a. </b>Includes estimated $0.06 benefit for share repurchases consistent with previous guidance.<br>
<b>2. </b>Expects depletions for US wine and spirits business to come in a bit below market trend and planned target for full year.<br><b>3. </b>Expects corresponding shortfall in sales volume to be somewhat offset by some mix benefits and cost reductions.<br><b>4. </b>Reduced interest expense guidance.<br><b>5. </b>Crown:<br>
<b>a. </b>Targeting low to mid single-digit depletion growth for the year and flat to slightly down operating earnings due to<br>
incremental marketing funding.<br>
<b>F. 4Q12 Comparison Items:</b><br>
<b>1. </b>For North American business, facing easier shipment comparison for 4Q12 as inventory build during FY11 was effectively<br>
completed by 3Q12-end.<br>
<b>2. </b>Expecting lower promotional expense and some additional mix benefit in 4Q12 vs. 4Q11.<br><b>3. </b>For Crown, in 4Q12, expects an improvement in sales growth and marketing spend to moderate vs. higher levels experienced<br>
in 2Q12 and 3Q12.<br>
<b>4. </b>Beer business continues to drive growth in a difficult category.<br><b>5. </b>Seeing improving depletions and marketplace trends for wine and spirit business.<br><b>6. </b>Focus brands performing better.<br><b>7. </b>New product development initiatives gaining traction.<br><b>8. </b>Strong free cash flow generation and deleveraging efforts created flexibility in capital structure management.<br>
<b>a. </b>This flexibility enabled to buy back significant number of shares.<br><b>b. </b>Repurchased $281m of stock through 3Q12, which is on top of the $300m repurchased in last FY.<br>
<b>c. </b>Expects to evaluate share repurchases as an opportunistic basis as part of ongoing efforts to optimize the capital structure<br>
of the business.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
(Operator Instructions) Kaumil Gajrawala, UBS.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Hi, everybody, good afternoon. If I could start maybe and see if you can quantify for us the impact that Arbor Mist and Vendage had<br>on your overall focus brand depletions.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes. It actually had quite a significant impact and if we stripped out just those two brands, we would have gained share in the overall<br>category, wine category, for the quarter. That really has been a big driver of our overall market share loss in total wine.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>142</i><br>
<hr>
<A name=143></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
Now if you look at just table wine, we did gain share in the quarter, and if you look at premium plus, we gained share in the quarter,<br>too. I mention that because clearly, the premium plus category above $5 is our primary focus.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Got it. And then also just a follow-up on quantification. Is there any way for you to give us some context on what growth may have<br>been on shipments, excluding the inventory build from -- at Crown last year?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes, this is Bob, Kaumil. I don't think we can get into that kind of detail.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Okay. No problem.Then just clarifying something on your guidance for Crown.You said improved sales growth and marketing spend<br>to moderate. Just want to understand, because was that from a depletions perspective, or is that from a shipments perspective. Also,<br>was the increased volume last year in 4Q also the replenishment of the supply issues?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes. So, the replenishment of the supply chain issues in the beer business was done by the end of the fourth quarter -- I mean the<br>third quarter. The fourth quarter, from a shipment-depletion perspective was pretty clean. Okay. So, we expect to -- for shipments<br>in depletions, to continue to have pretty good growth in the fourth quarter.<br>
Now this year, one of the reasons that the beer business's EBIT is down is incremental marketing spend. You'd think the majority of<br>that is behind us, as this year they spent the wide majority of that incremental monies in the peak summer season; so in Q2, Q3.<br>
That's why I said Q4, we expect continued or even slightly better sales growth, which would -- the same as depletion growth for the<br>fourth quarter, and reduced marketing, as opposed to the previous year.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Got it. And final question on prioritization of the free cash flow. You now have $100 million more than planned. Should we -- given<br>how often you talked about the buy-back in your prepared remarks -- should we assume that much of that can go toward incremental<br>buy-back?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes. I mean our Board authorization is still at the $500 million level, and we have a little bit over $200 left on that. We don't have any<br>additional Board authorization at this point. But as usual, we'll be looking at the market general trends to see whether we should be<br>out there buying back more of our shares.<br>
<b>Kaumil Gajrawala</b><i> - UBS - Analyst</i><br>
Okay, got it. Thanks, guys.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>143</i><br>
<hr>
<A name=144></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Operator</b><br>
Judy Hong, Goldman Sachs.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Good morning. Rob, just on the wine business, just as you think about the payback that you've gotten in the current quarter from<br>higher promotions. Obviously depletions improved sequentially, but it seems like it sort of came at the expense of higher promos.<br>Can you maybe help us understand, do you think you've got enough payback on those spendings? What will the competitive<br>environment look like?<br>
Then as you look out in fiscal 2013 with a lot of these new products coming in line, how should we think about the promotional<br>spending? Then is 2013 finally the year where you think you can get the wine business to grow in category growth?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes, so I think in terms of payback on promotional spending, we certainly feel that we are getting a payback, and you can sort of see<br>it as a result of the sequential improvement in growth when we increase promotional spending.<br>
Now, we do also mitigate that to a degree and fund it by taking some of the actions which we've taken, such as increasing net price<br>on our value brands, where we frankly don't care that much about share, to help fund and offset some of the costs of promoting our<br>premium plus portfolio. But in general, yes, promotional expense is up net, net, net, and yes, we think that it is paying back, given<br>where we would otherwise be if we didn't do so. What was your second question, Judy?<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
So, if that's the case--<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
As far as growing with the category next year, our plan is certainly to grow in line with the category next year, and as we build<br>momentum this year and are either -- depending on the category -- exceeding category growth rates or nearing total category<br>growth rates, we should go into next year with good momentum to achieve that.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Okay. And then Bob, just in terms of the whole shipment versus depletion delta on the wine business, are we completely now done<br>just in terms of the distortions in the fourth quarter? Are we still to start off cleanly as depletions matches shipments at your wholesaler<br>level?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes, I'd say the wide majority of it is done. There could still be some adjustments for the fourth quarter, because what we've said is<br>for the full year, shipments will equal depletions, right? So, you kind of adjust in the fourth quarter to get to the full-year balance.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>144</i><br>
<hr>
<A name=145></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Okay. And then on the Crown side, just any updated thinking just in terms of how you're thinking about pricing? Clearly your depletion<br>trends have been pretty healthy, but the margins have not really followed through. Just how you're thinking about pricing at this<br>point?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes, good question. So, as we know, the beer category has been experiencing negative volumes. The larger domestic players have<br>been taking some pricing. We actually at the Crown business took some front-line pricing in October. Not as much as the domestic<br>players, and the pricing was different by brands and by geographies.<br>
But the other thing that the Crown business is doing is reducing its promotion spending, which is in essence, an increase in the net<br>price to the consumer. Now that reduced promotion spending is reinvested in marketing. So, that's why when you see the Crown<br>income statement, you'll see a pretty big increase in marketing expense, because there's two things going on there.<br>
There's money coming from promotion down into marketing, and there's the incremental funding that's occurring on the Crown<br>P&amp;L versus the prior year. So it's a pretty big increase in the marketing spend.<br>
Looking at how volumes and how dollars sales growth has been doing versus the category, it seems to be being pretty successful.<br>And the marketing's been pretty well received, Rob gave some of those awards. I think those guys are doing a great job in feeling<br>good about their top line. I think the marketing overlaps from prior year are kind of hurting the bottom line. But that should abate<br>as we go into next year.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
So, if you take the front-line pricing and the reduced promo spending on Crown, the net price per barrel would have been up sort<br>of 1% to 2% kind of level?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
That's probably about right, maybe on the high end of that.<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Okay. All right, got it.<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Judy, you can kind of look at IRI and look at the volume growth versus the net sales growth. You'll see that the net pricing to the<br>consumer in IRI is up just north of 2%, which is less than the domestic guys, but still pretty healthy, especially when you compare<br>that to how the volumes are doing to prior year.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>145</i><br>
<hr>
<A name=146></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Judy Hong</b><i> - Goldman Sachs - Analyst</i><br>
Right. Okay. Great, thank you.<br>
<b>Operator</b><br>
Dara Mohsenian, Morgan Stanley.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
Good morning, guys.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Dara.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
You mentioned innovation is one of the primary drivers to drive, improve wine market share trends going forward. I think previously<br>you had thought that would play out this holiday season. I just want to get a sense from you on how much of an increase in innovation<br>contribution you're expecting in calendar 2012 versus 2011, or the pipeline of innovation you have planned versus this year, and if<br>there's a significant ramp-up going forward?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes, we expect pretty significant increase in the contribution of innovation to our growth in next year, whether it's calendar 2012 or<br>fiscal 2013. Almost probably double the rate of the contribution that innovation made in 2012 or calendar 2011.<br>
As I mentioned in my talk, we have very ramped up new product initiatives and expect to introduce almost 20 new products into<br>the market place. This year, it contributed roughly 200 basis points or 2% to our overall growth, and next year it should -- as I said,<br>contribute significantly more.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
Okay. That's helpful. And can you give us an update on your thoughts for the pricing environment in the wine category as we look<br>out to calendar 2012 year, and an update on the promotional environment?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes. I would say starting with the promotional environment and the holiday season, it has been fairly consistent with how things<br>have played out through the year, and basically with last year.<br>
Now, as you are aware from previous calls, this year's harvest in California was down, and in certain areas and in certain varietals,<br>oversupply is turning into under-supply, especially in the north coast.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>146</i><br>
<hr>
<A name=147></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
As a consequence of that, I would say that we probably think that you will see some pricing being taken on, especially higher-end<br>products that are suffering from some of the under-supply.<br>
Now, that said, are we seeing any widespread examples of that? No. I've put that just more in the category of what people think, as<br>opposed to what's really happening, so we're going to be watching it very carefully as we go into next year to see what's happening<br>out there in the market place.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
Okay, and are you anticipating adjusting pricing at all on the value wines given some of the demand elasticity issues, or are you more<br>focused on profitability at this point?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
We kind of pulse that activity, so we've taken some pricing up on some of the value wines, and then we've taken some of the pricing<br>back down on the value wines, depending on whether we think we're getting the benefit from the pricing or not, over an appropriate<br>period of time. It can kind of go both ways, but in general, I would say that we're going to be more inclined to price value wines than<br>the opposite, meaning take pricing down or drive for volume or share.<br>
<b>Dara Mohsenian</b><i> - Morgan Stanley - Analyst</i><br>
Okay. Thanks so much, guys.<br>
<b>Operator</b><br>
Tim Ramey with D.A. Davidson.<br>
<b>Tim Ramey</b><i> - D.A. Davidson &amp; Co. - Analyst</i><br>
Good morning. Just Rob, wondering how you think about the dollar price point positioning of your portfolio now versus the wine<br>category. It seems to me that it skews more favorably up the price point than it did several years ago. That's been kind of where the<br>growth is in the wine sector.<br>
Why shouldn't we think that you would out-perform the overall wine category in 2013, or fiscal 2013, I should say?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Well, again, whether we gain share or lose share in the category, it will be very dependent on sort of the decisions we make as to<br>how do we price various elements of our portfolio.<br>
Our portfolio is large, we've got a lot of wines -- and I'll say outside of mainstream categories -- whether it is beverage, dessert wines,<br>kosher wines, fruit-flavored varietal wines. We are very tactical in our decisions from a financial perspective as to whether to opt<br>more for pricing or whether to opt more for value.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>147</i><br>
<hr>
<A name=148></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
I would say that sort of the best measure of how we're doing overall is how we're doing on our focus brands, which is a relatively<br>small portfolio of 17 brands, and constitutes the vast majority of our profitability in the United States. There, we're particularly<br>interested in whether we're gaining or losing share.<br>
Now that said, one of the focus brands is the value brand. It is Arbor Mist. It's a big brand. As I have said, we have made the decision<br>and we did so last year -- this year, in actuality of the current year -- to tactically raise prices on that particular brand, and to sacrifice<br>the volume which did impact the overall growth rate of the focus brand. So, it's sum and sum.<br>
<b>Tim Ramey</b><i> - D.A. Davidson &amp; Co. - Analyst</i><br>
Got you. And just a quick one on some of the brands that you used to own over at Sentia. Any -- I hear that some of those are either<br>on the block or somewhat distressed. Any thoughts on that? You've managed those brands before. Would it make sense to look at<br>them again?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
No. We sold them.<br>
<b>Tim Ramey</b><i> - D.A. Davidson &amp; Co. - Analyst</i><br>
Okay. That's definitive.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Nothing that we sold that we want back at the moment.<br>
<b>Tim Ramey</b><i> - D.A. Davidson &amp; Co. - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Reza Vahabzadeh, Barclays Capital.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
You talked about optimizing the cap structure as well as the share buy-back activities. Can you continue with the share repurchase<br>activities and de-lever the balance sheet and get the leverage down to perhaps below three times in the coming year, given your<br>$600 million to $750 million cash flow?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Yes, Reza, this is Bob. Obviously you decide how much stock to buy back, right? So, this year we've given new guidance, which is<br>improved. And we decide if we're going to buy any more stock in the fourth quarter, and we have to decide, because next year, we<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>148</i><br>
<hr>
<A name=149></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
should have $500 million plus of free cash flow. Because it will be at least a sustainable year next year. We would be able to de-lever<br>and buy stock, depending on how much stock we buy back.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
Right. You still want to de-lever, right? In the past, I think you have thrown out two and a half, three turns, as well?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
No, I think what we've said is our ideal structure is three to four turns. You know, year-to-date, I think as of the -- if you just use our<br>guidance, and assume we don't buy back any more stock, I think we'll finish the year just under 3.4. Had we not bought any stock<br>back, we would have been closer to 3.0.We've made conscious decisions by buying back stock to stay north of 3.0, and we will assess<br>those as we go along.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
Fair enough. Have you commented on the food service channel, the restaurant channel and how sales are progressing in that channel<br>for your products?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes, I think that we're seeing the on-premise channel up for the first time in a long time. For us, we've probably gained share on a<br>dollar perspective and lost share on a volume perspective because we've significantly changed the mix of product that we're selling<br>in the on-premise to more high-end, premium plus product from I'd say lower end.<br>
So the on-premise is rebounding, it is up a bit we believe overall and we believe we're gaining share from a dollar perspective.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
So the category itself, on-premise is up in terms of sales.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Correct.<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
Thank you much.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Probably in the1% to 2% range.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>149</i><br>
<hr>
<A name=150></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Reza Vahabzadeh</b><i> - Barclays Capital - Analyst</i><br>
Got it. Thanks.<br>
<b>Operator</b><br>
Vivien Azer, Citigroup.<br>
<b>Vivien Azer</b><i> - Citigroup - Analyst</i><br>
Hi, good morning. My question has to do with the focus brand strategy. Specifically, while I recognize that the wine category is highly<br>fragmented so you need a number of offerings to compete effectively. I do wonder a little bit whether 19 focus brands is maybe too<br>many, and could you possibly better leverage your investments if you narrowed your focus a little bit? Is that under consideration<br>at all?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
I don't think that 19 is necessarily too many, but that said, we have had, I'll say, a strategy of narrowing our focus and investment<br>against a smaller number of brands, even within our focus brands.<br>
Fundamentally, the answer to your question is no, there are not too many, but yes, we agree that in terms of investment, that probably<br>narrowing the focus and making bigger bets against a smaller number of brands is probably strategically the way to go.<br>
On the other hand, a lot of the brands are very profitable and need to be looked after appropriately. Fundamentally, we agree<br>strategically with what you just suggested.<br>
<b>Vivien Azer</b><i> - Citigroup - Analyst</i><br>
Within that subset then, of maybe like focused focus brands, where do those fall generally across the pricing spectrum?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Well when you look at this -- first of all, we don't have a subset of focused focus brands -- you made that up, not us. But going along<br>with that concept, okay, you kind of start with what is the biggest piece of the portfolio, and that's the Mondavi franchise. Robert<br>Mondavi and Woodbridge by Robert Mondavi.That, in and of itself, is a large part of -- or the most important part of the focus brand<br>portfolio.<br>
Then you've got a few -- I'm not just talking wine here -- you've got a few other important brands, like SVEDKA vodka, like Kim<br>Crawford. Those would be examples of brands that really rise to the top in terms of their level of importance -- Clos Du Bois -- In the<br>overall focus brand portfolio.<br>
<b>Vivien Azer</b><i> - Citigroup - Analyst</i><br>
Great. That helps a lot. Thank you.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>150</i><br>
<hr>
<A name=151></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
I guess I didn't quite answer your question. If you look at Woodbridge, that's premium. If you look at Clos Du Bois, that's super<br>premium. If you look at Kim Crawford, that's luxury. If you look at Robert Mondavi Private Selection, that's super premium, and Robert<br>Mondavi Napa is luxury.<br>
<b>Operator</b><br>
Mark Swartzberg from Stifel Nicolaus.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Hi, Mark.<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Are you there, Mark?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
We can't hear you, Mark. Are you muted?<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
I'm trying to speak. Can you hear me?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Now, we can.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
Okay. Morning, guys. So, a couple of questions on wine and then one on Crown. Rob, you gave us that 2% depletion, or that 2%<br>contribution from innovation year-to-date for the wine business. Is that a contribution to depletions?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
Got it, great. As you think about, you remarked that you think you can grow in line with the wine category still, in spite of some of<br>these value challenges this year. How do you feel about your ability to grow operating income faster than the wine category, given<br>the experience with spending, and the mix issues, and so forth?<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>151</i><br>
<hr>
<A name=152></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
So, to your first question, we did not say that we would grow in line with the category this year. I would say that --<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
I'm sorry. I mean calendar 2012, fiscal 2013.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Okay. Yes. And then to your second question, we should be able to leverage the P&amp;L.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
You do expect it, great.Then over on Crown, are we kind of done with the structural step-up in marketing spend? Do you think fiscal<br>2013 is more of a operating income in line with revenue type type of year?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes, I mean I think we're done, Mark, with the step-up in marketing. There might still be some flux between promo spend and<br>marketing, but they kind of zero off at times, gets to the bottom line. All you'll be left with is pretty much pricing -- normal stuff,<br>pricing and mix. Now, we do have the contractual cost of goods sold increase.<br>
Okay, so just normal stuff, but I think the increased marketing and promotion spending will be behind us, and it will be [an]<br>apples-to-apples year if you look at fiscal 2013 over fiscal 2012 from a marketing and spending perspective at Crown.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
Great. And if I could build a little on the earlier question about operating income and wine growing faster than revenue. From where<br>I sit, it's hard to see why you have that view. Is that a function of your mix view? Is it simply leveraging of the fixed costs? Can you<br>talk a little bit more about that, Rob?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Yes. I think, Mark, most of it will come from we have some pretty robust plans in place to reduce costs of goods sold, and we've talked<br>about these a number of times, around things like reduced number of bottling lines, a higher fixed-cost leverage, some blend<br>changes, some better warehouse management, some better grape buying, things around that. I think that we will keep SG&amp;A growing<br>below net sales, okay? I think those two areas, and COGS is the big number, will be -- will help us leverage the P&amp;L.<br>
The wild card, I think will be promotion spending. Okay, because as you know, it's a pretty fractious industry. We're not the only<br>player. We kind of can't raise prices when nobody else is, which as you know, Rob mentioned some of that earlier. I think the things<br>within our control we feel pretty good about.<br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>152</i><br>
<hr>
<A name=153></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
I think that things that are a little less within our control, like pricing and promotions, well they're not within our control. That being<br>said, we've had two years in a row of short harvests, so you would hope that the industry would reduce promotion spend and maybe<br>increase prices, but time will tell.<br>
<b>Mark Swartzberg</b><i> - Stifel Nicolaus - Analyst</i><br>
Got it. That's great. Thank you.<br>
<b>Operator</b><br>
Gary Albanese, Auriga USA.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
I was wondering if you could just touch on inventory levels. Seems to be -- is that roughly what you were expecting, and was that<br>impacted from the cost of the high cost from you grape harvest this year?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
In terms of the harvest, the harvest from a dollar perspective will be smaller this year than it was last and therefore, it sent a positive<br>impact on our inventories and our cash flow this year. And I would say that the harvest was a bit smaller than we expected.<br>
Therefore, the inventory impact and positive cash flow impact was a bit greater than we expected to have. We started the year with<br>lower cash flow guidance than we're ending the year with. We've increased our cash flow guidance, and that was one of the<br>components of why cash flow is coming in higher than our initial guidance. Is that what you were asking me about, Gary?<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
To some degree. Let me move on to, looks like double-digit growth again in the quarter. Are you guys still on pace to exceed or --<br>was it 4 million cases, I think you said, the last quarter?<br>
<b>Bob Ryder</b><i> - Constellation Brands Inc - EVP and CFO</i><br>
Gary, I'm sorry. We're having a tough time hearing you.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Sure. SVEDKA, are you still on pace to exceed four million cases this year?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
No. We'll be slightly under it, but fundamentally on pace to be around four million cases.<br>
17<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>153</i><br>
<hr>
<A name=154></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Okay.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
So, yes. It will be around -- certainly, the run rate is at that level.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Okay.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
SVEDKA is generally meeting all of our expectations, and continues to grow double digits now on a very large base. It's the third<br>largest vodka brand.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Yes. I mean, being that's a smaller segment, I know the question's been posed in the past about whether it fits, but is that actually<br>an area that, the spirits business, that you've contemplated actually growing?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Well, our spirits business is three brands, basically. SVEDKA, Black Velvet and Paul Masson Grand Amber Brandy, three big brands.<br>
Yes, we're certainly consciously and specifically trying to grow that business, with our primary focus being on taking advantage of<br>our position in the vodka category with basically the hottest large brand.<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Okay. All right, thank you.<br>
<b>Operator</b><br>
Carla Casella, JPMorgan.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Hi, looking at your distributor markets, what percentage of your business now is in markets where it's a sole distributor, and is there<br>still more markets to go there?<br>
18<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>154</i><br>
<hr>
<A name=155></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
In terms of what we've consolidated, 60% of our business is -- has been consolidated in those markets where we've been able to do<br>that in the United States. So 60%.Then of the remaining 40%, there's probably about another 8%, for argument's sake, that in theory<br>could be more consolidated in the manner that we consolidated the initial 60%.<br>
The reason that there's only 8% of the remaining 40% is because you have to remember that some of the markets are control-state<br>markets like Pennsylvania, where there's really -- where the whole concept of consolidating distributors is inapplicable.<br>
And then another large percentage are what are called franchise-law states which means that we don't have the ability to necessarily<br>terminate the existing distributors pursuant to a consolidation plan, so it's difficult to change your distribution network in those<br>franchise markets, so 8%.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay, great. And then you see -- oh, go ahead, sorry?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Sorry, I was just saying 8%.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay. Do you see a big difference in performance between the distributor and -- I'm sorry, the sole distributor -- and the multiple<br>distributor markets?<br>
<b>Gary Albanese</b><i> - Auriga, USA - Analyst</i><br>
Yes. It's not so much sole distributor and multiple distributor, although that's a part of it. But what really -- yes, the answer is yes. We<br>definitely are out-performing in markets where we've implemented our distributor consolidation efforts but that -- what are some<br>of the things that really drive that, where we're able to consolidate, we're able to have exclusive sales forces within those distributors<br>selling only our products.<br>
That gives us a lot of additional focus on our portfolio, as being -- opposed to being just part of a general sales force and selling<br>multiple products. So, the answer is yes. We're outperforming in those markets.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Great. Then just one follow-up you may have already answered and I may have missed it. Did you say whether there has been any<br>change in terms of the timing of the Crown JV decision? Is that still an end -- think it was the end of 2012 event, we should know?<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
The initial term of the Crown contract was ten years, ending 2016. It cannot be terminated or altered for five more years. There are<br>notice provisions as to what they may propose that would require them to give us notice three years in advance of the termination<br>
19<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>155</i><br>
<hr>
<A name=156></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
at the end of 2016, but there's five years left on the Crown contract, period, and it automatically renews for another ten years, except<br>in the event of their giving us advanced notice of non-renewal.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay, great. So, the earliest would be the notice period would be end of 2013.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
That's only notice.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Right. Only notice for the termination 2012, if that were to occur. Okay.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Notice.<br>
<b>Carla Casella</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
That's all I have, thank you.<br>
<b>Operator</b><br>
That was our final question. I would like to turn the floor back over to Mr. Rob Sands for any closing remarks.<br>
<b>Rob Sands</b><i> - Constellation Brands Inc - President and CEO</i><br>
Okay, well thank you all for joining our call today. I would say that overall, I'm very satisfied with our third-quarter results, and would<br>summarize the highlights as follows. We generated very strong free cash flow, and as a result, have increased our guidance for the<br>year. Our strong free cash flow results have enabled us to fund share re-purchases, and we expect to be opportunistic in this regard<br>as part of our on-going efforts to optimize the capital structure of the business.<br>
We are experienced improving depletion momentum for our US wine business and the spirits business as well, and our new product<br>development initiatives are being well received in the market place. Our Crown imports beer business continues its strong market<br>place momentum. Our plan is to continue solid execution of our initiatives throughout the final quarter of the year. Thanks again,<br>everyone, for your participation.<br>
<b>Operator</b><br>
Thank you. This concludes today's conference call. You may now disconnect.<br>
20<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>156</i><br>
<hr>
<A name=157></a>JANUARY 05, 2012 / 3:30PM, STZ - Q3 2012 Constellation Brands, Inc. Earnings Conference Call<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4687961-7-2012-01-09T04:58:52.310</b><br>
21<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>157</i><br>
<hr>
<A name=158></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
WOR - Q2 2012 WORTHINGTON<br>INDUSTRIES INC EARNINGS<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 6:30PM GMT<br>
OVERVIEW:<br>
Co. reported 2Q12 sales decline of 2% and EPS before restructuring of $0.28.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>158</i><br>
<hr>
<A name=159></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Cathy Lyttle </b><i>Worthington Industries - VP, Corporate Communications and Investor Relations</i><br>
<b>John McConnell </b><i>Worthington Industries - Chairman and Chief Executive Officer</i><br>
<b>Andy Rose </b><i>Worthington Industries - VP and Chief Financial Officer</i><br>
<b>George Stoe </b><i>Worthington Industries - President and Chief Operating Officer</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Martin Englert</b><i> Jefferies &amp; Co - Analyst</i><br>
<b>Nate Carruthers</b><i> Steel Market Intelligence - Analyst</i><br>
<b>Chris Olin</b><i> Cleveland Research Company - Analyst</i><br>
<b>Sal Tharani</b><i> Goldman Sachs - Analyst</i><br>
<b>John Tumazos</b><i> John Tumazos's Very Independent Research - Analyst</i><br>
<b>Richard Garchitorena</b><i> Credit Suisse - Analyst</i><br>
<b>Mark Parr</b><i> KeyBanc Capital Markets - Analyst</i><br>
<b>Charles Bradford</b><i> Bradford Research - Analyst</i><br>
<b>Tim Hayes</b><i> Davenport &amp; Company - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Ladies and gentlemen, good afternoon and welcome to the Worthington Industries second quarter earnings results conference call. All participants<br>will be on listen only until the question and answer session of the call. This conference is being recorded at the request of Worthington Industries.<br>If anyone objects, you may disconnect at this time.<br>
I would like to introduce Ms. Cathy Lyttle, Vice President of Corporate Communications and Investor Relations. Ms. Lyttle, you may begin.<br>
<b>Cathy Lyttle</b><i> - Worthington Industries - VP, Corporate Communications and Investor Relations</i><br>
Thank you, and good afternoon, everyone. Welcome to our second-quarter earnings conference call.<br>
As a reminder, certain statements made on this call are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.<br>These statements are subject to risks and uncertainties and could cause actual results to differ from those suggested. Please refer to the Company's<br>second-quarter earnings release issued this morning for more detail on those factors that could cause actual results to differ materially.<br>
For anyone interested in listening to this call again, a replay will be available on our website, WorthingtonIndustries.com.<br>
On the call today are John McConnell, Chairman and Chief Executive Officer; George Stoe, President and Chief Operating Officer; Andy Rose, Vice<br>President and Chief Financial Officer; Bob McMaster, Senior Financial Advisor; and Richard Welch, Controller. We'll begin with John McConnell.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Well thank you, Cathy, and good afternoon to all. We appreciate your joining us today.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>159</i><br>
<hr>
<A name=160></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
Now as you read in our release this morning, I am very pleased with our results this quarter. We have consistently said, coming out of the 2008<br>recession, our expectation was to produce incremental increases on a year-over-year basis. Our second quarter contributed nicely to that expectation.<br>
In last quarter's call, I opened referring to a significant shift in our business platform that would result in a transitional gap in revenue and increased<br>corporate burden for the remaining companies. This quarter that revenue gap almost closed completely on a year-over-year basis, and going<br>forward, with the addition of Angus, the revenue gap is more than replaced and the corporate burden will approximate the previous levels in<br>cylinders of steel by year-end. Andy will discuss that further.<br>
Our two focal points to drive shareholder value will remain the same -- to decrease the volatility of our earnings, or said a better way, to increase<br>the consistency and stability of our earnings while increasing our overall operating margins. We have made and will continue to make progress<br>toward these goals, both in how we operate and in our acquisition strategy. Angus is a very welcome addition; you'll hear more about that as well<br>today.<br>
At this point, and going to turn the call over to Andy and George for more detail on the quarter.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Thanks, John. Happy new year, everyone. As you review our financial performance for the quarter and the balance of fiscal 2012, please keep in<br>mind that we are a company undergoing transformation. The goals of this process are simple -- higher margins and free cash flow and more<br>predictable and higher earnings for our shareholders.<br>
To accomplish our goals, we are both changing the way we manage our businesses and changing the mix of our businesses. Evidence of our<br>progress is visible in recent quarters.<br>
In the fourth quarter of 2011, we took two businesses, [Gerstenslager] and Dietrich Metal Framing, and formed two joint ventures to make them<br>stronger and more profitable. This resulted in the movement of businesses that were generating over $400 million in revenue from our operating<br>income to equity income from affiliates. The good news is that this decision appears to have benefited both businesses by making them more<br>profitable. However, the resulting corporate overhead allocations from these businesses were redistributed principally to our steel and cylinders<br>segments, making those segments look somewhat less profitable than they would have otherwise been over the past few quarters.<br>
We've also been active in acquiring new businesses -- Bernz in July, STAKO in September, Coleman and Angus in December.This comes with upfront<br>costs and requires resources to integrate and realize the full financial benefits. Many of these costs are one time in nature but also serve to reduce<br>the profitability of business segments on a temporary basis.<br>
We've also been investing in a few Greenfield businesses, principally through our global construction group, whose operations are included in our<br>Other segment. We are actively pursuing some large opportunities, much larger than our recent Mozambique project, and we'll continue on this<br>path to let these opportunities play out. Until then, the upfront investment will exceed the income being generated, and as a result, dampens<br>Worthington's overall performance. We do not intend for these Greenfield businesses to lose money for an extended period of time, but believe<br>the investment today will pay dividends in the future.<br>
Unfortunately, during the transition period, as businesses are moved in and out, and reinvestment and reengineering occurs, the true impact of<br>the changes in our profitability are difficult to isolate.We will do our best to provide some visibility, but the benefits will only become fully apparent<br>in future reporting periods as results unfold.<br>
Now, onto the quarter's results. Despite the slow growth economy, the Company performed reasonably well during the second quarter of fiscal<br>2012. Earnings per share before restructuring of $0.28 were up 47% compared to the prior year. Results included inventory holding losses from<br>the decline in steel prices, estimated at $0.09 per share. Inventory holding losses in the prior-year quarter were about $0.11 per share, about one<br>third of which was attributable to the metal framing business, which is no longer a consolidated entity.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>160</i><br>
<hr>
<A name=161></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
Sales for the quarter were down 2%, but would have been up 10% excluding acquisition and divestiture activity. In steel processing, volumes during<br>the quarter were up 12%, benefiting modestly from the MISA acquisition and strong toll processing activity. Margins were lower, principally due<br>to higher inventory holding losses when compared to the prior year.<br>
Volumes in cylinders were up 7% for the quarter, aided by acquisitions. We had a lot of questions on the call last quarter regarding the decline in<br>operating margins in the cylinder business, which declined again during the current quarter. Higher manufacturing costs, in the form of higher<br>wages and input costs for steel and propane; higher-than-normal conversion cost due to unexpected and nonrecurring repairs; elevated fees from<br>acquisitions; and higher corporate allocations resulting from the joint venture transactions explain the decline.<br>
We expect cylinder margins to recover the coming quarters as manufacturing costs return to more normalized levels and fees subside.<br>
Equity income from our joint ventures was up 35% over last year to $21.9 million.WAVE continues to perform well, and several other JVs contributed<br>over $2 million each during the quarter, including TWB, ArtiFlex, and ClarkDietrich. ClarkDietrich is on pace to generate in excess of $10 million of<br>equity income for us in its first full year, despite only owning 25% of the business. That compares quite favorably to the $2 million that Dietrich<br>contributed to Worthington Industries last year as a wholly-owned subsidiary.<br>
We received dividends of $24.7 million during the quarter from the joint ventures.<br>
Net cash generated from operating activities for the quarter was $64.4 million, driven by higher EBITDA and lower working capital. The Company<br>deployed $3.6 million for capital projects, $38.8 million for the acquisition of STAKO, and $8.4 million in dividends to shareholders. During the<br>quarter we also spent $16.7 million to repurchase 1.15 million shares. Our balance sheet at quarter end remains strong, with total debt of $476<br>million, cash of $54 million, and over $270 million in available debt capacity.<br>
Worth mentioning are two significant events that occurred during the month of December after the quarter close. First, we completed a recapitalization<br>of WAVE with a $225 million revolving credit facility, with $200 million drawn at closing and a $50 million 10-year private placement at a 4.9% rate.<br>The proceeds were used to repay the existing facility and to fund a $50 million special dividend to each partner.<br>
Second, we completed the acquisition of Angus Industries, the market leader in the design and manufacturing of custom-engineered operator<br>cabs for mobile equipment.The company provides an excellent opportunity for us to invest in and grow our presence in the market for manufactured<br>products and OEM supply chain solutions for the agriculture, mining, and construction equipment end markets. Angus has a strong management<br>team that will continue to run the business while leveraging Worthington's scale and capabilities to capture growth, and in Angus's core markets,<br>for new product introductions and in targeted international markets.<br>
We used proceeds from the recently received $50 million WAVE dividend and our revolving credit facilities to fund the $180 million purchase price.<br>Based on the Company's trailing 12 month EBITDA, we paid under six times EBITDA without factoring in synergies.<br>
Current interest rates on our credit facilities are just under 1%, so incremental interest cost from the transaction will be less than $1.5 million per<br>year based on current rates. As a result of the WAVE dividend and further reductions in working capital during the month of December, our funded<br>debt increased only modestly to $568 million, with $184 million of availability still remaining under our revolving lines of credit.<br>
Overall, this is a great business that we purchased at a reasonable price that fits well with our strategic goals of higher margins, more free cash<br>flow, and diversifying into higher growth end markets.We're excited to welcome the Angus team and its impressive customer base to the Worthington<br>family of businesses.<br>
While the economy continues to move forward slowly and the financial markets seem to react daily to events in Europe, we continue to execute<br>on our strategic plan to accelerate the growth of Worthington Industries' earnings. The success of our transformation is making our existing<br>businesses more profitable despite below-normal volumes. Our success in identifying, executing and integrating acquisitions at prices that make<br>financial sense is expanding our platform. As the economy continues its recovery in 2012, we are excited by the prospect of higher returns for our<br>shareholders.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>161</i><br>
<hr>
<A name=162></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
I will now pass the call on to George Stoe, who will discuss operations.<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
Thank you, Andy.<br>
Our steel processing business has experienced the normal year-end slowdown in shipments, but we have seen bookings continue into calendar<br>2012 increasing sharply. Several price increases have been initiated from the mills, and there seems to be growing strength in the backlogs for the<br>coming months. Our inventories and service levels are the best they have ever been. We are currently operating with 57 days of inventory while<br>still achieving a 95% on-time delivery performance.<br>
There is some concern in the marketplace about the situation about the situation with RG Steel. From our perspective, we had a careful and<br>thoughtful plan that we had in place for several months, with alternative supply options. Regardless of the outcome, we will not be adversely<br>affected, since we had backup supply plans for all of the business that we had with them.<br>
Our cylinders business is experiencing normal seasonal demand within most product lines. We're actively engaged in the integration process at<br>our new high-pressure cylinders facility in Poland, and our 16-ounce camping cylinder facility in Kansas. We're enthusiastic about both, as Poland<br>adds to our growing position within the alternative fuel segment, and the acquisition of the 16 ounce cylinder facility in Kansas will enable us to<br>better serve the rapidly expanding customer base for this product line while continuing under a licensing agreement to produce this product<br>under the iconic Coleman brand.<br>
As many of you know, we also added the BernzOmatic business into the Worthington fold last year. That integration is going well, and we fully<br>anticipate meeting or exceeding the projections we made when we acquired the business.<br>
We recently asked our centers of excellence to begin the transformation process that was so successful in our steel processing business throughout<br>our cylinders organization.That process is only a few months into its work, and we have already identified opportunities for production efficiencies<br>and cost savings.<br>
Our newest acquisition of Angus is a perfect fit for our long-term strategy of acquiring businesses that improve our margins and profitability and<br>are complementary to our core strengths of value-added manufacturing in market leading businesses.<br>
During our due diligence process, we met with several of the key customers and came away from that with a deep appreciation for the capabilities<br>and market reputation.We met with the employees at all four locations this week and are comfortable that the integration process will be smooth<br>and seamless. We are pleased that the professional and experienced management team we acquired as a result of this acquisition is committed<br>to continuing in their roles.The top four executives have taken a significant portion of the funds they received in Worthington stock to demonstrate<br>their commitment to this endeavor. The workforce appears to be equally dedicated and enthusiastic about the path forward.<br>
Our joint ventures continue to perform at a very high level.WAVE continues with outstanding results in spite of the challenges facing the commercial<br>construction market.Their percentage of remodeling work is higher than in the past and has helped to maintain their marketplace strength as new<br>commercial construction remains weak.<br>
The ClarkDietrich JV just finished an outstanding 2011. The consolidation of the two businesses has been completed, and the cost savings we<br>anticipated have exceeded our expectations. Almost all of the non-contributed facilities and assets that Worthington retained have now been sold<br>or are under contract to be sold. Our realizations from these transactions have also exceeded the expectations we originally modeled when we<br>formed the JV.<br>
Serviacero continues to grow and expand their presence in the rapidly developing Mexican market for flat rolled steel. Our new pickling there in<br>Monterey is on schedule to be operational by July.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>162</i><br>
<hr>
<A name=163></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
We look forward to calendar 2012 with great anticipation. We have a number of new businesses that we are integrating into the Worthington<br>family. We believe all of these will continue with our objectives and improving margins, decreasing volatility, increasing our shareholders' value.<br>
I will now turn the call back to John McConnell for his closing comments.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Well, thank you Andy and George, well done. At this point, we will take any questions that you might have.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions) Martin Englert, Jefferies &amp; Co.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Good afternoon, everyone.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Hello.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
For Angus Industries can you provide D&amp;A figures for 2011 and where you would expect that going forward? Also, in addition to that, where has<br>its historical revenue been and EBITDA margins throughout the peak trough and kind of average throughout the cycle?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Two -- well the first question, the historical D&amp;A, or the go-forward D&amp;A isn't finalized yet, because we haven't completed the purchase price<br>allocation, but a good benchmark is probably $8.5 million to $9.5 million.<br>
The second question -- in terms of their margins through the cycle-- it is a high variable cost business, and they've done a terrific job, actually,<br>through the cycle at maintaining margins. In fact, I think if you look back over the past several years, they've maintained double-digit margins.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay. Would that be within a low double-digit range? Like, 10%, 12%?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes, that would be the trough.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>163</i><br>
<hr>
<A name=164></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
what would be a good range for the peak? 15%, 17%?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I would say the low end of that range.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay. And if I could, one other question. Can you provide an update on your European cylinders business? How that contributed to earnings<br>through the past quarter here, and where you see the activity and volumes trending in upcoming quarters here going forward?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes.The European cylinder business continues to recover both volumes and earnings. It is nowhere near back where it was during the peak, which<br>is probably four-ish years ago in terms of its earnings, but the recovery does continue in that business.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay. And for -- within that segment, for restructuring charges, could we expect additional ones going forward in upcoming quarters here?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I'm sorry, for the cylinder segment?<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Yes, Sir.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
There will likely be some restructuring charges. You may recall we have started the transformation process there; our Centers of Excellence teams<br>have been through one facility. They are just kicking off the second facility. Charges related -- most of the restructuring charges to date have been<br>for outside consulting that we brought in. Those charges will be declining starting this quarter.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay, thanks for all the color.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
But there could be some -- I would call it nominal restructuring as we move through the facilities, but I wouldn't anticipate large dollars there.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>164</i><br>
<hr>
<A name=165></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Excellent, thank you.<br>
<b>Operator</b><br>
Nate Carruthers, Steel Market Intelligence.<br>
<b>Nate Carruthers</b><i> - Steel Market Intelligence - Analyst</i><br>
Hi guys. Great quarter. I had -- I guess I had a question about your Other segment. It sounds like you said that upfront investments right now are<br>hurting earnings there. How long do you expect that to continue? And can you elaborate a little bit on the opportunities that you're pursuing<br>there?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Nate -- and thank you for your earlier comment. Think of the investment is really -- as you know, we've done a project abroad in Mozambique very<br>successfully, and we had this operating in North America prior to moving to international. So this is really keeping in place the infrastructure that<br>allows us to do the engineering, to do the work that puts us in position to do these projects.<br>
We have, as Andy said, some very large opportunities, significantly larger than Mozambique, that will be difficult to put a timeframe on them. They<br>are government-involved, as was Mozambique, and so we'll see how they come to fruition. If they start to lose traction, whatever timeframe that<br>is, and I would suspect we'll know this someplace in a six to nine-month period, probably sooner, but I'm not sure.Then we will have to make some<br>judgments. But until then, as long as these opportunities appear like they're going to get traction, it is worthwhile leaving the infrastructure in<br>place so that we're able to do the work.<br>
<b>Nate Carruthers</b><i> - Steel Market Intelligence - Analyst</i><br>
Okay, thank you.<br>
<b>Operator</b><br>
Chris Olin, Cleveland Research.<br>
<b>Chris Olin</b><i> - Cleveland Research Company - Analyst</i><br>
Good afternoon, guys. First I wanted to ask a little bit on automotive. I think you guys have a pretty good view on what's going on there. It seems<br>like the sentiment is getting a little bit better across the channel. I'm just wondering what you guys are seeing? I guess if you could talk a little bit<br>more specifically, going into the next couple of months?.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I think we feel generally positive about automotive. As George pointed out, overall steel bookings are up. I couldn't go to it by segment, but we all<br>track it here in different ways, and every way we track it shows forward bookings strengthening quite a bit, particularly when I look on a year-over-year<br>basis. They're much stronger than they were at this time last year coming out of December. So that's very encouraging. I don't know if George has<br>any more color on automotive specifically for you or not.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>165</i><br>
<hr>
<A name=166></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
I would say, John, you hit the nail on the head. I think that we're seeing stronger bookings that we have over the past few months, and certainly<br>going into calendar 2012, we've seen a sharp increase in bookings coming from the automotive sector.<br>
<b>Chris Olin</b><i> - Cleveland Research Company - Analyst</i><br>
Is it realistic to think that the auto side of your business could improve by 10% to 15% in 2012, given where the production schedules are headed?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Certainly coming into this call, I did not sit down and calculate what I thought a percentage increase was with automotive. I do think it is going to<br>continue to improve, and I think in this -- the way everything is right now, the way -- is why we always work like we're going to do -- our goal is to<br>increase, year over year, our earnings and keep driving things forward.<br>
And I think we are continuing to incrementally do this. That is a good sign. You have people worried about what Europe could trigger here in the<br>US, and those kind of issues are still going on. And until they calm down, it is going to be very difficult for somebody to get really robust in their<br>predictions for you.<br>
<b>Chris Olin</b><i> - Cleveland Research Company - Analyst</i><br>
I know you guys talked a bit about how you are protected from the RG Steel issue; I'm just curious, since this announcement has been out there,<br>has that firmed up the pricing environment? Do you guys have any different thoughts on where the sheet prices could go?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
I certainly think that it has, Chris. I think some of the mills out there locked into putting additional increase on as a result of that, because they saw<br>that their backlogs were filling as a result of the uncertainty about that. But, I can't make a prediction on where the prices will go. I think there are<br>too many factors that weigh in on that. Obviously, we've seen a number of increases over the last few months.<br>
<b>Chris Olin</b><i> - Cleveland Research Company - Analyst</i><br>
Okay. I'll get in the queue.<br>
<b>Operator</b><br>
Sal Tharani, Goldman Sachs.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Thank you. Good afternoon, guys. The Nuconsteel closure announcement today by Nucor, how big of a player was it, then, in the field of framing?<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>166</i><br>
<hr>
<A name=167></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I would -- in the space in which we played, I would say not very large. They largely focused their efforts on smaller structures, single-family homes<br>and that kind of things. So we didn't see them that much. And abroad, I think they have been in some conversations that we have been in, but of<br>course that would tend to end that conversation. So, not huge.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Okay. On the Angus cab business, is it just the cab they make, or do they also work on the controls or incorporate controls in that cab when they<br>put that on the machines?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
They put controls in the machines; they do not make the controls. They typically are sourcing those from other third parties. But there is an<br>opportunity -- one of the opportunities for Angus is to continue to insource the manufacturing of other parts, obviously the metal components,<br>which they have a great deal of expertise would make the most sense, but electronics is not out of the question down the road.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
As I understand it, they're more likely -- or we are more likely at this point I should say to be concentrated on things that would touch the cab<br>around the piece of equipment. So you might come down into the fenders, or you might come down in the doorwell or the stairwell or something<br>like that, so that it all just fits together.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
And that growth will come from Angus, or you will do some bolt-on acquisitions around it?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
we think the growth -- that growth that I just discussed was on Angus's agenda before we acquired them.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Okay, great. One more question -- you mentioned, you did -- alluded to the RG Steel impact or steel sourcing impact. Are you having any difficulty<br>in sourcing steel?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
No, not at all, Sal. I mentioned in my comments, we had a careful plan in place as our business was growing somewhat with them, but we always<br>had a thought in our mind that we had to make sure that we were cautious in going forward with that, and we're hopeful that they're going to be<br>able to come out of the current challenges they are facing.They've been a good supplier for us in the time that we have been doing business with<br>them. We do nothing but wish them well and hope that they can recover.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>167</i><br>
<hr>
<A name=168></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
And one more question before I get in the queue.Your first half volume is about 13% up in the process steel section. I was wondering how can you<br>differentiate between tolling and non-tolling in there?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
It's about 51 direct and about 49 is toll business.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
And both have grown in similar fashion in the first half versus last year?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
No. The historic norm here would be something like 56/44. (multiple speakers)<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
56 for --<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
It would be more like that. A mid-50s number for direct and a mid-40s number or so for tolling, if you look back. This quarter was somewhat<br>aberrational in that sense.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Okay, great. Thank you very much.<br>
<b>Operator</b><br>
John Tumazos, John Tumazos's Very Independent Research.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Congratulations on good results, progress. With regard to Angus, roughly how much of the revenues is the steel they buy to make the cabs?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Is a smaller percentage than you would think, John. It's probably in the 15% range.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Was Angus an existing customer, where you were already processing their steel for them, or will that be a new synergy of the transaction?<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>168</i><br>
<hr>
<A name=169></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
It's a new opportunity.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
It is a new opportunity, and one which we're really just beginning to explore. We did not take that into account as we were doing this transaction,<br>didn't do the pricing based on that. And it's uncertain how much we will switch as a result. So we are going to take that very slowly, very cautiously.<br>They have good suppliers right now, and so it all depends on the material, where we have plants located, whether we have the capabilities to do<br>what they want to do. And all of that has been looked on a cursory basis, but not very deep at this point.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
John, where are the Angus facilities located?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
South Dakota, Iowa, Tennessee, and South Carolina.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Thank you. A couple of quick questions. I read that China has a goal of building 45 million housing units in five years. I was wondering if Worthington<br>is going to participate in that?<br>
And I had a very nice visit in Mozambique in October to an 80-foot-thick met coal seam of Vallet, and I was wondering if you could talk a little bit<br>more about your opportunity -- the business you did in Mozambique.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
In China, we would hope that we participate in the housing push.The project that the joint venture has taken on at the moment will be somewhat<br>oriented toward housing as part of a new industrial science center that is being built as part of a new ring city. But certainly all of -- eight story --<br>actually, six-story structures will come up in our building methodologies there. Some of that will be housing.<br>
Beyond that we will continue to look for projects. I think the housing market in China is a little unsettled at the moment. So the Ministry, I think,<br>has, I'm guessing, the motivation to hurry up on this lower-end housing to try to add stability to the housing market. Because as I would understand<br>it, that is one of the things that is putting uncertainty into buying homes, whether or not prices will go down or not. So the sooner they get this<br>floor of low-end housing out there and set up, I think they would expect to see stability come to the rest of the housing market. So they should be<br>motivated to do so, and we expect to participate in some.<br>
Now, with Mozambique, John, you said you were just there for something which I'm not sure I understood.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
There is a big metallurgical coal camp there Vallet and Rio Tinto have invested.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>169</i><br>
<hr>
<A name=170></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Okay. Our structures were all around the Pan-African Games, All-African Games, I believe it was called, to house the athletes.There were 22 buildings,<br>essentially 22.5 buildings, to house the athletes. I'm sure -- I'm not sure. I'm assuming that the Mozambique government will turn that into low-end<br>housing for their residents going forward.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
This was all in Maputo?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. Right next to the stadium.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Super. Congratulations on everything.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Thank you.<br>
<b>Operator</b><br>
Richard Garchitorena, Credit Suisse.<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
Thanks. Good afternoon. A couple of quick questions. I think you mentioned regarding steel processing that for this quarter, inventory holding<br>losses were roughly $0.09. Is it fair to say that we should expect this to reverse in the next quarter, given where steel prices have moved?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I wouldn't expect it to reverse such that you have $0.09 of gain next quarter. I would say we've reached the -- assuming steel prices continue to<br>migrate up, we've reached the inflection point, and that inflection point will occur sometime during the quarter to where we will start having gains.<br>In terms of whether or not we have losses or gains for the third quarter, I would say it is unclear at this point.You need to ultimately figure out what<br>the sales for the quarter are going to be, and that will unfold over the next couple of months.<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
Okay. Yes, that makes sense. And then regarding volumes, can you give us a sense of how shipments ran on a monthly basis through the quarter?<br>And if you could give us some color on -- I know you mentioned that things were -- demand was picking up, but maybe how December looked,<br>and January?<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>170</i><br>
<hr>
<A name=171></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
We have people digging. You're asking for the volumes related to cylinder, steel? Is that what you're asking?<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
Steel processing, I should just -- sort of how things shook out through the quarter and where we are.<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
Generally I would say, John, that in December we were probably in -- on the direct basis, we were probably in the 95,000 ton range on direct and<br>a little bit less than that on the toll side.<br>
But it goes back to my comments earlier about the bookings. Our bookings in December for the month going forward were much stronger than<br>that.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I don't know what the volumes were specifically, but I don't think there's any question they were stronger than they were this year or last year at<br>this time.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. Will have to get back to you on the monthly data, Richard. We don't have it at our fingertips.<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
That's great. Last question, on purchasing cylinders -- given the two acquisitions that happened with STAKO and Coleman, those are only partly<br>reflected in the second quarter, so we should see some more in the third quarter. Is that right?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Correct. They both came in in December?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
STAKO was September; Coleman was December 1.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
And then you have, really, starting January 1 forward with Angus.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>171</i><br>
<hr>
<A name=172></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
The other thing -- not to get too detailed, but purchase accounting sometimes minimizes the earnings in the first couple of months as you flow<br>through that inventory. So usually, when you complete an acquisition, the full benefit of the earnings don't materialize until -- I will call it the second<br>quarter, to be safe.<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
Got it. Thank you very much.<br>
<b>Operator</b><br>
Mark Parr, Keybanc.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Thanks very much. Good afternoon. Hey I've got a couple of questions. Just first from a housekeeping -- do you have the conversion and labor costs<br>per segment, and also the SG&amp;A per segment?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I'm not sure about the first one. I know we have the second one.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. You want SG&amp;A per segment?<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Yes.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
We'll have to get back to you on that one, Mark. We don't disclose that.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
A couple of other things. Automotive is your largest end market in steel processing; that business is getting much stronger. Could you talk a little<br>bit about some of the other end markets and what you have been seeing recently?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I think we've seen a general strengthening in the steel business across the board. Cylinders is some up, some down -- more up than down in demand.<br>George, you have any other color you want to throw on that?<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>172</i><br>
<hr>
<A name=173></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
No. I think as you well know, Mark, the construction area is still weaker, but we're seeing a little bit of strength coming back in there, and the<br>agricultural side that we have a relatively strong position in is coming along nicely.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Is the construction activity that you are seeing -- does it feel like it is a blip, or does it feel like it is a sustainable sort of movement?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I tell you, it feels like it's trying to get up off the bottom, which doesn't necessarily answer your question. It may continue to bump up and down<br>around these levels, which means it could be a blip, but it is nice to see it trying to get up. How about that?<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay. Then, back to the cylinders business, Andy, I think you had mentioned that Europe was recovering. And I was just curious, what sort of<br>trajectory is Europe on compared to, call it the US or the rest of the world? Can you give us some color on -- at least at this point, with the acquisitions<br>you've made, how big a percentage of your mix Europe will be?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. I guess it sounds strange to say that Europe is recovering, considering you pick up the newspaper or watch the news and listen to what's going<br>on. But you have to remember, our European cylinder business was off almost 70% in terms of the volumes during the downturn.<br>
And so as that business has recovered over the last 18 months, it's returned to profitability and continues to migrate upward. I would say -- you<br>heard me mention, also, it's nowhere near back to the level of profitability that it was three or four years -- four years ago, I guess at this point.<br>
In terms of the strength of the European economy, obviously we're not economists, but I think there's a lot of uncertainty there. So in terms of<br>where it goes from here, your guess is probably as good as mine.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
And what was the second part of your question there?<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
I was curious, what is the mix of Europe now overall for cylinders?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
The mix in terms of the profit contribution, Europe is probably 15%.<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>173</i><br>
<hr>
<A name=174></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay, so Europe has really got a ways to go?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
The other thing to add to that, you've got -- most of our retail product lines are in the US. We do have some retail in Europe, but I think less so than<br>in the US market. So it's a little bit of a different business mix over there as well.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay, that's helpful. Just a couple of other housekeeping things. The restructuring charges that you articulated, that $2 million dollars, was that<br>accounted for directly against the EBIT number for cylinders in the quarter? Or was that on a separate line item on the P&amp;L?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
separate. Did I say $2 million in restructuring?<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Yes, $2 million. Is that something you expect to continue? Is that more of a one-time thing in nature or -- ?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
It's related to our transformation. So I would say there will be more charges in this quarter, and then I would expect that those would go down<br>substantially.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
And then lastly, the M&amp;A fees in the November quarter, what is the delta looking like for the February quarter relative to November as far as M&amp;A<br>fees are concerned?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
So, as you know over the past couple of years, we've been active acquiring businesses. So there will be some fees in there related to due diligence<br>and other, but there was specifically in this quarter, Q2, just over $1 million in fees which I would characterize as one-time. One was for an investment<br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>174</i><br>
<hr>
<A name=175></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
banker in Europe related to the STAKO acquisition, and the second fee was related to that transaction; sort of a transfer tax, if you will. So it was<br>about $1.1 million that I would say would not be there next quarter.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
So the fee thing for February is less than November?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Correct.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay, and then the restructuring thing would be the same?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I think a little bit less than $2 million.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
And then I guess, lastly, the $5 million in other losses that you had, is that something we should view as recurring over the next couple of quarters,<br>John? It sounds like you were talking about continuing to make some pretty heavy investments. Is $5 million a better number than $3 million? I'm<br>just trying to plug in a number for the next couple of quarters.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I would hope, Mark, and I think our forecast says not continuing at that level.There were a few one-time items also in that segment for this quarter,<br>but there will be losses.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
And when we talk about the construction segment and its contribution to the losses in Other, it is not [off of ] the losses in Other. If that helps. Like<br>Andy said, there were some one-time charges. Some of that may go away, so it is likely to be less than $5 million.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay. All that color is really helpful. Appreciate it. Congratulations and good luck in the February quarter.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Thank you.<br>
17<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>175</i><br>
<hr>
<A name=176></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Operator</b><br>
Charles Bradford, Bradford Research.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
Can you tell us a bit more about how Angus sells its product? Does it do designs, is it basically a subcontractor?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
That's a good question that lets me start the answer saying that we feel very comfortable with this, because it is all about metal building bending<br>and welding, to a large degree. One component that we don't necessarily have the expertise in currently is the general engineering of this product,<br>which is largely a big part of their sales effort. It is all around the engineering. We're very good at metallurgical engineering, and might be helpful<br>there, but not in sign engineering, as they are. So that's a big part of the sales; it's direct with the OEMs? Andy, George, anybody got any?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
The only other thing I would tell you, Charles, is that their largest customers are the John Deeres and the Caterpillars of the world, and they do<br>specific jobs for them in designing cabs for a lot of the large mobile equipment that they have, and depending upon the volume, whether they do<br>them outside or inside those companies, and they've carved out a great niche for themselves and are really the market leader in this segment.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
Would they be supplying the onesies and twosies for very specialized cabs, or would they be on the more common excavator and large mining<br>trucks and what have you?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
They do some of both, but the majority of their business is in the more consistent runs of lesser volumes, but certainly where they might have<br>several thousand of one particular product line.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
When it comes to the steel component, what you said was about 15% of cost?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
Do they usually price their product with a cost index so they can pass through the change prices or are they more fixed price?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
It is probably not prudent for us to comment on their pricing strategies.<br>
18<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>176</i><br>
<hr>
<A name=177></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
Okay, understood. Well, thank you very much.<br>
<b>Operator</b><br>
Martin Englert.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Thanks for the follow-up opportunity. For Angus, I wanted to touch back again on the revenues. You'd reported in the release it was a little over<br>$200 million for 2011. Where would that have been in the cycle for the Company? Is this, like, a midcycle top-line number, or where do you see it?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I think that's probably as fair a characterization.They service three market segments, principally -- agriculture, construction, and mining.The largest<br>of those is construction, and then agriculture, and then mining. Ag and mining have been very strong. Construction has been more modest, and<br>so two of the segments, I would say, maybe are nearer the top end of the cycle, but the construction segment certainly is not and happens to be<br>the largest.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay. I'm just trying to get a sense of, maybe, going forward what to expect from top-line from within that business. What kind of ranges.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
You know, you could look at market growth forecasts as probably the best indicator. I think construction is forecast to grow over the next 10 years<br>at 6%, ag at maybe 3.5% and mining, maybe at slightly less than that.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Are you able to provide any color of what type of share that construction, ag, and mining has within that business?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I think he gave a general sense of order of magnitude, and that's probably good enough from our end.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
All right, thanks for the help.<br>
<b>Operator</b><br>
John Tumazos.<br>
19<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>177</i><br>
<hr>
<A name=178></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
What would be a good guess of the possible synergies of Angus and Worthington? 2% of sales?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
John, again, we didn't factor in any synergies into this deal. Clearly, things that we know over time, we'll probably be looking at migrating them<br>into the shared services that we do amongst all of our businesses around accounting, finance, payables, that kind of thing. Again we're not going<br>to be in a rush to do that. We want to get to know their employees better, and how we're going to go about it. So we really didn't bake any in, and<br>we're going to be out looking for ways, as our Center of Excellence team goes in there to perform the integration. One of the primary objectives<br>is to identify the areas of synergy when we go in, but we did not base the acquisition on that. Therefore I can't give you a number.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Tim Hayes, Davenport.<br>
<b>Tim Hayes</b><i> - Davenport &amp; Company - Analyst</i><br>
Good afternoon. My synergy question has just been asked. The follow-up question on your share buybacks, given that you've put some money<br>into buying Angus. Should we think of share buybacks, maybe fewer share buybacks in the next few quarters given what you're doing with cash<br>for Angus?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
You know, it's always going to be one of the arrows in our quiver that will always be there. So we will continue to look at it on an opportunistic<br>basis and where share values are. I think it is driven down, certainly we will be considering buying it again. Andy, I don't know if you have any other<br>-- ?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes, I we think about a number of factors. One is the current price; one is our leverage level, which obviously is elevated at this point. We think<br>about our investment grade credit rating, and we like to maintain that if at all possible. It doesn't mean we wouldn't push the envelope there, but<br>I think for the time being, we're certainly at an elevated leverage level. So the goal would be to delever, I think, at least in the short run.<br>
<b>Tim Hayes</b><i> - Davenport &amp; Company - Analyst</i><br>
And what do -- do you have a target on the leverage in mind?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
No. As little as possible.<br>
20<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>178</i><br>
<hr>
<A name=179></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Tim Hayes</b><i> - Davenport &amp; Company - Analyst</i><br>
Certainly lower than it is today.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes.<br>
<b>Tim Hayes</b><i> - Davenport &amp; Company - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Sal Tharani.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Thanks. The steel prices have moved up significantly, more than $100 in the last few weeks. I was wondering how quickly the service centers or<br>yourself have been able to pass it through? Are you seeing any resistance on the customers, or they have no choice and they will be accepting the<br>prices?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I think it is part of what kind of helps increase bookings to some degree. People looking at the increase that is coming at them. I don't, George I<br>don't know if you have any color for this. I don't know precisely all of the conversations we've had with customers concerning -- .<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
Certainly, the customers always have alternatives, but I think that there was, as John mentioned, an increase in bookings as people came to the<br>realization that prices were going up; and I think prior to that, there was some hesitation about where the bottom was. As soon as the bottom was<br>reached and prices started escalating, I think people started moving forward with bookings. And we think that will continue.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Did you made any opportunistic buying during that time? At the bottom?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
We don't speculate at all. I mentioned where our inventory levels are today. We're managing that very, very carefully, and I think we've talked to<br>you in the past about some of our strategies that we're employing today in buying of steel, and meeting some of the customers' needs, but we<br>make it a policy not to do any speculative buying.<br>
21<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>179</i><br>
<hr>
<A name=180></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Great, thank you very much.<br>
<b>Operator</b><br>
We have no further questions in queue. Please go ahead with any closing comments.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Thank you very much. Though the current equity markets are challenging to say the least, we're going to remain focused on what we control and<br>on producing results that historically drive shareholder value. Thank you, again, for joining us today, and we wish you all the best in the new year.<br>
<b>Operator</b><br>
Ladies and gentlemen, this conference is available for replay. It starts today at 3.30 PM Eastern. It will last until January 19 at midnight. You may<br>access the replay at any time by dialing 1-800-475-6701 or 320-365-3844.The access code is 226872.That does conclude your conference for today.<br>Thank you for your participation; you may now disconnect.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4681304-2012-01-09T12:53:28.090</b><br>
22<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>180</i><br>
<hr>
<A name=181></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
WOR - Q2 2012 WORTHINGTON<br>INDUSTRIES INC EARNINGS<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 6:30PM GMT<br>
OVERVIEW:<br>
Co. reported 2Q12 sales decline of 2% and EPS before restructuring of $0.28.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>181</i><br>
<hr>
<A name=182></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Cathy Lyttle </b><i>Worthington Industries - VP, Corporate Communications and Investor Relations</i><br>
<b>John McConnell </b><i>Worthington Industries - Chairman and Chief Executive Officer</i><br>
<b>Andy Rose </b><i>Worthington Industries - VP and Chief Financial Officer</i><br>
<b>George Stoe </b><i>Worthington Industries - President and Chief Operating Officer</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Martin Englert</b><i> Jefferies &amp; Co - Analyst</i><br>
<b>Nate Carruthers</b><i> Steel Market Intelligence - Analyst</i><br>
<b>Chris Olin</b><i> Cleveland Research Company - Analyst</i><br>
<b>Sal Tharani</b><i> Goldman Sachs - Analyst</i><br>
<b>John Tumazos</b><i> John Tumazos's Very Independent Research - Analyst</i><br>
<b>Richard Garchitorena</b><i> Credit Suisse - Analyst</i><br>
<b>Mark Parr</b><i> KeyBanc Capital Markets - Analyst</i><br>
<b>Charles Bradford</b><i> Bradford Research - Analyst</i><br>
<b>Tim Hayes</b><i> Davenport &amp; Company - Analyst</i><br>
<b>OVERVIEW</b><br>
Co. reported 2Q12 sales decline of 2% and EPS before restructuring of $0.28.<br>
<b>FINANCIAL DATA</b><br>
<b>A. 2Q12 sales decline = 2%.</b><br>
<b>B. 2Q12 EPS (before restructuring) = $0.28.</b><br>
<b>C. 2Q12-end cash = $54m.</b><br>
<b>D. 2Q12-end total debt = $476m.</b><br>
<b>E. 2Q12 share repurchase = 1.15m shares for $16.7m.</b><br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. 2Q12 BUSINESS REVIEW (J.M.)</b><br>
<b>A. Highlights:</b><br>
<b>1. </b>Co. has consistently said coming out of 2008 recession, expectation was to produce incremental increases on YoverY basis.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>182</i><br>
<hr>
<A name=183></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>a. </b>2Q contributed nicely to that expectation.<br>
<b>2. </b>In last qtr.'s call, referred to significant shift in business platform that would result in transitional gap in revenue and increase<br>
corporate burden for remaining companies.<br>
<b>a. </b>This qtr., that revenue gap almost closed completely on YoverY basis.<br><b>b. </b>Going forward with addition of Angus, revenue gap is more than replaced and corporate burden will approximate previous<br>
levels (indiscernible) by year-end.<br>
<b>3. </b>Two focal points to drive shareholder value will remain the same.<br>
<b>a. </b>To decrease volatility of earnings or set better way.<br><b>b. </b>To increase consistency and stability of earnings, while increasing overall operating margins.<br>
<b>4. </b>Has made and will continue to make progress toward aforementioned goals in how Co. operates and acquisition strategy.<br>
<b>II. 2Q12 FINANCIALS (A.R.)</b><br>
<b>A. Introduction:</b><br>
<b>1. </b>Co. is undergoing transformation.<br>
<b>a. </b>Goals:<br>
<b>i. </b>Higher margins and free cash flow.<br>
<b>ii. </b>More predictable and higher earnings for shareholders.<br>
<b>b. </b>To accomplish goals, Co. is changing:<br>
<b>i. </b>Ways of business management.<br>
<b>ii. </b>Business mix.<br>
<b>c. </b>Evidence of progress is visible in recent quarters.<br>
<b>2. </b>In 4Q11, took two businesses, Gerstenslager and Dietrich Metal Framing, and formed two JVs to make them stronger and<br>
more profitable.<br>
<b>a. </b>Resulted in movement of businesses that were generating over $400m in revenue from operating income to equity income<br>
from affiliates.<br>
<b>b. </b>Decision appears to have benefited both businesses by making them more profitable.<br>
<b>c. </b>Resulting corporate overhead allocations from these businesses were redistributed principally to Steel and Cylinders<br>
segments, making no segments look somewhat less profitable than they would have otherwise been over past few<br>quarters.<br>
<b>3. </b>Has been active in acquiring businesses.<br>
<b>a. </b>Bernz in July, STAKO in Sept. and Coleman and Angus in Dec.<br><b>b. </b>Comes with upfront costs.<br>
<b>c. </b>Requires resources to integrate and realize full financial benefits.<br>
<b>d. </b>Many aforementioned costs are one-time in nature that also serve to reduce profitability of business segments on temporary<br>
basis.<br>
<b>4. </b>Has been investing in a few greenfield businesses principally through global construction group, whose operations are<br>
included in other segment.<br>
<b>a. </b>Actively pursuing some large opportunities, much larger than recent Mozambique project and will continue on this path.<br>
<b>i. </b>Until then, upfront investments will exceed income being generated and as a result dampens Co.'s overall performance.<br>
<b>b. </b>Doesn't intend for these greenfield businesses to lose money for extended period of time; believes investment today will<br>
pay dividends in future.<br>
<b>5. </b>During transition period, as businesses are moved in and out and reinvestment and re-engineering occurs, true impact of<br>
changes in profitability are difficult to isolate.<br>
<b>a. </b>Co. will do its best to provide some visibility; benefits will only become fully apparent in future reporting periods as results<br>
unfold.<br>
<b>B. Highlights:</b><br>
<b>1. </b>Despite slow-growth economy, performed reasonably well.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>183</i><br>
<hr>
<A name=184></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>2. </b>EPS before restructuring, $0.28.<br>
<b>a. </b>Up 47% vs. prior-year.<br><b>b. </b>Results included inventory holding losses from decline in steel prices estimated at $0.09 per share.<br>
<b>c. </b>Inventory holding losses in prior-year qtr. were about $0.11 per share, about a third of which was attributable to Metal<br>
Framing business, which is no longer a consolidated entity.<br>
<b>3. </b>Sales:<br>
<b>a. </b>Down 2%.<br><b>b. </b>Would have been up 10%, excluding acquisition and divestiture activity.<br>
<b>4. </b>Steel Processing:<br>
<b>a. </b>Volumes up 12%.<br>
<b>i. </b>Benefiting modestly from MISA acquisition and strong toll processing activity.<br>
<b>b. </b>Margins were lower principally due to higher inventory holding losses vs. prior-year.<br>
<b>5. </b>Cylinders:<br>
<b>a. </b>Volumes up 7%.<br>
<b>i. </b>Aided by acquisitions.<br>
<b>b. </b>Operating margins declined again during current qtr. due to:<br>
<b>i. </b>Higher manufacturing costs in form of higher wages and input cost for steel and propane.<br>
<b>ii. </b>Higher-than-normal conversion cost due to unexpected and non-recurring repairs.<br>
<b>iii. </b>Elevated fees from acquisitions and higher corporate allocations resulting from JV transactions.<br>
<b>c. </b>Expects margins to recover in coming quarters, as manufacturing costs return to more normalized levels and fees subside.<br>
<b>C. Additional Information:</b><br>
<b>1. </b>Equity income from JVs up 35% over last year to $21.9m.<br>
<b>a. </b>WAVE continues to perform well.<br><b>b. </b>Several other JVs contributed over $2m each including:<br>
<b>i. </b>TWB.<br>
<b>ii. </b>ArtiFlex.<br>
<b>iii. </b>ClarkDietrich.<br>
<b>c. </b>ClarkDietrich is on pace to generate in excess of $10m of equity income for Co. in its first full-year, despite only [owning]<br>
25% of business.<br>
<b>i. </b>Compares quite favorably to $2m that Dietrich contributed to Co.'s last year as wholly-owned subsidiary.<br>
<b>2. </b>Dividends received from JVs, $24.7m.<br><b>3. </b>Net cash generated from operating activities, $64.4m driven by:<br>
<b>a. </b>Higher EBITDA.<br><b>b. </b>Lower working capital.<br>
<b>4. </b>Deployed:<br>
<b>a. </b>$3.6m for capital projects.<br><b>b. </b>$38.8m for STAKO acquisition.<br>
<b>c. </b>$8.4m in dividends to shareholders.<br>
<b>d. </b>$16.7m to repurchase 1.15m shares.<br>
<b>D. 2Q12-end Balance Sheet:</b><br>
<b>1. </b>Total debt, $476m.<br><b>2. </b>Cash, $54m.<br><b>3. </b>Available debt capacity, over $270m.<br>
<b>E. Significant Events in Dec. 2011:</b><br>
<b>1. </b>Completed recapitalization of WAVE with $225m of revolving credit facility with $200m drawn at closing and $50m ten-year<br>
private placement at 4.9% rate.<br>
<b>a. </b>Proceeds were used to repay existing facility and to fund $50m special dividend to each partner.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>184</i><br>
<hr>
<A name=185></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>2. </b>Completed acquisition of Angus Industries, market leader in design and manufacturing of custom engineered operator<br>
cabs for mobile equipment.<br>
<b>a. </b>Angus Industries:<br>
<b>i. </b>Provides excellent opportunity for Co. to invest in and grow its presence in market for manufactured products and OEM<br>
supply chain solutions for agriculture, mining and construction equipment end-markets.<br>
<b>ii. </b>Has strong management team that will continue to run business, while leveraging Co.'s scale and capabilities to capture<br>
growth in Angus' core markets for new product introductions and in targeted international markets.<br>
<b>b. </b>Used proceeds from recently received $50m WAVE dividend and revolving credit facilities to fund $180m purchase price.<br>
<b>c. </b>Based on co.'s trailing 12-month EBITDA, paid under six times EBITDA without factoring in synergies.<br>
<b>d. </b>Current interest rates on credit facilities are just under 1%.<br>
<b>i. </b>Incremental interest cost from transaction will be less than $1.5m per year based on current rates.<br>
<b>e. </b>As a result of WAVE dividend and further reductions in working capital during Dec., funded debt increased only modestly<br>
to $568m with $184m of availability still remaining under revolving lines of credit.<br>
<b>f. </b>Co. purchased aforementioned business at reasonable price; fits well with strategic goals of higher margins, more free<br>
cash flow and diversifying into higher growth end-markets.<br>
<b>F. Conclusion:</b><br>
<b>1. </b>While economy continues to move forward slowly and financial markets seem to react daily to events in Europe, continues<br>
to execute on strategic plan to accelerate growth of earnings.<br>
<b>2. </b>Success of transformation is making existing businesses more profitable, despite below-normal volumes.<br><b>3. </b>Success in identifying, executing and integrating acquisitions at prices that make financial sense is expanding platform.<br><b>4. </b>As economy continues its recovery in 2012, excited about prospect of higher returns for shareholders.<br>
<b>III. 2Q12 OPERATIONAL REVIEW (G.S.)</b><br>
<b>A. Steel Processing:</b><br>
<b>1. </b>Experienced normal year-end slowdown in shipments.<br>
<b>a. </b>Has seen bookings continue into calendar 2012 increasing sharply.<br>
<b>2. </b>Several price increases have been initiated from mills.<br>
<b>a. </b>There seems to be growing strength in backlogs for coming months.<br>
<b>3. </b>Inventories and service levels are the best they have ever been.<br>
<b>a. </b>Currently operating with [57] days of inventory, while achieving 95% on-time delivery performance.<br>
<b>4. </b>Situation with RG Steel:<br>
<b>a. </b>From Co.'s perspective, it had a careful and thoughtful plan that it had in place for several months with alternative supply<br>
options.<br>
<b>b. </b>Regardless of outcome, Co. will not be adversely affected since it has backup supply plans for all business WOR has with<br>
them.<br>
<b>B. Cylinders:</b><br>
<b>1. </b>Experiencing normal seasonal demand within most product lines.<br><b>2. </b>Actively engaged in integration process at new high-pressure cylinders facility in Poland and 16-ounce camping cylinder<br>
facility in Kansas.<br>
<b>a. </b>Poland adds to Co.'s growing position within alternative fuel segment and acquisition of 16-ounce cylinder facility in<br>
Kansas will enable it to better serve rapidly expanding customer base for this product line, while continuing under licensing<br>agreement to produce this product under iconic Coleman brand.<br>
<b>3. </b>Added BernzOmatic business into Worthington (indiscernible) last year.<br>
<b>a. </b>Integration is going well.<br><b>b. </b>Fully anticipates meeting or exceeding projections made when Co. acquired business.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>185</i><br>
<hr>
<A name=186></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>4. </b>Recently asked Centers of Excellence to begin transformation process that was so successful in Steel Processing business<br>
throughout Cylinders organization.<br>
<b>a. </b>Process is only a few months into its work.<br><b>b. </b>Already identified opportunities for production efficiencies and cost-savings.<br>
<b>C. Angus Acquisition:</b><br>
<b>1. </b>Perfect fit for Co.'s long-term strategy of acquiring businesses that improve margins and profitability and are complementary<br>
to core strengths of:<br>
<b>a. </b>Value-added manufacturing.<br><b>b. </b>Market leading businesses.<br>
<b>2. </b>During due diligence process, met with several key customers and came away from that with deep appreciation for:<br>
<b>a. </b>Capabilities.<br><b>b. </b>Market reputation.<br>
<b>3. </b>Met with employees at all four locations this week.<br>
<b>a. </b>Comfortable that integration process will be smooth and seamless.<br>
<b>4. </b>Professional and experienced management team Co. acquired as a result of this acquisition is committed to continuing in<br>
their roles.<br>
<b>a. </b>Top four executives have taken significant portion of funds they received in WOR stock to demonstrate their commitment<br>
to this endeavor.<br>
<b>D. JVs:</b><br>
<b>1. </b>Continue to perform at high level.<br><b>2. </b>WAVE continues with outstanding results, despite challenges facing commercial construction market.<br>
<b>a. </b>Their percentage of remodeling work is higher than in past and helped to maintain their marketplace strength as new<br>
commercial construction remains weak.<br>
<b>3. </b>ClarkDietrich just finished outstanding 2011.<br>
<b>a. </b>Consolidation of two businesses has been completed.<br><b>b. </b>Cost-savings Co. anticipated exceeded expectations.<br>
<b>c. </b>Almost all of non-contributing facilities and assets that Co. retained have now been sold or under contract to be sold.<br>
<b>i. </b>Realizations from aforementioned transactions exceeded expectations Co. originally modeled when it formed JV.<br>
<b>4. </b>Serviacero continues to grow and expand their presence in rapidly developing Mexican market for flat-rolled steel.<br>
<b>a. </b>New pickle line in Monterrey is on schedule to be operational by July.<br>
<b>5. </b>Looks forward to calendar 2012 with great anticipation.<br>
<b>a. </b>Integrating number of new businesses into Worthington family.<br><b>b. </b>Believes all aforementioned will continue with objectives of:<br>
<b>i. </b>Improving margins.<br>
<b>ii. </b>Decreasing volatility.<br>
<b>iii. </b>Increasing shareholder's value.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
(Operator Instructions) Martin Englert, Jefferies &amp; Co.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Good afternoon, everyone.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>186</i><br>
<hr>
<A name=187></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Hello.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
For Angus Industries can you provide D&amp;A figures for 2011 and where you would expect that going forward? Also, in addition to<br>that, where has its historical revenue been and EBITDA margins throughout the peak trough and kind of average throughout the<br>cycle?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Two -- well the first question, the historical D&amp;A, or the go-forward D&amp;A isn't finalized yet, because we haven't completed the purchase<br>price allocation, but a good benchmark is probably $8.5 million to $9.5 million.<br>
The second question -- in terms of their margins through the cycle-- it is a high variable cost business, and they've done a terrific<br>job, actually, through the cycle at maintaining margins. In fact, I think if you look back over the past several years, they've maintained<br>double-digit margins.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay. Would that be within a low double-digit range? Like, 10%, 12%?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes, that would be the trough.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
what would be a good range for the peak? 15%, 17%?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I would say the low end of that range.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay. And if I could, one other question. Can you provide an update on your European cylinders business? How that contributed to<br>earnings through the past quarter here, and where you see the activity and volumes trending in upcoming quarters here going<br>forward?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>187</i><br>
<hr>
<A name=188></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. The European cylinder business continues to recover both volumes and earnings. It is nowhere near back where it was during<br>the peak, which is probably four-ish years ago in terms of its earnings, but the recovery does continue in that business.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay. And for -- within that segment, for restructuring charges, could we expect additional ones going forward in upcoming quarters<br>here?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I'm sorry, for the cylinder segment?<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Yes, Sir.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
There will likely be some restructuring charges. You may recall we have started the transformation process there; our Centers of<br>Excellence teams have been through one facility.They are just kicking off the second facility. Charges related -- most of the restructuring<br>charges to date have been for outside consulting that we brought in. Those charges will be declining starting this quarter.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay, thanks for all the color.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
But there could be some -- I would call it nominal restructuring as we move through the facilities, but I wouldn't anticipate large<br>dollars there.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Excellent, thank you.<br>
<b>Operator</b><br>
Nate Carruthers, Steel Market Intelligence.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>188</i><br>
<hr>
<A name=189></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Nate Carruthers</b><i> - Steel Market Intelligence - Analyst</i><br>
Hi guys. Great quarter. I had -- I guess I had a question about your Other segment. It sounds like you said that upfront investments<br>right now are hurting earnings there. How long do you expect that to continue? And can you elaborate a little bit on the opportunities<br>that you're pursuing there?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Nate -- and thank you for your earlier comment. Think of the investment is really -- as you know, we've done a project abroad in<br>Mozambique very successfully, and we had this operating in North America prior to moving to international. So this is really keeping<br>in place the infrastructure that allows us to do the engineering, to do the work that puts us in position to do these projects.<br>
We have, as Andy said, some very large opportunities, significantly larger than Mozambique, that will be difficult to put a timeframe<br>on them.They are government-involved, as was Mozambique, and so we'll see how they come to fruition. If they start to lose traction,<br>whatever timeframe that is, and I would suspect we'll know this someplace in a six to nine-month period, probably sooner, but I'm<br>not sure. Then we will have to make some judgments. But until then, as long as these opportunities appear like they're going to get<br>traction, it is worthwhile leaving the infrastructure in place so that we're able to do the work.<br>
<b>Nate Carruthers</b><i> - Steel Market Intelligence - Analyst</i><br>
Okay, thank you.<br>
<b>Operator</b><br>
Chris Olin, Cleveland Research.<br>
<b>Chris Olin</b><i> - Cleveland Research Company - Analyst</i><br>
Good afternoon, guys. First I wanted to ask a little bit on automotive. I think you guys have a pretty good view on what's going on<br>there. It seems like the sentiment is getting a little bit better across the channel. I'm just wondering what you guys are seeing? I guess<br>if you could talk a little bit more specifically, going into the next couple of months?.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I think we feel generally positive about automotive. As George pointed out, overall steel bookings are up. I couldn't go to it by<br>segment, but we all track it here in different ways, and every way we track it shows forward bookings strengthening quite a bit,<br>particularly when I look on a year-over-year basis.They're much stronger than they were at this time last year coming out of December.<br>So that's very encouraging. I don't know if George has any more color on automotive specifically for you or not.<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
I would say, John, you hit the nail on the head. I think that we're seeing stronger bookings that we have over the past few months,<br>and certainly going into calendar 2012, we've seen a sharp increase in bookings coming from the automotive sector.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>189</i><br>
<hr>
<A name=190></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Chris Olin</b><i> - Cleveland Research Company - Analyst</i><br>
Is it realistic to think that the auto side of your business could improve by 10% to 15% in 2012, given where the production schedules<br>are headed?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Certainly coming into this call, I did not sit down and calculate what I thought a percentage increase was with automotive. I do think<br>it is going to continue to improve, and I think in this -- the way everything is right now, the way -- is why we always work like we're<br>going to do -- our goal is to increase, year over year, our earnings and keep driving things forward.<br>
And I think we are continuing to incrementally do this.That is a good sign.You have people worried about what Europe could trigger<br>here in the US, and those kind of issues are still going on. And until they calm down, it is going to be very difficult for somebody to<br>get really robust in their predictions for you.<br>
<b>Chris Olin</b><i> - Cleveland Research Company - Analyst</i><br>
I know you guys talked a bit about how you are protected from the RG Steel issue; I'm just curious, since this announcement has<br>been out there, has that firmed up the pricing environment? Do you guys have any different thoughts on where the sheet prices<br>could go?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
I certainly think that it has, Chris. I think some of the mills out there locked into putting additional increase on as a result of that,<br>because they saw that their backlogs were filling as a result of the uncertainty about that. But, I can't make a prediction on where<br>the prices will go. I think there are too many factors that weigh in on that. Obviously, we've seen a number of increases over the last<br>few months.<br>
<b>Chris Olin</b><i> - Cleveland Research Company - Analyst</i><br>
Okay. I'll get in the queue.<br>
<b>Operator</b><br>
Sal Tharani, Goldman Sachs.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Thank you. Good afternoon, guys. The Nuconsteel closure announcement today by Nucor, how big of a player was it, then, in the<br>field of framing?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I would -- in the space in which we played, I would say not very large. They largely focused their efforts on smaller structures,<br>single-family homes and that kind of things. So we didn't see them that much. And abroad, I think they have been in some conversations<br>that we have been in, but of course that would tend to end that conversation. So, not huge.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>190</i><br>
<hr>
<A name=191></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Okay. On the Angus cab business, is it just the cab they make, or do they also work on the controls or incorporate controls in that<br>cab when they put that on the machines?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
They put controls in the machines; they do not make the controls. They typically are sourcing those from other third parties. But<br>there is an opportunity -- one of the opportunities for Angus is to continue to insource the manufacturing of other parts, obviously<br>the metal components, which they have a great deal of expertise would make the most sense, but electronics is not out of the<br>question down the road.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
As I understand it, they're more likely -- or we are more likely at this point I should say to be concentrated on things that would touch<br>the cab around the piece of equipment. So you might come down into the fenders, or you might come down in the doorwell or the<br>stairwell or something like that, so that it all just fits together.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
And that growth will come from Angus, or you will do some bolt-on acquisitions around it?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
we think the growth -- that growth that I just discussed was on Angus's agenda before we acquired them.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Okay, great. One more question -- you mentioned, you did -- alluded to the RG Steel impact or steel sourcing impact. Are you having<br>any difficulty in sourcing steel?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
No, not at all, Sal. I mentioned in my comments, we had a careful plan in place as our business was growing somewhat with them,<br>but we always had a thought in our mind that we had to make sure that we were cautious in going forward with that, and we're<br>hopeful that they're going to be able to come out of the current challenges they are facing. They've been a good supplier for us in<br>the time that we have been doing business with them. We do nothing but wish them well and hope that they can recover.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
And one more question before I get in the queue.Your first half volume is about 13% up in the process steel section. I was wondering<br>how can you differentiate between tolling and non-tolling in there?<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>191</i><br>
<hr>
<A name=192></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
It's about 51 direct and about 49 is toll business.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
And both have grown in similar fashion in the first half versus last year?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
No. The historic norm here would be something like 56/44. (multiple speakers)<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
56 for --<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
It would be more like that. A mid-50s number for direct and a mid-40s number or so for tolling, if you look back. This quarter was<br>somewhat aberrational in that sense.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Okay, great. Thank you very much.<br>
<b>Operator</b><br>
John Tumazos, John Tumazos's Very Independent Research.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Congratulations on good results, progress. With regard to Angus, roughly how much of the revenues is the steel they buy to make<br>the cabs?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Is a smaller percentage than you would think, John. It's probably in the 15% range.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Was Angus an existing customer, where you were already processing their steel for them, or will that be a new synergy of the<br>transaction?<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>192</i><br>
<hr>
<A name=193></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
It's a new opportunity.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
It is a new opportunity, and one which we're really just beginning to explore. We did not take that into account as we were doing<br>this transaction, didn't do the pricing based on that. And it's uncertain how much we will switch as a result. So we are going to take<br>that very slowly, very cautiously. They have good suppliers right now, and so it all depends on the material, where we have plants<br>located, whether we have the capabilities to do what they want to do. And all of that has been looked on a cursory basis, but not<br>very deep at this point.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
John, where are the Angus facilities located?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
South Dakota, Iowa, Tennessee, and South Carolina.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Thank you. A couple of quick questions. I read that China has a goal of building 45 million housing units in five years. I was wondering<br>if Worthington is going to participate in that?<br>
And I had a very nice visit in Mozambique in October to an 80-foot-thick met coal seam of Vallet, and I was wondering if you could<br>talk a little bit more about your opportunity -- the business you did in Mozambique.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
In China, we would hope that we participate in the housing push. The project that the joint venture has taken on at the moment<br>will be somewhat oriented toward housing as part of a new industrial science center that is being built as part of a new ring city. But<br>certainly all of -- eight story -- actually, six-story structures will come up in our building methodologies there. Some of that will be<br>housing.<br>
Beyond that we will continue to look for projects. I think the housing market in China is a little unsettled at the moment. So the<br>Ministry, I think, has, I'm guessing, the motivation to hurry up on this lower-end housing to try to add stability to the housing market.<br>Because as I would understand it, that is one of the things that is putting uncertainty into buying homes, whether or not prices will<br>go down or not. So the sooner they get this floor of low-end housing out there and set up, I think they would expect to see stability<br>come to the rest of the housing market. So they should be motivated to do so, and we expect to participate in some.<br>
Now, with Mozambique, John, you said you were just there for something which I'm not sure I understood.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
There is a big metallurgical coal camp there Vallet and Rio Tinto have invested.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>193</i><br>
<hr>
<A name=194></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Okay. Our structures were all around the Pan-African Games, All-African Games, I believe it was called, to house the athletes. There<br>were 22 buildings, essentially 22.5 buildings, to house the athletes. I'm sure -- I'm not sure. I'm assuming that the Mozambique<br>government will turn that into low-end housing for their residents going forward.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
This was all in Maputo?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. Right next to the stadium.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Super. Congratulations on everything.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Thank you.<br>
<b>Operator</b><br>
Richard Garchitorena, Credit Suisse.<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
Thanks. Good afternoon. A couple of quick questions. I think you mentioned regarding steel processing that for this quarter, inventory<br>holding losses were roughly $0.09. Is it fair to say that we should expect this to reverse in the next quarter, given where steel prices<br>have moved?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I wouldn't expect it to reverse such that you have $0.09 of gain next quarter. I would say we've reached the -- assuming steel prices<br>continue to migrate up, we've reached the inflection point, and that inflection point will occur sometime during the quarter to where<br>we will start having gains. In terms of whether or not we have losses or gains for the third quarter, I would say it is unclear at this<br>point. You need to ultimately figure out what the sales for the quarter are going to be, and that will unfold over the next couple of<br>months.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>194</i><br>
<hr>
<A name=195></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
Okay.Yes, that makes sense. And then regarding volumes, can you give us a sense of how shipments ran on a monthly basis through<br>the quarter? And if you could give us some color on -- I know you mentioned that things were -- demand was picking up, but maybe<br>how December looked, and January?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
We have people digging. You're asking for the volumes related to cylinder, steel? Is that what you're asking?<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
Steel processing, I should just -- sort of how things shook out through the quarter and where we are.<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
Generally I would say, John, that in December we were probably in -- on the direct basis, we were probably in the 95,000 ton range<br>on direct and a little bit less than that on the toll side.<br>
But it goes back to my comments earlier about the bookings. Our bookings in December for the month going forward were much<br>stronger than that.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I don't know what the volumes were specifically, but I don't think there's any question they were stronger than they were this year<br>or last year at this time.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. Will have to get back to you on the monthly data, Richard. We don't have it at our fingertips.<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
That's great. Last question, on purchasing cylinders -- given the two acquisitions that happened with STAKO and Coleman, those<br>are only partly reflected in the second quarter, so we should see some more in the third quarter. Is that right?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Correct. They both came in in December?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
STAKO was September; Coleman was December 1.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>195</i><br>
<hr>
<A name=196></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
And then you have, really, starting January 1 forward with Angus.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
The other thing -- not to get too detailed, but purchase accounting sometimes minimizes the earnings in the first couple of months<br>as you flow through that inventory. So usually, when you complete an acquisition, the full benefit of the earnings don't materialize<br>until -- I will call it the second quarter, to be safe.<br>
<b>Richard Garchitorena</b><i> - Credit Suisse - Analyst</i><br>
Got it. Thank you very much.<br>
<b>Operator</b><br>
Mark Parr, Keybanc.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Thanks very much. Good afternoon. Hey I've got a couple of questions. Just first from a housekeeping -- do you have the conversion<br>and labor costs per segment, and also the SG&amp;A per segment?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I'm not sure about the first one. I know we have the second one.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. You want SG&amp;A per segment?<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Yes.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
We'll have to get back to you on that one, Mark. We don't disclose that.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
A couple of other things. Automotive is your largest end market in steel processing; that business is getting much stronger. Could<br>you talk a little bit about some of the other end markets and what you have been seeing recently?<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>196</i><br>
<hr>
<A name=197></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I think we've seen a general strengthening in the steel business across the board. Cylinders is some up, some down -- more up than<br>down in demand. George, you have any other color you want to throw on that?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
No. I think as you well know, Mark, the construction area is still weaker, but we're seeing a little bit of strength coming back in there,<br>and the agricultural side that we have a relatively strong position in is coming along nicely.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Is the construction activity that you are seeing -- does it feel like it is a blip, or does it feel like it is a sustainable sort of movement?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I tell you, it feels like it's trying to get up off the bottom, which doesn't necessarily answer your question. It may continue to bump<br>up and down around these levels, which means it could be a blip, but it is nice to see it trying to get up. How about that?<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay. Then, back to the cylinders business, Andy, I think you had mentioned that Europe was recovering. And I was just curious,<br>what sort of trajectory is Europe on compared to, call it the US or the rest of the world? Can you give us some color on -- at least at<br>this point, with the acquisitions you've made, how big a percentage of your mix Europe will be?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes. I guess it sounds strange to say that Europe is recovering, considering you pick up the newspaper or watch the news and listen<br>to what's going on. But you have to remember, our European cylinder business was off almost 70% in terms of the volumes during<br>the downturn.<br>
And so as that business has recovered over the last 18 months, it's returned to profitability and continues to migrate upward. I would<br>say -- you heard me mention, also, it's nowhere near back to the level of profitability that it was three or four years -- four years ago,<br>I guess at this point.<br>
In terms of the strength of the European economy, obviously we're not economists, but I think there's a lot of uncertainty there. So<br>in terms of where it goes from here, your guess is probably as good as mine.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
And what was the second part of your question there?<br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>197</i><br>
<hr>
<A name=198></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
I was curious, what is the mix of Europe now overall for cylinders?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
The mix in terms of the profit contribution, Europe is probably 15%.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay, so Europe has really got a ways to go?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
The other thing to add to that, you've got -- most of our retail product lines are in the US. We do have some retail in Europe, but I<br>think less so than in the US market. So it's a little bit of a different business mix over there as well.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay, that's helpful. Just a couple of other housekeeping things.The restructuring charges that you articulated, that $2 million dollars,<br>was that accounted for directly against the EBIT number for cylinders in the quarter? Or was that on a separate line item on the P&amp;L?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
separate. Did I say $2 million in restructuring?<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Yes, $2 million. Is that something you expect to continue? Is that more of a one-time thing in nature or -- ?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
It's related to our transformation. So I would say there will be more charges in this quarter, and then I would expect that those would<br>go down substantially.<br>
17<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>198</i><br>
<hr>
<A name=199></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
And then lastly, the M&amp;A fees in the November quarter, what is the delta looking like for the February quarter relative to November<br>as far as M&amp;A fees are concerned?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
So, as you know over the past couple of years, we've been active acquiring businesses. So there will be some fees in there related to<br>due diligence and other, but there was specifically in this quarter, Q2, just over $1 million in fees which I would characterize as<br>one-time. One was for an investment banker in Europe related to the STAKO acquisition, and the second fee was related to that<br>transaction; sort of a transfer tax, if you will. So it was about $1.1 million that I would say would not be there next quarter.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
So the fee thing for February is less than November?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Correct.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay, and then the restructuring thing would be the same?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I think a little bit less than $2 million.<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
And then I guess, lastly, the $5 million in other losses that you had, is that something we should view as recurring over the next<br>couple of quarters, John? It sounds like you were talking about continuing to make some pretty heavy investments. Is $5 million a<br>better number than $3 million? I'm just trying to plug in a number for the next couple of quarters.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I would hope, Mark, and I think our forecast says not continuing at that level. There were a few one-time items also in that segment<br>for this quarter, but there will be losses.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
And when we talk about the construction segment and its contribution to the losses in Other, it is not [off of ] the losses in Other. If<br>that helps. Like Andy said, there were some one-time charges. Some of that may go away, so it is likely to be less than $5 million.<br>
18<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>199</i><br>
<hr>
<A name=200></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Mark Parr</b><i> - KeyBanc Capital Markets - Analyst</i><br>
Okay. All that color is really helpful. Appreciate it. Congratulations and good luck in the February quarter.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Thank you.<br>
<b>Operator</b><br>
Charles Bradford, Bradford Research.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
Can you tell us a bit more about how Angus sells its product? Does it do designs, is it basically a subcontractor?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
That's a good question that lets me start the answer saying that we feel very comfortable with this, because it is all about metal<br>building bending and welding, to a large degree. One component that we don't necessarily have the expertise in currently is the<br>general engineering of this product, which is largely a big part of their sales effort. It is all around the engineering. We're very good<br>at metallurgical engineering, and might be helpful there, but not in sign engineering, as they are. So that's a big part of the sales;<br>it's direct with the OEMs? Andy, George, anybody got any?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
The only other thing I would tell you, Charles, is that their largest customers are the John Deeres and the Caterpillars of the world,<br>and they do specific jobs for them in designing cabs for a lot of the large mobile equipment that they have, and depending upon<br>the volume, whether they do them outside or inside those companies, and they've carved out a great niche for themselves and are<br>really the market leader in this segment.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
Would they be supplying the onesies and twosies for very specialized cabs, or would they be on the more common excavator and<br>large mining trucks and what have you?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
They do some of both, but the majority of their business is in the more consistent runs of lesser volumes, but certainly where they<br>might have several thousand of one particular product line.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
When it comes to the steel component, what you said was about 15% of cost?<br>
19<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>200</i><br>
<hr>
<A name=201></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
Do they usually price their product with a cost index so they can pass through the change prices or are they more fixed price?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
It is probably not prudent for us to comment on their pricing strategies.<br>
<b>Charles Bradford</b><i> - Bradford Research - Analyst</i><br>
Okay, understood. Well, thank you very much.<br>
<b>Operator</b><br>
Martin Englert.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Thanks for the follow-up opportunity. For Angus, I wanted to touch back again on the revenues.You'd reported in the release it was<br>a little over $200 million for 2011.Where would that have been in the cycle for the Company? Is this, like, a midcycle top-line number,<br>or where do you see it?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
I think that's probably as fair a characterization. They service three market segments, principally -- agriculture, construction, and<br>mining.The largest of those is construction, and then agriculture, and then mining. Ag and mining have been very strong. Construction<br>has been more modest, and so two of the segments, I would say, maybe are nearer the top end of the cycle, but the construction<br>segment certainly is not and happens to be the largest.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Okay. I'm just trying to get a sense of, maybe, going forward what to expect from top-line from within that business. What kind of<br>ranges.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
You know, you could look at market growth forecasts as probably the best indicator. I think construction is forecast to grow over<br>the next 10 years at 6%, ag at maybe 3.5% and mining, maybe at slightly less than that.<br>
20<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>201</i><br>
<hr>
<A name=202></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
Are you able to provide any color of what type of share that construction, ag, and mining has within that business?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I think he gave a general sense of order of magnitude, and that's probably good enough from our end.<br>
<b>Martin Englert</b><i> - Jefferies &amp; Co - Analyst</i><br>
All right, thanks for the help.<br>
<b>Operator</b><br>
John Tumazos.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
What would be a good guess of the possible synergies of Angus and Worthington? 2% of sales?<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
John, again, we didn't factor in any synergies into this deal. Clearly, things that we know over time, we'll probably be looking at<br>migrating them into the shared services that we do amongst all of our businesses around accounting, finance, payables, that kind<br>of thing. Again we're not going to be in a rush to do that. We want to get to know their employees better, and how we're going to<br>go about it. So we really didn't bake any in, and we're going to be out looking for ways, as our Center of Excellence team goes in<br>there to perform the integration. One of the primary objectives is to identify the areas of synergy when we go in, but we did not<br>base the acquisition on that. Therefore I can't give you a number.<br>
<b>John Tumazos</b><i> - John Tumazos's Very Independent Research - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Tim Hayes, Davenport.<br>
<b>Tim Hayes</b><i> - Davenport &amp; Company - Analyst</i><br>
Good afternoon. My synergy question has just been asked. The follow-up question on your share buybacks, given that you've put<br>some money into buying Angus. Should we think of share buybacks, maybe fewer share buybacks in the next few quarters given<br>what you're doing with cash for Angus?<br>
21<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>202</i><br>
<hr>
<A name=203></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
You know, it's always going to be one of the arrows in our quiver that will always be there. So we will continue to look at it on an<br>opportunistic basis and where share values are. I think it is driven down, certainly we will be considering buying it again. Andy, I<br>don't know if you have any other -- ?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes, I we think about a number of factors. One is the current price; one is our leverage level, which obviously is elevated at this point.<br>We think about our investment grade credit rating, and we like to maintain that if at all possible. It doesn't mean we wouldn't push<br>the envelope there, but I think for the time being, we're certainly at an elevated leverage level. So the goal would be to delever, I<br>think, at least in the short run.<br>
<b>Tim Hayes</b><i> - Davenport &amp; Company - Analyst</i><br>
And what do -- do you have a target on the leverage in mind?<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
No. As little as possible.<br>
<b>Tim Hayes</b><i> - Davenport &amp; Company - Analyst</i><br>
Certainly lower than it is today.<br>
<b>Andy Rose</b><i> - Worthington Industries - VP and Chief Financial Officer</i><br>
Yes.<br>
<b>Tim Hayes</b><i> - Davenport &amp; Company - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Sal Tharani.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Thanks.The steel prices have moved up significantly, more than $100 in the last few weeks. I was wondering how quickly the service<br>centers or yourself have been able to pass it through? Are you seeing any resistance on the customers, or they have no choice and<br>they will be accepting the prices?<br>
22<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>203</i><br>
<hr>
<A name=204></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
I think it is part of what kind of helps increase bookings to some degree. People looking at the increase that is coming at them. I<br>don't, George I don't know if you have any color for this. I don't know precisely all of the conversations we've had with customers<br>concerning -- .<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
Certainly, the customers always have alternatives, but I think that there was, as John mentioned, an increase in bookings as people<br>came to the realization that prices were going up; and I think prior to that, there was some hesitation about where the bottom was.<br>As soon as the bottom was reached and prices started escalating, I think people started moving forward with bookings. And we<br>think that will continue.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Did you made any opportunistic buying during that time? At the bottom?<br>
<b>George Stoe</b><i> - Worthington Industries - President and Chief Operating Officer</i><br>
We don't speculate at all. I mentioned where our inventory levels are today. We're managing that very, very carefully, and I think<br>we've talked to you in the past about some of our strategies that we're employing today in buying of steel, and meeting some of<br>the customers' needs, but we make it a policy not to do any speculative buying.<br>
<b>Sal Tharani</b><i> - Goldman Sachs - Analyst</i><br>
Great, thank you very much.<br>
<b>Operator</b><br>
We have no further questions in queue. Please go ahead with any closing comments.<br>
<b>John McConnell</b><i> - Worthington Industries - Chairman and Chief Executive Officer</i><br>
Thank you very much. Though the current equity markets are challenging to say the least, we're going to remain focused on what<br>we control and on producing results that historically drive shareholder value. Thank you, again, for joining us today, and we wish<br>you all the best in the new year.<br>
<b>Operator</b><br>
Ladies and gentlemen, this conference is available for replay. It starts today at 3.30 PM Eastern. It will last until January 19 at midnight.<br>You may access the replay at any time by dialing 1-800-475-6701 or 320-365-3844. The access code is 226872. That does conclude<br>your conference for today. Thank you for your participation; you may now disconnect.<br>
23<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>204</i><br>
<hr>
<A name=205></a>JANUARY 05, 2012 / 6:30PM, WOR - Q2 2012 Worthington Industries Inc Earnings Conference Call<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4681304-2-2012-01-09T12:53:28.090</b><br>
24<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>205</i><br>
<hr>
<A name=206></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
ROST - ROSS STORES, INC. DECEMBER<br>2011 SALES PRE-RECORDED CALL<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 1:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>206</i><br>
<hr>
<A name=207></a>JANUARY 05, 2012 / 1:30PM, ROST - Ross Stores, Inc. December 2011 Sales Pre-Recorded Call<br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>John Call</b><i> Ross Stores, Inc. - SVP and CFO</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>John Call</b><i> - Ross Stores, Inc. - SVP and CFO</i><br>
Good morning. Welcome to the Ross Stores pre-recorded message that provides additional information on our December sales release issued on<br>Thursday, January 5, 2012. This is John Call, the Company's Chief Financial Officer. This recording will be available until 8 PM Eastern time on Friday,<br>January 6. In addition, a written transcript will be available in the Investors section of the Company's website at www.RossStores.com.<br>
As a reminder, today's press release and the recorded comments and transcript on our website contain forward-looking statements regarding<br>expected sales, earnings levels, and other financial results in future periods that are subject to risks and uncertainties which could cause our actual<br>results to differ materially from management's current expectations.The words plan, expect, target, anticipate, estimate, believe, forecast, projected,<br>guidance, looking ahead, and similar expressions identify forward-looking statements. Risk factors for Ross Dress for Less and dd's DISCOUNTS are<br>set forth in our SEC filings, including without limitation the Form 10-K for fiscal 2010 and Form 10-Qs and 8-Ks for fiscal 2011.<br>
For the five weeks ended December 31, 2011, sales grew 14% to $1.149 billion, up from $1.008 billion in sales for the five weeks ended January 1,<br>2011. Same-store sales for the month rose 9% on top of 4% and 12% gains in the prior two years.<br>
For the 11 months ended December 31, 2011, sales totaled $8.125 billion, a 9% increase over the $7.425 billion in sales for the 11 months ended<br>January 1, 2011. Comparable store sales for the 11 months ended December 31, 2011, grew 5% on top of a 5% and 6% increases for 2010 and 2009,<br>respectively.<br>
We are very pleased with our much stronger-than-expected sales gains in December. These reflect results that value-seeking shoppers continue<br>to respond favorably to the wide array of compelling name brand bargains throughout our store.<br>
Juniors and shoes were the best performing merchandise categories in December, with same-store sales well above the Company average.<br>Geographic trends were broad-based. At the end of December, average in-store inventories were down about 6% from last year.Total consolidated<br>inventories were up about 10%, driven by packaway balances, which were approximately 48% of total inventories at month end compared to 47%<br>in the prior year period.<br>
Based on our above-plan sales and favorable gross margin trends for the first two months of the quarter, and our continued assumption for a 1%<br>to 2% increase in January same-store sales, we now project earnings per share of $0.82 to $0.83 for the 13 weeks ending January 28, 2012. This<br>updated range compares to our prior earnings guidance of $0.77 to $0.80 per share, and represents a forecasted increase of 19% to 20% over $0.69<br>in last year's fourth quarter.<br>
All current and prior-year earnings per share have been adjusted for our recent 2-for-1 stock split. We plan to report January 2012 sales results on<br>Thursday, February 2. If you have any questions, please do not hesitate to call Bobbi Chaville, Senior Director of Investor Relations, at 925.965.4289,<br>or me at 925.965.4315. Thank you.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>207</i><br>
<hr>
<A name=208></a>JANUARY 05, 2012 / 1:30PM, ROST - Ross Stores, Inc. December 2011 Sales Pre-Recorded Call<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4681261-2012-01-09T13:18:51.753</b><br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>208</i><br>
<hr>
<A name=209></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
MHR - MAGNUM HUNTER RES CORP<br>DEL AT PRITCHARD CAPITAL<br>PARTNERS LLC "ENERGIZE`<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 04, 2012 / 11:45PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>209</i><br>
<hr>
<A name=210></a>JANUARY 04, 2012 / 11:45PM, MHR - MAGNUM HUNTER RES CORP DEL at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Scott Doyle</b><i> Pritchard Capital Partners - Analyst</i><br>
<b>Gary Evans</b><i> Magnum Hunter Resources Corp. - Chairman and CEO</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Scott Doyle</b><i> - Pritchard Capital Partners - Analyst</i><br>
Our next presenter will be Magnum Hunter. We will have Gary Evans speaking. He will be in the Olympic Room following the presentation for a<br>breakout session. Gary?<br>
<b>Gary Evans</b><i> - Magnum Hunter Resources Corp. - Chairman and CEO</i><br>
Thank you, Scott. Some forward-looking statements.<br>
Today Magnum Hunter is about a $750 million market capitalization enterprise, about a $1.1 billion enterprise, $750 million market cap. We did<br>announce, I guess, during the holidays that we markedly beat our year-end production exit rate, which was 10,000 BOE a day. We were over 12.5,<br>and we upped our 2013, or 2012, I should say, exit rate to 14.5. So total reserves today are about 37 million barrels. It looks like with our drilling<br>efforts, we are adding about 1 million barrels a month to our total reserve base. That is based on the last year of what we have been achieving. We<br>also identified resource potential of about 500 million barrels, and we have over 4000 drilling locations in our inventory.<br>
Magnum Hunter today is really a truly unconventional resource company; that is all we do. We are focused in these three plays that you all well<br>know. Our job now that we have accumulated our acquisitions and leases is to become a drilling factory, and I think that is what the market is finally<br>beginning to realize, that we have a lot of technology in-house and have done, I think, a decent job in showing how we can develop these assets.<br>
So this is a map just depicting our acreage position. We are continuing to add acreage in the Eagle Ford. We have some transactions working right<br>now in the Utica to increase that acreage position. We are working on some in the Marcellus, some in the Bakken. So all areas we are continuing<br>to build upon. We don't really have any significant acquisition plans because we have such a large inventory. Our goal really is just to grow within<br>our existing portfolio.<br>
If you are going to be in resource plays -- this is a Credit Suisse slide showing where you ought to be, and we are in the three top. We are, I would<br>tell you, very concerned about natural gas prices. That is one reason we have put a lot of hedges in place in the last 60 days for 2012 and 2013. We<br>are actually having a management retreat over the next three days to discuss how we might realign our budget to more of our oil plays. So our<br>budget today is $200 million, $150 million upstream, $50 million up stream, divided equally in the three divisions, and I can tell you that will definitely<br>change over the next month.<br>
So this is our production growth that we have experienced since the first quarter of this year, and where we anticipate exiting at the end of 2012.<br>And I'm sure those numbers will gradually go up as we continue to produce these new properties.This is where we ended up in the last six months<br>coming from July to our fourth quarter estimate of 12.5, and where that production profile came from.<br>
Reserves, we have been doing reserve reports now every 6 months, because our reserves are growing so fast. That has enabled us to have -- we<br>had five different borrowing base increases with our Bank group in 2011. We are getting ready to go through another one here in the next 30 to<br>45 days. Our reserves have been finalized by our engineering firms and will be disclosed here in the next few weeks, but I can tell you we are over<br>40 million barrels. So, again, we are adding about 1 million barrels a month.<br>
So let's dive down a little deeper in the three plays. The Williston Basin is predominantly from our NuLoch acquisition, completed in May of this<br>past year. We have got total proved reserves of about 8.2 million barrels, of which PDP is only 3.7. It's about a 19-year reserve life, mostly crude. We<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>210</i><br>
<hr>
<A name=211></a>JANUARY 04, 2012 / 11:45PM, MHR - MAGNUM HUNTER RES CORP DEL at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
do have some associated gas. That is all being flared today. We are in the process of getting all that gathered and going into a new processing<br>facility in 2012.<br>
Today our acreage position is right at 82,000 acres, of which 50,000 of that is -- another 50,000 we have an Alberta, but up in the Tableland field of<br>Saskatchewan we have 35,000 acres. Large inventory, almost 500 drilling locations, and we currently have six rigs running in North Dakota, with<br>one rig running in Saskatchewan.<br>
This is a map just depicting our activity predominately in Divide and Burke counties, and then Tableland Field of Saskatchewan.This is the number<br>of wells that we currently have, a total in this Williston Basin division of 269 producing wells. We completed 58 in 2011.<br>
Kind of our chart showing you the Williston Basin gross production. You can see we were definitely impacted by the flooding that occurred from<br>the wet spring and the cold winter last year that had all the snow, and then all that production started coming back on in August/September. This<br>is another chart that shows you, again, how we were affected with shut-in production and how production has come back and grown. So we are<br>approaching 7000 barrels a day gross out of this division, about 2000 barrels a day net.<br>
We like to show these economic sensitivity analysis. Oil today was $103 a barrel, so we are on the far end of this chart. We show in the blue line the<br>North Dakota wells, which are two-mile lateral wells up in Saskatchewan. We only drill one-mile laterals because we have royalty relief on the first<br>100,000 barrels. So our net royalty interest in Saskatchewan is 97.5%. So that is why the economics are so good when you are just drilling one-mile<br>laterals. These wells only cost about $3 million to drill, and we are discovering now closer to 200,000, 220,000 barrels. We put our two best wells in<br>Saskatchewan on over the last month in the 600, 700 barrel a day range, and we owned 100% of it.<br>
So let's jump to the Eagle Ford. This is our Southern division. We have got proved reserves at September 30 right at six million barrels, of which<br>PDP is 1.5. We have 13 wells on production today, mostly crude oil, 85%, and the gas that we are selling, all of our gas is tied into a system going<br>to energy transfer. It is 1350 BTU gas, and we have about 25,000 net acres in the play. We have got 198 locations identified, of which right at 90 are<br>net to our interests.<br>
This is a map depicting our area. We are primarily in Gonzales and Lavaca County; that is where we are spending all of our time. We have two joint<br>ventures -- one with Hunt Oil and one with Petrosouthern down in Lavaca County. Our wells today are typically 2000 to 3000 barrels a day. We put<br>one on about four or five days ago that is about 2200 barrels a day still this morning. So very good production.<br>
This is a summary of all we are doing. The one we just tested, it was a Snipe Hunter; it was the one I mentioned. You see it is a lateral link with 7000<br>feet, and we did 25 frac stages. So further laterals, more frac stages, better results. The well we are fracing right now, the Snipe Hunter -- I'm sorry,<br>the Leopard Hunter -- is -- we are I think on stage 22 today, and it will be put on production here in the next week.<br>
So 2011 we had one rig running in this play. 2012 we have three rigs running, two that we operate and one that Hunt operates. So you will see<br>some dramatic production growth here. Today we are about 5000 barrels of oil gross, about 2000 net, coming from our interest in the Eagle Ford.<br>
And this shows you a chart through November 30 of our production growth. Again, it's now over 5000.<br>
Economic sensitivity -- one thing that is important to note in the Eagle Ford -- we are getting a $10 per barrel bump off WTI, so WTI today was at<br>$103, we are getting $113. I have got to extend that chart here pretty soon, but we are out on the very far end. Our results are now all in the blue<br>column. So that is over 150% internal rate of return. Not bad. So that is why you can see we increased our rig count from one to three rigs.<br>
Appalachia -- this is a combination of four transactions; Triad, Windsor, PostRock and NGAS. So all four of those companies were combined; they<br>are headed by a gentleman we moved from Houston up there as an engineer, named Jim Denny, and this is our biggest division. We have got 23<br>million barrels of proven reserves, 12 million barrels of PDP. It's about 25% oil liquids, 75% natural gas. Large acreage position, 370,000 acres. Most<br>of that is all held by production, so we have no gun to our head. Our activities have been focused predominantly in the Marcellus of Northwest<br>West Virginia, and we have got about 790 locations identified, but you will see, net, that is 774. So we own almost all of this.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>211</i><br>
<hr>
<A name=212></a>JANUARY 04, 2012 / 11:45PM, MHR - MAGNUM HUNTER RES CORP DEL at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
So the Marcellus, if you're going to be in natural gas today, which is, again, a horrible price, this is where you want to be. So we are focused only<br>on the gas development in the Marcellus and the Utica, and we will talk about that here in a minute. Again, longer laterals, more frac stages. We<br>keep changing up our cocktail on our -- the way we frac these wells, and we are getting better and better results. We just put three wells on over<br>the Christmas holidays. Collectively, those three wells are doing today 20 million cubic feet of gas. So very impactful. Most of this gas flows into<br>our own system, called Eureka Hunter, which I will give you a little more detail on.<br>
So when we bought Triad back in February 2010, people go, you are crazy. Marcellus is only in Pennsylvania. Well, we are putting on wells in the<br>Marcellus and Tyler,Wetzel, and Pleasants counties that are bigger than lots of Pennsylvania wells, and again, it is liquids-rich; 25% of our gas stream<br>is liquids.<br>
So we are very pleased with what we are doing here, continue to increase our acreage position. We have, I think, seven land guys out there leasing<br>acreage, and being able to do it for $1000, $1500 an acre, so very good prices, excellent returns.<br>
So this is our activity in the Marcellus since we got involved, a combination of Tyler, Monroe. We drilled one Marcellus well across the river. And<br>then -- so the three wells I just mentioned are all the Everett Weese wells. Those are all tested, collectively, over 20 million a day.<br>
This is our chart on Marcellus production. We announced about two weeks ago a new joint venture with Stone Energy out of Louisiana.The whole<br>purpose of this JV was we had bought acreage; that is the PostRock acreage we bought. Stone had acreage, and so we put everything together.<br>And you can see the reason we did that was to better optimize the value of this acreage by doing longer laterals in a joint venture. Also, Stone had<br>spent a lot of money on infrastructure -- between $10 million and $20 million building roads, bridges, frac ponds, what have you, and we got the<br>benefit of that in this transaction.<br>
So the purple line you see there is our new Eureka Hunter pipeline that is in the process of being built. And this program will be active in 2012<br>drilling this JV. 19 horizontal wells, of which Stone and ourselves will have the 50%-50% JV. It is only 2000 acres, so you can see how close -- if you<br>get a good and area and get a good partner, what you can do to develop this.<br>
This is our sensitivity analysis for Marcellus. Unfortunately, instead of being the oil, we are on the right-hand side of the column. Here we are on<br>gas in the left-hand side. And so even at $3.00, we are typically in the blue area on our wells now, and still a nice return at 40%. But I'm very concerned<br>we are going to be down in the $2.00 range if we keep putting wells on like we are doing up here in the Marcellus.<br>
So we are -- the beauty of being a diversified company like we are is we can take capital from here, move it to other divisions. We are not losing<br>any leases because everything is held by production.<br>
We do like the Utica a lot.The Utica, in the area that we are looking at, is more condensate liquids and oil. We have got about 16,000 acres. We have<br>another transaction will close by the end of January, we will announce, to increase our acreage position here. We are very much concentrated in<br>a county or two, and we will drill two Utica wells here in 2012.<br>
This is mostly our NGAS acreage, a lot of Huron acreage. We will probably de-emphasize this in 2012; again, though, most of this acreage is held<br>by production, so again, no problem in holding it until gas prices improve.<br>
I should say we do have a new program developing here called the Weir. We drilled four wells in that formation. We have 70,000 acres in the Weir,<br>and it is a very -- it's about 35%, 40% liquids, and we may develop that further in 2012. We are still debating that.<br>
If you are going to be involved in gas, no better place to be than the wet Marcellus. Unfortunately, though, to get a 10% internal rate of return, you<br>start getting down in the $2.00 range, which I think we may be headed, and then it gets difficult. So the beauty -- I have been in this business 30<br>years. The beauty of low gas prices is they fix low gas prices. So I am kind of in favor of, hey, let's get this fixed and be ready for the next couple of<br>years.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>212</i><br>
<hr>
<A name=213></a>JANUARY 04, 2012 / 11:45PM, MHR - MAGNUM HUNTER RES CORP DEL at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
So let's jump to the Eureka Hunter. This is our midstream asset that when we bought Triad, we also got this system. We have been substantially<br>building this out. It is 20-inch pipe, and we are tying in new production, predominately from ourselves as well as third-parties. So the map, just kind<br>of showing you in West Virginia where we are going.<br>
We have announced a transaction with MarkWest hydrocarbons where they are putting in a $200 million plant for us called the Mobley 2. And so<br>we expect this facility, this pipeline, to handle 200 million to 300 million cubic feet a day. Through the holidays I worked hard on a transaction that<br>we papered, and we will hopefully be announcing, where private equity investors come in for a substantial value to own a small piece of Eureka<br>Hunter. So we -- Eureka Hunter is basically focused in a 1000 square mile area, and we are the first in there. There are no other high-pressure lines.<br>
We are now -- we have made application to go under the Ohio River, and with our Utica acquisitions that we are doing, we will continue that<br>pipeline into Ohio in 2012. This shows you kind of a little idea of where that pipeline will go into Ohio and the kind of players that are involved in<br>this part of the Utica.<br>
This is the train we deal with, and it is very, very hilly. We have been building this line for about $1.1 million a mile. Our competition is in the $2.4<br>million mile range, and we have done that just because we do a lot of this in-house.<br>
So selected financing. As I mentioned, we have had five borrowing base increases in 2011. We have a $350 million credit line; fortunately, there is<br>no French banks in our credit. We have some Swiss and some German, but no French. We also have a new facility with our Eureka Hunter pipeline<br>that is in place so we don't have to use capital at the parent level for Eureka Hunter.We have got 2 series of preferred; none of these are convertible.<br>$100 million series C, $71 million series D. And then we have issued about $70 million in new equity since we took over the Company back in May<br>of last year.<br>
So a lot of the transactions we did this year were done in the $7.00 to $8.00 share price range. You see we issued about $400 million of equity on<br>the transactions we are now developing.<br>
This is a capitalization table showing our net debt to cap. At September 30 it was 20.5%. Our goal is to pay state under 30% for our capitalization.<br>One of the things we have been working hard on is trying to drive our lifting costs down, so if commodity prices increase and lifting costs go down,<br>your net margins improve, and we are able to do that consistently. Our goal is to get that down in the $10 range over the next year, and that just<br>takes a lot of hard work, and getting rid of your high lifting cost properties and continue to high-grade your portfolio.<br>
So financial goals in 2012 -- we will continue to increase our borrowing base with our bank group.We are constantly looking at moving our capital<br>around to the higher internal rate of return properties. Fortunately, we have that rich inventory, and we can do that. We will most likely redeem<br>this series C here over the next 90 days. The series D will remain out there, keep our debt-to-cap under, continue to improve our operating ratios,<br>and then we hope to take the Eureka Hunter pipeline system and put it in MLP sometime before the end of 2012.<br>
So we have got a management team. We have done this before. Nothing in the unconventional resource play, but we are pretty excited about the<br>portfolio.There is no reason to go anywhere else.We have got the best assets, we believe, in the business that we can develop, and we are continuing<br>to prove that by having better results than any of our competition.<br>
The stock has responded very well over the last 30 days, and I think will continue to do so. Our goal in 2012 was to underpromise, overperform and<br>show that we can add production. I think you will consistently see us raising our production targets as the year goes by.<br>
So it has been a fun 2.5 years. We have got a company that we are very proud of, and hopefully we will continue to show the results that we<br>anticipate as the year progresses. I think, again, most of our big transactions are done for a while. We just want to continue growing by the drill bit<br>now. So that is the end of my story.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>213</i><br>
<hr>
<A name=214></a>JANUARY 04, 2012 / 11:45PM, MHR - MAGNUM HUNTER RES CORP DEL at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4696556-2012-01-09T19:08:39.417</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>214</i><br>
<hr>
<A name=215></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
DRRX - DURECT CORP TO DISCUSS<br>POSIDUR CLINICAL TRIAL RESULTS<br>
EVENT DATE/TIME: JANUARY 06, 2012 / 1:30PM GMT<br>
OVERVIEW:<br>
Co. reported POSIDUR clinical trial results.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>215</i><br>
<hr>
<A name=216></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Matt Hogan</b><i> DURECT Corporation - CFO</i><br>
<b>Jim Brown</b><i> DURECT Corporation - President &amp; CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Robert Manning</b><i> - Analyst</i><br>
<b>Barrie Zesiger</b><i> Zesiger Capital Group LLC - Analyst</i><br>
<b>Walter Schenker </b><i>Titan Capital Management - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Greetings, and welcome to the DURECT third-quarter earnings meeting. At this time, all participants are in a listen-only mode. A brief<br>question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. It is now<br>my pleasure to introduce your host, Mr. Matt Hogan. Thank you, sir. You may begin.<br>
<b>Matt Hogan</b><i> - DURECT Corporation - CFO</i><br>
Okay, good morning. Welcome to our conference call to discuss the top-line results from BESST and our overall POSIDUR program. Sorry if there<br>was any confusion with the dial-in numbers, but it sounds like we have a critical mass of people on the call.This is Matt Hogan, the CFO at DURECT.<br>This call will begin with a brief presentation by Jim Brown, our President and CEO, and then we will open it up for a Q&amp;A session. Before beginning,<br>I would like to remind you of our Safe Harbor statement.<br>
During the course of this call, we may make forward-looking statements regarding DURECT's products and development, expected product benefits,<br>our development plans, future clinical trials, or projected financial results. These forward-looking statements involve risks and uncertainties that<br>can actual results to differ materially from these in such forward-looking statements. Further information regarding these and other risks are<br>included in our SEC filings, including our 10-Q under the heading Risk Factors. With that, let me hand it over to Jim Brown.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Thanks, Matt, and good morning, everyone.The results in BESST trended positive for pain reduction and opioid sparing. However, they didn't reach<br>statistical significance for the co-primary endpoints. Although we still have more analysis to perform, POSIDUR continues to appear to be safe, and<br>in all three cohorts, we saw a strong reduction in pain. The BESST trial provides us with additional safety information the FDA was seeking for this<br>program.<br>
In addition to being an efficacy study in older and sicker patients with larger wounds, BESST was a 300-patient study with extensive cardiac<br>monitoring. As a result, we have strong evidence of efficacy in our previous shoulder and hernia trials. Our plan is to combine the data from these<br>two models together with BESST, which gives us experience from a variety of abdominal surgeries to demonstrate the safety and effectiveness of<br>POSIDUR in controlling post-operative pain. Our next step is completing the analysis of the BESST data and combining these results with our<br>previous well-controlled studies into the integrated safety and efficacy reports that will lead to a pre-NDA meeting with the FDA. I will now review<br>BESST and the results in greater detail.<br>
A review of the design of BESST -- BESST was designed to test POSIDUR in a variety of settings; larger wound lengths, more serious surgical procedures,<br>and with an older, sicker population of patients. BESST consisted of three cohorts of patients undergoing different general abdominal surgical<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>216</i><br>
<hr>
<A name=217></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
procedures. In Cohort 1, there were 48 laparotomy patients who were randomized to receive either POSIDUR or bupivacaine solution, an active<br>comparator.<br>
Laparotomies are large incisions across the abdominal wall, typically used to access an organ for removal or for cancer staging. In Cohort 2, there<br>were 50 patients who were randomized to receive either POSIDUR or bupivacaine solution after laparoscopic removal of gallbladder. In Cohort 3,<br>we had 207 patients who were randomized to receive either POSIDUR or placebo after laparoscopically-assisted colectomy. These procedures<br>typically involved removal of part of the large intestine, due to cancer or diverticulitis. The top-line results are as follows -- first, with regard to<br>efficacy. For Cohort 3, with respect to the pain intensity endpoint, we received two reported outcomes -- one with a 7% reduction in pain and a<br>p-value of 0.1466; and one with a 10% reduction in pain intensity and a p-value of 0.0410.<br>
Let me explain the difference between these two figures.The first figure is based on a combination of two sets of data that were collected -- namely,<br>pain intensity on movement scores, as well as pain intensity recorded at the time when a patient took supplemental opioids. In this first set of data,<br>the pain intensity on movement scores were collected at scheduled time points over the first three days of the recovery period after surgery.These<br>patients were asked to sit up in bed and then to record their pain scores. This helps us delineate the incisional pain from any non-incisional pain.<br>
The second data set included in the 7% figure was collected at unscheduled time points, whenever a patient requested supplemental opioids. Let<br>me emphasize that these data points -- the patients in these data points did not do a sit-up that would help differentiate the incisional pain from<br>non-incisional pain. The combination of the pain intensity scores, both of the -- gives us that 7% reduction. When we look only at the incisional<br>pain, we saw that the scheduled pain scores after the sit-up -- we saw about a 10% reduction in pain intensity and a p-value below 0.05.<br>
To be clear, the second pain intensity score I just described is a pre-specified sensitivity analysis in the statistical analysis plan. But having a p-value<br>below 0.05 is not, strictly speaking, statistically significant in the context of BESST, because we weren't statistically significant on the other primary<br>endpoint, which was opioid sparing.We have gone into all this detail for two reasons -- first, we believe it's important to understand the distinction<br>between incisional pain and non-incisional pain intensity measures in this pain model; and second, because it would have been a statistically<br>significant signal if reduction in incisional pain had been our sole primary endpoint.<br>
With respect to the reduction in supplemental opioid use in Cohort 3, the other co-primary endpoint, POSIDUR patients used approximately 16%<br>fewer opioids than the placebo group, but the difference wasn't statistically significant in this cohort for this number of patients. With respect to<br>Cohorts 1 and 2, in order to increase the statistical power of these smaller cohorts, the SAP, or the statistical analysis plan, called for pooling of<br>these two groups. This was a secondary efficacy endpoint.<br>
For Cohorts 1 and 2 combined, POSIDUR patients experienced approximately a 20% reduction in their pain intensity, as measured by pain on<br>movement combined with the pain at the time of taking the supplemental opioids, or that same measurement that we described in Cohort 3 as<br>being a 7% reduction. And this was done in comparison to an active comparator control of bupivacaine hydrochloride. This was statistically<br>significant, with a p-value of 0.011. This is particularly interesting result, when you consider that it is against an active comparator. As in all of our<br>studies, all the patients were provided supplemental opioids as needed. And in these Cohorts 1 and 2, the POSIDUR patients took approximately<br>18% fewer opioids as compared to the active comparator group, although this data was not statistically significant. To summarize the efficacy<br>results, we did not meet the primary endpoints, but we reduced incisional pain by about 10% in Cohort 3 and pain on movement per the SAP by<br>about 20% in the combined Cohorts 1 and 2, which was a statistically significant secondary endpoint. We saw reductions in opioid use of 16% to<br>18%, but those results weren't statistically significant.<br>
Turning to safety -- the safety population in BESST consisted of 305 subjects. Overall, the POSIDUR patient group showed a similar systemic safety<br>profile as the patient groups treated with SABER-Placebo and active comparator. In this study, there were no signs of systemic safety issues. Local<br>site reactions were observed more frequently in the POSIDUR and SABER-Placebo groups than the active comparator groups. Most of these<br>observations were discolorations and the majority of which resolved without treatment during the trial. No negative safety signal was seen in the<br>initial cardiac and neurologic safety assessment in BESST, and additional analyses are underway. To review our overall program from a safety<br>standpoint, we have now dosed a total of over 1,075 patients in our clinical trials, of which over 680 patients received POSIDUR.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>217</i><br>
<hr>
<A name=218></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
For next steps, there are still a lot of data from BESST that we have to analyze. Then we intend to pull together an integrated safety and efficacy<br>report that will tie together the entire body of work we have done with POSIDUR to date. We next plan to hold a pre-NDA meeting with the FDA.<br>We believe that this meeting can happen by mid-year.We believe the overall program shows a positive risk/benefit profile for POSIDUR and supports<br>an NDA submission. Although we don't have the full reports for BESST yet in hand, at this point we don't see any systemic safety issues. Bupivacaine<br>is a well-established agent with long history of use, and it isn't a new chemical entity with a limited medical history.<br>
With respect to efficacy, we have shown in multiple models evidence of reduction in pain scores over three full days. And I do want to emphasize<br>the three full days, because if you look at the response of these patients and you look at whether it's on the spaghetti graphs that measure it on<br>multiple time points over time, or you just look at the pain scores as reported out from a statistical analysis looking out on a daily basis, this is truly<br>a product that works on day one, on day two, on day three.<br>
We have improvement in incisional pain in our Cohort 3, when only this true pain on movement score was analyzed.We have statistically significant<br>improvement in pain scores in Cohorts 1 and 2 pooled, against a bupivacaine active comparator. We have a statistically significant improvement<br>in pain scores in our earlier hernia trial, and a statistically significant improvement in our pain scores in our latest shoulder surgery model. In addition,<br>we have shown in multiple models and studies where we have seen a numerical superiority with respect to reduction in opioid use after surgery,<br>and in our hernia trial, this was over a threefold reduction, and with a p-value below 0.02.<br>
While we will be really pursuing an approval on the basis of pain reduction, this opiate reduction may contribute to the overall risk/benefit analysis<br>for POSIDUR. Our view is that this body of evidence in multiple surgical models is compelling, and may be the basis of a possible approval. Having<br>said that, we need to explore this with the FDA, which we intend to do. With that, we would now be happy to take any questions that you have.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
Thank you. (Operator Instructions) Robert Manning.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
My question -- these results are obviously a little disappointing, but I have always looked at this as the icing on the Remoxy cake. Any developments<br>in Remoxy since the kind of positive comments that came out of Pfizer in early November?<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Nothing new since Pfizer has made those comments, but we continue to work with them and continue to make progress. But I think I would like<br>to emphasize, although we are disappointed about the two co-primary endpoints, the fact is that we think there is still a nice opportunity for<br>POSIDUR. We have the very nice efficacy and opioid sparing results, particularly from our hernia trial, as well as our shoulder study. We have the<br>other data that you have seen here -- the incisional pain for Cohort 3 and Cohorts 1 and 2, where we had a very nice pain signal, as well. We think<br>that, plus all of the safety information, will give us a nice opportunity for this potential NDA submission. So, although it's -- one didn't hit on those<br>co-primary endpoints, it doesn't mean that this product doesn't work.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
Yes. Okay, thanks.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>218</i><br>
<hr>
<A name=219></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Okay.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
I'll get back in queue. If nobody else has anything to ask, I'd just -- I have another thing, but I'll let somebody else go ahead.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Go ahead. If you want to ask a question, go ahead.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
Well, the results in the hernia trial were so compelling, it looked like 50 to 1 that the results weren't a result of chance.Was there any methodological<br>difference between the two trials to account for that? I think this is more than just a 50 to 1 shot against us, where -- is there -- possibly the institutions<br>in the first trial for some reason preselected patients? I'm just a little bit mystified by the huge difference between the two trials. And I suspect<br>you're mystified, too. But anything that you could say to amplify that, I'd be interested in.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes, I think it isn't a matter of -- if we had done a 300-patient hernia trial, I think we would have had amazing results. But what we have done is we<br>have done additional abdominal surgeries, different abdominal surgeries. You remember, when we -- on the basis of the shoulder and the hernia<br>trial, our objective initially was to tell if you we couldn't submit an NDA at that point in time. But the FDA was wanting us to collect -- to kind of<br>push the boundaries for this product, collect -- especially more safety information with regard to it, because we're giving 660 mg of bupivacaine<br>here. And so, they wanted us to test these in these larger wounds, in these older, sicker patients, and that's what we have done.<br>
And so, if we just focus on the safety aspect for a minute, and I'll get back to the efficacy, we have shown no issues with regard to these. So, it was<br>effectively -- almost, one could call it a 300-patient QTc study.We saw no issues on the cardiovascular side or the CNS side. So, we have that in older<br>and sicker patients. We have nice efficacy. Then, reflecting back and looking -- excuse me, safety.<br>
Going back and looking at the efficacy now -- in these larger abdominal wounds, there's a lot more going on than there is in the hernia model. In<br>the hernia model, the entirety of the wound is the hernia itself. And so, you have to cut through the muscle, you go down, you put a mesh in over<br>where there was the tear.That's all sewn up. And POSIDUR is applied to all the various surfaces that were cut. And I think that's why we saw 3 times<br>less -- 300% less narcotics used. And it's statistically significant, obviously, and the efficacy as well. But if you are looking at these larger abdominal<br>wounds -- in this case, these were large wounds. For example, for some of the laparotomies, they had six holes because of the laparoscopically-assisted<br>aspect of this entire thing. And yet, if you look at the incisional pain, the pain from the wounds that were through the surface of the body, we had<br>a statistically significant signal there. Now, it doesn't count, because of the way this trial was structured, but the data are there. And you can't argue<br>with that.<br>
And so, what we have, though, is additional visceral pain. So, if you had diverticulitis or colon cancer -- and unfortunately, I have friends and family<br>members who have had both of those things, you end up with a visceral pain component to it all. So, it's not just the surgical wound that hurts.<br>And that's why when we had this secondary endpoint of pain collection, where the nurses were requested by the patients to give them an opioid<br>in order to try and control their -- whatever pain they might have outside of this incisional pain, as it were, those were the points by which we didn't<br>reach statistical significance. That being said, in the earlier trials, the shoulder and the hernia, those points -- the opioid consumption tracked very<br>closely with the incisional pain, pain on movement measures, scores that we had. These are different surgeries, obviously more complex.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>219</i><br>
<hr>
<A name=220></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
There's also another component to this that I don't think will be really teased out until one gets into Phase IV work and the like, and that is -- you<br>have to remember, these nurses have been trained to stay ahead of patients' pain. And in the case, you might have an 85-year-old grandmother<br>who has just been diagnosed with colon cancer, and she's in this trial, and that nurse is going to be compelled to make sure that she has the pain<br>control that she needs. And that's a very difficult piece to control in these studies. In order to get an opiate, you had to have a pain score of at least<br>4. This is my personal bias right now, but I believe once this product is out there and being utilized more, I think you will see a greater reduction in<br>narcotics, even in these larger wounds, because the nurses and the doctors will learn to trust POSIDUR more over time.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
Is there -- is one possible route just to get a limited label for shoulders and hernias? And is there enough of a market there that it would make it a<br>good drug?<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Well, I think there is certainly enough of a market around for this product entirely.The only way -- I think it's difficult, I think we have an opportunity<br>to be able to go for general surgical pain control, because we have shown incisional pain control beautifully in BESST, and as well, obviously, in<br>hernia and shoulder. And if one looks at [this here] as example, they used a hemorrhoid trial, which is certainly a very local thing, and bunion, which<br>is also a very local thing, and got a general surgical claim. And I think that was based on the strength and the body of work, as it were, from<br>bupivacaine itself over the last 30-plus years.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
Okay. Thanks very much.<br>
<b>Operator</b><br>
Albert Zesiger.<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
This is Barrie Zesiger. I just wanted to let you know -- we had tremendous trouble getting on, and perhaps other people did, too. Can you hear me?<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes, we can, Barrie.<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
Okay, sorry. The 877 number didn't work, and eventually we just kept looking at the Internet, and at that same notice, and there was a 201 number<br>that was put up. So, we missed your whole presentation. We got in at your first question. And so, I don't have any questions, because I haven't<br>listened to the presentation. We just wanted to let you know why there might be not more questions.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Oh, we appreciate that. Thank you.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>220</i><br>
<hr>
<A name=221></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
A lot of people might have had that problem.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes, we did -- unfortunately, there was a -- appeared to be a typo with regard to the number going in. And we got a heads-up from an investor<br>literally two minutes before we went on the air, and so we were able to send around a blast e-mail to everyone with a new number. But there was<br>a lag there.<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
Yes, unfortunately, we were just not in our office. So, anyway, we will come back and be looking forward to more information that you put out.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Thanks, Barrie. We also -- one can also go and access this, Matt, can't they? And listen to the -- it will be on the Internet, so one will be able to listen<br>to the talk, as well.<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
Excellent. Thank you very much.<br>
<b>Operator</b><br>
Walter Schenker.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
Realizing you don't know the answer, because you will have to have further discussions with the FDA, and someone once said -- the key to a good<br>clinical trial is getting the right endpoints before you start.You have to pick the right endpoint. A lot of them look like they're pretty good, but they<br>don't meet the endpoints, because people pick the endpoints wrong.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Right.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
Not that you should have total flexibility. But the question is -- as you speculate, and you may not be willing to do that, about the path forward,<br>you would expect that with the safety profile, you might have enough data to try and get a label and approval, or it probably requires another trial.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>221</i><br>
<hr>
<A name=222></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Right now, our -- and this is, you're right, this is our best guess from where we are today, is that based on the efficacy we have seen in the hernia<br>trial and the shoulder study, combined with the -- and the safety from those trials. But combined with the overall great safety experience in this<br>trial, and the kind of body of evidence of efficacy, as it were -- you're right, we didn't pick the right endpoint on this trial. But nonetheless, there are<br>some very compelling positive results from this trial, and I can't emphasize that enough. In all -- if we look at the analyses of Cohort 1 or -- Cohort<br>1, 2 and Cohort 3, as far as incisional pain and the overall pain experienced in Cohorts 1 and 2, we have that statistically significant motion -- result.<br>I think that those data in BESST, efficacy and safety combined with those other trials, will -- we believe, will give us enough for an NDA. And we<br>won't know that until we have that pre-NDA meeting. But we plan to sit down with the Agency and discuss that.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
And your expectation of the timeframe to know the next step forward is roughly what?<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Well, it's obviously early days. We will be putting together what is known as an ISE, which stands for integrated summary of efficacy, and an ISS, an<br>integrated summary of safety. Once we have completed both of these pieces, we will then have a request for a meeting with the Agency. I think<br>we're talking a number of months to do all that. And that's why we kind of said a mid-year, because it's difficult to say how long it takes to get<br>together with the Agency. Post that, if the meeting is good, then we will be submitting the NDA.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
Okay. So, the positive case is, you meet with the FDA somewhere around mid-year, they say -- yes, go ahead and file the NDA. And putting that<br>package then together, given what you have already put together, is three to six months? That's a question.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes, I think it shouldn't be outside of that, yes.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
Okay, thank you.<br>
<b>Operator</b><br>
Thank you. (Operator Instructions) There are no further questions at this time.<br>
<b>Matt Hogan</b><i> - DURECT Corporation - CFO</i><br>
Okay. Well, one more time, we'd like to apologize for any technical difficulties calling in, but if people do have further questions, please feel free to<br>call management, and we would be happy to talk further about the POSIDUR program or our other programs.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>222</i><br>
<hr>
<A name=223></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>Matt Hogan</b><i> - DURECT Corporation - CFO</i><br>
Thank you.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Thanks a lot.<br>
<b>Operator</b><br>
Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you all for your participation.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4701418-2012-01-09T05:47:36.963</b><br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>223</i><br>
<hr>
<A name=224></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
IHS - Q4 2011 IHS INC EARNINGS<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 06, 2012 / 1:00PM GMT<br>
OVERVIEW:<br>
IHS reported 4Q11 revenue of $371m and adjusted diluted EPS of $0.99. Expects<br>2012 all-in revenues to be $1.50-1.55b and adjusted diluted EPS to be $3.84-4.01.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>224</i><br>
<hr>
<A name=225></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Andy Schulz</b><i> IHS Inc. - VP IR</i><br>
<b>Jerre Stead</b><i> IHS Inc. - Chairman, CEO</i><br>
<b>Scott Key</b><i> IHS Inc. - President, COO</i><br>
<b>Rich Walker</b><i> IHS Inc. - EVP, CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Suzi Stein</b><i> Morgan Stanley - Analyst</i><br>
<b>Manav Patnaik</b><i> Barclays Capital - Analyst</i><br>
<b>Eric Boyer </b><i>Wells Fargo Securities, LLC - Analyst</i><br>
<b>Peter Appert</b><i> Piper Jaffray &amp; Co. - Analyst</i><br>
<b>Michael Meltz</b><i> JPMorgan - Analyst</i><br>
<b>Kelly Flynn</b><i> Credit Suisse - Analyst</i><br>
<b>Bill Sutherland</b><i> Northland Capital Markets - Analyst</i><br>
<b>Williaim Warmington</b><i> Raymond James &amp; Associates - Analyst</i><br>
<b>Brian Karimzad</b><i> Goldman Sachs - Analyst</i><br>
<b>Dan Leben</b><i> Robert W. Baird &amp; Company, Inc. - Analyst</i><br>
<b>Robert Riggs </b><i>William Blair &amp; Company - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Good day, ladies and gentlemen. And welcome to the fourth quarter 2011 IHS Inc. earnings conference call. My name is Lacey and I'll be your<br>coordinator for today. At this time all participants are in listen-only mode. Later, we will facilitate a question-and-answer session towards the end<br>of the presentation. (Operator Instructions). As a reminder, this conference is being recorded for replay purposes.<br>
I would now like to turn the presentation over to your host for today's call, Mr. Andy Schultz, Vice President of Investor Relations. Please proceed.<br>
<b>Andy Schulz</b><i> - IHS Inc. - VP IR</i><br>
Thank you, Lacey. Good morning and thank you for joining us for the IHS fourth quarter and fiscal 2011 earnings conference call. We issued our<br>Earnings Release and a supplemental presentation earlier this morning. If you do not have the release and the presentation, we issued today, you<br>will find copies of them on our website at IHS.com.<br>
Some of our comments and discussions on the quarter are based on non-GAAP measures. Our non-GAAP or adjusted numbers include stock-based<br>compensation and other non-cash charges and other items. Our Earnings Release includes both our GAAP-based income statement and statement<br>of cash flows, and reconciliations to the non-GAAP measures discussed during this call. These reconciliation schedules can also be found on our<br>web site. The non-GAAP results are a supplement to the GAAP financial statements. IHS believes this non-GAAP presentation and the elimination<br>of these items is useful in order to focus on what we deem to be a more reliable indicator of ongoing operating performance.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>225</i><br>
<hr>
<A name=226></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
As a reminder this conference call is being recorded and Webcast. And is the copyrighted property of IHS. Any rebroadcast of this information in<br>whole or in part without the prior written consent of IHS is prohibited.<br>
Please keep in mind that this conference call, especially the discussion of our outlook, may contain statements about expected future events that<br>are forward-looking and subject to risks and uncertainties. Factors that could cause actual results to differ and vary materially from expectations<br>can be found in IHS's filings with the SEC and on the IHS website.<br>
With that, it is my pleasure to turn the call to Jerre Stead, IHS Chairman and CEO. Jerre?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thank you, Andy. Good morning, welcome, and a very happy New Year to all of our investors and to my IHS colleagues. It is a great pleasure this<br>morning to share with you our outstanding results from the fourth quarter and for the full year of 2011. Before I do, I must begin with a real heart-felt<br>thank you to my IHS colleagues around the world. The performance I'm about to share with you is the direct result of the outstanding teamwork<br>and collaboration displayed by each of my colleagues. I'm very proud to be part of this team.<br>
I'll start with the quarterly financial highlights. Revenue was up 27% in the fourth quarter. Adjusted EBITDA increased by 33%. And our adjusted<br>EBITDA margin was 32.1%, the highest in our Company's history. The absolute dollar levels for Q4 revenue and profit were both Company records.<br>Q4 proved to be exactly what we thought it would be, accelerating organic growth on the top line, accompanied by meaningful margin expansion.<br>
Our fourth quarter performance is a fitting capstone on a year characterized by focus and performance. In early November of 2010, we shared our<br>vision for what we would accomplish in 2011. Since then, the world has seen many economic events that certainly have presented challenges for<br>businesses around the world. Despite these global economic challenges, we actively managed IHS to ensure that we continued to make the right<br>investment decisions to drive strong, profitable growth and to deliver ever-better insight, information, and analytics to our customers around the<br>globe every day. Therefore, I am proud to share with you these annual results.<br>
Revenue was up 25%. Adjusted EBITDA increased by 26%. And our adjusted EBITDA margin was 30.2%, up from last year, despite the significant<br>levels of investment in infrastructure that we've made during 2011. This performance is the direct outcome of the following. A clear vision of what<br>we're building. An intense focus on the four objectives we set for ourselves this year. And relentless execution while adapting our priorities to<br>changing market conditions throughout the year. Scott Key, our President and COO, and Rich Walker, our EVP and CFO, will provide more details<br>shortly.<br>
As you know, we have four Company objectives. Colleague success, customer delight, profitable top and bottom line growth, and share owner<br>success relative to our peer group. Execution of these objectives drove solid results. The foundation of this performance is the engagement of our<br>colleagues and the level of customer delight. During 2011, 97% of our colleagues participated in our annual engagement survey, providing us with<br>a clear view of actions and experiences that most affect our commitment and performance at IHS. Our colleague engagement score for 2011 was<br>59%. And represents a recalibration of our baseline with a new third-party survey firm that offers an excellent set of analytics and benchmarks as<br>we move to a new level of excellence.<br>
We have achieved world-class performance in a number of important areas, including the value colleagues derive from their work. And the freedom<br>of flexibility they have in delivering value to our customers. Importantly, we saw best-in-class levels in impact that our colleagues are having with<br>customers as a result of increased colleague collaboration at IHS in creating value. We also achieved best-in-class levels in our focus on customers.<br>This not only correlated to our financial performance. It's tied to the highest level of customer delight since we launched this critical effort five years<br>ago. This year, thousands of IHS customers provided their feedback and we were pleased with the results. Here are the highlights.<br>
Most global companies are scoring flat to down this year but we achieved a 4 point improvement to reach 63% customer delight. All three of our<br>regions improved. 100% of our product areas showed improved customer delight. Because we achieved our improvement target, we awarded to<br>each of our colleagues 50 IHS restricted stock units.This represents approximately $18 million in value.The shares will vest over the next 12 months.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>226</i><br>
<hr>
<A name=227></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
We award shares because the incentive directly drives the behavior we want and the results we enjoy. For example, in the fourth quarter we<br>delivered the highest level of subscription-based organic growth in 10 quarters.<br>
These results are directly connected to our overall performance. And highlight the shareholder value we create in connecting colleague and<br>customer metrics to shareholder returns for our stock-based incentives. We've driven substantial value for shareholders since our IPO, with a<br>compounded annual return of 32%, well above that of our peers and the overall market.This is a clear reflection of our focus on long-term profitable<br>growth and our share-based incentive programs that directly link every IHS colleague to key customer metrics and financial performance.<br>
Now, switching gears, we previously discussed the importance of strategic partnerships to our market growth and for new channel development.<br>We continue to create the right partnerships to drive our long-term profitable growth. I'm pleased to announce that IHS has signed a strategic<br>alliance agreement with IBM. This agreement will enable us to help clients meet complex enterprise sustainability management, ESM, challenges<br>by leveraging our combined strengths to provide the content, software and expertise that our customers need.This alliance is another step forward<br>in leveraging the growing opportunities in enterprise sustainability. By offering IHS content and systems, in combination with IBM's expertise in<br>technology implementation and integration, we will make it easier for our clients to turn traditional information management burdens into<br>competitive advantages. Organizations throughout the IHS and IBM customer base will have the opportunity to benefit from this new alliance.<br>We're pleased that IBM has recognized the importance of the ESM market and our technology leadership in that space.<br>
Let me wrap up with brief updates on our two major infrastructure projects,Vanguard and Newton.We've had another great success in the roll-out<br>of Vanguard. On December 5, we went live with the second release.This release included a significant part of our finance organization and customer<br>care in EMEA and Americas.With the successful implementation, approximately 40% of our business is now being processed through the Vanguard<br>system.<br>
In addition to the roll-out of Vanguard, our EMEA and Americas finance and customer care Centers of Excellence are now operational. And our<br>APAC Center of Excellence opened December 5 and will continue to grow with the needs of our business. My many thanks and congratulations<br>to the Vanguard team, to our finance and customer care teams, and to all other colleagues from across the Company who have worked diligently<br>to ensure we remain on schedule. It's rare for any Company to smoothly implement a global ERP, not to mention implementing a change that is<br>replacing 40-plus legacy systems in countries all over the world.<br>
In parallel, we've gone live with our SFA world-wide, including our automated commission system. I am very grateful for this very impressive<br>execution. Our current plan calls for substantially all of our finance and lead-through-cash systems to be migrated over to Vanguard by the end of<br>2012. And we are right on track with that goal. Another high priority initiative to support our multi-year growth strategy is Project Newton, which<br>is addressing the issue of our multiple data centers and content management and delivery system.We're making great progress here as we eliminate<br>redundant activities and shut down legacy data systems.<br>
With that, it's my pleasure to turn the call over to Scott.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Thanks, Jerre. I will give you an overview of our growth and progress during Q4 that helped to deliver the performance for the year, provide some<br>overarching thoughts about the strategic development of the business as we close 2011 and look to 2012, and finally, a brief update on SMT and<br>integration efforts.<br>
Q4 was a quarter of improving profitable growth for IHS. And a clear, well-executed step toward achieving our long-term profitable growth goals.<br>Just about any way you look at the results, we saw solid growth in operational performance. Overall we delivered 9.4% organic growth for the<br>quarter and we delivered 8.7% for the full year. Absent the Boiler Pressure Vessel Code recall in Q3 2010, we had to try a new release of the BPVC,<br>an engineering standard. All organic figures mentioned hereafter have been normalized to exclude the BPVC, as applicable. Our organic growth<br>performance marks positive acceleration sequentially and year on year.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>227</i><br>
<hr>
<A name=228></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
Looking at it by geography, Americas grew 8% organically, with strong positive improvement in EMEA, which also grew 8% organically. And<br>continued strong emerging market growth in APAC, which grew 22% organically. As evidenced by the 6% sequential improvement in our APAC<br>organic growth, we continue to see above average growth in the regions where we have made significant investments over the last 12 months,<br>like APAC and Latin America. By end market, energy growth continues to be robust worldwide, followed by solid performance in chemicals,<br>transportation, TMT and manufacturing. We also benefited by our focus on managing our product portfolio, and effectively aligning our resources<br>and investment to areas of long-term double-digit growth potential.<br>
Perhaps most importantly, we delivered meaningful, profitable growth as our subscription business grew 9.1% organically, up 1 full point sequentially,<br>and up 3 points over Q4 2010. Solid growth was also accompanied by significant adjusted EBITDA margin expansion. We delivered 32.1% for the<br>quarter, the highest quarterly margin performance in our history. Not only was margin performance strong, but in terms of absolute dollars our<br>quarterly adjusted EBITDA was also the best in the Company's history.<br>
Broadly speaking, we achieved this level of profit delivery by three means. First, robust top line growth, especially organic. Strong profit performance<br>always begins with terrific top line performance. Second, good cost control. As we continued to invest at historically high rates, we very actively<br>managed our spending rates and were actively prioritizing where our dollars would be spent.Third, continued improvement in margin performance<br>from our acquisitions. In Q4, our acquisitions' collective margin exceeded our 32% overall margin.<br>
We remain singularly focused on our primary goal of long-term, sustainable growth. And are continuing to make the right strategic investments<br>and acquisitions required to deliver for the long run. We have executed on a disciplined strategy to invest in, and have acquired the right assets in<br>targeted, high-growth markets like chemicals, automotive, energy, and the supply chains across TMT. We have established leading information<br>insight and analytics positions in each and are connecting capabilities across them to further enhance our leadership positions.<br>
We are also strategically investing in our colleagues, operational processes, key platforms and products. These investments are delivering scale,<br>breadth and depth. Scale to our delivery platforms, breadth to our offerings and market presence, and depth to our global talent pool. The right<br>strategic investments and the judicious deployment and prioritization of our capital enabled solid performance in growth in 2011. And are the<br>foundation for our profitable growth in 2012 and the years to come. Investment in our global infrastructure is key to our growth by delivering scale<br>and efficiencies. As a result of focused investment over several years, we are now for the first time in a position to scale to over $4 billion in revenue<br>in the future.<br>
We are also beginning to see the benefit on the top line from productivity gains. And on the bottom line from increasing efficiencies as we continue<br>to successfully execute on investments in our infrastructure through Vanguard, Centers of Excellence, sales force automation, and Newton. We<br>have also continued to evolve our structure and operations to realize sales, product and market synergies. And have rapidly and fully integrated<br>every acquired asset to ensure opportunity is translated into reality.<br>
The result is we will see introduced in 2012 the most new products in our Company's history. And as we discussed on our last call, we are working<br>to rationalize our portfolio of products, divesting under-performing assets. While we invest further in those with the greatest long-term potential.<br>Continued performance and growth also comes from strategic partnerships, as Jerre mentioned. And we will continue this path in 2012 and build<br>on 2011 performance. As we continue strategic alignment to the highest growth potential, prioritization of assets and spend, and continue<br>development of global infrastructure and scale, we will also restructure and rationalize. You can expect us to continue this as we enter 2012 and<br>continue to implement Vanguard and Newton and rationalize our portfolio.These will be important parts of our 2012 operating plan as we deploy<br>new infrastructure, fully migrate to our three Centers of Excellence, and upgrade systems globally.<br>
Before I conclude, let me provide you with an update on the terrific progress with the SMT acquisition where our integration efforts have exceeded<br>our expectations. We are ahead of schedule in nearly every area with integration essentially complete. We will see important Q1 upgrades to<br>Kingdom with seamless linkage to our highly valuable energy information offerings that will create significant efficiencies in customer work flows.<br>And provide them with expanded options and value. Our reception in the marketplace has also been terrific. We've stayed very close to our<br>customers throughout the transition. And they are very enthusiastic about the combination of IHS and SMT.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>228</i><br>
<hr>
<A name=229></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
And our financial results reflect this. We are ahead of our initial projections. And we enjoyed roughly 50% margins during our first full quarter of<br>ownership. My sincere thanks to our SMT colleagues and all of those involved in the integration efforts for a job well done. Keep up the great work.<br>
So, before I hand the call over to Rich, let me wrap up 2011 by saying we had a very good year. We enter 2012 with momentum, despite the<br>headwinds all of us are experiencing on the macroeconomic front. Our own experts do continue to view the macro climate soberly. We use their<br>wisdom to plan for the future and it is reflected in our guidance.<br>
Now let me hand the call over to Rich.<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
Thank you, Scott. I'll provide an overview of our results and an update to our 2012 annual guidance. Let's start with revenue. Fourth quarter 2011<br>revenue increased 27% to $371 million.The growth in revenue includes 9.4% organic growth, 17% growth from acquisitions, and virtually nothing<br>from currency fluctuations. The organic growth on subscriptions was 9.1% in the fourth quarter. And subscriptions accounted for 74% of revenue<br>during the quarter.This rate of organic growth is a sequential increase since the prior quarter, and lifted us to 8.7% organic growth for the full year.<br>On the non-subscription businesses, they also performed well, growing at 10.4% organically. Consulting had a terrific quarter, growing 16%<br>organically, where we saw strong demand for our offerings, particularly in energy, autos and chemicals.<br>
Looking at regional and domain performance, revenue growth was robust and broad-based as Americas grew revenue 23% all-in, with EMEA and<br>APAC growing 26%, and 49%, respectively. In terms of performance, EMEA was particularly notable. Its subscription business grew organically in<br>the low double digits for the quarter. It is really impressive performance in light of the broader economy. Relative to revenue performance by<br>domain, energy continues to be the stalwart performer. Energy was 45% of total revenue and was up 38% all-in for the quarter. Energy remains<br>strong across most every offering and in all three geographies. And grew organically at strong double-digit rates.<br>
Product life cycle was 31% of revenue, and increased 23% for the quarter. PLC benefited from the fourth quarter 2010 acquisition of iSuppli, which<br>grew at a double-digit organic growth rate during the quarter. Security was 8% of revenue, up 2% all-in for the quarter. Solid subscription performance<br>was partially offset by lower non-subscription results due to timing of sales. Environment was 8% of overall revenue, up 31% all-in for the quarter.<br>Environment benefited from acquisitions and solid organic growth.The remaining 7% of revenue is in our macroeconomic capabilities, which were<br>up 8% all-in for the quarter, almost all of which was organic growth.<br>
Turning now to profit and margins. Fourth quarter adjusted EBITDA totaled $119 million, up 33% from a year ago.To put this in context, this is only<br>the second time in our Company's history we've generated more than $100 million in adjusted EBITDA in a single quarter. And up almost $20<br>million sequentially from the third quarter. Our adjusted EBITDA margin improved, as expected, and was 32.1% in the fourth quarter. This is a 150<br>basis point increase over last year. Strong organic revenue growth, combined with good cost control, added about 120 basis points of margin<br>expansion in the quarter. The remaining 30 basis points came from acquisitions. FX had virtually no impact to margins during the quarter.<br>
Moving down the P&amp;L, adjusted EPS increased 24% to a record $0.99 per diluted share in the fourth quarter. Regarding segment profitability,<br>Americas adjusted EBITDA increased 27% to $86 million. While EMEA's adjusted EBITDA was up 29% to $32 million. And APAC's adjusted EBITDA<br>grew 60% to $15 million. The reported GAAP tax rate for the fourth quarter of 2011 was affected by the fourth quarter implementation of our<br>pension strategy. Excluding this impact, the tax rate was 24.2%. Looking at the balance sheet, we ended the quarter with $235 million of cash, and<br>$803 million of debt. Deferred revenue at the end of the fourth quarter was $487 million, which represents a year-over-year increase of $95 million<br>or 24%.<br>
Turning to cash flow. We generated $89 million of cash flow from operations and $80 million of free cash flow in the fourth quarter. In fiscal 2011,<br>we generated $288 million of free cash flow. And our ratio of free cash flow to adjusted EBITDA was 72%. As these measures suggest, we continued<br>to generate strong cash flow despite higher levels of investment in the business.<br>
One last item before I get to our 2012 guidance update. As I mentioned on our call in November, during 2011 we undertook a comprehensive<br>review of our US pension plan, designed to ensure we maintain market competitive employee benefits while decreasing volatility. I am pleased to<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>229</i><br>
<hr>
<A name=230></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
report we have completed our review. We have been proactive in our actions and believe we have made prudent business decisions with respect<br>to these plans that position us well on a go-forward basis. Many plan sponsors have employed similar steps to better manage their pension programs.<br>
These steps resulted in a one-time settlement of retiree pension obligation, a change to our pension plan investment strategy, a change in our<br>pension accounting policy, and an accelerated funding of plan contributions. It is not our intention to discuss these actions in detail on this call.<br>Alternatively, we have compiled a slide deck which explains in greater detail our objective, the steps we have taken, and their impact. This deck is<br>posted on our website and also furnished earlier today to the SEC.We encourage you to review these materials. And should you have any questions,<br>please give us a call to discuss further.<br>
Now let's go to 2012 guidance. Our guidance is on an all-in basis and assumes no further acquisitions, currency movements, mark-to-market pension<br>adjustments, or unanticipated events. For 2012, we expect all-in revenue in a range of $1.5 billion to $1.55 billion, including 7% to 10% organic<br>growth for the full year. All-in adjusted EBITDA in a range of $480 million to $495 million. Depreciation and amortization expense to approximate<br>$112 million. Net interest expense of roughly $17 million. Adjusted EPS between $3.84 to $4.01 per diluted share. Stock-based compensation<br>expense to approximate $115 million to $120 million. And adjusted tax rate of approximately 27% to 28%. And fully diluted shares to be approximately<br>67 million.<br>
A couple of additional items to note regarding guidance. As you consider our quarterly profit progression for 2012, remember that due to the<br>seasonality in our business, Q1 revenue and adjusted EBITDA tend to be lower sequentially relative to the fourth quarter. In fact, Q1 is traditionally<br>our lowest quarter of the year for both revenue and adjusted EBITDA, both in terms of absolute dollars and as a percent of the annual totals.<br>Moreover, this trend has been amplified going forward by the product mix from our 2011 acquisition and the recent pension strategy implementation.<br>To illustrate this point, please see the last slide in the supplemental deck posted to our website which shows our 2011 quarterly profit distribution,<br>adjusted as if we had made an $8 million pension expense similar to 2012. This slide highlights the fact the fourth quarter represented 30% of our<br>2011 adjusted profit, whereas the first quarter represented 21%.<br>
Last, we expect CapEx in 2012 to remain relatively flat to 2011 levels. Importantly, we expect CapEx to decrease as a percent of revenue from 4.1%<br>in 2011, to about 3.5% in 2012. Over the long run, we generally expect CapEx to annually represent between 3% to 4% of revenue. In summary,<br>we saw accelerating top-line organic growth, a resumption of meaningful overall margin expansion, and robust cash flow.<br>
With that, let me turn the call back over to Jerre.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thank you, Rich. That's a wrap on 2011. A remarkable year for IHS. We enter 2012 with great momentum and are looking forward to capitalizing<br>on the many opportunities we have in front of us. Scott, Rich and I are ready to answer your questions. So let's start with the Q&amp;A.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions). Suzi Stein with Morgan Stanley.<br>
<b>Suzi Stein</b><i> - Morgan Stanley - Analyst</i><br>
You saw a nice improvement in organic revenue growth. But how much of it is attributed to bringing in acquisitions that anniversaried, and moving<br>under-performing businesses to Discontinued Operations? What I'm trying to figure out is how did the underlying business perform if you were<br>to comp it to Q3 growth?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>230</i><br>
<hr>
<A name=231></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
That's a good question, Suzi. Scott would look forward to answering that.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Sure would. Suzi, we actually saw very broad and solid organic performance across the business. And I'll give you a few examples. We gave you the<br>region numbers where you saw positive growth. Our subscription base really trended up and positively across the globe. In Americas, we saw a<br>series of areas of double-digit organic growth in automotive, the transportation sector, our core economics offerings, and our offerings in<br>manufacturing and design and energy technical. We saw really positive improvement in our strategically managed accounts that drove organic<br>growth higher.<br>
And we saw that in all regions, real good progress, 3 to 5 percentage points of additional, above our average organic growth in strategically managed<br>accounts in the Americas, EMEA and APAC. And then the other point of growth driver, as you heard, Latin America, 20%-plus, and of course, APAC,<br>20%-plus. So, really strong fundamentals. And I think the other point to mention is that was matched, regardless of organic or inorganic on<br>acquisitions. Acquisitions in general delivered about 16% year-on-year growth on average. So, we really saw solid performance everywhere.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Great question, Suzi. Last quick comment on that. If you look, our fastest-growing business continued to be the energy business in Q4, remarkable<br>performance. There was no shift with the organic growth there. It did not include any acquisitions falling into Q4. So, just a really great quarter<br>everywhere. Thank you. Next question.<br>
<b>Operator</b><br>
Manav Patnaik with Barclays Capital.<br>
<b>Manav Patnaik</b><i> - Barclays Capital - Analyst</i><br>
In light of the economic environment, I just wanted to get a feel for visibility on your numbers. And maybe an example being how much percent<br>of your renewals to your subscriptions occur or have already occurred coming into 2012? And just somewhat related to that in terms of just, again,<br>on the back of the economic environment, what changes, if any, are there to your appetite for M&amp;A this year?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Great question. Let me pick it up, and we'll start with that, Manav. Actually, you just tried to sneak in a second question. But I'll probably respond<br>to that quickly for everybody. A very good question. 32% of our renewals occur in Q1. Q4 is our second strongest, and then the other two are a bit<br>lighter. If you think about the fact that we're a November 30 business, December is a big month for us, as you would expect, because a lot of<br>companies that are on a calendar year do renew then. So, 32%. I'm going to have Scott give a little color on that in just a second.<br>
On your question B, we are feeling very good. Continue to, with the acquisition pipeline we've got, complementary, fit our strategic goals and will<br>fit going forward. So, we feel very good about that. Before I color Scott on Manav's first question, then Rich, anything else you've got on M&amp;A?<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>231</i><br>
<hr>
<A name=232></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
I was just echoing the renewal profile. It's 60%, one-third of it in the first quarter. So, the visibility on how we exit the year gives us great confidence.<br>The M&amp;A pipeline, in general, it remains very robust. Very pleased with the broad-based distribution of it, particularly the focus on emerging and<br>growth economies and industries that we're keenly focused on.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
And, Manav, just in terms of thinking about our subscription base, Jerre said it well. As we sit at this point in time, we have visibility to about 60%<br>of our renewal base, as Rich mentioned. So, 30%-plus in Q1, and also a large portion in Q4. So, obviously we're working three, four, five months<br>ahead with customers. So, we really have great visibility to over 60% of the renewal base as we sit here in early January, good view on the year,<br>and obviously strong momentum coming out of the end of last year.<br>
The other thing to note is our renewals still, on average, tend to be above 90%. And really great discipline with new sales systems where you see,<br>first of all, the timeliness of renewals at the highest levels ever in the Company. And that's just a sales system we deployed over the last year, focused<br>on the right structure and organization in sales. And of course, good global sales operations processes.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thank you. Next question.<br>
<b>Operator</b><br>
Eric Boyer with Wells Fargo.<br>
<b>Eric Boyer</b><i> - Wells Fargo Securities, LLC - Analyst</i><br>
With you guys having organic subscription revenue growth already over 9%, and your organic guidance being 7% to 10% for the year, the question<br>comes -- how are you feeling about the demand environment for the non-subscription business right now? And are you still pushing towards that<br>9% for the overall year?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Excellent question. As you remember, on our 2012 guidance call, Scott told us that his personal goal was 9% organic. And your question's a good<br>one, Eric, because an important part of that is the Other category, about 22%, 23% of our total. So, Scott, pick up both pieces?<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Yes, thanks. And what you saw in Q4, actually, was those non-subscription areas lifting the business and performing really positively. And I'll tell<br>you, we've spent, Eric, a lot of time over the last two years ensuring that those non-subscription parts of our business were tightly connected with<br>the subscription part of the business. And that's helping us drive growth. So, I'd tell you three things. One, part of those nonrecurring businesses<br>are connections, integration, and tighter value creation around our information for customers. And we've launched some electronic information<br>management services over the last year, which are growing above 20%, and really tightly linked to our underlying information subscription base<br>growth. So, really strong performance there in nonrecurring that's driving growth.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>232</i><br>
<hr>
<A name=233></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
Then in terms of services, advisory services and consulting, we saw positive performance all through the year. And ended the year in double-digit<br>growth there in each region as a result of, again, tying our advisory services to our insight and analytics, and really measured growth of that business.<br>So, we feel good about the level where we have demand higher, we're able to fulfill. That's a great place to be right now.<br>
And then the last piece that's in that nonrecurring area, of course, is some of our software and platform sales, both in energy, great work flow tools<br>that tie our information with our analytics. And of course, in environment. So, all of those three areas of solid growth by region that we feel good<br>about as we head into the year.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thank you. Good question. Next?<br>
<b>Operator</b><br>
Peter Appert with Piper Jaffray.<br>
<b>Peter Appert</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Jerre, this is one question, and it revolves around margins. And what I'd like to know is, as we think about 2012, what are the key drivers of the<br>margin improvement? How important are Vanguard and Newton to the upside you see? And can you talk a little bit about the seasonality in<br>margins? Is it going to be as fourth-quarter loaded in '12 as it was in '11?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Excellent question, Peter. Thank you. I'll work backwards on it. As you heard Rich talk just now, in that package that's on our website, you'll see, to<br>make sure we see and help you with what goes on quarter by quarter, you'll see that adjusted 2011 quarter-by-quarter percent of profit -- 30% in<br>Q4, 21% in Q1. So, using that, there's three key factors that have happened. One, we did want to give you that perspective because with the<br>acquisitions we've actually seen a shift of an increase in EBITDA profit in Q4, and we've got that built in. Secondly, we're feeling very good, I must<br>say, about the amazing effort that has gone on with Vanguard, our Centers of Excellence, many other things at the same time.<br>
Scott mentioned in his part of the prepared script the fact that we'll also be introducing more new products in 2012 than we have in the history of<br>our business. So, if you think about new products taking a while to move in, and take on the opportunity for growth, all of those drive us pretty<br>clearly to that 30% that we say happened last year, as one that we would expect to see continue as a model. I'm going to ask Rich to pick up, and<br>Scott, in just a second.<br>
But the other thing is, we felt very good all year long. I know many of our investors were wondering whether we would indeed deliver the 32%<br>margin in Q4 that we were consistent about all year. We did that. We feel very good about where we're going into 2012. A lot of productivity<br>improvements, sales force automation, et cetera. Equally important is to think through into 2013 because as we exit 2012, many of the benefits of<br>scaling, as Scott mentioned in his call, for the first time will now be in place. So, increasing amount of confidence in our ability to give significant,<br>as Rich's comment was in his wrap-up, margin improvement in 2011, Q4, more to come in 2012.<br>
Rich?<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
The mix question is really critical to us, I think, Peter. The acquisitions, SMT and the size of that, and our new pension accounting going forward is<br>ratably and it is included in adjusted EBITDA. So, the table is one we would encourage you to study and come back. Profit and margin profile is a<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>233</i><br>
<hr>
<A name=234></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
function. It all begins with revenue. And we've demonstrated to you when we can grow the top line at an 8% to 10% level, and aggressively manage<br>the cost control, we can consistently deliver between 100 and 150 basis points of margin improvement. And that's a function of many things,<br>including prioritizing our investments. And I think we're keenly focused on doing that.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Scott, wrap up on it. Very important question.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Couple things to realize. So, 32% in the fourth quarter. And of course, our goal is to deliver that or better for the full year. So, just think about where<br>we are and then that full year delivery, Peter. But also a couple things that we've mentioned. We've spent the last four quarters investing in scale.<br>We now have three Centers of Excellence globally. We're rolling out Vanguard to almost half of the business right now, and sales force automation<br>tools everywhere.<br>
To your question about how things grow in scale, what I mentioned is we're starting to see the benefit of those investments, significant ones over<br>the last four quarters, in the top line. We're seeing it begin to drive our growth, and we're going to increasingly see it drive efficiencies. We have<br>another four quarters, as you know, of Vanguard deployment, of Newton, and sales force optimization tools in process. Those will help us all the<br>way through the year, and as Jerre said, into 2013. So, we should expect to see the benefit of that scale, some additional efficiencies build through<br>the year. So, that's what you should expect to see on our margin goals.<br>
<b>Operator</b><br>
Michael Meltz with JPM.<br>
<b>Michael Meltz</b><i> - JPMorgan - Analyst</i><br>
I have one question, one clarification. I'm not sure which one's which here though, so let me just start. On Peter's question, just to clarify the guidance<br>for '12, you did 32% margin in the fourth quarter. The '12 guidance is 32% or better. Is the expectation in Q1 or Q2 to be down from the Q4 you<br>just did, but still up year over year? I understand what you're talking about seasonality of the profit distribution, but can you talk more specifically<br>about the expectation of margin ramp? Then I have a follow-up.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
That's a good question, Michael. The answer is yes to your question. Yes, you're right on. And if you do that analysis, again, using that 21% Q1 of<br>our guidance EBITDA, 30% Q4, you'll get there. And you'll see a number that we'll do our very best to deliver in Q4 that is a significant improvement.<br>But Scott's point of 32% all-in year over year versus the 30.2% in 2011 gives you a pretty good thought. That's 180 basis points for openers.<br>
Now, the next clarification -- or your question.<br>
<b>Michael Meltz</b><i> - JPMorgan - Analyst</i><br>
Yes, this might be the question. I appreciate the slides on the pension changes. Perhaps this might be better offline, but the $57 million contribution,<br>or however you're defining it, you talked about some buyouts and other changes that might occur. Is there an additional expectation of cash that<br>will be done throughout '12, in addition to that?<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>234</i><br>
<hr>
<A name=235></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Actually, I'll answer that only. Just so we're clear though, and it's a good question, Michael; the answer's no to that question. So we're clear, we are<br>happy to take as much time afterwards on one-on-one calls, or anything else that we need to do, along with that deck that we put on the website.<br>And we'll also send that deck out to you, all of our investors, right after we finish this call, to make sure we do the clarification. Most important thing<br>is that we've now really positioned ourselves to take any future risk of consequence off the table with the pension program. But that clarification<br>question is a good one.<br>
Next questions, thank you.<br>
<b>Operator</b><br>
Kelly Flynn with Credit Suisse.<br>
<b>Kelly Flynn</b><i> - Credit Suisse - Analyst</i><br>
On the tax rate, I was wondering if you could just get into more detail on exactly what were the mechanics that drove the tax benefit? And on the<br>$0.99 adjusted earnings number, what is the tax rate being used to get to that number? Thanks.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
That's a good question, Kelly. Rich?<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
It's a bit two-part, Kelly. One, the fourth quarter rate is clearly an anomaly that's driven entirely by the pension adjustment. I think if you normalize<br>for that, the fourth quarter GAAP rate was 24.2%. And an adjusted tax rate at about a 27%, 28%, as well. So, really the combination of the discrete<br>items for the total year, and in the fourth quarter in particular, created a lot of noise in that metric.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
And let's just be crystal clear. That $0.99 was a solid impact that delivered the quarter that was not a one-time event of any part of the taxes.<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
Correct.The totality of the pension adjustments, a good clarification to have, the pension adjustments were below adjusted EBITDA. So, the adjusted<br>EPS of $0.99 is a clear, clean number without any of the impact. And that is a traditionally consistent metric from a tax rate perspective.<br>
<b>Operator</b><br>
Bill Sutherland with Northland Capital Markets.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>235</i><br>
<hr>
<A name=236></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Bill Sutherland</b><i> - Northland Capital Markets - Analyst</i><br>
I was just noticing that very solid organic growth trend you guys generated in EMEA in the quarter, particularly in subscription. Can we get a little<br>color maybe on some of the industry and vertical trends that you saw over there?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Yes, good question, Bill. And let me just go back. It was a shame on us, or me, in Q3. We actually had quite solid subscription-based organic growth<br>in Q3 in EMEA, 6%-plus. We didn't do our colleagues justice there because it was the transaction stuff that pulled it down to the less than 2%. So,<br>it was good and solid and significantly increasing in Q4.<br>
And Scott, you'll love giving him color on that.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Yes. Several things to realize there. Just as we said through the year, despite a challenging environment, we're focused in the right markets on the<br>right customers. And of course, bringing a lot of value to their operations. And we talked about the headwinds, and really seeing the bottom in<br>terms of, for example, defense and security. And that's what's played out. So, really solid double-digit subscription growth that's pretty broad-based,<br>Bill. Strong performance in energy. Very good performance in terms of defense and security.<br>
And then I would say the other areas that really performed well, performed well globally. So, chemicals performing very well. TMT, supply chains<br>around manufacturing doing quite well. And then transportations, and particularly, autos. And also, we had really solid growth in the nonrecurring<br>parts of the business in EMEA. And the last thing I would add is the strategically managed account program.We had a lot of great wins across those<br>markets, and good performance as we connected with very large customers, as well.<br>
<b>Operator</b><br>
William Warmington with Raymond James.<br>
<b>Williaim Warmington</b><i> - Raymond James &amp; Associates - Analyst</i><br>
Congratulations on the strong organic revenue growth and the EBITDA margins. A two-part question, borrowing from my peers' examples. The<br>first part is more of a bookkeeping here. I know, Rich, you gave the deferred revenue growth in total.What was the organic deferred revenue growth<br>on the balance sheet?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Rich? That's a good question, Bill.<br>
<b>Williaim Warmington</b><i> - Raymond James &amp; Associates - Analyst</i><br>
And then the second part, construed as a second separate question, if you could talk a little bit about what kind of productivity improvements are<br>being assumed for the sales force in 2012 to hit the 9% organic revenue growth?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Let's pick that up first because that's a really great question.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>236</i><br>
<hr>
<A name=237></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Several things are happening. We've talked in the past about inefficiencies as high as 30% to 40% in the sales force. So, we'll see several things<br>happen. Shifting resource and focus within the existing sales force and our sales costs to emerging markets. And we saw that last year. We'll see<br>that continue. Latin America, as well as APAC, where we have high opportunity and high growth rates. We'll also see Vanguard roll out through<br>the year. And what that does for us is it starts to give us a consistent view of customers globally, and then connects with our sales force automation<br>SFA tool. We've got about 95% of the sales force on SFA, and almost $1.8 billion in sales opportunities flowing through that system.<br>
Another thing that I'll mention quickly is we've got all three Centers of Excellence up and running in terms of order management. So, quote, all the<br>way through delivery. And we'll see that make the sales force more efficient as we move through the year. Probably the most of that benefit will<br>start to come from the back end as we get Vanguard fully deployed and we get people up in those Centers and fully trained. So, we'll see the benefit<br>continue. We saw it some in the last quarter. We'll see it increase through the year, and then strong benefit in 2013.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thanks, Scott. And, Rich, pick up Bill's first part on the deferred organic.<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
As you said, Bill, it grew to $487 million. That's up $95 million, 24% in absolute terms. That's about an 11% organic growth sitting underneath that.<br>
<b>Operator</b><br>
Brian Karimzad with Goldman Sachs.<br>
<b>Brian Karimzad</b><i> - Goldman Sachs - Analyst</i><br>
Related to that, you've talked about the sequential quarter-over-quarter progression of the absolute numbers on revenue, EBITDA, the seasonality<br>there we've got to keep an eye on. But on the organic growth rate for revenue, is there anything technical we need to be aware of as we head into<br>1Q and through the year that could cause that to accelerate or decelerate? Like, for example, in 4Q the anniversary effect certainly helped. And as<br>I think about the quick cadence of the acquisitions you had in the year you just completed, SMT is by far the largest. And so, should we be expecting<br>an acceleration baked into your outlook in 4Q because of that?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
That's actually a very good question, Brian. I'll start, and have Scott pick up on that. And I'll go back to pick up a bit on Suzi's, too. We look at some<br>30 different product revenue bases, actually daily, weekly, monthly, quarterly. If you'll remember, Scott said in the last two calls that 85% of our<br>revenue was exceeding 10%. It was actually in double-digit organic growth. And that doesn't include the acquisitions we've made. If you add those<br>in for their own internal organic growth, it's actually north of there.<br>
Just for color, to give you a view, we range anywhere from 22%, 23% organic growth in a given quarter on some product lines to flat or thereabouts<br>negative on some of the other product lines. Scott mentioned in his call, on the formal part of the call, what we're doing in having a continuing<br>effort looking forward to those that are not meeting our double-digit goals on organic growth. And how we'll review those businesses and products,<br>either to increase spending to get them into double digits or make other decisions.<br>
So with that as background, pick up on the rest of the question.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>237</i><br>
<hr>
<A name=238></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
And so, obviously, you saw the 9% in the fourth quarter, which is our aspiration for the year within that 7% to 10% range. So, Jerre's told you we<br>have a great part of the portfolio that's in double digit today. You heard us say in terms of acquisitions that their year-on-year growth rate on<br>average is about 16%. So, they're performing very well.What I would say is, as we've said for the last few months, we feel good about the foundation<br>of the business. We continue with the highest level of transformation as we continue to roll out Newton, and staff our Centers for order entry all<br>the way through delivery. And we're mindful of the economy that we're sitting in. So, we're balancing those factors with, I think, what is a strong<br>foundation to the year, and a plan that we believe we can deliver.<br>
<b>Operator</b><br>
Dan Leben with Robert W. Baird.<br>
<b>Dan Leben</b><i> - Robert W. Baird &amp; Company, Inc. - Analyst</i><br>
Just wanted to ask a little bit on the cost side related to margins. Particularly in the Americas region, margins down a little bit sequentially. Are<br>there any one-time factors in there that we should think about as we go into next year around Vanguard or Newton or any of these other projects<br>with the customer excellence centers that were more one-time in nature in the fourth quarter that held that down?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Actually, as usual, very thoughtful question, Dan. The answer is no, nothing in specific, other than we did mention that we now have fully running<br>the Centers of Excellence in both EMEA and in the Americas. And that's been an investment of significance in Q2, 3 and 4. And that APAC is now<br>up and running as we begin the first quarter of 2012. And we feel very good about that progress. Nothing unusual at all though, from a standpoint<br>in the Americas, just a really great performance in total. Thanks, Dan.<br>
<b>Operator</b><br>
Robert Riggs with William W. Blair.<br>
<b>Robert Riggs</b><i> - William Blair &amp; Company - Analyst</i><br>
I think it still holds that roughly 70% of the revenue comes from the top 1,000 customers. But you've also made the comment that they're relatively<br>still under-penetrated, maybe 25% penetrated. As we think about the product development over the next several quarters, will there be a focus<br>on driving increased penetration among those top 1,000? Or are you maybe making some adjustments to appeal to the customers outside that<br>1,000, or to look to bring on some brand-new clients? Thanks.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Very good question, Rob. Scott?<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
I'll give you three things to think about there. We're relentlessly focused on those 1,000. And as I said, there's a differential growth rate in those<br>accounts. Extra 6 points, 6% of customer delight in those accounts, and 2 to 3 points of organic growth in those accounts. We're expanding them<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>238</i><br>
<hr>
<A name=239></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
to 250. We've just made some changes, as you've seen. Announced a new global sales lead, a single global sales operations function. And the goal<br>there with SFA is to get laser focused on those 1,000 accounts, and to continue that momentum.<br>
The other thing we're doing is the transactions part of our business, all the way at the other end of the spectrum, has been an under-performer.<br>We've got great valuable information globally, and so we're investing in that this year. And in the middle what you have is inside sales and field<br>managed, which we're looking at process and efficiency in. So, really good focus on each, but certainly laser focused on the top 1,000.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thanks, Rob. With that, we'll wrap up. I just want to make one quick comment, and then I'll turn it over to Andy. This is the end of my 32nd year as<br>Chairman, Executive Chairman, or CEO of public companies. Never have I gone into a year, as we are now into 2012, with more confidence about<br>our ability to execute long-term, sustainable, profitable growth because we've built an amazing team. We've got great processes and products in<br>place. So, I look forward to representing all of our colleagues around the world and our calls for the year as we continue to make that progress.<br>
Andy?<br>
<b>Andy Schulz</b><i> - IHS Inc. - VP IR</i><br>
We thank each of you very much for your interest in IHS.This call can be accessed via replay at 888-286-8010, or international dial-in 617-801-6888.<br>Pass code 95966684. Beginning in about two hours, and running through January 13. In addition, the Webcast will be archived for one year on our<br>website at www.IHS.com.<br>
And, as always, you can contact IHS Investor Relations with any follow-up questions.We can be reached at 303-397-2969.Thank you.We appreciate<br>your interest and time.<br>
<b>Operator</b><br>
Thank you for your participation in today's conference. This concludes the presentation. And you may now disconnect. Good day, everyone.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4683393-2012-01-09T09:18:26.563</b><br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>239</i><br>
<hr>
<A name=240></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
ATEC - ALPHATEC HOLDINGS INC AND<br>CROSS MEDICAL PRODUCTS SETTLE<br>LICENSE AGREEMENT DISPUTE<br>CORPORATE CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 06, 2012 / 2:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>240</i><br>
<hr>
<A name=241></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Michael O'Neill</b><i> Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
<b>Dirk Kuyper</b><i> Alphatec Holding, Inc. - President &amp; CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Glenn Novarro</b><i> RBC Capital Markets - Analyst</i><br>
<b>Bill Plovanic</b><i> Canaccord Genuity - Analyst</i><br>
<b>Matt Dolan</b><i> Roth Capital Partners - Analyst</i><br>
<b>Eugene Peysakh</b><i> Stifel Nicolaus - Analyst</i><br>
<b>Raj Denhoy</b><i> Jefferies &amp; Company, Inc. - Analyst</i><br>
<b>Mark Landy</b><i> Summer Street Research - Analyst</i><br>
<b>Vivian Cervantes</b><i> Kaufman Brothers - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Good day, ladies and gentlemen, and welcome to the Alphatec Spine, Inc. litigation conference call. At this time all participants are in a listen-only<br>mode. Later we will conduct a question-and-answer session and instructions will be given at that time. (Operator Instructions). As a reminder, this<br>call may be recorded. I would now like to introduce your host for today's conference, Michael O'Neill. Sir, you may begin.<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
Thank you and good morning, everyone.Welcome to Alphatec Spine's conference call to discuss the global sediments we have reached with Cross<br>Medical which ends our litigation and associated legal expenses. With me today are Dirk Kuyper, President and Chief Executive Officer, and Ebun<br>Garner, our General Counsel.<br>
By now you should have seen a copy of yesterday's press release announcing Alphatec Spine's settlements of license agreement disputes with<br>Cross Medical. If you do not have a copy of today's press release you can find it in the Investor Relations section on our website at<br>www.AlphatecSpine.com.<br>
Before we start there are a couple of items we would like to cover. I'd like to remind you that this call is being webcast live and recorded. A replay<br>of the event will be available later today on our website and will remain available for at least 30 days following the call.<br>
We would like to remind you that our discussions today include forward-looking statements. These statements are based on certain assumptions<br>made by us based on historical trends, current conditions, expected future developments including business prospects, product development<br>objectives, future financial performance and other factors we believe to be appropriate in the circumstances.<br>
Risks and uncertainties that may cause our actual results to differ materially from those projected in these forward-looking statements. You can<br>find a discussion of these factors and more information about us in our filings with the SEC including the Risk Factor section in our annual report<br>on Form 10-K, subsequent quarterly reports on Form 10-Q and periodic filings on Form 8-K.<br>
Forward-looking statements are made as of the date of this call and we assume no obligation to update these statements publicly even if new<br>information becomes available in the future.This broadcast is covered by US copyright laws and any use or rebroadcast of all or any portion of this<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>241</i><br>
<hr>
<A name=242></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
conference call may only be used with our express written permission. I'll now hand the call over to Dirk Kuyper, Alphatec Spine's President and<br>Chief Executive Officer.<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
Thank you, Mike; good morning and thank you for joining us today. This morning I'll provide some brief highlights on the settlement that we<br>announced with Cross Medical Products which is a subsidiary of Biomet, and then we'll open the call up for questions.<br>
We're pleased to announce that we've reached a global settlement agreement of two pending lawsuits.The first lawsuit, Cross Medical, had claimed<br>that Alphatec Spine had breached the April 23, 2003 licensing agreement with Cross Medical by failing to make certain royalty payments. In the<br>second lawsuit Alphatec Spine had claimed that a subsidiary of Biomet infringed on a patent owned by Alphatec Spine.<br>
Under the terms of the settlement all parties obtained a release of all claims that were the subject of the disputes. No party has admitted liability<br>in connection with the settlement. The settlement also includes an amendment to the April 23, 2003 license agreement.<br>
While we continue to believe in the strength of our position in this dispute, we felt that it served the best interest of our shareholders to proactively<br>settle the matter to eliminate ongoing legal costs resulting from the litigation and remove any possibility of an unfavorable judgment that could've<br>had a material adverse effect on the Company.<br>
As recent judgments in our industry have shown, there is an inherent uncertainty in the litigation process. In addition, in reaching a settlement<br>agreement we can now fully focus our time and resources on executing on our 2012 business plan.<br>
As part of the settlement Alphatec Spine will pay Cross Medical an initial payment of $5 million in January 2012. In addition to the initial payment<br>Alphatec Spine will make 13 payments of $1 million with the payments made quarterly, and the first payment being due on August 1, 2012, and<br>each subsequent payment (technical difficulty) three months thereafter until the final payment, which is due August 1, 2015.<br>
A portion of the settlement expense will be applicable to the financial year 2011 and a portion applicable to subsequent periods.We'll provide the<br>accounting treatment as part of our 2011 year-end reporting and it will be incorporated in our 2012 guidance.<br>
In addition, pursuant to the settlement the parties have exchanged covenants not to sue for patent infringement with respect to products that<br>each respective company had on the market as of December 30, 2011.<br>
As you may recall, we generated $1.8 million in cash from operations in the third quarter. We've been public with our goal to generate cash for<br>full-year 2011 and I can confirm that the business accomplished this. As discussed in our third-quarter earnings call, our focus remains on growing<br>revenues faster than the category in regions where we compete, on improving our global gross margins, aggressively managing our operating<br>expenses and a laser focus on cash flow generation.<br>
We announced several cost reduction initiatives which have resulted in incremental improvements in our cash flow in late 2011. We launched a<br>set of three strategic initiatives aimed at improving our performance, the first is reducing our cost to goods sold and increasing efficiencies in our<br>US operations; second is reducing cost of goods sold in our international operations; and third is reducing SG&amp;A expenses internationally.<br>
The initiatives include insourcing currently outsourced manufacturing to maximize our capacity utilization and improve cash flow. Currently 80%<br>of Scient'x implants are purchased as finished goods in the European Union and we have initiated transfer of high-volume products to our US<br>production facility.<br>
Focusing on the vital few projects that most affect our success and elimination of duplications of efforts are other initiatives. All of these efforts are<br>driving incremental cash flow for the business in 2012.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>242</i><br>
<hr>
<A name=243></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
We remain comfortable that we can meet the ongoing settlement obligations and continue to generate cash for the full-year 2012. Based upon<br>this we do not anticipate the need to raise additional capital now or in the future to fund our operation.<br>
In closing, it's important to point out that over the last 18 months Alphatec has gone through a major transformation into a global company. During<br>this period we have made substantive upgrades to the senior and international management teams and are clearly beginning to see the positive<br>impacts from these changes.<br>
We're well positioned to take market share in the global spine market and to generate positive cash flow in 2012 and we remain committed to our<br>longer-term goal of achieving a non-GAAP adjusted EBITDA margin in the 20% range.<br>
As we transition to Q&amp;A I want to be clear that this call will not be -- we will not be discussing or commenting further on either our fourth-quarter<br>financial performance or guidance for 2012. We anticipate providing this information as part of the year-end conference call which should take<br>place towards the end of February. Thank you and I'd now like to open the call up for your questions.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions). Glenn Novarro, RBC Capital Markets.<br>
<b>Glenn Novarro</b><i> - RBC Capital Markets - Analyst</i><br>
Congratulations on the settlement; certainly the number came in well below what we were thinking. So good stuff. My one question has to do<br>with the level of wiggle room that you have to do other type of licensings and deals. In other words, you're telling us that you've got enough cash<br>flow to now cover these payments which is great. But is there wiggle room to license innovative products like an OsseoFix or an OsseoScrew like<br>you've done in the past? Thanks.<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
As we look at the business we were able to operate very effectively with our cash flow for operations in 2011 and still make the investments we<br>needed to make in the business. And we see that going forward into 2012. In a way the good news is that, because of the changes in the market,<br>that the opportunity to license those types of products has become somewhat easier. So we don't see this as an impediment to us taking advantage<br>of opportunities as they come up.<br>
<b>Glenn Novarro</b><i> - RBC Capital Markets - Analyst</i><br>
Okay, great. And congrats.<br>
<b>Operator</b><br>
Bill Plovanic, Canaccord.<br>
<b>Bill Plovanic</b><i> - Canaccord Genuity - Analyst</i><br>
Just, Mike, if you could help us out on the one-time charge and the ongoing charges. Where are these going to show up in the P&amp;L? Will this be in<br>COGS or SG&amp;A? And will the one-time charge -- will it be a one-time charge or do you amortize it over the balance of the settlement?<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>243</i><br>
<hr>
<A name=244></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
The accounting treatment on the -- or how the settlement will appear in the P&amp;L is still to be determined. It is a complex calculation on how much<br>of that would hit a charge in 2011 versus how much would appear in subsequent periods. But the licensing agreement expires at the end of 2013.<br>So that would be the end of any P&amp;L impact.<br>
It would normally show up -- ordinarily royalties show up as a piece of cost of goods sold.Whether this shows up there in future periods and whether<br>the one-time charge shows up there remains to be seen given the nature of the settlement. But it is still a TBD as far as we're concerned at this<br>point. But we'll be very clear when we come out with 2012 guidance as to what the impact is and where it shows up in the P&amp;L.<br>
<b>Bill Plovanic</b><i> - Canaccord Genuity - Analyst</i><br>
And secondly for Dirk. Just as I look at this settlement, the challenge you have here is we're coming out of this and you turn profitable and had<br>cash flow you could finally start reinvesting in the business and grow it. With this settlement you're basically taking -- half of your free cash flow<br>per quarter for the next year or two and having to pay it out rather than reinvest it in the business. How do you propose accelerating growth or<br>outgrowing the market without the cash flow to reinvest in the business to do so?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
Well, clearly we're very focused on increasing the amount of cash flow per quarter and have spent a lot of time and effort in 2011 positioning the<br>Company appropriately to do that. And we clearly are very focused on doing that in 2012 and on a go-forward basis. So we feel very good about<br>our ability to increase our cash flow as we move forward.<br>
So we believe we will have the resources we need to reinvest. As I said in 2011, even though we turned the corner in terms of generating positive<br>cash flow in total for the year, it wasn't substantive. But we were able to invest in the business as we needed to in order to grow.<br>
So we really don't see this impeding our ability to organically grow in 2012 and continue to take share. Obviously we would have preferred for it<br>not to happen, but it's well within our plan.<br>
<b>Bill Plovanic</b><i> - Canaccord Genuity - Analyst</i><br>
So, in sum, basically with the changes you made and the reductions in COGS and what have you and G&amp;A, you have enough to both grow the<br>business and to pay Biomet out without having to raise capital. Is that what you're telling me?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
That's correct, Bill.<br>
<b>Bill Plovanic</b><i> - Canaccord Genuity - Analyst</i><br>
All right, thank you.<br>
<b>Operator</b><br>
Matt Dolan, Roth Capital Partners.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>244</i><br>
<hr>
<A name=245></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
<b>Matt Dolan</b><i> - Roth Capital Partners - Analyst</i><br>
Just a couple housekeeping items. What was the legal spend related to this case versus your total annual legal budget?<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
We've spent over $1 million so far in 2011 and we would have -- if we had continued the litigation we would've had a similar burn rate in 2012.<br>
<b>Matt Dolan</b><i> - Roth Capital Partners - Analyst</i><br>
And how much revenue was in play relating to the agreement?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
You mean which products did it cover?<br>
<b>Matt Dolan</b><i> - Roth Capital Partners - Analyst</i><br>
Right, just maybe percent -- pedicle screws, but any more granularity we can get in terms of the amount of revenue associated with this exact<br>agreement?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
Yes, pedicle screws are obviously a substantial portion of our revenue.<br>
<b>Matt Dolan</b><i> - Roth Capital Partners - Analyst</i><br>
And finally, maybe following on some of these prior conversations, Dirk, does this in any way change your cost reduction strategy? Meaning is the<br>existing plan sufficient to offset some of the margin you're now sacrificing with this settlement? Or do you feel like the process might need to get<br>a little more aggressive in the future to hit some of the margin targets that you have in mind? Thanks.<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
That's a good question, Matt. We obviously have been very focused on setting this business up the right way going forward to both improve<br>margins and improve cash flow. And we don't see the settlement requiring us to make any additional drastic actions at this point. Within all of the<br>changes that we've been making we feel very comfortable. We don't see the need to do anything in addition to what we had already planned.<br>
<b>Matt Dolan</b><i> - Roth Capital Partners - Analyst</i><br>
Okay, thank you.<br>
<b>Operator</b><br>
Charles Chon, Stifel Nicolaus.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>245</i><br>
<hr>
<A name=246></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
<b>Eugene Peysakh</b><i> - Stifel Nicolaus - Analyst</i><br>
Hi, it's Eugene Peysakh on for Charlie. Can I just follow up on the last question in terms of getting a sense of had this litigation continued what<br>would have been the exposure to royalties? Is there any way to answer that?<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
Yes, hi, Eugene. So we're actually -- we're not going to be commenting on what the estimated full value of the potential ongoing cost would have<br>been. At this point in time we've got the settlement agreement between two parties; it's a cash value of $18 million.<br>
<b>Eugene Peysakh</b><i> - Stifel Nicolaus - Analyst</i><br>
You mentioned that this particular litigation would have been $1 million in expense. And was that -- I mean in previous quarters, if you can remind<br>me, was that included or excluded from your EPS?<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
No, all of our legal expenses were recorded in the P&amp;L through the SG&amp;A line.<br>
<b>Eugene Peysakh</b><i> - Stifel Nicolaus - Analyst</i><br>
Okay. All right, thank you so much.<br>
<b>Operator</b><br>
Raj Denhoy, Jefferies.<br>
<b>Raj Denhoy</b><i> - Jefferies &amp; Company, Inc. - Analyst</i><br>
I wonder if I could ask about any impact this has on your debt covenants. And also whether there's any debt payments that are going to be coming<br>due over the next year or so?<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
I think the bank is obviously fully aware and fully engaged with all aspects of the settlement. They've been very supportive of the Company and<br>we're not anticipating any major revisions to our covenant at this point in time.<br>
<b>Raj Denhoy</b><i> - Jefferies &amp; Company, Inc. - Analyst</i><br>
Okay. And then just sort of a follow up to all the questions on your margin expansion initiatives. I think you've been talking about these for a quarter<br>or so now, perhaps a bit longer I think. But we haven't yet seen them materialize. Even in the third quarter I think gross margins took a little bit of<br>a step back and even SG&amp;A spending as well.<br>
So as we look here into 2012 when do you think we'll start to see some material benefits from these initiatives maybe improve the margin structure<br>of the Company, the cash generation?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>246</i><br>
<hr>
<A name=247></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
I think without getting into specifics for 2012 guidance, I think we're going to see quarterly improvements in our gross margin as the year unfolds.<br>I don't think we would be characterizing a step function change in any one quarter given how some of the costs are absorbed between the balance<br>sheet and the P&amp;L.<br>
But we're beginning to see improvements in gross margin now and we would anticipate continuing to see that as the year unfolds. And we'll be<br>a little bit -- we'll be more forthcoming with that as we get into our 2012 guidance.<br>
<b>Operator</b><br>
Matt Miksic, Piper Jaffray.<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
Are we still on air?<br>
<b>Operator</b><br>
Once again, Matt Miksic, your line is open.<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
We can move on to the next question.<br>
<b>Operator</b><br>
Mark Landy, Summer Street.<br>
<b>Mark Landy</b><i> - Summer Street Research - Analyst</i><br>
Just my debt questions have been asked and answered. But with respect to some of the approval processes and the discussions that you've got<br>ongoing with the FDA, there's some discussion moving some of those from 510(k) submissions to PMA type submissions. How does your cash<br>position affect your ability to basically move those programs forward? Or could we expect some slowing down in the regulatory process relating<br>to new product?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
Thanks, Mark.That's a very good question. Obviously that's something we need to evaluate very carefully.We've obviously got some very innovative<br>products in the pipeline and we're going through the assessment in terms of our ability to handle clinical studies within this framework. We have<br>planned to increase our spending in clinicals in 2012 well within our plan.<br>
Again, I think a lot of the actions we took in the third quarter were really designed to reduce spending where we didn't need it so that we would<br>have room to operate where we didn't need to increase spending and clinical is one of those areas.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>247</i><br>
<hr>
<A name=248></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
So I think the answer to your question is we're evaluating that. And certainly I think as we get to the year-end and 2012 guidance call we'll be able<br>to provide a more thorough update on that. But at this point our intention is to bring those innovative products to market in the US.<br>
<b>Mark Landy</b><i> - Summer Street Research - Analyst</i><br>
And then just my last observation -- you did file a restructuring of your debt (inaudible) bank I think in the middle of December. In those negotiations<br>was this settlement contemplated or was the settlement just too early in the settlement process to contemplate in those negotiations?<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
Yes, the settlement negotiations occurred after we had renegotiated the debt structure with the bank.<br>
<b>Mark Landy</b><i> - Summer Street Research - Analyst</i><br>
Thanks, Mike; thanks, guys.<br>
<b>Michael O'Neill</b><i> - Alphatec Holding, Inc. - CFO, VP &amp; Treasurer</i><br>
Okay, thanks, Mark.<br>
<b>Operator</b><br>
Vivian Cervantes, Kaufman Brothers.<br>
<b>Vivian Cervantes</b><i> - Kaufman Brothers - Analyst</i><br>
Good morning, Happy New Year. Two-part question. First, obviously the settlement with Biomet is a big worry point off the table. When you take<br>a look at what other legal items you have pending, what's next on the docket in terms of worry points? I mean are we basically free and clear now<br>or do we still have a couple more that you'd like to get off the desk?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
The only other one that we have on the table is the shareholder suit that started last year, but that is covered by insurance.<br>
<b>Vivian Cervantes</b><i> - Kaufman Brothers - Analyst</i><br>
Okay, that's right. And then on the cost saving initiatives, at one point in time we had talked about the possibility of offsetting some of the royalty<br>payments with product redesign. Is that still on the docket?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
No, I don't think we have any products at this point that we would be redesigning to avoid royalties.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>248</i><br>
<hr>
<A name=249></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
<b>Vivian Cervantes</b><i> - Kaufman Brothers - Analyst</i><br>
Okay, so it seems like what you currently have in terms of in licensing or royalty type payment products you are fine with. And when it comes to<br>improving your cost of goods sold line item it's going to be more through driving efficiencies and also much product redesign or royalty/licensing<br>re-agreements?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
That's correct. We obviously continuously at look at the relicensing and based on how products are performing. But I don't think there's anything<br>substantive there. Mainly we're going to drive margins through improvements in our operations.<br>
<b>Vivian Cervantes</b><i> - Kaufman Brothers - Analyst</i><br>
Understood. And just one final question. Appreciate the recap that you gave in terms of some of your cost reduction programs and how this will<br>help you fund the Biomet cash settlement. So, from the sound of things the movement for Scient'x manufacturing into the US is moving along as<br>expected?<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
That's correct, it is.<br>
<b>Vivian Cervantes</b><i> - Kaufman Brothers - Analyst</i><br>
Okay, that's helpful. Thank you.<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
Okay, thank you very much.<br>
<b>Operator</b><br>
Thank you. I'm not showing any further questions. I would now like to turn the call back to our speakers for further remarks.<br>
<b>Dirk Kuyper</b><i> - Alphatec Holding, Inc. - President &amp; CEO</i><br>
Thank you very much. So the takeaways from the settlement we announced yesterday is that we have removed the legal uncertainty and can<br>dedicate our focus and energy on executing our 2012 plan. As we strive for operational excellence we have taken the necessary steps to improve<br>our cost structure and manufacturing efficiencies.<br>
With our broad and differentiated product portfolio, new product pipeline and our unique global distribution platform we think we are well<br>positioned to take market share. Thank you and good day.<br>
<b>Operator</b><br>
Ladies and gentlemen, thank you for participating in today's conference. This concludes today's program. You may all disconnect. Everyone have<br>a great day.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>249</i><br>
<hr>
<A name=250></a>JANUARY 06, 2012 / 2:00PM, ATEC - ALPHATEC HOLDINGS INC and Cross Medical Products Settle License<br>Agreement Dispute Corporate Conference Call<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4701516-2012-01-09T11:48:48.820</b><br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>250</i><br>
<hr>
<A name=251></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
IART - INTEGRA LIFESCIENCES<br>CORPORATION CONFERENCE CALL<br>TO DISCUSS PRELIMINARY Q4 2011<br>FINANCIAL RESULTS<br>
EVENT DATE/TIME: JANUARY 06, 2012 / 1:30PM GMT<br>
OVERVIEW:<br>
IART expects 4Q11 total revenues of approx. $202-203m, GAAP diluted EPS of<br>$0.08-0.20, and adjusted diluted EPS of $0.65-0.70. Expects full-year 2011 GAAP<br>diluted EPS of $0.87-0.99, and adjusted diluted EPS of $2.74-2.79. Co. also expects<br>2012 reported revenues to increase approx. 8% on constant currency basis and 7%<br>in aggregate over 2011 final revenues, and 2012 adjusted EPS growth of approx.<br>8-9% over 2011.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>251</i><br>
<hr>
<A name=252></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Angela Steinway</b><i> Integra Lifesciences Holdings Corp - IR</i><br>
<b>Peter Arduini</b><i> Integra Lifesciences Holdings Corp - CEO</i><br>
<b>Jack Henneman</b><i> Integra Lifesciences Holdings Corp - CFO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Raj Denhoy</b><i> Jefferies &amp; Company - Analyst</i><br>
<b>David Lewis</b><i> Morgan Stanley - Analyst</i><br>
<b>Matt Miksic</b><i> Piper Jaffray &amp; Co. - Analyst</i><br>
<b>Glenn Novarro</b><i> RBC Capital Markets - Analyst</i><br>
<b>Steven Lichtman</b><i> Oppenheimer &amp; Co. - Analyst</i><br>
<b>Robert Goldman</b><i> CL King - Analyst</i><br>
<b>Charles Chon</b><i> Stifel Nicolaus - Analyst</i><br>
<b>Chris Pasquale</b><i> JPMorgan Chase &amp; Co. - Analyst</i><br>
<b>Jayson Bedford</b><i> Raymond James &amp; Associates - Analyst</i><br>
<b>Bob Hopkins</b><i> BofA Merrill Lynch - Analyst</i><br>
<b>OVERVIEW</b><br>
IART expects 4Q11 total revenues of approx. $202-203m, GAAP diluted EPS of $0.08-0.20, and adjusted diluted EPS of $0.65-0.70.<br>Expects full-year 2011 GAAP diluted EPS of $0.87-0.99, and adjusted diluted EPS of $2.74-2.79. Co. also expects 2012 reported revenues<br>to increase approx. 8% on constant currency basis and 7% in aggregate over 2011 final revenues, and 2012 adjusted EPS growth of<br>approx. 8-9% over 2011.<br>
<b>FINANCIAL DATA</b><br>
<b>A. Expected 4Q11 total revenues = approx. $202-203m.</b><br>
<b>B. Expected full-year 2011 GAAP diluted EPS = $0.87-0.99.</b><br>
<b>C. Expected 4Q11 GAAP diluted EPS = $0.08-0.20.</b><br>
<b>D. Expected full-year adjusted diluted EPS = $2.74-2.79.</b><br>
<b>E. Expected 4Q11 adjusted diluted EPS = $0.65-0.70.</b><br>
<b>F. Expects 2012 reported revenues to increase approx. 8% on constant currency basis and 7% in aggregate over 2011</b><br>
<b>final revenues.</b><br>
<b>G. Expects 2012 adjusted EPS growth of approx. 8-9% over 2011.</b><br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>252</i><br>
<hr>
<A name=253></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. OPENING REMARKS (P.A.)</b><br>
<b>A. Highlights:</b><br>
<b>1. </b>Preliminary results and revisions to 2012 preliminary guidance, below prior estimates and Street expectation.<br><b>2. </b>Announcing preliminary results and guidance earlier than Co. ordinary would.<br><b>3. </b>Announced on 01/05/12 that Co. received anticipated warning letter regarding Plainsboro manufacturing facility.<br>
<b>II. PRELIMINARY 4Q11 &amp;AMP;AMP;AMP; FULL-YEAR 2011 FINANCIAL RESULTS (J.H.)</b><br>
<b>A. Highlights:</b><br>
<b>1. </b>Expectations:<br>
<b>a. </b>4Q11 total revenues approx. $202-203m; revenue shortfall resulted from:<br>
<b>i. </b>Inventory reduction initiatives by instruments distributors.<br>
<b>ii. </b>Weakness outside US.<br>
<b>iii. </b>Weaker-than-expected sales of domestic extremity products.<br>
<b>b. </b>Adjusted diluted EPS:<br>
<b>i. </b>4Q11 $0.65-0.70.<br>
<b>ii. </b>Full-year $2.74-2.79.<br>
<b>c. </b>GAAP diluted EPS:<br>
<b>i. </b>4Q11 $0.08-0.20.<br>
<b>ii. </b>Full-year 2011 $0.87-0.99.<br>
<b>2. </b>At this stage in close, has pretty good sense of revenues, but process takes few more weeks for other items.<br>
<b>a. </b>These reports are preliminary and numbers are subject to change.<br>
<b>3. </b>Expects Orthopedics revenues including products sold to foot, hand, spine, and orthopedic surgeons increased over 4Q10<br>
by approx. 19%.<br>
<b>a. </b>Extremity Reconstruction, largest component of Orthopedics category grew in low-teens.<br><b>b. </b>Sales of legacy foot and ankle products declined primarily because Co.'s sales force was devoting attention to learning<br>
Ascension product line and customer base, a process Co. believes will continue into 1Q but resolve by 2Q.<br>
<b>4. </b>Regenerative medicine products sold through extremity sales force increased mid-single digits vs. prior-year period.<br>
<b>a. </b>Backorder below previous estimates.<br><b>b. </b>Managing backorder with customers took significant selling time away from legacy products.<br>
<b>c. </b>Expects these issues to resolve by 2Q.<br>
<b>5. </b>Miss in domestic extremities products accounted for about 25% of revenue shortfall against internal estimates.<br><b>6. </b>Spine sales up significantly in qtr., driven by SeaSpine acquisition.<br>
<b>a. </b>Both spine hardware and orthobiologic product lines grew by double digits vs. prior-year period.<br>
<b>7. </b>Private label roughly flat vs. prior-year period.<br><b>8. </b>Neurosurgery revenues declined slightly in 4Q.<br>
<b>a. </b>While Europe held to expectations, delayed product registrations and weak performance by one of key distributors in<br>
Asia Pacific caused most of sales shortfall.<br>
<b>b. </b>US revenues down slightly.<br>
<b>i. </b>Sales of neuro capital products relatively light vs. strong performance in 4Q10.<br>
<b>ii. </b>Sales of implants and neuro critical care products grew well.<br>
<b>9. </b>Instrument revenue in 4Q11 down approx. 10% vs. last year.<br>
<b>a. </b>Sales of instruments in acute care setting decreased in low single-digits.<br><b>b. </b>Sales in alternate site channel substantially lower due to lower stocking purchases.<br>
<b>c. </b>Several of Co.'s key distributor customers reduced their inventory levels.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>253</i><br>
<hr>
<A name=254></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>d. </b>Miss in alternate site instruments accounted for more than 50% of revenue shortfall vs. internal estimates.<br>
<b>10. </b>Consolidated international revenue up approx. 1% over prior year.<br>
<b>a. </b>Combination of ongoing macro challenges in Europe and delayed product registration approvals in Asia Pacific caused<br>
shortfall in revenue performance for 4Q11.<br>
<b>b. </b>Miss in international sales accounted for about 25% of revenue shortfall against internal estimates.<br>
<b>11. </b>Not reporting preliminary results for GM percentage or Opex by line item, tax rate or cash flow, all of which will be available<br>
when Co. reports final 2011 results in late Feb.<br>
<b>III. ADDITIONAL METRICS (P.A.)</b><br>
<b>A. Highlights:</b><br>
<b>1. </b>Disappointed by loss of momentum in business in last seven weeks of qtr., particularly in last three weeks, which are usually<br>
strong.<br>
<b>a. </b>Biggest surprises came from instruments product lines particularly in alternate site, domestic extremities products, and<br>
certain international markets.<br>
<b>b. </b>Instruments product line underperformed primarily because of major distributors that reduced amount of inventory of<br>
Co.'s products that they typically carry at year-end.<br>
<b>c. </b>Knows alternate site product line is fundamentally sound because end user sales data Co. has suggest its products are<br>
holding up well.<br>
<b>d. </b>Domestic extremity products underperformed on topline vs. expectations due to two main reasons:<br>
<b>i. </b>While Ascension integration is proceeding according to plan, Co. underestimated extent to which integration activities<br>
would distract sales force from selling.<br>
<b>ii. </b>Reps spent more time than expected managing through collagen product supply issues.<br>
<b>e. </b>Aforementioned distractions adversely sales of legacy extremities products in qtr.<br>
<b>i. </b>Expects both issues will continue in 1Q but will be resolved by 2Q.<br>
<b>2. </b>Ascension integration, going well.<br><b>3. </b>International markets, disappointed with results.<br>
<b>B. 2012 Outlook:</b><br>
<b>1. </b>Due to slower revenue growth in 4Q, international challenges particularly in Europe, strengthening of dollar, and slightly<br>
lower growth expectations for domestic extremities products, revising view of 2012.<br>
<b>2. </b>Reported revenues to increase approx. 8% on constant currency basis and 7% in aggregate over 2011 final revenues.<br><b>3. </b>Adjusted EPS growth approx. 8-9% over 2011.<br><b>4. </b>Will provide detailed guidance regarding revenues by product category, GM, and expense lines with full-year 2011 financial<br>
results in Feb.<br>
<b>5. </b>In spite of tough environment, has numerous reasons to be optimistic about 2012 and beyond.<br>
<b>a. </b>Spine and biologics products, well positioned with integrated sales organization.<br><b>b. </b>Extremities organization is trained in selling Ascension products and excited to have new base of surgeons and products.<br>
<b>c. </b>Neuro sales force has new products on tap for later in year.<br>
<b>d. </b>Out-the-door sales of alternate site instruments and Co.'s share, stable.<br>
<b>i. </b>Expects revenues there to bounce back in 2012.<br>
<b>6. </b>Received warning letter with respect to Plainsboro facility, which is available as an exhibit to 8-K filed on 01/05/12.<br>
<b>a. </b>As reported in anticipation of it at Analyst Day in Nov., already reacting to last summer's inspection of Plainsboro facility<br>
as if Co. had gotten a warning letter; continues to do so.<br>
<b>b. </b>Remediation of facility has tracked to schedule outlined in Nov.<br>
<b>c. </b>All clean rooms were in production at Dec.-end.<br>
<b>d. </b>Now believes supply issues will recede by 1Q-end, which will remove a major distraction for extremities sales force in<br>
particular.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>254</i><br>
<hr>
<A name=255></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>C. Additional Details:</b><br>
<b>1. </b>Peter Arduini, first call as CEO.<br><b>2. </b>J.P. Morgan Conference on 01/11/12.<br><b>3. </b>Will not provide final or detailed results for 2011 or detailed guidance for 2012 until 4Q earnings call in late Feb.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
(Operator Instructions) Raj Denhoy, Jefferies.<br>
<b>Raj Denhoy</b><i> - Jefferies &amp; Company - Analyst</i><br>
Maybe I can ask a bit about -- at the analyst meeting back in November here, you guys laid out a pretty detailed strategy for how<br>you are going to grow the Company going forward, and I think what we took away from that was international growth was probably<br>the biggest opportunity from a revenue standpoint. And then on the margin side, you were really looking for kind of the mix to<br>Extremity's and Orthopedics broadly kind of driving the margin expansion. And yet, in the third quarter and then here now in the<br>fourth quarter, both of those things seem to have yet to really materialize. International, as you mentioned, still weak. Extremity's<br>weak for a number of reasons. But I'm curious whether what's going on here has really caused you to kind of go back and reassess<br>whether that strategy laid out is really the best one for growing the Company going forward?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Raj, thanks for the question. I think overall our strategy has not changed. I think when we take a look at our broader outlook,<br>the points that you made about our international opportunity -- as you know, it's over 77%, 75% of our overall growth is still domestic.<br>We have a large opportunity, and we're making good progress on registrations, infrastructure, our new office capabilities. So, when<br>I take a look at, over our next three- to five-year horizon, very, very solid from an international standpoint. Extremities, as you spoke<br>of and as we mentioned at the investor conference, relative to accretion really in Orthopedics bringing higher gross margin rates to<br>the overall business, we still believe is there. The reality of it is though our expectations for the growth that we thought we would<br>have in Q4 didn't meet our expectations, and with that we've tempered our 2012 expectations because of that.<br>
Then Jack, if you'd like to add any comments?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Yes. I mean, I think that the main point around Extremities, just to pound the point home because we just said it in the script, is that<br>we think we've got specific rifle shot issues that are transitory. And we are, I think, doing everything we need to do on the Ascension<br>integration, but moving sales from a distributed sales force to a direct sales force requires a lot of training, a lot of attention, the<br>absorption of a lot of knowledge.<br>
Similarly, we've been managing our supply issues out of the Plainsboro plant well, I think. The backorder came in well below the<br>number we had sort of put out there back in November. But I think the thing we didn't quite appreciate was how much time it would<br>take the sales force to respond to the needs of the customer by moving product around.We're trying to be realistic, and say we think<br>that will continue into the first quarter. So, that has also tempered our view of things. But overall, we think the business is healthy,<br>the sales force is very excited by the Ascension opportunity. We have unique material in the Pyrocarbon that is opening all kinds of<br>new doors and exciting the existing doctors. So again, we believe this to be temporary, not longer term, and hope that by the<br>Summer, we are rocking.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>255</i><br>
<hr>
<A name=256></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Raj Denhoy</b><i> - Jefferies &amp; Company - Analyst</i><br>
Okay, good, thank you.<br>
<b>Operator</b><br>
David Lewis, Morgan Stanley.<br>
<b>David Lewis</b><i> - Morgan Stanley - Analyst</i><br>
Jack, just sort of walk through the rifle shot as it relates to Ascension -- I guess we were a little surprised that Ascension caused that<br>kind of disruption. I guess post the analyst day and heading into 2012, SeaSpine for example, we thought the cross-selling associated<br>with that transaction was going to be very, very important to Spine growth throughout 2012. I just wonder as we think about some<br>of these integration-related disruptions in the fourth quarter, how confident are you in sort of SeaSpine integration and no disruption<br>to the Spine business broadly defined heading into 2012?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
David, it's Peter, I'll comment and then Jack, you can add some thoughts to that. I think where we are with the SeaSpine integration,<br>we feel very good that we've integrated the distributor structure. We're cross-pollinating our products; we've got a lot of systems in<br>place and marketing structure in place that took a good chunk in 2011. And so we had stable results really in Q4, and we see that<br>continuing really into 2012.<br>
On the Extremity aside, remind you that we were actually integrating a distributor structure into a direct sales force as to combining<br>two distributor structures as we did in Spine. And some of that activity obviously now in retrospect is taking a little bit more time to<br>get that integrated into our direct team. That being said, our teams are well trained, as I mentioned, now, up to speed on those<br>product lines, feeling good about the new surgeon relationships that they have. And we believe obviously starting into the new<br>year we'll be able to get some of that disruption behind us.<br>
Jack, you may want to --?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
I think that's exactly right. I mean, when we look back over these two integrations, I'd say we think we're doing the right things in<br>both cases. That doesn't mean that we have perfectly anticipated what would happen to revenues in every circumstance, which is<br>a question about anticipating forecasting rather than actually executing. But the thing to bear in mind is that they are different in --<br>the integration of these distribution systems, as Pete said, are different. One was SeaSpine, distributor to distributor where there<br>was very little overlap, and indeed, most distributors in both organizations were retained. In the Ascension side, we were terminating<br>most, not all, but most of the distribution network, and moving those sales to a direct sales force; that obviously causes more conflict.<br>Overall, it held up pretty well. I'd say we should have anticipated more disruption than we did.<br>
<b>David Lewis</b><i> - Morgan Stanley - Analyst</i><br>
Okay, thank you very much.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>256</i><br>
<hr>
<A name=257></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Operator</b><br>
Matt Miksic, Piper Jaffray.<br>
<b>Matt Miksic</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Just a follow-up, not to beat a dead horse here with Extremity's, but it's been up and down kind of throughout 2011. And it sounded<br>like there were some issues in the third quarter that weren't necessarily the same issues in the fourth quarter, specifically thinking<br>of the training. And again going back to the meeting coming off of the third quarter call and your analyst meeting, it sounded like<br>some of the third quarter issues were transitory. Can you give us some color in terms of the end market and maybe the availability<br>of some of your Biologics, your Collagen products, were those things that, all other things being equal, ex the distraction of your<br>sales force, do you believe that the end market, the demand, the volume was there and this was more of a sales distraction?<br>
And then second, if you could give some sense as to when -- you mentioned middle of the year or the Summer, is it going to be a<br>couple of quarters? Can we see an improvement in Q1? Any color on sort of timing would be helpful. Thanks.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Matt, it's Pete; I'll make some comments on it. Relative to the market and our growth, I mean we still believe that the market, as<br>was mentioned in Q3, had softened from, say, previous points in the first half of 2011. But we don't believe there's been any substantial<br>changes in the market at this point. Now, the fact is, we don't have a lot of other information from other folks reporting in with our<br>reporting early, but we don't have any indications that procedures have substantially changed or anything of that nature.<br>
From a Biologics standpoint and our proliferation of our product, that's advancing well within our Extremity's business. It also has<br>done well within our Spine business as well, just to mention. And so, the main focus is, as we mentioned, is the distraction relative<br>to the two areas. The integration components that we spoke to, and really, as we were actually tight on supply on a lot of the<br>Regenerative products, in the fourth quarter matching up the right level of products to the right customers, while the combination<br>of training and while also doing the integration, we overestimated the amount of burden it would put on the sales team. To your<br>point about, into the new year, as Jack commented on, we believe that in Q2, we'll be able to get this resolved and get it behind us.<br>
<b>Matt Miksic</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Thanks.<br>
<b>Operator</b><br>
Glenn Novarro, RBC Capital Markets.<br>
<b>Glenn Novarro</b><i> - RBC Capital Markets - Analyst</i><br>
You've clearly lost some market share as a result of sales force distraction. Are you saying to us that you expect that share to come<br>right back by the second quarter? I would imagine your competitors aren't just going to sit back and let you come right back into<br>accounts and gain share back, so maybe talk to us a little about your expectations for share recapture. Because it sounds to me like<br>you're expecting the run rates to return back to normal levels by 2Q? Thanks.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>257</i><br>
<hr>
<A name=258></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Glenn, from a standpoint of overall share, if you take a look at our broader businesses, we believe overall Neuro was in the round,<br>our Spine business was on track with the growth that we've had. And if you highlight the discussion on Instruments, which Jack<br>commented on was our biggest component of the miss, that ties with reduced levels of inventory. We know that that share is being<br>consistent, so that we haven't had share loss there. In Extremity's area, whether we have had loss from share in the mid foot, hind<br>foot area, we don't necessarily have all of that data yet. The key though is, is the integration of 20 new products, new coverage of<br>surgeons and capability just of our new reach, we're going to be able to pull back share. The question of -- is it the exact surgeons<br>and things that we might have lost some cases to? Yet to be seen. But with the opportunities of growth with bringing Ascension in<br>to bring both of our products together, we feel confident that we'll be able to grow share.<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
The only thing I would add to that, Glenn, is, against our internal estimates, about two-thirds of our miss in Extremity's was Skin and<br>Wound. And that's a very different market. And we think we'll get that back. We have unique products there. It's really a different<br>animal than the Orthopedics hardware.<br>
<b>Glenn Novarro</b><i> - RBC Capital Markets - Analyst</i><br>
Actually, Jack, thanks. That's very good color.<br>
Can I just hit one more follow-up, just on the warning letter, it sounds like the warning letter is not going to cost the Company any<br>more from an expense point of view. Is that correct? And then second, usually when a company gets a warning letter, the FDA doesn't<br>approve any more products that would be pending at the FDA that would be made at that facility. Is that the case, and do you have<br>any products pending approval that would have been made by the facility in Plainsboro? Thanks.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Glenn, it's Pete. Let me just kind of remind you and remind everyone -- so, we received the 483 back in early Fall, late Summer.<br>And on the call and also at the investor day, we went through the details, and specifically talked about that we were treating this as<br>severe as if we were going to get a warning letter. And put a lot of the aggressive plans in place between facility updates, changes<br>within structure, and such that we believe currently with the warning letter that there really isn't a scope in the change of what the<br>costs are to remediate. In fact, as I mentioned, we look at what the observations are in the warning letter, and they match up well<br>to the 483, which is aligned well with the plans that we already have in place.<br>
Relative to what a warning letter means versus, say, a 483 as many of you know, PMA approvals are not approved until the warning<br>letter is lifted. We don't have any major products planned as far as for PMA launches right now within the 2012 window tied to that<br>facility. And again, this is specifically tied to the 105 facility; it doesn't affect other facilities. Secondly, and relative to that is certificates<br>to foreign governments, those that don't have their own equivalent of an FDA that rely on FDA. FDA won't certify that. We believe<br>that that impact is minimal at this point. We're going through and assessing that to take a look at it. There is some details relative to<br>if it's already approved or asking for a new CFG. But those are typically the two areas that would impact.<br>
510k's are okay. And we will be able to continue shipping our existing products. Obviously, we're treating this very aggressively. We<br>want to be able to get all of these items addressed, and have the FDA come back in and inspect us and give us a clean bill of health.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>258</i><br>
<hr>
<A name=259></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Glenn Novarro</b><i> - RBC Capital Markets - Analyst</i><br>
Okay, thanks, Pete.<br>
<b>Operator</b><br>
(Operator Instructions) Steven Lichtman, Oppenheimer &amp; Co.<br>
<b>Steven Lichtman</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Just following up on the warning letter, I just want to make sure I understand where we're at when the back and forth with FDA,<br>because in the warning letter, FDA notes that some of your responses were not adequate. So, are the current remediation post that,<br>so now you're feeling like what you're doing is going to satisfy FDA, particularly after they talked about some not being adequate<br>in some of your responses?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Steven, it's Pete. Good question. I think, as all of you get a chance to look at the warning letter, comments on September responses<br>and things of that nature, and as we had told you actually in early November, we had done quite a bit of work month by month. And<br>so the Agency has had a chance to see some of that. The warning letter from our view potentially doesn't incorporate all of that<br>change that we had put in place. So, simple example would be, at the time of that response, the new roof for the whole facility wasn't<br>completed; that's completed now, as an example.<br>
So yes, we have advanced a lot of the different changes within the overall facility, and we believe that we've made substantial changes<br>since the initial component of that. That being said, we have to prove to the FDA that all of those are adequate, that we're in<br>compliance, but we've been aggressively working towards that plan. And again, one of the key points that we talked about, we<br>talked about structure changes and things of that nature, and we would have those completed by December, and have the clean<br>rooms throughout the facility all up and running. That was achieved on plan, and we are back up and running.<br>
<b>Steven Lichtman</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Great, that's helpful. Just -- I know it's typically tough, but any sense generally about when we'll see a reinspection in 2012?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Steven, I don't want to speculate. I mean we just -- we personally just received the letter not that long ago, even though the letter<br>was actually dated on the 21st.We really didn't receive it until multiple days later with the holidays.We've had correspondence with<br>the district office, but at this point, we really don't have a whole lot more to comment on relative to timing.<br>
<b>Steven Lichtman</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay, fair enough, thanks, Pete.<br>
<b>Operator</b><br>
Robert Goldman, CL King.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>259</i><br>
<hr>
<A name=260></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Robert Goldman</b><i> - CL King - Analyst</i><br>
Couple questions as well related to the quality control and the warning letter. Well, not a couple; we'll call it one. First, it's unclear<br>to me if the ongoing expenses on the quality control initiatives resulting from the 483 and the warning letter are in your non-GAAP<br>earnings, or if those are stripped out of the non-GAAP earnings? And then related to that, seems rational to me that you would need<br>to front load a bit to capital expenditure spending into 2012 to address these issues, so it would seem like free cash flow per share<br>should be well under earnings per share in 2012, but perhaps you could comment on that?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Bob, I'll turn it over to Jack to comment on those.<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
So, a couple of things. One, we are excluding expenses for remediation and underabsorption in the 105 plan. So, in that sense, we<br>are proposing to break those out, which puts the investor community in the position of analyzing our numbers how they see fit. We<br>do believe that both the out-of-pocket expense component and the underabsorption component is a short-term item, and won't<br>reflect the long-term performance of the Company. So, we break it out, and exclude it from the adjusted EPS.<br>
The second item is -- with regard to CapEx, there had been capital expenditure, mostly in Q4, for remediation of that plan. There<br>may have been a little in Q3 already -- have to go back and look. We do not now anticipate substantial incremental CapEx for this<br>purpose in that plan in Q1.There's always ongoing, but the main [bolus], the new roof and the construction inside the plant happened<br>all within Q4; and no, we don't have a broken out, granular number on that yet. That's part of the results that we need to finalize,<br>and we'll probably -- I'm sure we'll have that number if people want it on the February call.<br>
<b>Robert Goldman</b><i> - CL King - Analyst</i><br>
Okay, thank you very much.<br>
<b>Operator</b><br>
Charles Chon, Stifel.<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
Would you mind telling us how much Ascension Orthopedics and SeaSpine revenues contribute to the quarter?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Charles, we don't break those out. I think we've mentioned in the past that both of those, because of the level of integration that<br>we've done, we fundamentally don't have separate entities anymore. And so, we've actually cannibalized some product lines for the<br>benefit of others, and integrated those in, so the numbers separately really don't represent where the business is.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>260</i><br>
<hr>
<A name=261></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
Okay. Right. Well, please don't blame me for trying. What I'm trying to figure out here is, as I look into 2012 and the revenue growth<br>guidance that you've provided, by my estimate I'm thinking those acquisitions contribute somewhere on the order of incremental<br>4% or so, give or take. And so, that would mean that organic growth would be somewhere in that 4% range for 2012. And based on<br>my math, I think revenues may have declined year over year on an organic basis as core. So, I just was hoping that you could take<br>us through the businesses again to help us understand the building blocks of how we get to positive organic revenue growth in<br>2012. Thank you.<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Sure. Well, as far as your 2012 breakdown goes, Charles, at least at the consolidated level, it sounds like you're right on target. Of the<br>growth that we forecast for 2012, about 0.5 will come from the full-year effect of the SeaSpine and Ascension acquisitions. And about<br>0.5 will come from, shall we say, growth in the legacy business and so forth. And then we expect to have a negative headwind of<br>about 1% from currency effect. So, that's sort of the high level take on those numbers.<br>
Now, you might say, well, if you know how much is organic and how much is accretive -- or how much is incremental from the<br>existing business, why don't we give the break-out? The answer is, they are estimates for the reasons Pete described, where it's a<br>judgment call, the truth is -- they are integrated businesses, sales reps make choices about what products to sell and what not. So,<br>when we talk about next year, what we say is -- look, those were existing businesses that had certain performance last year, and this<br>is how you can kind of think about it, about 4% from the full-year effect, about 4% from growth in legacy, and then take away about<br>one all-in for currency effect, and that's about where we are.<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
Does your guidance, especially with respect to this legacy business, does your 2012 guidance contemplate these end markets, some<br>of the end markets as it relates to Spine, Extremity, actually experiencing a positive inflection point going forward?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
No, we're --.<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
And then on the Instrument side, I was just curious, should we anticipate that this inventory stocking issue could -- it's just more of<br>-- we should think of that as more of a one-quarter phenomenon as opposed to something that needs to be annualized before we<br>see positive inflection in that business as well?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Okay, so I'm going to take those in reverse order. On the Instruments side, yes, we believe that the Alternate Site underperformance<br>this quarter will resolve itself in the first half. We've actually seen this phenomenon before. And we saw a significant destocking in<br>Alternate Site in the first quarter of 2009. And it took about six months to sort of get fully back to normal. It seemed to be more rapid<br>this time, and it may mean that it will recover more quickly as a result. We do know from at-the-store sales data that our distributors<br>continue to sell our products about as expected. So, we don't think we've lost any share. So, overall, we think that business is<br>fundamentally sound.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>261</i><br>
<hr>
<A name=262></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
Now, as far as the end market assumptions go, we've made no dramatic assumptions about any of our end markets changing in any<br>fundamental way. We've seen a fair amount of pressure in Europe, especially in the countries that have become famous for having<br>economic issues. But that's -- I'd say we made no heroic assumptions about market expansion changes, macro conditions or anything<br>else.<br>
Just to remind the team, try to keep it to one question each.<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
Thank you.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Just to comment off Jack's point on the Instruments, again, our distributors made conscious decisions to actually reduce their overall<br>inventory levels, and then we actually see the data of what they're actually selling to end users, to doctors and customers. And so<br>we know that that end-user data hasn't fundamentally changed, that's why we know we haven't lost share. And they made conscious<br>decisions not to carry as much inventory, but they will need X level of inventory to meet their needs in the go-forward basis; that's<br>why we believe that the recovery, as Jack stated, will happen the way he outlined.<br>
<b>Operator</b><br>
Chris Pasquale, JPMorgan.<br>
<b>Chris Pasquale</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Neuro has probably been one of your more consistent business segments over the past year or two, so the shortfall there is somewhat<br>concerning. Can you talk a little bit more about what exactly happened in Asia, and whether the US weakness was just because of<br>capital equipment lumpiness or it was something more?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Yes, Chris, I mean, just from a standpoint of the overall Neuro business, it was down a little bit based upon our expectations, but the<br>capital market in 2010 was a very strong capital Q4 market for us. And so, we didn't have the same level of surge in that area. We<br>had some good Disposables response, so we don't see anything that says that there's any major changes there from that standpoint.<br>
As we look at Neuro in Asia, we commented that there was some certain areas with distributors based on timing and whatnot that<br>they didn't take the same level of product that they had normally taken from a standpoint of some of our capital equipment. But<br>again, I don't see any major longer-term effects. We are watching Europe quite a bit, particularly with the austerity measures. As you<br>know, many of the first things that get focused on and reduced are the amount of capital expenditures. And so, part of how we've<br>taken a look at Neuro in Europe going into 2012 is to make sure that we have a very realistic view of what that growth rate can be.<br>
<b>Chris Pasquale</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay. Are you seeing any incremental pricing pressure in the Neuro business?<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>262</i><br>
<hr>
<A name=263></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
I would just say at this point it's kind of too early to tell. At this point in time, we've had, as you know, we've spoken about in the past,<br>Neuro tends to be one of our areas that we've had stronger overall pricing in the amount of the product lines based on the differentiated<br>value they bring, as well as just the structure of the market. That being said, with a lot of the economic factors around the world,<br>there is definitely areas of the world where we're feeling more pressure than we have in the past. I don't think I could quantify it for<br>you though.<br>
<b>Chris Pasquale</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay, thanks.<br>
<b>Operator</b><br>
Jayson Bedford, Raymond James.<br>
<b>Jayson Bedford</b><i> - Raymond James &amp; Associates - Analyst</i><br>
Just to follow on the last question a little bit, in terms of the international weakness, it sounded like the fourth quarter hiccup was<br>more related to delayed product approvals in Asia-Pacific versus weakness in Europe. But just in terms of the commentary around<br>the 2012 guidance, the revisions seemed more related to Europe. So, can you just kind of reconcile what the issue is, and maybe<br>when you look at 2012, what geographies will grow? What may be flattish?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes. So, I'll give a little bit of a level, and then Jack, you may want to comment a little bit as well. And I think you understood it well,<br>I mean, what caused some of the changes in Q4 were as we highlighted in the comments relative to some of the product approvals<br>and such. As we look forward out into 2012, we're more cautious about our Europe overall expectations, clearly in what we're looking<br>for in our guidance. Some of the markets, such as traditional markets, such as Japan versus, say, China, we may be not as expecting<br>as much growth out as a mature market as Japan as we might have six months ago. Latin America and some of the other markets,<br>we see it still continuing actually aligned with our overall expectations. And then obviously there's the broader question of currency<br>with the strengthening of the overall dollar. But I think our main concern and focus is just ultimately where Europe is going to shape<br>up from a healthcare standpoint next year.<br>
Jack, I don't know if you want to add any color?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Yes, I mean, I think that the important thing to remember is, for us, international is in the area of 22%, 23% of revenue, about 0.5 is<br>Europe. And the rest is all over the place, which means that any given country, a pretty small decision can make a given country look<br>strong or weak in a quarter. The other two significant places where we have stand-alone direct business is outside of the US or, of<br>course, Australia and Canada, and they've done pretty well.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>263</i><br>
<hr>
<A name=264></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes. And I think, Jayson, to the point Jack's going is our biggest components in Europe are some of the markets within Spain and<br>Italy and such, where it's been tough. And so, we've been obviously expanding and we still have room to expand in other markets<br>and even traditional Europe as an example bring Spine new into Europe. But with that, we've wanted to actually be, I'll just say<br>conservative of how we think about ultimately how Europe is going to play out.<br>
<b>Jayson Bedford</b><i> - Raymond James &amp; Associates - Analyst</i><br>
Got you, thank you.<br>
<b>Operator</b><br>
Bob Hopkins, Bank of America.<br>
<b>Bob Hopkins</b><i> - BofA Merrill Lynch - Analyst</i><br>
So, just two really quick things. Just to wrap up on Extremity's, it sounds like the message from you guys is that, as far as you can tell,<br>especially on the metal side, you're not really seeing any change to market trends relative to what you saw last quarter? Is that a fair<br>representation?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
I think that's a fair representation.<br>
<b>Bob Hopkins</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay. And then on the Spine side, if you looked at it, at the business pro forma, assuming these acquisitions were fully in the numbers<br>in the year-ago period, not surprisingly, it doesn't look like that business is growing, again, especially on the metal side. So, I guess<br>my question is, how long do you think it will take before you can realize the growth goals within that Spine division, especially on<br>the hardware side that you had envisioned? And I ask the question just because historically when I look at the companies that have<br>tried to build through acquisitions in Spine, like BioMed and Zimmer, the process of integration and getting everything settled out<br>has taken a number of quarters, if not a well over a year before things settled out. So, within that context, I'm just curious as to your<br>expectations for when and how you can get that business to grow the way you want it to.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Bob, I think, a very good question. We take a look at it from a hardware and an Orthobiologic standpoint, two things. First of all,<br>to the point about getting the distribution structure settled, working cross-pollination, we really crossed that chasm in 2011, and<br>there was a significant amount of work that went into that. And we feel quite good about that structure. Just even, as you mentioned,<br>the cross-pollination of products from one business to the other to the distribution structure, the amount of capital outlay and how<br>we've done that, I think we've done that responsibly and we have a good structure in place.<br>
That being said, the market is where the market is, and so part of our overall expectations for 2012 are to be a little bit cautious<br>relative to the overall growth that we think is going to be achieved in Orthopedics, and keeping in mind that the majority of our<br>Spine business is heavily US weighted. As in the next few years, we're going to be growing outside. That being said, our Biologics<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>264</i><br>
<hr>
<A name=265></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
portfolio, which really adds, I think, quite a differentiator for us as other individual metal suppliers stand out there, is doing very<br>nicely. And between our demineralized bone products, our mosaic product, and the expansion of distributors that we've been able<br>to bring into it, we see that as a major component of our growth for Spine really in 2012. And really our hope and strategy, which<br>hasn't changed, is bringing those two together that we can bring differentiated value. All that being said though, we've tempered<br>some of our overall expectations in 2012 just based on how we see the market.<br>
Jack, I don't know if you would like to add any other comments?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
The only other thing I would just specifically say in response to Bob's point about some of the large Spine companies, the large<br>companies that have integrated Spine acquisitions is, they have typically had to terminate distributors and bring them into their<br>existing distributor network. In the case of this SeaSpine acquisition for us, there was very little overlap, and so we've had a few<br>places with sort of fights at the borderlands, but in general, it hasn't required the same kind of distributor bloodbath that you often<br>get when you see a big company acquire a smaller Spine company.<br>
<b>Bob Hopkins</b><i> - BofA Merrill Lynch - Analyst</i><br>
Great, thanks, guys.<br>
<b>Operator</b><br>
(Operator Instructions) Amit Bhalla, Citi.<br>
<b>Unidentified Participant</b><i> - - Analyst</i><br>
This is actually Adam in for Amit today. I just had a question on -- I know you talked about the miss really came from the last three<br>weeks in the quarter, but can you just talk about that level of deterioration? I mean, it's pretty significant when it moves your EPS<br>that much below guidance for the quarter, so I was just curious about that; could you add more color on that?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Let me address two points, which is, I'll address the top line, and then I'll address the guidance for Q4 adjusted EPS. On the top line,<br>the point about the surprise versus our internal expectations, if you will, the speed of the deterioration came from really these three<br>points we've identified. Half, or actually a bit more than half came from Instruments, and almost all of that was Alternate Site. That<br>was actually a few, call it, rifle shot decisions by big companies that we do business with. We could have -- in some circumstances,<br>probably given away economics and gotten some of those revenues, and we made a decision not to do that. So, that was a pretty<br>quick shortfall.<br>
The second impact, about a 0.25 of our internal disappointment was on international, and that was in, again, a few specific locations.<br>Also some systematic stuff in Europe, but a few specific locations. And the third was Extremity's, which we've talked about at length<br>on this call. So, that was the top line hit.<br>
Then as far as the adjusted EPS is concerned, there are people who have actually emailed in questions saying -- well, it seems that<br>the range for that is a little low given the top line miss, that there ought to have been some effect. And that's straightforward math.<br>We are mindful of the fact that at this very early stage in our financial reporting, to be very direct, there's a whole bunch of stuff we<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>265</i><br>
<hr>
<A name=266></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
have to finish doing, ranging from a lot of the end of the year testing, to the tax rate and so forth. And so we are being careful there.<br>That follows a quarter in which, on the one hand, we had a tremendous amount going on, the Ascension integration, the remediation<br>work, and a number of other initiatives. And at the same time, we were focusing hard on expenses because obviously once you<br>move past Thanksgiving, we begin to see that it was not shaping up into at least an excellent quarter.<br>
So, Pete, I don't know if you want to elaborate on some of that, but that's how we think of all of that.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, I mean, just two other points. Obviously we've been taking a hard look at our broader expenses; we'll continue to do so. I think<br>from a strategy standpoint, we'll talk more about that and some of our focus areas actually next week with different investors and<br>analysts. I think just to reinforce Jack's point on the quarter, the surprise piece, our Instruments business is half Alt Site, half Acute<br>Care -- Acute Care with Spine. Alt Site, to give you some relative statistics, 30% of the year in the last few years has come in the fourth<br>quarter, and a vast majority of that comes from distributors making buys really in the last three to four weeks. That didn't happen.<br>That's what really caused the surprise. Now one may ask themselves -- gee, is you're forecasting structure as adequate as it should<br>be to see that? And the answer is obviously, no, it's not. So, we're doing things to change that to get more visibility to make sure<br>that we understand it.<br>
<b>Unidentified Participant</b><i> - - Analyst</i><br>
All right, thank you very much.<br>
<b>Operator</b><br>
Matt Miksic, Piper Jaffray.<br>
<b>Matt Miksic</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Yes, I just wanted to follow-up on Spine. The questions that have come across, just wanted to make sure we're looking at this the<br>right way. With the market kind of flat, and the combined businesses, because of some of the rationalization mitigation you been<br>doing, I guess the way we've been looking at it is that business on a combined basis has actually been down year over year as we<br>kind of do the math to get to what we think organic growth could be next year. And where growth will settle out as you get through<br>the final quarter or two of having cross-pollinated and maybe swapped out some products from those two businesses and swapped<br>in some products. Does this settle into -- should we think about market growth for the remaining part of the year? Or putting aside<br>the integration, I'd love to get your sense as to what kind of account wins or action you're seeing in the market that would lead you<br>to believe that you're either going to grow with the market, tail end of next year, or you're going to be potentially in a position to<br>grow a bit better than the market? Thanks.<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Well, the mission -- this is Jack, I'll take part of it. And remind you of a couple items, and then I'm sure Pete will elaborate. So, I think<br>a couple of things. One, the Orthobiologics business is done particularly well, that's part of it. That may be the area where we have<br>the greatest edge. So, that's fully part of that business.<br>
Secondly, the mission of our Spine business is certainly to grow faster than the market. Now, whether that's fast enough, or what<br>that translates to is partly a function of the argument you have over what's happening in the market. But it is certainly the objective<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>266</i><br>
<hr>
<A name=267></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
of that group to grow faster than the market, and they are seeing that the cross-pollinization of these products are -- it's attractive<br>to the dealers involved. So, we are optimistic that we can hold our own and do better, but that's not by any means a foregone<br>conclusion.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Matt, I mean, the way I like to think about -- this is Pete -- is fundamentally, we have tempered our overall expectations for the<br>market for 2012. But we believe we can grow above it, I think mainly for one key reason. We had two separate distribution teams<br>that had two separate product lines, both of those product lines weren't fully adequate to meet all of the needs, even in the surgeons<br>that we're calling on, so they went to other products.We're already seeing, as we get the products cross-pollinated, that we're picking<br>up procedural growth with our current surgeons just because we can fill out the products that we have. Obviously on a go-forward<br>basis, beyond that, picking up new surgeons and growing beyond that is what we need to be able to prove to ourselves and show<br>that we can grow and take share more broadly. But that's how we kind of take a look at the share growth in 2012. And the fact that<br>we have our distribution structure settled, as well as our cross-pollination of our products well on their way, gives us confidence in<br>that area.<br>
<b>Matt Miksic</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Thanks, that's helpful.<br>
<b>Operator</b><br>
At this time, there are no further questions. I'd like to turn it back over to our speakers for any additional or closing remarks.<br>
<b>Angela Steinway</b><i> - Integra Lifesciences Holdings Corp - IR</i><br>
All right, thanks everyone for dialing in. We'll look forward to talking to you again in late February.<br>
<b>Operator</b><br>
And that does conclude today's conference. We thank everyone for their participation.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4701496-5-2012-01-09T06:58:20</b><br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>267</i><br>
<hr>
<A name=268></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
IART - INTEGRA LIFESCIENCES<br>CORPORATION CONFERENCE CALL TO<br>DISCUSS PRELIMINARY Q4 2011<br>FINANCIAL RESULTS<br>
EVENT DATE/TIME: JANUARY 06, 2012 / 1:30PM GMT<br>
OVERVIEW:<br>
IART expects 4Q11 total revenues of approx. $202-203m, GAAP diluted EPS of<br>$0.08-0.20, and adjusted diluted EPS of $0.65-0.70. Expects full-year 2011 GAAP<br>diluted EPS of $0.87-0.99, and adjusted diluted EPS of $2.74-2.79. Co. also expects<br>2012 reported revenues to increase approx. 8% on constant currency basis and 7%<br>in aggregate over 2011 final revenues, and 2012 adjusted EPS growth of approx.<br>8-9% over 2011.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>268</i><br>
<hr>
<A name=269></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Angela Steinway</b><i> Integra Lifesciences Holdings Corp - IR</i><br>
<b>Peter Arduini</b><i> Integra Lifesciences Holdings Corp - CEO</i><br>
<b>Jack Henneman</b><i> Integra Lifesciences Holdings Corp - CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Raj Denhoy</b><i> Jefferies &amp; Company - Analyst</i><br>
<b>David Lewis</b><i> Morgan Stanley - Analyst</i><br>
<b>Matt Miksic</b><i> Piper Jaffray &amp; Co. - Analyst</i><br>
<b>Glenn Novarro</b><i> RBC Capital Markets - Analyst</i><br>
<b>Steven Lichtman</b><i> Oppenheimer &amp; Co. - Analyst</i><br>
<b>Robert Goldman</b><i> CL King - Analyst</i><br>
<b>Charles Chon</b><i> Stifel Nicolaus - Analyst</i><br>
<b>Chris Pasquale</b><i> JPMorgan Chase &amp; Co. - Analyst</i><br>
<b>Jayson Bedford</b><i> Raymond James &amp; Associates - Analyst</i><br>
<b>Bob Hopkins</b><i> BofA Merrill Lynch - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Welcome to today's Integra LifeSciences fourth quarter 2011 update conference call. As a reminder today's call is being recorded. At this time I'd<br>like to turn the call over to Ms Angela Steinway, Head of Investor Relations. Please go ahead, ma'am.<br>
<b>Angela Steinway</b><i> - Integra Lifesciences Holdings Corp - IR</i><br>
Good morning and thank you for joining us for the Integra LifeSciences fourth quarter update call. Joining me today are -- Peter Arduini, Chief<br>Executive Officer; Jack Henneman, Chief Financial Officer; and Stuart Essig, Executive Chairman. Yesterday afternoon, we issued a press release<br>announcing certain preliminary fourth quarter and full-year financial results and announcing this conference call. Certain statements made during<br>this call are forward-looking and actual results might differ materially from those projected in any forward-looking statements. Additional information<br>concerning factors that could cause actual results to differ is contained in our periodic reports filed with the SEC. The forward-looking statements<br>are made only as of the date hereof and the Company undertakes no obligation to update or revise forward-looking statements. Certain non-GAAP<br>financial measures are disclosed in the press release and will be disclosed on this conference call. A reconciliation of these non-GAAP financial<br>measures is available on the Investors section of our website at Integralife.com. I will now turn the call over to Pete.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Thank you Angela, good morning.Yesterday afternoon we issued a press release announcing this conference call. Certain preliminary and estimated<br>financial results for the fourth quarter and full-year 2011 and certain preliminary guidance for 2012. Both the preliminary results and the revisions<br>to our 2012 preliminary guidance are below our prior estimates and Street expectations. We are announcing preliminary results and guidance<br>earlier than we ordinarily would so that we can have useful conversations with analysts and investors about our expected results between now<br>and the announcement of our audited 2011 results at the end of February, including meetings with investors next week. Jack will review the<br>preliminary results with more detail than in yesterday's release, and then I will discuss the trends in the business that drove the results and shape<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>269</i><br>
<hr>
<A name=270></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
our expectations for 2012. We also announced yesterday that we received the anticipated warning letter regarding our Plainsboro manufacturing<br>facility. I will also update you on our assessment of it and on the status of our Plainsboro manufacturing facility. At the end of the call we will take<br>your questions on these topics. Jack?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Thank you, Pete. We expect total revenues in the fourth quarter to be approximately $202 million to $203 million. The revenue shortfall resulted<br>from inventory reduction initiatives by our instruments distributors, weakness outside the US, and weaker than expected sales of our domestic<br>Extremity products.We expect adjusted diluted earnings per share to be in the range of $0.65 to $0.70 for the fourth quarter of 2011, and between<br>$2.74 to $2.79 for the full-year. We expect GAAP diluted earnings per share to be in the range of $0.08 to $0.20 for the fourth quarter of 2011, and<br>between $0.87 and $0.99 for the full-year 2011. At this stage in our close we have a pretty good sense of revenue but our process takes a few more<br>weeks for other items. Keep in mind these reports are preliminary and numbers are subject to change. We estimate that Orthopedics revenue,<br>which includes products sold to foot, hand, spine and orthopedic surgeons increased over the fourth quarter of 2010 by approximately 19%.<br>Extremity Reconstruction which is the largest component of our Orthopedics category grew in the low teens. Sales of legacy Foot and Ankle<br>products declined primarily because our sales force was devoting its attention to learning the Ascension product line and customer base. A process<br>that we believe will continue into the first quarter but resolved by Q2.<br>
Our Regenerative Medicine products sold through the Extremity sales force increased mid-single digits versus the prior-year period.The backorder<br>was below our previous estimates, but managing the backorder with customers took significant selling time away from legacy products. We also<br>expect these issues to resolve by the second quarter. The minutes in our domestic Extremity's products accounted for about 25% of our revenue<br>shortfall against our internal estimates. Spine sales increased significantly in the quarter driven by the SeaSpine acquisition. Both our Spine hardware<br>and Orthobiologic product lines grew by double digits compared to the prior-year period. Private label was roughly flat versus the prior-year period.<br>Neurosurgery revenues declined slightly in the fourth quarter. While Europe held to our expectations, delayed product registrations and weak<br>performance by one of our key distributors in Asia-Pacific caused most of the sales shortfall. In the United States, revenues were down slightly.<br>Sales of Neuro capital products were relatively light versus a strong performance in the fourth quarter of 2010 while sales of implants and neuro<br>critical care products grew well.<br>
Instrument revenue in the fourth quarter decreased approximately 10% compared to last year. Sales of Instruments in the acute care setting<br>decreased in the low single digits. Sales in the Alternate Site channel were substantially lower, due to lower stocking purchases. Several of Integra's<br>key distributor customers reduce their inventory levels.The miss in Alternate Site instruments accounted for more than 50% of the revenue shortfall<br>versus our internal estimates. Consolidated international revenue increased approximately 1% over prior-year. A combination of ongoing macro<br>challenges in Europe and delayed product registration approvals in Asia-Pacific cause the shortfall in the revenue performance for the fourth<br>quarter. The miss in international sales accounted for about 25% of the revenue shortfall against our internal estimates. We are not reporting<br>preliminary results for gross margin percentage, operating expenses by line item, tax rate or cash flow, all of which will be available when we report<br>our final 2011 results in late February. Now I'll turn the call back over to Pete.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Thank you, Jack. Obviously we're disappointed by the loss of momentum in our business in the last seven weeks of the quarter, particularly in the<br>last three weeks.Which are usually very strong for us.The biggest surprises for us came from the Instruments product lines particularly in Alternate<br>Site, the domestic Extremity's products and certain international markets.The Instruments product line under performed primarily because of the<br>major distributors that reduced the amount of inventory of our products that they typically carry at the end of the year. We know the Alternate<br>Site product line is fundamentally sound because the end-user sales data we have suggests our products are holding up well.<br>
The domestic Extremity products under performed on the top line compared to our expectations for two main reasons. First, while the Ascension<br>integration is proceeding according to plan, we underestimated the extent to which the integration activities would distract the sales force from<br>selling. Second, the reps spent more time than we expected managing through the Collagen product supply issues. These distractions adversely<br>affect sales of our legacy Extremity's products in the quarter. We expect that both issues will continue into the first quarter but will be resolved by<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>270</i><br>
<hr>
<A name=271></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
Q2. All of that said, the integration of Ascension is going well and we are more excited than ever about the potential of these products in our hands.<br>And finally we were disappointed with our results in the international markets.<br>
Now, switching over to talk about 2012 -- because of the slower revenue growth in the fourth quarter; the international challenges particularly in<br>Europe; the strengthening of the dollar; and slightly lower growth expectations for domestic Extremity's products, we are revising our view of 2012.<br>We expect reported revenues to in increase approximately 8% on a constant currency basis and 7% on in the aggregate over 2011 final revenues.<br>We expect to grow our adjusted earnings per share by approximately 8% to 9% over 2011. As Jack commented earlier, we will provide detailed<br>guidance regarding revenues by product category, gross margin, and expense lines with our full-year 2011 financial results in February. In spite of<br>the tough environment, we have numerous reasons to be optimistic about 2012 and beyond. Our Spine and Biologics products are well-positioned<br>with integrated sales organization, the Extremity's organization is trained in selling the Ascension products, and excited to have a new base of<br>surgeons and products. Our Neuro sales force has new products on tap for later in the year, and out the door sales of our Alternate Site Instruments<br>remain stable, as is our share. So we also expect revenues there to bounce back in 2012.<br>
Finally, we did receive a warning letter with respect to our Plainsboro facility. The letter is available as an exhibit to the 8-K we filed last night. And<br>you will see it contains no surprises. As we said in anticipation of it at our analyst day in November, we were already reacting to last summer's<br>inspection of our Plainsboro facility as if we had gotten a warning letter. And we continue to do so. Indeed our remediation of the facility has tracked<br>the schedule we outlined in November and all clean rooms were in production at the end of December.We now believe that our supply issues will<br>recede by the end of the first quarter, which will remove a major distraction for the Extremity sales force in particular. While I obviously wish I had<br>better financial news to deliver on my first call as Integra's CEO, my enthusiasm for Integra's future is undiminished. We have a great organization<br>that puts surgeons and patients first, unique products in Regenerative Medicine, Orthobiologics and Pyrocarbon implants, and are in businesses<br>that have opportunities to grow for years and years to come.<br>
I'll see many of you I'm sure in San Francisco next week, and we'll talk about Integra's growth prospects in more detail during my presentation at<br>the JPMorgan conference on Wednesday. Now I'll take your questions. In an effort to keep this call to a reasonable length, please do limit yourself<br>to one question and remember, that we will not provide final or detailed results for 2011 or detailed guidance for 2012 until the fourth quarter<br>earnings call in late February. Rejoin the queue if you have more questions. Operator, you may now turn the call over to our participants.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions) Raj Denhoy, Jefferies.<br>
<b>Raj Denhoy</b><i> - Jefferies &amp; Company - Analyst</i><br>
Maybe I can ask a bit about -- at the analyst meeting back in November here, you guys laid out a pretty detailed strategy for how you are going to<br>grow the Company going forward, and I think what we took away from that was international growth was probably the biggest opportunity from<br>a revenue standpoint. And then on the margin side, you were really looking for kind of the mix to Extremity's and Orthopedics broadly kind of<br>driving the margin expansion. And yet, in the third quarter and then here now in the fourth quarter, both of those things seem to have yet to really<br>materialize. International, as you mentioned, still weak. Extremity's weak for a number of reasons. But I'm curious whether what's going on here<br>has really caused you to kind of go back and reassess whether that strategy laid out is really the best one for growing the Company going forward?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Raj, thanks for the question. I think overall our strategy has not changed. I think when we take a look at our broader outlook, the points that<br>you made about our international opportunity -- as you know, it's over 77%, 75% of our overall growth is still domestic.We have a large opportunity,<br>and we're making good progress on registrations, infrastructure, our new office capabilities. So, when I take a look at, over our next three- to<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>271</i><br>
<hr>
<A name=272></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
five-year horizon, very, very solid from an international standpoint. Extremities, as you spoke of and as we mentioned at the investor conference,<br>relative to accretion really in Orthopedics bringing higher gross margin rates to the overall business, we still believe is there. The reality of it is<br>though our expectations for the growth that we thought we would have in Q4 didn't meet our expectations, and with that we've tempered our<br>2012 expectations because of that.<br>
Then Jack, if you'd like to add any comments?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Yes. I mean, I think that the main point around Extremities, just to pound the point home because we just said it in the script, is that we think we've<br>got specific rifle shot issues that are transitory. And we are, I think, doing everything we need to do on the Ascension integration, but moving sales<br>from a distributed sales force to a direct sales force requires a lot of training, a lot of attention, the absorption of a lot of knowledge.<br>
Similarly, we've been managing our supply issues out of the Plainsboro plant well, I think. The backorder came in well below the number we had<br>sort of put out there back in November. But I think the thing we didn't quite appreciate was how much time it would take the sales force to respond<br>to the needs of the customer by moving product around. We're trying to be realistic, and say we think that will continue into the first quarter. So,<br>that has also tempered our view of things. But overall, we think the business is healthy, the sales force is very excited by the Ascension opportunity.<br>We have unique material in the Pyrocarbon that is opening all kinds of new doors and exciting the existing doctors. So again, we believe this to be<br>temporary, not longer term, and hope that by the Summer, we are rocking.<br>
<b>Raj Denhoy</b><i> - Jefferies &amp; Company - Analyst</i><br>
Okay, good, thank you.<br>
<b>Operator</b><br>
David Lewis, Morgan Stanley.<br>
<b>David Lewis</b><i> - Morgan Stanley - Analyst</i><br>
Jack, just sort of walk through the rifle shot as it relates to Ascension -- I guess we were a little surprised that Ascension caused that kind of disruption.<br>I guess post the analyst day and heading into 2012, SeaSpine for example, we thought the cross-selling associated with that transaction was going<br>to be very, very important to Spine growth throughout 2012. I just wonder as we think about some of these integration-related disruptions in the<br>fourth quarter, how confident are you in sort of SeaSpine integration and no disruption to the Spine business broadly defined heading into 2012?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
David, it's Peter, I'll comment and then Jack, you can add some thoughts to that. I think where we are with the SeaSpine integration, we feel very<br>good that we've integrated the distributor structure. We're cross-pollinating our products; we've got a lot of systems in place and marketing<br>structure in place that took a good chunk in 2011. And so we had stable results really in Q4, and we see that continuing really into 2012.<br>
On the Extremity aside, remind you that we were actually integrating a distributor structure into a direct sales force as to combining two distributor<br>structures as we did in Spine. And some of that activity obviously now in retrospect is taking a little bit more time to get that integrated into our<br>direct team. That being said, our teams are well trained, as I mentioned, now, up to speed on those product lines, feeling good about the new<br>surgeon relationships that they have. And we believe obviously starting into the new year we'll be able to get some of that disruption behind us.<br>
Jack, you may want to --?<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>272</i><br>
<hr>
<A name=273></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
I think that's exactly right. I mean, when we look back over these two integrations, I'd say we think we're doing the right things in both cases. That<br>doesn't mean that we have perfectly anticipated what would happen to revenues in every circumstance, which is a question about anticipating<br>forecasting rather than actually executing. But the thing to bear in mind is that they are different in -- the integration of these distribution systems,<br>as Pete said, are different. One was SeaSpine, distributor to distributor where there was very little overlap, and indeed, most distributors in both<br>organizations were retained. In the Ascension side, we were terminating most, not all, but most of the distribution network, and moving those<br>sales to a direct sales force; that obviously causes more conflict. Overall, it held up pretty well. I'd say we should have anticipated more disruption<br>than we did.<br>
<b>David Lewis</b><i> - Morgan Stanley - Analyst</i><br>
Okay, thank you very much.<br>
<b>Operator</b><br>
Matt Miksic, Piper Jaffray.<br>
<b>Matt Miksic</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Just a follow-up, not to beat a dead horse here with Extremity's, but it's been up and down kind of throughout 2011. And it sounded like there<br>were some issues in the third quarter that weren't necessarily the same issues in the fourth quarter, specifically thinking of the training. And again<br>going back to the meeting coming off of the third quarter call and your analyst meeting, it sounded like some of the third quarter issues were<br>transitory. Can you give us some color in terms of the end market and maybe the availability of some of your Biologics, your Collagen products,<br>were those things that, all other things being equal, ex the distraction of your sales force, do you believe that the end market, the demand, the<br>volume was there and this was more of a sales distraction?<br>
And then second, if you could give some sense as to when -- you mentioned middle of the year or the Summer, is it going to be a couple of quarters?<br>Can we see an improvement in Q1? Any color on sort of timing would be helpful. Thanks.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Matt, it's Pete; I'll make some comments on it. Relative to the market and our growth, I mean we still believe that the market, as was mentioned<br>in Q3, had softened from, say, previous points in the first half of 2011. But we don't believe there's been any substantial changes in the market at<br>this point. Now, the fact is, we don't have a lot of other information from other folks reporting in with our reporting early, but we don't have any<br>indications that procedures have substantially changed or anything of that nature.<br>
From a Biologics standpoint and our proliferation of our product, that's advancing well within our Extremity's business. It also has done well within<br>our Spine business as well, just to mention. And so, the main focus is, as we mentioned, is the distraction relative to the two areas. The integration<br>components that we spoke to, and really, as we were actually tight on supply on a lot of the Regenerative products, in the fourth quarter matching<br>up the right level of products to the right customers, while the combination of training and while also doing the integration, we overestimated<br>the amount of burden it would put on the sales team. To your point about, into the new year, as Jack commented on, we believe that in Q2, we'll<br>be able to get this resolved and get it behind us.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>273</i><br>
<hr>
<A name=274></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Matt Miksic</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Thanks.<br>
<b>Operator</b><br>
Glenn Novarro, RBC Capital Markets.<br>
<b>Glenn Novarro</b><i> - RBC Capital Markets - Analyst</i><br>
You've clearly lost some market share as a result of sales force distraction. Are you saying to us that you expect that share to come right back by<br>the second quarter? I would imagine your competitors aren't just going to sit back and let you come right back into accounts and gain share back,<br>so maybe talk to us a little about your expectations for share recapture. Because it sounds to me like you're expecting the run rates to return back<br>to normal levels by 2Q? Thanks.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Glenn, from a standpoint of overall share, if you take a look at our broader businesses, we believe overall Neuro was in the round, our Spine<br>business was on track with the growth that we've had. And if you highlight the discussion on Instruments, which Jack commented on was our<br>biggest component of the miss, that ties with reduced levels of inventory. We know that that share is being consistent, so that we haven't had<br>share loss there. In Extremity's area, whether we have had loss from share in the mid foot, hind foot area, we don't necessarily have all of that data<br>yet. The key though is, is the integration of 20 new products, new coverage of surgeons and capability just of our new reach, we're going to be<br>able to pull back share. The question of -- is it the exact surgeons and things that we might have lost some cases to? Yet to be seen. But with the<br>opportunities of growth with bringing Ascension in to bring both of our products together, we feel confident that we'll be able to grow share.<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
The only thing I would add to that, Glenn, is, against our internal estimates, about two-thirds of our miss in Extremity's was Skin and Wound. And<br>that's a very different market. And we think we'll get that back. We have unique products there. It's really a different animal than the Orthopedics<br>hardware.<br>
<b>Glenn Novarro</b><i> - RBC Capital Markets - Analyst</i><br>
Actually, Jack, thanks. That's very good color.<br>
Can I just hit one more follow-up, just on the warning letter, it sounds like the warning letter is not going to cost the Company any more from an<br>expense point of view. Is that correct? And then second, usually when a company gets a warning letter, the FDA doesn't approve any more products<br>that would be pending at the FDA that would be made at that facility. Is that the case, and do you have any products pending approval that would<br>have been made by the facility in Plainsboro? Thanks.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Glenn, it's Pete. Let me just kind of remind you and remind everyone -- so, we received the 483 back in early Fall, late Summer. And on the call<br>and also at the investor day, we went through the details, and specifically talked about that we were treating this as severe as if we were going to<br>get a warning letter. And put a lot of the aggressive plans in place between facility updates, changes within structure, and such that we believe<br>currently with the warning letter that there really isn't a scope in the change of what the costs are to remediate. In fact, as I mentioned, we look at<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>274</i><br>
<hr>
<A name=275></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
what the observations are in the warning letter, and they match up well to the 483, which is aligned well with the plans that we already have in<br>place.<br>
Relative to what a warning letter means versus, say, a 483 as many of you know, PMA approvals are not approved until the warning letter is lifted.<br>We don't have any major products planned as far as for PMA launches right now within the 2012 window tied to that facility. And again, this is<br>specifically tied to the 105 facility; it doesn't affect other facilities. Secondly, and relative to that is certificates to foreign governments, those that<br>don't have their own equivalent of an FDA that rely on FDA. FDA won't certify that.We believe that that impact is minimal at this point.We're going<br>through and assessing that to take a look at it.There is some details relative to if it's already approved or asking for a new CFG. But those are typically<br>the two areas that would impact.<br>
510k's are okay. And we will be able to continue shipping our existing products. Obviously, we're treating this very aggressively. We want to be<br>able to get all of these items addressed, and have the FDA come back in and inspect us and give us a clean bill of health.<br>
<b>Glenn Novarro</b><i> - RBC Capital Markets - Analyst</i><br>
Okay, thanks, Pete.<br>
<b>Operator</b><br>
(Operator Instructions) Steven Lichtman, Oppenheimer &amp; Co.<br>
<b>Steven Lichtman</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Just following up on the warning letter, I just want to make sure I understand where we're at when the back and forth with FDA, because in the<br>warning letter, FDA notes that some of your responses were not adequate. So, are the current remediation post that, so now you're feeling like<br>what you're doing is going to satisfy FDA, particularly after they talked about some not being adequate in some of your responses?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Steven, it's Pete. Good question. I think, as all of you get a chance to look at the warning letter, comments on September responses and things of<br>that nature, and as we had told you actually in early November, we had done quite a bit of work month by month. And so the Agency has had a<br>chance to see some of that.The warning letter from our view potentially doesn't incorporate all of that change that we had put in place. So, simple<br>example would be, at the time of that response, the new roof for the whole facility wasn't completed; that's completed now, as an example.<br>
So yes, we have advanced a lot of the different changes within the overall facility, and we believe that we've made substantial changes since the<br>initial component of that. That being said, we have to prove to the FDA that all of those are adequate, that we're in compliance, but we've been<br>aggressively working towards that plan. And again, one of the key points that we talked about, we talked about structure changes and things of<br>that nature, and we would have those completed by December, and have the clean rooms throughout the facility all up and running. That was<br>achieved on plan, and we are back up and running.<br>
<b>Steven Lichtman</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Great, that's helpful. Just -- I know it's typically tough, but any sense generally about when we'll see a reinspection in 2012?<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>275</i><br>
<hr>
<A name=276></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Steven, I don't want to speculate. I mean we just -- we personally just received the letter not that long ago, even though the letter was actually<br>dated on the 21st. We really didn't receive it until multiple days later with the holidays. We've had correspondence with the district office, but at<br>this point, we really don't have a whole lot more to comment on relative to timing.<br>
<b>Steven Lichtman</b><i> - Oppenheimer &amp; Co. - Analyst</i><br>
Okay, fair enough, thanks, Pete.<br>
<b>Operator</b><br>
Robert Goldman, CL King.<br>
<b>Robert Goldman</b><i> - CL King - Analyst</i><br>
Couple questions as well related to the quality control and the warning letter. Well, not a couple; we'll call it one. First, it's unclear to me if the<br>ongoing expenses on the quality control initiatives resulting from the 483 and the warning letter are in your non-GAAP earnings, or if those are<br>stripped out of the non-GAAP earnings? And then related to that, seems rational to me that you would need to front load a bit to capital expenditure<br>spending into 2012 to address these issues, so it would seem like free cash flow per share should be well under earnings per share in 2012, but<br>perhaps you could comment on that?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Bob, I'll turn it over to Jack to comment on those.<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
So, a couple of things. One, we are excluding expenses for remediation and underabsorption in the 105 plan. So, in that sense, we are proposing<br>to break those out, which puts the investor community in the position of analyzing our numbers how they see fit. We do believe that both the<br>out-of-pocket expense component and the underabsorption component is a short-term item, and won't reflect the long-term performance of the<br>Company. So, we break it out, and exclude it from the adjusted EPS.<br>
The second item is -- with regard to CapEx, there had been capital expenditure, mostly in Q4, for remediation of that plan. There may have been a<br>little in Q3 already -- have to go back and look. We do not now anticipate substantial incremental CapEx for this purpose in that plan in Q1. There's<br>always ongoing, but the main [bolus], the new roof and the construction inside the plant happened all within Q4; and no, we don't have a broken<br>out, granular number on that yet. That's part of the results that we need to finalize, and we'll probably -- I'm sure we'll have that number if people<br>want it on the February call.<br>
<b>Robert Goldman</b><i> - CL King - Analyst</i><br>
Okay, thank you very much.<br>
<b>Operator</b><br>
Charles Chon, Stifel.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>276</i><br>
<hr>
<A name=277></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
Would you mind telling us how much Ascension Orthopedics and SeaSpine revenues contribute to the quarter?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Charles, we don't break those out. I think we've mentioned in the past that both of those, because of the level of integration that we've done, we<br>fundamentally don't have separate entities anymore. And so, we've actually cannibalized some product lines for the benefit of others, and integrated<br>those in, so the numbers separately really don't represent where the business is.<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
Okay. Right. Well, please don't blame me for trying. What I'm trying to figure out here is, as I look into 2012 and the revenue growth guidance that<br>you've provided, by my estimate I'm thinking those acquisitions contribute somewhere on the order of incremental 4% or so, give or take. And so,<br>that would mean that organic growth would be somewhere in that 4% range for 2012. And based on my math, I think revenues may have declined<br>year over year on an organic basis as core. So, I just was hoping that you could take us through the businesses again to help us understand the<br>building blocks of how we get to positive organic revenue growth in 2012. Thank you.<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Sure. Well, as far as your 2012 breakdown goes, Charles, at least at the consolidated level, it sounds like you're right on target. Of the growth that<br>we forecast for 2012, about 0.5 will come from the full-year effect of the SeaSpine and Ascension acquisitions. And about 0.5 will come from, shall<br>we say, growth in the legacy business and so forth. And then we expect to have a negative headwind of about 1% from currency effect. So, that's<br>sort of the high level take on those numbers.<br>
Now, you might say, well, if you know how much is organic and how much is accretive -- or how much is incremental from the existing business,<br>why don't we give the break-out? The answer is, they are estimates for the reasons Pete described, where it's a judgment call, the truth is -- they<br>are integrated businesses, sales reps make choices about what products to sell and what not. So, when we talk about next year, what we say is --<br>look, those were existing businesses that had certain performance last year, and this is how you can kind of think about it, about 4% from the<br>full-year effect, about 4% from growth in legacy, and then take away about one all-in for currency effect, and that's about where we are.<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
Does your guidance, especially with respect to this legacy business, does your 2012 guidance contemplate these end markets, some of the end<br>markets as it relates to Spine, Extremity, actually experiencing a positive inflection point going forward?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
No, we're --.<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
And then on the Instrument side, I was just curious, should we anticipate that this inventory stocking issue could -- it's just more of -- we should<br>think of that as more of a one-quarter phenomenon as opposed to something that needs to be annualized before we see positive inflection in that<br>business as well?<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>277</i><br>
<hr>
<A name=278></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Okay, so I'm going to take those in reverse order. On the Instruments side, yes, we believe that the Alternate Site underperformance this quarter<br>will resolve itself in the first half. We've actually seen this phenomenon before. And we saw a significant destocking in Alternate Site in the first<br>quarter of 2009. And it took about six months to sort of get fully back to normal. It seemed to be more rapid this time, and it may mean that it will<br>recover more quickly as a result. We do know from at-the-store sales data that our distributors continue to sell our products about as expected.<br>So, we don't think we've lost any share. So, overall, we think that business is fundamentally sound.<br>
Now, as far as the end market assumptions go, we've made no dramatic assumptions about any of our end markets changing in any fundamental<br>way. We've seen a fair amount of pressure in Europe, especially in the countries that have become famous for having economic issues. But that's<br>-- I'd say we made no heroic assumptions about market expansion changes, macro conditions or anything else.<br>
Just to remind the team, try to keep it to one question each.<br>
<b>Charles Chon</b><i> - Stifel Nicolaus - Analyst</i><br>
Thank you.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Just to comment off Jack's point on the Instruments, again, our distributors made conscious decisions to actually reduce their overall inventory<br>levels, and then we actually see the data of what they're actually selling to end users, to doctors and customers. And so we know that that end-user<br>data hasn't fundamentally changed, that's why we know we haven't lost share. And they made conscious decisions not to carry as much inventory,<br>but they will need X level of inventory to meet their needs in the go-forward basis; that's why we believe that the recovery, as Jack stated, will<br>happen the way he outlined.<br>
<b>Operator</b><br>
Chris Pasquale, JPMorgan.<br>
<b>Chris Pasquale</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Neuro has probably been one of your more consistent business segments over the past year or two, so the shortfall there is somewhat concerning.<br>Can you talk a little bit more about what exactly happened in Asia, and whether the US weakness was just because of capital equipment lumpiness<br>or it was something more?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Yes, Chris, I mean, just from a standpoint of the overall Neuro business, it was down a little bit based upon our expectations, but the capital market<br>in 2010 was a very strong capital Q4 market for us. And so, we didn't have the same level of surge in that area. We had some good Disposables<br>response, so we don't see anything that says that there's any major changes there from that standpoint.<br>
As we look at Neuro in Asia, we commented that there was some certain areas with distributors based on timing and whatnot that they didn't take<br>the same level of product that they had normally taken from a standpoint of some of our capital equipment. But again, I don't see any major<br>longer-term effects. We are watching Europe quite a bit, particularly with the austerity measures. As you know, many of the first things that get<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>278</i><br>
<hr>
<A name=279></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
focused on and reduced are the amount of capital expenditures. And so, part of how we've taken a look at Neuro in Europe going into 2012 is to<br>make sure that we have a very realistic view of what that growth rate can be.<br>
<b>Chris Pasquale</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay. Are you seeing any incremental pricing pressure in the Neuro business?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
I would just say at this point it's kind of too early to tell. At this point in time, we've had, as you know, we've spoken about in the past, Neuro tends<br>to be one of our areas that we've had stronger overall pricing in the amount of the product lines based on the differentiated value they bring, as<br>well as just the structure of the market. That being said, with a lot of the economic factors around the world, there is definitely areas of the world<br>where we're feeling more pressure than we have in the past. I don't think I could quantify it for you though.<br>
<b>Chris Pasquale</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay, thanks.<br>
<b>Operator</b><br>
Jayson Bedford, Raymond James.<br>
<b>Jayson Bedford</b><i> - Raymond James &amp; Associates - Analyst</i><br>
Just to follow on the last question a little bit, in terms of the international weakness, it sounded like the fourth quarter hiccup was more related to<br>delayed product approvals in Asia-Pacific versus weakness in Europe. But just in terms of the commentary around the 2012 guidance, the revisions<br>seemed more related to Europe. So, can you just kind of reconcile what the issue is, and maybe when you look at 2012, what geographies will<br>grow? What may be flattish?<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes. So, I'll give a little bit of a level, and then Jack, you may want to comment a little bit as well. And I think you understood it well, I mean, what<br>caused some of the changes in Q4 were as we highlighted in the comments relative to some of the product approvals and such. As we look forward<br>out into 2012, we're more cautious about our Europe overall expectations, clearly in what we're looking for in our guidance. Some of the markets,<br>such as traditional markets, such as Japan versus, say, China, we may be not as expecting as much growth out as a mature market as Japan as we<br>might have six months ago. Latin America and some of the other markets, we see it still continuing actually aligned with our overall expectations.<br>And then obviously there's the broader question of currency with the strengthening of the overall dollar. But I think our main concern and focus<br>is just ultimately where Europe is going to shape up from a healthcare standpoint next year.<br>
Jack, I don't know if you want to add any color?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Yes, I mean, I think that the important thing to remember is, for us, international is in the area of 22%, 23% of revenue, about 0.5 is Europe. And<br>the rest is all over the place, which means that any given country, a pretty small decision can make a given country look strong or weak in a quarter.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>279</i><br>
<hr>
<A name=280></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
The other two significant places where we have stand-alone direct business is outside of the US or, of course, Australia and Canada, and they've<br>done pretty well.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes. And I think, Jayson, to the point Jack's going is our biggest components in Europe are some of the markets within Spain and Italy and such,<br>where it's been tough. And so, we've been obviously expanding and we still have room to expand in other markets and even traditional Europe<br>as an example bring Spine new into Europe. But with that, we've wanted to actually be, I'll just say conservative of how we think about ultimately<br>how Europe is going to play out.<br>
<b>Jayson Bedford</b><i> - Raymond James &amp; Associates - Analyst</i><br>
Got you, thank you.<br>
<b>Operator</b><br>
Bob Hopkins, Bank of America.<br>
<b>Bob Hopkins</b><i> - BofA Merrill Lynch - Analyst</i><br>
So, just two really quick things. Just to wrap up on Extremity's, it sounds like the message from you guys is that, as far as you can tell, especially on<br>the metal side, you're not really seeing any change to market trends relative to what you saw last quarter? Is that a fair representation?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
I think that's a fair representation.<br>
<b>Bob Hopkins</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay. And then on the Spine side, if you looked at it, at the business pro forma, assuming these acquisitions were fully in the numbers in the year-ago<br>period, not surprisingly, it doesn't look like that business is growing, again, especially on the metal side. So, I guess my question is, how long do<br>you think it will take before you can realize the growth goals within that Spine division, especially on the hardware side that you had envisioned?<br>And I ask the question just because historically when I look at the companies that have tried to build through acquisitions in Spine, like BioMed<br>and Zimmer, the process of integration and getting everything settled out has taken a number of quarters, if not a well over a year before things<br>settled out. So, within that context, I'm just curious as to your expectations for when and how you can get that business to grow the way you want<br>it to.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Bob, I think, a very good question. We take a look at it from a hardware and an Orthobiologic standpoint, two things. First of all, to the point<br>about getting the distribution structure settled, working cross-pollination, we really crossed that chasm in 2011, and there was a significant amount<br>of work that went into that. And we feel quite good about that structure. Just even, as you mentioned, the cross-pollination of products from one<br>business to the other to the distribution structure, the amount of capital outlay and how we've done that, I think we've done that responsibly and<br>we have a good structure in place.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>280</i><br>
<hr>
<A name=281></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
That being said, the market is where the market is, and so part of our overall expectations for 2012 are to be a little bit cautious relative to the<br>overall growth that we think is going to be achieved in Orthopedics, and keeping in mind that the majority of our Spine business is heavily US<br>weighted. As in the next few years, we're going to be growing outside. That being said, our Biologics portfolio, which really adds, I think, quite a<br>differentiator for us as other individual metal suppliers stand out there, is doing very nicely. And between our demineralized bone products, our<br>mosaic product, and the expansion of distributors that we've been able to bring into it, we see that as a major component of our growth for Spine<br>really in 2012. And really our hope and strategy, which hasn't changed, is bringing those two together that we can bring differentiated value. All<br>that being said though, we've tempered some of our overall expectations in 2012 just based on how we see the market.<br>
Jack, I don't know if you would like to add any other comments?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
The only other thing I would just specifically say in response to Bob's point about some of the large Spine companies, the large companies that<br>have integrated Spine acquisitions is, they have typically had to terminate distributors and bring them into their existing distributor network. In<br>the case of this SeaSpine acquisition for us, there was very little overlap, and so we've had a few places with sort of fights at the borderlands, but<br>in general, it hasn't required the same kind of distributor bloodbath that you often get when you see a big company acquire a smaller Spine<br>company.<br>
<b>Bob Hopkins</b><i> - BofA Merrill Lynch - Analyst</i><br>
Great, thanks, guys.<br>
<b>Operator</b><br>
(Operator Instructions) Amit Bhalla, Citi.<br>
<b>Unidentified Participant</b><i> - - Analyst</i><br>
This is actually Adam in for Amit today. I just had a question on -- I know you talked about the miss really came from the last three weeks in the<br>quarter, but can you just talk about that level of deterioration? I mean, it's pretty significant when it moves your EPS that much below guidance<br>for the quarter, so I was just curious about that; could you add more color on that?<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Let me address two points, which is, I'll address the top line, and then I'll address the guidance for Q4 adjusted EPS. On the top line, the point about<br>the surprise versus our internal expectations, if you will, the speed of the deterioration came from really these three points we've identified. Half,<br>or actually a bit more than half came from Instruments, and almost all of that was Alternate Site. That was actually a few, call it, rifle shot decisions<br>by big companies that we do business with. We could have -- in some circumstances, probably given away economics and gotten some of those<br>revenues, and we made a decision not to do that. So, that was a pretty quick shortfall.<br>
The second impact, about a 0.25 of our internal disappointment was on international, and that was in, again, a few specific locations. Also some<br>systematic stuff in Europe, but a few specific locations. And the third was Extremity's, which we've talked about at length on this call. So, that was<br>the top line hit.<br>
Then as far as the adjusted EPS is concerned, there are people who have actually emailed in questions saying -- well, it seems that the range for<br>that is a little low given the top line miss, that there ought to have been some effect. And that's straightforward math. We are mindful of the fact<br>that at this very early stage in our financial reporting, to be very direct, there's a whole bunch of stuff we have to finish doing, ranging from a lot<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>281</i><br>
<hr>
<A name=282></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
of the end of the year testing, to the tax rate and so forth. And so we are being careful there. That follows a quarter in which, on the one hand, we<br>had a tremendous amount going on, the Ascension integration, the remediation work, and a number of other initiatives. And at the same time,<br>we were focusing hard on expenses because obviously once you move past Thanksgiving, we begin to see that it was not shaping up into at least<br>an excellent quarter.<br>
So, Pete, I don't know if you want to elaborate on some of that, but that's how we think of all of that.<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, I mean, just two other points. Obviously we've been taking a hard look at our broader expenses; we'll continue to do so. I think from a strategy<br>standpoint, we'll talk more about that and some of our focus areas actually next week with different investors and analysts. I think just to reinforce<br>Jack's point on the quarter, the surprise piece, our Instruments business is half Alt Site, half Acute Care -- Acute Care with Spine. Alt Site, to give<br>you some relative statistics, 30% of the year in the last few years has come in the fourth quarter, and a vast majority of that comes from distributors<br>making buys really in the last three to four weeks. That didn't happen. That's what really caused the surprise. Now one may ask themselves -- gee,<br>is you're forecasting structure as adequate as it should be to see that? And the answer is obviously, no, it's not. So, we're doing things to change<br>that to get more visibility to make sure that we understand it.<br>
<b>Unidentified Participant</b><i> - - Analyst</i><br>
All right, thank you very much.<br>
<b>Operator</b><br>
Matt Miksic, Piper Jaffray.<br>
<b>Matt Miksic</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Yes, I just wanted to follow-up on Spine. The questions that have come across, just wanted to make sure we're looking at this the right way. With<br>the market kind of flat, and the combined businesses, because of some of the rationalization mitigation you been doing, I guess the way we've<br>been looking at it is that business on a combined basis has actually been down year over year as we kind of do the math to get to what we think<br>organic growth could be next year. And where growth will settle out as you get through the final quarter or two of having cross-pollinated and<br>maybe swapped out some products from those two businesses and swapped in some products. Does this settle into -- should we think about<br>market growth for the remaining part of the year? Or putting aside the integration, I'd love to get your sense as to what kind of account wins or<br>action you're seeing in the market that would lead you to believe that you're either going to grow with the market, tail end of next year, or you're<br>going to be potentially in a position to grow a bit better than the market? Thanks.<br>
<b>Jack Henneman</b><i> - Integra Lifesciences Holdings Corp - CFO</i><br>
Well, the mission -- this is Jack, I'll take part of it. And remind you of a couple items, and then I'm sure Pete will elaborate. So, I think a couple of<br>things. One, the Orthobiologics business is done particularly well, that's part of it.That may be the area where we have the greatest edge. So, that's<br>fully part of that business.<br>
Secondly, the mission of our Spine business is certainly to grow faster than the market. Now, whether that's fast enough, or what that translates<br>to is partly a function of the argument you have over what's happening in the market. But it is certainly the objective of that group to grow faster<br>than the market, and they are seeing that the cross-pollinization of these products are -- it's attractive to the dealers involved. So, we are optimistic<br>that we can hold our own and do better, but that's not by any means a foregone conclusion.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>282</i><br>
<hr>
<A name=283></a>JANUARY 06, 2012 / 1:30PM, IART - Integra LifeSciences Corporation Conference Call To Discuss Preliminary<br>Q4 2011 Financial Results<br>
<b>Peter Arduini</b><i> - Integra Lifesciences Holdings Corp - CEO</i><br>
Yes, Matt, I mean, the way I like to think about -- this is Pete -- is fundamentally, we have tempered our overall expectations for the market for 2012.<br>But we believe we can grow above it, I think mainly for one key reason. We had two separate distribution teams that had two separate product<br>lines, both of those product lines weren't fully adequate to meet all of the needs, even in the surgeons that we're calling on, so they went to other<br>products. We're already seeing, as we get the products cross-pollinated, that we're picking up procedural growth with our current surgeons just<br>because we can fill out the products that we have. Obviously on a go-forward basis, beyond that, picking up new surgeons and growing beyond<br>that is what we need to be able to prove to ourselves and show that we can grow and take share more broadly. But that's how we kind of take a<br>look at the share growth in 2012. And the fact that we have our distribution structure settled, as well as our cross-pollination of our products well<br>on their way, gives us confidence in that area.<br>
<b>Matt Miksic</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Thanks, that's helpful.<br>
<b>Operator</b><br>
At this time, there are no further questions. I'd like to turn it back over to our speakers for any additional or closing remarks.<br>
<b>Angela Steinway</b><i> - Integra Lifesciences Holdings Corp - IR</i><br>
All right, thanks everyone for dialing in. We'll look forward to talking to you again in late February.<br>
<b>Operator</b><br>
And that does conclude today's conference. We thank everyone for their participation.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4701496-2012-01-09T06:58:20</b><br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>283</i><br>
<hr>
<A name=284></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
DRRX - DURECT CORP TO DISCUSS<br>POSIDUR CLINICAL TRIAL RESULTS<br>
EVENT DATE/TIME: JANUARY 06, 2012 / 1:30PM GMT<br>
OVERVIEW:<br>
Co. reported POSIDUR clinical trial results.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>284</i><br>
<hr>
<A name=285></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Matt Hogan</b><i> DURECT Corporation - CFO</i><br>
<b>Jim Brown</b><i> DURECT Corporation - President &amp; CEO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Robert Manning</b><i> - Analyst</i><br>
<b>Barrie Zesiger</b><i> Zesiger Capital Group LLC - Analyst</i><br>
<b>Walter Schenker </b><i>Titan Capital Management - Analyst</i><br>
<b>OVERVIEW</b><br>
Co. reported POSIDUR clinical trial results.<br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. TRIAL RESULTS UPDATE (J.B.)</b><br>
<b>A. Highlights:</b><br>
<b>1. </b>Results in BESST trended positive for pain reduction and opioid-sparing.<br>
<b>a. </b>Did not reach statistical significance for co-primary endpoint.<br><b>b. </b>Has more analysis to perform.<br>
<b>2. </b>POSIDUR appears to be safe; strong reduction in pain in all three cohorts.<br><b>3. </b>BESST trial provides additional safety information sought by FDA.<br>
<b>a. </b>An efficacy study in older and sicker patients with larger wounds.<br><b>b. </b>300-patient study with extensive cardiac (indiscernible).<br>
<b>4. </b>Strong evidence of efficacy in previous shoulder and hernia trials.<br><b>5. </b>Plans to combine data from these two models together with BESST which gives experience from variety of abdominal<br>
surgeries to demonstrate safety and effectiveness of POSIDUR in controlling post-operative pain.<br>
<b>6. </b>Has to complete analysis of BESST data and combine results with previous well controlled studies into integrated safety<br>
and efficacy reports that will lead to a pre-NDA meeting with the FDA.<br>
<b>B. BESST Design:</b><br>
<b>1. </b>Designed to test POSIDUR in variety of settings:<br>
<b>a. </b>Larger wound lengths.<br><b>b. </b>More serious surgical procedures.<br>
<b>c. </b>With older, sicker population of patients.<br>
<b>2. </b>Consisted of three cohorts of patients undergoing different, general, abdominal surgical procedures.<br>
<b>a. </b>In Cohort 1, 48 laparotomy patients were randomized to receive either POSIDUR or Bupivacaine solution (an active<br>
comparator).<br>
<b>i. </b>Laparotomies are large incisions across the abdominal wall typically used to access an organ for removal or for cancer<br>
staging.<br>
<b>b. </b>In Cohort 2, 50 patients were randomized to receive either POSIDUR or Bupivacaine solution after laparoscopic removal<br>
of gallbladder.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>285</i><br>
<hr>
<A name=286></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>c. </b>In Cohort 3, 207 patients were randomized to receive either POSIDUR or placebo after laparoscopically-assisted colectomy.<br>
<b>i. </b>These procedures typically involve removal of part of large intestine due to cancer or diverticulitis.<br>
<b>C. Efficacy:</b><br>
<b>1. </b>For Cohort 3 with respect to pain intensity endpoint, received two reported outcomes:<br>
<b>a. </b>7% reduction in pain and p value of 0.1466.<br><b>b. </b>10% reduction in pain intensity and p value of 0.0410.<br>
<b>2. </b>First figure based on combination of two data sets collected:<br>
<b>a. </b>Pain intensity on movement scores.<br><b>b. </b>Pain intensity recorded at the time a patient took supplemental opioids.<br>
<b>3. </b>In first set of data, pain intensity on movement scores were collected at scheduled time points over first three days of<br>
recovery period after surgery.<br>
<b>a. </b>Patients were asked to sit up in bed and record pain scores.<br>
<b>i. </b>Helps delineate incisional pain from any non-incisional pain.<br>
<b>4. </b>Second data set included in 7% figure was collected at unscheduled time points whenever a patient requested supplemental<br>
opioids.<br>
<b>a. </b>Patients in these data points did not do a sit-up that would help differentiate incisional pain from non-incisional pain.<br><b>b. </b>Combination of pain intensity scores gives 7% reduction.<br>
<b>c. </b>Looking at only incisional pain and scheduled pain scores after the sit-up, saw about 10% reduction in pain intensity and<br>
a p value below 0.05.<br>
<b>d. </b>Second pain intensity score is a pre-specified sensitivity analysis in statistical analysis plan.<br><b>e. </b>Having a p value below 0.05 is not statistically significant in the context of BESST because Co. was not statistically significant<br>
on the other primary endpoint which was opioid-sparing.<br>
<b>5. </b>Believes it is important to understand the distinction between incisional pain and non-incisional pain intensity measured<br>
in this pain model.<br>
<b>a. </b>It would have been a statistically significant signal if reduction in incisional pain had been the sole primary endpoint.<br>
<b>6. </b>With respect to reduction in supplemental opioid use in Cohort 3, the other co-primary endpoint, POSIDUR patients used<br>
approx. 16% fewer opioids than the placebo group but the difference was not statistically significant in this cohort for this<br>number of patients.<br>
<b>7. </b>With respect to Cohorts 1 and 2, in order to increase statistical power of these smaller cohorts, the SAP (Statistical Analysis<br>
Plan) called for pooling of these two groups.<br>
<b>a. </b>This was a secondary efficacy endpoint.<br><b>b. </b>For Cohorts 1 and 2 combined, POSIDUR patients experienced approx. 20% reduction in pain intensity as measured by<br>
pain on movement combined with pain at time of taking supplemental opioids or that same measurement described in<br>Cohort 3 as being a 7% reduction.<br>
<b>i. </b>Done in comparison to an active comparator control of Bupivacaine hydrochloride.<br>
<b>ii. </b>Statistically significant with a p value of 0.011.<br>
<b>iii. </b>Interesting result when considering this against an active comparator.<br>
<b>8. </b>All patients were provided supplemental opioids as needed and in these Cohorts 1 and 2 the POSIDUR patients took approx.<br>
18% pure opioids as compared to the active comparator group.<br>
<b>a. </b>Data not statistically significant.<br>
<b>9. </b>Did not meet primary endpoints but reduced incisional pain by about 10% in Cohort 3 and pain on movement for SAP by<br>
about 20% in combined Cohorts 1 and 2 which was a statistically significant secondary endpoint.<br>
<b>10. </b>Saw reductions in opioid use of 16-18%; results not statistically significant.<br>
<b>D. Safety:</b><br>
<b>1. </b>Safety population in BESST consisted of 305 subjects.<br><b>2. </b>POSIDUR patient group showed similar systemic safety profile as patient groups treated with SABER-Placebo, an active<br>
comparator.<br>
<b>3. </b>No signs of systemic safety issues.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>286</i><br>
<hr>
<A name=287></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>4. </b>Local site reactions observed more frequently in POSIDUR and SABER-Placebo groups than in active comparator groups.<br><b>5. </b>Most of these observations were discolorations, the majority of which resolved without treatment during trial.<br><b>6. </b>No negative safety signal was seen in initial cardiac and neurologic safety assessment in BESST; additional analysis is<br>
underway.<br>
<b>7. </b>To review overall program from safety standpoint, dosed total of over 1,075 patients in clinical trials of which over 680<br>
patients received POSIDUR.<br>
<b>E. Future Plans:</b><br>
<b>1. </b>There is still a lot of data from BESST to be analyzed.<br><b>2. </b>Intends to pull together an integrated safety and efficacy report that will tie together the entire body work done with<br>
POSIDUR to date.<br>
<b>3. </b>Plans to hold pre-NDA meeting with the FDA; believes this meeting can happen by mid-year.<br>
<b>a. </b>Believes overall program shows positive risk benefit profile for POSIDUR and supports an NDA submission.<br><b>b. </b>Does not have full reports for BESST yet in hand; at this point does not see any systemic safety issues.<br>
<b>4. </b>Bupivacaine is a well-established agent with a long history of use.<br><b>5. </b>Efficacy:<br>
<b>a. </b>Shown in multiple models evidence of reduction in pain scores over three full days.<br><b>b. </b>Has proven incisional pain in Cohort 3 when only this true pain on movement score was analyzed.<br>
<b>c. </b>Has statistically significant improvement in pain scores in Cohorts 1 and 2 pooled against Bupivacaine active comparator.<br>
<b>d. </b>Has statistically significant improvement in pain scores in earlier hernia trial and in latest shoulder surgery model.<br><b>e. </b>Has shown in multiple models and studies where Co. saw a numerical superiority with respect to reduction in opioid use<br>
after surgery.<br>
<b>f. </b>In a hernia trial this was over a three-fold reduction and with a p value below 0.02.<br>
<b>g. </b>While Co. might be pursuing an approval on basis of pain reduction, this opioid reduction may contribute to overall risk<br>
benefit analysis for POSIDUR.<br>
<b>6. </b>This body of evidence in multiple surgical models is compelling and may be the basis of a possible approval.<br>
<b>a. </b>Needs to explore this with the FDA.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
Thank you. (Operator Instructions) Robert Manning.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
My question -- these results are obviously a little disappointing, but I have always looked at this as the icing on the Remoxy cake.<br>Any developments in Remoxy since the kind of positive comments that came out of Pfizer in early November?<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Nothing new since Pfizer has made those comments, but we continue to work with them and continue to make progress. But I think<br>I would like to emphasize, although we are disappointed about the two co-primary endpoints, the fact is that we think there is still<br>a nice opportunity for POSIDUR. We have the very nice efficacy and opioid sparing results, particularly from our hernia trial, as well<br>as our shoulder study.We have the other data that you have seen here -- the incisional pain for Cohort 3 and Cohorts 1 and 2, where<br>we had a very nice pain signal, as well.We think that, plus all of the safety information, will give us a nice opportunity for this potential<br>NDA submission. So, although it's -- one didn't hit on those co-primary endpoints, it doesn't mean that this product doesn't work.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>287</i><br>
<hr>
<A name=288></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
Yes. Okay, thanks.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Okay.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
I'll get back in queue. If nobody else has anything to ask, I'd just -- I have another thing, but I'll let somebody else go ahead.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Go ahead. If you want to ask a question, go ahead.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
Well, the results in the hernia trial were so compelling, it looked like 50 to 1 that the results weren't a result of chance. Was there any<br>methodological difference between the two trials to account for that? I think this is more than just a 50 to 1 shot against us, where<br>-- is there -- possibly the institutions in the first trial for some reason preselected patients? I'm just a little bit mystified by the huge<br>difference between the two trials. And I suspect you're mystified, too. But anything that you could say to amplify that, I'd be interested<br>in.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes, I think it isn't a matter of -- if we had done a 300-patient hernia trial, I think we would have had amazing results. But what we<br>have done is we have done additional abdominal surgeries, different abdominal surgeries. You remember, when we -- on the basis<br>of the shoulder and the hernia trial, our objective initially was to tell if you we couldn't submit an NDA at that point in time. But the<br>FDA was wanting us to collect -- to kind of push the boundaries for this product, collect -- especially more safety information with<br>regard to it, because we're giving 660 mg of bupivacaine here. And so, they wanted us to test these in these larger wounds, in these<br>older, sicker patients, and that's what we have done.<br>
And so, if we just focus on the safety aspect for a minute, and I'll get back to the efficacy, we have shown no issues with regard to<br>these. So, it was effectively -- almost, one could call it a 300-patient QTc study. We saw no issues on the cardiovascular side or the<br>CNS side. So, we have that in older and sicker patients. We have nice efficacy. Then, reflecting back and looking -- excuse me, safety.<br>
Going back and looking at the efficacy now -- in these larger abdominal wounds, there's a lot more going on than there is in the<br>hernia model. In the hernia model, the entirety of the wound is the hernia itself. And so, you have to cut through the muscle, you<br>go down, you put a mesh in over where there was the tear. That's all sewn up. And POSIDUR is applied to all the various surfaces<br>that were cut. And I think that's why we saw 3 times less -- 300% less narcotics used. And it's statistically significant, obviously, and<br>the efficacy as well. But if you are looking at these larger abdominal wounds -- in this case, these were large wounds. For example,<br>for some of the laparotomies, they had six holes because of the laparoscopically-assisted aspect of this entire thing. And yet, if you<br>look at the incisional pain, the pain from the wounds that were through the surface of the body, we had a statistically significant<br>signal there. Now, it doesn't count, because of the way this trial was structured, but the data are there. And you can't argue with<br>that.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>288</i><br>
<hr>
<A name=289></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
And so, what we have, though, is additional visceral pain. So, if you had diverticulitis or colon cancer -- and unfortunately, I have<br>friends and family members who have had both of those things, you end up with a visceral pain component to it all. So, it's not just<br>the surgical wound that hurts. And that's why when we had this secondary endpoint of pain collection, where the nurses were<br>requested by the patients to give them an opioid in order to try and control their -- whatever pain they might have outside of this<br>incisional pain, as it were, those were the points by which we didn't reach statistical significance. That being said, in the earlier trials,<br>the shoulder and the hernia, those points -- the opioid consumption tracked very closely with the incisional pain, pain on movement<br>measures, scores that we had. These are different surgeries, obviously more complex.<br>
There's also another component to this that I don't think will be really teased out until one gets into Phase IV work and the like, and<br>that is -- you have to remember, these nurses have been trained to stay ahead of patients' pain. And in the case, you might have an<br>85-year-old grandmother who has just been diagnosed with colon cancer, and she's in this trial, and that nurse is going to be<br>compelled to make sure that she has the pain control that she needs. And that's a very difficult piece to control in these studies. In<br>order to get an opiate, you had to have a pain score of at least 4. This is my personal bias right now, but I believe once this product<br>is out there and being utilized more, I think you will see a greater reduction in narcotics, even in these larger wounds, because the<br>nurses and the doctors will learn to trust POSIDUR more over time.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
Is there -- is one possible route just to get a limited label for shoulders and hernias? And is there enough of a market there that it<br>would make it a good drug?<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Well, I think there is certainly enough of a market around for this product entirely. The only way -- I think it's difficult, I think we have<br>an opportunity to be able to go for general surgical pain control, because we have shown incisional pain control beautifully in BESST,<br>and as well, obviously, in hernia and shoulder. And if one looks at [this here] as example, they used a hemorrhoid trial, which is<br>certainly a very local thing, and bunion, which is also a very local thing, and got a general surgical claim. And I think that was based<br>on the strength and the body of work, as it were, from bupivacaine itself over the last 30-plus years.<br>
<b>Robert Manning</b><i> - - Analyst</i><br>
Okay. Thanks very much.<br>
<b>Operator</b><br>
Albert Zesiger.<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
This is Barrie Zesiger. I just wanted to let you know -- we had tremendous trouble getting on, and perhaps other people did, too.<br>Can you hear me?<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes, we can, Barrie.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>289</i><br>
<hr>
<A name=290></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
Okay, sorry. The 877 number didn't work, and eventually we just kept looking at the Internet, and at that same notice, and there was<br>a 201 number that was put up. So, we missed your whole presentation. We got in at your first question. And so, I don't have any<br>questions, because I haven't listened to the presentation. We just wanted to let you know why there might be not more questions.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Oh, we appreciate that. Thank you.<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
A lot of people might have had that problem.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes, we did -- unfortunately, there was a -- appeared to be a typo with regard to the number going in. And we got a heads-up from<br>an investor literally two minutes before we went on the air, and so we were able to send around a blast e-mail to everyone with a<br>new number. But there was a lag there.<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
Yes, unfortunately, we were just not in our office. So, anyway, we will come back and be looking forward to more information that<br>you put out.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Thanks, Barrie. We also -- one can also go and access this, Matt, can't they? And listen to the -- it will be on the Internet, so one will<br>be able to listen to the talk, as well.<br>
<b>Barrie Zesiger</b><i> - Zesiger Capital Group LLC - Analyst</i><br>
Excellent. Thank you very much.<br>
<b>Operator</b><br>
Walter Schenker.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
Realizing you don't know the answer, because you will have to have further discussions with the FDA, and someone once said -- the<br>key to a good clinical trial is getting the right endpoints before you start.You have to pick the right endpoint. A lot of them look like<br>they're pretty good, but they don't meet the endpoints, because people pick the endpoints wrong.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>290</i><br>
<hr>
<A name=291></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Right.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
Not that you should have total flexibility. But the question is -- as you speculate, and you may not be willing to do that, about the<br>path forward, you would expect that with the safety profile, you might have enough data to try and get a label and approval, or it<br>probably requires another trial.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Right now, our -- and this is, you're right, this is our best guess from where we are today, is that based on the efficacy we have seen<br>in the hernia trial and the shoulder study, combined with the -- and the safety from those trials. But combined with the overall great<br>safety experience in this trial, and the kind of body of evidence of efficacy, as it were -- you're right, we didn't pick the right endpoint<br>on this trial. But nonetheless, there are some very compelling positive results from this trial, and I can't emphasize that enough. In<br>all -- if we look at the analyses of Cohort 1 or -- Cohort 1, 2 and Cohort 3, as far as incisional pain and the overall pain experienced in<br>Cohorts 1 and 2, we have that statistically significant motion -- result. I think that those data in BESST, efficacy and safety combined<br>with those other trials, will -- we believe, will give us enough for an NDA. And we won't know that until we have that pre-NDA meeting.<br>But we plan to sit down with the Agency and discuss that.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
And your expectation of the timeframe to know the next step forward is roughly what?<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Well, it's obviously early days. We will be putting together what is known as an ISE, which stands for integrated summary of efficacy,<br>and an ISS, an integrated summary of safety. Once we have completed both of these pieces, we will then have a request for a meeting<br>with the Agency. I think we're talking a number of months to do all that. And that's why we kind of said a mid-year, because it's<br>difficult to say how long it takes to get together with the Agency. Post that, if the meeting is good, then we will be submitting the<br>NDA.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
Okay. So, the positive case is, you meet with the FDA somewhere around mid-year, they say -- yes, go ahead and file the NDA. And<br>putting that package then together, given what you have already put together, is three to six months? That's a question.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes, I think it shouldn't be outside of that, yes.<br>
<b>Walter Schenker</b><i> - Titan Capital Management - Analyst</i><br>
Okay, thank you.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>291</i><br>
<hr>
<A name=292></a>JANUARY 06, 2012 / 1:30PM, DRRX - Durect Corp to Discuss POSIDUR Clinical Trial Results<br>
<b>Operator</b><br>
Thank you. (Operator Instructions) There are no further questions at this time.<br>
<b>Matt Hogan</b><i> - DURECT Corporation - CFO</i><br>
Okay. Well, one more time, we'd like to apologize for any technical difficulties calling in, but if people do have further questions,<br>please feel free to call management, and we would be happy to talk further about the POSIDUR program or our other programs.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Yes.<br>
<b>Matt Hogan</b><i> - DURECT Corporation - CFO</i><br>
Thank you.<br>
<b>Jim Brown</b><i> - DURECT Corporation - President &amp; CEO</i><br>
Thanks a lot.<br>
<b>Operator</b><br>
Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you all for your participation.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4701418-5-2012-01-09T05:47:36.963</b><br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>292</i><br>
<hr>
<A name=293></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
IHS - Q4 2011 IHS INC EARNINGS<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 06, 2012 / 1:00PM GMT<br>
OVERVIEW:<br>
IHS reported 4Q11 revenue of $371m and adjusted diluted EPS of $0.99. Expects<br>2012 all-in revenues to be $1.50-1.55b and adjusted diluted EPS to be $3.84-4.01.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>293</i><br>
<hr>
<A name=294></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Andy Schulz</b><i> IHS Inc. - VP IR</i><br>
<b>Jerre Stead</b><i> IHS Inc. - Chairman, CEO</i><br>
<b>Scott Key</b><i> IHS Inc. - President, COO</i><br>
<b>Rich Walker</b><i> IHS Inc. - EVP, CFO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Suzi Stein</b><i> Morgan Stanley - Analyst</i><br>
<b>Manav Patnaik</b><i> Barclays Capital - Analyst</i><br>
<b>Eric Boyer </b><i>Wells Fargo Securities, LLC - Analyst</i><br>
<b>Peter Appert</b><i> Piper Jaffray &amp; Co. - Analyst</i><br>
<b>Michael Meltz</b><i> JPMorgan - Analyst</i><br>
<b>Kelly Flynn</b><i> Credit Suisse - Analyst</i><br>
<b>Bill Sutherland</b><i> Northland Capital Markets - Analyst</i><br>
<b>Williaim Warmington</b><i> Raymond James &amp; Associates - Analyst</i><br>
<b>Brian Karimzad</b><i> Goldman Sachs - Analyst</i><br>
<b>Dan Leben</b><i> Robert W. Baird &amp; Company, Inc. - Analyst</i><br>
<b>Robert Riggs </b><i>William Blair &amp; Company - Analyst</i><br>
<b>OVERVIEW</b><br>
IHS reported 4Q11 revenue of $371m and adjusted diluted EPS of $0.99. Expects 2012 all-in revenues to be $1.50-1.55b and adjusted<br>diluted EPS to be $3.84-4.01.<br>
<b>FINANCIAL DATA</b><br>
<b>A. 4Q11 revenue = $371m.</b><br>
<b>B. 4Q11 adjusted diluted EPS = $0.99.</b><br>
<b>C. Full-year 2011 revenue growth = 25%.</b><br>
<b>D. 4Q11 revenue up 27% vs. 4Q10.</b><br>
<b>E. 4Q11-end cash = $235m.</b><br>
<b>F. 4Q11-end debt = $803m.</b><br>
<b>G. 2012 all-in revenue guidance = $1.50-1.55b.</b><br>
<b>H. 2012 adjusted diluted EPS guidance = $3.84-4.01.</b><br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>294</i><br>
<hr>
<A name=295></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. BUSINESS REVIEW (J.S.)</b><br>
<b>A. 4Q11 Results:</b><br>
<b>1. </b>Revenue up 27%.<br><b>2. </b>Adjusted EBITDA up 33%.<br><b>3. </b>Adjusted EBITDA margin 32.1%.<br>
<b>a. </b>Highest in Co.'s history.<br>
<b>4. </b>Absolute dollar levels for revenue and profit were Co. records.<br><b>5. </b>4Q11 proved to be exactly what Co. thought it would be.<br>
<b>a. </b>Accelerating organic growth on topline accompanied by meaningful margin expansion.<br>
<b>6. </b>In early Nov. 2010, Co. shared vision for what it would accomplish in 2011.<br>
<b>a. </b>Since then, world has seen many economic events that have presented challenges for businesses around the world.<br><b>b. </b>Despite aforementioned global economic challenges, actively managed IHS to ensure that it continued to make right<br>
investment decisions, to drive strong profitable growth and to deliver ever better insight information and analytics to<br>customers around the globe everyday.<br>
<b>B. Full-year 2011 Results:</b><br>
<b>1. </b>Revenue up 25%.<br><b>2. </b>Adjusted EBITDA up 26%.<br><b>3. </b>Adjusted EBITDA margin 30.2%.<br>
<b>a. </b>Up from last year despite significant levels of investment in infrastructure made during 2011.<br><b>b. </b>This performance is direct outcome of:<br>
<b>i. </b>Clear vision of what Co. is building.<br>
<b>ii. </b>Intense focus on four objectives Co. set for itself this year.<br>
<b>iii. </b>Relentless execution while adapting priorities to changing market conditions throughout the year.<br>
<b>4. </b>Four Co. objectives:<br>
<b>a. </b>Colleague success.<br><b>b. </b>Customer delight.<br>
<b>c. </b>Profitable top and bottom line growth.<br>
<b>d. </b>Shareowner success relative to peer group.<br>
<b>5. </b>Execution of aforementioned objectives drove solid results.<br>
<b>a. </b>Foundation of this performance is engagement of colleagues in level of customer delight.<br>
<b>i. </b>During 2011, 97% of colleagues participated in annual engagement survey, providing Co. with clear view of actions and<br>
experiences that most affect its commitment and performance at IHS.<br>
<b>b. </b>2011 colleague engagement score 59%.<br>
<b>i. </b>Represents recalibration of baseline with new third-party survey firm that offers excellent set of analytics and benchmarks<br>
as Co. moves to new level of excellence.<br>
<b>6. </b>Achieved world-class performance in a number of important areas, including value colleagues derive from their work and<br>
freedom of flexibility they have in delivering value to customers.<br>
<b>a. </b>Saw best-in-class levels in impact that Co.'s colleagues are having with customers due to increased colleague collaboration<br>
at IHS in creating value.<br>
<b>7. </b>Achieved best-in-class levels in focus on customers.<br>
<b>a. </b>This not only correlated to financial performance, it's tied to highest level of customer delight since Co. launched this<br>
critical effort five years ago.<br>
<b>b. </b>This year thousands of customers provided their feedback and Co. is pleased with results.<br>
<b>c. </b>Most global companies are scoring flat to down this year.<br>
<b>d. </b>Co. achieved four point improvement to reach 63% customer delight.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>295</i><br>
<hr>
<A name=296></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>e. </b>All three regions improved.<br>
<b>f. </b>100% of product areas showed improved customer delight.<br>
<b>i. </b>Because Co. achieved improvement target, Co. awarded to each of colleagues 50 IHS restricted stock units; represents<br>
approx. $18m in value.<br>
<b>ii. </b>Shares will vest over next 12 months.<br>
<b>g. </b>In 4Q11, delivered the highest level of subscription-based organic growth in ten quarters.<br>
<b>i. </b>Aforementioned results are directly connected to overall performance and highlight shareholder value Co. creates in<br>
connecting colleague and customer metrics to shareholder returns for stock-based incentives.<br>
<b>h. </b>Has driven substantial value for shareholders since IPO with compounded annual return of 32%, well above ahead of<br>
peers and overall market.<br>
<b>8. </b>Co. previously discussed importance of strategic partnerships to market growth and for new channel development.<br>
<b>a. </b>Continues to create right partnerships to drive long-term profitable growth.<br><b>b. </b>Signed strategic alliance agreement with IBM.<br>
<b>i. </b>Agreement will enable Co. to help clients meet complex enterprise sustainability management (ESM) challenges by<br>
leveraging combined strengths to provide content, software and expertise that customers need.<br>
<b>ii. </b>Another step forward in leveraging growing opportunities in enterprise sustainability.<br>
<b>iii. </b>By offering IHS content and systems in combination with IBM's expertise and technology implementation and integration,<br>
will make it easier for clients to turn traditional information management burdens into competitive advantages.<br>
<b>iv. </b>Organizations throughout Co. and IBM customer base will have opportunity to benefit from this new alliance.<br>
<b>v. </b>Pleased that IBM has recognized importance of ESM market and Co.'s technology leadership in that space.<br>
<b>C. Infrastructure Projects:</b><br>
<b>1. </b>Vanguard:<br>
<b>a. </b>Had another great success in roll out.<br><b>b. </b>On Dec. 5, went live with second release.<br>
<b>i. </b>Included significant part of finance organization and customer care in EMEA and Americas.<br>
<b>ii. </b>With this successful implementation approx. 40% of business is now being processed through Vanguard system.<br>
<b>iii. </b>EMEA and Americas finance and customer care centers of excellence are now operational.<br>
<b>iv. </b>APAC center of excellence opened [in Dec. 1] and will continue to grow with needs of Co.'s business.<br>
<b>c. </b>Implemented global ERP; replaced 40 plus legacy systems in countries all over the world.<br>
<b>d. </b>Gone live with SFA worldwide including automated commission system.<br><b>e. </b>Current plan calls for substantially all of Co.'s finance and lead through cash systems to be migrated over to Vanguard by<br>
2012-end.<br>
<b>i. </b>On track with that goal.<br>
<b>2. </b>Newton:<br>
<b>a. </b>High priority initiative to support multi-year growth strategy.<br><b>b. </b>Addressing issue of multiple data centers and content management and delivery systems.<br>
<b>c. </b>Making great progress as Co. eliminates redundant activities and shut down legacy data systems.<br>
<b>II. 4Q11 OPERATIONAL REVIEW (S.K.)</b><br>
<b>A. Overview:</b><br>
<b>1. </b>4Q11 was qtr. of improving profitable growth and clear, well-executed step toward achieving long-term profitable growth<br>
goals.<br>
<b>2. </b>Overall, delivered 9.4% organic growth for 4Q11 and delivered 8.7% for full-year, absent Boiler Pressure Vessel Code (in<br>
3Q10, had triennial release of BPVC, an engineering standard).<br>
<b>a. </b>All organic figures mentioned hereafter have been normalized to exclude BPVC as applicable.<br><b>b. </b>Organic growth performance marks positive acceleration sequentially and YonY.<br>
<b>3. </b>Geographically:<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>296</i><br>
<hr>
<A name=297></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>a. </b>Americas grew 8% organically.<br><b>b. </b>Strong positive improvement in EMEA; grew 8% organically.<br>
<b>c. </b>Continued strong emerging market growth in APAC; grew 22% organically.<br>
<b>d. </b>As evidenced by 6% sequential improvement in APAC organic growth, continues to see above avg. growth in the regions<br>
where Co. has made significant investments over last 12 months like APAC and Latin America.<br>
<b>4. </b>End market:<br>
<b>a. </b>Energy growth continues to be robust worldwide.<br><b>b. </b>Solid performance in chemicals, transportation, TMT and manufacturing.<br>
<b>5. </b>Benefited by Co.'s focus on managing product portfolio and effectively aligning resources and investment to areas of<br>
long-term double-digit growth potential.<br>
<b>6. </b>Delivered meaningful profitable growth as subscription business grew 9.1% organically.<br>
<b>a. </b>Up [a full point] sequentially.<br><b>b. </b>Up three points over 4Q10.<br>
<b>7. </b>Solid growth results were accompanied by significant adjusted EBITDA margin expansion.<br>
<b>a. </b>Delivered 32.1% for 4Q11; highest quarterly margin performance in Co.'s history.<br><b>b. </b>In terms of absolute dollars, quarterly adjusted EBITDA was also the best in Co.'s history.<br>
<b>8. </b>Achieved aforementioned level of profit delivery by three means:<br>
<b>a. </b>Robust topline growth, especially organic.<br><b>b. </b>Good cost control.<br>
<b>i. </b>As Co. continued to invest the historically high rates, actively managed spending rates and actively prioritizing where<br>
dollars would be spent.<br>
<b>c. </b>Continued improvement in margin performance from acquisitions.<br>
<b>i. </b>Acquisitions' collective margin exceeded 32% overall margin.<br>
<b>9. </b>Remains focused on primarily goal of long-term sustainable growth and continuing to make right strategic investments<br>
and acquisitions required to deliver for long run.<br>
<b>B. Other Details:</b><br>
<b>1. </b>Executed on disciplined strategy to invest in and acquired right assets in targeted high growth markets like chemicals,<br>
automotive, energy and supply chains across TMT.<br>
<b>a. </b>Established leading information insight and analytics positions in each and connecting capabilities across them to further<br>
enhance leadership positions.<br>
<b>2. </b>Strategically investing in colleagues, operational processes, key platforms and products.<br>
<b>a. </b>These investments are delivering scale, breadth and depth.<br>
<b>i. </b>Scale to delivery platforms.<br>
<b>ii. </b>Breadth to offerings and market presence.<br>
<b>iii. </b>Depth to global talent pool.<br>
<b>3. </b>Right strategic investments and judicious deployment and prioritization of capital, enabled solid performance and growth<br>
in 2011 and are the foundation for profitable growth in 2012 and in years to come.<br>
<b>4. </b>Investment in global infrastructure is key to growth by delivering scale and efficiencies.<br>
<b>a. </b>Due to focused investment over several years, Co. is now for the first time in a position to scale to over $4b in revenue in<br>
future.<br>
<b>5. </b>Beginning to see benefit on topline from productivity gains than bottom line from increasing efficiencies as Co. continues<br>
to successfully execute on investments in infrastructures through Vanguard, centers of excellence, sales force automation<br>and Newton.<br>
<b>6. </b>Continues to evolve structure and operations to realize sales, product and market synergies and rapidly and fully integrated<br>
every acquired asset to ensure opportunity is translated into reality.<br>
<b>a. </b>In 2012, expects to introduce the most new products in Co.'s history.<br>
<b>7. </b>Working to rationalize portfolio of products by vesting underperforming assets, while Co. invests further in those with<br>
greatest long-term potential.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>297</i><br>
<hr>
<A name=298></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>8. </b>Continued performance in growth comes from strategic partnerships.<br>
<b>a. </b>Will continue this path in 2012 and build on 2011 performance.<br>
<b>9. </b>As Co. continues strategic alignment to highest growth potential, prioritization of assets and spend continued development<br>
of global infrastructure and scale, will also restructure and rationalize.<br>
<b>a. </b>Will continue this as Co. enters 2012 and continue to implement Vanguard and Newton and rationalize portfolio.<br>
<b>10. </b>These will be important parts of 2012 operating plans as Co. deploys new infrastructure, fully migrate to three centers of<br>
excellence and upgrade systems globally.<br>
<b>C. SMT Acquisition:</b><br>
<b>1. </b>Integration efforts exceeded expectations.<br><b>2. </b>Ahead of schedule in nearly every area with integration essentially complete.<br><b>3. </b>Will see important 1Q upgrades to KINGDOM with seamless linkage to highly valuable energy information offerings that<br>
will create significant efficiencies in customer workflows and provide them with expanded options and value.<br>
<b>4. </b>Reception in marketplace has also been terrific.<br><b>5. </b>Stayed close to customers throughout transition.<br><b>6. </b>Co. is ahead of initial projections.<br><b>7. </b>Enjoyed roughly 50% margins during first full qtr. of ownership.<br>
<b>D. Summary:</b><br>
<b>1. </b>Enters 2012 with momentum, despite macroeconomic headwinds.<br>
<b>III. 4Q11 FINANCIALS (R.W.)</b><br>
<b>A. Revenue:</b><br>
<b>1. </b>$371m; up 27%.<br>
<b>a. </b>Growth includes:<br>
<b>i. </b>9.4% organic growth.<br>
<b>ii. </b>17% growth from acquisitions.<br>
<b>iii. </b>Virtually nothing from currency fluctuations.<br>
<b>b. </b>Organic growth on subscriptions 9.1%.<br>
<b>i. </b>Subscriptions accounted for 74% of revenue.<br>
<b>ii. </b>Organic growth rate increased sequentially since prior-qtr. and lifted Co. to 8.7% organic growth for full-year.<br>
<b>c. </b>Non-subscription businesses performed well.<br>
<b>i. </b>Grew 10.4% organically.<br>
<b>ii. </b>Consulting grew 16% organically; strong demand for Co.'s offerings particularly in energy, autos and chemicals.<br>
<b>2. </b>Regionally:<br>
<b>a. </b>Robust and broad-based revenue growth.<br>
<b>i. </b>Americas all-in revenue grew 23%.<br>
<b>ii. </b>EMEA and APAC grew 26% and 49% respectively.<br>
<b>iii. </b>EMEA subscription business grew organically in low double-digits; impressive performance in light of broader economy.<br>
<b>3. </b>By domain:<br>
<b>a. </b>Energy:<br>
<b>i. </b>Continues to be stalwart performer.<br>
<b>ii. </b>45% of total revenue.<br>
<b>iii. </b>Up 38% all-in.<br>
<b>iv. </b>Remains strong across most every offering and in all three geographies.<br>
<b>v. </b>Grew organically at strong double-digit rates.<br>
<b>b. </b>Product life cycle:<br>
<b>i. </b>31% of revenue.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>298</i><br>
<hr>
<A name=299></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>ii. </b>Increased 23%.<br>
<b>iii. </b>Benefited from 4Q10 acquisition of iSuppli, which grew at double-digit organic growth rate during 4Q11.<br>
<b>c. </b>Security:<br>
<b>i. </b>8% of revenue.<br>
<b>ii. </b>Up 2% all-in.<br>
<b>iii. </b>Solid subscription performance was partially offset by lower non-subscription results due to timing of sales.<br>
<b>d. </b>Environment:<br>
<b>i. </b>8% of overall revenue.<br>
<b>ii. </b>Up 31% all-in.<br>
<b>iii. </b>Benefited from acquisitions and solid organic growth.<br>
<b>e. </b>Remaining 7% of revenue is in macroeconomic capabilities.<br>
<b>i. </b>Up 8% all-in; almost all of which was organic growth.<br>
<b>B. Other Metrics:</b><br>
<b>1. </b>Adjusted EBITDA $119m.<br>
<b>a. </b>Up 33% from 4Q10.<br><b>b. </b>Second time in Co.'s history generated more than $100m in adjusted EBITDA in single qtr.<br>
<b>c. </b>Up almost $20m sequentially from 3Q11.<br>
<b>2. </b>Adjusted EBITDA margin 32.1%.<br>
<b>a. </b>Improved as expected.<br><b>b. </b>150 BP increase over 4Q10.<br>
<b>i. </b>Strong organic revenue growth, combined with good cost control added about 120 BP of margin expansion.<br>
<b>ii. </b>Remaining 30 BP came from acquisitions.<br>
<b>iii. </b>FX had virtually no impact.<br>
<b>3. </b>Adjusted diluted EPS $0.99.<br>
<b>a. </b>Up 24%.<br>
<b>4. </b>Segment profitability:<br>
<b>a. </b>Adjusted EBITDA:<br>
<b>i. </b>Americas increased 27% to $86m.<br>
<b>ii. </b>EMEA up 29% to $32m.<br>
<b>iii. </b>APAC grew 60% to $15m.<br>
<b>5. </b>Reported GAAP tax rate was affected by 4Q implementation of pension strategy.<br>
<b>a. </b>Excluding this impact, tax rate was 24.2%.<br>
<b>C. Balance Sheet (4Q11-end):</b><br>
<b>1. </b>Cash $235m.<br><b>2. </b>Debt $803m.<br><b>3. </b>Deferred revenue $487m.<br>
<b>a. </b>Up $95m or 24% YoverY.<br>
<b>D. Cash Flow:</b><br>
<b>1. </b>Cash flow from operations $89m.<br><b>2. </b>4Q11 free cash flow $80m.<br><b>3. </b>In FY11, generated $288m of free cash flow and ratio of free cash flow to adjusted EBITDA was 72%.<br>
<b>a. </b>Continues to generate strong cash flow despite higher levels of investment in business.<br>
<b>E. Pension Plan Strategy:</b><br>
<b>1. </b>During 2011, undertook comprehensive review of US pension plan, designed to ensure Co. maintains market competitive<br>
employee benefits, while decreasing volatility.<br>
<b>a. </b>Completed review.<br><b>b. </b>Believes Co. has made prudent business decisions with respect to these plans that positions it well on go-forward basis.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>299</i><br>
<hr>
<A name=300></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>c. </b>Many plan sponsors have employed similar steps to better manage their pension programs.<br>
<b>i. </b>Steps resulted in one-time settlement of retiree pension obligation, a change to pension plan investment strategy, a<br>
change in pension accounting policy and accelerated funding of plan contributions.<br>
<b>F. 2012 Guidance:</b><br>
<b>1. </b>All-in basis.<br><b>2. </b>Assumes no further acquisitions, currency movements, mark-to-market pension adjustments or unanticipated events.<br><b>3. </b>All-in revenue $1.50-1.55b.<br>
<b>a. </b>7-10% organic growth.<br>
<b>4. </b>All-in adjusted EBITDA $480-495m.<br><b>5. </b>Depreciation and amortization expense to approximate $112m.<br><b>6. </b>Net interest expense roughly $17m.<br><b>7. </b>Adjusted diluted EPS $3.84-4.01.<br><b>8. </b>Stock-based compensation expense to approximate $115-120m.<br><b>9. </b>Adjusted tax rate approx. 27-28%.<br>
<b>10. </b>Fully diluted shares approx. 67m.<br><b>11. </b>Considering quarterly profit progression for 2012, due to seasonality in business 1Q revenue and adjusted EBITDA tend to<br>
be lower sequentially relative to 4Q.<br>
<b>a. </b>1Q, traditionally lowest qtr. of year for revenue and adjusted EBITDA; both in terms of absolute dollars and as a percent<br>
of annual totals.<br>
<b>i. </b>This trend has been amplified going forward by product mix from 2011 acquisitions and recent pension strategy<br>
implementation.<br>
<b>b. </b>2011 quarterly profit distribution adjusted as if Co. had made $8m pension expense similar to 2012.<br>
<b>i. </b>4Q11 represented 30% of 2011 adjusted profit, whereas 1Q11 represented 21%.<br>
<b>12. </b>CapEx to:<br>
<b>a. </b>Remain relatively flat to 2011.<br><b>b. </b>Decrease as a percent of revenue from 4.1% in 2011 to about 3.5% in 2012.<br>
<b>13. </b>Over the long run, generally expects CapEx to annually represent 3-4% of revenue.<br>
<b>G. Summary:</b><br>
<b>1. </b>Saw accelerating topline organic growth, resumption of meaningful overall margin expansion and robust cash flows.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
(Operator Instructions). Suzi Stein with Morgan Stanley.<br>
<b>Suzi Stein</b><i> - Morgan Stanley - Analyst</i><br>
You saw a nice improvement in organic revenue growth. But how much of it is attributed to bringing in acquisitions that anniversaried,<br>and moving under-performing businesses to Discontinued Operations? What I'm trying to figure out is how did the underlying<br>business perform if you were to comp it to Q3 growth?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
That's a good question, Suzi. Scott would look forward to answering that.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>300</i><br>
<hr>
<A name=301></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Sure would. Suzi, we actually saw very broad and solid organic performance across the business. And I'll give you a few examples.<br>We gave you the region numbers where you saw positive growth. Our subscription base really trended up and positively across the<br>globe. In Americas, we saw a series of areas of double-digit organic growth in automotive, the transportation sector, our core<br>economics offerings, and our offerings in manufacturing and design and energy technical. We saw really positive improvement in<br>our strategically managed accounts that drove organic growth higher.<br>
And we saw that in all regions, real good progress, 3 to 5 percentage points of additional, above our average organic growth in<br>strategically managed accounts in the Americas, EMEA and APAC. And then the other point of growth driver, as you heard, Latin<br>America, 20%-plus, and of course, APAC, 20%-plus. So, really strong fundamentals. And I think the other point to mention is that<br>was matched, regardless of organic or inorganic on acquisitions. Acquisitions in general delivered about 16% year-on-year growth<br>on average. So, we really saw solid performance everywhere.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Great question, Suzi. Last quick comment on that. If you look, our fastest-growing business continued to be the energy business in<br>Q4, remarkable performance. There was no shift with the organic growth there. It did not include any acquisitions falling into Q4.<br>So, just a really great quarter everywhere. Thank you. Next question.<br>
<b>Operator</b><br>
Manav Patnaik with Barclays Capital.<br>
<b>Manav Patnaik</b><i> - Barclays Capital - Analyst</i><br>
In light of the economic environment, I just wanted to get a feel for visibility on your numbers. And maybe an example being how<br>much percent of your renewals to your subscriptions occur or have already occurred coming into 2012? And just somewhat related<br>to that in terms of just, again, on the back of the economic environment, what changes, if any, are there to your appetite for M&amp;A<br>this year?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Great question. Let me pick it up, and we'll start with that, Manav. Actually, you just tried to sneak in a second question. But I'll<br>probably respond to that quickly for everybody. A very good question. 32% of our renewals occur in Q1. Q4 is our second strongest,<br>and then the other two are a bit lighter. If you think about the fact that we're a November 30 business, December is a big month for<br>us, as you would expect, because a lot of companies that are on a calendar year do renew then. So, 32%. I'm going to have Scott<br>give a little color on that in just a second.<br>
On your question B, we are feeling very good. Continue to, with the acquisition pipeline we've got, complementary, fit our strategic<br>goals and will fit going forward. So, we feel very good about that. Before I color Scott on Manav's first question, then Rich, anything<br>else you've got on M&amp;A?<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>301</i><br>
<hr>
<A name=302></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
I was just echoing the renewal profile. It's 60%, one-third of it in the first quarter. So, the visibility on how we exit the year gives us<br>great confidence.The M&amp;A pipeline, in general, it remains very robust.Very pleased with the broad-based distribution of it, particularly<br>the focus on emerging and growth economies and industries that we're keenly focused on.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
And, Manav, just in terms of thinking about our subscription base, Jerre said it well. As we sit at this point in time, we have visibility<br>to about 60% of our renewal base, as Rich mentioned. So, 30%-plus in Q1, and also a large portion in Q4. So, obviously we're working<br>three, four, five months ahead with customers. So, we really have great visibility to over 60% of the renewal base as we sit here in<br>early January, good view on the year, and obviously strong momentum coming out of the end of last year.<br>
The other thing to note is our renewals still, on average, tend to be above 90%. And really great discipline with new sales systems<br>where you see, first of all, the timeliness of renewals at the highest levels ever in the Company. And that's just a sales system we<br>deployed over the last year, focused on the right structure and organization in sales. And of course, good global sales operations<br>processes.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thank you. Next question.<br>
<b>Operator</b><br>
Eric Boyer with Wells Fargo.<br>
<b>Eric Boyer</b><i> - Wells Fargo Securities, LLC - Analyst</i><br>
With you guys having organic subscription revenue growth already over 9%, and your organic guidance being 7% to 10% for the<br>year, the question comes -- how are you feeling about the demand environment for the non-subscription business right now? And<br>are you still pushing towards that 9% for the overall year?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Excellent question. As you remember, on our 2012 guidance call, Scott told us that his personal goal was 9% organic. And your<br>question's a good one, Eric, because an important part of that is the Other category, about 22%, 23% of our total. So, Scott, pick up<br>both pieces?<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Yes, thanks. And what you saw in Q4, actually, was those non-subscription areas lifting the business and performing really positively.<br>And I'll tell you, we've spent, Eric, a lot of time over the last two years ensuring that those non-subscription parts of our business<br>were tightly connected with the subscription part of the business. And that's helping us drive growth. So, I'd tell you three things.<br>One, part of those nonrecurring businesses are connections, integration, and tighter value creation around our information for<br>customers. And we've launched some electronic information management services over the last year, which are growing above<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>302</i><br>
<hr>
<A name=303></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
20%, and really tightly linked to our underlying information subscription base growth. So, really strong performance there in<br>nonrecurring that's driving growth.<br>
Then in terms of services, advisory services and consulting, we saw positive performance all through the year. And ended the year<br>in double-digit growth there in each region as a result of, again, tying our advisory services to our insight and analytics, and really<br>measured growth of that business. So, we feel good about the level where we have demand higher, we're able to fulfill. That's a<br>great place to be right now.<br>
And then the last piece that's in that nonrecurring area, of course, is some of our software and platform sales, both in energy, great<br>work flow tools that tie our information with our analytics. And of course, in environment. So, all of those three areas of solid growth<br>by region that we feel good about as we head into the year.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thank you. Good question. Next?<br>
<b>Operator</b><br>
Peter Appert with Piper Jaffray.<br>
<b>Peter Appert</b><i> - Piper Jaffray &amp; Co. - Analyst</i><br>
Jerre, this is one question, and it revolves around margins. And what I'd like to know is, as we think about 2012, what are the key<br>drivers of the margin improvement? How important are Vanguard and Newton to the upside you see? And can you talk a little bit<br>about the seasonality in margins? Is it going to be as fourth-quarter loaded in '12 as it was in '11?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Excellent question, Peter. Thank you. I'll work backwards on it. As you heard Rich talk just now, in that package that's on our website,<br>you'll see, to make sure we see and help you with what goes on quarter by quarter, you'll see that adjusted 2011 quarter-by-quarter<br>percent of profit -- 30% in Q4, 21% in Q1. So, using that, there's three key factors that have happened. One, we did want to give you<br>that perspective because with the acquisitions we've actually seen a shift of an increase in EBITDA profit in Q4, and we've got that<br>built in. Secondly, we're feeling very good, I must say, about the amazing effort that has gone on with Vanguard, our Centers of<br>Excellence, many other things at the same time.<br>
Scott mentioned in his part of the prepared script the fact that we'll also be introducing more new products in 2012 than we have<br>in the history of our business. So, if you think about new products taking a while to move in, and take on the opportunity for growth,<br>all of those drive us pretty clearly to that 30% that we say happened last year, as one that we would expect to see continue as a<br>model. I'm going to ask Rich to pick up, and Scott, in just a second.<br>
But the other thing is, we felt very good all year long. I know many of our investors were wondering whether we would indeed deliver<br>the 32% margin in Q4 that we were consistent about all year. We did that. We feel very good about where we're going into 2012. A<br>lot of productivity improvements, sales force automation, et cetera. Equally important is to think through into 2013 because as we<br>exit 2012, many of the benefits of scaling, as Scott mentioned in his call, for the first time will now be in place. So, increasing amount<br>of confidence in our ability to give significant, as Rich's comment was in his wrap-up, margin improvement in 2011, Q4, more to<br>come in 2012.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>303</i><br>
<hr>
<A name=304></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
Rich?<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
The mix question is really critical to us, I think, Peter. The acquisitions, SMT and the size of that, and our new pension accounting<br>going forward is ratably and it is included in adjusted EBITDA. So, the table is one we would encourage you to study and come back.<br>Profit and margin profile is a function. It all begins with revenue. And we've demonstrated to you when we can grow the top line at<br>an 8% to 10% level, and aggressively manage the cost control, we can consistently deliver between 100 and 150 basis points of<br>margin improvement. And that's a function of many things, including prioritizing our investments. And I think we're keenly focused<br>on doing that.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Scott, wrap up on it. Very important question.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Couple things to realize. So, 32% in the fourth quarter. And of course, our goal is to deliver that or better for the full year. So, just<br>think about where we are and then that full year delivery, Peter. But also a couple things that we've mentioned. We've spent the last<br>four quarters investing in scale. We now have three Centers of Excellence globally. We're rolling out Vanguard to almost half of the<br>business right now, and sales force automation tools everywhere.<br>
To your question about how things grow in scale, what I mentioned is we're starting to see the benefit of those investments, significant<br>ones over the last four quarters, in the top line.We're seeing it begin to drive our growth, and we're going to increasingly see it drive<br>efficiencies. We have another four quarters, as you know, of Vanguard deployment, of Newton, and sales force optimization tools<br>in process. Those will help us all the way through the year, and as Jerre said, into 2013. So, we should expect to see the benefit of<br>that scale, some additional efficiencies build through the year. So, that's what you should expect to see on our margin goals.<br>
<b>Operator</b><br>
Michael Meltz with JPM.<br>
<b>Michael Meltz</b><i> - JPMorgan - Analyst</i><br>
I have one question, one clarification. I'm not sure which one's which here though, so let me just start. On Peter's question, just to<br>clarify the guidance for '12, you did 32% margin in the fourth quarter. The '12 guidance is 32% or better. Is the expectation in Q1 or<br>Q2 to be down from the Q4 you just did, but still up year over year? I understand what you're talking about seasonality of the profit<br>distribution, but can you talk more specifically about the expectation of margin ramp? Then I have a follow-up.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
That's a good question, Michael. The answer is yes to your question. Yes, you're right on. And if you do that analysis, again, using<br>that 21% Q1 of our guidance EBITDA, 30% Q4, you'll get there. And you'll see a number that we'll do our very best to deliver in Q4<br>that is a significant improvement. But Scott's point of 32% all-in year over year versus the 30.2% in 2011 gives you a pretty good<br>thought. That's 180 basis points for openers.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>304</i><br>
<hr>
<A name=305></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
Now, the next clarification -- or your question.<br>
<b>Michael Meltz</b><i> - JPMorgan - Analyst</i><br>
Yes, this might be the question. I appreciate the slides on the pension changes. Perhaps this might be better offline, but the $57<br>million contribution, or however you're defining it, you talked about some buyouts and other changes that might occur. Is there an<br>additional expectation of cash that will be done throughout '12, in addition to that?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Actually, I'll answer that only. Just so we're clear though, and it's a good question, Michael; the answer's no to that question. So we're<br>clear, we are happy to take as much time afterwards on one-on-one calls, or anything else that we need to do, along with that deck<br>that we put on the website. And we'll also send that deck out to you, all of our investors, right after we finish this call, to make sure<br>we do the clarification. Most important thing is that we've now really positioned ourselves to take any future risk of consequence<br>off the table with the pension program. But that clarification question is a good one.<br>
Next questions, thank you.<br>
<b>Operator</b><br>
Kelly Flynn with Credit Suisse.<br>
<b>Kelly Flynn</b><i> - Credit Suisse - Analyst</i><br>
On the tax rate, I was wondering if you could just get into more detail on exactly what were the mechanics that drove the tax benefit?<br>And on the $0.99 adjusted earnings number, what is the tax rate being used to get to that number? Thanks.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
That's a good question, Kelly. Rich?<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
It's a bit two-part, Kelly. One, the fourth quarter rate is clearly an anomaly that's driven entirely by the pension adjustment. I think if<br>you normalize for that, the fourth quarter GAAP rate was 24.2%. And an adjusted tax rate at about a 27%, 28%, as well. So, really the<br>combination of the discrete items for the total year, and in the fourth quarter in particular, created a lot of noise in that metric.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
And let's just be crystal clear. That $0.99 was a solid impact that delivered the quarter that was not a one-time event of any part of<br>the taxes.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>305</i><br>
<hr>
<A name=306></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
Correct.The totality of the pension adjustments, a good clarification to have, the pension adjustments were below adjusted EBITDA.<br>So, the adjusted EPS of $0.99 is a clear, clean number without any of the impact. And that is a traditionally consistent metric from a<br>tax rate perspective.<br>
<b>Operator</b><br>
Bill Sutherland with Northland Capital Markets.<br>
<b>Bill Sutherland</b><i> - Northland Capital Markets - Analyst</i><br>
I was just noticing that very solid organic growth trend you guys generated in EMEA in the quarter, particularly in subscription. Can<br>we get a little color maybe on some of the industry and vertical trends that you saw over there?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Yes, good question, Bill. And let me just go back. It was a shame on us, or me, in Q3. We actually had quite solid subscription-based<br>organic growth in Q3 in EMEA, 6%-plus. We didn't do our colleagues justice there because it was the transaction stuff that pulled it<br>down to the less than 2%. So, it was good and solid and significantly increasing in Q4.<br>
And Scott, you'll love giving him color on that.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Yes. Several things to realize there. Just as we said through the year, despite a challenging environment, we're focused in the right<br>markets on the right customers. And of course, bringing a lot of value to their operations. And we talked about the headwinds, and<br>really seeing the bottom in terms of, for example, defense and security. And that's what's played out. So, really solid double-digit<br>subscription growth that's pretty broad-based, Bill. Strong performance in energy. Very good performance in terms of defense and<br>security.<br>
And then I would say the other areas that really performed well, performed well globally. So, chemicals performing very well. TMT,<br>supply chains around manufacturing doing quite well. And then transportations, and particularly, autos. And also, we had really<br>solid growth in the nonrecurring parts of the business in EMEA. And the last thing I would add is the strategically managed account<br>program. We had a lot of great wins across those markets, and good performance as we connected with very large customers, as<br>well.<br>
<b>Operator</b><br>
William Warmington with Raymond James.<br>
<b>Williaim Warmington</b><i> - Raymond James &amp; Associates - Analyst</i><br>
Congratulations on the strong organic revenue growth and the EBITDA margins. A two-part question, borrowing from my peers'<br>examples. The first part is more of a bookkeeping here. I know, Rich, you gave the deferred revenue growth in total. What was the<br>organic deferred revenue growth on the balance sheet?<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>306</i><br>
<hr>
<A name=307></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Rich? That's a good question, Bill.<br>
<b>Williaim Warmington</b><i> - Raymond James &amp; Associates - Analyst</i><br>
And then the second part, construed as a second separate question, if you could talk a little bit about what kind of productivity<br>improvements are being assumed for the sales force in 2012 to hit the 9% organic revenue growth?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Let's pick that up first because that's a really great question.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
Several things are happening. We've talked in the past about inefficiencies as high as 30% to 40% in the sales force. So, we'll see<br>several things happen. Shifting resource and focus within the existing sales force and our sales costs to emerging markets. And we<br>saw that last year. We'll see that continue. Latin America, as well as APAC, where we have high opportunity and high growth rates.<br>We'll also see Vanguard roll out through the year. And what that does for us is it starts to give us a consistent view of customers<br>globally, and then connects with our sales force automation SFA tool. We've got about 95% of the sales force on SFA, and almost<br>$1.8 billion in sales opportunities flowing through that system.<br>
Another thing that I'll mention quickly is we've got all three Centers of Excellence up and running in terms of order management.<br>So, quote, all the way through delivery. And we'll see that make the sales force more efficient as we move through the year. Probably<br>the most of that benefit will start to come from the back end as we get Vanguard fully deployed and we get people up in those<br>Centers and fully trained. So, we'll see the benefit continue. We saw it some in the last quarter. We'll see it increase through the year,<br>and then strong benefit in 2013.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thanks, Scott. And, Rich, pick up Bill's first part on the deferred organic.<br>
<b>Rich Walker</b><i> - IHS Inc. - EVP, CFO</i><br>
As you said, Bill, it grew to $487 million. That's up $95 million, 24% in absolute terms. That's about an 11% organic growth sitting<br>underneath that.<br>
<b>Operator</b><br>
Brian Karimzad with Goldman Sachs.<br>
<b>Brian Karimzad</b><i> - Goldman Sachs - Analyst</i><br>
Related to that, you've talked about the sequential quarter-over-quarter progression of the absolute numbers on revenue, EBITDA,<br>the seasonality there we've got to keep an eye on. But on the organic growth rate for revenue, is there anything technical we need<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>307</i><br>
<hr>
<A name=308></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
to be aware of as we head into 1Q and through the year that could cause that to accelerate or decelerate? Like, for example, in 4Q<br>the anniversary effect certainly helped. And as I think about the quick cadence of the acquisitions you had in the year you just<br>completed, SMT is by far the largest. And so, should we be expecting an acceleration baked into your outlook in 4Q because of that?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
That's actually a very good question, Brian. I'll start, and have Scott pick up on that. And I'll go back to pick up a bit on Suzi's, too. We<br>look at some 30 different product revenue bases, actually daily, weekly, monthly, quarterly. If you'll remember, Scott said in the last<br>two calls that 85% of our revenue was exceeding 10%. It was actually in double-digit organic growth. And that doesn't include the<br>acquisitions we've made. If you add those in for their own internal organic growth, it's actually north of there.<br>
Just for color, to give you a view, we range anywhere from 22%, 23% organic growth in a given quarter on some product lines to<br>flat or thereabouts negative on some of the other product lines. Scott mentioned in his call, on the formal part of the call, what we're<br>doing in having a continuing effort looking forward to those that are not meeting our double-digit goals on organic growth. And<br>how we'll review those businesses and products, either to increase spending to get them into double digits or make other decisions.<br>
So with that as background, pick up on the rest of the question.<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
And so, obviously, you saw the 9% in the fourth quarter, which is our aspiration for the year within that 7% to 10% range. So, Jerre's<br>told you we have a great part of the portfolio that's in double digit today. You heard us say in terms of acquisitions that their<br>year-on-year growth rate on average is about 16%. So, they're performing very well. What I would say is, as we've said for the last<br>few months, we feel good about the foundation of the business.We continue with the highest level of transformation as we continue<br>to roll out Newton, and staff our Centers for order entry all the way through delivery. And we're mindful of the economy that we're<br>sitting in. So, we're balancing those factors with, I think, what is a strong foundation to the year, and a plan that we believe we can<br>deliver.<br>
<b>Operator</b><br>
Dan Leben with Robert W. Baird.<br>
<b>Dan Leben</b><i> - Robert W. Baird &amp; Company, Inc. - Analyst</i><br>
Just wanted to ask a little bit on the cost side related to margins. Particularly in the Americas region, margins down a little bit<br>sequentially. Are there any one-time factors in there that we should think about as we go into next year around Vanguard or Newton<br>or any of these other projects with the customer excellence centers that were more one-time in nature in the fourth quarter that<br>held that down?<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Actually, as usual, very thoughtful question, Dan. The answer is no, nothing in specific, other than we did mention that we now have<br>fully running the Centers of Excellence in both EMEA and in the Americas. And that's been an investment of significance in Q2, 3 and<br>4. And that APAC is now up and running as we begin the first quarter of 2012. And we feel very good about that progress. Nothing<br>unusual at all though, from a standpoint in the Americas, just a really great performance in total. Thanks, Dan.<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>308</i><br>
<hr>
<A name=309></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Operator</b><br>
Robert Riggs with William W. Blair.<br>
<b>Robert Riggs</b><i> - William Blair &amp; Company - Analyst</i><br>
I think it still holds that roughly 70% of the revenue comes from the top 1,000 customers. But you've also made the comment that<br>they're relatively still under-penetrated, maybe 25% penetrated. As we think about the product development over the next several<br>quarters, will there be a focus on driving increased penetration among those top 1,000? Or are you maybe making some adjustments<br>to appeal to the customers outside that 1,000, or to look to bring on some brand-new clients? Thanks.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Very good question, Rob. Scott?<br>
<b>Scott Key</b><i> - IHS Inc. - President, COO</i><br>
I'll give you three things to think about there. We're relentlessly focused on those 1,000. And as I said, there's a differential growth<br>rate in those accounts. Extra 6 points, 6% of customer delight in those accounts, and 2 to 3 points of organic growth in those accounts.<br>We're expanding them to 250. We've just made some changes, as you've seen. Announced a new global sales lead, a single global<br>sales operations function. And the goal there with SFA is to get laser focused on those 1,000 accounts, and to continue that momentum.<br>
The other thing we're doing is the transactions part of our business, all the way at the other end of the spectrum, has been an<br>under-performer. We've got great valuable information globally, and so we're investing in that this year. And in the middle what<br>you have is inside sales and field managed, which we're looking at process and efficiency in. So, really good focus on each, but<br>certainly laser focused on the top 1,000.<br>
<b>Jerre Stead</b><i> - IHS Inc. - Chairman, CEO</i><br>
Thanks, Rob. With that, we'll wrap up. I just want to make one quick comment, and then I'll turn it over to Andy. This is the end of<br>my 32nd year as Chairman, Executive Chairman, or CEO of public companies. Never have I gone into a year, as we are now into 2012,<br>with more confidence about our ability to execute long-term, sustainable, profitable growth because we've built an amazing team.<br>We've got great processes and products in place. So, I look forward to representing all of our colleagues around the world and our<br>calls for the year as we continue to make that progress.<br>
Andy?<br>
<b>Andy Schulz</b><i> - IHS Inc. - VP IR</i><br>
We thank each of you very much for your interest in IHS.This call can be accessed via replay at 888-286-8010, or international dial-in<br>617-801-6888. Pass code 95966684. Beginning in about two hours, and running through January 13. In addition, the Webcast will<br>be archived for one year on our website at www.IHS.com.<br>
And, as always, you can contact IHS Investor Relations with any follow-up questions. We can be reached at 303-397-2969. Thank<br>you. We appreciate your interest and time.<br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>309</i><br>
<hr>
<A name=310></a>JANUARY 06, 2012 / 1:00PM, IHS - Q4 2011 IHS Inc Earnings Conference Call<br>
<b>Operator</b><br>
Thank you for your participation in today's conference. This concludes the presentation. And you may now disconnect. Good day,<br>everyone.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4683393-5-2012-01-09T09:18:26.563</b><br>
17<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>310</i><br>
<hr>
<A name=311></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
ACTV - ACTIVE NETWORK INC TO<br>DISCUSS THE STARCITE ACQUISITION<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 06, 2012 / 4:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>311</i><br>
<hr>
<A name=312></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Brenley Johnson</b><i> Active Network Inc - IR,The Bluechip Group</i><br>
<b>Dave Alberga</b><i> Active Network Inc - CEO</i><br>
<b>Scott Mendel</b><i> Active Network Inc - CFO</i><br>
<b>Matt Landa</b><i> Active Network Inc - President</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Rohit Kulkarni</b><i> Citigroup - Analyst</i><br>
<b>Brian Pitz</b><i> UBS - Analyst</i><br>
<b>Nathaniel Schindler</b><i> BofA Merrill Lynch - Analyst</i><br>
<b>Aaron Kessler</b><i> Raymond James - Analyst</i><br>
<b>Brian Schwartz </b><i>Thinkequity - Analyst</i><br>
<b>Steven Rubis</b><i> Stifel Nicolaus - Analyst</i><br>
<b>Collis Boyce</b><i> Levin Capital - Analyst</i><br>
<b>George Askew</b><i> Stifel Nicolaus - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Good day, ladies and gentlemen, and welcome to the Active Network call to discuss the StarCite acquisition conference call. My name is Lacey, and<br>I will be your coordinator for today. At this time, all participants are in listen-only mode. Later, we will facilitate a question and answer session<br>towards the end of the presentation.<br>
(Operator Instructions).<br>
I would now like to turn the presentation over to your host for today's call, Ms. Brinlea Johnson with The Blueshirt Group. Please proceed.<br>
<b>Brenley Johnson</b><i> - Active Network Inc - IR,The Bluechip Group</i><br>
Good morning. Before we get started, we would like to remind you that our statements today that are not purely historical are forward-looking<br>statements. Our actual results may differ materially from those projected in any forward-looking statements due to various risks and uncertainties,<br>including but are not limited to, the risk that we may not be able to achieve expected strategic benefits from the acquisition of StarCite, the risk<br>that we will not be able to successfully integrate the operations of StarCite with or into our operations, the risk that revenues following the StarCite<br>acquisition will be lower than expected, and the risk that our business disruption, including without limitation, difficulties in maintaining customer<br>relationships is greater than expected following the StarCite acquisition.<br>
Additional information regarding risks and uncertainties of our Company is set forth in our public filings with the SEC. All forward-looking statements<br>are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update these statements to reflect events<br>or circumstances after the date hereof. This conference call will also be recorded, and will be available for replay and broadcast on the internet on<br>Active Network's Investor Relation site at www.activenetwork.com under webcasts and presentations. With that, I will now turn the call over to<br>Dave Alberga, Chief Executive Officer of Active Network.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>312</i><br>
<hr>
<A name=313></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
Thanks, Brinlea, Good morning, everyone, and thanks for joining our call. We're very excited to announce that we've acquired StarCite, a leader in<br>the global corporate strategic meetings management space. In addition to it's global customer base and leading strategic management -- meetings<br>management software-as-a-service technology, StarCite provides Active Network's customers access to a vast access online marketplace of the<br>top hotels, destinations and venue suppliers world-wide. The combination of StarCite and Active Network delivers three critical advantages that<br>are unmatched by any other offering.<br>
First, we now have the most robust end-to-end technology platform that scales to address events and meetings of all sizes, from large externally<br>focused events like Oracle Open World to smaller employee meetings. Second, only Active Network has the leading attendee management<br>functionality, coupled with the most sophisticated strategic meetings management capabilities for our customers. And finally, we have the largest<br>footprint in the business events market, building upon Active Network's current leadership position.<br>
This acquisition puts us in position to more effectively manage costs for procurement and logistics departments, while at the same time using our<br>existing solutions to engage event attendees more deeply, and as a result drive additional revenue for sales and marking departments. This<br>acquisition is a key step we are taking to evolve the events industry, from one that focuses on meetings logistics and spend management, to one<br>that includes continuous community engagement, enabling organizations to build lifetime value with their customers and employees.<br>
With a single technology suite we power customers of all sizes, including small and medium size businesses, enterprise corporations, associations,<br>trade shows and expos, for their entire event management needs. Combined, our customers now include 10 of the largest 15 financial services<br>institutions, 10 of the largest 15 technology corporations, nine of the largest 15 pharmaceutical companies, and over 1,000 associations. The fact<br>that we now provide the most comprehensive technology solution, and that we have limited customer overlap gives us significant opportunity<br>for cross-selling our technology solutions. With that, I will turn the call over to Scott to discuss the financial terms of the deal.<br>
<b>Scott Mendel</b><i> - Active Network Inc - CFO</i><br>
Hello, everyone, and thanks for listening in. I would like to echo Dave's sentiment, and say that we're very excited about our acquisition of StarCite.<br>As we stated on previous calls, we're focusing on leveraging acquisitions to accelerate the natural progression of our solutions into our current<br>customer groups. And we believe that the StarCite acquisition is consistent with that growth strategy. We purchased StarCite for $57.7 million, $40<br>million of it in cash, and 1.35 million shares valued at $17.7 million. Additionally, there's potential for 150,000 shares of contingent consideration.<br>This implies a purchase price of approximately 1.2 times the 2012 pro forma revenue, and 9.7 times the 2012 EBITDA, after the impact of purchase<br>accounting reduction on deferred revenue.<br>
Now we'd like to provide with you some of the key variables for modeling purposes. We estimate additional revenue of $35 million to $37 million<br>in 2012, assuming a purchase accounting deferred revenue haircut of approximately $10 million to 12 million. We anticipate EBITDA of negative<br>$5 million to negative $6 million in 2012, driven mainly by this purchase accounting deferred revenue haircut. This also includes integration costs<br>of approximately $2 million in the 2012 time frame. Historically, we have seen intangibles of approximately 40% of the purchase price, and typical<br>amortization periods for an acquisition like this are three to five years.<br>
We anticipate the revenue will be a 50/50 split between registration and other technology revenue. Historically, StarCite has had approximately<br>2.5 million registrations per year.We expect the StarCite acquisition to be accretive beyond 2012, and we expect future revenue growth to be equal<br>to or greater than our existing businesses. With that, I will turn the call over to Dave for a few closing comments. And then we'll conduct Q&amp;A.<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
I will just reiterate our excitement around the acquisition of StarCite, which is a powerful complement to Active Network's attendee management<br>solutions.We see very exciting opportunities within the business events customer vertical, and believe StarCite, in combination with Active Network,<br>provides an unbeatable end-to-end technology solution. We continue to execute on our strategic goals, and look forward to sharing our fourth<br>quarter results on our fiscal 2011 earnings call. With that, I will turn the call over to the operator to conduct Q&amp;A.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>313</i><br>
<hr>
<A name=314></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
Thank you. (Operator Instructions). And our first question will come from the line of Mark Mahaney with Citi. Please proceed.<br>
<b>Rohit Kulkarni</b><i> - Citigroup - Analyst</i><br>
Hi, this is Rohit filling in for Mark. I'm so sorry, I joined a couple minutes late. Can you please elaborate or recap the time frame for the integration<br>of StarCite with Active Network technology? Do you have any plans to do that? Within the guidance that you give, to what extent does profitability<br>of StarCite is included in that, plus just any new or additional costs that you layer onto the model?<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
Yes. So in terms of the time frame, we're actually not prepared to give you a time frame for that right now, but we do plan to integrate this in with<br>the product.The attendee management functionality that we have with our existing products will slot in very nicely with what they have, in terms<br>of their strategic meetings management piece, and also their vendor relationship piece of technology. And we'll be looking to put those together<br>rather seamlessly as we move forward. And we'll get back to you with kind of a more precise time line after we have a little more time to dig into<br>this and make sure we can give you better dates on that.<br>
In terms of additional costs associated with that process, we really don't believe there are going to be any above and beyond costs associated with<br>that process. It is more so going to be, just part of the ongoing development efforts of the team. And in fact, there are people associated with that<br>particular project already within StarCite, in terms of bringing attendee management up. And they will be able to focus primarily on the integration<br>efforts for us. So we think that, that's going to work out well for us from a cost standpoint.<br>
<b>Scott Mendel</b><i> - Active Network Inc - CFO</i><br>
And, Rohit, Scott here. I would just reiterate, the impact on long-term model is really the two things that I have called out. Number one, is the<br>purchase accounting impact of the deferred revenue, so that's about $10 million to $12 million impact in 2012. We do have the $2 million or so of<br>integration costs in 2012. Then, obviously, the non-cash items going forward would impact our GAAP income projections. It's probably moved it<br>out another 18 months or so.<br>
<b>Operator</b><br>
And our next question will come from the line of Brian Pitz with UBS. Please proceed.<br>
<b>Brian Pitz</b><i> - UBS - Analyst</i><br>
Thanks. Congratulations on the acquisition. Sounds like a really great asset. With the launch of the Business Solutions division, as you mentioned<br>in the release, does this suggest that this acquisition is adding a new vertical for you, and/or is there any increase in the $10 billion-plus TAM that<br>you've discussed? And then I have a quick follow-up.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>314</i><br>
<hr>
<A name=315></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes. So I wouldn't call it new vertical. Right? I think this is just kind of a natural extension of solutions into our existing customer base, if you will.<br>But what it does do, is it does increase our TAM, as we look at the opportunity. Right? So in terms of how we think about this, the idea of meetings<br>management and the spend associated with that for corporate meetings over time, is at issue very large. Right? If you look at it on an annual basis,<br>you are looking at about $350 billion that gets spent by corporations around the world on this segment.<br>
We are looking at being able to address somewhere around 1% additional of that spend with this solution, as we look forward. So you think of this<br>as kind of a total available market as something around $3.5 billion. So when you think about it, yes, this actually does expand our market. It's<br>actually is a pretty big market opportunity for us going forward, and we feel really good about the fact that now we have a real complete end-to-end<br>solution for the customer base.<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
Brian, I would add -- it's Alberga. I would add that what's interesting about it maybe, for us, we felt like it had the best of both worlds in that, we're<br>not going to a new customer set. We certainly expand our customer base with it, but we have lots of experience calling on this customer set. And<br>so, it's not a new vertical from that perspective. It is really just an expansion of our services to the same verticals in which we've operated before.<br>
<b>Brian Pitz</b><i> - UBS - Analyst</i><br>
Okay. And then I guess my follow-up, from a build versus buy perspective, is this something -- did you buy it more for the asset and the technology,<br>or more for the customer base? Because it sounds like they have a pretty good entree. You mentioned some of the customers are the same, but<br>are you really buying additional technology here, that's going to be folded into your existing platform? Maybe can you just us give a little color?<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
The answer is -- the answer is both. We're going to retain their technology platform. It's very good technology. It would have taken us a very big<br>effort to build the level of functionality that they've built over the years. And the second piece is, obviously, the fact that, that comes along with a<br>much broader expanded customer base that is not already necessarily using our attendee management software. That's a very nice complement.<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes, and some of the customers -- this is Matt -- some of the customers that we're adding like Deutsche Bank and Goldman Sachs, JPMorgan,<br>Microsoft, Apple, Pfizer, J&amp;J, GlaxoSmithKline, they are some great customers that we're adding. And the fact that these are not existing customers,<br>right? So most of these, the vast majority are complementary or additional new customer opportunities for us -- kind of, really heightens the interest<br>from that customer base standpoint as well.<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
But it's definitely not a, bring their customer base on and kind of throw away the technology, and roll our own technology out. That's not it. We're<br>going to integrate the technologies. They have very good technology. And so from both factors, it's a really good move for us. Both sides of it.<br>
<b>Brian Pitz</b><i> - UBS - Analyst</i><br>
Great. Thanks for the color.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>315</i><br>
<hr>
<A name=316></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
Yes.<br>
<b>Operator</b><br>
And our next question will come from the line of Nathaniel Schindler with Bank of America Merrill Lynch. Please proceed.<br>
<b>Nathaniel Schindler</b><i> - BofA Merrill Lynch - Analyst</i><br>
Two questions. One, just how their model has traditionally been done on a -- has it been paid on a per registration basis? I know you said they do<br>about 2.5 million registrations a year, but I wanted to know if they were ever actually paid that way, or whether that's just an artifact of the system?<br>Additionally, are there any modules that you -- that come with StarCite that you can leverage outside of the business vertical into some of your<br>other verticals? Or is this going to be really tied into expanding deeper into the business vertical?<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes. So I think from a standpoint of revenue, right? So I think primarily what they've done in the past, they've done in the past is a subscription-based<br>SaaS model. Right? So they're kind of going down that, so most of the revenue is based on that. Now, they actually will do it based on the number<br>of registrations and dollars spend, and they'll come up with that equation based on that, but it's actually a subscription model for SaaS. Right? So<br>that's what that other revenue category is. Having said that, the movement now is potentially towards this registration model, if you will, this per<br>sign-up model, if you will, and something that we'll be continuing to push. And I think that you will see continued growth in both sides of the<br>equation, both on a subscription SaaS-based revenue, and then also on the registration going forward.The second question was, sorry, the second<br>question was -- Nat, what was the second question again?<br>
<b>Nathaniel Schindler</b><i> - BofA Merrill Lynch - Analyst</i><br>
I was wondering if there were any modules that were useful outside of the business vertical?<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes. So we've chosen not to talk a ton about that, but my belief is that -- that this -- the ability to essentially to create this marketplace for suppliers<br>for this space is very applicable in our other verticals as well.<br>
<b>Nathaniel Schindler</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay. Would it be something like suppliers for hotel and lodging and the like in -- an Ironman Triathlon?<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Sure.<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
Yes.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>316</i><br>
<hr>
<A name=317></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Sure. Yes.<br>
<b>Operator</b><br>
And our next question will come from the line of Aaron Kessler with Raymond James. Please proceed.<br>
<b>Aaron Kessler</b><i> - Raymond James - Analyst</i><br>
Yes, hi, and congrats. A couple questions. Just on the financials, can you give us a sense of maybe what the normalized revenues in EBITDA would<br>be, if it wasn't for the purchase accounting treatment?<br>
<b>Scott Mendel</b><i> - Active Network Inc - CFO</i><br>
Yes. So the purchase accounting treatment in 2012, as I mentioned, about -- between $10 million and $12 million on the deferred revenue haircut,<br>and $2 million on integration costs. Without that, we would expect it to be more like a $47 million revenue number for 2012, and about $6 million<br>of EBITDA.<br>
<b>Aaron Kessler</b><i> - Raymond James - Analyst</i><br>
Okay. Great. Where is the company headquarters and number of employees?<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
Yes, so about 300 employees in the headquarters -- the major facility is in Philadelphia, with a development group in San Jose, California, and then<br>also one over in Shanghai.<br>
<b>Aaron Kessler</b><i> - Raymond James - Analyst</i><br>
Okay, great. Thank you.<br>
<b>Operator</b><br>
And our next question will come from the line of Brian Schwartz with ThinkEquity. Please proceed.<br>
<b>Brian Schwartz</b><i> - Thinkequity - Analyst</i><br>
Yes, hi. Thanks for taking my questions. And I, too, would add the congratulations. I think it's the biggest deal you've done here since becoming<br>public. Two questions. First question, Dave, StarCite was pretty well-known in the SaaS community. They were an early SaaS company that was<br>growing really fast. And along the way the business slowed here. And I don't know if that was because of the recession, or they reached market<br>saturation, or what really happened. I had been hearing recently, though, that that business had reaccelerated and was doing better. My question<br>really for you is, can you talk a little bit about -- I guess the go-to-market strategy, or what gives you the confidence that this business will grow<br>faster 12 months from now than the rest of your segments? And then I have one follow-up. Thanks.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>317</i><br>
<hr>
<A name=318></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
I'll -- I'm going to let Matt field the question. He's indicating to me, he'd like to field it, so that's fine. Go ahead, Matt.<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes. So actually, the slowdown, primarily, initially, was due to the recession and the economy. No question there. And then the second piece of it<br>was really a move to work away from, or work the business away from a particular channel. And it was a low profitability channel, and really just<br>disintermediation of a particular partner within that channel to allow for the business to move forward directly with the vendor marketplace. And<br>that actually has slowed down the growth, but that had been worked out really as part of -- largely in 2010, then also kind of trailing off in 2011, in<br>those two years. So that now the underlying growth should be able to come to the surface and should be able to accelerate. So I think those are<br>the two major factors, in terms of slowing growth. And as that process gets worked through, and quite honestly, as the distractions of the acquisition<br>fall to the wayside here, and they're working with us, and a larger sales effort and sales team, with a better, more robust solution set, we really feel<br>very positive that you are going to start seeing that revenue accelerate.<br>
<b>Brian Schwartz</b><i> - Thinkequity - Analyst</i><br>
Great. Thank you for that color. That was very helpful. Then my follow-up question really for Scott is, I was just wondering if StarCite, if they had<br>any revenue internationally? Or again, for Matt, if they were distributing internationally, just wondering if this is additive at all to your overall<br>international exposure? Thanks.<br>
<b>Scott Mendel</b><i> - Active Network Inc - CFO</i><br>
They do have a little bit of international revenue, but nothing material. So it won't radically change our revenue footprint internationally. They do<br>service global events, just like we have in the past, as well, and Matt mentioned a couple of the big marquee customers that they service.<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes, we view international is a big opportunity for us, for the very reason that they don't have a lot of revenue in that category now. The product<br>is actually available in 14 languages, right? Yes.<br>
<b>Operator</b><br>
(Operator Instructions).<br>
And our next question will come from the line of Steve Rubis with Stifel Nicolaus. Please proceed.<br>
<b>Steven Rubis</b><i> - Stifel Nicolaus - Analyst</i><br>
Hi. Thanks for taking my question, and congratulations on the acquisition. Can you discuss your outlook for the professional event management<br>industry in 2012? And then can you provide some details around the seasonality of the professional management business, and StarCite as well?<br>And how it compares to the current seasonality for you?<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>318</i><br>
<hr>
<A name=319></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes, our outlook on the businesses that we see it continuing to be a strong business moving forward. Right? So I think that 2011 for us was a strong<br>business -- we saw a lot -- we saw a strong year. A lot of the issues from the recession seem to have gone away, and general optimism is out there<br>within our customer base. So we feel good that this will continue as we move into next year.<br>
<b>Scott Mendel</b><i> - Active Network Inc - CFO</i><br>
Seasonality-wise, given the subscription revenue model, with over half of being that, and there's no real seasonality to the business event space.<br>It doesn't have -- it doesn't exhibit the same seasonality that our large legacy businesses do.<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes. If anything, it would be counter cyclical, just because a lot of the events occur towards the Q4 time frame, and generally don't occur during<br>the same summer months, where you have a lot of our other business that occurs. So in general, it's a nice fit with us going forward, but as Scott<br>said, due to the subscription nature of StarCite, there's not as much seasonality there.<br>
<b>Steven Rubis</b><i> - Stifel Nicolaus - Analyst</i><br>
Great. And then secondly, would you mind discussing your thoughts on future M&amp;A opportunities? Obviously, probably won't be able to name<br>names or anything like that, but could you kind of give us some color, in terms of whether you are probably going to still focus on the professional<br>management segment? Or do you see opportunities in some of your other verticals, both going forward?<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Yes, in terms of -- just in general, we view the market -- it's a big marketplace. It's highly fragmented. And in general, we think there are M&amp;A<br>opportunities through all our different verticals as we move forward. And in fact, there's a decent pipeline of those opportunities. Once again, we're<br>looking for the right opportunities that fit both strategically and are accretive. And as we identify those and believe that it's the right timing to do<br>those types of deals, I think we will continue to do those.<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
We're not, to be clear, we're not specifically only looking at the business event space exclusively. That's not part of our strategy.<br>
<b>Steven Rubis</b><i> - Stifel Nicolaus - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
And our next question will come from the line of Collis Boyce with Levin Capital. Please proceed.<br>
<b>Collis Boyce</b><i> - Levin Capital - Analyst</i><br>
Hi. Could you just clarify, I'm not sure I heard it properly. Was the $6 million, roughly $6 million EBITDA for the business, was that a 2011 number,<br>or was that the Company's forecast for 2012?<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>319</i><br>
<hr>
<A name=320></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Scott Mendel</b><i> - Active Network Inc - CFO</i><br>
That's the forecast for 2012, relative to StarCite's stand-alone. So between negative 5 and negative 6, for how it would be reported. On a pro forma<br>basis -- it would be positive.<br>
<b>Collis Boyce</b><i> - Levin Capital - Analyst</i><br>
No, no, when you were talking about the price, was that based on a 2011 number or 2012 number?<br>
<b>Scott Mendel</b><i> - Active Network Inc - CFO</i><br>
2012.<br>
<b>Collis Boyce</b><i> - Levin Capital - Analyst</i><br>
Okay. Got it. Thank you.<br>
<b>Operator</b><br>
Our next question will come from the line of George Askew with Stifel Nicolaus. Please proceed.<br>
<b>George Askew</b><i> - Stifel Nicolaus - Analyst</i><br>
Yes, thanks. Steve Rubis and I are in different spots, and I joined a little bit late, so I apologize if I am going to ask you to repeat yourself. But the<br>deal obviously gives Active scale in the business event space. Would you share with us your positioning now in the industry? Are you, for example,<br>the clear number one player? Is there a collection of players at the top, including yourselves, Cvent and others, or kind of where are you in that<br>leadership scale?<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
Well, from a revenue standpoint, we believe we're the clear number one in the space, probably close to at least twice the size of the next biggest,<br>right? And from a high-end solutions standpoint, right -- top of the line, we believe we're the clear number one, as well in terms of dealing with<br>major corporations going forward. I think that there's different niches within the business, and that we've got some serious competitors, there's<br>no question about it, in terms of how it breaks out from a pyramid standpoint. But we feel like we're very well-positioned now within the Fortune<br>500 and even the Global 2000 with the StarCite acquisition, and clearly number one in terms of revenue.<br>
<b>George Askew</b><i> - Stifel Nicolaus - Analyst</i><br>
Is there a market share number you can give us that makes sense?<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
Too many private companies.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>320</i><br>
<hr>
<A name=321></a>JANUARY 06, 2012 / 4:00PM, ACTV - Active Network Inc to Discuss the StarCite Acquisition Conference Call<br>
<b>Matt Landa</b><i> - Active Network Inc - President</i><br>
George, it's awfully tough. It's a lot of guesswork there. So there are just too many -- there are too many private companies with significant position<br>in the market.<br>
<b>George Askew</b><i> - Stifel Nicolaus - Analyst</i><br>
Okay. Fair enough. Thank you very much.<br>
<b>Operator</b><br>
Thank you. Ladies and gentlemen, this concludes our question and answer portion of today's call. I would now like to turn the call back over to<br>CEO Dave Alberga for closing comments.<br>
<b>Dave Alberga</b><i> - Active Network Inc - CEO</i><br>
I actually didn't have further closing comments. It's something, I've actually spent time with a lot of you recently. It's something we're very excited<br>about. We think it's a very easy and natural extension of what we're already doing in the space. We continue to look at other opportunities. This is<br>not -- we look across all four verticals that we're operating in for opportunities like this.<br>
So please don't get the impression that, in fact, we're on some kind of strategic shift, over specifically over to this vertical over others. We are not.<br>We just felt like the strategic fit of this business with our existing business was warranted doing this deal. And so we're very, very excited about it.<br>We -- I look forward to being able to show you how the integration is going in the future. So thank you very much. I really appreciate you being on<br>the call, and giving us the time you have.<br>
<b>Operator</b><br>
Thank you for your participation in today's conference. This concludes the presentation. You may now disconnect. Good day, everyone.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4701110-2012-01-09T12:30:45.960</b><br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>321</i><br>
<hr>
<A name=322></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
HMV.L - HMV GROUP PLC CHRISTMAS<br>TRADING UPDATE CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 8:00AM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>322</i><br>
<hr>
<A name=323></a>JANUARY 09, 2012 / 8:00AM, HMV.L - HMV Group PLC Christmas Trading Update Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Simon Fox</b><i> HMV Group plc - CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>James Davey </b><i>Thomson Reuters - Media</i><br>
<b>Katie Linsell</b><i> Bloomberg - Media</i><br>
<b>Zoe Wood </b><i>The Guardian - Media</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Thank you for standing by and welcome to the HMV trading update conference call. (Operator Instructions). I must advise you that the conference<br>is being recorded today, Monday, January 9, 2012. I'd now like to hand the conference over to your speaker today, Mr. Simon Fox. Please go ahead,<br>sir.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Thank you. Good morning everyone. Happy New Year. We last spoke on December 19 when we announced the Group's interim results and since<br>then we've seen a better overall picture for the December period. HMV Retail like-for-like sales showed an improvement in their trajectory, down<br>8.2% for the five weeks to December 31 compared with the previously reported seven weeks to December 17 when HMV retail like-for-like sales<br>were down 13.2%.<br>
The numbers have been particularly affected by a very weak games market. As you may have seen reported, the games market was down 16%<br>over the festive period.<br>
We achieved strong market share in our core categories of music and film, in part due to our highly competitive pricing. On DVD and Blu-Ray, our<br>Christmas best sellers included the Inbetweeners movie, which sold well over 1m copies across the market in its first seven days and became our<br>biggest ever week one DVD release. Harry Potter and the Deathly Hallows Part 2 and Hangover Part 2 also performed strongly. And we experienced<br>impressive sales of comedy DVDs from the likes of Peter Kay, Lee Evans and Sarah Millican, who became the fastest ever selling female stand-up<br>artiste. Frozen Planet led the way in TV-related product.<br>
In music HMV did particularly well with Michael Buble's chart-topping Christmas album, while our press and PR activities helped to play a key part<br>in getting the Military Wives' Choir single to be the Christmas number one.<br>
We also saw strong numbers in sales of our personal technology products over the Christmas period. In the 144 stores refitted with an extended<br>range of portable digital products, technology like-for-like sales rose 51% in the five weeks to December 31, an improvement in the previously<br>reported average of 42% since the respective store refit dates.We've sold 500,000 pairs of headphones in December -- that's one every two seconds<br>-- and 20,000 tablet computers.<br>
The strategic review of HMV Live announced at the interims is continuing to make good progress.<br>
Of course we anticipate that trading conditions and the consumer environment will continue to be challenging, but we remain confident in the<br>HMV brand and in the future prospects of our business.<br>
And, with that, over to your questions.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>323</i><br>
<hr>
<A name=324></a>JANUARY 09, 2012 / 8:00AM, HMV.L - HMV Group PLC Christmas Trading Update Conference Call<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
Thank you. We will now begin the question and answer session. (Operator Instructions). And your first question comes from James Davey from<br>Reuters. Please go ahead.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Good morning, Simon. Happy New Year to you.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
And to you, James.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Just on I wonder if you could just say a few words about why you still have the confidence in HMV's future prospects given that obviously what<br>you've said about the going concern earlier in December?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Well, look, I think we feel confident because, firstly, the measures we're taking to start to turn the business around are starting to bear fruit. So the,<br>in particular obviously, the technology initiative, and in particular, and it's very early days, some of the things we're doing to drive online and digital.<br>We have a very supportive supplier base. We have a supportive banking base. And therefore although we've repeated, as we have to, what we said<br>before Christmas, we still feel confident in the future of the business and the fact that it's going to be around for some time to come.We're heading<br>in the right direction and we have a supportive group of stakeholders.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Okay. Just on the progress you're making on technology, in those 144 stores can you give a like, an overall like-for-like figure to see how, get a<br>sense of how those stores compare to the rest of the estate?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Overall those stores will be tracking 4% better than the Group that haven't had the refit.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Right, okay. And the difference between the 13.2% you reported in December for the first seven weeks and then the 8.2% you reported now, that<br>difference, would you -- you did say that there would be an improvement. The improvement that you achieved, was that in line with what you<br>expected? Or obviously you were hoping for more, but did -- was that basically what you thought would happen?<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>324</i><br>
<hr>
<A name=325></a>JANUARY 09, 2012 / 8:00AM, HMV.L - HMV Group PLC Christmas Trading Update Conference Call<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Yes, it's broadly in line with what we were expecting. Clearly these are still disappointing results, but they're broadly in line with our expectations.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Okay. And in terms of the full year consensus, what was your understanding of what that was going into today? Was it about breakeven and are<br>you anticipating any changes?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
No, we're not anticipating any changes. It was about breakeven when we last reported on the 17th -- sorry, on the 19th. We didn't see any changes<br>then and we don't expect to see any changes as a result of today's figures.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Okay. So two years of breakeven, do you need to see an improvement in the like-for-like?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
That's a very specific question. I think that we wouldn't expect to see much variation from the numbers that you've been seeing as we run into the<br>final few months.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Okay. Thank you very much.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
Your next question comes from Katie Linsell from Bloomberg. Please go ahead.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Morning, Simon.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Morning.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>325</i><br>
<hr>
<A name=326></a>JANUARY 09, 2012 / 8:00AM, HMV.L - HMV Group PLC Christmas Trading Update Conference Call<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
I wanted to ask a few more questions about the HMV Live strategic review. You've been saying how you're seeing good progress, but I wonder<br>whether it's possible to tell us any more about whether a sale is likely and whether you might have a deadline on that sale. I know before we've<br>talked about your debt having a factor on that.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Yes. No, I can't give you any more detail at this stage other than to say that we kicked the process off a couple of weeks ago. It will take some weeks.<br>And when there is more to say we will certainly let you know. But there is no specific deadline that we're working to.<br>
Specifically your question about the debt, what we said last time in terms of why a sale might be the outcome of the review is that we do have a<br>tranche of debt, called tranche B, which attracts an interest rate that rises over a period of time, ratcheting up in particular in January 2013. And<br>clearly one of the options we have is to pay that debt down before the interest rate becomes onerous.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Okay, thank you. And also previously on the last call you talked about the opening on December 24 and that Saturday could help your Christmas<br>sales. Can you give us any kind of figure as to what sales were made that day or how that day might have helped your sales figures?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Yes. What I talked about obviously with Christmas falling on a Sunday was that the run-up to Christmas for us and every other retailer was quite<br>different this year. What we found, and I suspect most other retailers found, that was that in fact the Thursday and Friday before Christmas turned<br>out to be the busiest days, and that Christmas Eve itself, the 24th, whilst an important day, actually I think most people had done their shopping<br>by then. So in the end it was the Thursday and Friday that were the peak of Christmas.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Okay, brilliant. And is it possible to give any kind of percentage as to what your -- what December represented in terms of annual sales?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
December is about 20%, a little more than 20% of annual sales.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Okay. Is that in the average year for you or --<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Yes. Yes, it's always about that.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Okay. And do you think it will represent the same for this year as previous years?<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>326</i><br>
<hr>
<A name=327></a>JANUARY 09, 2012 / 8:00AM, HMV.L - HMV Group PLC Christmas Trading Update Conference Call<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Yes.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Okay, brilliant. And a lot of focus is going into this switch to technology products, the MP3 players and headphones. It was interesting to hear a<br>few figures about those that were sold. How did they compare with sales of CDs and DVDs?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Technology is now representing about 12% of our sales so it's still a small category in relation to our other categories. So CD is about a quarter and<br>DVD is about 45%, and the balance is games. It's clearly growing fast and over the next few years we have said that we expect technology to grow<br>to up to about 30% of our sales mix.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Okay.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
In terms of our other categories, it was actually good, it was a particularly good Christmas for DVD and music was broadly where expected, and<br>games was weak.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Okay. Okay.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
I'm sorry, I've just been tapping my calculator and I think December is nearer 25% than 20%. And that again, same this year as previous years.<br>
<b>Katie Linsell</b><i> - Bloomberg - Media</i><br>
Okay. Thanks for your time.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
(Operator Instructions). Your next question comes from Zoe Wood from The Guardian. Please go ahead.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>327</i><br>
<hr>
<A name=328></a>JANUARY 09, 2012 / 8:00AM, HMV.L - HMV Group PLC Christmas Trading Update Conference Call<br>
<b>Zoe Wood</b><i> - The Guardian - Media</i><br>
Hi, Simon.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Hello, Zoe.<br>
<b>Zoe Wood</b><i> - The Guardian - Media</i><br>
Hi, just returning to your overall view of Christmas, I think going into the period you said fingers crossed. These are in line. Did it pan out better<br>than you expected or was in line with your worst expectations?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
I think neither. It was broadly in line with our expectations. You always hope that your expectations will be exceeded. In the end the trading was<br>broadly on the trajectory we expected it to be on.<br>
<b>Zoe Wood</b><i> - The Guardian - Media</i><br>
Okay. So that at least is encouraging given that it's -- we're seeing an acceleration.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Yes, indeed.<br>
<b>Zoe Wood</b><i> - The Guardian - Media</i><br>
Okay. And you mentioned in last month's results about the need to speak to suppliers and negotiate a material improvement in conditions. Are<br>those negotiations continuing or did you get what you asked for?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
I don't think you'd expect me to go into the details of commercially sensitive discussions with our suppliers. So as I said earlier, we have supportive<br>suppliers. They've been supportive right through last year. They continue to be supportive. And so we're important to them and they're very<br>important to us.<br>
<b>Zoe Wood</b><i> - The Guardian - Media</i><br>
Okay. And then just finally a bit more, a bit about the consumer mood. Do you think that people were being more frugal this year or what was the<br>transaction value like?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>328</i><br>
<hr>
<A name=329></a>JANUARY 09, 2012 / 8:00AM, HMV.L - HMV Group PLC Christmas Trading Update Conference Call<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Our transaction value was a little bit down year on year so I do think people were very cautious and price-sensitive. Our own prices were highly<br>competitive, which certainly helped us, particularly on our DVD offer. But no doubt we're going to continue to see a very price-sensitive and careful<br>customer.<br>
<b>Zoe Wood</b><i> - The Guardian - Media</i><br>
And did you see sales immediately tail off post-Christmas? Other retailers are suggesting that people used up their money in the run-up to Christmas<br>and there was nothing left for the sale.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
We are a very pre-Christmas retailer so by far our biggest week is the week in the run-up to Christmas and that's probably four times the size of the<br>week after Christmas. So unlike, for example, big ticket retailers, electricals and furniture, who would seek bigger sales post-Christmas, we are a<br>gift, a gifting retailer.<br>
<b>Zoe Wood</b><i> - The Guardian - Media</i><br>
Okay, thank you.<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Thank you, Zoe.<br>
<b>Operator</b><br>
You have a further question from James Davey from Reuters. Please go ahead.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Yes, hi. Some of the analysts seem to be suggesting they may have to look at other asset sales in addition to HMV Live. Is it possible that your stake<br>in 7digital could come on the block as well?<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
I think we've said that it's something that we could look at. But I can certainly tell you at the moment there is no process ongoing in relation to<br>that. But it is a valuable asset. But there's no process at the moment in respect of it.<br>
<b>James Davey</b><i> - Thomson Reuters - Media</i><br>
Okay. Okay, thank you.<br>
<b>Operator</b><br>
(Operator Instructions). We have no further questions at this time, sir. Please continue.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>329</i><br>
<hr>
<A name=330></a>JANUARY 09, 2012 / 8:00AM, HMV.L - HMV Group PLC Christmas Trading Update Conference Call<br>
<b>Simon Fox</b><i> - HMV Group plc - CEO</i><br>
Thank you very much everybody for joining us and for your interest, and we will speak before too long. Thank you very much. Happy new year.<br>
<b>Operator</b><br>
That does conclude our conference for today. Thank you all for participating. You may now disconnect.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4702993-2012-01-09T14:59:22.183</b><br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>330</i><br>
<hr>
<A name=331></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
PENX - Q1 2012 PENFORD CORP<br>EARNINGS CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 4:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>331</i><br>
<hr>
<A name=332></a>JANUARY 09, 2012 / 4:00PM, PENX - Q1 2012 Penford Corp Earnings Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Steve Cordier</b><i> Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
<b>Tom Malkoski</b><i> Penford Corporation - President, CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Lucy Watson</b><i> Jefferies &amp; Company - Analyst</i><br>
<b>Frank Rango</b><i> Purchase Capital Management - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Greetings and welcome to the Penford Corporation fiscal-year 2012 first-quarter results. At this time, all participants are in a listen-only mode. A<br>brief question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder, this conference is being recorded.<br>
It is now my pleasure to introduce your host, Steve Cordier, CFO for Penford Corporation. Thank you, sir. You may begin.<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
Thank you, Dan. Good morning, everyone. Thank you for participating on our conference call to discuss Penford's first-quarter fiscal 2012 financial<br>results. Joining me on the call is Tom Malkoski, President and Chief Executive Officer of Penford Corporation.<br>
Before we get started, let me caution you about any forward-looking comments we might make this morning. Any forward-looking statements<br>regarding future events or the financial performance of the Company are just predictions, and actual events or results may differ materially. These<br>forward-looking statements are subject to numerous risks and uncertainties. These include the performance of the economy as a whole and its<br>impact on Penford's customers; increased competition; raw material chemical and energy costs; litigation; the Company's ability to access financial<br>markets; interest-rate changes; changes in returns on pension plan assets and/or assumptions used for determining employee benefit expenses<br>and obligations.<br>
Please refer to the documents that we file from time to time with the Securities and Exchange Commission for a discussion of these and other risks<br>and uncertainties. And finally, we do not undertake to update publicly any forward-looking statements to reflect new information, events or<br>circumstances after the date of this call or to reflect the occurrence of unanticipated events.<br>
I will offer some comments on the financial results and segment operations.Tom will discuss future prospects for Penford and the pending acquisition<br>of Carolina Starches.<br>
Today, we reported that consolidated sales for the first quarter of fiscal 2012 rose 26% to $90.7 million from $72.3 million last year. Both business<br>segments achieved record sales levels for the quarter.<br>
Volume gains in the Food business and Industrial Specialty Bioproducts, along with improved unit pricing in both segments, contributed to the<br>revenue increase.<br>
Quarterly gross margin of $11.8 million expanded 28% over last year, and gross margin as a percent of sales was 13% compared with 11.9% a year<br>ago. This improvement reflects higher revenues, an increasing contribution to growth and profitability by the Food Ingredients and Industrial<br>Specialty Bioproducts businesses, as well as better processing and manufacturing fees in the Industrial division.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>332</i><br>
<hr>
<A name=333></a>JANUARY 09, 2012 / 4:00PM, PENX - Q1 2012 Penford Corp Earnings Conference Call<br>
Operating expenses were $6.1 million or 6.7% of sales compared with 7.2% last year. Research and development costs rose 22% from a year ago<br>to $1.3 million, reflecting our commitment to investments in technical staff, applications development and new product trials.<br>
Consolidated operating income for the first quarter of $4.4 million was 47% higher than a year ago. Interest expense increased $100,000 to $2.4<br>million, and reflects dividends at a rate of 15% on the redeemable preferred stock issued in April 2010. The tax rate was 70%, primarily due to the<br>effect of the preferred stock dividends, which are not deductible for tax purposes.<br>
Consolidated cash flow from operations for the first quarter was $12.2 million versus $4.7 million a year ago, reflecting lower working capital<br>requirements, particularly for corn funding needs. Capital spending was $2.5 million for the first quarter, and we expect capital spending to ramp<br>up in the next three quarters to total approximately $16 million for fiscal 2012.<br>
Total debt, including preferred stock, capitalized leases and $1.6 million payable to the state of Iowa, was $58.4 million. The debt-to-capital ratio<br>was 41%. At November 30, 2012, the Company had $16.1 million outstanding on its $60 million revolving credit facility, down $6 million from the<br>end of the previous quarter. And I referred to November 30, 2011. Sorry about that.<br>
Food Ingredients reported record quarterly revenue of $25.9 million, an increase of 41% over the first quarter a year ago. Sales of products in all<br>end categories, including coating applications, expanded at double-digit rates, while sales of gluten-free and companion pet applications more<br>than doubled in the period. Sales of non-coating applications now contribute over 60% of segment revenue and a substantial portion of revenue<br>growth in the quarter.<br>
Sales of coatings applications showed strong sequential and year-on-year growth this quarter, driven largely by a significant customer conversion<br>to a new formula supplied by Penford. This product conversion reflected an inventory drawdown in our fourth quarter, followed by restocking of<br>the new formulation in our first quarter of fiscal 2012.<br>
Gross margin climbed 29% to a record $8.2 million from $6.4 million last year increased volumes, higher manufacturing utilization rates and lower<br>product launch costs.<br>
Operating income increased 24% to $6 million from $4.8 million a year ago, also a record for our Food business.<br>
Industrial Ingredients sales were $64.8 million in the first quarter, a 20% increase over last year. The growth in revenue reflects the corn costs that<br>were passed through to customers, as well as better unit pricing for industrial starches and stronger market prices for ethanol.<br>
Sales of Specialty Bioproducts expanded by more than 40% in the quarter on improvements in both volume and average unit pricing.<br>
Fuel ethanol prices market prices have increased 25% from a year ago. Penford's ethanol revenue expanded 32% to $32.4 million in the first quarter,<br>and the VTEC credit expiration on December 31 could affect demand in the short-term.<br>
Penford's manufacturing input costs remain at historically elevated levels, with industry net corn prices more than 50% above the prior year and<br>key chemicals rising by more than 20% year-over-year.The corn basis quantifying the local premium or discount applied to obtain physical supplies<br>remains above historical levels, but is decreased from the very high premiums paid in the fourth quarter of fiscal 2011.<br>
Corn pass-through pricing programs, better procurement results and the increasing proportion of Specialized Products in the sales mix have<br>allowed the business to largely overcome these cost factors.<br>
Industrial gross margin for the first quarter increased $700,000 from last year. Changes in average unit pricing for both industrial starch and ethanol<br>more than offset higher input costs for corn and chemicals. Strong growth in Specialty Bioproducts also contributed to the better overall result.<br>
Operating income in the first quarter rose to $700,000 from $100,000 a year ago. I will now turn the call over to Tom.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>333</i><br>
<hr>
<A name=334></a>JANUARY 09, 2012 / 4:00PM, PENX - Q1 2012 Penford Corp Earnings Conference Call<br>
<b>Tom Malkoski</b><i> - Penford Corporation - President, CEO</i><br>
Thank you, Steve. The Company's businesses turned in a solid start to our new fiscal year in terms of revenue growth, improved profitability and<br>new business gains in Food and in Specialty Industrial Bioproducts. Both segments reported record revenue in the quarter, driven by volume and<br>new business gains, better pricing and pass-through of higher corn costs. Operating income was the best quarterly result in over three years.<br>
And I am particularly encouraged by the strong revenue gains in segments where we have strategically targeted to grow, food ingredients that<br>provide functional properties and health and wellness benefits and specialty clean technology bioproducts for more sustainable industrial<br>applications.<br>
As Steve mentioned, both our Food business and our Industrial Bioproducts grew by more than 40% in the quarter.<br>
We are cautiously optimistic in our view on fiscal 2012. First, we are nearing completion of Industrial starch contract negotiations, and expect to<br>realize significant improvement in pricing by the end of our second quarter versus 2011. Second, our ability to manage the wide fluctuations in<br>commodity markets has improved, corn prices and chemical costs remain at elevated levels, and ethanol market dynamics fluctuate constantly.<br>Improved management of these market factors should contribute to more favorable net corn costs, starch margins and ethanol fresh margins.<br>
Third, the pacing of commercial success of introducing differentiated, higher-value products and applications has accelerated, and this is an<br>important element of sustainable profitable growth for Penford.We've committed more resources, both investment capital for specialized equipment<br>and human capital, to developing technologies and applications that have a measurable impact on the performance of our customers' products<br>and their cost and use. We expect the strong growth in Food and Specialty Bioproducts to continue into 2012.<br>
Lastly, we have reached agreement with our bargaining unit employees at our Cedar Rapids facility to extend the current labor agreement by three<br>years through July 2015.<br>
The Carolina Starches acquisition is progressing, and we plan to close the transaction shortly. We will provide more information following the<br>closing of this strategic acquisition.<br>
Finally, in addition to our own internal efforts to develop sustainable bioproducts, we continue to evaluate external prospects for partnering to<br>develop, manufacture and commercialize novel green technologies. We believe that the combination of innovative starch products, flexible<br>chemical and fermentation processes and our culture of selling highly-specialized bioproducts can create future business opportunities for PENX.<br>
To this end, we will soon be formally announcing a joint development agreement with Novomer in which our companies will work cooperatively<br>toward the creation of novel, high-performance biopolymers that are both sustainable and cost-effective.<br>
We thank you for your interest in Penford and please open the call for questions.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions) Laurence Alexander, Jefferies.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>334</i><br>
<hr>
<A name=335></a>JANUARY 09, 2012 / 4:00PM, PENX - Q1 2012 Penford Corp Earnings Conference Call<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
Good morning.This is Lucy Watson on for Laurence today. A couple of quick questions on ethanol. It looks like ethanol margins are likely to compress<br>in Q2. Have you taken any measures to offset that, or could you provide a little bit more color on the comments about mitigating the volatility in<br>ethanol?<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
Industry crush margins in ethanol have come down in the second quarter of our fiscal year. We had anticipated that and mentioned it on prior<br>conference calls.<br>
Since we had looked at that coming toward us, we have taken some hedges where possible, and we expect that while the sequential<br>quarter-over-quarter comparison will probably dip a bit for Penford, we will probably be in a higher crush margin outcome than most of the current<br>market projections for people who are doing spot ethanol trades.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
Okay, and you also made a comment about the VTEC credit expiration possibly affecting demand in the near term. Since it has been a few days<br>since the credit expired, have you seen any difference or fluctuation yet?<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
I think most of the impact -- and those two elements are related, by the way. I think that the drop in anticipated demand is contributing to the<br>prediction of lower crush margins in our second fiscal quarter for the marketplace.<br>
We think there is evidence of the beginning of some inventory build as production continues to run, while some of the demand is being taken<br>from inventory stores, and that the supply-demand fulcrum is probably going to be tilted a little bit more towards supply for at least the 60 days<br>following the beginning of the calendar year.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
Okay. And a question on liquid natural additives in your other specialty products -- how large a percent of sales are those? Is that the remaining<br>40% that is non-coating? I guess would you be able to provide a breakdown in the Industrial Ingredients segment? And how fast are the specialty<br>products growing?<br>
<b>Tom Malkoski</b><i> - Penford Corporation - President, CEO</i><br>
Let me separate out. I think you have two topics in there.When we refer to the coatings or non-coatings, that really is our Food side of our business.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
Okay.<br>
<b>Tom Malkoski</b><i> - Penford Corporation - President, CEO</i><br>
And when we refer to the Specialty Bioproducts, that is in our Industrial segment, along with our starch and ethanol.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>335</i><br>
<hr>
<A name=336></a>JANUARY 09, 2012 / 4:00PM, PENX - Q1 2012 Penford Corp Earnings Conference Call<br>
Starch and ethanol still make up the vast majority of the Industrial business on a volume and revenue basis. Combined, they would account for<br>somewhere near 90% of the Industrial segment. And the Specialty products would be approaching that 10% or so.<br>
The growth rate in the Specialty products has been running around 25% quarter over quarter for a number of quarters, going back the last couple<br>of years. The pacing on that has accelerated; this quarter, we announced it was more than 40%, and we expect that we will continue to see a more<br>accelerated growth than that 25% pacing that we've had in the past.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
So that 40% was a sequential increase, not a year-over-year?<br>
<b>Tom Malkoski</b><i> - Penford Corporation - President, CEO</i><br>
It was year-over-year.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
Okay. And how are the margins on those Specialty products compared to the rest of the Industrial business?<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
They are significantly higher. So the contribution of the specialty bioproducts, including the liquid natural additives, is a significantly higher<br>proportion than the volume of 10% that Tom just mentioned.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
Okay, and then just one question on Food Ingredients. Are you seeing customers do trials to try and formulate new product ingredients now, or<br>are they still more focused on finding products to reduce cost?<br>
<b>Tom Malkoski</b><i> - Penford Corporation - President, CEO</i><br>
On our side, both the health and wellness side of our Food business has seen significant interest in new products rather than cost reformulations.<br>A lot of the basic parts of our Food Ingredients business, where I would've said that the balance was more towards cost savings opportunities in<br>the past couple of years, we have seen a shift, where there is a significant increase in the interest for new product news and new formulations.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
[Frank Rango, Purchase Capital Management]<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>336</i><br>
<hr>
<A name=337></a>JANUARY 09, 2012 / 4:00PM, PENX - Q1 2012 Penford Corp Earnings Conference Call<br>
<b>Frank Rango</b><i> - Purchase Capital Management - Analyst</i><br>
Good morning, gentlemen. Congratulations. Great quarter.Two questions. Number one, Tom, I didn't catch the partnership you were talking about<br>towards the end of your statements, name of your partner there.<br>
<b>Tom Malkoski</b><i> - Penford Corporation - President, CEO</i><br>
It is a joint development agreement with Novomer, N-o-v-o-m-e-r. And they are a small startup biotech. And there is a fair amount of information<br>available in the public domain about their business. But we expect to be announcing something more formally shortly.<br>
So both companies have agreed that we will hold back further comments until we get to that more public announcement.<br>
<b>Frank Rango</b><i> - Purchase Capital Management - Analyst</i><br>
Okay. Second question, with regards to the planned expansion, I know you guys are trying to purchase some land adjacent to the Cedar Rapids<br>plant. What is your thinking there? What do you plan to put there if you actually secure that property?<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
There are a number of opportunities that we believe that footprint can provide space to accommodate, certainly along the lines that we've talked<br>about with Specialty Bioproducts and the ability for us to in a more comfortable footprint put additional opportunities for product lines. That is<br>probably the primary purpose.<br>
Another ancillary purpose is that it does provide us with some opportunity, which we still have to evaluate, for optimizing our internal flow of<br>product inside the plant, as well as some additional opportunities for protecting the plant from flood. That was the area along the park where we<br>were first encroached during the flood of 2008.<br>
<b>Frank Rango</b><i> - Purchase Capital Management - Analyst</i><br>
Okay, got it. Other question was with regard to the Food business margins, which were obviously a record this quarter, how much of that bottom<br>line do you think was caused from the inventory loading from the coating product that you alluded to, which I assume is the french-fry coatings?<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
That's correct. I would say it was a notable part, but not a large fraction; probably less than 25% of the improvement.<br>
<b>Frank Rango</b><i> - Purchase Capital Management - Analyst</i><br>
Of the improvement -- quarter-over-quarter or year or sequentially?<br>
<b>Tom Malkoski</b><i> - Penford Corporation - President, CEO</i><br>
Year-over-year.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>337</i><br>
<hr>
<A name=338></a>JANUARY 09, 2012 / 4:00PM, PENX - Q1 2012 Penford Corp Earnings Conference Call<br>
<b>Frank Rango</b><i> - Purchase Capital Management - Analyst</i><br>
Year-over-year. Okay. Great. And just -- if you could just help me understand a little better.You know, with the fuel credit -- with the blending credit<br>going away on the ethanol, is that going to cause in the future just a $0.45 a loss of margin per gallon for ethanol? How does that work? That was<br>a pretty big prop under the price of ethanol.<br>
So you seem to be guiding towards lower margins, obviously, lower crush margins. But I am just trying to get a little better understanding of losing<br>that big prop, how is that going to affect the margins going forward more specifically?<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
I believe the change in the near term is really inventory management more than anything else.The VTEC credit is applied to blenders, so it doesn't<br>affect producers like Penford and our peers. Those who blend ethanol with gasoline do so for a number of reasons, importantly because of the<br>Renewable Fuel Standard, which still remains in effect, and calls for an increasing consumption of ethanol as we proceed through that program.<br>
The blender credit was helpful but not critical to that demand situation, in my opinion. But as that became an expiration threshold, a number of<br>people were rushing, as you would expect, to take advantage of the credit before it expired, and so they built up a finite amount of inventory that<br>now will be drained over the next 30,60, 90 days.<br>
<b>Frank Rango</b><i> - Purchase Capital Management - Analyst</i><br>
Okay, thanks. And one final question. Any more thoughts on doing something with the preferred stock come the April two-year anniversary, when<br>you guys will be permitted to retire that or repurchase it?<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
We have a number of choices facing us with the money that is available under our existing credit facility. We have less than $20 million drawn on<br>a $60 million facility.<br>
The preferred stock is redeemable at par in early April 2012. The use of our liquidity will certainly reflect a number of choices between taking that<br>preferred and redeeming some of that, our capital spending program, as well as the external opportunities. We are well aware that the economic<br>impact of the preferred stock on our reported results is significant and that will factor into those considerations.<br>
<b>Frank Rango</b><i> - Purchase Capital Management - Analyst</i><br>
Great. Thank you.<br>
<b>Operator</b><br>
(Operator Instructions) Laurence Alexander.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
This is Lucy on with just a quick follow-up. What percentage of your customer contracts are still up for renegotiation this year or completing<br>negotiations?<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>338</i><br>
<hr>
<A name=339></a>JANUARY 09, 2012 / 4:00PM, PENX - Q1 2012 Penford Corp Earnings Conference Call<br>
<b>Tom Malkoski</b><i> - Penford Corporation - President, CEO</i><br>
We have over 80% already contracted, and it actually might be slightly higher than that on a total percentage basis. And there are just a few more<br>that will likely get completed in the next four to six weeks.<br>
<b>Lucy Watson</b><i> - Jefferies &amp; Company - Analyst</i><br>
Okay, thank you.<br>
<b>Operator</b><br>
(Operator Instructions) It appears we have no further questions at this time. I would now like to turn the floor back to management for closing<br>comments.<br>
<b>Steve Cordier</b><i> - Penford Corporation - SVP, CFO, Asst. Secretary</i><br>
Thanks for your interest. If there are any further questions, you can reach Steve Cordier at the number at the top of the press release. Thank you<br>very much.<br>
<b>Operator</b><br>
This concludes today's teleconference. You may now disconnect your lines at this time and thank you for your participation.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4691525-2012-01-09T16:50:04.780</b><br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>339</i><br>
<hr>
<A name=340></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
NOVN.VX - NOVARTIS AG AT<br>JPMORGAN GLOBAL HEALTHCARE<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 4:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>340</i><br>
<hr>
<A name=341></a>JANUARY 09, 2012 / 4:00PM, NOVN.VX - Novartis AG at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Joe Jimenez</b><i> Novartis International AG - CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Alexandra Hauber</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Alexandra Hauber</b><i> - JPMorgan - Analyst</i><br>
Good morning, ladies and gentlemen. Welcome to the 30th Annual JP Morgan Healthcare Conference here in San Francisco.<br>
We should all have a few very interesting days ahead of us, and I believe this is actually one of the largest conferences we have ever hosted, with<br>7,600 registered participants. That's about 10% by more than we had last year, which will require a bit of discipline amongst all of us in terms of<br>our behavior in the aisles and mobile phone usage and things like that, so thanks for your cooperation here.<br>
I am Alexandra Hauber, European pharmaceutical analyst at JPMorgan, and I am very pleased to introduce now the first speaker this morning in<br>the Colonial Room, Mr. Joe Jimenez, CEO of Novartis. He will be giving a presentation for 25 minutes, and then be available for your questions<br>across the hall in the Georgia Room in a breakout session.<br>
Joe, thank you very much for being here today. The floor is yours.<br>
<b>Joe Jimenez</b><i> - Novartis International AG - CEO</i><br>
Thank you. Good morning. I think there's no better place than the Bay Area to talk about innovation, and today what I would like to do is talk about<br>how Novartis is changing the game in healthcare. But I want to do it in the context of the Novartis strategy and talking about how we leverage<br>what we call focused diversification. And then I want to talk a little bit about the future and why I believe that Novartis is one of the best positioned<br>healthcare companies for the next 10 years.<br>
Now, it's no surprise; everybody knows that the healthcare landscape is changing rapidly and it's changing dramatically. By the year 2020, there<br>will be over 700 million people who are over the age of 65, and we all know how that correlates very closely with demand for healthcare. At the<br>same time there will be more than 3 billion people on earth who are clinically obese, and all of the comorbidities that go with obesity.<br>
But if you just forget about the trends for a second and look at where we stand today, there is still huge unmet medical need in the world today.<br>For example in China there are over 900,000 people who need to be treated for cataracts, so cataract surgery, that don't have access to medicines.<br>In the US almost 75% of the total healthcare budget is spent on managing chronic disease.<br>
So there is a high level of unmet medical need, and trends suggest this is going to continue. So we are in a growth industry, and it's going to remain<br>a growth industry. The segments in which Novartis competes we project will grow between 5% and 6% per year for the next five years.<br>
But the issue is healthcare costs. Healthcare costs have increased as a percent of GDP for 50 years. Everybody continues to say they don't see how<br>this is going to continue; but if you look at trends and you look at history, it most likely is going to continue.<br>
So the question is -- who is going to win in this environment? I believe that the companies that are going to win are companies that are part of the<br>solution -- part of the solution on the cost side and also part of the solution on the innovation side to address unmet medical need.<br>
At Novartis, we have shaped our portfolio to be part of the solution in this new healthcare reality. So for example, we have a very large generics<br>division. If you look at our launch of enoxaparin in the US, which is generic Lovenox, we saved the US healthcare system over $700 million last year<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>341</i><br>
<hr>
<A name=342></a>JANUARY 09, 2012 / 4:00PM, NOVN.VX - Novartis AG at JPMorgan Global Healthcare Conference<br>
through this launch alone. Now, we are able to take this fact to developing markets around the world, single-payer systems, healthcare systems,<br>and this has great play.<br>
But it's not just the cost side where we are the solution. We are also one of the most innovative healthcare companies in the world. You look at<br>Novartis's history and the launch of Gleevec, the first genetically targeted oncology medication for chronic myeloid leukemia; the follow-on Tasigna,<br>which is an even more potent compound than Gleevec; and Gilenya, our first oral -- the first oral therapy for multiple sclerosis, which is a deadly<br>disease. So we are positioning Novartis as part of the solution both on the cost side and on the innovation side.<br>
Now let me talk a little bit about how we are leveraging this focused diversification, but I want to start with our strategy. Our strategy at Novartis<br>is crystal clear and it's very simple. We are winning through science-based innovation that is focused on high-growth segments of healthcare. So<br>it starts with the patient needs -- innovative medicines for breakthrough therapies, but all the way to affordable options through generics, and<br>self-care through over-the-counter drugs. So we have spent many years shaping this portfolio in a way that delivers on these needs.<br>
Within that strategy we have three simple priorities that we repeat every quarter, and we talk about how we're making progress.The first is extending<br>our lead in innovation. This is to ensure that our pipelines are best-in-class in the industry.<br>
The second is to accelerate growth.This means translating that innovation into sales and profit growth that hits the P&amp;L. And then the third priority<br>every quarter is to drive productivity that will improve our margins.<br>
Now many people ask me, what is the benefit of having a diversified healthcare company? Why aren't you just a pure-play pharma company? But<br>there are some very specific reasons.<br>
The first benefit that we use -- diversification as a competitive advantage -- is in our R&amp;D. So we share R&amp;D expense and expertise across all of our<br>divisions to accelerate development of the pipeline in those divisions.<br>
A perfect example is what we are doing with Sandoz, which is our generics division, and the Pharmaceutical division, working very closely to develop<br>biosimilars. All of the other divisions at Novartis are able to tap into the research center, the Novartis Institute of Biomedical Research. For example,<br>Animal Health has recently added 35 new compounds to their pipeline just by mining what is already in the Novartis Institute of Biomedical Research,<br>being developed for the Pharmaceutical business.<br>
The second way we leverage our diversification is through our product portfolio, and that's offering healthcare systems around the world integrated<br>solutions. An example of this is what we are doing with COPD in a number of health systems around the world, chronic obstructive pulmonary<br>disease.<br>
Not only are we able to go with an entire package of innovative pharmaceuticals like indacaterol, generics; over-the-counter drug products like<br>smoking-cessation products; and even vaccines for flu vaccine -- because if you've got COPD getting the flu can have serious consequences.Taking<br>those therapies, wrapping them in an integrated program, adding compliance programs to it.<br>
And we are shifting away from a transactional approach with these health systems where we are physically just selling pills, to an outcomes-based<br>approach where we are helping the healthcare system deliver a positive patient outcome. I believe that with the future over the next 10 years in<br>healthcare, this is going to be the way that companies are going to win.<br>
The third way that we leverage our portfolio is with governments to become a preferred partner. Examples. In Russia we have started programs<br>with regional health systems in Russia, government-owned health systems, where we are attacking cardiovascular disease much in the same way<br>that I talked about COPD, and we are helping them measure positive patient outcomes.<br>
This changes the way those governments think about Novartis. And it benefits the entire portfolio, from accelerated approval of some of our<br>compounds to accelerated reimbursement.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>342</i><br>
<hr>
<A name=343></a>JANUARY 09, 2012 / 4:00PM, NOVN.VX - Novartis AG at JPMorgan Global Healthcare Conference<br>
In China, same thing. We just received approval to Lucentis for wet macular degeneration in China, and this is going to be a new growth driver for<br>us in that business.<br>
The fourth way and final way that I think we are able to leverage this diversification is to build better talent. So for example, because we have<br>different divisions that have different key drivers, we are able to move our talent around.<br>
In Pharma we will learn innovation at its core; but in generics we learn how to move fast, how to opportunistically take advantage of opportunities<br>as we see them. Alcon is all about owning the retina specialist, the customer.They are all different skill sets, but they allow people to become better<br>leaders and better managers.<br>
If you just look at my direct reports, Jeff George, who runs the generics division, and Andrin Oswald, who runs the vaccines division, have both<br>spent time in multiple divisions and at relatively young ages are very strong managers. So I think this is another advantage that we have.<br>
Now we have a very strong track record that gives me confidence that we are on the right track. So if you just look at the last decade, Novartis has<br>been able to generate double-digit earnings growth, compound annual growth rate.<br>
We've been able to generate double-digit operating income growth. These are in US dollars, so in constant currencies they look even better than<br>this in terms of the growth rate on operating income. Double-digit EPS and double-digit dividend increases over a 10-year period.<br>
Now as everybody knows we're about to enter two relatively lean years at Novartis as we lose patent expiration on Diovan, which is our largest<br>antihypertensive. We have already lost exclusivity in Europe; that happened in November. And we will lose the US in late 2012. But the strength of<br>this portfolio and the fact that today Pharmaceuticals is just over 50% of our total healthcare portfolio allows us to overcome issues like patent<br>expirations in ways that other healthcare companies don't.<br>
Now let me spend just a minute talking about why I believe we are one of the best-positioned healthcare companies in the world. It starts with the<br>fact that our innovation has continued to be very successful in 2011.<br>
So if you look at the number of approvals of new drugs that we had in 2011, two very important ones were Gilenya, where we received approval<br>in Europe and in Japan; we already had approval in the US.This is our new multiple sclerosis drug.Those two approvals were critical for the long-term<br>ramp-up of Gilenya, and they were delivered in 2011.<br>
Another important approval up there is Lucentis for retinal vein occlusion and diabetic macular edema. As we are now seeing new competition in<br>wet AMD, these two new indications will allow us to focus and to drive Lucentis' growth continually even with that competition.<br>
Now, not everything went well in 2011. In fact many of you may have heard that in the month of December we announced that our ALTITUDE trial<br>was being stopped. Altitude is an outcomes study -- mortality and morbidity -- among diabetic patients that are renally impaired. It was an outcomes<br>study with aliskiren under the brand name Tekturna, the antihypertensive, added to standard of care.<br>
The DMC recommended that we stop this trial for futility, but also because there were a higher number of adverse events aliskiren arm. So we are<br>currently having discussions with the FDA and the EMA about the future of that brand. But you will have to assume that that is going to impact<br>the volume going forward.<br>
The second issue was in the area of quality.We received a warning letter on three sites in the Sandoz unit.Those sites continue to produce product.<br>
We have developed a remediation plan. We're investing about $150 million in capital to upgrade equipment at those sites. We have shared that<br>plan with the FDA, and we continue that remediation process.<br>
The other quality issue was in our OTC business.This is relatively recent. Just yesterday we announced that we were recalling Excedrin and a couple<br>of minor brands.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>343</i><br>
<hr>
<A name=344></a>JANUARY 09, 2012 / 4:00PM, NOVN.VX - Novartis AG at JPMorgan Global Healthcare Conference<br>
We took this brand down -- we took the Lincoln site down temporarily in the month of December so that we could accelerate maintenance and<br>improvements at that site. During the process of that shutdown and the investigation of the consumer complaints -- we were getting a large<br>number of complaints around chipped and broken pills, stray tablets. So we decided to go get that product and bring it back, and we took a $120<br>million charge in the fourth quarter because of it.<br>
But it's a symbol that there is one quality standard at Novartis, and it is the quality standard that is driven by the Pharmaceutical division, the Alcon<br>division, Vaccines and Diagnostics. Every plant at Novartis is going to be held to the same quality standard, and we are going to be best in class.<br>
There's a lot to look forward to in the Pharmaceutical division. Over the next five years, the Pharmaceutical group has a number of drugs that have<br>been already approved that will or should become blockbusters. This is critically important, because with every launch the launch machine in the<br>Pharmaceutical division becomes better and better, particularly at specialty launches. This is the power of the portfolio rejuvenation that we are<br>going to have that will continue to replenish this business, despite the fact that we are going to have patent expirations coming up.<br>
Another very strong positive about the future is the Sandoz unit. Sandoz is probably the best-positioned unit for biosimilars. The reason for that<br>is that it exists within Novartis, so we have the scientific and technical capability of a pharmaceutical company and we have the commercial capability<br>of a generics company, all in one at Sandoz. None of our competitors -- whether they are generics competitor trying to get into biosimilars, or<br>whether they are a pure-play pharma company or one of the big pharma companies -- none of them have both of those things. So that's why I<br>think the Sandoz unit is number one in biosimilars, and we see this as a huge opportunity over the next 10 years.<br>
The third reason to believe is Alcon. The Alcon acquisition and integration has gone extremely well. Kevin Buehler, who was the CEO of Alcon as a<br>public company, is now part of Novartis. He is leading this business, working for me. He is doing an incredible job.<br>
He has been able to integrate the Alcon business into Novartis, together with taking our CIBA Vision contact lens business and putting it into Alcon.<br>So now we have about a $10 billion ophthalmology platform that is a leader in eyecare.<br>
If you think about the trends and the need for eyecare over the next 10 years, this is going to be a key growth driver. We have three in this unit.<br>
In the surgical business, which is primarily around cataract surgery and intraocular lenses, this business has grown year-to-date through the first<br>nine months at about 8% because of the need for cataract surgery. In ophthalmology, pharmaceuticals up 10% for the first nine months. So this<br>Alcon business is going to be a machine of the growth driver for Novartis.<br>
The next reason to believe is our Vaccines and Diagnostics unit. This is a relatively small unit, but it is about to become transformed.<br>
We expect to receive approval of Bexsero in Europe. Bexsero is the first vaccine for meningitis B. It's a deadly, devastating disease with very high<br>prevalence in Europe, and we are right now readying those markets for a successful launch of Bexsero. We see this as a huge growth driver for the<br>Vaccines business going forward.<br>
And then finally Consumer Health.This is all about building strong brands.The role of Consumer Health in our portfolio is that these are nonreimbursed<br>businesses. These are self-pay businesses.<br>
So when you think about the healthcare environment and pricing pressure and reimbursement pressure around the world, only about 60% of<br>Novartis products have some kind of private or public reimbursement. And that's because of the diversity of this portfolio. So that insulates our<br>company in a way that many companies cannot be insulated from the external environment.<br>
So just to conclude, the strategy for Novartis is very simple and clear. It's to win through science-based innovation that's focused on high-growth<br>segments of healthcare. We truly believe that our diversification gives us a competitive advantage and allows us to link with governments and<br>with healthcare systems in ways that our peers cannot.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>344</i><br>
<hr>
<A name=345></a>JANUARY 09, 2012 / 4:00PM, NOVN.VX - Novartis AG at JPMorgan Global Healthcare Conference<br>
We are going to announce our full-year results on January 25, so I cannot provide an outlook today; but we will be providing a full summary of our<br>2011 results webcast on January 26. And I will also talk about how we are moving through the Diovan patent expiration with this portfolio in a way<br>that I think may surprise some people.<br>
So thank you very much, and I think we will be happy to take questions at the breakout session across the hall. Thank you.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4690495-2012-01-09T17:24:33.770</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>345</i><br>
<hr>
<A name=346></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
MIND - MITCHAM INDUSTRIES INC AT<br>PRITCHARD CAPITAL PARTNERS LLC<br>"ENERGIZE` CONFERENCE<br>
EVENT DATE/TIME: JANUARY 04, 2012 / 6:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>346</i><br>
<hr>
<A name=347></a>JANUARY 04, 2012 / 6:30PM, MIND - Mitcham Industries Inc at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Bill Mitcham</b><i> Mitcham Industries, Inc. - CEO and President</i><br>
<b>Rob Capps</b><i> Mitcham Industries, Inc. - EVP of Finance and CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Bill Conroy</b><i> Pritchard Capital - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Bill Conroy</b><i> - Pritchard Capital - Analyst</i><br>
Well, in the interest of keeping things on schedule, the next company that we are going to have present is Mitcham Industries. We are fortunate<br>to have Bill Mitcham and Rob Capps, both of whom are going to make a presentation today -- very interesting company. I had Rob in Southern<br>California back in the summer and I only wish I had done a better job of getting the message across. A lot of people would be up about 50%, I<br>believe.<br>
But at any rate, turn it over to you gentlemen; look forward to hearing your remarks.<br>
<b>Bill Mitcham</b><i> - Mitcham Industries, Inc. - CEO and President</i><br>
Thank you, Bill. Good morning, everyone, and thank you for your interest in Mitcham, and a very special thank you to all of you from Pritchard<br>Capital for having us again this year. We appreciate your support over the years.<br>
As Bill said, I'm Bill Mitcham, President and CEO of Mitcham Industries, and with me today is Rob Capps, our EVP of Finance and CFO. I'll give you<br>a brief overview of the Company and Rob will follow with financial information and a wrap-up. Then if you have any questions, we'll be happy to<br>meet with you in the breakout room.<br>
Our business is pretty simple. It consists of two segments -- seismic Equipment Leasing and sales of Seamap equipment that we manufacture. Since<br>our founding in 1987, we have grown to be the world's largest independent lessor of seismic equipment. No other leasing or rental company in<br>the seismic industry approaches the breadth or scale of the equipment that we have to offer. Our customers are the worldwide seismic contractors<br>and a few -- and the large oilfield service companies. We currently have nine locations around the world, which allows us to provide equipment<br>24 hours a day, 7 days week, quickly and efficiently to meet our customers' needs.<br>
Through our Seamap unit, we design, manufacture and sell certain specialized equipment for the marine seismic industry. I guess I should have<br>gone up one slide, right? There we go, sorry; there's the overview slide, missed it. So now you can see from this that you can see our -- quit laughing,<br>Miles. So you can see here we trade under the symbol MIND. Our market cap -- you see it -- over the first nine months of this year, we have already<br>surpassed our complete year-end -- last year revenues.<br>
We continue to see an increasing demand for oil and gas throughout the world. This demand will drive increased exploration activity, many more<br>seismic surveys. The more seismic that we see -- all the seismic surveys are requiring higher channel counts, higher equipment on each job, and<br>that's equipment that we believe that the contractors will continue to rent. The demand will be the same on the marine side of our business --<br>more streamers in the water, more energy sources on each vessel. This trend also drives higher demand for our Seamap equipment products as<br>well as marine rentals. We are also seeing seismic used in new applications, such as frac monitoring, life of field monitoring, which utilize our<br>downhole equipment and some surface seismic.<br>
This slide is the seismic market; it kind of gives you an idea. There are several companies here that are presenting this week. And it kind of gives<br>you an idea of how we compare to them in terms of products and the services we offer.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>347</i><br>
<hr>
<A name=348></a>JANUARY 04, 2012 / 6:30PM, MIND - Mitcham Industries Inc at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
One of the largest single costs for the life of the seismic contractors is labor to operate their equipment.We don't provide people; we don't provide<br>labor. All we provide is equipment. So we can easily add $10 million to $15 million of new equipment to our lease pool with very little incremental<br>costs, other than depreciation, which certainly helps our operating cost and gives us a lower risk business model than many others in this business.<br>
So there's a number of aspects to owning the world's largest seismic equipment lease pool.We have various types of equipment for all the seismic<br>surveys, from the dry land out into the deep marine environments and anything in between, which gives our customers a one-stop shop for all<br>their equipment needs.With more than 170,000 land recording channels, 20 kilometers streamer and all the peripheral support equipment to take<br>care of all this, we have enough equipment to meet the needs of all of our customers, all the time, as opposed to just a few some of the time. Our<br>equipment is strategically positioned around the world, which enables us to meet the customers' needs quickly and efficiently. Over the past few<br>years we have added some highly specialized to our equipment lease pool, like the downhole-level seismic tools that we're talking about here.<br>
Seamap, our manufacturing division, has grown into a very important piece of our business, and developed into a highly profitable manufacturing<br>operation. Our primary products are the GunLink series, marine energy source or air gun controllers and the BuoyLink RGPS streamer positioning<br>streamer and source tracking system. Additionally, Seamap produces a variety of other products, such as streamer weight collars, umbilical<br>terminations, depth transducers and portable containerized sources.<br>
GunLink and BuoyLink are market-leading products that have gained a dominant position in our industry and our growing installed base of products<br>gives us a steady revenue stream of repairs, parts sales, training and support services. Our GunLink source controllers over the past few years have<br>earned more than a 60% market share, and despite this growth we believe there's still substantial opportunity for GunLink to increase market share,<br>to upgrade existing customers from GunLink 2000 to GunLink 4000 and to newer versions of GunLink that we develop in the future. We estimate<br>our BuoyLink products to have about a 30% market share today, which certainly leaves a lot of room for growth in the area.<br>
So why do customers lease instead of buy? A recent industry article said that there are only three constants in seismic operations. The seismic<br>contractors never have enough money, they never have enough time and they never have enough equipment. Everything else is a variable. So<br>our customers buy all the equipment that they have budget for each year, but they never seem to have enough equipment at the right place at<br>the right time. So leasing allows our customers to add additional capacity for jobs when they don't have enough at that point in time or in that<br>country. It decreases their prospect of idle equipment between jobs and it frees up capital for equipment or services that are not available by<br>leasing or renting.<br>
So, leasing also allows our customers to supplement their inventories for specific jobs that require highly specialized equipment like our digital<br>sensor units, our downhole system and our wire -- and our UNITE cable free system. Few of our customers can afford an inventory that includes all<br>the techniques of recording, so they use our lease pool to supplement theirs, which enhances their operational and financial efficiencies. Our<br>customers know that they can acquire equipment from Mitcham generally within 24 to 48 hours of their first contact.<br>
So leasing equipment, leasing seismic equipment, in particular, has been our core business for more than 25 years. As I said earlier, we don't provide<br>personnel or labor; we only provide equipment. So the contribution to margin from incremental business is generally 90% or greater. Most of our<br>costs other than depreciation are fixed, giving us tremendous operating leverage.<br>
Our targeted payback on new lease pool purchases is just over two years, but most of our equipment has an economic life of some seven to 10<br>years. We depreciate our equipment over three to seven years, depending on what it is. Our exclusive agreement with Sercel, the world's leading<br>seismic equipment manufacturer and supplier, gives us a number of operational advantages. It gives us access to the latest state-of-the-art<br>technology without the recurring R&amp;D cost. We're the exclusive sole source for certain types of equipment, rental equipment, worldwide. And our<br>volume purchase agreements give us the best possible pricing and preferential delivery.<br>
So if you follow the seismic space, you know that the market conditions in the seismic industry have improved greatly over the past year or so and<br>the demand for seismic is increasing. We've seen our bids, our inquiries, our contracted business increase substantially over the past year while<br>almost all seismic contractors are reporting increasing and in some cases record backlogs. International markets continue to show positive growth.<br>We see Latin America as well as Eastern Europe and Southeast Asia as areas where activity is very brisk.The Gulf of Mexico is open again for business<br>and we expect to see our share of marine rentals increase with renewed activity there.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>348</i><br>
<hr>
<A name=349></a>JANUARY 04, 2012 / 6:30PM, MIND - Mitcham Industries Inc at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
Seamap continues to see great demand for their GunLink and BuoyLink products.This demand comes from rigging out of new vessels, contractors<br>moving to newer leading-edge technology and our existing customer base upgrading to newer and more advanced versions of our GunLink<br>products.<br>
So over the past few years, our strategic planning has helped guide us through the recovery years and it positions us well for the growth cycle we<br>now see in the seismic industry. Over the past six years we have added over $200 million of new equipment, latest state-of-the-art cable and<br>cable-free recording systems, downhole tools and digital sensors. We've had experienced personnel into our organization and we have expanded<br>geographically. Our newest facility in Budapest, Hungary was just opened in October of last year to serve the Eastern European area, and we have<br>more than 10,000 channels and peripherals on lease in that region already. We also have recently expanded our facility in Bogota, Colombia, and<br>added additional equipment to meet new demand there.<br>
The operating leverage inherent in our leasing model simply means that an increase in utilization by approximately 5 percentage points increases<br>our operating income by almost $10 million. Now, that's a real number and we work hard every day to increase that number.<br>
Seamap brings an added dimension to our rental business with strong recurring profits and best-in-class products. During the third quarter we<br>almost doubled the size of our facility there in Singapore. We expanded -- the expanded facility will provide space for our marine lease pool that<br>we're housing there and provide Seamap with dearly needed additional expanded manufacturing facilities.<br>
Now I'm going to turn the podium over to Rob, and he's going to walk you through some of our financials.<br>
<b>Rob Capps</b><i> - Mitcham Industries, Inc. - EVP of Finance and CFO</i><br>
Okay, thanks, Bill. As Bill said, I'll just walk through some of the financial information quickly for you.<br>
Fiscal 2012 has been a good year for us so far. In the first nine months of the fiscal year, we reported rack or results in terms of revenues, EBITDA,<br>EPS, pretty much every metric we have. Now one thing to keep in mind, that we are a January year-end, so the fiscal 2012 is ending in this month.<br>So the nine months we talk about was ended on October 31.<br>
Now, these year-to-date results, we think, are really being driven by strong fundamentals in the seismic industry in general, increased demand in<br>South America, improvement in the US, increased marine demand as well as excellent results in Seamap, as Bill talked about. And one thing to<br>point out is the third quarter this year was the best quarter we've ever had. And that's very unusual in that typically our first fiscal quarter is our<br>strongest, due to seasonal factors. So this is the first year in our history that our third quarter has been better than our first in terms of leasing results.<br>We really think this demonstrates the strong revenue generating capacity that we have put into the business in the past several years.<br>
Let's take a look at total revenues, and it really gives you a picture of the long-term growth we have seen in our revenue and our top line as well<br>as the dramatic growth we've seen in the last two years. Again, remember these -- our fiscal year ends on January 31, just to keep it in perspective.<br>You will notice the decline we saw in our fiscal 2009-2010 correlate to the global economic downturn that really kicked off in the fall of 2008.We've<br>seen a strong rebound from that.<br>
EBITDA obviously tracks revenue pretty closely, in our case. Depreciation is by far our largest cost, so therefore we look at EBITDA as one of our key<br>performance metrics. Very important characteristics of our business is our strong cash flow generating capacity, as we demonstrate here. If you<br>look at the results year to date, for the first nine months we had EBITDA of over $41 million, which was a record and represents an EBITDA margin<br>of about 54%, just over 54%. And as Bill mentioned or alluded to, the EBITDA for the first nine months of the year exceeded any previous full fiscal<br>year in the Company's history.<br>
Core leasing revenues is one of the key metrics for us, so this is our rental revenue with no equipment sales whatsoever. And again, we see the<br>downturn. In 2010, we are coming out pretty strongly on the heels of that in that fiscal 2011 and so far, fiscal 2012. Again, first nine months are a<br>record for us in leasing revenues, up 93% from the previous year. And as with EBITDA, our leasing revenues year-to-date for nine months exceeded<br>any previous full fiscal year.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>349</i><br>
<hr>
<A name=350></a>JANUARY 04, 2012 / 6:30PM, MIND - Mitcham Industries Inc at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
This increase in leasing revenues, as you might assume, is the real key driver in increasing our EBITDA and our earnings overall.<br>
We acquired Seamap in 2005, July of 2005. And since that time, it has really become a very important contributor to our financial results. It has<br>consistently produced solid results and is on track this year to have record results. One thing you might be able to see from this graph is that each<br>year since we've acquired Seamap, we've been able to improve the gross profit margin from the business. And we think that's an important factor<br>in ability to show the strong results year after year.<br>
Bill mentioned to you about our capital expenditure program over the past several years. We have added over $200 million in the last five or six<br>years. That includes equipment that is being delivered in the fourth quarter of this fiscal year, so equipment has just now or is just now being<br>delivered. These additions not only increase the amount of equipment, but also the breadth, so the different types of equipment that we have<br>available for our customers, as Bill mentioned. This represents an increase of over 100,000 land channels to about 170,000 today that we have.<br>We've added new land technologies, such as three-component recording systems, cable-free systems.We've added a significant amount of marine<br>equipment to our pool as well as downhole seismic equipment. We think these additions really demonstrate the significant revenue generating<br>capacity that we've put into the Company over these past several years.<br>
I'm asked a lot about utilization and how we measure utilization, and this is one metric that we use. It's not perfect, but it does give some insight<br>into our equipment utilization and the revenue-generating capacity that we have. All we do here is take leasing revenues and divide it by our<br>average gross investment or our acquisition cost of our lease pool. And with this demonstrates is that, if we are able to increase that utilization<br>factor by about 5% -- so from 32% to 37%, for example -- that would increase our leasing revenues by almost $10 million. And if you base that off<br>today's lease pool, which is about $215 million, of acquisition cost, that potential is even greater.<br>
Mitcham is a very fiscally conservative company. We've always sought to maintain a capital structure with very limited debt. Historically, we have<br>funded our expansion with cash flow from operations that we've supplemented from time to time with a revolving credit facility.This past summer,<br>however, we did tap the equity markets for the first time since 1997 and we raised about $31 million in common stock. We did this in response to<br>demand we were seeing for increased equipment in areas such as South America and in Europe. And we've used the proceeds to deploy equipment<br>in those areas.<br>
So, between the proceeds from that offering, our cash flow from our operations, or our ongoing cash glow from our operations as well as our $35<br>million revolving credit facility, that gives us very significant liquidity with which we can respond to any opportunities that we see that present<br>themselves to us.<br>
So finally, I'd just like to highlight a few things. We think Mitcham is really a unique investment opportunity within the oilfield services industry, in<br>general, and the seismic industry in particular. We have a global footprint with exposure to growing markets. We have a leasing model which<br>delivers superior margins to most other businesses in the industry. We have a profitable and growing manufacturing business, and we have a<br>financial position which is strong and stable which gives us, again, the liquidity and the resources to respond to any opportunities that we see<br>come before us.<br>
So with that, I would like to thank you for your interest in Mitcham and look forward to talking with many of you in the breakout session. Thank<br>you.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>350</i><br>
<hr>
<A name=351></a>JANUARY 04, 2012 / 6:30PM, MIND - Mitcham Industries Inc at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4696527-2012-01-09T17:25:11.800</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>351</i><br>
<hr>
<A name=352></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
EPM - EVOLUTION PETROLEUM<br>CORPORATION AT PRITCHARD CAPITAL<br>PARTNERS LLC "ENERGIZE`<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 04, 2012 / 6:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>352</i><br>
<hr>
<A name=353></a>JANUARY 04, 2012 / 6:30PM, EPM - Evolution Petroleum Corporation at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Bob Herlin</b><i> Evolution Petroleum Corporation - Chairman, President and CEO</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Unidentified Participant</b><br>
All right, everyone quiet down, you're too loud. Just trying to liven up the room. All right. We're going to get started with Evolution Petroleum. We<br>have Bob Herlin, Chairman, President and CEO. After you.<br>
<b>Bob Herlin</b><i> - Evolution Petroleum Corporation - Chairman, President and CEO</i><br>
Thanks, and thanks to Prichard for sponsoring us today. Happy New Year to all of us. I am Bob Herlin. I'm the founder of the Company; been around<br>now for going on eight years. Direct you to our forward-looking statement cautionary notes.<br>
Evolution is an engineering-based company focused on putting together development projects based on our particular expertise.We're a low-risk<br>development company. The one thing that may set us apart from others is that our focus is strictly on building value per share as opposed to<br>earnings per share every quarter, whatever. Our focus is strictly on how do we get the value per share up for our shareholders and get that value<br>to them?<br>
Quick facts. We are an American Stock Exchange company. We have both a common and a perpetual preferred share that just came on the market<br>this summer. We have a June 30 fiscal year-end date; so, again, that sets us a little apart from a lot of our peer group.<br>
Market cap is roughly $260 million with enterprise value of about $250 million, since we have no debt. So, therefore, our enterprise value is less<br>than our market cap. We have very strong balance sheet; since there is no debt, we have a very strong working capital, and a great team record<br>going forward.<br>
We really look at the Company as having three phases of growth so far. Initial phase was a core acquisition, core asset acquisition, and consolidating<br>that asset. Second was positioning ourselves for growth, taking our cash that we have from our farmout in '06 and redeploying it into new projects.<br>And where we are right now is our Phase III, our redeployment phase, where we're starting to generate substantial cash flow from our core assets.<br>And we're redeploying that cash into new areas of development growth.<br>
Our assets are in Northern -- Northeastern Louisiana. That's where our CO2 project is, which is our biggest asset. 100% oil, around 16.7 million<br>barrels of reserves net to the Company. 41% of that is developed and producing as of June 30 of 2011.<br>
Our other assets include the Giddings Field in Central Texas, which is really more of an interim project for us. It's 50% oil condensate and gas liquid,<br>and 50% gas. We have current production there. We have some additional proved locations to drill. In South Texas, we have 100% oil project that's<br>a redevelopment of an oil field, and then we have a pure gas play in East Oklahoma; but given current gas prices, that is a project that's on our back<br>burner.<br>
Looking at standard valuation metrics of the Company, we have approximately 20 million barrels of net reserves to the Company; almost 14 million<br>of that is proved; 6 million is probable -- those are high-quality probable reserves; almost all associated -- essentially all associated with our CO2<br>project.<br>
As you can see, we're extremely oily, and this is a black oil, not condensate, not gas liquids. And high -- fairly high level of development. PV-10 net<br>of CapEx is about $450 million, which [$376 million] is proved. On a PV-10 per fully diluted share, that works out to about $13.50 per share. One of<br>the things, again, that sets us apart from our peer group -- and I'd really like to point this out -- is what is the required future capital expenditures<br>going forward to net those 20 million barrels reserves?<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>353</i><br>
<hr>
<A name=354></a>JANUARY 04, 2012 / 6:30PM, EPM - Evolution Petroleum Corporation at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
And that works out to only $3 of future capital per BOE.That's extremely low number. If you look at other companies that talk about all these proved<br>reserves, you look at their future capital, it's a very high number -- $10, $15, $20 per BOE of future capital. In our case, we have very little capital<br>required to realize our reserves.<br>
Again, looking at our peer group on a valuation comparison, we're very -- have a very favorable comparison. We only have enterprise value equal<br>to about two-thirds of our PV-10 proved reserves -- which, again, is a very low number, when you consider that we're extremely oily and have a<br>little future capital requirement.<br>
So, why would someone -- why should own our stock today? Why should they go out and buy it today? Again, we have a very high level of PV-10<br>compared to our current enterprise value. We have continuing and growing value of growth in cash flow at Delhi, our biggest asset. Production<br>was up 48% quarter-over-quarter -- most recent quarters that we have. That production is projected to continue to grow substantially over the<br>next couple of years, and not peak until 2015 and '16 from Delhi. Pretax cash flow in fiscal '12 alone from Delhi is expected to increase by as much<br>as three times over fiscal '11, based on our reserve report.<br>
In addition to that, in end-of-calendar 2013, we have [a various] working interest that kicks in, which takes our revenue interest at Delhi from 7.5%<br>up to 26.5%. Again, that's a very substantial increase in revenues. And we have no capital expenditures at Delhi required until fiscal -- or calendar<br>2014; after that, working interest reverts back to us. And all -- until then, 100% of our cash flows can be redeployed into our other projects.<br>
So let's talk about some of our core assets -- or our core asset, which is Delhi. It's a field in Northeast Louisiana discovered back in the '40s. It's<br>produced close to 200 million barrels of oil in its time. We bought the property in 2003 for about $2.5 million. We invested another $2.5 million to<br>get production up further. We paid another $1.5 million to acquire our 7.5% royalty in '06. And then we farmed out the project to Denbury in '06<br>to convert the project into a CO2-enhanced oil recovery effort. They paid us $50 million upfront; they agreed to fully fund the cost of installation<br>of the project, and operate the field.<br>
We think there's quite a bit of upside at Delhi.We think the original oil in place is much greater than initially thought.We believe that the enhanced<br>oil recovery percentage is likely to be higher based on Denbury's averages in that general area. We also think there's a possibility the amount of<br>CO2 required is going to be less than initially forecast.<br>
There's details on [when] exactly [we own] is basically a 7.5% overriding royalty interest, which is free of any capital or operating costs. And then<br>we have 24% reversionary reworking interest, which is an additional 19% revenue interest, that kicks in -- is scheduled to kick in sometime around<br>the end of calendar 2013. It is based solely on a [deemed] payout number of $200 million, regardless of how much capital Denbury spends. That<br>was something we negotiated right upfront. Our current reserve report projects that to be occurring at the end of calendar '13, based on the $95<br>oil price in the field, which is actually far less than what we're actually netting there.<br>
This is a little plot showing production in the fields -- it's gross production in the fields. Since we acquired it in '03, you can see how we increased<br>production substantially with our own investments. And then, in 2006, we farmed that out. Denbury let production drop off while they installed<br>the project, with initial oil response recurring in the spring of 2010. And then a substantial and steady increase in gross production in the field. At<br>this point in time, the expectation is that production in the field will peak around 11,000 or so barrel-a-day range in the next couple of years.<br>Currently, it's running about 4,500 barrels a day.<br>
This is a plot of cash flows on an annual basis from our reserve report. We have taken -- done is taken the cash flows each year and divided that by<br>the number of fully diluted shares to the Company. This is our net cash flow pretax. And what you can see is the dark green column is our cash<br>flows pretax from our overriding royalty interest, which are ongoing today, and continue to increase and peak around 2017 timeframe.<br>
And then, in 2014, calendar of 2014, the working interest back-end occurs. That takes us up to over $2 per share per day -- per year of pretax cash<br>flow. We pretty much maintain that level for about an eight-year period, and then start gradually declining over time. So what we're looking at is<br>a very substantial future cash flow per share on a fully diluted basis.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>354</i><br>
<hr>
<A name=355></a>JANUARY 04, 2012 / 6:30PM, EPM - Evolution Petroleum Corporation at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
Again, taking those same numbers and now looking at it from the viewpoint of saying, okay, what is the present value of the remaining cash flows<br>each year -- the residual cash flows? So, every year, you take off what's already been produced and what's the present value of what's left; and you<br>take that present value and divide it by, again, the number of fully diluted shares -- and that's what the dark green column is.<br>
What it shows is that our present value per share is steadily increasing from today until a peak level in 2014/'15 timeframe, a level of about $14 per<br>share. In addition to that increasing present value per share, we're actually generating cash flow.That's what the light green portion of that column<br>is. That's taking that pretax cash flow and sticking it into a cigar box in my office and doing nothing with it. And [net] would be -- it shows the<br>increasing value from the project as it increases over the years. Again, I like to compare that to our current stock price of $8 a share.<br>
They're some sensitivities here showing, okay, what happens to the value per -- or PV-10 per diluted share, if you have different levels of gross<br>recovery; and then what happens if you have different amounts of oil price. And again, you can see that the value, regardless of how you look at<br>it, is still far greater than our current stock price -- which is that little star there to the bottom right-hand area.<br>
One thing I do like to point out about Delhi is, is that oil is sold at a price that tracks Louisiana light sweet, which tracks Brent price. So, since the<br>beginning this summer, we've been netting an oil price ranging from $103 to $120 per barrel consistently. So we get far greater price than WTI<br>might be.<br>
So we can take cash flow from that core project and reinvest in other projects. Well, what basis do we have to believe that we're going to be able<br>to do that and be a good steward of that cash for shareholders? Well, we think we have a fairly good track record today. We have added about $8.5<br>million of common equity paid into the Company in our total history. With that, we generated some $66 million in cash, and we still have proved<br>PV-10 of $375 million in addition to probable PV-10.<br>
So what we're going to do with this cash flow going forward, we have some current projects in-hand to invest in. We have a project in South Texas<br>-- it's something that we started up about a year or so ago. It's a redevelopment of an old oil field, somewhat shallow, about 2,500 feet; a field that<br>was developed on 10-acre spacing and abandoned in the late '90s, when oil price was still around [$15].<br>
We've gone in and have demonstrated that we can still produce substantial amounts of oil at fairly low cost.These wells cost us a little over $500,000<br>to drill and produce -- to drill and complete a producing well, and then the associated saltwater injection well in the field. Our target is to get a well<br>that produces 10 to 20 barrels of oil a day with a very, very low decline over a long period of time. We think this is generating 100% oil reserves at<br>a cost of anywhere from $5 to $15 per net barrel.<br>
We initiated testing in calendar 2010.We had some issues in getting injection permits and some mechanical issues with injection wells that caused<br>us to put this on a back burner. And then we reestablished our effort down there in '11 with excellent results. And we initiated full-scale development<br>this fall with our first four wells in the program. We have two producers, two injection wells. And at this point in time, based on what we've seen,<br>I fully expect us to be drilling quite a few additional wells this spring down there.<br>
All together, our current leasehold gives us some 40 locations.That really is not a big deal on its own.We wouldn't be doing this for just 40 locations.<br>The opportunity here is to expand this and extend it, not just in this field, but in other similar fields, where we can end up doing hundreds of these<br>wells.<br>
We also have our patented artificial lift technology. This is for increasing recovery in existing horizontal wells. We started the patent process about<br>four years ago; finally received our patent last summer. And subsequent to that, have entered into two commercialization test programs or<br>agreements with two companies. The first well has already been installed and we are producing it. The second we'll be installing here in the next<br>week or so.<br>
As soon as we have sufficient test data to publicly reveal the results, we'll probably discuss that more in February. Right now, everything is very<br>encouraging and we look forward to expanding that commercialization effort.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>355</i><br>
<hr>
<A name=356></a>JANUARY 04, 2012 / 6:30PM, EPM - Evolution Petroleum Corporation at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
In the Giddings field, that's just an area that we have a lot of expertise in our Company. It was never intended to be a long-term growth project; it<br>was more of an interim project or a reinvestment of the cash that we have back in '06 from our farmout with Denbury. We've drilled a number of<br>wells in there to date. Those are currently producing; has got quite good -- has quite a bit of reserves there.<br>
We still have some 13 locations to drill. These reserves are about 50% gas, 50% oil and condensate and gas liquids. The cost to drill and complete<br>these wells is a little over $10 per net BOE; about $1.5 million per reentry and about $3 million for each of the grassroot wells. Because of the high<br>gas content and the current gas price, this isn't real high on our list of priorities to go forward with. But we still have substantial reserves here.<br>
We have a gas play in Eastern Oklahoma. This is a very attractive play when gas prices were about [$4.50] or better. At the Henry Hub, we're not at<br>[$4.50], obviously, at the Henry Hub. So, consequently, we're not pursuing this project aggressively at this point in time. It's on our back burner.<br>
So what our plan is for this current year, which we're halfway through fiscal '12 already, is a $5 million base plan to resume or continue development<br>in South Texas, our Lopez Field; to continue the demonstrations and commercialization of our GARP technology; and some development in Giddings,<br>with a potential expanded up to $10 million by additional drilling in South Texas. But really more of a focus on a new oil project that we're looking<br>at on several candidates for, and also to take an opportunity -- advantage of opportunities in the market due to dislocation and volatility, based<br>on commodity prices. This project, even on an expanded basis, is fully funded with cash in-hand. And, again, we have no debt.<br>
Our record, I think, stands -- speaks for itself. And from beginnings in '03/'04 timeframe, we've had substantial growth in net reserves; again, with<br>very little capital investment on our part. We've grown revenue substantially on an annual basis. Last year, we finished $7.5 million in revenues,<br>which doesn't sound like a lot. However, if you look at it on a quarterly basis in the last four quarters, you can see that our revenues are growing<br>rapidly. Our last quarter, which ended in September 30, we approached $4 million in revenues.<br>
And again, on the earnings basis, although I'd say that our focuses on what is our value per share, I am pleased to see that our earnings are<br>corresponding to that growth and value. And we did reach $1 million of net income in the last quarter based on that nearly $4 million of revenues.<br>
So, in summary, why I think that people should own our stock, we have a very high level of proved PV-10 compared to our enterprise value. So<br>your risk level is very low in terms of valuation. Our value is growing and our cash flow is growing at Delhi on its own. And we're redeploying that<br>cash flow into very prospective projects that are heavily oil-related. We're oil-based company and we continue to be oily. In fact, we'll probably<br>increase our level of oil content.<br>
We have the upside of our patented technology, which is continuing to improve in partiality, but that will take some time. We have new projects<br>that we're looking at and we have our proved locations at Giddings Field. We have no debt. We have excellent liquidity; a great amount of working<br>capital.<br>
But probably the most important thing is the employees are totally in line with the shareholder sense of the employees, as a whole, control or own<br>beneficially about 19% of the Company. Again, that explains why our focus is on getting the value per share higher, because that goes near and<br>dear to our own heart.<br>
There's additional information in the exhibits, including our last balance sheet. Otherwise, I look forward to talking with you at our breakout, which<br>will be in the Commonwealth Room. Thank you very much.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>356</i><br>
<hr>
<A name=357></a>JANUARY 04, 2012 / 6:30PM, EPM - Evolution Petroleum Corporation at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4696529-2012-01-09T17:46:55.447</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>357</i><br>
<hr>
<A name=358></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
ARTC - ARTHROCARE AT JPMORGAN<br>GLOBAL HEALTHCARE CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 5:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>358</i><br>
<hr>
<A name=359></a>JANUARY 09, 2012 / 5:00PM, ARTC - ArthroCare at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>David Fitzgerald</b><i> ArthroCare - President and CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Ross Como</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Ross Como</b><i> - JPMorgan - Analyst</i><br>
Good morning. We're going to get started with the next session. I'm [Ross Como] on the med tech team and it's my pleasure to introduce David<br>Fitzgerald, President and CEO of ArthroCare. David?<br>
<b>David Fitzgerald</b><i> - ArthroCare - President and CEO</i><br>
Thank you. Good morning, everybody. This is our forward-looking statement disclosure and today my comments may contain forward-looking<br>statements. In my prepared remarks this morning, I will provide a high-level introduction of ArthroCare for those of you who are not familiar with<br>the Company, followed by a broad review of the performance for each of our businesses.<br>
ArthroCare is basically a surgical device company with instruments and implants that enhance surgical techniques and procedures to improve<br>patient outcomes. Many of our devices use our internationally patented Coblation technology which use RF energy to precisely ablate tissue and<br>while limiting the damage to surrounding healthy tissue.<br>
We conduct our business through two core product areas, sports medicine and ENT, which together comprise 95% of our product sales. Our<br>products are the standard of care for soft tissue shoulder procedures in sports medicine and tonsillectomies in ENT.<br>
2011 has been a notable year of significant structural change for ArthroCare. In April we announced that we would close our Sunnyvale, California<br>operations and relocate its activities to a new corporate campus in Austin, Texas. At this time the campus consolidation effort is complete and we<br>are fully operation in our new Austin campus.<br>
We believe this is in the best long-term interest of our business and we have already seen an increase in ease and communication, improvements<br>in the alignment of corporate priorities and improvements in daily operation. We also expect this program will reduce our costs.<br>
At the end of the second half of 2011, we began the initiative to progressively increase the employee portion of our America Sports Medicine<br>salesforce over the next couple of years. As a result of this initiative, product sales can be negatively affected in the short term and in the third<br>quarter, our product sales to stock distributors in the United States were about one million lower than in 2010.<br>
But our goal is to improve the performance of the Sports Medicine sales organization particularly in regards to how we market new products and<br>technologies in the future.<br>
Over the timeframe of the next couple of years we expect to shift from a 30% employee and 70% agent to something more approaching a balanced<br>50-50 mix.<br>
In July, we entered into a supply agreement with Wright Medical which will combine our OPUS fixation technologies with Wright's leading foot<br>and ankle distribution organization. We are optimistic about medium-term growth opportunity that this supply agreement presents.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>359</i><br>
<hr>
<A name=360></a>JANUARY 09, 2012 / 5:00PM, ARTC - ArthroCare at JPMorgan Global Healthcare Conference<br>
Lastly, we resolved three of our four major contingencies facing the Company that originated in 2008. Through these restructuring efforts, our<br>management team has remained focused on three principle targets on attributes we think add value to our shareholders in both the short and<br>long term.<br>
On the slide you will see these three targets, revenue, operating margin, and free cash flow. We set these targets based on topline growth that is<br>faster than the underlying procedure market growth rate, an operating margin that establishes favorable profitability in comparison to other<br>companies of our size in the industry and cash flow generation sufficient to address uncertainties about the availability of cost-effective capital as<br>we work to resolve our legal contingencies.<br>
Over the next couple of slides, I will talk each about more of each of these 2011 targets.<br>
In the past five years, our revenue has increased from just over $235 million in 2006 to over $355 million in 2010 resulting in a topline compound<br>annual growth rate of over 10%.<br>
2011 was a year with a difficult comparative period as our revenue in 2010 included sizable one-time revenue for product sales in the first quarter<br>of last year that related to earlier years but had been deferred pending resolution of certain contract matters with customers and unusually high<br>contract manufacturing product sales into the third quarter of 2010.These one-time items together added $13 million or approximately 4% to the<br>2010 revenue baseline.<br>
We revised our 2011 target in midsummer and we were assuming that we had a range of 3% to 5% growth in our most important markets such as<br>the United States. We believed that we would grow faster in that market as a result of the new product introductions.<br>
And in the summer of 2011, we announced our second-quarter results in early August to a revenue range of $365 million to $370 million on the<br>basis of slower underlying procedure volumes and delays in our new product launches.<br>
During the second half of 2011, macroeconomic conditions continued to create weaknesses in underlying US and European procedure volumes<br>particularly in our Sports Medicine market. But we closed the year with all of our new products available at least in the US market.<br>
At the end of the third quarter, we stated many things would have to go in the right direction in the fourth quarter for us to meet the whole year<br>revenue target. We are uncertain and in a highly competitive market and we acknowledge that meeting our revenue target would be difficult for<br>2011. We anticipate reporting our 2011 final results in mid February.<br>
Through the end of the third quarter, we had a strong balance sheet with cash and cash equivalents of almost $208 million and no debt. We've<br>expressed good working capital management throughout 2011 with our accounts receivable balances declining with our internal emphasis on<br>cash conversion.<br>
Net accounts receivables balances declined by $9 million or 18% as of September 2011 compared to December 31, 2010. For the first three quarters<br>of this year, we reported cash flow of almost $70 million compared to $64 million for the first three quarters of 2010. Free cash flow for the first<br>nine months of 2011 was $78.6 million, nearly reaching in nine months our full year free cash flow target for 2011 of $80 million.<br>
While our books are not closed, we think we will meet or exceed our profitability and cash flow targets for 2011.<br>
In the United States, there are nearly three million Sports Medicine surgical procedures performed arthroscopically or using mini-open approach<br>in the shoulder, neat, hip and small joints each year. Our Sports Medicine business has historically focused primarily on improving shoulder<br>procedures which represent about 25% of all sports medicine procedures.<br>
However, as we continue to build our product portfolio and our clinical programs we are focused on driving adoption of our technologies particularly<br>our RF technologies in all areas of Sports Medicine.There are approximately three times as many knee procedures as shoulder procedures performed<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>360</i><br>
<hr>
<A name=361></a>JANUARY 09, 2012 / 5:00PM, ARTC - ArthroCare at JPMorgan Global Healthcare Conference<br>
each year. As reflected on the right graphic, RF uptake in the knee procedures is very low. These two facts together are why we believe the knee<br>represents a significant opportunity for future growth for our business.<br>
RF uptake in the knee is low due to historical concerns about the damage that heat will do on cartilage and that RF devices could be a source of<br>heat during an arthroscopic knee procedure. We are addressing this concern through both product development and clinical efforts.<br>
During 2011, we continued to build a market of our Ambient family of ArthroWands. Ambient technology provides the orthopedic surgeon with<br>accurate real-time temperature monitoring of the circulating fluid within the arthroscopic environment. By doing so, Ambient is a key building<br>block to address the historical concern of whether an RF device is the source of unacceptably high temperature during an arthroscopic procedure<br>through its real-time feedback mechanism, thus providing service and value to our surgeon community.<br>
No other competitive RF system on the market offers this valuable feature. We've begun to see notable shifts by our customers in adopting the<br>Ambient platform and at the end of the third quarter, approximately 25% of our Sports Medicine Coblation sales are now Ambient Wands.<br>
Through our Ambient Advantage program, our goal is to continue to move existing customers to the Ambient platform. Clinically we are investing<br>in a prospective randomized multi-center trial which will describe the effects of RF energy on articulating cartilage compared to the standard<br>surgical treatment methods.<br>
We anticipate completion of patient enrollment in late first quarter of 2012.The study's primary six-month post-op endpoint would then be reached<br>in the latter part of 2012.<br>
The shoulder is a segment within the Sports Medicine that is the largest of our Sports Medicine business and also where we have the most complete<br>portfolio of products. We think the shoulder still represents a growth opportunity for us with over 850,000 procedures being performed in the US.<br>
The completeness of our Coblation and soft tissue fixation product lines for the most typical shoulder procedure is represented by the chart on<br>the right. In 2011, we made several additions to our shoulder product portfolio particularly in the soft tissue fixation area.<br>
First, we wanted to address a lack of competitive fixation products for labrum repairs. In the shoulder market, there is approximately one labrum<br>repair for every five rotator cuff repairs performed. Our market share has been lower than that, approximately one labrum repair for every eight to<br>ten rotator cuffs.<br>
In the fourth quarter, we launched two eagerly awaited anchors especially for the labrum -- SpeedLock, a knotless anchor with independent suture<br>tensioning made of PEEK; and SpeedFix, a traditional preloaded suture anchor also made of PEEK.<br>
These products have had a good start based on our initial fourth-quarter commercial and clinical experience. In addition to addressing the labrum<br>market, we also introduced two traditional anchors for rotator cuff repairs to complement our full line of competitive knotless fixation implants.<br>These two anchors were the Titan anchor made of metal and the Spartan anchor made of PEEK. Prior to their launch, we did not have traditional<br>anchor offerings for the rotator cuff as most of our OPUS products were designed to facilitate knotless repairs.<br>
Both the Titan and the Spartan complement the FirstPass suture passing device that was launched in early 2011. Entering into 2012, we had the<br>most complete soft tissue fixation portfolio for shoulder repairs that ArthroCare has ever had.<br>
In 2012, we intend to continue to develop in line Coblation and fixation products to meet the current and emerging needs of the Sports Medicine<br>physician.<br>
The knee market is the largest market from a procedural standpoint with over 1.9 million procedures being performed. We have a full product<br>offering in the knee and our Coblation platform. We are committed to increasing RF utilization in the knee by investment in clinical and preclinical<br>programs supporting the use of Coblation in knee arthroscopy. We are focused on opportunities to strategically build out our soft tissue offering<br>in the knee.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>361</i><br>
<hr>
<A name=362></a>JANUARY 09, 2012 / 5:00PM, ARTC - ArthroCare at JPMorgan Global Healthcare Conference<br>
Hip arthroscopy represents a small subset of the broader Sports Medicine market with approximately 70,000 procedures performed annually.<br>However, it is currently the fastest growing segment in Sports Medicine. In 2011, we launched the HipVac ArthroWand specifically designed for<br>hip arthroscopy. Our goal was to continue to develop our hip portfolio in both Coblation and soft tissue fixation portfolios to capitalize on this<br>growing market.<br>
ENT represents our second largest product area and has been a high-growth business during the recent market slowdown in healthcare utilization.<br>We attribute resiliency of our ENT franchise two strengths, our 100% direct US ENT salesforce and a unique suitability of our Coblation technology<br>to improve patient outcomes through less invasive tonsillectomy procedure.<br>
In 2011, we strengthened the breadth of our tonsil and adenoid product portfolio with the introduction of PROcise mAx and EXcise PDW. Today<br>we think our Coblation products as a standard of care in the United States for tonsillectomies with a market share close to 50% and we think that<br>tonsillectomy patients, particularly pediatric patients, experience more favorable outcomes from Coblation.<br>
In addition to tonsil and adenoid area, we think we can grow our Coblation-based ENT franchise further through in-line product development. For<br>example later in 2012, we intend to revitalize our Turbinate Coblation product line which today is approximately 20% of our ENT business.<br>
One of the emerging trends for ENT is functional endoscopic sinus surgery or FESS, where key market participants are expending significant<br>resources to advance balloon-based minimally invasive techniques to move FESS procedures from the operating room to the ENT physicians office.<br>We believe our Coblation-based Turbinate products have the potential to piggyback on the balloon should the balloon succeed in moving procedures<br>out of the OR.<br>
Outside of Coblation, our Rapid Rhino line has been a catalyst for growth. Rapid Rhino represents a line of nasal packing, epistaxis products used<br>to treat severe nose bleeding in both an operating room and emergency room setting.<br>
In the latter half of 2011, our ENT growth rate was slowed as a result of supplier issues which disrupted Rapid Rhino product availability but we are<br>confident that the supply issues are largely corrected.<br>
In 2012, we expect the underlying US tonsil and adenoid procedure market to grow 2% to 3% and we expect our ENT business to grow more than<br>the market.<br>
We have approximately 1600 employees worldwide. Our R&amp;D and G&amp;A functions are based at our corporate headquarters in Austin, Texas; our<br>primary manufacturing facility is in San Jose, Costa Rica; and we have sales and marketing and product development teams in Austin along with<br>offices in Europe, Asia to support our international markets.<br>
International markets comprise an increasing portion of our total product sales and represent one of our most important drivers to achieving our<br>revenue target for 2011 and beyond. Today international markets contribute one-third of consolidated product sales.<br>
Our international markets are generally segmented into direct markets where we build end-users and sales activities occur through a combination<br>of agents and employed sales reps as well as distributor markets. Most of our direct presence is in Northern Europe and Australia as shown in blue<br>on the graphic.<br>
Internationally, our ENT products do not constantly receive reimbursement across all countries and our growth opportunity is to support both<br>local market reimbursement needs and doctor training efforts.Today international revenues represent about 15% of our overall ENT product sales.<br>
This past year we have invested in activities to support the clinical adoption of Coblation for tonsils and adenoids in key international markets. In<br>the coming year, this needs to continue as well as invest in physician training and building stronger distribution throughout our international<br>markets.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>362</i><br>
<hr>
<A name=363></a>JANUARY 09, 2012 / 5:00PM, ARTC - ArthroCare at JPMorgan Global Healthcare Conference<br>
Finally, bringing closure to our remaining contingencies have been a goal for our leadership team. In February, we announced a settlement with<br>the SEC that fully resolved the SEC investigation of the Company that was first announced in July of 2008.<br>
As we announced in late November, we have also reached an agreement in principal to settle all private securities class action suits pending against<br>us for $74 million. This settlement is contingent on final documentation and court approval. We expect to fund our settlement obligation in the<br>first quarter of 2012.<br>
On December 8, 2011, the court granted final approval to a settlement in the federal court and state court derivative actions that were pending<br>against us consistent with the terms that we previously announced.With regards to the other remaining contingency, the DOJ investigation remains<br>active and we are continuing to cooperate fully in the investigation. At this point, we do not know the timing nor are we able to estimate what a<br>resolution to this matter will entail.<br>
Looking ahead in 2011, our product development efforts were largely centered around improving our product portfolio. In 2012, we anticipate a<br>greater portion of our product developments and will be directed toward platform technology advancements as well as clinical expansion for our<br>technology.<br>
Today we are a Company known as an innovative leader within our core technologies. We own over 200 issued US patents and close to 200 issued<br>international patents. In Sports Medicine, we are working to expand acceptance of RF in the knee through clinical studies.<br>
In ENT, we continue to see the demand from clinicians to study the efficacy of the Coblation technology as part of the surgical treatment for patients<br>who suffer from sleep apnea and are not compliant with conventional treatment. This initiative is still under consideration.<br>
As we have previously mentioned, we are very interested in leveraging our US ENT salesforce in new areas such as sinus surgery that have the same<br>cold point. We are also expanding our investment Asia-Pacific and we believe this region represents key opportunity for us.<br>
We're currently cooperating with the DOJ investigation and hope to bring this matter to a conclusion in 2012, resolving the last of the legacy issues.<br>
In mid-February, we will announce our earnings for 2011 and at that time we plan to announce our 2012 targets. Our 2012 targets will be focused<br>on the same core elements of shareholder value that we based on 2011 targets, those being revenue growth, profitability and cash flow.<br>
Thank you. That concludes my remarks for today. Thank you for your time and attention.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4697166-2012-01-09T17:53:37.880</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>363</i><br>
<hr>
<A name=364></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
THRX - THERAVANCE INC GSK AND<br>THERAVANCE ANNOUNCE INITIAL<br>OUTCOMES FROM PIVOTAL PHASE III<br>STUDIES FOR ONCE-DAILY<br>RELOVAIRTM IN COPD AND ASTHMA<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 1:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>364</i><br>
<hr>
<A name=365></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Mike Aguiar </b><i>Theravance, Inc. - SVP &amp; CFO</i><br>
<b>Rick Winningham </b><i>Theravance, Inc. - Chairman &amp; CEO</i><br>
<b>Mathai Mammen </b><i>Theravance, Inc. - SVP, Research and Early Clinical Development</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Ronny Gal</b><i> Sanford Bernstein - Analyst</i><br>
<b>Ian Somaiya</b><i> Piper Jaffray - Analyst</i><br>
<b>Howard Liang</b><i> Leerink Swann - Analyst</i><br>
<b>Ian Sanderson</b><i> Cowen and Company - Analyst</i><br>
<b>Stephen Willey</b><i> Stifel Nicolaus - Analyst</i><br>
<b>Mark Beards</b><i> Goldman Sachs - Analyst</i><br>
<b>Andrew Vong</b><i> Citigroup - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Ladies and gentlemen, good morning. At this time I would like to welcome everyone to the Theravance conference call.<br>
During the presentation all participants will be in a listen-only mode. A question-and-answer session will follow the Company's formal remarks.<br>(Operator Instructions) Today's conference call is being recorded.<br>
Now I would like to turn the call over to Mike Aguiar, Senior Vice President and Chief Financial Officer. Please go ahead, sir.<br>
<b>Mike Aguiar</b><i> - Theravance, Inc. - SVP &amp; CFO</i><br>
Good morning, everyone, and thank you for joining us as we announce the global filing timeline for Relovair and discuss the completion of the<br>Phase 3 registration program in patients with chronic obstructive pulmonary disease, or COPD. We will also be discussing the asthma pivotal<br>program.<br>
As a supplement to today's call, we have posted slides on our website that can be accessed during the call.<br>
With me today is Rick Winningham, our Chief Executive Officer, and Mathai Mammen, Senior Vice President of Research and Early Clinical Development.<br>We have prepared a few brief remarks and then we will open it up for questions. A copy of the press release and slide presentation can be downloaded<br>from our website, or you can call investor relations at 650-808-4100 and we will be happy to assist you.<br>
Before we get started we would like to remind you that this conference called contains forward-looking statements regarding future events and<br>the future performance of Theravance. Forward-looking statements include anticipated results and other statements regarding Theravance's goals,<br>expectations, strategies, and beliefs.<br>
These statements are based upon the information available to the Company today and Theravance assumes no obligation to update these<br>statements as circumstances change. Future events and actual results could differ materially from those projected in the Company's forward-looking<br>statements.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>365</i><br>
<hr>
<A name=366></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
Additional information concerning the factors that could cause results to differ materially from our forward-looking statements are described in<br>greater detail in the Company's Form 10-Q filed with the SEC. I will now turn the call over to Rick Winningham, our Chief Executive Officer. Rick?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Good morning, everyone. Thank you for joining us. I would like you to turn your attention to the first slide after the Safe Harbor statement in the<br>slide deck.<br>
We are pleased to announce that earlier this morning GSK and Theravance issued a release announcing a decision to commence regulatory filings<br>in Europe and the US for COPD and the EU for asthma in mid-2012. We also announced that given the data in the program with -- asthma data in<br>the program with GSK, GSK intends to continue their discussions with FDA regarding the asthma package.The release also announces the completion<br>of the Phase 3 registrational program for Relovair in COPD and all but one of the studies in asthma.<br>
The release provides a top-line summary of all Phase 3 studies completed to date.The six-month COPD studies were omitted because top-line data<br>were previously communicated last June. These studies collectively represent the largest initial registration package of an inhaled respiratory<br>medicine for the treatment of these debilitating diseases completed to date.<br>
With the release today, we now have reported data for Phase 3 studies that enrolled approximately 11,000 patients. GSK and Theravance believe<br>that the overall results from these studies show that Relovair, dosed once a day, demonstrated improvements in lung function and reductions in<br>exacerbations in both COPD and asthma. In addition, GSK plans to begin additional clinical work to investigate the potential effects of Relovair in<br>real-world effectiveness studies.<br>
As a reminder, Relovair is an inhaled combination treatment comprised of a once-daily corticosteroid fluticasone furoate and a once daily long-acting<br>beta agonist, vilanterol, currently under development for both COPD and asthma. The Phase 3 pivotal program in COPD consists of five studies<br>and approximately 6,000 patients. In asthma the Phase 3 pivotal program consists of seven studies and approximately 5,000 patients.<br>
In addition to the pivotal studies, GSK is conducting a 16,000 patient outcome study, real-world effectiveness studies that I mentioned earlier, and<br>head-to-head comparator studies as a part of a comprehensive Phase 3b program. Given the large number of studies being reported today, it<br>would be impossible to review the top-line results from each one on a single conference call. As a result, we will focus our prepared remarks on<br>the two COPD exacerbation studies and the asthma exacerbation study.<br>
Since the data disclosed from these studies only constitute a fraction of the overall dataset, I would like to note that both programs were designed<br>to be evaluated in their entirety to formulate a complete view of the safety and effectiveness of Relovair and its components. I would also like to<br>note that, consistent with GSK communication policies, we are only announcing filing timeline and providing high-level results from these studies<br>at this time as GSK will be presenting full results from all the studies in the Phase 3 programs in future scientific forum.<br>
Now turning to the studies. I will be reviewing the two COPD studies.Then I will turn the call over to Mathai who will review the asthma study. Now<br>I like you to turn to the next slide, Relovair with GSK Phase 3a in COPD.<br>
The two COPD exacerbation studies were double blind parallel group studies that each randomized approximately 1,620 patients with moderate<br>to severe COPD. Patients received either vilanterol alone or one of three doses of Relovair. The studies were designed with a primary efficacy<br>endpoint comparing the annual rate of moderate to severe exacerbations in patients receiving one of three doses of Relovair versus patients<br>receiving vilanterol.<br>
In both studies Relovair at all doses demonstrated reductions in the annual rate of moderate to severe exacerbations compared with vilanterol<br>alone. In the first study the reductions were statistically significant at all doses. At the 200/25 dose the p-value is 0.001, at the 100/25 microgram<br>dose the p-value to 0.024, and at the 50/25 micrograms dose the p-value was 0.040.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>366</i><br>
<hr>
<A name=367></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
In the second study the reductions were not statistically significant at the highest dose. The p-values in the study were p=0.109 at the 200/25<br>microgram dose, p=0.001 at the 100/25 microgram dose, and p=0.181 for the 50/25 dose.The 50/25 dose demonstrated the smallest effect in both<br>studies. All doses of Relovair in both studies demonstrated numerical increases in lung function compared with vilanterol, but not all increases<br>were statistically significant.<br>
From a technical statistical perspective, the hierarchal testing plan limits strict statistical interpretation of the second study as the 200/25 microgram<br>dose did not demonstrate statistical significance in the second study. Despite this, GSK and Theravance believe it is appropriate to request that<br>regulatory authorities review the totality of the exacerbation data.<br>
GSK believes that the overall weight of evidence from these studies, as well as the program overall, demonstrate that Relovair provided a reduction<br>in COPD exacerbation rate at the 100/25 microgram dose for patients with moderate to severe COPD versus vilanterol alone.<br>
As a reminder, the efficacy of vilanterol as a bronchodilator was demonstrated in six-month studies that were announced in June.The 100/25 dose<br>will be the focus of GSK's global submission for COPD.The most common adverse events for patients receiving Relovair included nasal pharyngitis,<br>upper respiratory tract infection, oral candidiasis, headache, COPD, back pain, pneumonia, bronchitis, and sinusitis.<br>
GSK is investigating reports of fatal pneumonia on the Relovair arms, primarily at the 200/25 micrograms dose. Also, an integrated safety and<br>tolerability analysis is underway to evaluate overall safety across the program. We are encouraged by the overall outcomes from the two Phase 3<br>exacerbation studies and the dataset generated in the COPD program more broadly. Based upon these results, GSK again intends to commence<br>the global registration process with the 100/25 microgram dose of Relovair later this year.<br>
We have also seen some exciting data from the asthma exacerbation study, and I would now like to turn the call over to Mathai to discuss the<br>results of the asthma exacerbation study. Mathai?<br>
<b>Mathai Mammen</b><i> - Theravance, Inc. - SVP, Research and Early Clinical Development</i><br>
Thank you very much, Rick, and good morning, everyone. Please turn to the third slide after the Safe Harbor side.<br>
The asthma exacerbation study was the largest study in the asthma program and had treatment periods ranging up to 76 weeks. It was a double-blind,<br>parallel group study that randomized approximately 2,000 patients -- 1,000 in each arm -- with moderate to severe asthma. Patients were randomized<br>one-to-one and received either 100 micrograms of FF alone or Relovair 100/25.<br>
This was an event-driven study with a primary efficacy endpoint comparing the time to persevere exacerbation for patients receiving Relovair<br>versus patients receiving FF alone.That is, we are testing a hypothesis that the addition of vilanterol to FF provides value to the patient by reducing<br>the number of asthma exacerbations. We powered this study for superiority.<br>
A severe asthma exacerbation is defined here as deterioration of asthma requiring the use of systemic corticosteroids for at least three days or an<br>inpatient hospitalization or emergency department visit due to asthma that requires systemic corticosteroid. In addition to evaluating exacerbation,<br>this study evaluated the contribution of vilanterol to the effectiveness of Relovair on lung function as a key secondary endpoint.<br>
We are pleased to report that this study demonstrated that patients receiving Relovair had statistically significant improvements in both time to<br>first severe exacerbation with p-value of 0.036 and in the annual rate of severe exacerbations with a p-value of 0.014. This is an important finding<br>and clearly shows the benefit of adding a long acting beta agonist to an inhaled corticosteroid on an important outcome measure like exacerbations.<br>
In addition, we are pleased to report that this study also demonstrated a statistically significant improvement in lung function of 125 micrograms<br>versus 100 micrograms of FF at all predefined time points over the 76-week period with a p-value less than 0.001.The most frequent adverse events<br>were headache, nasal pharyngitis, upper respiratory tract infection, bronchitis, cough or pharyngeal pain, and influenza.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>367</i><br>
<hr>
<A name=368></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
There were no asthma-related deaths in this study. An integrated safety and tolerability analysis is underway to evaluate the overall safety across<br>the program.<br>
We are highly encouraged by the data from this Phase 3 asthma exacerbation study as well as the overall data set generated in the full asthma<br>program. Based upon these results, GSK intends to commence the EU registration process in mid-2012. In the US, GSK will continue discussions<br>with the FDA on regulatory requirements for a US asthma indication.<br>
I would like to now turn the call back over to Rick for a few closing remarks. Rick?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Thanks, Mathai.We believe that the totality of data across both the COPD and asthma programs support the plan to submit to regulatory agencies<br>for mid-2012, a great step forward for Theravance and GSK.<br>
While we have only discussed three exacerbation studies during this call, today's release and the June release included results covering all but one<br>of the registration all programs. We are pleased to have reached this important milestone for Relovair.<br>
With one exception in the 12-week salmeterol VI asthma study, each study provides components necessary and supportive for the US EU filings.<br>These data are quite new to us. We have seen top-line analysis and additional analyses are underway to support regulatory filings by GSK. As<br>previously noted, GSK will present more complete data sets at future scientific and medical meetings.<br>
Relovair is the lead program of our three late-stage respiratory programs with GSK. What is next in respiratory? The remaining Phase 3b program<br>for Relovair, some of which will be finished this year, and then the LAMA/LABA Phase 3 registrational program for COPD. Data from this LAMA/LABA<br>Phase 3 program are projected to report before the end of 2012.<br>
The MABA Phase 2b clinical study was recently completed and we expect to update you in the near future. We believe that together these three<br>programs have the potential to address the needs of a wide range of COPD and asthma patients suffering from debilitating disease.<br>
In addition to our programs with GSK, Theravance has a number of significant pipeline products that are being developed internally in a number<br>of therapeutic areas. We are excited about 2012 and look forward to bringing you further updates later this year.<br>
Now I would like to turn the call over to the conference facilitator and open the call for questions.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions) Ronny Gal, Bernstein.<br>
<b>Ronny Gal</b><i> - Sanford Bernstein - Analyst</i><br>
Good morning, everybody, and thank you for having this call today. First question is really about the pneumonia cases. Can you tell a little bit more<br>about those? How do they compare to similar pneumonia-adverse events in other trials? It's a generally [class phenomena], but did you have more<br>than were visible in other trials?<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>368</i><br>
<hr>
<A name=369></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
<b>Mathai Mammen</b><i> - Theravance, Inc. - SVP, Research and Early Clinical Development</i><br>
This is Mathai. The data are relatively new to us so we are still in evaluation mode. What we are aware of right now were that we see no unusual<br>incidence of pneumonia relative to other products. The fatal pneumonias that we reported were predominantly at the high dose.<br>
<b>Ronny Gal</b><i> - Sanford Bernstein - Analyst</i><br>
Second question, regarding the [exacerbation] trials, do you actually meet the statistical requirements on the FPRP? Two exacerbation trials for<br>submission essentially since your second trial, at least nominally failed. Is that -- does that not negate the entire program? Can you give us a little<br>bit more of your initial perspective here?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Sure and, no, I don't believe that it negates the entire program because of the strength of evidence around the effect, particularly at the 100/25<br>microgram dose of Relovair.<br>
In the case of Relovair, we guessed that increasing the dose of the steroid would reduce exacerbations compared with vilanterol because of a, at<br>the time, relatively limited understanding of the drug effect. As the data indicate, the drug had a consistent effect across both studies in reduction<br>and exacerbations being most predominant in both studies really at the 100/25 microgram dose. So I think we are quite confident in the exacerbation<br>data in the COPD studies.<br>
<b>Ronny Gal</b><i> - Sanford Bernstein - Analyst</i><br>
So I am hearing from you that on that one you are fairly confident your data supports, at least on the efficacy side, approval?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
I am confident that the data support the reduction in exacerbations, and we will turn it in -- submit it to the FDA. But I believe that we have satisfied<br>demonstrating the contribution of the steroid to Relovair in the case of exacerbations.<br>
<b>Ronny Gal</b><i> - Sanford Bernstein - Analyst</i><br>
Great. And on asthma you seem to be more clear-cut about expectations for submission in Europe on asthma than you are in the United States.<br>Can you explain to us how do you see the regulatory regimes as being different in the two geographies as they look in respect to the data?<br>
<b>Mike Aguiar</b><i> - Theravance, Inc. - SVP &amp; CFO</i><br>
Sure, Ron; this is Mike. I think the language you are seeing today reflects two things. One, we are quite excited about the results of the asthma<br>exacerbation study. We had hoped to see this data; this is really terrific data and it's certainly something that gives GSK and Theravance more<br>confidence overall.<br>
Now as you think about the specific question on the revelatory environment, we have been communicating for quite a period of time that as of<br>today the regulatory path in Europe is a little clearer than that in the US. And so there is really no change in our guidance whatsoever where we<br>have been.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>369</i><br>
<hr>
<A name=370></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
With regard to the US, as you probably know, when we started the program we had not received final signoff from the FDA on the Phase 3 program<br>here. And as of today we still haven't received a final sign-off on exactly what it's going to take to get regulatory approval in the US. And so that is<br>really -- the language you see in the press release is reflecting that.<br>
I think we feel pretty good about the overall package and we are going to have discussions with the FDA and we will see where we end up. But,<br>again, there is really no change whatsoever in the regulatory guidance, but I think again we feel quite good about the results of the asthma<br>exacerbation study.<br>
<b>Ronny Gal</b><i> - Sanford Bernstein - Analyst</i><br>
Great, thank you very much.<br>
<b>Operator</b><br>
Ian Somaiya, Piper Jaffray.<br>
<b>Ian Somaiya</b><i> - Piper Jaffray - Analyst</i><br>
Couple of questions. First, on the COPD side just obvious questions. Why the difference in the two trial outcomes? I don't know if there were initial<br>thoughts on why the highest dose did not show significance in the second trial.<br>
Geographic differences; have you looked at baseline characteristics? Is there anything you can point to which led to the different outcomes?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
At this time, Ian, there is nothing I can really point to. These are all very, very top-line data. I would just say in terms, I think we believe that the two<br>studies actually are very consistent, particularly around the -- at the 100/25 microgram dose.<br>
Each study showed reductions in exacerbations and it was more profound across both studies in the 100/25 microgram dose. I would just like to<br>go back that in this case we guessed that increasing the dose of the steroid would result in a reduction in exacerbations compared with vilanterol.<br>
Keep in mind that this is an active controlled study. Because of a limited understanding of really the drug affect and in fact whether there would<br>be a dose response to reduction in exacerbations related to be steroid. We didn't see it here, but I think that in no way diminishes our confidence<br>around the 100/25 dose of vilanterol and reduction in exacerbations.<br>
<b>Mathai Mammen</b><i> - Theravance, Inc. - SVP, Research and Early Clinical Development</i><br>
Ian, I think you guys can certainly appreciate this is an extremely large and robust database and there will be work going on at GSK and Theravance<br>to understand this for quite a period of time. We, literally, have only had this data for a couple of days here. As consistent with our practice, we get<br>it out extremely quickly at the top level.<br>
So there will be a lot of work being done, particularly at GSK, going back, looking at the data in very, very deep level of detail, adjudicating the<br>various cases as required, etc. And so we will be continuing to inform our understanding of this data as we go forward, but as of today, given the<br>rapidity with which we are bringing the information to you folks, we don't have quite that level of detail yet. I think I would probably point you to<br>the upcoming scientific conferences when we present the full data set as the likely time when we will have additional information.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>370</i><br>
<hr>
<A name=371></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
<b>Ian Somaiya</b><i> - Piper Jaffray - Analyst</i><br>
That is fine. I was hoping to get a comment on the lung function data.That seems like the second time you have very carefully crafted the statements<br>related to the benefit shown on lung function.<br>
Can you just help us compare the 12-month data to the six-month data in terms of FEV1 benefit? Was it seen at the predefined time point at the<br>end of the study? Was it seen at any time point during the trial in terms of reaching statistical significance and at what doses?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
I think overall the improvement in lung function as measured by increase in FEV1 by the steroid component of Relovair is consistent now across<br>four different studies and three different doses of the steroid. I think we -- while in both instances we had observations of statistical significance<br>at specific doses, they -- all changes were in the same direction and they were consistent with what has been seen historically with the administration<br>of a steroid and its impact on lung function in COPD patients.<br>
So I would just say that this provides yet another dataset with regard to the impact on lung function of the steroid. It's less than -- the impact of<br>the steroid is less than the impact of vilanterol but it is additive to the effect of vilanterol.<br>
<b>Ian Somaiya</b><i> - Piper Jaffray - Analyst</i><br>
And did the 100 dose, did that reach significance or not?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Well, we didn't disclose the doses, but the doses -- the effect between the two studies -- between the four studies in COPD is consistent. Mathai?<br>
<b>Mathai Mammen</b><i> - Theravance, Inc. - SVP, Research and Early Clinical Development</i><br>
Yes, I would want to reinforce that.The majority effect of a steroid in a LABA/ICS product is of course intended to be on the inflammatory components<br>that predispose to exacerbation. And that is the exacerbation study.<br>
The lung function affects of the steroid across all the studies that Rick mentioned were exactly in line with what steroids have done historically in<br>other LABA/ICS product. In this particular exacerbation study in 12 months, as we disclosed, some of those numbers, even though consistent across<br>both studies, were statistically significant and other ones or not.<br>
<b>Ian Somaiya</b><i> - Piper Jaffray - Analyst</i><br>
Okay. And just one last question, maybe just bigger picture. Just from the regulatory viewpoint are there -- is the focus going to defer the FDA<br>versus the EMEA in terms of the endpoint exacerbation versus lung function? Just what will they put greater weight on and what gives you<br>confidence that the data will lead to a positive outcome?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Well, I think that the regulatory authorities around the world today generally view that, as Mathai stated, that the role of the steroid is to reduce<br>inflammation and reduce the potential for exacerbations. There is an effect on lung function. It is less than the affect, on a relative scale, than<br>Vilanterol.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>371</i><br>
<hr>
<A name=372></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
But I think, clearly, the data that we see from the two exacerbation studies give us and GSK confidence with the regulatory filings in both Europe<br>and the United States. Mathai, would you like to add something?<br>
<b>Mathai Mammen</b><i> - Theravance, Inc. - SVP, Research and Early Clinical Development</i><br>
I would just agree with that. I think that it's exactly as you said. In Europe there is an explicit statement that steroids, the role of steroids is for<br>exacerbations period. In the US it's likely that they will look at everything, including the lung function changes. But as we have said just a minute<br>ago, the data on lung function for the steroid is in fact consistent across the program.<br>
<b>Ian Somaiya</b><i> - Piper Jaffray - Analyst</i><br>
Okay, thank you very much.<br>
<b>Operator</b><br>
Howard Liang, Leerink Swann.<br>
<b>Howard Liang</b><i> - Leerink Swann - Analyst</i><br>
Thanks. I guess I don't suppose there has been FDA regulatory feedback on the filing, is that correct?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
No, Howard. We have just had this data for a couple of days; we haven't gotten any feedback yet.<br>
<b>Howard Liang</b><i> - Leerink Swann - Analyst</i><br>
Okay. Can you -- just going back to the fatal pneumonia cases, can you say how many cases were there at each dose? And I think typically you do<br>see an increase of pneumonia in general in the combination. In this case is there a greater increase of all ammonia cases for the combo versus LABA<br>as compared to Advair, for example?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
No, I think pneumonia is a known risk with COPD patients in the -- with COPD patients. It's a known risk with patients in an ICS/LABA class. There<br>are reports of pneumonia in COPD patients who have died receiving products other than ICS/LABAs as well as ICS/LABAs historically.<br>
I think it's too soon to compare with previous experience. However, overall the rates of pneumonia are very consistent with historical experience.<br>We called out in the press release the dose of the 200/25 where the fatal pneumonias occurred. If we had a concern about other doses in the<br>program, a specific concern, we certainly would have called those out in the release.<br>
<b>Howard Liang</b><i> - Leerink Swann - Analyst</i><br>
Okay, great. Thanks very much.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>372</i><br>
<hr>
<A name=373></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
<b>Operator</b><br>
Steve Scala, Cowen.<br>
<b>Ian Sanderson</b><i> - Cowen and Company - Analyst</i><br>
It's Ian Sanderson for Steve. Do you have any available information on the number of the exacerbations in the two exacerbation trials? Going in<br>one of the concerns was that it may be difficult to get enough exacerbating patients and I don't know if it's the law of small numbers that hurt the<br>second trial. Do you have any of those details?<br>
<b>Mike Aguiar</b><i> - Theravance, Inc. - SVP &amp; CFO</i><br>
Ian, this is Mike. I can't give you any specific numbers here at this point. What I would just say is it's largely in line with other historic studies. I mean<br>this wasn't dramatically, dramatically different, but again I don't have any very specific numbers for you today.<br>
<b>Mathai Mammen</b><i> - Theravance, Inc. - SVP, Research and Early Clinical Development</i><br>
As would not surprise you, with improving standard of care the percentage of exacerbations are probably in these future trials to be a little lower<br>than historically seen. But we haven't disclosed details there yet.<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Keep in mind the control that we are comparing to in the study is vilanterol, which vilanterol has been now demonstrated across both the asthma<br>and the COPD programs really as a very good beta2-agonist.<br>
<b>Ian Sanderson</b><i> - Cowen and Company - Analyst</i><br>
Can you remind us, if there are data out there for Advair, how fluticasone proprionate did against salmeterol in their exacerbation studies, if they<br>exist?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Sure, they are in the -- I am not going to get into it, but I can direct you to the label of salmeterol -- of Advair. For further discussion I am sure you<br>can consult the regulatory documents that led to the approval of a reduction in exacerbations claim in the Advair label in the United States.<br>
<b>Ian Sanderson</b><i> - Cowen and Company - Analyst</i><br>
Okay, thank you. Third, just to confirm -- and I think it's here -- that the long-term safety trial is using the 100/25 microgram dose, correct?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Yes, it is and thanks for bringing that up, Ian. Because I think if you look across the programs and you look at the studies that were initiated in 2010<br>and 2011, what you see is that the predominant dose used in the studies were the 100/25 microgram dose of Relovair. It was our overall expectation,<br>I believe, going in that the most frequent -- most frequently used dose of this product, if approved and marketed, would be at the 100/25 dose,<br>which is why we have studied that dose of 100/25 more than any other dose in the program.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>373</i><br>
<hr>
<A name=374></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
<b>Ian Sanderson</b><i> - Cowen and Company - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Stephen Willey, Stifel Nicolaus.<br>
<b>Stephen Willey</b><i> - Stifel Nicolaus - Analyst</i><br>
Thanks for taking the question. Mike, I know you said that you guys don't have any specific numbers at this point, but was just wondering if the<br>degree of disease reversibility if you guys know whether or not that kind of fell into the range of where your expectations were pegged for the<br>COPD trials?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Again, I don't want to get into any specific -- I would say broadly speaking these studies came out within our range of expectations on most of the<br>parameters. So I don't think we were hugely outside of what we considered possibilities. Again, I don't want to get into very specific numbers.<br>
But at the end of the day we have these two studies here that had a consistent reduction in exacerbations across all groups. We had one study<br>where every group was statistically significant and so again things fell kind of broadly within that, but I wouldn't want to get to very specifics about<br>reversibility or things like that at this particular juncture. But, again, just broadly speaking within our expectations.<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
So that others on the call are aware comments that we made after the June exacerbations or the June FEV1 studies is that we had had patients<br>with a little bit more severe COPD in that study. Clearly, the patients in the exacerbation studies have moderate to severe COPD, so these people<br>are -- have significantly compromised lung function going into the study which, of course, is one of the things that made them at risk for COPD<br>exacerbation.<br>
<b>Stephen Willey</b><i> - Stifel Nicolaus - Analyst</i><br>
Okay. And then obviously I think the emphasis here seems to be on COPD data, just given the fact that that appears to be the most well-defined<br>regulatory path, at least here in the US. But I am just wondering as you kind of look at the asthma data -- and I know that there was some discussion<br>as to kind of when and how you guys would pursue a filing in the US.<br>
But do you really see anything in the asthma data that kind of exceeded your expectations? And do you kind of expect that to meaningfully impact<br>the path and the pace at which GSK decides to pursue a filing, at least here in the US?<br>
<b>Mike Aguiar</b><i> - Theravance, Inc. - SVP &amp; CFO</i><br>
Well, I will start off with just an opening comment on the second part and I know Rick probably wants to talk.<br>
I am just going to reiterate how pleased we were with the outcome of the asthma exacerbation study. This was a very, very large study; 2,000<br>patients, 1,000 in each arm. Very clear statistical benefit on exacerbations and FEV1. FEV1, literally, at every time point looked quite good.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>374</i><br>
<hr>
<A name=375></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
So if you were to ask me what was, I think, my personal biggest surprise on the upside here in this study it was the results from this particular one.<br>So that really I think has given us a fair amount of confidence that we have now statistically shown in a very large study that the addition of the<br>beta agonist to a steroid reduced the overall rates of exasperation and it proved FEV1 in patients with asthma. So I think we were quite pleased<br>about that.<br>
Rick, do you want --?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
No, I completely agree, and I have said many times since this Phase 3 program started, one of the areas that -- just because we hadn't looked, done<br>a study like this before with GSK and with this program was the asthma exacerbation study. Clearly there was concern in some camps that the<br>addition of a beta agonist to a steroid would increase the rates of asthma exacerbations.<br>
We didn't see that. We saw in this study 2,000 patients that the addition of a beta agonist to a steroid reduces exacerbations across a couple of<br>different parameters and provides consistently superior lung function to those patients. So I am very, very pleased with the outcome of the asthma<br>exacerbation study.<br>
<b>Stephen Willey</b><i> - Stifel Nicolaus - Analyst</i><br>
All right, thanks a lot.<br>
<b>Operator</b><br>
Mark Beards, Goldman Sachs.<br>
<b>Mark Beards</b><i> - Goldman Sachs - Analyst</i><br>
Thanks for taking my question. Firstly, very quickly, when will we see the data? Will you be able to make ATS? And then, secondly, can you just help<br>us understand how regulators might interpret these pivotal studies when both the active and the comparator are unlicensed medications?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Sure. On your first question, will we make ATS; no, I don't think we will make ATS. I think we are committed with GSK to get this data out in front<br>of the medical and scientific community just as soon as we can but we won't be able to make ATS.<br>
Relative to your second question and the expectations, I mean clearly the scope and the size of the asthma and COPD program here for an initial<br>registration package are unparalleled. As I said in my remarks and as Mathai reiterated, each of these studies provides a level of contribution to the<br>overall package. So the COPD exacerbation data clearly, at least in our mind, show that at the 100/25 microgram dose there is a benefit to reduction<br>in exacerbations in COPD patients.<br>
We have already shown that vilanterol in COPD patients is a highly statistically significant bronchodilator. We have also shown that Relovair, as a<br>combination product, is highly statistically significant bronchodilator.<br>
Turning to the asthma program and how the strength of evidence really of the asthma program, we talked about the exacerbation study so I won't<br>cover that again. The moderate to severe study in asthma, a 24-week study, statistically significant contribution here from the product and an<br>improvement in FEV1 of the combination over 200 microgram dose of the FF and trough FEV1 and weighted mean FEV1.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>375</i><br>
<hr>
<A name=376></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
That is an important outcome for us because also in the study the FF 200 microgram dose dosed once daily was non- inferior to fluticasone<br>propionate. That is another important element of the registrational package.<br>
While the 12-week placebo-controlled study evaluating lung function in mild to moderate asthmatics didn't demonstrate an improvement of the<br>combination over the single agent steroid, importantly it did demonstrate a statistically significant improvement over placebo for the steroid. And<br>then I think the safety data, large safety, 12-month safety study in asthmatics supports both the asthma and the COPD programs.<br>
Then just closing off, with the two comparator studies -- one in asthma, one in COPD -- versus Seretide, while in these initial studies we did not see<br>superiority of Relovair versus Seretide what we did see was a comparable impact on FEV1 between Relovair and Seretide, which I think is also<br>somewhat supportive from a regulatory process. I think overall GSK really has designed a very comprehensive Phase 3 program that should be<br>well received by regulators.<br>
<b>Mike Aguiar</b><i> - Theravance, Inc. - SVP &amp; CFO</i><br>
Andrew, this is Mike Aguiar; I just want to add one thing. I am not going to get it to the very specifics of regulatory interactions, but clearly GSK<br>designed these programs after consultations with the regulators and clearly these consultations contemplated these were brand-new products<br>and these were unapproved products. So I would just say that I think GSK has done a thorough job on that and the programs are designed with<br>the view these were unapproved products at this point.<br>
<b>Mark Beards</b><i> - Goldman Sachs - Analyst</i><br>
Okay, thanks.<br>
<b>Operator</b><br>
[Andrew Vong], Citigroup.<br>
<b>Andrew Vong</b><i> - Citigroup - Analyst</i><br>
Thank you for taking my call. A couple of questions, please.<br>
Clearly there have been background concerns about the safety of ICS administration in COPD patients with regards to pneumonia, albeit non-fatal.<br>This additional trial data suggests that it may be indeed a material issue, dose dependent or not. In addition, as you have obviously admitted and<br>shown in the data, LABAs are very effective in monotherapy in the disease.<br>
My point being that looking at the totality of the data you could argue that perhaps LABA/LAMA increasingly might look like the gold standard for<br>management of COPD. So with that in mind, given your recent initiation of a lower dosage trial for the LAMA component of your LABA/LAMA,<br>could you just restate your confidence that in fact GSK and Theravance have selected the optimal doses, in particular of the LAMA, to ensure US<br>regulatory approval?<br>
So that is the first question. There is a short second one which is to provide some further information on the scale and duration of the real-world<br>outcome trials that you alluded to.<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
So I think we will all contribute different pieces to this answer. First of all, with your perspective on LABA/ICS I think clearly the role of LABA/ICS<br>going forward in COPD is around exacerbations and the reduction in rate of exacerbations. It's critically important, as it is with any drug that is<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>376</i><br>
<hr>
<A name=377></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
developed, to get the dose right in treating those patients. And that is clearly what we have attempted to do with these two very large COPD<br>exacerbation studies, and I believe we have done that.<br>
I think you bring up an excellent point with regard to LAMA/LABA because in the -- with the LABA/ICS you have one bronchodilator plus an<br>anti-inflammatory medicine, whereas the LAMA/LABA program combines two bronchodilators. And I think we are very excited about the potential<br>of bringing both type of products to patients. Mike?<br>
<b>Mike Aguiar</b><i> - Theravance, Inc. - SVP &amp; CFO</i><br>
Yes, I think you have hit it on the head, Rick. With regard to the confidence around the LABA/ICS, we have a very, very large series of studies here<br>(multiple speakers)<br>
<b>Andrew Vong</b><i> - Citigroup - Analyst</i><br>
Sorry, maybe I wasn't -- I was referring to your confidence about dose selection for the LAMA within the LABA/LAMA not LABA/ICS.<br>
<b>Mike Aguiar</b><i> - Theravance, Inc. - SVP &amp; CFO</i><br>
We will get there. So just to close out on the LABA/ICS, again I think we have quite a bit of confidence where we are today.<br>
Now with regard to the LAMA/LABA. This is a very important asset to both Theravance and GSK. I think Theravance's view is that going forward<br>this will have a larger proportion of the market today. I think LAMAs are going to have an increasing role in COPD. The LAMA/LABA in particular is<br>a very well-positioned asset, as Rick had mentioned.<br>
Now going to your specific question, we have taken two doses forward the [62.5] and the 100/25. Based upon where we are today we think the<br>100/25 is the most likely. We sort of took the 62.5 into the studies as a belt and suspenders. You are correct, we do have another study that is<br>ongoing and that data will continue to inform our opinion.<br>
But I think based upon the totality of the data that GSK generated up to this point we feel quite good about the 100/25 and the 62.5. Obviously,<br>we will need to get to the finish line for that, but I think today we feel quite good about that. Mathai?<br>
<b>Mathai Mammen</b><i> - Theravance, Inc. - SVP, Research and Early Clinical Development</i><br>
Yes, thanks. I want to reiterate that there are going to be a group of patients that have exacerbations, that have inflammation in their lungs with<br>COPD where they are best treated with a LABA/ICS product. So that is going to be a very important product for a large subset of patients with<br>COPD.<br>
And we are equally excited about patients that don't need that anti-inflammatory that need excellent bronchodilation. So there we have -- the<br>LAMA/LABA program in collaboration with GSK is exciting.<br>
And with respect to doses, first on the LABA/ICS. It is important there to get the ICS dose exactly right. You need it to be high enough that it does<br>in fact control exacerbations.<br>
As a reminder, the 50 dose was the least effective dose in both our exacerbations studies, so it needs to be north of 50. And it can't be so high that<br>it causes its own issues. So there was a lot of confidence around the 100/25 dose on the heels of the study just reported.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>377</i><br>
<hr>
<A name=378></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
And on the LAMA/LABA side, the LABA dose is of course fixed at 25 micrograms. As Mike said, there is no change in confidence.We remain confident<br>that the two doses selected for the Phase 3 study are right, and until the data comment that are from the low-dose study there is no reason to<br>change that level of confidence.<br>
The 100/25, as a reminder, looked a tad better to us than the 62.5, and the 62.5 was taken into Phase 3 as a risk mitigation strategy.<br>
<b>Andrew Vong</b><i> - Citigroup - Analyst</i><br>
Thank you. And just maybe a quick comment on the real-world outcome trials scale and duration?<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Sure.Theravance and GSK will be rolling those real-world effectiveness studies out in the immediate future and I think, Andrew, we will update the<br>public once we get these rolled out. I think rolling them out is an indication of the confidence that we have got overall in the program and the<br>program going forward.<br>
<b>Andrew Vong</b><i> - Citigroup - Analyst</i><br>
Okay, thank you very much.<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
It appears we have no further questions on the phone. I would now like to turn the conference back to Mr. Winningham. Please go ahead, sir.<br>
<b>Rick Winningham</b><i> - Theravance, Inc. - Chairman &amp; CEO</i><br>
Thank you very much, operator.<br>
Just in closing I would like to thank the people at GSK for all of their work in bringing the relatively large set of studies to closure, and to the physicians<br>and the patients that were involved in these really unprecedented initial registrational program. I would also like to wish everyone to have a good<br>day and we look forward to talking to you in the near future. Thank you.<br>
<b>Operator</b><br>
Discussed include today's conference call. We thank you for your participation. You may now disconnect.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>378</i><br>
<hr>
<A name=379></a>JANUARY 09, 2012 / 1:30PM, THRX - THERAVANCE INC GSK and Theravance Announce Initial Outcomes<br>from Pivotal Phase III Studies for Once-daily RelovairTM in COPD and Asthma Conference Call<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4703063-2012-01-09T18:01:20.880</b><br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>379</i><br>
<hr>
<A name=380></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
ASEN.OB - AMERICAN STANDARD<br>ENERGY CORP AT PRITCHARD CAPITAL<br>PARTNERS LLC "ENERGIZE`<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 04, 2012 / 9:40PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>380</i><br>
<hr>
<A name=381></a>JANUARY 04, 2012 / 9:40PM, ASEN.OB - American Standard Energy Corp at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Scott Mahoney</b><i> American Standard Energy Corp. - CFO</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Unidentified Participant</b><br>
Good afternoon. Thanks for coming to the Pritchard Energize Conference. Today we have American Standard Energy. We have Richard MacQueen<br>and Scott Mahoney. So I think we're going to let Scott take it away here.<br>
<b>Scott Mahoney</b><i> - American Standard Energy Corp. - CFO</i><br>
so I think we are going to let Scott take it away here.<br>
<b>Scott Mahoney</b><i> - American Standard Energy Corp. - CFO</i><br>
The areas of concentration [for family] have been centered in the Permian Basin, South Texas, and the Eagle Ford and in the Williston Basin in North<br>Dakota. The rationale for the public company has been very simple.<br>
Year one was to assemble some of the family's assets to do two basic things. Gain access to the public markets and have something that was highly<br>marketable, primarily centered around the non-operating position that the family had access to and we can bring in to the public sands, Center<br>on the Williston Basin. There are a number of notable comparable Company business profiles, Northern owned gas, Voyager Triangle that evolved<br>on something very similar over the last several years and that was ultimately our business model in the Bakken.<br>
But unlike some of the other basin-specific non-ops our end goal was to leverage the family's portfolio in the Permian Basin and in South Texas.<br>Year one's top priority was to get the scale to be relevant in the public markets. And secondly, to structure a portfolio of proven producing reserves<br>primarily in the Permian Basin that would give us access to a credit facility.<br>
That large credit facility was put in place in September through an Australian bank called Macquarie. The most important thing to take away from<br>that credit facility is that it is not a line of credit. It is project financing. They gave us $300 million worth of dry powder through which to put into<br>developing the family's assets.<br>
We are now in the middle of what will ultimately become a more mature platform. So let's compare and contrast what do you see on page 5 and<br>what will you see in the very near term.<br>
We have announced the market that we are acquiring approximately 80,000 net acres. The majority of those net acres are in the Permian Basin,<br>the Bakken, and in the Eagle Ford. That is our area of focus.<br>
Any other assets brought in are primarily brought in for appreciation potential, for divestiture. So that the reinvested capital can go back into those<br>three basins I just listed. So we will have approximately 125,000 net acres, the majority of which are in the three basins you look at.<br>
So when you see a summary that describes 6,500 net acres today in the Permian, that is irrelevant. That is where we are temporarily, but in the<br>short term we will disclose exactly how many acres we have by county in the Permian Basin. It is all held by production.The majority of what we're<br>bringing in is focused on two very basic opportunities.<br>
One, for us to continue to rapidly develop our production base and we will speak of that in a moment. We want to take the lowest drillbit risk<br>possible. We will drill as many low risk vertical wells in very derisked plays as possible. We will continue to push our BOE up while leaving the<br>optionality to pursue what the real economic opportunity is and, ultimately, maybe what makes us very attractive for drilling partnerships or other<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>381</i><br>
<hr>
<A name=382></a>JANUARY 04, 2012 / 9:40PM, ASEN.OB - American Standard Energy Corp at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
arrangements is the access to 100% of our production working interests leveraged against shale in places like Reagan, Crockett, Crane, Upton and<br>a number of other counties where the acreage is very precious. It is very valuable and it is increasingly becoming derisked for unconventional shale<br>opportunities.<br>
That is the main thrust for American Standard going forward, is to leverage ourselves against the family's hard work in the Permian Basin,<br>unconventionally and conventionally.<br>
Similarly in the Eagle Ford, you will see us expand our position from the 1,200 net acres that we have today to something much more meaningful.<br>And the acreage will have opportunities -- in some counties you can drill unconventionally and have very, very fruitful results. In others you can<br>also drill conventional. You can drill into the Georgetown and [McKnight], the Buddha, the Piersall and others.<br>
For us, we are causally about evaluating what is the right drillbit risk given the pace of growth.<br>
Finally, in the Bakken, today we have a little over 33,000 net acres we are getting rapidly drilled up. Our acreage has increasingly become in the<br>strike zone for additional [AFEs].To give you a sense as to the rate of growth -- in our first 15 months, we had one net well AFE'd over 80 gross wells.<br>In the last 90 days of last year, we had over 1.5 net wells AFE'd.<br>
Coming into this year, we expect that rate of development to increase because we have staged our acreage in the Bakken so that we are increasingly<br>in the way of drillbit activity as we can afford it.<br>
To give you a quick snapshot on what did last year look like and what do we think this year will look like, in 2001, we started the year with about<br>25 BOE a day. We have articulated to the market that we will have exited the year at about 2,000 BOE. Still the dust has to settle, we are not non-op<br>so some of our acreage takes a little while to aggregate all the data, but we are pretty comfortable sticking to that guidance of 2,000 barrel exit<br>rate for the year.<br>
It is over 3,400% growth rate for the first year of business.<br>
We spent very close to $100 million on CapEx, both acquisition acreage and development of that acreage. 2012, we expect to do three very basic<br>things and this is all on the acreage that we have today. We drilled 17 wells in the Permian Basin in the fourth quarter of 2011. We expect to drill<br>30 in 2012. These are all primarily Wolfberry-focused wells. What we have typically done in the counties where we are now is look to stimulate<br>Wolfcamp, Spraberry, and at least one other formation. In most cases, it's the Strawn. In some cases it is the Clearfork. Looking to get 100,000 to<br>125,000 EUR, 100 barrels of oil at a 30-day IP, coming quickly off that, down into the 50 range, net to us. Very solid singles and doubles that are<br>highly accretive to the Company's growth rate.<br>
We will spend approximately $60 million in that program in the Permian Basin this year. And basically what we are guiding is that's going to be<br>our level baseline performance this year and for the foreseeable future. We don't expect to accelerate beyond maybe three rigs running full time<br>throughout the year.<br>
In the Bakken, this year we expect to layer on incrementally between four and six net wells using a midpoint of five net wells. We should spend<br>approximately $50 million in the Bakken. For us it is very much like a mutual fund or an ETF.<br>
We are diversified by county. We are diversified by operator.<br>
There are slides in our handouts that will be very good references to that if you want to look at those and have any questions.<br>
In the Eagle Ford, we have invested in 17 gross wells.We expect to get to 35 gross wells by the end of this year.We will end up spending somewhere<br>between $15 million and $18 million to achieve that to us.We have a 10% AMI, so we will have exited the year with about 1.7 net wells in the Eagle<br>Ford paid for, not yet producing. And in 2012, we'll layer on another two net wells.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>382</i><br>
<hr>
<A name=383></a>JANUARY 04, 2012 / 9:40PM, ASEN.OB - American Standard Energy Corp at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
That takes us to about $125 million in CapEx and, essentially, with our credit facility is paid for. We should generate, based upon today's oil and gas<br>prices, somewhere between $45 million and $55 million worth of EBITDA in 2012. So if you look at what I just said and say, well, where is the $75<br>million coming from? It is coming from the project financing commitment from Macquarie. We don't need to raise equity, we don't seek outside<br>capital. It is set up for us to grow.<br>
Going into the year with approximately 2,000 BOE a day rate, where do we go in the near term? What are the major catalysts for growth early in<br>the year?<br>
As I had mentioned, we have invested heavily over the last 18 months and a program with Cheyenne and Chesapeake down in La Salle and Frio<br>counties. Very, very derisked, very, very attractive acreage.<br>
We have invested in 17 wells to date. The majority of those wells are expected to come online approximately simultaneously, probably in the next<br>30 to 45 days.They were just about done cooking everything up to infrastructure in December, and for us that means probably somewhere around<br>1.5 net wells coming online simultaneously, early in Q1. That is a fairly meaningful lift to our daily production.<br>
To be conservative, using the data that they have already provided us with when we published in the markets, our first five wells had 1,189 BOE<br>on a peak 24-hour basis.<br>
So use that kind of math, back it into 17 gross wells instead of five, and I think you'll quickly get comfortable that with traditional decline rates<br>throwing out some guidance that we are going to probably add about 500 barrels a day net to us from that program in Q1 at some point during<br>the quarter is fairly substantial, but also very conservative.<br>
We are also in the middle of completing 7 fracced wells in the fourth quarter in the Permian Basin, Wolfberry wells. We have already four frac dates<br>in January. We are looking to frac the rest of that backlog as early as possible in the quarter and then begin ramping back up for our new wellbore<br>drilling activities sometime in the second half of Q1.<br>
So I see some pretty meaningful incremental production coming out of those wells.<br>
So in closing, the big catalyst for us is basically where are we today and where do we think we will be over the next three to four month? Right now,<br>the market is waiting to understand how the things that we have got has done -- will play out.<br>
One, I think they all want to see that the guidance towards 2,000 BOE exit rate for the year is substantiated. I think the second thing they would<br>like to see is our ability to convert to being an operator profile in the Permian Basin, drilling our own wells, getting the logistics behind us and<br>creating meaningful value through drillbit activity.<br>
I think another thing they'd like to see is, when will the Eagle Ford come on and how meaningful will it be to our daily production?<br>
And the other major question that needs to be answered, we already know it to be true, but we need to demonstrate to the markets and explain<br>how is how are we financing these wells. The project financing we have created with our bank partner is unique. That is good because it is a<br>competitive advantage. In these times, we don't have to raise equity.<br>
But it is bad when you are on the [boss] side and you are trying to interpret and figure out what this means for our ability to grow and sell finance<br>our growth for the foreseeable future.<br>
So this unique opportunity for us to really help the market understand our potential, the assets are high-quality. Now the growth trajectory and<br>how we can afford it need to be substantiated and we think this can be a very interesting period for us and investors over the next three to four<br>months.<br>
Given the time, why don't we take a few questions if there are any?<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>383</i><br>
<hr>
<A name=384></a>JANUARY 04, 2012 / 9:40PM, ASEN.OB - American Standard Energy Corp at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Unidentified Audience Member</b><br>
(Inaudible - microphone inaccessible).<br>
<b>Scott Mahoney</b><i> - American Standard Energy Corp. - CFO</i><br>
Yes. I think there are three equity analysts that cover us now.They are all pretty consistent about the math and how it produces exit rate calculations<br>by well and in aggregate. I think realistically what you would see us do is layer on probably somewhere between 400 and 600 barrels in the first<br>three to four months of the year.<br>
So realistically, we have a very reasonable shot at layering on approximately 500 barrels, somewhere towards the end of Q1, early Q2. Again I don't<br>want to pigeonhole us based upon specifics, but that is basically where the outlook is in the reasonable year term. I think by the end of the year if<br>we do exactly what I described as far as incremental well activity throughout the year, our exit rate in the fourth quarter should somewhere be<br>between maybe 3,400 to 3,500 barrels and it could be higher than that substantially.<br>
I think in our models we have a pretty clear path to essentially close to a double in production rates by the end of the year. But let's just play it safe<br>and say that we are somewhere in the mid-3,000s.<br>
We haven't given public guidance on exit rates for the year. But we -- basically the analysts are all in pretty good consensus on where the numbers<br>kind of play out.<br>
Anything else?<br>
<b>Unidentified Audience Member</b><br>
(Inaudible - microphone inaccessible).<br>
<b>Scott Mahoney</b><i> - American Standard Energy Corp. - CFO</i><br>
Good question. So, no, I think the most important thing to understand is our strategy in creating value is to leverage the scarcity of value of what<br>the family has already aggregated. So our only position in the Eagle Ford today is one, AMI, and the operator is Cheyenne. And the only other<br>meaningful participants in that acreage is Chesapeake.<br>
So, they are doing just fine. They are doing a great job in drilling up. We have got some excellent production prospects for us. But the acreage we<br>will be bringing in, we control 100% of. So we can farm it out to the appropriate partners to drill it at scale if we choose to do so. Or we can proceed<br>with alternate ways to develop those assets, but the most important thing to differentiate is in the Permian Basin and in the Eagle Ford, in the near<br>term, we will be a 100% working interest, held by production operator of record controlling those assets.<br>
Our main thrust is to take advantage of the scarcity value and what the family has aggregated over time. Good question.<br>
<b>Unidentified Audience Member</b><br>
(Inaudible - microphone inaccessible).<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>384</i><br>
<hr>
<A name=385></a>JANUARY 04, 2012 / 9:40PM, ASEN.OB - American Standard Energy Corp at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
<b>Scott Mahoney</b><i> - American Standard Energy Corp. - CFO</i><br>
Yes. We have about 40,000 net acres almost exactly today. We have articulated that we are adding about 80,000. Just take me on my word and say<br>it is going to be right now 120,000, 125,000.<br>
So obviously, we are going to look very little like what we do today. And that is the other major question the market needs to see addressed is what<br>do we look like when we're done, county by county, lease by lease, and how do we pay for it. Obviously needs time to market so it is always going<br>to have a fear factor. [Extremely] worried how many shares do we have to issue to get this deal done? I mean the family already owns 40% of the<br>public company and we are tripling the size of the Company so they own 90% of the stock when this thing is done.<br>
And respectively speaking, the answer is no. But the specifics of the deal have not been disclosed. I think it is just prudent to say I think when the<br>terms of the deal are disclosed, the market will be reasonably pleased.<br>
Anything else? Great. Thank you very much for your time.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4696547-2012-01-09T18:16:16.337</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>385</i><br>
<hr>
<A name=386></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
HNT - HEALTH NET, INC. AT JPMORGAN<br>GLOBAL HEALTHCARE CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 4:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>386</i><br>
<hr>
<A name=387></a>JANUARY 09, 2012 / 4:30PM, HNT - Health Net, Inc. at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>John Rex</b><i> JPMorgan Securities Inc. - Analyst</i><br>
<b>Jay Gellert</b><i> Health Net Inc. - President, CEO</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>John Rex</b><i> - JPMorgan Securities Inc. - Analyst</i><br>
All right. I think we're ready to begin. My name is John Rex, and I cover managed-care stocks here for JP Morgan. Thanks for joining us here for the<br>30th annual conference. Hopefully, everyone's making it through the registration okay.<br>
Presenting now, Health Net. Up here on the stand with me is Jay Gellert, the CEO. He'll be going through the story, and then we have the breakout<br>just down the hall in the Yorkshire. Jay, I'll go ahead and turn it over to you.<br>
<b>Jay Gellert</b><i> - Health Net Inc. - President, CEO</i><br>
Thank you, John. Thank you everyone for being here. I thought it's the 30th -- you said the 38th.<br>
<b>John Rex</b><i> - JPMorgan Securities Inc. - Analyst</i><br>
Did I say 38?<br>
<b>Jay Gellert</b><i> - Health Net Inc. - President, CEO</i><br>
Yes. I thought you said -- it's only the 30th. I mean, you know, okay.<br>
I'd like to talk a little bit about where we are, where we've come from, and kind of how we see the future. First of all, just in terms of our basic<br>foundation of thinking, our foundation of thinking which is -- this slide has existed for like at least a couple of years -- is that the system is already<br>changing, that everybody's all agitated over the Supreme Court and the election, and all these events, and that most of them will not be nearly as<br>material as what is already going on. And so it's really thinking through the business model and the business opportunities based on facts that are<br>already existent. There will be some nuances, some day trade events in the interim, but I think the trends and the direction are very obvious. So I'd<br>like to talk about it from that standpoint, and then kind of walk you through what we think based on that.<br>
Two key things are fundamentally changing healthcare. One is the economy. People no longer are planning on taking $50,000 a year out of their<br>house, so they actually are value shoppers in terms of healthcare. That will only intensify; that won't diminish. We're going through basically a<br>five-year period, which we basically just started, where we're moving from a revenue driven to a cost driven business. Just as simple as that. The<br>last 10 years have been years of kind of a revenue orgy. They've been time when you've really been tracking the top line. That's not the future.<br>
The future is going to be about providing products at an affordable price that provide adequate coverage.That will mean dramatic transformation<br>of every element of the system. It won't be transformation that is purely structural; in fact, the structural change is less relevant. It will be, at its core,<br>economic, which means what actually pencils, what actually works, not what actually gets regulated or structured or thought about and all of those<br>things.We're already seeing it.We're seeing it, in our case, with a dramatic change in our commercial business towards an efficient network strategy,<br>where people are really buying value, buying limits on their providers, looking at price points in a two dimensional way, benefits on the one hand<br>and network on the other, and that we're beginning a process of fundamentally attacking unit costs top to bottom in the healthcare system.That's<br>going to be exacerbated by the budget pressures at the federal and state level.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>387</i><br>
<hr>
<A name=388></a>JANUARY 09, 2012 / 4:30PM, HNT - Health Net, Inc. at JPMorgan Global Healthcare Conference<br>
There's no question that, in many instances, we've had costs shift from the private sector and relative inattention on the public side that has allowed<br>for the revenue situation. Well, both of those are gone. Those trapdoors are both gone, and so we are also seeing very aggressive actions on the<br>part of the federal, state entities to focus on costs.<br>
A lot of things we've done before that things people have thought were efficient didn't yield any numbers. I mean, we don't see any evidence in<br>the federal budget picture of all the efficiencies that have gone on over the last five or ten years.We don't see any evidence in commercial premiums<br>of those. So we will be moving from conceptual change to real change and conceptual demand to real demand.<br>
I think what we've seen already in California is a forerunner of what we are going to see throughout the rest of the country. So that's our fundamental<br>hypothesis, that we're past the area -- the era of faux structure, and we're entering the era of real cost accountability, and that the Accountable<br>Care Act will have some effect. It will likely expedite the existing trends.There are certain markets, like the individual market, which it will profoundly<br>affect, but that the core basis of what's going on will not be defined or determined by the Accountable Care Act. It could be exacerbated.<br>
So when we look at things, we say that where you want to be is in a diverse book of businesses, all targeted at making yourself a key part of the<br>cost solution, not making yourself a key part of the revenue equation so that you gain revenue by being efficient in cost, rather than vice versa on<br>a going-forward basis. That will profoundly affect everyone who is here at the conference. I actually think it's good for our sector, because we are<br>on the side of cost containment. Most everybody else is on the side of revenue enhancement. I think that will be the fundamental divide as we<br>look forward over the course of the next three or four years.<br>
So what's our strategy been in that context? It's been a very simple one. A mixture of risk and fee business, our fee business primarily in terms of<br>DOD with a five-year contract, mix of commercial, Medicaid, Medicare, and tri-care. And TRICARE, and a view that some of those are going to start<br>converging so that Medicare won't only be Medicare; the duals are an example of that. Medicaid won't only be Medicaid; that will be evident when<br>the exchanges come in. Commercial won't only be commercial, and TRICARE will increasingly mix, because a lot of its elements are providing<br>commercial-like services to military people -- that when we talk about value-based products, there are two ways to look at it. Sometimes people<br>use value as an alternative to cost. We don't think that's true. Value for the longest time has been a place where people excuse high costs.<br>
In the future, that's not what we see it to be. We see value meaning benefits at an affordable price. So when I hear people say, well, we're a value<br>leader, but our costs are in the top quartile, that doesn't make me think that they are defining value the way we do, or the way we foresee it in the<br>coming years.Value will be differentiated -- differentiation below the mediated median, not excuse above the median. So we see that's a very, very<br>fundamental change going on, and that will put enormous pressure pressures on the system. I'd like to talk a little later about some of the things<br>we're seeing.<br>
Very important to bring G&amp;A down. Part of bringing G&amp;A down is a focus on some core businesses; part of bringing G&amp;A down is intelligently doing<br>what you do well and taking advantage of what is out there, which is a buyers' market in terms of support services.There are numerous opportunities<br>for us to solve any scale problem we have by buying on the open market, because there are more vendors than you can imagine; focusing again<br>on where you actually can meet the criteria of offering value, of offering good products, of being a cost leader, and having the ability to continue<br>to move in that direction, and maintaining a strong balance sheet.<br>
The key way, in our view, to maintain a strong balance sheet -- the more you do organically, the less you have to do through acquisition, the better<br>your balance sheet will be, because you're not using your balance sheet in order to grow. So our goal has been to really focus on building an organic<br>machine through this integration of our strategy.<br>
On the commercial side, again, a third of our business is in narrow network products.We see it going towards 50% over the next two or three years.<br>We think we are way ahead of most others in terms of that. Part of that is because we have the medical group model. We do think there's going to<br>be more organization of providers. We actually like that. We actually think that organized providers give you the ability to implement high-quality<br>and cost-effective networks. One of the key things about organized providers, it's really hard to build narrow networks when you disrupt referral<br>patterns, but when you do it among integrated referral patterns, it's a very -- it increases the satisfaction with the product on the part of the<br>consumer. The consumer doesn't like a network product where their doctor says, I really wanted to send you to X but I have to send you to Y. That<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>388</i><br>
<hr>
<A name=389></a>JANUARY 09, 2012 / 4:30PM, HNT - Health Net, Inc. at JPMorgan Global Healthcare Conference<br>
isn't a healthy thing; that isn't good. But when they are integrated into units, and it's all an integrated entity, people really like it. So that's one of<br>the things we've really focused on. We've seen more and more, in all segments, an interest in these kind of products.<br>
Now, what they let you do is offer reasonable coverage. One of the best things that's happened to us is after people go so far up in terms of high<br>deductibles, then people view narrow networks as an advance, as an enhancement, because they're not paying as much for their care, they're not<br>paying as much for their services. So we see a progression, interestingly enough, towards high deductibles and then into narrow networks. That's<br>more and more going on within our business.We're seeing it significantly move in large employers. Once it begins to get hold, we are seeing much<br>more dramatic in-group growth than we ever anticipated.<br>
So the good thing about this is it's not -- it's that the penetration in accounts increases fairly dramatically once the account is sold, which is a much<br>better story than you're picking up a bunch of new accounts and you're shedding a lot of members. So we see this as the future, and we see that<br>it solves a lot of problems. Then it evolves quite naturally into provider partnerships, because as people see that people are willing to purchase<br>narrow networks, then providers want to get into integrated entity.<br>
We've seen -- in 2008, 2009, we sold these narrow network products, generally with the lower-cost, less-favored providers. Now, we have arrangements<br>with, really, the most favored providers in this kind of a structure, because they've come to conclude that it's really the only viable way to move<br>the market. Some of the leaders of the hospital industry in California have basically said that this is the future; this is the way we are going; this is<br>what's going to happen.We now have virtually everyone in the network interested in various forms of partnerships and different kinds of networks.<br>
I guess the final point I'd make on this is if you bear in mind that, for most providers, the commercial business provides 140% to 150% of costs,<br>subsidizing the rest of the business, they increasingly realize they can't lose share on the commercial side. So in effect, they have to make these<br>alterations and changes, and I think we're beginning to see this become a centerpiece of the business going forward, so we see a pretty dramatic<br>change.<br>
Then the secondary effect is that, when you get here, you begin to see the providers themselves focusing on inefficiencies, the providers themselves<br>moving from five different devices that do the same thing into one, the providers themselves looking at how do they squeeze costs down out?<br>Because that, in the long haul, will be the key.<br>
I feel, for us, we've kind of crossed the bridge over the course of the last 12 months to seeing in our markets revenue driven to cost driven systems.<br>I think California is ahead of the rest of the country, but I think it's going to move very fast throughout the rest of the country.<br>
In terms of Medicare, we've had network-modeled HMO products. We've really not been in anything else. We went through a sanctioned process<br>which we're out of.We're very encouraged by our enrollment that we're seeing in 2012.We picked up where we left off in 2010, so it's an encouraging<br>picture.<br>
Part of it, also, is in terms of provider partnerships, we'll see some margin improvement, because there was some adversity as a result of the sanctions.<br>Today, we announced that we were selling our standalone Medicare business, our Part D business, because we think we have other, better<br>opportunities. We think this is an opportunity for us, basically, to get additional cash, give us an opportunity to continue our share repurchase<br>program, not have any kind of negative impact on our earnings, and kind of strengthen our position in terms of Medicare.<br>
Medicaid is -- this is the first year.This is one of the most exciting things.This is the first year at this conference everybody wasn't frightened by the<br>California budget. This is the year where everyone's encouraged by the California budget. So we kind of turned the page. It's because, I think, the<br>state has realized, partially because of the success with the seniors and persons with disabilities, that the only way the state is going to really solve<br>its fiscal problem is to move more and more into managed care in this segment.<br>
We believe that there are tremendous opportunities in the dual-eligible program. We believe it's going to be state driven; it is going to be state<br>driven. It requires expertise in CAID end care to effectively do it. There's absolutely no question that solely doing CAID, solely doing M.A., it doesn't<br>get you into this population.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>389</i><br>
<hr>
<A name=390></a>JANUARY 09, 2012 / 4:30PM, HNT - Health Net, Inc. at JPMorgan Global Healthcare Conference<br>
And so we think California is probably going to lead the nation in this. Exactly how it's going to do it is still the subject of a lot of debate. But I think<br>that Governor Brown's budget I think showed a real commitment to reform, a real commitment to efficiency, a real commitment to California again<br>kind of leading the country in terms of showing how to do this.<br>
We think we are well positioned. The Medicaid core we have does two things for us. It opens up this dual opportunity to be defined. At the same<br>time, it opens up low-cost capitated networks for the commercial and exchange side.<br>
So what we've really tried to do is build now this continuum among all of our programs. And so we don't view them as separate programs. You<br>have commercial, efficient networks; you have Medicare built off efficient networks; you have Medicaid, which feeds the efficient networks and<br>links to Medicare in order to be dual eligibles. So you have kind of this comprehensive program of healthcare delivery that will also serve as<br>populations moved from one end to the other.<br>
I think that the concept we've had of diversity of products is actually supported by this kind of overall strategy, and I think it's going to see its fruition<br>over the next -- the course of the next 12 to 18 months. So we are very encouraged by seeing some of this coalesce.<br>
We are also seeing interest outside of our core service areas in this kind of an overall strategy. A strategy that really isn't as predominant so far in<br>the rest of the country. We think this is the kind of change that you're going to see that's going to mean real healthcare reform, that's going to be<br>a real change in the way the system operates, a real change in the way the system serves populations.<br>
Entering 2012 and 2013, I think the efforts we've made over the last two or three years will come to some significant, tangible fruition over the<br>course of the next 12 to 18 months.<br>
Our TRICARE business is good and solid. We're the only ones who have a new contract so far. The other two areas are still in contention. We think<br>that's a good thing.<br>
We also think there are some really significant opportunities on the healthcare side in DOD as it faces budget pressure. The DOD is going to have<br>enough problems making capital expenses to deal with military equipment; it's going to have enough pressure keeping a viable military. It will<br>diminish the DOD interest in building new hospitals and expanding medical services. That means that there's an opening for more opportunities<br>built off the TRICARE model.<br>
The TRICARE program is the most popular health-care program in the country whenever it's surveyed. And so there's a real opening here to begin<br>to look at different ways of expanding on this business, too, going forward, and doing it in a meaningful, significant way, again aligned with the<br>needs of the public sector.<br>
I think one of the key things that we've learned is if you're on the same side of the table doing things that they need done, it's a much more<br>sustainable business than being in conflict with the government, that the long-term viability of being in conflict with the government isn't that<br>good, because they are a customer, and that what we've seen in all these areas where we're talking about, it's really they have pressure. We have<br>opportunities to solve some problems. It's built on kind of an organized model. It's aligned with the provider community, and it allows us to really<br>build something that has sustainability over time and that isn't the old days of just haggling and contract disputes and trying to each side one up<br>the other side and haggling over rates, and haggling over everything else. So I think that this change is really evident to us.<br>
Again, the most encouraging thing to me is that the provider community is really taking this on collaboratively. They are looking at the sources of<br>costs; they're not doing this only as a way to gain revenue. I think you're going to see really increasingly dramatic changes on the supply side in<br>terms of pharma, in terms of devices, because we are all going to be in organized systems, and we're all going to be looking at the whole economics<br>of this differently. I think it will be a difficult transition for some in the provider community, but I think the strong players there, I think, recognize<br>where they need to go, and it's just a totally different environment than it was a couple of years ago.<br>
A key thing for us is really at the same time taking G&amp;A down.We've been successful to this point, but we think there's some increasing opportunities<br>for us. We are exploring these additional opportunities, and we think the combination of shedding some of the excess businesses, the Part D<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>390</i><br>
<hr>
<A name=391></a>JANUARY 09, 2012 / 4:30PM, HNT - Health Net, Inc. at JPMorgan Global Healthcare Conference<br>
business, the Northeast, some of these businesses that really impaired our G&amp;A efficiency, combined with the opportunities out there in terms of<br>outsourcing and looking at new technologies, will allow us to significantly reduce G&amp;A as a percent of our overall costs over the coming years.<br>
The only way to solve the MLR problem is to reduce G&amp;A. The only way to increase competitiveness is through increased G&amp;A -- through reduced<br>And I think that one of the main reasons why, in all these instances, you want a simple, clear organization is because that lets you do things efficiently,<br>both in-source and outsource. So we think we've already shown reduction in G&amp;A. We see some opportunities to go much further, and we think<br>this is going to be one of the key platforms we'll be talking about over the course of the next couple of years.<br>
Again, I think the concept of an integrated product entity is really linked very closely to efficient G&amp;A. I mean, if you look at companies that have<br>efficient G&amp;A, they are not companies with 5 billion different businesses that they build a G&amp;A machine that is able to do it; they are companies<br>with a coherence of products to an efficiency of G&amp;A. I think that's what we've moved towards, and we think that that's going to be key to being<br>successful going forward. Not 12 different -- 1200 different businesses, but a few core businesses that are integrated so you can build an integrated<br>G&amp;A chassis to support them, and so you can use best-in-class, internal and external sources by simplifying your business.<br>
So where we are -- we been able to show stable enrollment. We've not had to follow any pricing. I think we feel comfortable that we're going to<br>be showing positive spread in commercial in 2012. We've been able to make up for a very significant diminution in earnings from our federal<br>services business through increased strength in Medicare and commercial. We've been able to show the management of G&amp;A and the ability to<br>look further down the road on the G&amp;A side and look for another click down as part of some of the strategic moves we've made. We've retained<br>strong cash, and over the course of the last two years, we've repurchased probably about 15 million shares. So we've done a huge repurchase, and<br>we intend to continue. So we've been able to do this, and the way we've been able to do it is because we are doing organic growth. With organic<br>growth, you then can repurchase, and I think you'll continue to see that on a going-forward basis as a key objective of ours.<br>
2011 -- we are not changing any guidance. I just put that up so that no one thinks they are going to do something that will scare us.<br>
2012 -- let me talk a little bit about '12. So we announced the Part D sale today. We haven't changed guidance. I say this in two ways. One, we think<br>we have some other trade-offs that will allow us to hit the same PTI that we earlier projected, despite the sale. We are not going to take into<br>consideration the sale in terms of share repurchase or any other use of cash until it closes. We may have -- we'll look at this all again, but at this<br>point in time, we feel comfortable with our guidance staying as it is. Again, our guidance at the start did not assume the use of cash for repurchase,<br>so we're not assuming any of the use of cash or repurchased from this transaction until it closes.<br>
So basically, what we're showing you is 2012 stays as it is. We intend to use some of the cash that we receive for share repurchase when it closes,<br>but it's not included in our guidance at this point in time. So you can kind of see that that's where we stand at this point in time.<br>
So in closing, I think we've mapped a strategy that we think makes sense. That's probably the first place to be. It's kind of a strategy for all seasons,<br>because we tested it. We said, what if the Supreme Court does anything from any extreme? Are we okay? We feel as good as we do under just<br>about any of those options, so we feel okay about that.<br>
What do we think about the election? As little as possible. It's amazing that Saturday Night Live is on every hour on TV now. It is.<br>
So I think our basic view is that we built a business that is really oriented towards economics rather than politics, and that we understand the<br>politics, but that the politics and the economics are converging, that a diverse book of business all off the same chassis protects you, because no<br>one can predict which of these moving parts are going to move in exactly what direction over the next two or three years. But if you have your leg<br>in all of them, we know that healthcare is going to continue without regard.We think there are opportunities for growth, some really tangible ones<br>we've talked about. We're not counting on them; we're not relying on them. But the opportunities exist. We've been able to build a commercial<br>product that will continue to have some margin improvement in this coming year, which we think is a very favorable thing. We'll also get some in<br>Medicare, and we've been able to make up for the reduction in the TRICARE net income, which we've been talking about for the last couple of<br>years.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>391</i><br>
<hr>
<A name=392></a>JANUARY 09, 2012 / 4:30PM, HNT - Health Net, Inc. at JPMorgan Global Healthcare Conference<br>
We see opportunities on the G&amp;A front, which we think are critical to be successful on a going-forward basis. We have financial flexibility for the<br>reasons I articulated. So I think we look forward with some excitement to what will be a very, very volatile year, and we think we are positioned<br>well to deal with it. Thank you.<br>
<b>John Rex</b><i> - JPMorgan Securities Inc. - Analyst</i><br>
Thank you. We'll be down the hall, just to your left, in the Yorkshire room for the breakout.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4699553-2012-01-09T18:24:00.667</b><br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>392</i><br>
<hr>
<A name=393></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
INCY - INCYTE CORPORATION AT<br>JPMORGAN GLOBAL HEALTHCARE<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 4:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>393</i><br>
<hr>
<A name=394></a>JANUARY 09, 2012 / 4:30PM, INCY - Incyte Corporation at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Paul Friedman</b><i> Incyte Corporation - President and CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Cory Kasimov</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Cory Kasimov</b><i> - JPMorgan - Analyst</i><br>
All right, good morning everybody. My name is Cory Kasimov. I'm a senior biotech analyst at JPMorgan, and let me also extend my will come<br>welcome to you all here for the 30th Annual J.P. Morgan Healthcare Conference.<br>
Our next Company to present this morning is Incyte Corporation. A very exciting time for Incyte with the recent approval and now launch of the<br>Company's first product, Jakafi. Here to tell us much more about the story and the launch is the Company's President and CEO, Paul Friedman. And<br>please note that following Paul's presentation there will be a breakout session down the hall to the left in the Olympic room. So with that, I will<br>turn it over to Paul.<br>
<b>Paul Friedman</b><i> - Incyte Corporation - President and CEO</i><br>
Thanks, Cory. Good morning everyone. Please note that Safe Harbor rules govern my remarks and forward-looking statements, and we ask that<br>you review our latest SEC filings including our most recent 10-Q for a summary of risk factors that could cause actual results to differ materially<br>from any forward-looking statements. We hope that's not the case.<br>
The approval by FDA in November of our first JAK1 and JAK2 inhibitor, Jakafi, for the treatment of intermediate to high risk myelofibrosis was<br>obviously very important and highly gratifying to all of us at Incyte. Immediately following this anticipated approval, and after rigorous and<br>systematic preparation, our experienced marketing and sales teams launched an intensive commercial effort to reach physicians, other healthcare<br>professionals, payers, patients and patient advocacy groups. While I'm going to describe the launch in greater detail later in the presentation, I can<br>tell you that it is going well.<br>
Beyond the launch, we have studied and are studying Jakafi in a number of other indications that could add to its therapeutic and commercial<br>value. Most advanced is the clinical development of Jakafi in polycythemia vera, another MPN. PV patients can exhibit the signs and symptoms<br>similar to those of myelofibrosis, and our Phase 2 results indicate that Jakafi is very effective in reducing disease burden in patients with PV.<br>
A global Phase 3 study, pivotal study, conducted under an SPA in collaboration with Novartis is underway and on track to complete next year. Key<br>programs with two of our strategic collaborators, Novartis and Lilly, are progressing well. In addition to the Phase 3 PV trial, in June of 2011 Novartis<br>filed the MAA for Jakafi for myelofibrosis and expects to begin commercializing Jakafi outside the US later this year.<br>
Lilly is advancing our second JAK1 and JAK2 inhibitor in rheumatoid arthritis and now another indication, moderate to severe psoriasis. I'm not<br>going to have time to describe some of our earlier stage development or discovery programs, but I want to convey that I'm confident in the skill<br>and the proven productivity of Incyte's research team. Jakafi is an important first medicine, but it's only the beginning.<br>
We remain in a strong financial position, having ended the third quarter of 2011 with total cash of $317 million. That doesn't include $28.5 million<br>held in escrow for interest payments through 2012 on our convertible senior notes. Our cash use guidance for last year is $185 million to $200<br>million, and that doesn't include milestones from partners, nor proceeds from stock option exercises.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>394</i><br>
<hr>
<A name=395></a>JANUARY 09, 2012 / 4:30PM, INCY - Incyte Corporation at JPMorgan Global Healthcare Conference<br>
As I said, we received approval for Jakafi on November 16, a couple of weeks before our PDUFA date. Because our sales and marketing preparations<br>were essentially complete, we were able to launch Jakafi almost immediately. Within an hour of approval, Jakafi.com, our brand website, was<br>operational. And shortly after that, our digital program was initiated and many of the key educational materials were printed and ready to distribute.<br>
As a planned training session was taking place the day we received approval, our field force completed training on the final label, went through<br>testing to ensure a high level of knowledge and were ready to start calling on physicians. Our comprehensive support program, IncyteCARES, was<br>handling calls within the first two hours. Within one week the specialty pharmacies had product and began dispensing scripts. This rapid efficient<br>launch, coupled with the compelling label we received, gave me high confidence that Jakafi has the potential to be a successful product.<br>
With regard to the package insert, final insert, I think it is worth mentioning that the FDA accepted nearly all of our proposed labeling. We were<br>particularly gratified to see that the label includes figures showing both symptom and spleen changes in patients treated with Jakafi as compared<br>to patients treated with placebo or best available care.<br>
Jakafi is indicated for the treatment of patients with intermediate to high risk myelofibrosis, including primary post polycythemia vera and post<br>essential thrombocythemia myelofibrosis. And of this 16,000 to 18,500 patients in the US, we believe 80% to 90% are intermediate or high risk. As<br>shown here is a waterfall plot in the label comparing from COMFORT-I data Jakafi to placebo, and it clearly illustrates that nearly all that the patients<br>treated with Jakafi have a spleen volume reduction, while the clear majority of placebo treated patients have notable growth in spleen volume<br>over only six months.<br>
The product label also includes some key data to illustrate the efficacy of Jakafi in reducing the symptomatic burden in patients with MF. And here's<br>a table showing the percentage of patients who achieved a 50% improvement in the total symptom score. This score is based on the sum of six<br>core symptoms including abdominal pain or discomfort, pain under the left ribs, night sweats, itching, bone or muscle pain and early satiety. At<br>least 50% improvement was reached by 46% of patients treated with Jakafi, but only 5% of patients treated with placebo at week 24.<br>
This graph is also in the label, and it shows the percentage of patients with at least 50% improvement in each of the symptoms that make up that<br>total score. And you can see that all six core symptoms contribute to the improvement in the total score.<br>
Looking at the change in total symptom score for each individual patient at week 24, as illustrated in this waterfall plot, you see that most patients<br>receiving Jakafi experience reductions in symptom burden while the majority of patients receiving no treatment continue to see their symptoms<br>worsen. Inclusion of these extensive data on symptoms in the Jakafi label was an important achievement and -- if this thing were to work. (inaudible)<br>(technical difficulty)<br>
I'm supposed to point at this, (inaudible) but you can see what [Pasner] had to say. He noted in a recent BioCentury article, by working closely with<br>the FDA we were able to capture the patient reported outcomes in a manner that was acceptable to the agency. It's not very common, and very<br>important to this product.<br>
Based on our market research, among several hundred treating physicians, we believe these data will be important drivers in the use of Jakafi.<br>Almost all physicians in the survey indicated that reducing the large spleen and its debilitating symptoms that affect the lives daily of MF patients<br>would be an important and much needed improvement. Although these physicians didn't consider a survival benefit to be a requirement for use,<br>new data presented at ASH suggest that Jakafi may also provide improved survival.<br>
An updated analysis from COMFORT-I, the randomized placebo-controlled trial, suggest Jakafi provided a survival benefit over placebo with a<br>hazard ratio of 0.5. This analysis occurred at the time of a planned safety update with a median follow-up of 51 weeks. Although COMFORT-I was<br>not powered to show a survival benefit, we were encouraged by these findings as well as the results from the independent analysis coming up on<br>the next couple slides of survival from the ongoing Phase 2 study.<br>
That oral presentation, also just made at ASH, reported long-term follow-up on patients treated with Jakafi in the Phase 2 study at MD Anderson,<br>and these patients represent about two-thirds of the total population studied in Phase 2.The Anderson patients treated with Jakafi were compared<br>with a matched historical control using criteria that would've allowed these historical patients to enroll in the study. Consistent with the COMFORT-I<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>395</i><br>
<hr>
<A name=396></a>JANUARY 09, 2012 / 4:30PM, INCY - Incyte Corporation at JPMorgan Global Healthcare Conference<br>
results, these data suggest that patients treated with Jakafi had a survival advantage compared with the historical control group with a hazard<br>ratio of 0.6.<br>
Now, the experience from the other center in the Phase 2 study, the Mayo Clinic, was recently described in a letter to the New England Journal of<br>Medicine and it did not show a survival advantage.When you recognize that to achieve and maintain the benefits of Jakafi it's necessary to remain<br>on an adequate dose, the reasons for the different experience at Mayo compared with both the MD Anderson site and the over 90 Phase 3 sites<br>become obvious.There were many more premature discontinuations of subjects participating in the Mayo Clinic site as a result of decisions of the<br>investigators and/or decisions by patients under their care.When patients are given the opportunity to stay on Jakafi, increased survival rates have<br>been achieved in two independent studies.<br>
The MD Anderson group also conducted a second very interesting, completely internally controlled additional analysis to further investigate survival<br>with Jakafi treatment. The life expectancy of patients with myelofibrosis varies depending on risk factors, so the investigators at MD Anderson<br>compared with survival curves of Jakafi-treated patients by risk category. Importantly, this was independent of any comparison with a historical<br>control group.<br>
All of the data analyzed come from patients within the MD Anderson Phase 2 study, and hence it's completely internally controlled. To me, this is<br>the most compelling of the slides, in my personal opinion.<br>
And as you can see here, Jakafi-treated patients who are categorized as having high risk of myelofibrosis defined by IPSS criteria have a survival<br>profile similar to intermediate-2 risk patients. So by shifting the survival curve of the high risk patients, the median survival of which historically<br>has been 26 to 28 months to that of the intermediate-2 risk group, the Jakafi treatment abrogates the prognostic significance of high risk status.<br>
As median survival of intermediate-2 risk patients is in the 44 to 46 month range, it's obvious we need longer follow-up with that group to better<br>understand any effects on survival profile for the intermediate-2 risk patients. So, not surprisingly, given the compelling efficacy, encouraging<br>trends in survival and the fact that this is the first FDA-approved product for myelofibrosis, we're seeing a lot of interest in Jakafi.<br>
Patient interest is high, and the individual shown here is fairly typical. As he noted, his spleen size decreased and his symptoms improved, including<br>his fatigue and itching, which subsided completely with treatment.<br>
We've had good and frequent communication over these past years with the two key patient groups that focus exclusively on patients with<br>myeloproliferative neoplasms, and have recently broadened our advocacy outreach to include several other cancer groups who expressed an<br>interest in collaborating on patient education initiatives and ensuring that accurate and appropriate information is widely available for MF patients,<br>their families and their caregivers.<br>
There've been more than 12,000 hits on Jakafi.com since approval.We believe many of these are patients are caregivers seeking more information<br>about the disease, the product and the support programs.<br>
We're encouraged by our first market research survey conducted shortly after approval, as well as our exchanges with physicians at ASH. Both<br>suggest awareness of ASH is already quite high, as is physician interest in using Jakafi.<br>
Our survey included approximately 50 HemOncs who have had at least -- have seen at least one patient in the previous two weeks. A few key<br>findings include almost four out of five physicians are aware that Jakafi is approved for use in intermediate to high-risk patients. The vast majority<br>of physicians surveyed, over 85%, intend to use it, with the others wanting more information before knowing if they would.<br>
As field force activities have just begun at the time of the survey, most physicians have learned about Jakafi from peer-reviewed sources such as<br>conferences and journals. Adding to the momentum of the launch and the ability to reach the physicians quickly was our strong and highly visible<br>presence at ASH, including the airport signage depicted here.The enthusiasm for Jakafi that we observed at our commercial booth was also reflected<br>in the MPN scientific sessions that were very well attended. And it was encouraging to see that an Incyte-supported CME satellite symposium<br>entitled Myelofibrosis, an Old Disease with New Developments, had standing room only with about 600 participants.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>396</i><br>
<hr>
<A name=397></a>JANUARY 09, 2012 / 4:30PM, INCY - Incyte Corporation at JPMorgan Global Healthcare Conference<br>
We have a strong commitment to help ensure that every patient with MF who is likely to benefit from Jakafi can get the product. IncyteCARES is a<br>comprehensive program to assist patients in gaining access to Jakafi as well as connecting patients to ongoing support and resources during their<br>treatment.<br>
Now, the financial support in IncyteCARES has three major components.The financial support for eligible uninsured patients, which we expect will<br>represent 10% to 15%, we'll provide a free drug. For eligible commercially insured individuals, expected to be about 40% to 45%, we will provide<br>co-pay assistance.<br>
For MF patients who aren't eligible for financial support from Incyte such as those insured by a federal health care program, we've made contributions<br>to a couple of charitable foundations.We expect that 25% to 50% of all Medicare Part D patients will seek some financial help during their treatment,<br>particularly to make it through the doughnut hole. And we expect Medicare to account for about 40% of our patients.<br>
IncyteCARES will provide educational and counseling support to encourage appropriate use adherence. The program also provides services to<br>help patients navigate the increasingly complex insurance environment.We believe that providing these services increases the likelihood that any<br>patient with intermediate or high risk MF who is prescribed Jakafi will get the product, regardless of ability to pay.<br>
Incyte has established a distribution network for Jakafi of five specialty pharmacies that have worked closely with IncyteCARES. We selected the<br>specialty pharmacies based on specific criteria including the number of patients they serve, their payer network and their experience with oral<br>oncolytics. But while not all payers have these specialty pharmacies in their network, it is common practice that exceptions are made for orphan<br>drugs because of the relatively low volume.<br>
Additionally, Medicare has in place that any willing provider clause, which opens up closed networks for Medicare patients. (technical difficulty)<br>Though early in the launch, the distribution network is operating effectively with excellent communication between the specialty pharmacies and<br>IncyteCARES, supporting increased access to Jakafi.<br>
Because MF is a life-threatening illness with a heavy disease burden and no approved therapies, we expect nearly all payers to cover Jakafi. While<br>most payers take 90 to 180 days to determine formulary coverage, tiers and restrictions, until that time scripts for a new therapy are processed as<br>exceptions. There are hundreds of payers and they handle the exceptions in numerous ways.<br>
In the exact time it takes to go from sending an enrollment form to IncyteCARES to actually have drugs dispensed by the specialty pharmacy to<br>the patient varies depending on the patient's insurance coverage and financial circumstances. Once the first script has been processed for a patient,<br>subsequent scripts tend to flow through quickly as the patient's coverage and financial assistance have already been determined. Additionally,<br>once payers have made coverage decisions and are no longer processing scripts as exceptions, the cycle time becomes more predictable.<br>
On November 23, just one week after approval, the first patient, a Medicare patient, was shipped commercial product. We've subsequently had<br>patients covered under the exceptions process across a wide range of commercial Medicare and other government payers. So, to reiterate, the<br>launch is going well.<br>
We continue to expect a steady and sustained uptake of MF. But MF is just the first of many potential indications for Jakafi.The JAK pathway appears<br>to be involved in the growth and survival of numerous other cancers, and both Novartis and Incyte plans involve moving into other MPNs,<br>hematologic cancers and solid tumors either separately or collaboratively. And both companies are also supporting investigator sponsored trials<br>as well.<br>
Specifically, in addition to the ongoing extensions of our Phase 2 and Phase 3 trials in MF there's the ongoing Phase 3 trial and advanced P vera,<br>which I will describe on the next slide. There also trials in leukemias, lymphomas and in pancreatic cancer.<br>
The Phase 3 trial in PV, called RESPONSE, is a global pivotal trial we are conducting with Novartis.The protocol was recently amended, and importantly,<br>the FDA concluded that the amendment does not affect the SPA agreement already in place.The primary dual end point of phlebotomy independence<br>and spleen size reduction remains unchanged.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>397</i><br>
<hr>
<A name=398></a>JANUARY 09, 2012 / 4:30PM, INCY - Incyte Corporation at JPMorgan Global Healthcare Conference<br>
Our proposal to amend entry criteria and reduce the size of the study was accepted.The trial now involves 200 randomized -- patients randomized<br>1 to 1 to ruxolitinib versus best available therapy. And we continue to expect the study to complete in 2013 and to obtain FDA approval of the<br>sNDA in 2014.<br>
We've also -- we're also conducting a Phase 2b trial with pancreatic cancer. This is an area of high therapeutic need, as evidenced by the relative<br>lack of efficacy with existing agents. In preclinical models of pancreatic cancer, Jakafi works well. In addition, since there's a high incidence of<br>cachexia in this patient group, we think our very positive effects on cachexia in MF have the potential to be carried over to pancreatic cancer, since<br>cytokine over-signaling and hyper catabolism are thought to play major roles in solid tumor cachexia as well.<br>
RECAP is actually enrolling patients and has the potential to generate topline results in 2013.<br>
Our other strategic alliance is with Lilly. Lilly has worldwide rights to our second JAK1 and JAK2 inhibitor for all chronic inflammatory diseases. And<br>as Lilly will describe in its presentation, the Phase 2b trial and rheumatoid arthritis patients will complete in 2012 and is expected to result in public<br>disclosures possibly at EULAR and/or at ACR.While the final decisions depend on the not-yet-seen Phase 2b data, plans for Phase 3 are well underway<br>and we expect the Phase 3 program will start later this year.<br>
Prior to the initiation of the Phase 2b trial, we exercised our co-development option for RA. This means we are now responsible for funding 30%<br>of the associated future development costs for this indication. This increase is our tiered royalties up to the high [20s].<br>
Lilly recently began a 240 patient, randomized, double-blind, placebo-controlled dose ranging study 248 or 10 milligrams once a day to explore<br>the efficacy and safety of the JAK1 and JAK2 inhibitor in adults with moderate to severe psoriasis.The primary objective is to demonstrate superiority<br>to placebo at week 12 as measured by the proportion of patients with at least a 75% improvement from baseline in their PASI score. And while it<br>is obviously dependent on enrollment and could change, currently we expect to see data for the primary endpoint in the first half of 2013.<br>
So, to conclude, 2011 has obviously been a pivotal watershed year for Incyte with the approval of our first product, Jakafi, for the treatment of MF<br>and its steady advancement in other indications. Our second JAK inhibitor for chronic inflammatory diseases is also progressing well with Lilly, and<br>we look forward to seeing a third indication selected with clinical evaluation beginning in 2012.<br>
Beyond the JAK inhibitors, our early stage oncology programs for c-Met and IDO inhibitors are ongoing. These both look very promising and are<br>expected to move into Phase 2 trials this year.<br>
We have several new proprietary programs in oncology and inflammation that I look forward to describing once there is meaningful Phase 2 data<br>to report. Given the knowledge, skill and productivity of our research and development teams, I'm confident you will see other important medicines<br>coming from Incyte in the future.<br>
I thank you for your attention and look forward to seeing some of you in the breakout session.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4691664-2012-01-09T18:46:29.550</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>398</i><br>
<hr>
<A name=399></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
COV - COVIDIEN PLC AT JPMORGAN<br>GLOBAL HEALTHCARE CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 4:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>399</i><br>
<hr>
<A name=400></a>JANUARY 09, 2012 / 4:30PM, COV - Covidien plc at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Joe Almeida</b><i> Covidien plc - President, CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Mike Weinstein</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Mike Weinstein</b><i> - JPMorgan - Analyst</i><br>
Good morning, everybody. I am Mike Weinstein. We are going to go ahead and get started with our next session.<br>
It is my great pleasure to introduce the Chief Executive Officer of Covidien, Joe Almeida. Joe is going to give us a brief update on the Company;<br>then we will have a Q&amp;A session across the hall. Thank you. Joe?<br>
<b>Joe Almeida</b><i> - Covidien plc - President, CEO</i><br>
Good morning. I am going to take the next 25 minutes to cover several topics I think will be of great importance to you today. I would like before<br>we start to go over the forward-looking statements, if you read them.<br>
We are going to be talking about the changing market dynamics. We get asked a lot of questions about pressure in terms of volume, in terms of<br>price. We are going to talk a little bit about that, and how Covidien is going to deal with that in terms of long-term perspective for growth, top line<br>and also bottom line.<br>
Go back and look at some of the performance that Covidien has demonstrated in the last four years, as well is what will be the growth drivers so<br>Covidien can continue to deliver sales and OI above market.<br>
The changing market dynamics, the tailwinds are pretty clear.We still have the need for healthcare across the globe.You look at emerging markets.<br>
I was recently in Brazil about three weeks ago, and the ascension of the middle class is unbelievable. And the need for healthcare is ever -- has not<br>been so high in the 23, 25 years since I left the country.<br>
You look at the demographics across the globe, the aging populations. So all the demographics are there, and so the demand for medical devices<br>are still in place.<br>
What concerns us is that there is a significant change in terms of market growth rate in some of the developed markets like the US and Europe.We<br>see that happen in the last 12 to 18 months.<br>
We also see a shift in the dynamics between what used to be a volume-driven business to a value-driven business. That is key for us in terms of --<br>when we look forward, where Covidien put its monies and where we put our focus will be in the areas that will bring that value instead of bringing<br>only the volume.<br>
And lastly the environmental aspects of the regulatory aspects in all countries are being scrutinized in a much higher level. We always think there<br>is a great opportunity and we invest significantly in emerging markets; but there are significant barriers to entry there as well. Not only in China,<br>but Brazil as well, places like India.<br>
So you have got to be able to have an organization that can cope with that. These are the changes that concerns us, and we are adapting the<br>Company to continue to thrive in this environment.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>400</i><br>
<hr>
<A name=401></a>JANUARY 09, 2012 / 4:30PM, COV - Covidien plc at JPMorgan Global Healthcare Conference<br>
So if you look at the strategic initiatives that we have, how do we position the Company to win in this environment? First and foremost is the<br>innovation.<br>
And innovation is not the launch of a new technology or a new product line extension that will just add volume to your sales reps' bag. The<br>innovation is the ability to provide the products that are clinically more relevant than what is in the market today and has the ability to be cost<br>effective to the provider.<br>
To be able to get into an innovation cycle that is effective, Covidien needs to continue to improve its ability to launch products on time and launch<br>larger platforms every so often.<br>
So we have made tremendous progress since we went public in 2007. I am happy with the progress.<br>
I am not satisfied with the pace. We are going to continue to improve our ability to deliver those new products, because the largest amount of<br>value to any shareholder of Covidien is Covidien's ability to take our technology and put in the hands of clinicians technology that adds clinical<br>value and economical value.<br>
So if we look what we have done in the last couple of years in terms of product development and launches, we have in front of you an example<br>why Covidien was so successful in bringing growth to our top line. The majority of the growth that you see in Covidien's top line in the last four<br>years is attributable to new products, and they are displayed here.<br>
I would like also to give you some comfort that going into 2012 and 2013 and '14 we have the same focus in delivering new products. The new<br>products are not only coming from the legacy business that Covidien has, but also is coming from the acquisitions that we made in the last 24<br>months vis-a-vis ev3, Somanetics, Aspect. Those businesses and those acquisitions are doing quite well and they have a significant contribution<br>to Covidien's top line. So we have more than 100 products planned to launch in the next two years.<br>
When it comes to Pharmaceutical, that is something that I am amazed with the amount in the pipeline that we were able to create in the last two<br>years. If you think about it, we have about 12 ANDAs in process. We have the Depomed patents that we acquired about two years ago. We have<br>two products that will be launched within the next 18 to 36 months, and those look very, very promising.<br>
So the strategy for Pharmaceutical, when you shore up your efficiencies in all your operations and drive the growth of that business by bringing<br>specific pain molecules to the market that are exclusive to us, is a winning proposition for that business.<br>
So I would like now to double-click on portfolio management. We are going to continue to aggressively manage our portfolio. Let's talk about<br>some of the acquisitions and some of the philosophy that Covidien has on acquisitions.<br>
First of all, acquisitions are opportunistic. Second, Covidien will continue to do tuck-ins.<br>
As an example of that, we acquired BARRX Medical; great technology to treat dysplasia, high cases of dysplasia and severity. That technology will<br>open Covidien to a brand-new area of care, new space in terms of call-points. That technology has future use in medical therapies.<br>
So when we acquire companies now, the first thing we do -- we do a deep dive in those technologies that we acquire and find out what are the<br>other areas of care that can immediately be made available with that technology. Not only will we know from due diligence, but also we do this<br>rapid due diligence that understands how can we go deeper in a company like BARRX. And this is happening as we speak, and we find that<br>opportunity very unique.<br>
We also will continue to acquire tuck-in technologies such as total vessel occlusion that we just -- we will be announcing soon. We also have other<br>plans for smaller tuck-ins across our business. It is mostly medical devices.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>401</i><br>
<hr>
<A name=402></a>JANUARY 09, 2012 / 4:30PM, COV - Covidien plc at JPMorgan Global Healthcare Conference<br>
I want to speak to you now about the recent announcement that of divestiture of Pharma business. We spoke enough about why we've decided<br>to divest and why now. Let me just talk to you specifically about three things.<br>
One is the divestiture of Pharma will not affect Covidien's FY12 numbers. Second, the spin is an 18-month spin, and the reason is quite simply it is<br>a highly complex spin.<br>
When you think about how Covidien is integrated, Covidien is integrated on a global basis. You go to Paris, you see Covidien France. That has all<br>business of Covidien. So will take us a fair amount of time to disentangle our Pharmaceutical business from the rest of Covidien.<br>
And third, that this is a tax-free spin for US shareholders.<br>
So what are the things that will not change after the spin of Pharma? We are not going to change Covidien's focus in delivering mid-single-digit<br>growth on the top line and double-digit growth on the bottom line. We are going to continue to invest in R&amp;D. And our focus is to continue to<br>deliver on OI that is consistent with our top-line growth.<br>
Going back to the areas of opportunities for Covidien, the third one is the emerging markets. We have been talking about the emerging markets<br>the last 18 months with all of you. We are very serious about that.<br>
We have invested. Of our 1,000 sales reps that are currently in plan to be hired, more than half are hired. The back-office is being augmented. We<br>have a new ERP system going in place.<br>
The whole infrastructure is well ahead of schedule, and we have opened now three R&amp;D centers -- one in India in Hyderabad, one in China in<br>Shanghai, and Singapore. We should have the first product for emerging markets designed and ready to be commercialized at the end of FY12.<br>
So things are going well. We just surpassed $1 billion in sales, and that business under the leadership of Brian King is doing quite well.<br>
Covidien has done a very good job in managing our gross margin. A great portion of that increasing gross margin is not only mix shift but is also<br>the ability to deliver on cost reductions.<br>
This is something that is our second nature. It comes with the DNA of the Company, and we have done a significant amount of investment. Now<br>we just announced in July 2011 our restructuring plan that is going into effect now, and a great part of that restructuring plan is continue to deliver<br>on operational improvements.<br>
So we are reducing our manufacturing footprint by 26% since 2007. We had right-sized our footprint on a global basis.<br>
We now have a global shared organization in the US. That US organization is one business away from being a total US service center. So we don't<br>have several customer services across the country; we don't have several areas where people collect and pay bills. We have one shared service for<br>the Company in Massachusetts.<br>
We also have done the same thing in Europe. As we look at Europe, the opportunity is to continue to improve our ROIC in our business in Europe;<br>it is continue to become more effective and more efficient in everything we do.We consolidated our back office for most of our countries in Europe<br>and the Czech Republic. Our customer service is up in Dublin. So we continue to look at ways of becoming more effective, more efficiency.<br>
We also recently -- for obvious reasons we brought our surgical division and our energy division together. That in Europe eliminated two layers of<br>management, in the US one layer of management; and that business continues to do quite well. It was a logical move for Covidien to bring them<br>in place.<br>
So if you think about the things that we are doing in terms of continuing to deliver operational efficiencies to the business, Covidien's goal is to<br>become the most efficient medical technology company in the world. We are going to continue to pursue that target.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>402</i><br>
<hr>
<A name=403></a>JANUARY 09, 2012 / 4:30PM, COV - Covidien plc at JPMorgan Global Healthcare Conference<br>
So if you have to take four things away in terms of how Covidien is going to deal with all the headwind and all the changes and uncertainties in<br>the marketplace, we are redefining our strategy to continue to deliver growth. We are going to be doing that through innovation, by delivering<br>clinically relevant products with economically sound solutions to the provider.<br>
We are going to grow above market by being able to allocate our resources. When we talk about portfolio management, it is not only about<br>acquisitions and divestitures; it is about taking the money from businesses that have lower growth potential and putting it in higher growth<br>potential.We do those reviews every three months, and we make sure our businesses on the business-unit level is doing that and also at a Company<br>level we are doing that.<br>
We are taking money from businesses that are underperforming, businesses that have commoditized a portfolio, and invest in white spaces.<br>Covidien today has four investigational white spaces in process internally. We probably end up one or two areas of growth that Covidien is going<br>to continue to invest further in 2013.<br>
We have a strong cash flow that will allow us to do that without deviating the fact that we have to return cash to shareholders, and we do that<br>effectively. So our objective through innovation, through efficiencies, through understanding how to grow the top line, by reallocating money<br>between our business units and going into whitespace will continue to deliver increased shareholder value.<br>
If we take a look at our financial performance the last four years you can see we accelerated our top-line growth, significantly improved our gross<br>margins, and have delivered even with increased R&amp;D and increase SG&amp;A investment a better adjusted operating margin, without impacting our<br>free cash flow.<br>
When you look at the last seven years, top-line growth close to 7%. And if you look at the driver of growth here it is primarily mix shift, which is<br>driven by new products. By growing the most profitable business at Covidien, which is the Medical Device segment, within the Medical Devices<br>the endomechanical franchise, the energy franchise, the vascular franchise, that mix has generated significant growth in the top line for the<br>Company.<br>
We talk a great deal about pricing. Is Covidien affected by pricing? Sure we are. You see in front of you here about $183 million; but it is a small<br>fraction.<br>
We tell you that our margin, our price erosion is about 50 to 100 basis points a year. And that is what it is.<br>
Do we have price pressures? We sure do. You talk to our Medical Supplies President, Jim Clemmer, he will tell you the fight is hard, and we fight<br>for price every single day.<br>
It didn't get easier. It got tougher. But through a series of changes in portfolio and rapid portfolio moves, which at the end will add shareholder<br>value, we are able to minimize that.<br>
Our earnings per share adjusted have a CAGR of 11%. So we are on track to what we told you in 2007, and we will continue to deliver low double-digit<br>growth in our earnings.<br>
Let's talk a little bit about our free cash flow and how we are deploying our cash. We have said specifically that Covidien will not hoard cash in its<br>balance sheet.<br>
We have no reason for doing that. If we don't have a specific acquisition, if we don't have a specific use for the cash, we will deliver the cash back<br>to the shareholder either by share buybacks and/or dividends.<br>
In 2011 it was a year that we did not have an acquisition within the Company. That was not because we didn't try. We tried hard, but we didn't find<br>a company that had the right value and the right strategy that will match value and the strategy for the Company. In that case we were able to<br>deliver over 75% of our free cash flow to shareholders, a total of close to $1.4 billion.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>403</i><br>
<hr>
<A name=404></a>JANUARY 09, 2012 / 4:30PM, COV - Covidien plc at JPMorgan Global Healthcare Conference<br>
So I would like to close today by talking to you specifically about what are the growth drivers. Why am I sitting up here today, standing up here in<br>front of you and telling you that our underlying organic growth for the business is solid? They're areas that I am very confident that we will continue<br>to execute.<br>
We had a tremendous turnaround in Pharmaceuticals in 2011. That business has done well. There were poised for in 2012 to deliver solid growth.<br>
Our endomechanical franchise continued to gain market share. Our Tri-Staple product within endomechanical is doing quite well, as well as our<br>energy base. And the neurovascular division is doing extremely well with very high growth.<br>
We are going to continue to allocate resources. As I said, we will take from businesses which we don't think have growth potential; we are going<br>to turn that to businesses that have higher potential.<br>
And why do I underscore that so much? Because in 2007 when we became a public company, we had a value proposition to you and we said we<br>were going to increase R&amp;D. We gave a shot to almost all businesses, with the exception of a few.<br>
Today Covidien has a more sophisticated portfolio management capability and is drilling specifically in businesses and white spaces that have<br>higher potential to deliver top-line growth. We do understand the ROIC is highly important to the shareholders, and we are focused on that as we<br>continue to trend then the right direction.<br>
We do understand that top-line growth is what creates the most amount of value. We understand that R&amp;D is the biggest vehicle for delivering<br>value to our shareholders.<br>
We have the capital flexibility in the Company to support our growth. We generate close to $2 billion in free cash flow. We are going to continue<br>to use that in our advantage.<br>
If we don't find the acquisitions, if we don't find the right opportunities we will deliver that cash back to the shareholders. And we have proven<br>that we can do that.<br>
We have a proven management team that understands how to create shareholder value. And we have above all one of the best teams in healthcare.<br>We have a great bench.<br>
In 2007 we had to hire a lot of people from the outside to bring this Company to what it is today. But today I stand up here and say that we have<br>a phenomenal team that can deliver on the top-line growth and the OI that we have promised investors. And the bench is deep.<br>
So with that I would like to conclude our presentation, and I think we have Q&amp;A across the hall.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4698640-2012-01-09T18:49:38.877</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>404</i><br>
<hr>
<A name=405></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
BNK.TO - BANKERS PETROLEUM<br>OPERATIONAL UPDATE FOR THE<br>FOURTH QUARTER 2011 - CONFERENCE<br>CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 1:45PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>405</i><br>
<hr>
<A name=406></a>JANUARY 09, 2012 / 1:45PM, BNK.TO - Bankers Petroleum Operational Update For The Fourth Quarter 2011<br>- Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Abby Badwi</b><i> Bankers Petroleum Ltd. - President, CEO</i><br>
<b>Suneel Gupta</b><i> Bankers Petroleum Ltd. - EVP, COO</i><br>
<b>Craig Nardone</b><i> Bankers Petroleum Ltd. - VP, Exploration and Development</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>George Toriola</b><i> UBS - Analyst</i><br>
<b>Alex Klein</b><i> Dundee Securities - Analyst</i><br>
<b>Greg Chornoboy</b><i> Jennings Capital - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Good morning. My name is Denise, and I will be your conference operator today. At this time, I would like to welcome everyone to the Bankers<br>Petroleum operations update conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks,<br>there will be a question-and-answer session. (Operator Instructions).<br>
Thank you. Mr. Abby Badwi, President and CEO, you may begin your conference.<br>
<b>Abby Badwi</b><i> - Bankers Petroleum Ltd. - President, CEO</i><br>
Thank you, Denise. Ladies and gentlemen, good morning and happy new year. With me on this call this morning is all of Bankers' executive team,<br>who will also be available to answer your questions.<br>
To start 2012 was a bit of a difficult year globally, but also for international E&amp;P companies losing a significant percentage of our equity value.<br>Bankers also had its issues in trying to meet its early projections for production targets due to lack of historical data from the new horizontal wells.<br>I believe we now have a better handle on individual well performance and a good understanding of difficulties associated with the development<br>of an old oilfield and also learned what we needed to do to overcome some of these issues.<br>
Despite these challenges, Bankers had a record year of operational and financial results. Production grew by more than 30% and we will probably<br>more than double last year's cash flow. Our 2011 reserves audit will be completed by mid-February, and after producing close to 5 million barrels<br>in 2011, I am confident that we will see another year of reserves growth.<br>
Suneel Gupta, our COO, will provide you with an update on our operation in Q4, and will be followed by Craig Nardone, our VP, Exploration and<br>Development. Suneel.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Thank you, Abby. I'd like to start by wishing everybody a happy new year. The fourth quarter was a very productive quarter with several projects<br>underway, including drilling, production optimization, infrastructure construction, commencement of the thermal pilot, expansion into the deeper<br>Bubullima formations in the north and further development planning.<br>
We achieved record production levels, approaching 16,000 barrels per day by the end of the year, and we are currently over 16,000 barrels of oil<br>per day. The average production for the quarter was up 5% and 13,833 barrels of oil per day from the previous quarter with the continued growth<br>quarter on quarter.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>406</i><br>
<hr>
<A name=407></a>JANUARY 09, 2012 / 1:45PM, BNK.TO - Bankers Petroleum Operational Update For The Fourth Quarter 2011<br>- Conference Call<br>
With the addition of the fifth drilling rig bringing the rig count up to five, three from the Croatian company, Crosco, and two from Canadian company,<br>Simmons, we continued drilling in the fourth quarter at a high pace to drill 26 wells in the quarter. This is a record number in a single quarter for<br>the Company.<br>
The drilling targeted production growth as well as reserves growth, with the year-end reserves review approaching. Several of the drill locations<br>were focused on expanding into new areas of the field to establish production from horizontal completions and compiled development plans to<br>access recoverable reserves in new areas. The production optimization efforts continued in the quarter, including well speedups, sand cleanouts<br>and well configuration reviews to improve the performance from the horizontal and vertical walls.The work has associated downtime to complete<br>the well intervention work, but resulted in improved performance from several wells.<br>
The water handling capacity was also expanded in the quarter with the addition of a new drill disposal well. We are now able to dispose of over<br>30,000 barrels of water per day from 12 disposal wells, which enabled further production optimization efforts and resumption of production from<br>higher water-cut wells after offset water control work.The benefit of the water control [is to] restrict water cross-flow and influxes early, but definite<br>improvement examples are present.<br>
We continued significant infrastructure expansion during the quarter with completion of the bridge over the Seman River and Phase 1 of the sales<br>pipeline and near completion of the Fier Hub and central treatment facility expansion.These key infrastructure projects will enable further production<br>growth, increasing our treating capacity to 25,000 barrels of oil per day.<br>
The thermal project reached a milestone in the fourth quarter with first steam injection in December. The generated calibration and operation<br>worked well, with the good interactivity into the reservoir.We are planning to ramp up to full injection later in January, followed by first production<br>cycle with initial results projected for the second quarter.<br>
Reactivation expansion into the north area of the field in the deeper Bubullima sands was started in the quarter.The geologic mapping and presence<br>of undeveloped sandstone zones below the Marinza Sands is promising in this area. We have reactivated the first well, K-8, and we will follow up<br>with a second well this year, followed by new drilling to further define potential in this area.<br>
The Kucova water flood is also underway. We've activated two producers around the first injector and have seen some good fluid level response<br>on the wells. Initial flush production is at higher rates. At a higher water cut, the flood pattern balancing is underway to improve the oil sweep.<br>
With that, I will pass it on to Craig Nardone to give you some further details on the drilling in the fourth quarter.<br>
<b>Craig Nardone</b><i> - Bankers Petroleum Ltd. - VP, Exploration and Development</i><br>
Thank you, Suneel. In the fourth quarter, the drilling program continued onto land with four rigs drilling throughout the quarter, as Suneel said,<br>with the addition of the fifth rig, which spudded its first well November 28. 25 horizontal oil wells and one horizontal water disposal well were<br>rig-released during the quarter for the total of 26 wells. Of the 25 oil wells, five were drilled in Goran zones and 20 were drilled in Driza zones, with<br>initial production meeting forecast expectations.<br>
For the year, 76 horizontal oil wells and eight other wells were drilled for a total of 84 wells, which was on plan for the year.<br>
Drilling plans for Q1 2012 include 22 horizontal oil wells and three other wells for a total of 25 wells.The 22 horizontal wells are allocated approximately<br>75% for production in Area 1 of the field, including the Driza 1 zone, and 25% for production and reserves growth in both the Driza and Goran<br>reservoir zones in Areas 2 and 3.<br>
Highlights of drilling for the fourth quarter; Goran development continued with the testing of the third Goran reservoir zone by drilling three<br>horizontal wells in the Goran 4. This is in addition to the Goran 5 and 6 tested earlier this year. Initial production from the G4 ranges from 100 to<br>150 barrels of oil per day. These G4 zone horizontal wells were drilled in Area 2 and open up additional Goran development potential. Currently,<br>there are eight Goran wells on production in Areas 1 and 2, with initial production ranging from 40 to 210 barrels of oil per day and averaging 105.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>407</i><br>
<hr>
<A name=408></a>JANUARY 09, 2012 / 1:45PM, BNK.TO - Bankers Petroleum Operational Update For The Fourth Quarter 2011<br>- Conference Call<br>
Following up on this success, Goran zone development will continue in Area 2 further south in the field.This new drilling could potentially expand<br>the Goran reserve base in Area 2, where there are currently limited reserve bookings.<br>
Driza stepout horizontal wells are the other highlight for the quarter. During the fourth quarter, six D1 zone horizontal wells were drilled from the<br>western edge of the current field development into Area 3. These wells have initial production ranging from 70 to 270 barrels of oil per day and<br>are currently averaging 190 barrels.<br>
Based on this success, additional horizontal wells are planned for 2012, with the potential to increase proven reserves and future development<br>into the undeveloped western side of the field in Area 3. And as Suneel mentioned, we also drilled one additional horizontal water disposal well<br>in Q4, with plans to continue water disposal expansion with two additional wells in Q1. Thank you.<br>
<b>Abby Badwi</b><i> - Bankers Petroleum Ltd. - President, CEO</i><br>
Thanks, Craig. Denise, we are now ready to take questions.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions) George Toriola, UBS.<br>
<b>George Toriola</b><i> - UBS - Analyst</i><br>
Thanks and good morning, guys. Happy new year. I've got two questions. The first is on the production profile that you have on I think it is slide<br>15 in your presentation. Just going through that phase, sort of three periods where the slope of that growth for horizontal production changes<br>between the first 50 wells -- sorry, the first 30 wells, the next sort of 40 wells and then the last 30 wells or so.<br>
The question here is to Suneel. What do you think is the primary driver here? Is it a difference in the completion? Is it decline rates? What is the<br>primary driver of the change in slope of that curve here?<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Hi, George. With regards to the change in the slope, there are several things happening. Obviously, the early wells that were brought on, as we<br>talked about about a year ago, we had some very good performance from the early wells where the rates were fairly high.<br>
As we get more wells into that mix, then the decline impact in the early decline period does get mixed in with some of the new production that is<br>coming on. So it is a combination. We also did go through a change in the operational practices, where we are not pulling as hard from the wells<br>and we are not going after the peak production rate from the wells. We are looking more for the stabilized production, which addresses some of<br>the limitations in the well bore configuration, the artificial lip design at these depths, things like that.<br>
So the slope that we see more recently in the latest wells that have come on, that is more of a sustainable slope. But it does still average in all of<br>the earlier wells as well as the new wells.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>408</i><br>
<hr>
<A name=409></a>JANUARY 09, 2012 / 1:45PM, BNK.TO - Bankers Petroleum Operational Update For The Fourth Quarter 2011<br>- Conference Call<br>
<b>George Toriola</b><i> - UBS - Analyst</i><br>
Okay, thanks a lot. And the other question is just following on your -- this is a slide 17 in your presentation that talks about reserve growth potential.<br>The most material one there is the Goran in Area 2, where you have the recovery factor going from 0.4% up to 10%. So it is a two-part question.<br>
First is over how over what period of time do you think you will be able to see that recovery factor expand? And secondly, what is behind the<br>expansion of that recovery factor? What are you doing or expecting that you would see that recovery factor expand?<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
I think you are addressing Area 3 primarily. Area 3 represents an area that has very little additional -- or early well control. It is an area where we<br>still have to do a lot of delineation in order to properly understand reservoir.<br>
<b>George Toriola</b><i> - UBS - Analyst</i><br>
It is area -- as you have it here on slide --<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Oh, the Gorani Area 2 is what you're addressing?<br>
<b>George Toriola</b><i> - UBS - Analyst</i><br>
That's right.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Okay. The Gorani Area 2 is the southern area. This -- it will take a few years for us to really get recognition of that full recovery. We currently have<br>drilled a total of eight Gorani wells. Several of these are down in Area 2. So with these wells, it will give us a start to getting some recognition for<br>that reserves. But it will take additional wells and further development in Area 2 in order to realize the full 10%.<br>
And it can be quite a bit higher than the 10%; it can also be approaching towards the 20%, as the Driza is, as we continue to develop and see the<br>positive performance from the Gorani in that area. So it will take some time as we continue to drill wells in that area.<br>
<b>George Toriola</b><i> - UBS - Analyst</i><br>
Thanks a lot.<br>
<b>Operator</b><br>
(Operator Instructions) Alex Klein, Dundee Securities.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>409</i><br>
<hr>
<A name=410></a>JANUARY 09, 2012 / 1:45PM, BNK.TO - Bankers Petroleum Operational Update For The Fourth Quarter 2011<br>- Conference Call<br>
<b>Alex Klein</b><i> - Dundee Securities - Analyst</i><br>
Thanks. Good morning, guys. Just a question on your thermal project. If I was reading the press release correctly, it said you were actually going to<br>resume steam injection later in January. I didn't realize you actually stopped. I wonder if you could just clarify that. And I wonder if you could just<br>refresh our memories on the steam injection cycle and when you expect first production to occur.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
With regards to the thermal project, what we did in December was we wanted to -- we started the first steam, but it was primarily targeted at<br>ensuring the steam generator was working properly, that we were able to get the injection rates into the reservoir that we were hoping for. So we<br>were able to attach this. We did get the generator up to full capacity, and we injected about 4000 cubes of steam, the water-equivalent steam.<br>
So with that, though, we then started looking at the offset wells that may be affected as we get further into the full cycle of steam. Some of these<br>well bores we didn't have access to initially. They were in Albpetrol's inventory still. So we recently took those over, and what we are doing now is<br>just isolating those wells, basically putting a new wellhead on there and putting some gauges so we can monitor the pressure and temperature<br>conditions. And then we will ramp to the full-steam cycle.<br>
With the full steam cycle, it will end up being roughly about two months, so 60 days. And then following that will be a soak period and then the<br>production cycle. So we should see first-production results in second quarter.<br>
<b>Alex Klein</b><i> - Dundee Securities - Analyst</i><br>
So you are saying now that the full 60-day steam cycle is going to take us through January and February.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Yes.<br>
<b>Alex Klein</b><i> - Dundee Securities - Analyst</i><br>
And then sort of production maybe later in March/April -- is that what you're saying now?<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
That is correct.<br>
<b>Alex Klein</b><i> - Dundee Securities - Analyst</i><br>
Okay, thank you.<br>
<b>Operator</b><br>
Greg Chornoboy, Jennings Capital.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>410</i><br>
<hr>
<A name=411></a>JANUARY 09, 2012 / 1:45PM, BNK.TO - Bankers Petroleum Operational Update For The Fourth Quarter 2011<br>- Conference Call<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Good morning, guys. Just to follow up on what Alex was asking there, if you are not currently injecting steam right now, it is going to be around<br>the end of January, then your 60-day injections actually are going to last essentially February, March, if I do the calendar math right.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
We were hoping to get the steam started again here by the middle of the month; so within a week, we are hoping to get steam started again. So<br>it most likely will be early March to mid-March by the time we finish the steam cycle.<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Okay, and then -- so then -- then you add a week of soaking it and then two or three or four weeks of hot-water production.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Correct.<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Okay, so it will be mid-April before we see any meaningful oil rates then?<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
That's right.<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Okay.The other thing I wanted to ask, just on the production, with the 13,833 that you produced for the quarter, I am just looking at this and saying,<br>okay, a great number of the new wells must have come on in December, all backloaded, since it is only 600-odd barrels a day over Q3.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Yes, correct. What we did in the fourth quarter, we drilled 26 wells; one was a disposal well, 25 were horizontal production wells. Of those 25 wells,<br>there is roughly 9 to 10 of those were what we would call reserves-focused wells. So it means some of these wells, as Craig had mentioned, came<br>on at some decent rates. But they were the earlier wells that we drilled in the quarter. Later in the quarter, we started shifting towards production<br>focus, so they came on later in the year.<br>
And you know, the exit production we achieved was 15,535, and yet we are over 16 now. So there is a few of those wells that just came on over<br>the last week here, and they've come on at very good rates. So it just is the timing of when the wells came on that impacted that average rate.<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Okay. On the water flood at Kucova, you said you've started up the two offsets. Are you getting any kind of oil rates at all or is this just mostly water<br>breaking through?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>411</i><br>
<hr>
<A name=412></a>JANUARY 09, 2012 / 1:45PM, BNK.TO - Bankers Petroleum Operational Update For The Fourth Quarter 2011<br>- Conference Call<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
The initial flush production was primarily oil, but yes, we are -- there is quite a bit of water coming through. We are still seeing oil rates that are<br>higher than they were before.<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Okay. Now a previous release, you had said that you were seeing higher fluid levels in those offsets, I believe.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
That's correct.<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Okay. And you've continued to observe that?<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Yes.<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Until you obviously started them up, then I'd presume the fluid level would go down some.<br>
<b>Suneel Gupta</b><i> - Bankers Petroleum Ltd. - EVP, COO</i><br>
Exactly. I mean, as we optimize the wells and start drawing down the wells, the fluid level will of course go down. But the important thing is the<br>total amount of fluid that we can pull from the well is significantly higher than that capacity prior to start of the water flood.<br>
<b>Greg Chornoboy</b><i> - Jennings Capital - Analyst</i><br>
Okay. All right. That's it. Thanks, guys.<br>
<b>Operator</b><br>
There are no further questions queued up at this time.<br>
<b>Abby Badwi</b><i> - Bankers Petroleum Ltd. - President, CEO</i><br>
All right. Thank you. With no further questions, let me conclude with we are starting 2012 on a positive note, meeting the 16,000 barrels per day<br>target. All of our production and pipeline facilities are completed to handle up to 25,000 barrels of production.We have five drilling rigs, 12 service<br>rigs available to execute a $250 million capital program. And with $100 oil, Bankers is positioned to deliver another record year in 2012.Thank you,<br>and best wishes.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>412</i><br>
<hr>
<A name=413></a>JANUARY 09, 2012 / 1:45PM, BNK.TO - Bankers Petroleum Operational Update For The Fourth Quarter 2011<br>- Conference Call<br>
<b>Operator</b><br>
This concludes today's conference call. You may now disconnect.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4703344-2012-01-09T18:53:07.593</b><br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>413</i><br>
<hr>
<A name=414></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
UDRL - UNION DRILLING INC AT<br>PRITCHARD CAPITAL PARTNERS LLC<br>"ENERGIZE` CONFERENCE<br>
EVENT DATE/TIME: JANUARY 04, 2012 / 10:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>414</i><br>
<hr>
<A name=415></a>JANUARY 04, 2012 / 10:30PM, UDRL - Union Drilling Inc at Pritchard Capital Partners LLC "Energize` Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Chris Strong</b><i> Union Drilling, Inc. - President, CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Brad Dease</b><i> Pritchard Capital - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Brad Dease</b><i> - Pritchard Capital - Analyst</i><br>
We would like to thank Chris Strong, President and CEO of Union Drilling, for presenting here. And the breakout for Union will be in the press room<br>afterwards. But, Chris --.<br>
<b>Chris Strong</b><i> - Union Drilling, Inc. - President, CEO</i><br>
Thank you, Brad. Good afternoon.Thank you to Pritchard for having Union Drilling invited to present today.We are a land driller, primarily supporting<br>oil and gas production in the United States. At the moment 51 drilling rigs, and most of what we are doing, like the rest of the publicly traded<br>drillers, is focusing on horizontal drilling in major US formations. As of just before the end of the year our market cap was $145 million.<br>
We operate in several of the major basins -- Appalachia. We are in the Marcellus, Huron and very recently over in Ohio in the Utica Shale, which is<br>picking up steam, 19 rigs in that market. Of the 14 that are operating those are mostly our large rigs. We have a few remaining smaller rigs up in<br>that market that we are using to do verticals, top hole type work, that sort of thing, but pretty well utilized as far as the larger rigs in our fleet.<br>
Texas, 20 rigs running. That is Barnett Shale. Much lower Barnett concentration now, as you might imagine, with the advent of much lower natural<br>gas prices. In the beginning of 2010 we only had one rig running in the Permian. At this point we have 16 of those 20 rigs running in the Permian,<br>with the other four in the Barnett. We are probably going to see more activity on the oil side. It is also probably an area where we will see some<br>expansion of margins in 2012.<br>
Then the Arkoma Basin, Fayetteville area, we are pretty solidly grounded there. We do a lot of work for XTO, or Exxon now that XTO has been<br>purchased by Exxon in that market. We are also seeing BHB with its recent $5 billion acquisition from Chesapeake of acreage there. That has been<br>a positive for us, given that Chesapeake ran its own rigs in the market and BHP is using non-Chesapeake rigs going forward.<br>
We are also seeing similar size rig demand in this market over in North-Central Oklahoma and in Southern Kansas with the Mississippi and horizontal<br>oil play picking up steam. Also, we have several rigs at this point out of this 12 that are running in the Granite Wash a little further west in Oklahoma.<br>
What is our strategy? Really to be able to run rigs for the kinds of customers that we are working for.There has been a huge uptick in the attention<br>to safety. We have invested heavily in our crews, training programs, our equipment.<br>
As far as modernizing the fleet, we recently in the fourth quarter sold off 31 of our smaller rigs at auction. Those rigs where legacy rigs from when<br>we started in the Appalachian Basin and some legacy rigs that we acquired to enter into the Arkoma Basin market. We have essentially replaced<br>those smaller rigs with larger, more capable rigs, newer rigs that are more able to drill the long horizontals that we are seeing in demand these<br>days.<br>
I think it has been very important for us as well to continue to focus on markets with low F&amp;D costs. A lot of the E&amp;P presentations will show that<br>the Marcellus has attractive economics at much lower natural gas prices than some of the other basins.That is also why we have moved out of the<br>Barnett over into the Permian Basin, to shift from oil to natural gas.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>415</i><br>
<hr>
<A name=416></a>JANUARY 04, 2012 / 10:30PM, UDRL - Union Drilling Inc at Pritchard Capital Partners LLC "Energize` Conference<br>
The adequate takeaway capacity is a very important factor. I think Ohio with the Utica, fortunately, has sufficient takeaway capacity. As that oil play<br>comes online, I don't really see the kinds of bottlenecks that you might experience in new markets that haven't previously had a large amount of<br>oil and gas exploration.<br>
There are refineries over in Toledo, Ohio and Chicago with excess capacity, so I think the oil can move fairly quickly to be refined if that market<br>really grows in terms of production pretty quickly.<br>
Large acreage positions, long-term plans that is certainly something that we focus on as far as customers that help smooth out the dips that keeps<br>your workforce together through periods of low commodity prices if you have those kinds of customers with long-term planning horizons.<br>
We have moved rigs around a good bit. As I mentioned, the Barnett, the Permian is just one of those cases. We have moved rigs as necessary up<br>into the Appalachia or into Western Oklahoma now to do some of the Granite Wash, and soon up into Kansas to do the Mississippian work.<br>
In these days the commodity mix is very important. We are probably 40% to 45% oil now with another perhaps 20% up in Appalachia that would<br>be the high liquids content natural gas drilling that augments the yield to our customers.<br>
Investment considerations for Union Drilling. Positioning, I think, again the Marcellus Shale and the Utica can withstand a period of low commodity<br>prices much better than other basins. Very little of this is HBP. Companies have spent billions of dollars acquiring acreage. And at this point there<br>is a lot of need simply to drill those locations to hold the leases for which they have spent all that money.<br>
West Texas, we have got really two different kinds of plays going on there, some of the older, less capable rigs are doing these stacked vertical<br>plays in and around Midland and Odessa. Multiple fracs, but multiple fracs going vertically instead of horizontally.<br>
So a lot of that old stuff in the Permian Basin is working just fine at $90 to $100, as well as the new horizontal oil drilling, which in general is a good<br>bit further west out into Pecos and then up into New Mexico. The Carlsbad area in particular is pretty hot right now.<br>
Arkoma, I mentioned the Fayetteville Shale is actually growing for us. It may not be quite as good economically as the Marcellus, but a very solid<br>customer base there with a lot of capital invested.<br>
We have a very low debt to cap relative to some of the other folks in the industry. We are down around 26% right now. We have got capacity on<br>our lines of credit if there are acquisitions or newbuilds that we want to enter into going forward into 2012.<br>
Challenges, certainly the complexity of the drilling.You can see on this chart it is all really about going horizontal.The vertical rig count really never<br>recovered from the dip in 2009 that the industry went into. And the horizontal part of the rig count dipped, but has come back, retraced and gone<br>very much right through the former high in 2009.<br>
I mentioned earlier, as far as the demand on safety, it is a big deal in our industry. Certainly Macondo is a part of it. The majors coming onshore are<br>a part of it.This is where we focused a lot of our efforts over the past couple of years to remain and grow our marketshare on these kinds of vendor<br>lists.<br>
So what is our solution here? It is not only the equipment as far as selling off the old, investing in the new. It is the people and it is the process, the<br>procedures, the policies, a lot of that less sexy back-office and headcount intensive part of the business to get that all right.<br>
So you focus on the health, safety and environmental. You focus on lowering your well costs for your customers; doing it safely. That results in<br>long-term relationships and we feel a better return over the long haul to our shareholders.<br>
On the people side we have moved into putting in dedicated recruiters in each of our markets.The screening process on new hires has really been<br>amped up a lot. We have moved from the urinalysis to the hair follicle drug testing; that has made a really big difference. We are just not seeing<br>nearly as much hotline traffic about problems on the rigs.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>416</i><br>
<hr>
<A name=417></a>JANUARY 04, 2012 / 10:30PM, UDRL - Union Drilling Inc at Pritchard Capital Partners LLC "Energize` Conference<br>
We are doing psychological profiling as far as integrity testing. We are doing physical ability testing in the pre-hire environment to make sure that<br>we cut down on the turnover and those kinds of accidents that can occur in the first hitch or two with a new hire.<br>
Retaining, again, very important as far as cutting down the turnover that leads to cutting down the incident rate. We have really -- aligning with<br>these large customers, again, that provides a workforce that is there for the long haul as opposed to something that expands and contracts with<br>every movement in commodity prices.<br>
And then it is a performance-based environment. We have bonus programs in place, equity for our top performers, matching 401(k) plan, those<br>sorts of benefits.<br>
Process, a lot more focus on the training programs. We are hiring more trainers in 2012. We have put everybody through offsite behavior-based<br>training. We are doing middle-management leadership training. And we are cutting down the number of rigs per full-time safety auditor.<br>
We were probably around four or five this past year. We are going to hire additional full-time safety people to go out and audit these rigs. And we<br>will be down at about two or three rigs per full-time employee in the safety department as we get into 2012.<br>
We also have retained, where necessary, third-party safety coaches that are full-time out on the rigs that are 24 hours a day. And then we are<br>complying with some of these larger standards organizations. ISNetworld is one of them. SafeLand is another one that has come onshore that is<br>sort of mimicking the offshore requirements called SafeGulf.<br>
As far as what our fleet looks like and what it has looked like, where it is going, it has really been a significant change. June of last year moving<br>forward to the present and into the future you can see that the horsepower profile of the fleet is moving up very quickly. A lot of this is through<br>the result of the rig sale. We have gone from 71 rigs back in June down to 51 currently.<br>
Although we sold 31 rigs, we had already decommissioned 10 of them, but we put them in the auction as well. The future state as far as March 31,<br>that reflects three additional newbuilds we will be taking delivery of in the first quarter. Two of those are going to go into the Fayetteville Shale<br>for XTO and one of them is headed up into the Marcellus.<br>
As far as what has been going on with upgrades of the fleet, in 2011 a little over $100 million spent. You can see I'm not going to tick through all<br>of this, but a lot of these investments are the kinds of things you would see in other peer company fleets.<br>
A lot more a topdrives, a lot more large pumps, iron roughnecks, the walking and skidding systems for pad drilling, more of a focus on electric rigs,<br>the hydraulics catwalks for automated pipe handling. It is just where the industry is heading through<br>
And with the sale we are really essentially eliminating the use of spinning chains, hands next to drilling pipe where fingers can get mashed, those<br>sorts of things. We are moving away from those.<br>
A picture over here where the arrow is, the iron roughnecks are coming much more into our fleet to avoid this use of manual labor at the pipe<br>when it is turning. And then in the bottom you can see the topdrives, walking systems to the far right in this picture.<br>
As far as the types of rigs we are building, we are not solely about AC rigs or one particular design.We will build rigs that meet customer demands.<br>A little more variability in our fleet than say in H&amp;P, which focuses on specific types of designs.<br>
But what we are looking for is a similar type of return on capital. You look at a 1,000 horsepower mechanical, that would be a rig that we would<br>build with a topdrive and probably a skidding system, big pumps. Same basic capability as an AC rig, but not quite as fast, not quite as capital<br>intensive.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>417</i><br>
<hr>
<A name=418></a>JANUARY 04, 2012 / 10:30PM, UDRL - Union Drilling Inc at Pritchard Capital Partners LLC "Energize` Conference<br>
So we can put those out at a lower dayrate for customers, and because of the lower capital costs we are not having to go quite as far out on the<br>term contract.We will typically do a two-year deal on 1,000 horsepower rig or a three-year deal on a 1,500 horsepower electric. But we are basically<br>looking for the same kinds of return on capital over the contract term from our customers.<br>
So we have built some of each of these in the past year.The one that delivered in the fall for XTO was a mechanical.The next one -- the next couple<br>that are going to deliver are going to be AC rigs. And then we have yet another mechanical delivering towards the end of the first quarter.<br>
Financial overview, a lot of this is -- I'm going to go fairly quickly on this. A lot of this is available either on our website or on Edgar, obviously.<br>
But the expansion of margins, we have been through the dip. We are seeing the margins expand back out. We are seeing the topline improve as<br>the business recovers from the 2009 and 2010 period.<br>
As far as utilization and EBITDA through the quarters, the same sort of pattern that you see with a lot of these other companies going through a<br>tough stretch in 2009 and 2010.<br>
The orange and green line charts here are reflecting pro forma what our utilization would have been in the green had we sold those small legacy<br>rigs previously, but we sold them in the fourth quarter of 2011. So the fleet now is probably in that 80% to 85% utilization area.<br>
Just quickly, I mentioned a little earlier about our capital structure, 26% debt to cap, $150 million revolving line of credit in place. We have got<br>about a little over $75 million available right now.<br>
So combined with cash flow from operations and available credit on our revolving facility, a good bit of room for us to enter into additional newbuild<br>contracts in 2012, which I would expect we will be doing fairly soon.<br>
Term contract coverage. We haven't done any significant spec building and I don't plan to be doing any significant spec building. You can see we<br>have got a significant amount of term contract cover. I don't feel uncomfortable at all about the contracts that are expiring in either Q4 -- well, I<br>don't feel uncomfortable about them at all since we are fairly well-utilized. And I don't see any issues with the roll-off of contracts in the first quarter<br>of 2012. Those essentially are all spoken for and renewed.<br>
Just to summarize, I really feel like Union Drilling has really been transformed since where we were five years ago. But in this industry, given the<br>speed of which -- with which the shale drilling has picked up, you really need to have either transformed your fleet or have gotten out of the<br>business.<br>
Our position in each of our markets, about 60% term contract cover.We have moved significantly over the past couple of years where we are about<br>45% oil and then, as I said earlier, maybe 20% liquids. So we have some gassy exposure, and obviously that is a concern, but I think that is well<br>taken care of by the particular kinds of markets we are in for gas and the types of customers we have.<br>
Plenty of room on the balance sheet. And I think we have got a good track record of growth with the fleet. Thank you very much.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>418</i><br>
<hr>
<A name=419></a>JANUARY 04, 2012 / 10:30PM, UDRL - Union Drilling Inc at Pritchard Capital Partners LLC "Energize` Conference<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4696515-2012-01-09T18:58:52.890</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>419</i><br>
<hr>
<A name=420></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
AMGN - AMGEN INC AT JPMORGAN<br>GLOBAL HEALTHCARE CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 6:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>420</i><br>
<hr>
<A name=421></a>JANUARY 09, 2012 / 6:00PM, AMGN - Amgen Inc at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Bob Bradway</b><i> Amgen Inc. - President and COO and CEO-Elect</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Geoff Meacham</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Geoff Meacham</b><i> - JPMorgan - Analyst</i><br>
Okay, welcome to the morning sessions of the 30th annual JPMorgan Healthcare Conference. I'm Geoff Meacham, the senior biotech analyst here<br>at JPMorgan. It's my pleasure to have Amgen speak. Amgen is one of the bellwethers of the biotech group with leading franchises in hematology,<br>oncology, inflammation, as well as infectious -- I'm sorry -- as well as bone disorders.<br>
And speaking on behalf of Amgen is Bob Bradway, President and COO and CEO-elect. Bob?<br>
<b>Bob Bradway</b><i> - Amgen Inc. - President and COO and CEO-Elect</i><br>
Good morning, and happy new year. Delighted to have the opportunity to talk to you this morning about Amgen and to share with you the reasons<br>why I'm excited about the new year at our Company.<br>
But before I do that, I'd like to spend a few minutes talking about the year just past, 2011. And I'm pleased with how we ended 2011 in particular,<br>pleased with the momentum that we had at the end of the year.<br>
We'll report results in a few weeks time and when we do, you will see that our performance in 2011 was solid across the board. You'll see that we<br>delivered revenue and adjusted earnings per share growth again this year and we did that off the back of strength and growth in the newly launched<br>products, in particular our denosumab franchise, which includes both XGEVA and Prolia. And in their first year on the market together, we generated<br>in excess of $500 million of revenues from this new franchise.<br>
So we're delighted with the performance in particular of XGEVA, which as you know launched very strongly in the United States early in the year.<br>We demonstrated once again the power in this industry of a simple word, a single simple word and that word is superiority.<br>
So XGEVA has demonstrated again the power of being able to launch a medicine that has been demonstrated with three pivotal Phase III trials to<br>be superior to the standard of care and physicians and patients have rapidly adopted XGEVA here in the US.<br>
Prolia for those of you who have been following Prolia closely including in the fourth quarter, you will know that the momentum for Prolia built<br>again in the fourth quarter and we are following the progress of this launch very carefully as you would expect and pleased with the growth that<br>we saw for Prolia in the fourth quarter and we'll have more to say about that obviously on the earnings call in a few week's time.<br>
In addition, we're pleased with the progress of Neulasta in 2011. It's been an objective of ours for some time to grow the Neulasta franchise worldwide<br>and I'm delighted that we did just that in 2011. So grastim is about a $5 billion franchise for us worldwide; Neulasta comprises about three-quarters<br>of that and we demonstrated solid unit volume growth from Neulasta last year as well as price growth. So Neulasta was a strong contributor to our<br>results in 2011 and we have good momentum heading into 2012 for that franchise.<br>
Enbrel, as you know, Enbrel is our leading molecule in the rheumatoid arthritis and psoriasis space and we're delighted again with the progress<br>that we demonstrated in maintaining leading market shares for Enbrel throughout 2011.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>421</i><br>
<hr>
<A name=422></a>JANUARY 09, 2012 / 6:00PM, AMGN - Amgen Inc at JPMorgan Global Healthcare Conference<br>
Commercially we feel very good about how we ended the year 2011. From a research and development perspective, 2011 was also a solid year for<br>us. We expanded the pipeline early in the year by acquiring a company called BioVex, which brought to us an innovative and interesting molecule<br>with potential to treat malignant melanoma. And I'll talk more about that in a moment.<br>
In addition, we moved a few of our important oncology medicines toward Phase III trials and again, I'll talk about those and generated important<br>Phase II data for our anti-sclerostin antibody in the setting of bone health and for our PCSK9 antibody in the setting of hypercholesterolemia. So<br>we are pleased with the progress that we've made in both expanding and advancing the pipeline in 2011.<br>
Financially 2011 was an important year for us as well. We initiated a dividend in 2011, announced that at our meeting with shareholders in April of<br>last year. In addition, we announced and completed a major tender offer in the fourth quarter for our shares and we're delighted at the results of<br>the Dutch auction that we commenced in the fourth quarter.<br>
We provided in April long-term operating and capital guidance as well for the business. And I'm pleased by the progress that we made during the<br>course of the year in advancing towards the achievement of those objectives.<br>
And finally at the end of the year, we announced an orderly and clear management succession plan and obviously I'm excited and humbled to be<br>assuming the role of Chief Executive of Amgen beginning in May. And I'm delighted and encouraged by the strength of the team that we have in<br>place to help lead the Company forward with me.<br>
So 2011 was a solid year. But I am even more confident about the outlook for 2012. 2012 should be an even stronger year for us at Amgen than<br>2011.<br>
We enter 2012 with momentum for both XGEVA and Prolia and we have catalysts that we think will enable us to increase the growth of both of<br>these molecules during the course of the year. Now remember that XGEVA was launched in the US but we're only now launching XGEVA internationally.<br>
And of course, we also have the prospect of an important new indication for XGEVA which we'll learn more about early in the year and I'll say more<br>about that in a moment. So ended the year with momentum, clearly have opportunity to build on that in 2012.<br>
Similarly for Prolia, we in 2012 have the opportunity to continue to launch in new international markets including some of what we think will be<br>the larger international markets for Prolia so we're excited about that opportunity as well as the opportunity to continue to invest and to activate<br>patients through a direct to consumer campaign during the course of 2012. So XGEVA and Prolia will clearly be important sources of growth for<br>us in the new year.<br>
Now in addition, our recently launched products, Sensipar, Vectibix and Nplate, all of which are growing at a healthy double-digit rates also enter<br>the year with momentum and we have important potential catalysts for each of these molecules as well in 2012.<br>
Sensipar is a molecule for which we are running a very large Phase III trial which we expect to read out in 2012. That trial is designed to show<br>whether Sensipar improves cardiovascular mortality and morbidity for patients who are suffering from SHPT and we think that has the potential<br>to be a practice changing opportunity for us if the Phase III results are indeed positive for Sensipar.<br>
So Sensipar is about $1 billion or headed toward being a $1 billion franchise for us and again, this is a source of potential upside for us in 2012.<br>
Vectibix, we have the benefit of an expanded label in Europe, the benefit of being able to promote Vectibix now in the first and second line colorectal<br>cancer settings. So we are excited about that as a source of potential growth for Vectibix.<br>
And then finally, Nplate here in the US we're pleased that the removal or pleased by the removal of the REMS for Nplate and we think for those<br>physicians who wish to use Nplate to treat patients with ITP. This will make it that much easier for them to adopt Nplate.<br>
So these three products all growing at a healthy double-digit rates all with interesting catalysts for us in 2012.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>422</i><br>
<hr>
<A name=423></a>JANUARY 09, 2012 / 6:00PM, AMGN - Amgen Inc at JPMorgan Global Healthcare Conference<br>
And our core franchises in 2012 are strong. We enter 2012 as I said earlier with momentum for Neulasta and with a desire to continue to grow unit<br>volume of this product in the setting of chemotherapy.<br>
Now some of you are aware there are still in the US alone at more than 60,000 patients a year who are hospitalized with febrile neutropenia, so the<br>opportunity for Neulasta even in the US continues to be considerable. And when you consider that one in nine of those patients who are hospitalized<br>with febrile neutropenia die from complications of their infection, the need for us to continue to grow Neulasta is considerable and we're pleased<br>that the Center for Disease Control has made it a focus of its efforts as well to spread the word about the importance of preventing infection during<br>chemotherapy.<br>
So Neulasta, strong performance last year, strong momentum heading into 2012, important for us to continue to try to increase in particular our<br>penetration of chemotherapy for cycle chemotherapy patients.<br>
Enbrel, we maintain our leadership again heading into 2012 in both rheumatoid arthritis and the psoriasis markets and we will continue to focus<br>on growing that important franchise and continue to invest in that important franchise in 2012.<br>
And I want to spend a moment on EPOGEN, because of course 2011 was a year of considerable change for our ESA franchise owing to the<br>implementation of bundling in the US and then a significant change in the label for our ESA franchise. And so whereas 2011 was a year in which<br>we experienced significant decrease in dose utilization for the ESAs, we think this is a year where will see much more stability.<br>
We are pleased to have been able to agree a long-term exclusive arrangement with DaVita. We announced that we had reached a seven-year<br>partnership with them in the fourth quarter of last year and we're delighted at about that contract and looking forward to building a close partnership<br>with DaVita over the next seven years.<br>
In addition, we are pleased to have nonexclusive but multiyear contracts in place with Fresenius and other providers as well. So we enter 2012<br>feeling like the decrement that we told you to expect in 2011 for the ESA franchise has largely played out as we expected.<br>
Recall that we thought we would express on the order of a 20% to 25% decrease in utilization of EPOGEN in 2011 and there might be some spill<br>over into beginning of 2012 and the market has evolved pretty much as we expected it would. And we think these contracts will be very helpful<br>here early in the new year.<br>
So gain from a commercial standpoint, we feel very good about the opportunity in 2012 and the bottom line for us on the commercial side is that<br>we expect to see revenue acceleration in the new year.<br>
Now from an R&amp;D standpoint, our pipeline will continue to advance here in 2012. One of the early events for us in the year will be the review of<br>XGEVA by the FDA. I'll say a few words about that in a moment in particular I will talk about the ODAC hearing which will take place on February 8<br>for XGEVA.<br>
In addition, I just want to reiterate that we will have during the course of the year Phase III data on Sensipar, and again that has the potential to be<br>very important in the setting of patients who are on dialysis and suffering from secondary hyperparathyroidism.<br>
And then finally, we would expect during the course of the year to be able to see Phase III data from the molecule that we acquired last year which<br>we are now calling [T-VEC], which is the molecule that we are exploring in the setting of malignant melanoma. So those will be three of the important<br>clinical events for us to share with you during the course of 2012 on the R&amp;D side.<br>
Let me just spend a moment more talking about XGEVA, which as I said will be reviewed at an ODAC on February 8. So this will be an early event<br>for us this year and it will be reviewed in the setting of whether XGEVA can prevent or be approved for the prevention or delay of the spread of<br>prostate cancer to bone.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>423</i><br>
<hr>
<A name=424></a>JANUARY 09, 2012 / 6:00PM, AMGN - Amgen Inc at JPMorgan Global Healthcare Conference<br>
Now bone metastases develop in about 90% of men who have advanced prostate cancer so this is a significant important medical issue.There are<br>no approved therapies for the prevention of bone metastases in men with castrate resistant prostate cancer. So XGEVA is the first and only medicine<br>to demonstrate that it can statistically significantly delay the progression of prostate cancer to bone.<br>
And so we are anxiously looking forward to having the opportunity to talk about this with the panel at the FDA in February. Again to remind you,<br>that sBLA is under review, the ODAC, as I said February 8, and then of course we will have a PDUFA date of April 26 for XGEVA.<br>
So while this is an important new indication for XGEVA, bear in mind that the biggest opportunity by far and for us in 2012 is to continue to grow<br>the market and continue to take share in the treatment of skeletal related events for patients whose cancer has already spread to bone. So that's<br>the bigger opportunity, the biggest opportunity for us in 2012; this is an important new opportunity however as well.<br>
Now I'm confident about 2012 but I'm optimistic about our prospects beyond 2012 as well. When you think about 2013 and beyond, you should<br>expect that Prolia and XGEVA will continue to grow, will be continuing to build momentum in the period of 2013 and beyond. And in addition, we<br>would expect Sensipar, Vectibix and Nplate will also continue to grow through that period.<br>
Now we've talked at length this year about our confidence in the long-term outlook for Enbrel but I went to reiterate this morning that our confidence<br>only grew in the long-term outlook for Enbrel in November when a patent was issued in favor of Enbrel that gives us patent protection extending<br>now well into the future. So we believe we have a strong broad intellectual property estate covering Enbrel and we intend to invest and try to<br>maintain another decade of leadership for this important molecule for Amgen.<br>
Now also recognize that the profit share that is currently in place for Enbrel which requires that we share significant profits generated from Enbrel<br>to Pfizer expires in 2013 and as we have said before, the expiration of that profit sharing agreement which is replaced by a declining royalty<br>agreement will result in significant margin expansion for us beginning at the end of 2013 and carrying forward to 2014, 2015 and beyond.<br>
So we're excited about what the current flow of our recently launched products can do for us, excited about the margin expansion that comes<br>from our core $3.5 billion plus Enbrel franchise, but also excited about what will start to emerge from our R&amp;D pipeline as we move beyond 2012<br>as well.<br>
So I want to talk a little bit about that as well as what the contribution to our business from international expansion and biosimilars could be in the<br>longer term as well.<br>
We operate today commercially in about 52 countries. We're committed to expanding that to 75 countries by 2015 and we expect that that<br>expansion will be accretive both to the revenue growth rate as well as earnings during that period. So international expansion will remain a focus<br>of ours over the period beyond 2012.<br>
Now let me talk about our R&amp;D pipeline. As you're probably aware, five programs in our research and development pipeline will produce five --<br>sorry -- five programs will produce Phase III data over the next five years. And those five are listed here. T-VEC is the one I've already talked about<br>a couple of times this morning. That is our program for malignant melanoma and again we will have data on that in the Phase III setting this year.<br>
386 and 479 are two more of our oncology molecules; 386 is our anti-angiopoietin peptibody and we expect to advance that in Phase III ovarian<br>cancer trials this year. 479 is our anti-insulin-like growth factor antibody and we are advancing that in Phase III trials for pancreatic cancer and<br>anxious to see results on that molecule as well over the next several years.<br>
827 is our anti-IL-17 antibody for which we generated very intriguing data in the psoriasis setting in 2011. We are still waiting for the asthma data,<br>but the data in psoriasis look very compelling very compelling for 827.<br>
I want to spend just a moment or two on AMG 785 and AMG 145. These are newer products in our pipeline so they haven't had quite as much<br>attention in the investment community as the others but these represent very attractive opportunities for us as well.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>424</i><br>
<hr>
<A name=425></a>JANUARY 09, 2012 / 6:00PM, AMGN - Amgen Inc at JPMorgan Global Healthcare Conference<br>
785 is our antibody to the sclerostin molecule. And this is a product that looked very intriguing again in the setting of bone health.This is an anabolic<br>agent for which we will report detailed Phase II data at the ASBMR in 2012.<br>
And then finally, AMG 145 is our anti-PCSK9 antibody which looks again very intriguing in the setting of hypercholesterolemia and we have five<br>very significant Phase II trials underway now and we look forward to generating and reporting on data from those trials during the course of 2012.<br>So it will be a busy year for us from a research and development standpoint in 2012.<br>
Now late in the year, late in 2011, we announced a partnership with Watson in the biosimilar area and I just want to spend a moment talking about<br>this. This is our first opportunity to talk publicly about the partnership that we have struck with Watson to try to commercialize several molecules<br>in the oncology space, several biosimilar molecules in the oncology space and we are very pleased about the complementary nature of this<br>partnership for us.<br>
We think in order to be successful in biosimilars, the Company will have to have strong biologics manufacturing, regulatory and commercial<br>capabilities and obviously we think we have that and we expect that these biosimilar molecules will enable us to grow not just in the US but in<br>international markets as well.<br>
We are delighted to partnership with Watson, however, not just to reduce the financial risk. They will be contributing up to $400 million to help us<br>codevelop several oncology molecules, but were also pleased to have their insight and experiences from their years competing in the specialty<br>pharma and generics segments as well. We also are excited about how their commercial and distribution capabilities are complementary with<br>ours.<br>
So we are excited about this partnership. This is a growth potential for us though that is still several years out so I'll move on and talk about some<br>of the other important things for 2012.<br>
I said that one of the important accomplishments for us in 2011 was that we began to -- we initiated a dividend and we aggressively return capital<br>to our shareholders and we will continue to do that in 2012. Again our Dutch auction for $5 billion of shares underscores our confidence in the<br>long-term value of Amgen.<br>
We would expect to continue to buy back shares in the open market. We announced in December that we have increased our dividend by 29%<br>heading into 2012 and I want to point out that we believe we also retain significant strategic flexibility to grow the business by acquiring and<br>licensing important innovative new medicines as well.<br>
So our focus for the year in 2012, our focus will be on growing revenues. Again, accelerating revenues heading into 2012 is a very important objective<br>for us and it's one we are confident we can achieve. We expect to grow earnings per share and cash flow as well in 2012.<br>
An important feature of that will be accelerating the growth of Prolia and XGEVA.We will focus as well on advancing the pipeline.We are committed<br>to returning at least 60% of our adjusted net income to you, our shareholders in 2012. And finally, are committed to working closely with you to<br>see that we deliver value for you as our shareholders.<br>
So I'm pleased about our progress and how we ended the year in 2011. I'm confident about the outlook for 2012 and optimistic about the longer<br>term as well.<br>
Thank you very much. I look forward to hearing your questions in the breakout session in a few minute's time. Thank you.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>425</i><br>
<hr>
<A name=426></a>JANUARY 09, 2012 / 6:00PM, AMGN - Amgen Inc at JPMorgan Global Healthcare Conference<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4686049-2012-01-09T19:00:51.263</b><br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>426</i><br>
<hr>
<A name=427></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
CFN - CAREFUSION CONFERENCE<br>CALL TO DISCUSS PRELIMINARY<br>SECOND QUARTER RESULTS<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 2:00PM GMT<br>
OVERVIEW:<br>
CFN expects 2Q12 revenue of $910-915m, adjusted operating income of $148-153m,<br>and adjusted EPS of $0.41-0.45. Co. also expects full-year 2012 EPS to be $1.75-1.90.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>427</i><br>
<hr>
<A name=428></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Jim Mazzola</b><i> CareFusion Corporation - SVP of Global Marketing, Communication &amp; Investor Relations</i><br>
<b>Kieran Gallahue</b><i> CareFusion Corporation - Chairman, CEO</i><br>
<b>Jim Hinrichs</b><i> CareFusion Corporation - CFO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Amit Bhalla</b><i> Citi - Analyst</i><br>
<b>Matt Taylor</b><i> Barclays Capital - Analyst</i><br>
<b>Mike Weinstein</b><i> JPMorgan - Analyst</i><br>
<b>David Roman</b><i> Goldman Sachs - Analyst</i><br>
<b>David Lewis</b><i> Morgan Stanley - Analyst</i><br>
<b>Lennox Ketner</b><i> BofA Merrill Lynch - Analyst</i><br>
<b>Kristen Stewart</b><i> Deutsche Bank - Analyst</i><br>
<b>OVERVIEW</b><br>
CFN expects 2Q12 revenue of $910-915m, adjusted operating income of $148-153m, and adjusted EPS of $0.41-0.45. Co. also expects<br>full-year 2012 EPS to be $1.75-1.90.<br>
<b>FINANCIAL DATA</b><br>
<b>A. Expected 2Q12 revenue = $910-915m.</b><br>
<b>B. Expected 2Q12 adjusted operating income = $148-153m.</b><br>
<b>C. Expected 2Q12 adjusted EPS = $0.41-0.45.</b><br>
<b>D. Expected full-year 2012 EPS = $1.75-1.90.</b><br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. PRELIMINARY 2Q12 RESULTS (K.G.)</b><br>
<b>A. Highlights:</b><br>
<b>1. </b>Still in process of closing 2Q.<br>
<b>a. </b>Will report full results on Feb. 2.<br>
<b>2. </b>2Q12 Expectations:<br>
<b>a. </b>Revenue $910-915m.<br><b>b. </b>Adjusted operating income $148-153m.<br>
<b>c. </b>Adjusted EPS $0.41-0.45.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>428</i><br>
<hr>
<A name=429></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>3. </b>Medical Systems:<br>
<b>a. </b>Largest segment.<br><b>b. </b>Grew high-single digits.<br>
<b>c. </b>Continued its positive organic growth momentum.<br>
<b>d. </b>Bookings in all three businesses, Dispensing, Infusion, and Ventilation, strong and remain in good position for full-year.<br>
<b>4. </b>Procedural Solutions:<br>
<b>a. </b>Sales and GM lower-than-forecasted; primary reason operating income is lower than expectations.<br><b>b. </b>Revenue down about 5% or about 2% after adjusting out revenue from OnSite divestiture in prior year.<br>
<b>c. </b>Is comprised of four business groupings:<br>
<b>i. </b>Infection Prevention.<br>
<b>ii. </b>Medical Specialties.<br>
<b>iii. </b>Specialty Disposables.<br>
<b>iv. </b>Diagnostics.<br>
<b>d. </b>Core products continued to grow faster than market, just slightly below Co.'s internal expectations.<br><b>e. </b>Margins negatively affected by pricing pressure [on Co.'s] less clinically differentiated products.<br>
<b>i. </b>Net effect, lighter conversion volumes for products like ChloraPrep and MaxGuard, and margin pressure on respiratory<br>
disposables and medical specialties.<br>
<b>ii. </b>Not losing share in clinically differentiated products; believes growth rates will continue to be above market in ChloraPrep<br>
and Medegen.<br>
<b>iii. </b>ChloraPrep grew in mid-single digits; revised FY12 forecasts to reflects this trend.<br>
<b>f. </b>When Co. announces full-qtr., it expects to revise downward, FY12 revenue guidance for Procedural Solutions segment<br>
and Infection Prevention businesses.<br>
<b>g. </b>On positive side, seeing benefits of reorganization last year into two business segments.<br>
<b>i. </b>It provides Co. and its investors greater transparency into business.<br>
<b>ii. </b>Focused on investment in core businesses and isolating areas where Co. needs to take action.<br>
<b>iii. </b>Reorganized at Procedural Solutions segment level during qtr. and realigned sales territories to decrease windshield<br>
time of reps and increase selling capacity.<br>
<b>iv. </b>Aforementioned will take a qtr. or so to ramp, but Co. expects will drive additional growth in near-term.<br>
<b>5. </b>Across Co., making necessary investments reported to strengthen foundation to grow faster over long-term.<br>
<b>a. </b>Must continue to invest during FY balance.<br><b>b. </b>Continues to have scenarios that enable Co. to meet original full-year EPS guidance, .<br>
<b>i. </b>Felt it was prudent to lower bottom end of adjusted EPS range by $0.05 to new range of $1.75-1.90.<br>
<b>c. </b>Aforementioned revision will be reflected in Procedural Solutions segment and largely in Infection Prevention business<br>
within that segment.<br>
<b>d. </b>There are four components of Infection Prevention business, ChloraPrep and Medegen, which continue to grow above<br>
market rates, and legacy skin and legacy non-dedicated infusion disposables, which are more subject to pricing pressure.<br>
<b>e. </b>Aforementioned new EPS range reflects some upside Co. anticipates below operating income line, largely due to tax rate,<br>
which is due to Co.'s geographic business mix and tax planning efforts.<br>
<b>6. </b>As Co. is providing preliminary results so early in close process, it would be premature to give a tax rate for qtr. or year.<br>
<b>a. </b>Based on where it comes in, should be in a position to tighten EPS guidance when Co. reports on Feb. 2.<br>
<b>7. </b>Across both segments, environment continues to look similar to what Co. reported last qtr.<br>
<b>a. </b>Hospitals in US continue to prioritize their investments based on products necessary to their operations.<br>
<b>i. </b>This trend has highlighted strength of Medical Systems' products.<br>
<b>8. </b>In Procedural Solutions segment, continues to take share and convert markets at a slower rate for aforementioned reasons.<br><b>9. </b>Outside US, Western Europe remains soft but not materially different than indicated last qtr.<br>
<b>a. </b>Still growing international presence, so impact there is relatively minor.<br>
<b>10. </b>Has lot of good things going on.<br>
<b>a. </b>Feels more confident than ever in plan laid out.<br>
<b>i. </b>Segment split, going well and giving Co. greater visibility.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>429</i><br>
<hr>
<A name=430></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>ii. </b>Work Co. is doing to simplify business is on track and ongoing.<br>
<b>iii. </b>Building foundation for growth and remains optimistic and committed to those plans including [20% plus] operating<br>
margin goal exiting FY14.<br>
<b>11. </b>Full results, Feb. 2.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
(Operation Instructions) Amit Bhalla, Citi.<br>
<b>Amit Bhalla</b><i> - Citi - Analyst</i><br>
Good morning. Two quick questions for you. First, last quarter, when you were talking about the infection prevention business, you<br>talked about the impact of procedure volumes and distributor purchasing being slightly weaker. Can you comment on that in<br>particular? And then just secondly, can you quantify the level of pricing pressure that you are seeing? Thanks.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
It's Jim Hinrichs, and Kieran can chime in here if he'd like. We are not seeing increased pressure in procedure volumes. I wouldn't say<br>that things are rebounding dramatically, but we are not pointing at that as a major driver here.<br>
And when it comes to -- the second part of your question was about pricing pressure -- about pricing pressure, we do continue to<br>see pricing pressure in specific businesses, and those are the ones that are less clinically differentiated. So when I look at our product<br>lines in respiratory disposables and legacy prep, as well as our legacy non-dedicated infusion sets, those are the areas where we are<br>seeing pricing pressure. I think it ranges from a few points into the mid single digits of pricing push back to us from our customers.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Just a chip shot on that, Amit. It's not as if we're seeing a rebound on a procedure volumes side. It's just that we wouldn't point to<br>that as the primary driver. We are seeing it across both of our conversion-oriented businesses. What we are seeing is that we're not<br>losing market share. We still feel very good from a competitive perspective, and that's the feedback that we are getting from the<br>orthogonal checkpoints in the field.<br>
What it does seem is that in the environment that we are at, some of the conversion efforts are just taking a bit longer than they<br>have in the past. And what you do is when you are sitting across from these hospital administrators, they see the value. Sometimes<br>what you will do is you'll get a conversion of 50% of the hospital or the hospital systems, and that second part of the conversion is<br>usually a lot of street fighting, where you are in there, you are looking for different levels of the organization to support you in that<br>conversion.<br>
Right now, they are a bit distracted, and we are not seeing that same level of support simply because they've got multiple priorities.<br>But the good news, we are not losing market share there. We are still growing above market rates, and we are steady as she goes.<br>
Also, this adjustment in the sales force is going to allow us to have greater resources being focused in front of the customers as<br>opposed to in front of the windshield. So we are taking the actions to become more efficient and more effective with our customers<br>as well.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>430</i><br>
<hr>
<A name=431></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Amit Bhalla</b><i> - Citi - Analyst</i><br>
Kieran, you mentioned distributors as an issue last quarter. Was that resolved or are distributors --?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
It's Jim. That very specific -- obviously, inventory changes throughout the channel all the time in all the product lines. The specific<br>issue we pointed to last quarter did not repeat in this quarter, so that seems to have leveled itself out. That was specifically, if you<br>remember, destocking in the infection prevention businesses, which seems to have leveled off now. So we are kind of -- we feel like<br>we are back to normal in that part of the business from that perspective.<br>
<b>Amit Bhalla</b><i> - Citi - Analyst</i><br>
Okay. Thank you.<br>
<b>Operator</b><br>
Matt Taylor, Barclays.<br>
<b>Matt Taylor</b><i> - Barclays Capital - Analyst</i><br>
A couple of quick ones. One, I just wanted to understand within Procedural Solutions, I know you talked about pressure on products<br>that were not clinically differentiated. But was there any one or two areas in particular with the surgical tools or some of the disposables<br>where the pressure was kind of outside?<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Well, Jim and I will sort of tag team a little bit on this. Certain areas such as the respiratory disposables, where there is very little<br>clinical differentiation -- I mean, some segments, there's a lot, but there is other niches within that where there's not as much<br>differentiation. That is subject much more to the pricing pressures we have seen.<br>
We haven't really on the surgical tools side seen dramatic pricing pressure at all. In fact, we feel like we're doing -- we are not doing<br>gangbusters there, but we feel like from a competitive perspective as we looked around, we actually feel like we are doing better<br>than competitors and feel like we're gaining some share.<br>
So it is in some very targeted areas, some on the valve business. The newer stuff, like the Medegens and whatnot, very clinically<br>differentiated. Some of the existing product lines that have been in the market for a longer time, they're going to be a little bit more<br>subject to those pressures.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
That's exactly right. Again, the three product lines we have mentioned that have pricing pressure -- respiratory disposables, legacy<br>prep, legacy non-dedicated -- all those products that are just not as clinically differentiated; therefore tougher to command a price<br>premium.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>431</i><br>
<hr>
<A name=432></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Matt Taylor</b><i> - Barclays Capital - Analyst</i><br>
Okay. And you lowered the low end of the EPS guidance, but I think you mentioned at the beginning of your comments that you<br>saw really no change to your longer-term margin improvement goals. And I was just curious with this increased pressure how you<br>are going to be able to absorb or offset that and still achieve those goals.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Look, we've got a lot of things going on around the Company; there's a lot of shots on goal when it comes to building efficiencies<br>to reducing complexities to be helping us become more efficient in front of those customers.<br>
When you are going through these changes, sometimes it can get a little bit bumpy on a quarterly basis. And I think we have been<br>pretty open about that from the beginning. So when you have a little bit of changes in the mix like we have seen this time, we are<br>feeling pretty good about year-end on the top line overall. It's just about sort of the mix of getting there.<br>
And so we think that the focus that we have on simplifying the business, on continuing to gain efficiencies, on some of the<br>improvements we are making in the sales force, particularly in the Procedural Solutions side, to be able to help those reps be able<br>to spend more time in front of the customers, we think they are going to pay dividends, and we are steady as she goes on those<br>things. We don't want to pull back on the investment on those.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
Exactly.<br>
<b>Matt Taylor</b><i> - Barclays Capital - Analyst</i><br>
All right, thanks a lot, guys.<br>
<b>Operator</b><br>
Mike Weinstein, JPMorgan.<br>
<b>Mike Weinstein</b><i> - JPMorgan - Analyst</i><br>
Help me out here. I just wanted to understand a couple items. So If I look at the details you gave out in the release, your revenues<br>actually are pretty close to where we were at, but there's a much bigger drop-off on the EBIT line. And then when you guide to EPS,<br>it's actually relatively close.<br>
So can you just explain that sequence there? So revenues don't appear like they are that different than we were forecasting, but<br>there's a much larger drop on the EBIT line. And then EPS, it seems like you seem to make up some of the gap. So is the expectation<br>for the quarter and then for the year that you'll make up some of the -- some of an EBIT shortfall below that line with a lower tax<br>rate?<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>432</i><br>
<hr>
<A name=433></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
Yes, a couple -- that's a great question, Mike, and this is probably worth taking a minute to go through. A couple of things going on.<br>
The first is revenue came in a little bit light. We were facing an EBIT number for the quarter, based on preliminary results, that was<br>different enough from our expectations that we thought it worthwhile saying it now, so when we are out in front of 50% or 60% of<br>our shareholders today we could have meaningful conversations. And so that was sort of the reason for the preannouncement.<br>
Revenue, as you mentioned, coming in just slightly below what the Street was expecting, also below what our expectations were.<br>But two things are really going on. One is there is a revenue shortfall, and the revenue shortfall is largely in our higher-margin<br>products. So that's driving a larger -- or a disproportionately large EBIT miss.<br>
The second thing going on is these less differentiated products, with the pricing pressure we have seen in this quarter, is also driving<br>a margin push -- driving margin pressure. So you end up with what I would describe as a disproportionate gross margin and EBIT<br>impact on our bottom line for the quarter. And that was really the reason for the release.<br>
Now, we do have some below-the-line upside in interest and other, and we believe in the tax rate, although the tax rate won't be<br>finalized until the end of this week, that will offset some of the difference, and that will carry through to the year. So when you take<br>what we have said today and translate it for the year, the way you need to look at it is to say, look, revenue probably still within the<br>range we provided, but we are losing some revenue growth in the higher-margin products.<br>
We've got gross margin pressure creating sort of what I would describe as a dime of EBIT pressure out of Procedural Solutions that<br>we will make up below the line, primarily on the tax rate, which is why we only took that tax rate -- the EPS number, the bottom of<br>the range, down by a nickel until we can get our tax forecast done, and then we will retighten up the range back to a dime. That's<br>the goal. So did that make sense?<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Sounds like (inaudible). But let me just make one final comment on that, which is maybe a bit more qualitative. When you walk<br>through this, I think it's not unlikely that maybe 90% of the companies would not have pre-released an earnings today with regards<br>to this. We feel that the environment is out there -- clearly, there's a lot going on in the world economy and the stock markets, et<br>cetera. We have committed that we would be as transparent as we can with everybody. And even in situations where we think we<br>can claw back quite a bit through things like our very aggressive and worthwhile tax management strategies, our view is that if we<br>got there different, we wanted to be able to talk openly and give you as much visibility as we can. So that's the intention of doing<br>this.<br>
<b>Operator</b><br>
David Roman, Goldman Sachs.<br>
<b>David Roman</b><i> - Goldman Sachs - Analyst</i><br>
I had two quick questions. One is -- am I correct that FX -neutral revenue growth for the first half of the year is running between 2%<br>and 2.5%? And if that is correct, can you maybe bridge these current levels to the 3% to 5% you are guiding to for the full year?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>433</i><br>
<hr>
<A name=434></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
David, it's Jim. I don't have those constant currency revenue growth yet. But I think the first quarter was around 2%, and then this<br>quarter, don't have that adjusted out yet completely. But that's probably about right.We are expecting a pickup, obviously, in revenue<br>in the back half of the year. We'll give all of that detail as to where we expect that to take place in the earnings release.<br>
<b>David Roman</b><i> - Goldman Sachs - Analyst</i><br>
Okay. And then secondly, and maybe more broadly, if you look at the long-term operating margin targets that you have put out<br>there and we look at this quarter, can you maybe just remind us to what extent top-line performance and EBIT margin performance<br>are connected and what flexibility you have to continue to expand EBIT margins should in fact the top line remain under pressure?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
Yes, sure. Certainly the two things are connected. We believe we have different plans and different contingencies that continue to<br>allow us to drive margins, even in a lower growth environment. Certainly top line helps -- as we have been very consistent in saying<br>all along, top-line growth certainly helps our leverage story, but we are not dependent on it.<br>
What we saw this quarter was mix working against us a little bit, and we saw pricing pressure working against us a little bit. But we<br>are now -- just as Kieran mentioned earlier, we're doing some things that are making changes that we think will reignite the mix<br>back in our favor in terms of putting our sales forces together and making them more productive and filling their bags more and<br>increasing their overall capacity.<br>
So I think there continue to be opportunities to get mix working back in our favor. We are still very committed to that long-term<br>growth, the long-term margin target. It does require top-line growth, but we have scenarios planned out under low growth and sort<br>of medium or higher growth that can still get us there, which is why we are still absolutely committed to those targets. It just requires<br>a slightly different way of getting there.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Just to add on a little bit. As you might expect, when we look at our investment philosophy within the business, we are certainly<br>targeting those areas that we think, A, have the most opportunity for expansion and growth, and B, would have a disproportionate<br>impact on the profitability. So you would expect that of us and that's certainly what we are doing.<br>
This movement to the two-segment structure, it was really critical in that process. Because by separating out the Medical Systems<br>businesses and the Procedural Solutions, you invest differently in each of those businesses and you need to manage them different.<br>And they were subsumed in these more complicated business units before that didn't allow for true execution on a differentiated<br>investment strategy.<br>
So the benefits of that are going to be yielded over time, but the structural changes are the things that were absolutely required for<br>us to gain the visibility and be able to differentially invest in those businesses.<br>
<b>David Roman</b><i> - Goldman Sachs - Analyst</i><br>
Okay, that's very helpful. Thank you very much.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>434</i><br>
<hr>
<A name=435></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Operator</b><br>
David Lewis, Morgan Stanley.<br>
<b>David Lewis</b><i> - Morgan Stanley - Analyst</i><br>
Good morning. Jim, I know you don't have the specifics on sort of where the leverage, both gross margin and EBIT, kind of landed<br>for the quarter. But I wonder, given that gross margin pressures would seem obvious, whether they are pricing or mix, last quarter<br>we didn't see the type of SG&amp;A leverage I think some investors were hoping for. Is it possible to share with us whether despite that<br>gross margin pressure whether you think there was evidence that you drove SG&amp;A leverage in this particular quarter as you<br>anniversaried some of that front-end spend last quarter?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
Certainly, my expectation is and preliminary results would indicate that our SG&amp;A as a percent of sales was considerably lower in<br>the second quarter than in the first quarter. Again, numbers aren't final, but that is my expectation. That was my expectation, and<br>the preliminary results indicate that that is the case.<br>
Year over year, given some of the gross margin pressure that we've seen and given some of the revenue pressures that we had, I<br>think it's probably going to be -- SG&amp;A as a percent of sales will likely be in line with what we saw last year -- I don't think either a<br>strong move one way or the other. Again, very preliminary results, so you're not going to see a reduction, but you're also not going<br>to see an increase. So we continue to look at that line; that's one of the things we're taking a look at over the course of the next 30<br>days, to figure out what we can do there to continue the trend that we want to see.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
But it's also important to note that in that SG&amp;A is where some of our investments for simplification and investment for growth are.<br>A good example of that would be some of the outside resources that we've pulled in in order to help us work through the<br>project-planning process to make sure that as we attack the complexity and we attack the cost structure, that we do it in a way that<br>orients us towards growth and towards execution capability, as opposed to sort of meandering your way through it. So there is some<br>investment in that as well that I think is important for us to know.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
The other thing we look for on that line, too -- just to continue on that theme -- the other thing we look for on that line, and we will<br>be getting that over the next couple of weeks, is where were we spending, and was it in the front office versus the back office? Last<br>quarter, we were quite successful in getting spend moved from administrative functions into customer-facing and revenue-generating<br>and R&amp;D and innovation type spend. And I'm assuming and hoping that we will see that continued trend in the second quarter.<br>
<b>David Lewis</b><i> - Morgan Stanley - Analyst</i><br>
Okay. And Kieran, one quick question on ChloraPrep. What we've seen with this business is some periods of acceleration and<br>deceleration. Most specifically coming off the New England Journal of Medicine article, we saw an acceleration in this business and<br>a renewed sales effort. Is what we are seeing now sort of a relative level of maturation in the ChloraPrep product line, or do you think<br>this is just really more of kind of a breathing quarter for the product, if you will?<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>435</i><br>
<hr>
<A name=436></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
It's a good question, and it's one that we are obviously trying to dig in and understand at a very deep level. I think what would give<br>me confidence to say that we still have a lot of headroom in that business is that we saw very similar dynamics with the Medegen<br>business as we did with the ChloraPrep business. And both those businesses have the same core drivers, which is their conversion<br>businesses. And when you tend to convert, you convert large parts of hospital systems and then have to street fight to get it all the<br>way across and change behavior.<br>
So the fact that they had similar dynamics would lead us to believe that -- and obviously, as I said it was orthogonally checked; you're<br>out in the field and you're asking questions -- that that was the primary driver.<br>
Now obviously, whenever you get -- the more penetrated you get, it does get harder, and so there's no question about that. And<br>the percentage change is always a change over time, right, the law of big numbers. But again, I think just from what we think<br>happened this quarter, I think it was much more about converting practices across the businesses as opposed to any specific line<br>item.<br>
<b>Jim Mazzola</b><i> - CareFusion Corporation - SVP of Global Marketing, Communication &amp; Investor Relations</i><br>
Okay, thank you very much.<br>
<b>Operator</b><br>
Lennox Ketner, Bank of America Merrill Lynch.<br>
<b>Lennox Ketner</b><i> - BofA Merrill Lynch - Analyst</i><br>
Thanks. Just to follow up on the ChloraPrep line, I am just wondering -- you're saying it has become more difficult to convert accounts.<br>I'm just wondering if you're assuming that that changes going forward. In other words, is 5% growth kind of the new normal or are<br>you assuming in your guidance that improves?<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Again, good question, and I think it's too early to say near-term what we think those figures will be. And we will certainly, I think, in<br>February at the release time be able to give a little bit more detail on that.<br>
I think the conservative way that we are looking at it is to say near-term, there's probably still going to be some reticence on the part<br>of the hospitals to convert their practices at the same rate that they were converting, say, a year or two ago. That being said, that<br>doesn't mean it's going to stay that way and it's not going to change back.<br>
And from our perspective, part of what we are doing to help that along is to recognize that we have the ability to put more effective<br>resources in front of the customers. And so this adjustment I've referred to a couple of times in the sales force that we did during<br>the second quarter was really taking reps that had different products, but they had the same call points, the same customers, the<br>same territories overall. And by combining their bags and helping them manage the way that they message in front of the customer,<br>it makes their interactions with the customers more holistic. They are able to sell the full portfolio of products that are oriented in<br>our infection prevention area on one side. And on the other side, it says that they don't have to spend most of the life traveling<br>around their territory, but they can actually use it in a more practical way.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>436</i><br>
<hr>
<A name=437></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
So there's lots of things that influence. There is the behavior of the customers themselves, and then there is how we help manage<br>it. Because our job is not to accept market growth; it's to drive market growth. And we will continue to focus on that.<br>
<b>Lennox Ketner</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay, and then one more just big-picture question. I think Jim talked about you guys grew about 2% on an organic constant-currency<br>basis for the first of the year, which is actually 3% just on a constant-currency basis, so within your guidance range.<br>
But comps get tougher in the back half of the year, so I'm just wondering kind of what -- how investors can get comfort that you<br>guys can keep top-line growth within that range even in spite of difficult comps. Are there certain areas where you expect to see<br>growth accelerate? Or maybe if you can just speak a little bit to the back half of the year.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
And again, we will give a much more complete update -- and I wouldn't want to be -- like I said, there's constant currency growth<br>rates. All of that will be out in the second quarter. So until we get -- I don't want to get pinned down to any specific numbers in the<br>first half or second quarter until we have all the results in front of us.<br>
Kieran can chime in on this as well.We have set in place at the beginning of the year and continue to see faster growth in the second<br>half of the year than we will see in the first half of the year. There are a number of businesses where we would expect to see that.<br>Certainly that we initially expected that the Procedural Solutions business would grow faster in the second half of the year than the<br>first half. I think we still believe that to be the case absolutely; it's just not going to be as much as what we had originally planned.<br>
In addition, some of the businesses in Medical Systems are getting traction. In particular, I'd point to respiratory technologies and<br>ventilation, where, if you remember, we started off the year a little bit down in the first quarter. And I think we're going to see<br>continued improvement in that business through the year. That will drive some growth in the second half of the year. And some of<br>the other businesses in the Medical Systems, infusion as well, might continue to accelerate growth in the back half of the year.<br>
So there will be faster growth in the second half -- or we believe there will be faster growth in the second half of the year versus the<br>first half of the year. And again, as I said, once we get everything buttoned down, we will make sure we give you the detail on where<br>we think that's going to come from on February 2.<br>
<b>Lennox Ketner</b><i> - BofA Merrill Lynch - Analyst</i><br>
Great, thanks so much.<br>
<b>Operator</b><br>
Kristen Stewart, Deutsche Bank.<br>
<b>Jim Mazzola</b><i> - CareFusion Corporation - SVP of Global Marketing, Communication &amp; Investor Relations</i><br>
Kristen, you there?<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>437</i><br>
<hr>
<A name=438></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
We don't hear it. Maybe because we had promised to cut the call off at half past, maybe we have lost that ability. Pamela, can you<br>still hear me?<br>
<b>Operator</b><br>
I can hear you. Ms. Stewart, your line is open.<br>
<b>Kristen Stewart</b><i> - Deutsche Bank - Analyst</i><br>
Can you guys hear me okay? Great, thanks. I just wanted to double check.You guys had said you expect I guess in February to revise<br>down for the Procedural Solutions, and that was just because of the infection prevention business. Is that correct?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
It is primarily [due to] infection prevention, but there's also some pricing pressure in some of these non-differentiated businesses<br>that will probably continue through the year. So we will be making that revision -- as I mentioned earlier, we are looking at a revision<br>downward in EBIT, primarily in the Procedural Solutions business. And then we believe there's some upside below the line that we<br>will also be taking into account. So when we narrow that range, it will be somewhere between the $1.75 to $1.90, that's correct.<br>
<b>Kristen Stewart</b><i> - Deutsche Bank - Analyst</i><br>
Okay. And then just on the Medical Systems sales, you had mentioned dispensing, infusion and ventilation were all strong. Could<br>you just maybe give us a little bit more color there? It sounds like you're not seeing any changes with like hospital CapEx or anything<br>in that regard. I was a little bit surprised by ventilation also being up.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Yes, so we can't at this point go into all the details. We will certainly go until more details as we get to the release. But I will say that,<br>yes, the business segment overall is performing very well.<br>
I think we are very fortunate that the medical systems that we sell are essential to the efficient operations of hospitals. And we are<br>seeing a lot of interest from customers as they look to try to get better scale on their human capital, particularly in the nursing area,<br>where they are trying to get better control over their supply chain and particularly in pharmacy. And we help in each of those areas.<br>So we are quite fortunate. And yes, I can appreciate the question on ventilation, but the ventilation business has been performing<br>well. So that was across the segment.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
It's always -- life is easier in general when your biggest businesses -- not that there's anything easy about this -- but life in general is<br>good when your biggest businesses are performing well, and that continues to be the case in Medical Systems. So that's a good<br>thing.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>438</i><br>
<hr>
<A name=439></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Kristen Stewart</b><i> - Deutsche Bank - Analyst</i><br>
Okay. Thank you.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Pamela, we're going to enter wrapup mode here. I know people have things to do. So again, I want to thank everybody for getting<br>on the phone call on very short notice. I hope what you see here is our continued commitment to being as transparent as possible<br>with you and to bring you along this journey of improvement.<br>
We continue to have a lot of great things going on at the Company. We feel very comfortable and confident in the improvements<br>that are being made throughout the organization. As always, I would like to take the opportunity to thank the CareFusion team<br>throughout the world for their stellar efforts. And I look forward to updating you in a couple of weeks as we get on to the Q2 earnings<br>call. Thanks, everybody.<br>
<b>Operator</b><br>
Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation. You may now<br>disconnect and have a great day.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4703292-4-2012-01-09T19:12:53.023</b><br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>439</i><br>
<hr>
<A name=440></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
CFN - CAREFUSION CONFERENCE CALL<br>TO DISCUSS PRELIMINARY SECOND<br>QUARTER RESULTS<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 2:00PM GMT<br>
OVERVIEW:<br>
CFN expects 2Q12 revenue of $910-915m, adjusted operating income of $148-153m,<br>and adjusted EPS of $0.41-0.45. Co. also expects full-year 2012 EPS to be $1.75-1.90.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>440</i><br>
<hr>
<A name=441></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Jim Mazzola</b><i> CareFusion Corporation - SVP of Global Marketing, Communication &amp; Investor Relations</i><br>
<b>Kieran Gallahue</b><i> CareFusion Corporation - Chairman, CEO</i><br>
<b>Jim Hinrichs</b><i> CareFusion Corporation - CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Amit Bhalla</b><i> Citi - Analyst</i><br>
<b>Matt Taylor</b><i> Barclays Capital - Analyst</i><br>
<b>Mike Weinstein</b><i> JPMorgan - Analyst</i><br>
<b>David Roman</b><i> Goldman Sachs - Analyst</i><br>
<b>David Lewis</b><i> Morgan Stanley - Analyst</i><br>
<b>Lennox Ketner</b><i> BofA Merrill Lynch - Analyst</i><br>
<b>Kristen Stewart</b><i> Deutsche Bank - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Good day, ladies and gentlemen, and welcome to the CareFusion Corporation investor meeting. My name is Pamela and I will be your operator for<br>today. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. (Operation Instructions) As a<br>reminder, this call is being recorded for replay purposes.<br>
At this time, I would like to turn the conference over to Mr. Jim Mazzola. Please proceed.<br>
<b>Jim Mazzola</b><i> - CareFusion Corporation - SVP of Global Marketing, Communication &amp; Investor Relations</i><br>
Thank you, Pamela. This is Jim Mazzola and thanks for joining us on today's call as we discuss CareFusion's preliminary results for the second fiscal<br>quarter ended December 31, 2011 and provide updated guidance for our fiscal 2012.<br>
We issued a news release containing our preliminary financial results this morning at 8 a.m. Eastern Time, which is posted on our website at<br>CareFusion.com, and filed on form 8-K with the SEC. Joining me on today's call are Kieran Gallahue, our Chairman and CEO, and Jim Hinrichs, our<br>CFO. Before I turn the call over to Kieran, I would like to make a few remarks.<br>
In today's call, we will discuss some non-GAAP financial measures, including financial results on an adjusted basis. A reconciliation to GAAP measures<br>can be found in today's release and on the investors section of our website. We believe these adjusted financial measures can facilitate a more<br>complete analysis and greater transparency into CareFusion's ongoing results of operations, particularly in comparing underlying results from<br>period to period.<br>
Additionally during today's call we will be making some statements that are forward-looking, including statements about expected financial results<br>for the fiscal quarter and our fiscal 2012 guidance. These results are preliminary and subject to change as we complete our quarterly close and<br>reporting process. Our actual results could differ materially from those expressed in our forward-looking statements due to the risks and uncertainties,<br>including the risk factors set forth in today's release and our filings with the SEC. We ask that you refer to these materials for a more detailed<br>explanation of the inherent limitations of such forward-looking statements. With that, let me turn the call over to Kieran.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>441</i><br>
<hr>
<A name=442></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
All right. Thanks, Jim, and thanks, everyone, for joining us on this call on such short notice. We're in San Francisco today, meeting with a large<br>portion of our investors, and as such, we wanted to provide this update in order to be as transparent as possible and to make those discussions<br>today as productive as possible.<br>
While we're still in the process of closing our second quarter and will report our full results on February 2, we felt it was important to release these<br>preliminary results.<br>
Revenue for the quarter is expected to be between $910 million to $915 million, and adjusted operating income is expected to be $148 million to<br>$153 million. Adjusted EPS is expected to be $0.41 to $0.45.<br>
Our largest segment, Medical Systems, performed very well in the quarter, growing in the high single digits and continuing its positive organic<br>growth momentum. Bookings in all three Medical Systems businesses, dispensing, infusion, and in ventilation, were strong and remain in a good<br>position for the full year.<br>
Sales and gross margins in Procedural Solutions were lower than we had forecasted, which is the primary reason operating income is lower than<br>our expectations. Segment revenue declined about 5%, or about 2% after adjusting out revenue from our on-site divestiture in the prior year.<br>Procedural Solutions is comprised of four business groupings -- infection prevention, medical specialties, specialty disposables, and our diagnostics<br>businesses. Our core products in this segment continued to grow faster than the market, just slightly below our internal expectations.<br>
In addition, our margins in the segment were negatively affected by pricing pressure on our less clinically differentiated products. The net effect<br>was lighter conversion volumes for our products like ChloraPrep and MaxGuard and margin pressure on respiratory disposables and medical<br>specialties.<br>
It's important to note that we are not losing share in our clinically differentiated products.We believe growth rates will continue to be above market<br>in ChloraPrep and the Medegen. ChloraPrep grew in the mid-single digits during the quarter, for example, and we have revised our fiscal year '12<br>forecasts to reflect this trend.<br>
When we announce the full quarter, we expect to revise downward our fiscal year '12 revenue guidance for the Procedural Solutions segment and<br>the infection prevention businesses.<br>
On the positive side, we continue to see the benefits of our reorganization last year into the two business segments. It provides us and our investors<br>greater transparency into the business. We are focused on investment in our core businesses and isolating those areas where we need to take<br>action.<br>
As an example, we reorganized at the Procedural Solutions segment level during the quarter, and realigned our sales territories to decrease the<br>windshield time of our reps and increase the selling capacity. This will take a quarter or so to ramp, but we expect will drive additional growth in<br>the near term.<br>
Across the Company, we continue in Q2 to make the necessary investments we have talked about to strengthen our foundation to grow faster<br>over the long term.We must continue to invest during the balance of the fiscal year. So while we continue to have scenarios that enable us to meet<br>our original full-year EPS guidance, we felt it was prudent to lower the bottom end of the adjusted EPS range by $0.05 to a new range of $1.75 to<br>$1.90. This revision will be reflected in the Procedural Solutions segment and largely in the infection prevention business within that segment.<br>
Recall again, there are four components of infection prevention business -- ChloraPrep and Medegen, which continue to grow above market rates;<br>and our legacy skin and legacy non-dedicated infusion disposables, which are more subject to pricing pressure.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>442</i><br>
<hr>
<A name=443></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
This new EPS range reflects some upside we anticipate below the operating income line, largely due to our tax rate, which is a result of our geographic<br>business mix and our tax planning efforts. Because we are providing you with preliminary results so early in our close process, it would be premature<br>to give a tax rate for the quarter or the year. Based on where it comes in, we should be in a position to tighten the EPS guidance when we report<br>on February 2.<br>
Across both segments, the environment continues to look similar to what we discussed last quarter. Hospitals in the US continue to prioritize their<br>investments based on those products necessary to their operations. This trend has highlighted the strength of our Medical Systems products.<br>
In the Procedural Solutions segment, we continue to take share and convert markets, but as I said, at a slower rate for the reasons I described earlier.<br>Outside the US, Western Europe remains soft, but not materially different than we indicated last quarter. And recall we are still growing our<br>international presence, so the impact there is relatively minor.<br>
We have a lot of good things going on and I feel more confident than ever in the plan that we have laid out. The segment split is going well and<br>giving us greater visibility. The work we are doing to simplify the business is on track and ongoing. We are building a foundation for growth and<br>remain optimistic and committed to those plans, including our 20% plus operating margin goal exiting fiscal year 2014.<br>
We will provide a more complete update when we have the full results of February 2, so I'm going to say in advance that we won't have all the<br>detail today, but wanted to provide you with as much detail as we can at this early point in our close process.<br>
With that, I want to make sure that Jim and I have time for your questions, so, Pamela, if we can open up the Q&amp;A line, we will begin.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operation Instructions) Amit Bhalla, Citi.<br>
<b>Amit Bhalla</b><i> - Citi - Analyst</i><br>
Good morning. Two quick questions for you. First, last quarter, when you were talking about the infection prevention business, you talked about<br>the impact of procedure volumes and distributor purchasing being slightly weaker. Can you comment on that in particular? And then just secondly,<br>can you quantify the level of pricing pressure that you are seeing? Thanks.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
It's Jim Hinrichs, and Kieran can chime in here if he'd like. We are not seeing increased pressure in procedure volumes. I wouldn't say that things<br>are rebounding dramatically, but we are not pointing at that as a major driver here.<br>
And when it comes to -- the second part of your question was about pricing pressure -- about pricing pressure, we do continue to see pricing<br>pressure in specific businesses, and those are the ones that are less clinically differentiated. So when I look at our product lines in respiratory<br>disposables and legacy prep, as well as our legacy non-dedicated infusion sets, those are the areas where we are seeing pricing pressure. I think it<br>ranges from a few points into the mid single digits of pricing push back to us from our customers.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>443</i><br>
<hr>
<A name=444></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Just a chip shot on that, Amit. It's not as if we're seeing a rebound on a procedure volumes side. It's just that we wouldn't point to that as the primary<br>driver. We are seeing it across both of our conversion-oriented businesses. What we are seeing is that we're not losing market share. We still feel<br>very good from a competitive perspective, and that's the feedback that we are getting from the orthogonal checkpoints in the field.<br>
What it does seem is that in the environment that we are at, some of the conversion efforts are just taking a bit longer than they have in the past.<br>And what you do is when you are sitting across from these hospital administrators, they see the value. Sometimes what you will do is you'll get a<br>conversion of 50% of the hospital or the hospital systems, and that second part of the conversion is usually a lot of street fighting, where you are<br>in there, you are looking for different levels of the organization to support you in that conversion.<br>
Right now, they are a bit distracted, and we are not seeing that same level of support simply because they've got multiple priorities. But the good<br>news, we are not losing market share there. We are still growing above market rates, and we are steady as she goes.<br>
Also, this adjustment in the sales force is going to allow us to have greater resources being focused in front of the customers as opposed to in front<br>of the windshield. So we are taking the actions to become more efficient and more effective with our customers as well.<br>
<b>Amit Bhalla</b><i> - Citi - Analyst</i><br>
Kieran, you mentioned distributors as an issue last quarter. Was that resolved or are distributors --?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
It's Jim.That very specific -- obviously, inventory changes throughout the channel all the time in all the product lines.The specific issue we pointed<br>to last quarter did not repeat in this quarter, so that seems to have leveled itself out. That was specifically, if you remember, destocking in the<br>infection prevention businesses, which seems to have leveled off now. So we are kind of -- we feel like we are back to normal in that part of the<br>business from that perspective.<br>
<b>Amit Bhalla</b><i> - Citi - Analyst</i><br>
Okay. Thank you.<br>
<b>Operator</b><br>
Matt Taylor, Barclays.<br>
<b>Matt Taylor</b><i> - Barclays Capital - Analyst</i><br>
A couple of quick ones. One, I just wanted to understand within Procedural Solutions, I know you talked about pressure on products that were not<br>clinically differentiated. But was there any one or two areas in particular with the surgical tools or some of the disposables where the pressure was<br>kind of outside?<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Well, Jim and I will sort of tag team a little bit on this. Certain areas such as the respiratory disposables, where there is very little clinical differentiation<br>-- I mean, some segments, there's a lot, but there is other niches within that where there's not as much differentiation. That is subject much more<br>to the pricing pressures we have seen.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>444</i><br>
<hr>
<A name=445></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
We haven't really on the surgical tools side seen dramatic pricing pressure at all. In fact, we feel like we're doing -- we are not doing gangbusters<br>there, but we feel like from a competitive perspective as we looked around, we actually feel like we are doing better than competitors and feel like<br>we're gaining some share.<br>
So it is in some very targeted areas, some on the valve business. The newer stuff, like the Medegens and whatnot, very clinically differentiated.<br>Some of the existing product lines that have been in the market for a longer time, they're going to be a little bit more subject to those pressures.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
That's exactly right. Again, the three product lines we have mentioned that have pricing pressure -- respiratory disposables, legacy prep, legacy<br>non-dedicated -- all those products that are just not as clinically differentiated; therefore tougher to command a price premium.<br>
<b>Matt Taylor</b><i> - Barclays Capital - Analyst</i><br>
Okay. And you lowered the low end of the EPS guidance, but I think you mentioned at the beginning of your comments that you saw really no<br>change to your longer-term margin improvement goals. And I was just curious with this increased pressure how you are going to be able to absorb<br>or offset that and still achieve those goals.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Look, we've got a lot of things going on around the Company; there's a lot of shots on goal when it comes to building efficiencies to reducing<br>complexities to be helping us become more efficient in front of those customers.<br>
When you are going through these changes, sometimes it can get a little bit bumpy on a quarterly basis. And I think we have been pretty open<br>about that from the beginning. So when you have a little bit of changes in the mix like we have seen this time, we are feeling pretty good about<br>year-end on the top line overall. It's just about sort of the mix of getting there.<br>
And so we think that the focus that we have on simplifying the business, on continuing to gain efficiencies, on some of the improvements we are<br>making in the sales force, particularly in the Procedural Solutions side, to be able to help those reps be able to spend more time in front of the<br>customers, we think they are going to pay dividends, and we are steady as she goes on those things.We don't want to pull back on the investment<br>on those.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
Exactly.<br>
<b>Matt Taylor</b><i> - Barclays Capital - Analyst</i><br>
All right, thanks a lot, guys.<br>
<b>Operator</b><br>
Mike Weinstein, JPMorgan.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>445</i><br>
<hr>
<A name=446></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Mike Weinstein</b><i> - JPMorgan - Analyst</i><br>
Help me out here. I just wanted to understand a couple items. So If I look at the details you gave out in the release, your revenues actually are pretty<br>close to where we were at, but there's a much bigger drop-off on the EBIT line. And then when you guide to EPS, it's actually relatively close.<br>
So can you just explain that sequence there? So revenues don't appear like they are that different than we were forecasting, but there's a much<br>larger drop on the EBIT line. And then EPS, it seems like you seem to make up some of the gap. So is the expectation for the quarter and then for<br>the year that you'll make up some of the -- some of an EBIT shortfall below that line with a lower tax rate?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
Yes, a couple -- that's a great question, Mike, and this is probably worth taking a minute to go through. A couple of things going on.<br>
The first is revenue came in a little bit light.We were facing an EBIT number for the quarter, based on preliminary results, that was different enough<br>from our expectations that we thought it worthwhile saying it now, so when we are out in front of 50% or 60% of our shareholders today we could<br>have meaningful conversations. And so that was sort of the reason for the preannouncement.<br>
Revenue, as you mentioned, coming in just slightly below what the Street was expecting, also below what our expectations were. But two things<br>are really going on. One is there is a revenue shortfall, and the revenue shortfall is largely in our higher-margin products. So that's driving a larger<br>-- or a disproportionately large EBIT miss.<br>
The second thing going on is these less differentiated products, with the pricing pressure we have seen in this quarter, is also driving a margin<br>push -- driving margin pressure. So you end up with what I would describe as a disproportionate gross margin and EBIT impact on our bottom line<br>for the quarter. And that was really the reason for the release.<br>
Now, we do have some below-the-line upside in interest and other, and we believe in the tax rate, although the tax rate won't be finalized until<br>the end of this week, that will offset some of the difference, and that will carry through to the year. So when you take what we have said today and<br>translate it for the year, the way you need to look at it is to say, look, revenue probably still within the range we provided, but we are losing some<br>revenue growth in the higher-margin products.<br>
We've got gross margin pressure creating sort of what I would describe as a dime of EBIT pressure out of Procedural Solutions that we will make<br>up below the line, primarily on the tax rate, which is why we only took that tax rate -- the EPS number, the bottom of the range, down by a nickel<br>until we can get our tax forecast done, and then we will retighten up the range back to a dime. That's the goal. So did that make sense?<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Sounds like (inaudible). But let me just make one final comment on that, which is maybe a bit more qualitative.When you walk through this, I think<br>it's not unlikely that maybe 90% of the companies would not have pre-released an earnings today with regards to this.We feel that the environment<br>is out there -- clearly, there's a lot going on in the world economy and the stock markets, et cetera. We have committed that we would be as<br>transparent as we can with everybody. And even in situations where we think we can claw back quite a bit through things like our very aggressive<br>and worthwhile tax management strategies, our view is that if we got there different, we wanted to be able to talk openly and give you as much<br>visibility as we can. So that's the intention of doing this.<br>
<b>Operator</b><br>
David Roman, Goldman Sachs.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>446</i><br>
<hr>
<A name=447></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>David Roman</b><i> - Goldman Sachs - Analyst</i><br>
I had two quick questions. One is -- am I correct that FX -neutral revenue growth for the first half of the year is running between 2% and 2.5%? And<br>if that is correct, can you maybe bridge these current levels to the 3% to 5% you are guiding to for the full year?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
David, it's Jim. I don't have those constant currency revenue growth yet. But I think the first quarter was around 2%, and then this quarter, don't<br>have that adjusted out yet completely. But that's probably about right. We are expecting a pickup, obviously, in revenue in the back half of the<br>year. We'll give all of that detail as to where we expect that to take place in the earnings release.<br>
<b>David Roman</b><i> - Goldman Sachs - Analyst</i><br>
Okay. And then secondly, and maybe more broadly, if you look at the long-term operating margin targets that you have put out there and we look<br>at this quarter, can you maybe just remind us to what extent top-line performance and EBIT margin performance are connected and what flexibility<br>you have to continue to expand EBIT margins should in fact the top line remain under pressure?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
Yes, sure. Certainly the two things are connected.We believe we have different plans and different contingencies that continue to allow us to drive<br>margins, even in a lower growth environment. Certainly top line helps -- as we have been very consistent in saying all along, top-line growth<br>certainly helps our leverage story, but we are not dependent on it.<br>
What we saw this quarter was mix working against us a little bit, and we saw pricing pressure working against us a little bit. But we are now -- just<br>as Kieran mentioned earlier, we're doing some things that are making changes that we think will reignite the mix back in our favor in terms of<br>putting our sales forces together and making them more productive and filling their bags more and increasing their overall capacity.<br>
So I think there continue to be opportunities to get mix working back in our favor. We are still very committed to that long-term growth, the<br>long-term margin target. It does require top-line growth, but we have scenarios planned out under low growth and sort of medium or higher<br>growth that can still get us there, which is why we are still absolutely committed to those targets. It just requires a slightly different way of getting<br>there.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Just to add on a little bit. As you might expect, when we look at our investment philosophy within the business, we are certainly targeting those<br>areas that we think, A, have the most opportunity for expansion and growth, and B, would have a disproportionate impact on the profitability. So<br>you would expect that of us and that's certainly what we are doing.<br>
This movement to the two-segment structure, it was really critical in that process. Because by separating out the Medical Systems businesses and<br>the Procedural Solutions, you invest differently in each of those businesses and you need to manage them different. And they were subsumed in<br>these more complicated business units before that didn't allow for true execution on a differentiated investment strategy.<br>
So the benefits of that are going to be yielded over time, but the structural changes are the things that were absolutely required for us to gain the<br>visibility and be able to differentially invest in those businesses.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>447</i><br>
<hr>
<A name=448></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>David Roman</b><i> - Goldman Sachs - Analyst</i><br>
Okay, that's very helpful. Thank you very much.<br>
<b>Operator</b><br>
David Lewis, Morgan Stanley.<br>
<b>David Lewis</b><i> - Morgan Stanley - Analyst</i><br>
Good morning. Jim, I know you don't have the specifics on sort of where the leverage, both gross margin and EBIT, kind of landed for the quarter.<br>But I wonder, given that gross margin pressures would seem obvious, whether they are pricing or mix, last quarter we didn't see the type of SG&amp;A<br>leverage I think some investors were hoping for. Is it possible to share with us whether despite that gross margin pressure whether you think there<br>was evidence that you drove SG&amp;A leverage in this particular quarter as you anniversaried some of that front-end spend last quarter?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
Certainly, my expectation is and preliminary results would indicate that our SG&amp;A as a percent of sales was considerably lower in the second quarter<br>than in the first quarter. Again, numbers aren't final, but that is my expectation. That was my expectation, and the preliminary results indicate that<br>that is the case.<br>
Year over year, given some of the gross margin pressure that we've seen and given some of the revenue pressures that we had, I think it's probably<br>going to be -- SG&amp;A as a percent of sales will likely be in line with what we saw last year -- I don't think either a strong move one way or the other.<br>Again, very preliminary results, so you're not going to see a reduction, but you're also not going to see an increase. So we continue to look at that<br>line; that's one of the things we're taking a look at over the course of the next 30 days, to figure out what we can do there to continue the trend<br>that we want to see.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
But it's also important to note that in that SG&amp;A is where some of our investments for simplification and investment for growth are. A good example<br>of that would be some of the outside resources that we've pulled in in order to help us work through the project-planning process to make sure<br>that as we attack the complexity and we attack the cost structure, that we do it in a way that orients us towards growth and towards execution<br>capability, as opposed to sort of meandering your way through it. So there is some investment in that as well that I think is important for us to<br>know.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
The other thing we look for on that line, too -- just to continue on that theme -- the other thing we look for on that line, and we will be getting that<br>over the next couple of weeks, is where were we spending, and was it in the front office versus the back office? Last quarter, we were quite successful<br>in getting spend moved from administrative functions into customer-facing and revenue-generating and R&amp;D and innovation type spend. And<br>I'm assuming and hoping that we will see that continued trend in the second quarter.<br>
<b>David Lewis</b><i> - Morgan Stanley - Analyst</i><br>
Okay. And Kieran, one quick question on ChloraPrep. What we've seen with this business is some periods of acceleration and deceleration. Most<br>specifically coming off the New England Journal of Medicine article, we saw an acceleration in this business and a renewed sales effort. Is what we<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>448</i><br>
<hr>
<A name=449></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
are seeing now sort of a relative level of maturation in the ChloraPrep product line, or do you think this is just really more of kind of a breathing<br>quarter for the product, if you will?<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
It's a good question, and it's one that we are obviously trying to dig in and understand at a very deep level. I think what would give me confidence<br>to say that we still have a lot of headroom in that business is that we saw very similar dynamics with the Medegen business as we did with the<br>ChloraPrep business. And both those businesses have the same core drivers, which is their conversion businesses. And when you tend to convert,<br>you convert large parts of hospital systems and then have to street fight to get it all the way across and change behavior.<br>
So the fact that they had similar dynamics would lead us to believe that -- and obviously, as I said it was orthogonally checked; you're out in the<br>field and you're asking questions -- that that was the primary driver.<br>
Now obviously, whenever you get -- the more penetrated you get, it does get harder, and so there's no question about that. And the percentage<br>change is always a change over time, right, the law of big numbers. But again, I think just from what we think happened this quarter, I think it was<br>much more about converting practices across the businesses as opposed to any specific line item.<br>
<b>Jim Mazzola</b><i> - CareFusion Corporation - SVP of Global Marketing, Communication &amp; Investor Relations</i><br>
Okay, thank you very much.<br>
<b>Operator</b><br>
Lennox Ketner, Bank of America Merrill Lynch.<br>
<b>Lennox Ketner</b><i> - BofA Merrill Lynch - Analyst</i><br>
Thanks. Just to follow up on the ChloraPrep line, I am just wondering -- you're saying it has become more difficult to convert accounts. I'm just<br>wondering if you're assuming that that changes going forward. In other words, is 5% growth kind of the new normal or are you assuming in your<br>guidance that improves?<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Again, good question, and I think it's too early to say near-term what we think those figures will be. And we will certainly, I think, in February at the<br>release time be able to give a little bit more detail on that.<br>
I think the conservative way that we are looking at it is to say near-term, there's probably still going to be some reticence on the part of the hospitals<br>to convert their practices at the same rate that they were converting, say, a year or two ago. That being said, that doesn't mean it's going to stay<br>that way and it's not going to change back.<br>
And from our perspective, part of what we are doing to help that along is to recognize that we have the ability to put more effective resources in<br>front of the customers. And so this adjustment I've referred to a couple of times in the sales force that we did during the second quarter was really<br>taking reps that had different products, but they had the same call points, the same customers, the same territories overall. And by combining their<br>bags and helping them manage the way that they message in front of the customer, it makes their interactions with the customers more holistic.<br>They are able to sell the full portfolio of products that are oriented in our infection prevention area on one side. And on the other side, it says that<br>they don't have to spend most of the life traveling around their territory, but they can actually use it in a more practical way.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>449</i><br>
<hr>
<A name=450></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
So there's lots of things that influence. There is the behavior of the customers themselves, and then there is how we help manage it. Because our<br>job is not to accept market growth; it's to drive market growth. And we will continue to focus on that.<br>
<b>Lennox Ketner</b><i> - BofA Merrill Lynch - Analyst</i><br>
Okay, and then one more just big-picture question. I think Jim talked about you guys grew about 2% on an organic constant-currency basis for the<br>first of the year, which is actually 3% just on a constant-currency basis, so within your guidance range.<br>
But comps get tougher in the back half of the year, so I'm just wondering kind of what -- how investors can get comfort that you guys can keep<br>top-line growth within that range even in spite of difficult comps. Are there certain areas where you expect to see growth accelerate? Or maybe if<br>you can just speak a little bit to the back half of the year.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
And again, we will give a much more complete update -- and I wouldn't want to be -- like I said, there's constant currency growth rates. All of that<br>will be out in the second quarter. So until we get -- I don't want to get pinned down to any specific numbers in the first half or second quarter until<br>we have all the results in front of us.<br>
Kieran can chime in on this as well. We have set in place at the beginning of the year and continue to see faster growth in the second half of the<br>year than we will see in the first half of the year. There are a number of businesses where we would expect to see that. Certainly that we initially<br>expected that the Procedural Solutions business would grow faster in the second half of the year than the first half. I think we still believe that to<br>be the case absolutely; it's just not going to be as much as what we had originally planned.<br>
In addition, some of the businesses in Medical Systems are getting traction. In particular, I'd point to respiratory technologies and ventilation,<br>where, if you remember, we started off the year a little bit down in the first quarter. And I think we're going to see continued improvement in that<br>business through the year. That will drive some growth in the second half of the year. And some of the other businesses in the Medical Systems,<br>infusion as well, might continue to accelerate growth in the back half of the year.<br>
So there will be faster growth in the second half -- or we believe there will be faster growth in the second half of the year versus the first half of the<br>year. And again, as I said, once we get everything buttoned down, we will make sure we give you the detail on where we think that's going to come<br>from on February 2.<br>
<b>Lennox Ketner</b><i> - BofA Merrill Lynch - Analyst</i><br>
Great, thanks so much.<br>
<b>Operator</b><br>
Kristen Stewart, Deutsche Bank.<br>
<b>Jim Mazzola</b><i> - CareFusion Corporation - SVP of Global Marketing, Communication &amp; Investor Relations</i><br>
Kristen, you there?<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>450</i><br>
<hr>
<A name=451></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
We don't hear it. Maybe because we had promised to cut the call off at half past, maybe we have lost that ability. Pamela, can you still hear me?<br>
<b>Operator</b><br>
I can hear you. Ms. Stewart, your line is open.<br>
<b>Kristen Stewart</b><i> - Deutsche Bank - Analyst</i><br>
Can you guys hear me okay? Great, thanks. I just wanted to double check. You guys had said you expect I guess in February to revise down for the<br>Procedural Solutions, and that was just because of the infection prevention business. Is that correct?<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
It is primarily [due to] infection prevention, but there's also some pricing pressure in some of these non-differentiated businesses that will probably<br>continue through the year. So we will be making that revision -- as I mentioned earlier, we are looking at a revision downward in EBIT, primarily in<br>the Procedural Solutions business. And then we believe there's some upside below the line that we will also be taking into account. So when we<br>narrow that range, it will be somewhere between the $1.75 to $1.90, that's correct.<br>
<b>Kristen Stewart</b><i> - Deutsche Bank - Analyst</i><br>
Okay. And then just on the Medical Systems sales, you had mentioned dispensing, infusion and ventilation were all strong. Could you just maybe<br>give us a little bit more color there? It sounds like you're not seeing any changes with like hospital CapEx or anything in that regard. I was a little<br>bit surprised by ventilation also being up.<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Yes, so we can't at this point go into all the details.We will certainly go until more details as we get to the release. But I will say that, yes, the business<br>segment overall is performing very well.<br>
I think we are very fortunate that the medical systems that we sell are essential to the efficient operations of hospitals. And we are seeing a lot of<br>interest from customers as they look to try to get better scale on their human capital, particularly in the nursing area, where they are trying to get<br>better control over their supply chain and particularly in pharmacy. And we help in each of those areas. So we are quite fortunate. And yes, I can<br>appreciate the question on ventilation, but the ventilation business has been performing well. So that was across the segment.<br>
<b>Jim Hinrichs</b><i> - CareFusion Corporation - CFO</i><br>
It's always -- life is easier in general when your biggest businesses -- not that there's anything easy about this -- but life in general is good when<br>your biggest businesses are performing well, and that continues to be the case in Medical Systems. So that's a good thing.<br>
<b>Kristen Stewart</b><i> - Deutsche Bank - Analyst</i><br>
Okay. Thank you.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>451</i><br>
<hr>
<A name=452></a>JANUARY 09, 2012 / 2:00PM, CFN - CareFusion Conference Call to Discuss Preliminary Second Quarter Results<br>
<b>Kieran Gallahue</b><i> - CareFusion Corporation - Chairman, CEO</i><br>
Pamela, we're going to enter wrapup mode here. I know people have things to do. So again, I want to thank everybody for getting on the phone<br>call on very short notice. I hope what you see here is our continued commitment to being as transparent as possible with you and to bring you<br>along this journey of improvement.<br>
We continue to have a lot of great things going on at the Company. We feel very comfortable and confident in the improvements that are being<br>made throughout the organization. As always, I would like to take the opportunity to thank the CareFusion team throughout the world for their<br>stellar efforts. And I look forward to updating you in a couple of weeks as we get on to the Q2 earnings call. Thanks, everybody.<br>
<b>Operator</b><br>
Ladies and gentlemen, thank you for your participation in today's conference. This concludes the presentation.You may now disconnect and have<br>a great day.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4703292-2012-01-09T19:12:53.023</b><br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>452</i><br>
<hr>
<A name=453></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
MCF - CONTANGO OIL &amp; GAS COMPANY<br>AT PRITCHARD CAPITAL PARTNERS LLC<br>"ENERGIZE` CONFERENCE<br>
EVENT DATE/TIME: JANUARY 04, 2012 / 6:55PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>453</i><br>
<hr>
<A name=454></a>JANUARY 04, 2012 / 6:55PM, MCF - CONTANGO OIL &amp; GAS COMPANY at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Ken Peak</b><i> Contango Oil &amp; Gas Company - Chairman, CEO and Director</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Unidentified Participant</b><br>
Great. We're going to go ahead and get started with Ken Peak from Contango. Ken's breakout room will be in the Boardroom afterwards. And the<br>presentation will be up shortly. Ken is just going to go ahead and get started, and we'll have that up shortly. Ken?<br>
<b>Ken Peak</b><i> - Contango Oil &amp; Gas Company - Chairman, CEO and Director</i><br>
Okay, thank you. Okay, this is also being webcast, if I'm not mistaken. So it's, I guess, the people at home will have the slides -- this is a twist -- the<br>people in the room do not have the slides. But the slides are on their way. They'll be here in about maybe less than five minutes, hopefully.<br>
I think I'll try to give the same presentation so that when the slides do get here, we can go straight to it. I don't have all 20 slides memorized, but<br>I've got a couple of them sitting fresh on my memory bank.<br>
The first slide is something that I start with every time. And when I look at the value creation event in our business, is when someone takes risk<br>capital and turns the drill bit to the right, and finds reserves that didn't exist yesterday. And that has -- I believe that's true for all companies, whether<br>you're in the shale business or the shelf. And that is where we have focus.<br>
We started the Company in 1999 with an exploration focus. We continue to do that. 100% of our production and 100% of our prospects are in the<br>Gulf of Mexico with one exception, which is an investment in a shale joint venture, which I'll mention briefly later on in my talk.<br>
The other, and sort of critical part of our vision and our goals that have been since the beginning of the Company, is that commodity prices are<br>determined by the market.There's nothing that -- our Mcf's and our oil is basically indistinguishable from others. And therefore, the only long-term<br>competitive advantage in the oil and gas business -- or for that matter, any commodity business -- is to be the low-cost producer.That has certainly<br>been our focus.<br>
I will have a slide that is worth presenting, that shows us ranked against 41 other independents. And we -- our operating costs are about half of<br>the -- I'll say the industry average, although the average is really only for these 41 other independents. But these independents are companies from<br>Chesapeake and Apache, down to companies the size -- Contango is a billion-dollar market cap company. And so these are down to our size and<br>some of the companies are, I think, even smaller than Contango.<br>
And then, finally, the third bullet point on my slide is that the only rationale for buying stock in any Company is the return on capital. And therefore,<br>it's about profitability -- since return is some profit number in the enumerator, and some investment number in the denominator. You can come<br>up with different ways to measure profit and different ways to measure investment, but that's what return is.<br>
And our share count, we have stayed very focused -- what should we do -- where should we put the slides? Oh, we're going to -- okay. I guess it's<br>going -- the little CD is about to be inserted here. That's why we've stayed very focused on keeping our share count extremely low. Excuse me one<br>second, I think the slide is going to be put in. Okay, this goes sideways -- there we go. All right.<br>
Lawyer stuff; I'm going to skip that -- even though I think it's funny. This is the slide I was talking about -- I was talking about shareholder wealth<br>per share. The whole point of business is only and always increase shareholder wealth per share.<br>
Contango is low cost.You can see this is our cost for the fiscal year that ended June 30, and it's less than $3. DD&amp;A is $1.68. I talk about the differences<br>between full cost companies and successful efforts companies. Full cost, of course, you throw everything in to your full-cost pool. But because<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>454</i><br>
<hr>
<A name=455></a>JANUARY 04, 2012 / 6:55PM, MCF - CONTANGO OIL &amp; GAS COMPANY at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
you're allowed to capitalize your G&amp;A and capitalize a portion of interest, this pool can get very large. And periodically, in fact, you'll probably see<br>it with this 12/31 coming up -- since gas is $3, the people who are full-cost companies won't be surprised to see a bunch of full-cost pool writedowns.<br>
And I can tell you the press release will say that it's a non-cash charge. And my comment to that is, it wasn't non-cash when you spent it. It was real<br>money. So, this is -- when you look at DD&amp;A rates, you have to be careful, because if you take enough full-cost charges to your full-cost pool, you<br>can get your DD&amp;A down to zero. But your finding costs really weren't in.<br>
So what that forces you to do is then look to the balance sheet -- the bottom right-hand side of the balance sheet, and see who has retained<br>earnings, and see whether or not retained earnings are growing. Because you can drive your cost to zero, but your profits, your retained earnings,<br>will be a negative number.<br>
Contango is successful efforts.We benefit in the DD&amp;A calculation because when we drill a dry hole, we don't capitalize it.We expense it immediately<br>-- which, again, it gets -- all gets caught up in retained earnings on the right-hand side of the balance sheet. But at the end of the day, you have to<br>be profitable. And that's a theme of Contango's. And we have consistently been profitable since we started the Company 12 years ago, and expect<br>to continue to be profitable with gas at $3.<br>
Here's the slide I was talking to you about. This is 41 independents. The source here is ISI, which is a great group of economists and researchers.<br>They do great stuff on looking at the industry. And this is apples and apples. Everything is in there -- the total cost structure includes operating<br>costs, which is LOE, including production taxes. It's interest and it's G&amp;A, and of course, it's the DD&amp;A that we mentioned earlier.<br>
Contango is the blue. And you can just see by looking at it that Contango is about half the cost of the average. And to my knowledge, there may<br>be someone who is cheaper; but to my knowledge, there's no one that's got a lower operating cost than Contango. And my hat's off to them if<br>they do, because it's not easy.<br>
I wanted to take a look at what's going on with profit margins and how the price of liquids is driving this industry, and it's driving Contango as well.<br>Our margins are actually holding in there, as gas prices come down -- gas is that orange line and the purple line is liquids. It looks like it's coming<br>down, because the average is the last line that really [isn't any]. Of course, you'll see gas is going to -- gas for the quarter that will end December<br>31, isn't going to be $3; but it certainly has come down from the $4.<br>
And for the quarter ending March 31, gas is $3 today; we could see an average gas price of $3 and change. So that chart is fixing to really change.<br>Crude oil will probably stay the same, somewhere in that $100 range, from a, say, $90 to $110. But the margins are certainly supporting Contango's<br>-- I mean, the liquids are certainly supporting margins at Contango and I dare say everywhere else in the business.<br>
And this slide just shows the rising -- the green line is the percentage of revenues that we get from our liquids. And that's up to 50%, even though,<br>as a percentage of production, is pretty constant. Liquids are about 25% of our production, but half of our revenue. And our revenue -- our crude<br>is priced off of Brent. It's actually light Louisiana Sweet. It's a very high 48-degree gravity condensate; virtually no sulfur. And we're set offshore,<br>and we tie right into the petrochemical complex sitting right onshore Louisiana. And so we get exceptionally high prices for it.<br>
It's great to be profitable. The worst thing about being profitable is we pay a lot of income taxes. And you can see that in the year that just ended,<br>we paid $32 million. On GAAP pretax income of about [$100 million], we paid $32 million to the federal government. And I'd like not to -- the only<br>thing we can really do to shield that is to drill wells. And of course, I'm going to talk about our wells that we've got coming up.<br>
Return on capital -- incentives drive behavior. And of course, our first priority is always to protect the people who work for us, whether they're our<br>partners or contractors out on any rig. We spend an enormous amount of time, energy and effort, and worrying about making sure that things are<br>as safe as we know how to make them. Also, we never want to spill anything out on the water. And again, we spend an enormous amount of time<br>trying to make sure that never happens to us.<br>
Third priority, though, is shareholder earnings. By that, I define it as retained earnings, when -- again, go to the bottom right-hand side of the<br>balance sheet. If you're a dividend payor, you can add back your dividends, because that belongs to the shareholders. Shareholder earnings means<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>455</i><br>
<hr>
<A name=456></a>JANUARY 04, 2012 / 6:55PM, MCF - CONTANGO OIL &amp; GAS COMPANY at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
earnings -- what belongs to the shareholder. If you own a share of stock, what do you get? Well, you get the retained earnings; you get the dividends;<br>and then any share repurchases that the Company does.<br>
The invested capital is the amount of common and preferred stock that you've raised since inception. And in our case, we've raised -- it says $79<br>million, and we've had -- retained earnings of $450 million.We've bought stock back of about [$105 million] and we did have some preferred stock.<br>So there's $5.4 million of dividends in there. And that seven -- that ratio of seven -- I don't run this ratio against any other company in the business,<br>but I'll be surprised again and my hat's off to them if anybody's even close to that number.<br>
Many in our industry have very little in the way of retained earnings. It's either a small number or it's negative. And they've had massive amounts<br>of stock issuances. And of course, if you're looking for return on capital, those are bad things. You want a big numerator and a small denominator.<br>
Here is our stock and how it looks since going back to -- starting the Company. And I started in 1999. But you can see that, as we were growing the<br>Company, we did a Series A, a Series B, a C, D and E. And we actually peaked out at 17.8 million shares. And I do fully diluted, since that's the one<br>that really counts. Those are fully diluted shares. And today, we're at 15.4 million fully diluted. We're down to 45,000 options. So there's really very<br>-- and I haven't taken an option in four years, and stopped paying them to the Board two years ago, and stopped paying them to my employees<br>three years ago.<br>
Here's the owners of the Company. Great shareholder list; all very solid companies. Many of whom have been with us for a long period of time.<br>There's 23 names on that sheet. The bottom name is ourselves. So, with 22 phone calls, I could talk to 75% of the owners of the Company.<br>
As proud of what we don't have as I am of what we do have, we don't have a lot of shares; we don't have a lot of options. We don't have lots of<br>PUDs -- we're about 90% proved developed; actually very little in the way of PUDs. We don't have lots of employees; don't have lots of wells -- 12<br>wells. That's it. Not many companies only have 12 wells. But these are big, prolific wells that produce a lot of production and are all very profitable.<br>
Only two landowners -- the state of Louisiana and the federal government and the federal offshore waters. Regulators are four -- of course, the<br>BOE/BOEM, the old MMS, the Coast Guard, the EPA, and then, of course, the people of the state of Louisiana.<br>
We don't have winner's curse. We've been the sole bidder for four of our last offshore lease sales. And this is really important -- I wish I had more<br>time. But one of the most exciting things that's going on for Contango right now is that the quality of our prospects are getting better and more<br>plentiful. The reason they're getting better is there's less competition.<br>
A number of the people that we compete with have moved to the offshore.That was the trend before Macondo, that has accelerated post-Macondo,<br>with the increased regulatory issues, as well as just the price of natural gas. And thirdly, just the rewards that Wall Street is willing to pay for people<br>who invest in shale, and you can show quarter-to-quarter growth in production. Contango can't necessarily do that. We drill two to four wells a<br>year. There will be quarters when we don't drill. And, of course, any quarter when you don't drill and you don't have a discovery, production is<br>going to come down. So we're lumpy, but profitable.<br>
We don't have a lot of near-term leases expiring; we don't have many leases. We have very little invested in leases. We don't have long-term rig<br>contracts. We don't have any debt. We don't pay severance taxes in the federal offshore, and we don't hedge.<br>
Here is our budget. And when I -- the nice thing about this budget is if you go to the right-hand column and you see expected spud date under<br>the four prospect ideas, you see Q1 through Q4 of 2013. So what I'm telling you is that we have a full plate of prospect inventory -- assuming we're<br>successful with our prospects, and lease sales and getting farm-ins through 2013. So, that takes some pressure off. But we've got lots to do for the<br>next two years. And, of course, hopefully in the intervening two years, we'll come up with some more prospects. But it's nice to have a two-year<br>list of things to do.<br>
Let's talk about shale for a minute and what it's doing to America, and how it's really improved the manufacturing cost component of America.<br>America is now the low-cost country in the world. I'll say that even against China. Because of the productivity of the American worker, where about<br>nine Chinese workers are equal to about one American worker, in terms of productivity.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>456</i><br>
<hr>
<A name=457></a>JANUARY 04, 2012 / 6:55PM, MCF - CONTANGO OIL &amp; GAS COMPANY at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
We're the low-cost person by energy by a long shot -- we're paying $3 now for natural gas. And try being a steel producer and buy gas at $3; and<br>try doing it in China and compete with $12 to $18 gas that you've imported in the form of LNG. And the same thing, the same gas has the potential<br>to drive our transportation costs, to drive our power costs, as we move towards gas and away from coal, and can do wonders for us, vis-a-vis the<br>Middle East and the Venezuelans.<br>
Just a couple slides -- again, this from ISI. But you look at the employment that this industry has created, and the industrial production. You see<br>how gas is growing and is back up to 1988 levels. And that's -- that was a chart that was headed down for about 15, 17 years, and now has, thanks<br>to shale, is moving back up.<br>
This is -- I borrowed this one from my good friends at Cheniere, but it shows -- the top-line shows what production has been -- or consumption,<br>rather, and the blue lines are production. And you can see the imports are down. There's less need to import from either Canada or from LNG. And<br>production continues to grow and it's -- I see no way it's not going to grow in 2012, and for that matter, probably 2013. So I'm not very good at<br>forecasting, but if I were trying to forecast, I'd say $3 gas is probably in our future for a while to come. So get used to it and compete.<br>
This just shows how the shale gas is driving our reserves. We're now up to about 100 Tcf and these numbers will continue to grow. And I like this<br>joke -- I'm not going to tell the joke, but you can probably use your imagination -- Adam's first words to Eve, &quot;Stand back, baby; there's no telling<br>how big this thing could get.&quot; I'll let you use your imagination.<br>
This one I borrowed -- it says sourced with McKenzie, but it was really taken out of a slide that BHP did. And it's just great that, you know, a picture<br>is worth 1,000 words. And what can you say? You look at Haynesville at zero in 2008, and it's up to about 6 Bcf a day in July of 2011. The Barnett is<br>fairly flat; rising slightly from above 3 to probably just at 4.<br>
Look at the Marcellus coming on. Marcellus hasn't even really kicked in yet. As they build out the infrastructure there, the Marcellus and the Eagle<br>Ford are both going to continue to grow. Haynesville is probably going to go into decline, since it's really not economic at $3. Fayetteville will have<br>a hard time at $3 as well. And for that matter, so will the -- any play that's just dry gas is probably going to have a very hard time being economic<br>at $3 gas.<br>
So you'll see conventional gas wells decline. The racehorse or the race is whether or not they decline fast enough to offset the increase from the<br>liquids-driven gas plays in the Marcellus and the Eagle Ford.<br>
So shelf or shale, I vote for the shelf. Not everybody can or will, and there's lots of reasons why people don't want to be on the shelf. And I'm happy<br>about that. We're happy to be there, because the key skill goes back to the first slide that I showed, which was talking about the value creation<br>event is when somebody takes a drill bit and turns it to the right, and finds reserves that didn't used to exist.<br>
We have an exceptional group of really just two individuals who are very good at finding oil and gas at 15,000 feet using 3-D seismic. And the<br>economics are overwhelmingly in favor of the shelf versus shale.The problem is, is you have to have people who are able to develop viable prospects<br>that work more often than not. And we're blessed with that.<br>
Our investment thesis is fairly simple. We have about 300 Bcfe, which, if you take our debt and adjust for the debt, I think this is a fair comparison;<br>because if people have debt -- as I sit and look at a balance sheet, I'm sitting down here and with just common equity. And above me, I have P&amp;A<br>obligations, which is an obligations to the federal government; and above that, I have obligations to my creditors, the banks.<br>
So I don't care how many Mcfe you have on the left-hand side; first claim on those goes to two other entities. So I net-debt-adjust. And when you<br>do that for Contango, since we're positive cash, we assume that we bought our shares back at market at the time we'd run this calculation. But 22<br>Mcfe, when you own a piece of Contango shares, that one share -- that one little piece of paper is worth 22 Mcfe; and again, 90% of those are proved<br>developed. There's not a lot of PUDs in that.<br>
Again, I haven't run these numbers against other companies, but I'll challenge anybody to see if they have that many Mcfe's per share. And again,<br>if they can beat that, my hat's off to them.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>457</i><br>
<hr>
<A name=458></a>JANUARY 04, 2012 / 6:55PM, MCF - CONTANGO OIL &amp; GAS COMPANY at Pritchard Capital Partners LLC<br>"Energize` Conference<br>
We have $120 million in cash, which is about [$7.50] per share. No debt; 12 wells; seven prospect ideas is going to cost us about $135 million over<br>the next two years, and we are sitting with $120 million of cash. So it's only $85 million -- I say only, but it's -- when you have a partner for 40% of<br>everything you do, which we do, the federal government takes 40% of the risk with us when we drill wells.<br>
Outstanding shares -- I'm not going -- not issuing -- haven't issued options. Not a fan of options; don't want to issue any options. So, that number<br>continues to come down. If something goes crazy in Greece, and Wall Street wants to take all stocks down in a massive way for a totally unrelated<br>reason, and it looks like people want to just give us our stock, we'll take it. And eight employees.<br>
Yes. And I'm about to wrap up here -- I know I've got time. In golf, it's not how; it's how many. And this comes back to the number of shares, the<br>number of Mcfe's per share. In investing, it's not how many -- it's not how big you are on the left-hand side of the balance sheet, but how many of<br>those do I own after I've adjusted? And, again, that's -- the 22 is pretty good. I'm showing where other production is coming in to replace our Dutch<br>and Mary Rose as it depletes.<br>
And finally, there's America's Energy Company. I did that as really as a rift against the Cowboys, who I can't stand; they're calling themselves America's<br>Football Team. So, here's 8 people -- not exactly America's Energy Company, but there we were at Christmas having a good time. Thank you very<br>much.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4696531-2012-01-09T19:27:22.190</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>458</i><br>
<hr>
<A name=459></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
A - AGILENT TECHNOLOGIES INC. AT<br>JPMORGAN GLOBAL HEALTHCARE<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 4:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>459</i><br>
<hr>
<A name=460></a>JANUARY 09, 2012 / 4:30PM, A - Agilent Technologies Inc. at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Bill Sullivan</b><i> Agilent Technologies Inc. - President, CEO</i><br>
<b>Nick Roelofs</b><i> Agilent Technologies Inc. - SVP, President Life Sciences Group</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Tycho Peterson</b><i> JPMorgan Chase &amp; Co. - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Tycho Peterson</b><i> - JPMorgan Chase &amp; Co. - Analyst</i><br>
Okay, we're going to go ahead and get started. Good morning. My name is Tycho Peterson from the life science tools diagnostics team. Welcome<br>to the 30th JPMorgan healthcare conference. I know there are a few people that have been here for all of them. So it's quite a tradition.<br>
Anyway, let me introduce our next company this morning, Agilent Technologies. And here to kick it off, I'm pleased to introduce Bill Sullivan.<br>
<b>Bill Sullivan</b><i> - Agilent Technologies Inc. - President, CEO</i><br>
Thank you. It's a real pleasure for us to be here today to talk about our efforts in life science.<br>
As many of you know that we had started this transformation from moving from a diversified technology company to continue to leverage our<br>core foundation from over seven years ago, but to continue to grow in the life science space.<br>
Before I give a brief overview regarding Agilent, I do want to share with you the Safe Harbor. Essentially, we may be making future-looking statements,<br>and again, the Company has no obligation to follow up on any of the statements that Nick and I may make.<br>
If you look at Agilent Technologies, we're organized into three major business groups. And our fiscal-year 2011 that ended on October 31 was the<br>best performance in the history of the Company, the best performance since we separated from Hewlett-Packard in 1999.<br>
Our revenue at $6.6 billion was 17% organic growth rate. We are essentially an organic-growth company, other than we did make the Varian<br>acquisition over a year ago, and again, largest in our history. We continue to make smaller bolt-on acquisitions, but essentially we're a Company<br>that likes to invent things. And as a result of that, the expectation should be that we should have higher-than-industry organic growth rate, and<br>for the second year in a road that was the case.<br>
We also hit record operating profit of 20%, and as you can see we had an outstanding performance in our Electronic Measurement Group, as well<br>as our Chemical Analysis group. In a moment, Nick Roelofs will speak about Life Science, and there the operating margins are obviously lower. It's<br>the biggest investment that we're making. We're making huge investments in building a channel, building our R&amp;D portfolio, and Nick will talk<br>about that.<br>
And finally, we ended with record EPS in 2011.<br>
In terms of our outlook, this is the outlook for Q1 and for fiscal 2012 that we presented November 15, 2001 (sic - see Website), and again we will<br>be making no adjustments or comments regarding that guidance today.<br>
In terms of Agilent's ability to win, the strategy over the last two years where we've had this outstanding organic growth rate remains the same.<br>The foundation of our strategy is based on our operating model, an operating model that has resulted in very, very predictable incrementals, very<br>strong commitment to deliver 40% incrementals in our Electronic and Chemical Analysis and 30% profit incrementals in our Life Science business.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>460</i><br>
<hr>
<A name=461></a>JANUARY 09, 2012 / 4:30PM, A - Agilent Technologies Inc. at JPMorgan Global Healthcare Conference<br>
Our number-one focus continues to be in building our market reach and customer trust.We continue to aggressively move into emerging markets.<br>Essentially 80% of our business is through our direct sales force, complemented with our value-added resellers, our distribution channel, but we<br>are committed to remain number one in customer satisfaction in the life science tool space, the chemical area, as well as in electronic measurement.<br>
And of course, now, the majority of our -- or not the majority, but the plurality of our business is, in fact, in Asia. Only 28% of our business is in the<br>United States as we continue to leverage our reach into China, India, Brazil, Russia, and all the other developing countries.<br>
We also continue to be committed to be a technology leader. We spend more as a percent of revenue of any of our competitors at 10%. We have<br>over 2,600 researchers absolutely committed to have the highest performance instrumentation in the world, and continue to provide solutions<br>around our core platform instrumentations. And again, Nick will talk a lot about that in a moment.<br>
And finally, it's our scale. We have spent an enormous amount of effort to be able to scale our manufacturing, to be able to aggressively move into<br>low-cost countries when it was warranted, to ensure that on the hardware side that we would have the best gross margins in the industry.<br>
We've also done a very good job of leveraging our purchasing power, and through our corporate efforts with one IT systems, one ledger, one effort<br>to be able to maximize our real estate, we have done a very, very good job of being able to act as one Agilent even though that we are organized<br>under these three groups.<br>
And finally, our people. Again, at the end of the day, it's not people like myself that wins. All the thousands and thousands employees that work in<br>Agilent. We have a below-market turnover rate, particularly in emerging markets; a very, very driven team; a team that, in fact, we're able to attract<br>new talent to and a team that people want to spend a career in Agilent. So as a result of that, we can perceive ourselves to be in very, very good<br>position to be able to manage through the economic uncertainties ahead.<br>
One organization change that we have made recently, and that was the naming of Ron Nersesian as Executive Vice President and CEO for the<br>Company moving forward.<br>
And the reason for that was really twofold. First of all, it was to allow us to again continue to leverage the operational excellence that this Company<br>is known for. With this reorganization and with Ron taking over the day-to-day management of the Company, we're also formed a Company-wide<br>order fulfillment and supply chain position. Gooi Soon Chai, who in fact had that responsibility in our Electronic Measurement Group, now is<br>responsible for that.<br>
So for these two changes, essentially what we're going to focus on is how do we continue to accelerate the leverage that we have in the company<br>across all three of our manufacturing entities in each of her three groups, and secondly, ensuring that we can do the best we can to leverage the<br>investments that we're making in China, India, and Brazil so that we can capitalize in emerging markets moving forward.<br>
So far, this transformation -- or this organizational change and the efforts has gone very, very well, and I'm very, very excited about the energy the<br>team is putting in place to be able to drive Agilent forward after two outstanding years.<br>
And finally, in terms of the outlook, I must admit I've been in this business for a long, long time, and making an economic prediction has been quite<br>difficult. We shared with you our outlook at essentially an 8% growth rate. We had shared in the last quarter that we thought the range of that<br>would be in the 4% to 8% range.<br>
Through all of these economic uncertainties over the years, they're typical recessions related to capacity, they're financial crises that we saw in<br>2009. This one is a political problem. Political dysfunction, in my opinion in both Europe and the U.S., has resulted in an enormous amount of<br>economic uncertainty.<br>
I have been very, very open -- in fact, in March of last year at our analyst meeting in New York -- that I had thought that growth prospects in Europe<br>and the U.S. were 2% at best. Some people said that I was quite pessimistic last year. Some people said now that I'm optimistic moving forward.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>461</i><br>
<hr>
<A name=462></a>JANUARY 09, 2012 / 4:30PM, A - Agilent Technologies Inc. at JPMorgan Global Healthcare Conference<br>
Clearly, the opportunity is in emerging markets. That is where Agilent has been making its largest investment not only in sales and marketing, but<br>to support in terms of research and development.<br>
So when you look at these eight markets, it is really a mixed bag of what's going to happen. I think the companies that are going to do better in<br>this environment are the ones that are going to be able to navigate through this economic uncertainty. I'm sure that every CEO up here will tell<br>you that their company's going to do a better job of navigating that, but I believe that our four-point strategy, based on our operational discipline,<br>will allow us to continue to do as well as one can expect in this economic environment.<br>
A couple of highlights, though, in terms of the plus side. Clearly, communications continues to be an opportunity for us. I have always said that<br>the LTE rollout, G4, which right now is a U.S. phenomenon, will in fact be a secondary impact to the rollout of smartphones, 3G, into developing<br>markets.<br>
Secondly, the petrochemical market is very, very exciting for us. We are very, very well positioned, I believe, with the continued focus in not only<br>in alternate energy, but more importantly in fossil fuel-based energy that we are very well positioned to be able to provide the instrumentation<br>and continue to participate in that opportunity.<br>
Obviously, aerospace and defense industry, given the situation in the U.S., which is half the market, is in question. Fortunately, we have done very,<br>very well in aerospace and defense outside the United States and we continue to shift resources into operational surveillance.<br>
So given that it is a mixed bag, what we need to do is to make sure that we are allocating our resources to where the opportunity is.<br>
In a moment, Nick is going to talk, and I'll let him talk about the outlook for pharma and academic and research. But I will put a plug in for his team<br>and how well we've done in academic/government. We have enormous -- you can talk about what's going to happen in the National Institute of<br>Health, what's going to happen to investment. And if you go back three years ago, academic/government life science business in this Company<br>was only 3% of our revenue.<br>
As you can see on the slide, today it is 8% of the revenue. And this is an example of Agilent's ability to focus on a market, to get the right people in<br>place with the right solutions, and we can in fact dramatically grow our position in that market irregardless of the overall economic environment.<br>And this is a case where we have had outstanding performance across the Company, so for this segment of our business to be at 8% of our overall<br>business, I believe, is a real accomplishment to Nick and his team.<br>
So with that, what I'd like to do is turn it over to Nick and have him talk specifically about our life science effort.<br>
<b>Nick Roelofs</b><i> - Agilent Technologies Inc. - SVP, President Life Sciences Group</i><br>
Thanks, Bill, and good morning, everybody. Thank you for coming and attending.<br>
I'm going to take a dive into the Life Science group in Agilent, and I'll start with a little bit of a market view of the way we see this market. So we<br>see the life science market at about a $20 billion number. That represents a little bit less than 50% of the market opportunity for Agilent.<br>
And we see this market as being very stable, so the growth -- these are probably some of the lower growth numbers we've seen recently, in srt of<br>the 3% to 6% range as a market. But we see it as stable. We see a lot more clarity in academic/government now with the fiscal year starting for<br>many countries. And so, we're pretty optimistic about this market. So Agilent's Life Science Group, which is about 27% of the Company, sees this<br>as about 50% of the Company's opportunity. So there's a lot of growth upside for us as a group in taking share, et cetera.<br>
Bill mentioned academic/government; we continue to invest there. This has been a focus for the team, and we see lots of opportunity in taking<br>share.We think academic/government is about half of this market, and that funding, while it has been battered in first-world countries, is still stable,<br>and so we see that as real opportunity.We're putting resource into continue to invest in the channel, and I'll talk about the product side in a moment.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>462</i><br>
<hr>
<A name=463></a>JANUARY 09, 2012 / 4:30PM, A - Agilent Technologies Inc. at JPMorgan Global Healthcare Conference<br>
We also are doing very well on the pharmaceutical side. We see the pharmaceutical industry with a lot of cash in hand and a lot of opportunity for<br>them to invest in new technologies. And so, under the covers, there's a couple of new technology cycles. A few of them are bullet-point highlighted<br>here.<br>
One is the continuing growth in new biologic entities, and that is really a cycle that's driving investment in equipment that does protein analysis,<br>antibody analysis, et cetera. We're strong in that suit.<br>
We also see a continued acceleration of technology investment and product upgrade on the separation side of the pharmaceutical industry. And<br>so, we see that doing well for the liquid chromatography portfolio that we have.<br>
We look at that whole therapeutic pharmaceutic world as an actual world investment, so it is true that there's geographic relocation. And so if you<br>get into any specific geography, particularly in the G-8 countries, you start to see some softness, but that relocation is moving to places where<br>we're well positioned, like India, Korea, and so we think we're in very good shape from a macro market sense to attack and win and do what we<br>need to do to outgrow the market as a group within Agilent.<br>
Now to give you a feel for why we're pretty confident here, this is the Life Science portfolio of products. I don't expect all of you to try to read all<br>the detail on this slide. The takeaway message here is we have critical platform technologies across this portfolio and we're very diverse.<br>
So you see mass spectrometry in the lower left. You see liquid chromatography in the upper left. You see a bunch of sample prep, and we're very<br>focused on that. I'll come back to another comment there, and then you see the informatics in the lower right.<br>
We are deep across this entire portfolio of technologies and products, and so we think that we're positioned not only to weather any environment<br>out there, but also to continue to take share across these portfolios.<br>
One thing that I want to make a special point on, because in the next slide I'm going to point at, which is we have long been a solid player in<br>separations. We have been in the high end of detection in terms of mass spectrometry and now entering x-ray and NMR with our acquisition of<br>Varian, and so that's relatively recent.<br>
But the place that we continue to have real opportunity from a product point of view is sample prep, the opportunity to complete customer<br>workflows, and to put technologies in front of our core platforms. We are a core platform company from an instrument point of view. And that's<br>what you'll continue to see us do. We've made a lot of mileage over the past few years out of this, and it really gives us an opportunity to move the<br>market by creating greenfields that are adjacent to our core instrumentation platforms.<br>
With that, we announced in November, at the end of November, two small acquisitions. For those of you that follow us, we've been doing a lot of<br>little technology acquisitions in the Life Science Group, and this is partially -- as Bill said, we are primarily an organic growth group. We've done<br>most of our growth by actual organic R&amp;D investment. That 13% operating profit is a reflection of a significant investment by the corporation in<br>this group, and most of that investment is going into channel and into R&amp;D. But we need to add additional technologies around our core platforms<br>to make sure that we're completing those workflows.<br>
Halo Genomics is a technology company that we bought in Uppsala, Sweden.These are little tiny companies, but they have tremendous technology<br>potential.We have participated in or arguably led the expansion of a greenfield, which is genome partitioning in front of next-generation sequencing.<br>We're doing very well with a product portfolio that we have derived from our microarray technology, and now with the addition of Halo Genomics<br>we add the PCR genome-partitioning technology capabilities to our portfolio. And so from a technology point of view, we are now complete in<br>any way you might want to partition a genome in front of next-generation sequencing, and that was the reason to buy this asset.<br>
The second asset is a small technology group sitting in Madison, Wisconsin. Again, this technology is, in fact, the little plastic tip you see there.<br>Without going into a lot of detail, it is a breakthrough in the way that fluidics move around plastics and allows us to use this tip to do sample<br>preparation and separation.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>463</i><br>
<hr>
<A name=464></a>JANUARY 09, 2012 / 4:30PM, A - Agilent Technologies Inc. at JPMorgan Global Healthcare Conference<br>
Currently, the predominant use is in the area of protein. We also are moving it to separate a nucleic acid, and it fits with an automation acquisition<br>that we did about three years ago called Velocity11. So this goes right on the robot and really accelerates that workflow in front of mass spectrometry<br>and the protein, antibody, and peptides phase, and in front of next-generation sequencing as part of our solution there for genome partitioning.<br>
Next comment is sort of the one about emerging markets.What we've really seen in the Life Science Group is a tremendous transition. Let me focus<br>you on the upper right -- I'm sorry, the upper left-hand picture. For those of you that have followed us, what you have seen is you've seen that<br>green pie, which is the Asia-Pacific, expand radically.<br>
So for Agilent's Life Science Group, it is still not the dominant wedge, but it is becoming the dominant wedge very rapidly, and I'll talk a little bit<br>more in the next slide about the specific countries underneath that. But we are just seeing tremendous growth in Asia, and so that's where our<br>revenue is moving.That's where our distribution is moving.We're seeing life science tools expand there, particularly in applied senses, and so we're<br>following that trend.<br>
And so in the right-hand circle, what you see is our headcount as a group, and what we are doing as a group is we are continuing to follow the<br>customer base, as well as leverage the tremendous scale and capabilities of Agilent around the world in terms of manufacturing and supply chain,<br>and so you see our wedge of headcount, and if you follow us you'll watch that green wedge get significantly bigger over time.<br>
We've moved our automation instrumentation to Singapore. We did that in 2009. We've moved our LCMS manufacturing to Singapore in 2011.<br>We've moved the electronics from our acquisition of Varian for NMR in 2011 to Penang, Malaysia, which is actually the single largest Agilent site,<br>mostly electronics at this point, but becoming a real site for Life Science.<br>
We've got a Life Science Research Center in Bangalore, India. I will be in India tonight, actually, well, tomorrow when the plane lands, and we're<br>continuing to really push into the Indian market. And then, we're doing R&amp;D in India as well for PCR.<br>
So, those are the things that are mechanically under the covers. Over the covers, we're following our customer. We're building out channel, we're<br>putting in service, and we believe that we have been a first mover in these emerging markets. We believe we can continue to be a first mover in<br>emerging markets, and by doing that we also believe that we can be a greenfield product creator as these markets evolve their own needs and<br>own technologies. So it's something that the Life Science Group has demonstrated, and you'll continue to see significant presence moving to Asia<br>from our group.<br>
To give you -- obvious the reason why -- where's the beef on this one? China, India, Brazil. I could go into the next emerging as well, but let's stay<br>with these. China, it's been a very strong market driver for us at Agilent as a whole. It's been a very strong market driver for the Life Science Group.<br>
This is now the second-largest country for Life Science, and I think from a market point of view it's probably the second largest market for Life<br>Science at this point. It's very rapidly moving up in the market ranking for the world and is certainly moving up for us. 29% year-over-year growth,<br>and we're not small in China, so this is really great.<br>
A lot of government investment in academics, a lot of government investment in sort of protein sciences. Also, a repatriation of ex-pat PhDs into<br>China has been tremendous. Pharmaceutical growth, a lot of investment there. So we're following it. We're putting in people in the field. We have<br>a very big presence in China. We have manufacturing in Pudong. We have manufacturing in Chengdu as a Company. People in Beijing are doing<br>software. So this is an area we continue to think we're ahead.<br>
India, there's been a strong rebound. They had a soft patch in terms of pharmaceutical; that's been the biggest market there in India.<br>Academic/government is starting to come along.Their own bureaucracy and government takes a while to get spending going, but they have been<br>focused on science investment in academic/government for about five years.We're starting to see some results of that as well, so 15% year-over-year<br>growth for us. Investment in a technology center there with PhDs doing world-class applications for entire world, someplace that we're really<br>excited about.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>464</i><br>
<hr>
<A name=465></a>JANUARY 09, 2012 / 4:30PM, A - Agilent Technologies Inc. at JPMorgan Global Healthcare Conference<br>
And then Brazil, frankly Agilent did not play strongly in Brazil.When we got Varian two years ago, that gave us some real footprint in Brazil because<br>they had done reasonably well, but in the applied markets. And we're now investing quite a bit in the life science markets.<br>
Brazil itself has a big loan program in terms of pharma, near zero interest loans, and so they're putting in a lot of pharmaceutical capacity, both<br>local and generic, and they're investing a lot in academic. So, we see real opportunity for the life science market and for ourselves in Brazil in the<br>coming year and years.<br>
So, the Life Science Group strategy to win, this obviously leverages off the corporate strategy and the strengths of the corporate, but the biggest<br>number one element of the Life Science strategy is grow share. Obviously, we've taken a lot of shareholder money to invest in R&amp;D. We've taken<br>a lot of shareholder money to invest in channel development. That's why that operating profit is not where we want it to be, and we're moving<br>that operating profit up.<br>
Underneath that operating-profit movement, we are investing to drive that share growth. To be a leader in developing emerging applications, as<br>I said, we're trying to pay attention to emerging markets to see if there are niches there that we can lead, and we're certainly disseminating first-world<br>applications anywhere we can to leverage our capacity and expenses.<br>
And then, we're moving to increase our mix, so we've done a lot more to go after consumables and reagents. The acquisition that I was talking<br>about with little plastic tips, as well as Halo Genomics with the reagents, is part of that, but we're putting a lot of energy into balancing our portfolio<br>not only to capture workflow and market share in the customer base and wallet share, but also to really go after leveraging the cycles in the economy<br>so that we're balanced there.<br>
Strengthen technology base, this is what Agilent is all about, making breakthrough products. We've come in mass spectrometry from not having<br>a multisector instrument to what we believe are the leading-edge tools in triple quadripolar and certainly a significant tool in quadripolar time of<br>flight. And that's a period of five years.<br>
So we're putting a lot of money in the technology. We're going through and looking for technology restatements, whether that's a microarray<br>restating something that is microscopy in the semi-diagnostics space or whether that's a restatement of things on to better mass spectrometry or<br>better NMR platforms with metabolomics.<br>
We are leveraging across Agilent's technology capability, and so some of you have heard us talk about the fact that the Electronics Group has<br>tremendous RF and wireless and that that is going into our NMR portfolio, and we're in the process of fixing that portfolio and probably within 12<br>months of the runway of having real technology breakthrough out on the market. We also are leveraging the A to D converter technologies from<br>the electronics groups into our technology portfolio.<br>
So we think by leveraging the spend of Agilent, the $600 million-plus that Agilent spends in R&amp;D, we really can put some energy into the Life<br>Science portfolio.<br>
Finally, breadth and scale. You heard Bill talk about our structural rearrangement with a COO and a channel for supply chain and order fulfillment<br>being centralized across Agilent. I mentioned the fact that we've moved a lot of manufacturing in the LS group over to Penang, over to Singapore,<br>and that's part of leveraging the Company.<br>
So, we obviously have opportunity in gross margin.We have opportunity to use that leverage, both with new technology on the gross margin side,<br>but also with the manufacturing leverage, and that's a place that we're going rapidly with the Life Science Group to deliver to you world-class<br>operating profit, as opposed to pack-trailing operating profit.<br>
So with that, I will conclude, and we'll look forward to talking to you across the hall for the breakout session. Thank you very much for your time.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>465</i><br>
<hr>
<A name=466></a>JANUARY 09, 2012 / 4:30PM, A - Agilent Technologies Inc. at JPMorgan Global Healthcare Conference<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4693895-2012-01-09T19:46:12.480</b><br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>466</i><br>
<hr>
<A name=467></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
CELG - CELGENE CORP. AT JPMORGAN<br>GLOBAL HEALTHCARE CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 4:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>467</i><br>
<hr>
<A name=468></a>JANUARY 09, 2012 / 4:00PM, CELG - Celgene Corp. at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Bob Hugin</b><i> Celgene Corporation - President &amp; CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Geoff Meacham</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Geoff Meacham</b><i> - JPMorgan - Analyst</i><br>
Good morning, everybody. Welcome to the 30th Annual JPMorgan Healthcare Conference. I am Geoff Meacham; I am the senior biotech analyst<br>here at JPMorgan. And today is the first day of what is set to be four very busy days.<br>
It's a tradition that Celgene is one of -- is the first presenter at the conference. Celgene is one of the global leaders in hematology and oncology<br>led by lead value-driver REVLIMID. Speaking on behalf of Celgene today is its CEO, Bob Hugin, and also on stage is CFO Jackie Fouse. Bob?<br>
<b>Bob Hugin</b><i> - Celgene Corporation - President &amp; CEO</i><br>
Thank you very much, Geoff. Thank you very much and thank you JPMorgan for including Celgene at this important conference. Hopefully, today<br>we will give you a great update on the very important results, very promising results of 2011.<br>
And also discuss those results and those achievements of 2011 and how they position us to capitalize on the multiple, multiple transformation<br>inflection points that 2012 provides. I am very honored to be here today representing all the men and women of Celgene that are so committed<br>to making a difference in accomplishing and advancing our mission and our vision.<br>
The presentation today does include forward-looking statements which actual results may or may not be as we discuss here today.<br>
Celgene is a company that has been transformed a number of times in many positive ways, but our mission and our vision is our constant. We are<br>committed to building the leading preeminent, global, fully-integrated biopharmaceutical company; drug discovery, development, and<br>commercialization manufacturing globally. And we are focused on discovering and developing innovative therapies in the areas of cancer and<br>immune-inflammatory diseases.<br>
This is a very important mission. It's one that unifies us as part of the Celgene team, and it takes committed, dedicated, and passionate people to<br>produce the outstanding results that we have been able to produce year after year after year.<br>
It is also, to us, the ultimate shareholder value creation proposition. The discovery of proprietary novel compounds in your own laboratories,<br>developing them through your clinical operations around the world, and ultimately commercializing, retaining the full economic value for the<br>Company and your shareholders, is in our view the ultimate shareholder value creation proposition.<br>
And it's also an incredibly important, valuable business proposition in the world we are in today. It's extremely hard for me to believe that a company<br>like Celgene or any company can extract a fair return for the risks that it takes and the investments that we make without making a meaningful<br>difference in the lives of patients in breakthrough therapies. So it's an important business proposition for us all.<br>
We have made and are continuing to make tremendous progress in building this market-leading company. We are beginning to see the promise<br>of a decade of very focused, intensive R&amp;D investments, but also we are beginning to see the incredible benefits of the risk decision we made. The<br>investment we made to make Celgene a global company, to transform from a US-based company to one that today operates in more than 50<br>countries with our drugs sold in more than 70 countries.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>468</i><br>
<hr>
<A name=469></a>JANUARY 09, 2012 / 4:00PM, CELG - Celgene Corp. at JPMorgan Global Healthcare Conference<br>
And the type virtuous cycle of focusing on operational excellence and producing near-term results, which gives us the financial capacity to invest<br>in the future. Also, to take advantage of dislocations in the marketplace if needed in a strategic way, as we did in this past year when we saw market<br>dislocations leading to changes in our stock price that justified us repurchasing more than $2 billion of our shares.<br>
So we have made great progress in building our company and it's really based around four pillars and strategic imperatives that we are focused<br>on every day in advancing Celgene. In 2011 we made tremendous progress on all of these strategic initiatives; operational excellence and all we<br>do is something we are focused on every day. If you look at -- whether it's 34% year-over-year revenue growth or 36% year-over-year earnings per<br>share growth, we are focused on near-term execution and excellence in what we do.<br>
But throughout 2011 we made tremendous advances both strengthening and broadening our franchises in myeloma, in different lymphomas,<br>and certainly expanding in solid tumor oncology and strengthening our immune inflammatory franchises. There is a tangible feeling of increased<br>productivity in our research area where we are taking transforming technologies, translational medicine and we are accelerating timelines from<br>drug candidates into human testing and from Phase I to proof-of-concept. Accelerating timelines; maximizing our potential.<br>
And 2011 was a year of great success in doing that. It was a year of great operating momentum across all geographies in our company and all<br>functions of our company. We produce, again, strong earnings growth, strong revenue growth, and strong clinical research development results<br>and regulatory milestones in the context of the face of very, very challenging markets.<br>
We produced the near-term financial results. But most importantly, we continued the investment in the future, both with our near-stage pipeline,<br>our medium-term, and our early-stage, very promising research efforts.<br>
A company is only as strong as the quality and depth of its pipeline. We are very excited about the deep and diversified pipeline that we have at<br>Celgene and we made tremendous progress in 2011 advancing this deep and diversified, highly promising pipeline.<br>
In the hematology area we definitely advanced new indications for REVLIMID, which will continue to be an important growth driver for us for the<br>years to come.We also accelerated very clearly the potential of Pomalidomide and I am going to talk about that specifically in a couple of minutes.<br>And we broadened the global potential of ISTODAX in 2011.<br>
On the oncology front we also made important advances in the pipeline. We advanced three new chemical entities into clinical development in<br>2011 alone.We filed ABRAXANE in non-small cell lung cancer. And we have built a clinical program and we are beginning to execute on a broad-based<br>clinical program to maximize the full potential of ABRAXANE.<br>
2011 was an exceptional year in advancing our immune inflammatory franchise. We have brought Apremilast to the point of decision. 2012 will<br>be a major inflection point for us as we have now fully accrued our pivotal trials in psoriasis and psoriatic arthritis. We have identified two new<br>potential indications in 2011 for future development to expand the potential usefulness of Apremilast. And we advanced five other<br>immune-inflammatory programs in the clinic.<br>
And the promise of our pipeline is exciting because it is significantly a near-term and broad-based potential pipeline. It has multiple indications,<br>multiple products across all high potential areas of unmet medical need from cancer to immune-inflammatory diseases.<br>
It is a late-stage pipeline that gives us the opportunity and the responsibility to translate this data, when positive, into regulatory approvals around<br>the world.To leverage the investments that we have made to ensure that we will make the access of our novel compounds and products available<br>to patients all across the world. And we expect to see an increasing potential of regulatory approvals over 2012, 2013, 2014, and 2015 which will<br>clearly broaden the market access of our products to patients around the world.<br>
And that near-term potential is incredibly important to us and we are focused on the here and now, but we have been a company that has been<br>committed to research and changing the practice of medicine in areas where we believe we have innovative therapies. And that is a fundamental<br>concept of the value of Celgene and we remain as committed to that concept today as we ever have.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>469</i><br>
<hr>
<A name=470></a>JANUARY 09, 2012 / 4:00PM, CELG - Celgene Corp. at JPMorgan Global Healthcare Conference<br>
We are making great progress in advancing our early-stage research and pipeline efforts. As I already mentioned, three new chemical entities in<br>one year and accelerating research productivity to increasing new chemical entities into the clinic every single year. We are focused on where we<br>have competitive advantage and where we have the knowledge to exploit the opportunity to produce a meaningful impact on patients with<br>innovative therapies, but we can't do everything ourselves.<br>
Our challenge is to, again, be defocused where we have competitive advantage and leverage the great expertise of many partners outside -- in<br>academia, in government, and obviously in other companies that have great people like Celgene does. We are just beginning to see the benefit<br>and the impact on our pipeline for the numerous strategic collaborations that we have with many high potential, promising companies with strong<br>people, with strong intellectual property, and great compounds.<br>
Overall, 2011 was a spectacular year for us with many challenges and we weathered the storms that we had to deal with, and I will mention a couple<br>of them in a few minutes, and we maximized the opportunities. Strong revenue growth, stronger earnings per share growth, and an acceleration<br>of the near, medium, and long-term pipeline of our company. And we are a stronger company today than we have ever been.<br>
I think the promise of 2012 is extremely, extremely bright. I can't imagine or remember a year that presents the multiple, the number, the opportunity<br>of potential transformational milestones, inflection points. Never in the history of our company.The only thing that rivals it is maybe the year before<br>REVLIMID is approved.<br>
But we have multiple transformational inflection points coming in 2012 and we are obviously optimistic that a number of them are going to produce<br>highly significantly, successful, positive data. I categorize them in these five areas.<br>
Clearly, REVLIMID continues to be an important driver for us. Accelerating Pomalidomide to the marketplace is an important driver for us in 2012.<br>Validating and strengthening the ABRAXANE franchise is critical to us this coming year or this year. And Apremilast is now at the inflection point.<br>
We have accrued the trials, the data is coming this year, and we have multiple mid-stage programs that have the potential to produce proof-of-concept<br>data throughout the course of 2012. So let me quickly go through each of these in just a minute or two to give you a sense of what we are focused<br>on to capitalize on this tremendous opportunity of 2012.<br>
We have made tremendous investments in REVLIMID, both in the research area, in the clinic area, in medical affairs, and the commercial globally.<br>It is our job in 2012 that we continue to maximize the potential of those investments, the existing data, and the existing regulatory approvals that<br>we have.<br>
And we are committed to continue to maximize the value of REVLIMID globally. You can see some of the regulatory milestones, the market access<br>milestones, the reimbursement and commercial milestones that we have for REVLIMID. It will be an important driver for us in 2012.<br>
But it's not just the existing franchise in REVLIMID that we are committed to maximizing. We have tremendous intellectual property. We have<br>intellectual property that we feel so strongly about in the United States that 2027 we know more about the mechanistic activity at the molecular<br>level of REVLIMID than we have ever known. We are much better able to target where it should go, in what combinations, and we are committed<br>to broadening and maximizing the full potential of REVLIMID in a wide range of indications.<br>
I think the excitement at ASH in just B-cell malignancies in combination with rituximab is instructive of the potential in numerous indications and<br>we are getting clarity on the timing that we can get the final, pivotal data available and actually make this product and those indications available<br>to patients around the world.<br>
Let me go to Pomalidomide, because I think 2012 has the potential to be a tremendous defining year for this next blockbuster for us. At ASH in the<br>oral session we saw updated, more mature data for Pomalidomide and dexamethasone.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>470</i><br>
<hr>
<A name=471></a>JANUARY 09, 2012 / 4:00PM, CELG - Celgene Corp. at JPMorgan Global Healthcare Conference<br>
34% overall response rate in heavily, heavily pre-treated, relapse/refractory patients. Patients who have progressed through REVLIMID, who have<br>progressed through thalidomide, and have progressed through bortezomib. 34% response rate; nearly eight-month duration of response and a<br>median overall survival of almost 17 months in a population that does not have very bright prospects at all.<br>
So very encouraging data. At ASH we also gave an update to everyone that said we had a breakthrough in the possibility of accelerating the<br>regulatory filing strategy for Pomalidomide in Europe. That we had committed in December to say we believe we have the opportunity to submit<br>the Pomalidomide application in Europe before the end of the first half of 2012.<br>
An important multiple -- a year to two- to three-year acceleration of the potential availability of Pomalidomide to patients in Europe. Since ASH I<br>am here to tell you today that we received fast track designation from the FDA for Pomalidomide, in the United States obviously, and it is our clear<br>target announcing today it is our intention to complete the submission of Pomalidomide in the United States before the end of the first quarter<br>of this year.<br>
And we will continue to invest in other indications in myelofibrosis. It is a compound that has important benefit to patients and we are working<br>hard to accelerate its availability to patients all around the world.<br>
When we can make Pomalidomide available to patients it really strengthens and extends our myeloma franchise. We have outstanding data from<br>REVLIMID and thalidomide, from smoldering myeloma where patients are not symptomatic but high risk for disease; exciting data there. All the<br>way through newly diagnosed stem cell transplant maintenance therapy, second line, third line. Pomalidomide addresses a very serious unmet<br>medical need and it's incredibly complementary to our myeloma franchise.<br>
It is an important product for patients and one that has tremendous strategic impact on Celgene, and 2012 is an incredibly transformative year for<br>our development of Pomalidomide.<br>
We introduced ABRAXANE to you last year as part of the Celgene portfolio and we made great progress in 2011. We integrated our commercial<br>organizations and produced growth for ABRAXANE. We submitted, as I mentioned, the non-small cell lung cancer application for ABRAXANE.<br>
We finished the accrual, importantly, of the Phase III melanoma study that we have the potential to see data the middle of this year. And we<br>accelerated the accrual of the pancreatic trial that we expect to complete accrual this quarter. And we have really, in our mind, built an extensive,<br>thoughtful, effective clinical plan for ABRAXANE and we have begun to execute on that clinical plan.<br>
We have showed increased progress at about a 15% year-over-year growth in the approved indications, filed in non-small cell lung cancer, and<br>accelerating the clinical development. And it is our obligation and our opportunity to maximize the full potential of this brand.<br>
I mentioned earlier that 2012 is the year of answers for Apremilast. This is a compound that was discovered in the Celgene laboratories and has<br>been developed exclusively through the Celgene organization, and we own 100% of the economic value of this property.<br>
There is tremendous discussion in the marketplace and among all people here at the conference about the need and the opportunity for a safe<br>and effective oral anti-inflammatory compound in advance of biologics. We believe Apremilast can be that solution to that tremendous market<br>need and that tremendous opportunity.<br>
But it's not a question of waiting a long time. 2012 is the year of answers. We have fully accrued psoriasis, we have fully accrued psoriatic arthritis,<br>and we have identified new opportunities in rheumatoid arthritis and ankylosing spondylitis for Apremilast. And 2012 is important.<br>
On a regulatory point of view we have targeted three indications initially, three large indications with significant unmet medical need. Psoriasis,<br>where there is a global need for better, more effective oral therapies, and so far Apremilast has demonstrated a very encouraging side effect profile.<br>And we look to see the data in the second half of 2012 as the potential in this indication.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>471</i><br>
<hr>
<A name=472></a>JANUARY 09, 2012 / 4:00PM, CELG - Celgene Corp. at JPMorgan Global Healthcare Conference<br>
Likely, our first filing, if the data is positive, will be in psoriatic arthritis. What is really exciting here is early on we see indications of not just signs<br>and symptoms, but also potential structural benefit through this compound.<br>
One thing I want you to note is that we have seen a very favorable safety profile with Apremilast. The Phase III trials have both 20 milligram BID<br>and 30 milligram BID. The Phase II trial it was only 20 milligram BID.<br>
If we are able to maintain the same safety profile at 30 milligrams BID and we see the same type of dose response in 20 to 30 milligrams that we<br>saw in psoriasis, which was a 40% increase in activity from 20 to 30 milligram with virtually no difference in safety profile, that will be incredibly<br>compelling in psoriatic arthritis. We will see the data in the middle of this year and it is likely to be, if we are successful, our first submission.<br>
At the American College of Rheumatology in November the first data from Apremilast in ankylosing spondylitis was done, and it wasn't just signs<br>and symptoms.There isn't an oral therapy that really is meaningful to treat not just signs and symptoms but actually structural damage of ankylosing<br>spondylitis. We believe that Apremilast has the potential to answer that question and be that product.<br>
We are beginning the Phase III trial for Apremilast in ankylosing spondylitis this quarter.<br>
We, unfortunately, don't have the time to spend much on the mid-stage program, but we are incredibly excited about the potential that we have.<br>It's a deep and diverse mid-stage pipeline. Some of you are very familiar with it -- ACE-011, ACE-56 (sic) from Acceleron; PDA001, our proprietary<br>placental stem cell product that we have the potential for proof-of-concept controlled in 2012. I am very optimistic that we will advance these<br>programs in 2012 and they will be center stage next year at this conference.<br>
So overall, 2012 is a year of tremendous milestones, very many important ones. Regulatory approvals, multiple pivotal data presentations, and<br>many, many major regulatory submissions. A year of multiple transformational inflection points for Celgene.<br>
Now let me turn in our closing minutes here to a little bit of a review of the financial results of 2011 and our outlook on 2012.<br>
2011 was an outstanding year, financially and operationally. I was here last year and told you about the challenging European economic environment,<br>the first full year of healthcare reform implementation in the United States, and the dreaded second primary malignancies that we had to deal<br>with. In spite of those challenges incredible, strong revenue growth exceeding our expectations of the year ago, certainly significantly exceeding<br>them, and increasing our bottom line even more significantly as we have demonstrated the leverage of the Celgene model.<br>
I also want to point out in the fourth quarter we saw some very encouraging signs that give us promise as we look to 2012.We saw higher sequential<br>quarter-over-quarter growth for REVLIMID in the fourth quarter over the third quarter, of what we saw in the third quarter of sequential growth<br>over the second quarter. So promising sequential growth for increasing sequential growth for REVLIMID in the fourth quarter.<br>
And on the bottom line front we had strong bottom-line results. In fact, those results had to absorb $20 million, $25 million of unanticipated<br>expenses related to stopping the prostate trial and quality issues that we, along with other companies, had from contract manufacturers. We<br>overcame them, absorbed those costs, and still produced outstanding bottom-line results. So 2011 an outstanding year for Celgene.<br>
We think 2012 is also promise, not just of inflection points for the future, but execution of the near and now results. Strong revenue growth; $5.5<br>billion in total revenue we are targeting, targeting REVLIMID at $3.8 billion; and an earnings per share growth to $4.75 is the middle of the range<br>accentuating the leverage that we have in our system and the growth profile in our products.<br>
The performance that we have had over the last couple of years gives us great comfort that we are on track to not just meet the very ambitious<br>longer-term financial targets we set at this meeting a year ago of $8 billion in revenue in 2015 and $8 of earnings per share, but we are on track to<br>exceed that. And we think it's more relevant to target for revenue in 2015 to be $8 billion to $9 billion and the earnings per share target to be $8<br>to $9 per share in 2015.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>472</i><br>
<hr>
<A name=473></a>JANUARY 09, 2012 / 4:00PM, CELG - Celgene Corp. at JPMorgan Global Healthcare Conference<br>
So as I close here today I want to leave you with a message that the state of Celgene has never been stronger. From an internal quality of our people,<br>the commitment dedicated and the expertise that they bring to the opportunities that we pursue; the opportunity for our products and what we<br>do the state of Celgene has never been stronger and the prospects of the future have never been brighter for us.<br>
We remain committed and true to our mission and our vision of discovering, developing, and commercializing breakthrough, innovative therapies<br>that are designed to make a meaningful difference in the lives of patients who are so tremendously underserved today. And we are true to that<br>commitment.<br>
Want to wish you all a happy and successful 2012.Thank you for your interest and very much look forward to updating you throughout the course<br>of the year on our exciting 2012 results.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4695514-2012-01-09T19:56:53.553</b><br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>473</i><br>
<hr>
<A name=474></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
ADES - ADA ES INC AT PRITCHARD<br>CAPITAL PARTNERS LLC "ENERGIZE`<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 12:35AM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>474</i><br>
<hr>
<A name=475></a>JANUARY 05, 2012 / 12:35AM, ADES - ADA ES INC at Pritchard Capital Partners LLC "Energize` Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Michael Durham</b><i> ADA-ES, Inc. - President &amp; CEO</i><br>
<b>Mark McKinnies</b><i> ADA-ES, Inc. - SVP &amp; CFO</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Unidentified Participant</b><br>
Since we are kind of coming toward the end of the program, we want to get Michael Durham here to tell us about ADA. And we look forward to<br>your remarks and learning a little bit more about your company. And with that, I will turn it over to you. Thank you very much, Mike.<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
Thank you. Thanks. Well, those of you who aren't familiar with us, we're a clean coal technology company. We provide emission control equipment<br>for the coal-fired power industry.<br>
As far as investment highlights, we've just completed a pretty remarkable year for us and are pretty excited about 2012 and what it's going to mean<br>for the company.We expect very rapid expansion of our refined coal business.This is a business in which we had two facilities, refined coal facilities,<br>up and running for over 1.5 years now. And then in the first year of operation, it generated over $20 million of revenue for us and $7 million of EBIT<br>for ADA.<br>
Last year, we placed in service 26 new refined coal facilities that will be coming up and operating in 2012. We expect these to generate pretax<br>income of up to $50 million by the end of 2012 for the next 10 years.<br>
In December, EPA passed the Mercury Air Toxics Standard. This requires 1200 power plants to control mercury for the first time. The EPA predicts<br>that this will create a market of about $9 million per year for emission control technology.<br>
ADA is the market leader in mercury control technology, and we have three different technologies for controlling mercury. We provide activated<br>carbon injection equipment. We provide refined coal. And we also -- we provide enhanced coal that we license to Arch Coal. Keep in mind as we<br>talk about the earnings potential of these we have 10 million shares.<br>
So the type of emission control equipment that we provide is low-cost CapEx relative to the large scrubber-type projects, which are very high<br>CapEx.<br>
If you look at the fleet of coal-fired power plants, we have about 1200 of them across the country, and the average age is over 50 years old.<br>
So, as these old power plants have to address these new emission controls, something that has a very high capital cost may not be justified because<br>they may not have a 20-year life on which to pay for that equipment.<br>
What ADA provides are lower capital costs in which we essentially -- most of the cost is in the cost of a chemical, so it provides an operating cost<br>instead of a capital cost. For example, a scrubber might cost a plant $200 million to $300 million, whereas we provide for mercury control, activated<br>carbon injection equipment, that's about $1 million.<br>
We provide dry sorbent injection equipment for acid gases.That's about $3 million; and our refined coal, which actually gives them mercury control<br>for free, and they actually profit somewhat from the tax credit.<br>
Enhanced coal requires no capital equipment for the plant, but they will be paying for it in a premium for the fuel costs.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>475</i><br>
<hr>
<A name=476></a>JANUARY 05, 2012 / 12:35AM, ADES - ADA ES INC at Pritchard Capital Partners LLC "Energize` Conference<br>
So, to give you an idea of a picture of what this means, this is a new coal-fired power plant. And what you see is that over half of that plant is the<br>downstream emission control equipment needed to control SOx, NOx, and particulates. So here you're seeing the scrubbers, the SCRs, bag houses<br>to capture that. And this could be $200 million to $300 million worth of equipment.<br>
Not all plants have this equipment. So, when an old plant gets a new regulation that might have to control sulfur, adding a large piece of equipment<br>like a scrubber will be an extensive burden.<br>
The kind of equipment ADA provides is shown here in the activated carbon injection system, a small silo system which blows activated carbon into<br>the gas stream, captures the mercury in this equipment. So, essentially with a $1 million additional piece of equipment to this, it allows mercury<br>to be captured at a 90% level in the rest of the equipment. So, our dry sorbent injection equipment is relatively the same scale.<br>
I'd also like to use this picture to talk about our refined coal. This plant does not have a refined coal facility, but if it did, it would be located in that<br>lower left-hand corner. That's every power plant, you see this same kind of situation. You got a coal pile out there. You've got an incline belt that<br>carries that coal up to the boiler.<br>
When we install our refined coal facility, it is located down near the ground where we treat that coal on the coal belt as it's carrying it up to the<br>boiler.<br>
So I'll talk about three different segments of our business. Our refined coal business, this is -- we have two different technologies that control<br>mercury and NOx and, thus, qualify for Section 45 tax credit. This is sold through a joint venture, of which we are a 42.5% owner with NexGen and<br>Goldman Sachs.<br>
I'll talk about the two existing facilities that we've got 1.5 years of operation on and 26 new systems that we expect to begin operating this year<br>that could be generating $50 million of EBIT for us over the next 10 years.<br>
Under the emission control systems, I'll talk primarily about equipment. So this includes our activated carbon injection equipment. These are<br>systems that we sell for about $1 million. In states where mercury has been regulated we have -- we are the market leader in that. We have about<br>a 35% market share in this. And with this new regulation that was just passed a couple weeks ago, we expect it to create about a $500 million to<br>$600 million market for these activated carbon injection systems.<br>
We also sell the dry sorbent injection equipment, and these are for acid gases because this new mercury rule, it's not just mercury. It's mercury and<br>air toxins. So some of the things that will have to be reduced are some of the acid gases like hydrochloric acid and sulfuric acid. And so the dry<br>sorbent injection equipments help control those. And EPA expects that this will be also about a $600 million market for the DSI equipment.<br>
On the technology side, we have our technology in which we can treat coal at the mine so that when that coal is burned it burns with reduced<br>mercury.We have licensed this to Arch Coal, so this will be a royalty-based business for us. And we are also developing new technologies for future<br>emissions control in the form of carbon dioxide capture.<br>
So, let me talk about the joint venture, Clean Coal Solutions, that provides our refined coal technology. This is a joint venture, originally a 50-50<br>joint venture with NexGen Resources. Last May we sold a 15% interest in CCS to Goldman Sachs for about $60 million.<br>
CCS markets two different refined coal technologies that qualify for a $6.33 per ton tax credit for refined coal.This lasts for the next 10 years; doesn't<br>take any action by Congress -- take to -- year by year to extend it. So, it's already out for 10 years.<br>
We use third-party monetizes to turn this from a tax credit into a revenue for the company. While I've got this out here, here, you can see the<br>relatively simple equipment we have for -- that feed the chemicals, what you see, the brown facility that's going up at a diagonal. That's the coal<br>belt. Our equipment there is in the gray, and that's adding the chemicals onto the coal belt that create the refined coal.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>476</i><br>
<hr>
<A name=477></a>JANUARY 05, 2012 / 12:35AM, ADES - ADA ES INC at Pritchard Capital Partners LLC "Energize` Conference<br>
So, let me talk about the financial structure on how this works. Right in the middle here, you see CCS LLC; that's the joint venture. Above that, you<br>see the ownership structure of that joint venture. NexGen and ADA owning 42.5% and Goldman Sachs owing 15%.<br>
CCS -- we have these placed-in-service facilities. We locate them at a plant. And then what we do is we lease that equipment to a tax financing<br>partner. When we lease that equipment to them, they become the taxpayer. And then for every ton of coal that they produce, they qualify for a<br>$6.33 tax credit.<br>
So, what they do with that tax credit, we have an agreement in which we are on about a par basis. They pay us as a revenue. Part of that goes to<br>the utility plant operator. So there's a number of agreements that the tax equity partner has to have with the utility plant because what he's doing,<br>he's buying coal from that pile, treating it on the belt and then reselling it back to them. That's the process of producing refined coal. So there's<br>contracts for buying and selling of the coal. And so in addition to the plant getting the free mercury control, they are also getting about $1.00 a<br>ton out of the tax credit. So, of the $6.00 a ton that's generated out of that, $1.00 goes to the power plant.<br>
You see the lines going up to see CCSS; that's the operating entity that will actually provide the chemicals and the people to run that plant. And<br>that costs about $2.00 a ton. So what that leaves is payments that are made back to CCS of about $3.00 a ton. So, that's how we generate our<br>revenues.<br>
ADA consolidates all the financials of Clean Coal Solutions, so we will show all of that $3.00 a ton on a consolidated basis and then we distribute<br>the payments to our minority partners.<br>
So as I mentioned, we've been operating two systems for about 1.5 years. They're producing a little over 6 million tons a year, so at $6.33, at that<br>about $3.00 a ton you see, that generated about $20 million in revenue for us. Once we paid out our minority partners, that leaves about $7 million<br>or $8 million a year. And we expect that to continue for the next 10 years.<br>
So let me talk about the refined coal business in two stages. The original deadline for refined coal, as amended in the 2008 TARP bill, was this<br>equipment had to be placed in service by the end of 2009. We built and installed two systems that met that deadline by the end of 2009 and then<br>takes about six months to get that equipment -- all the contracts in place, the permitting for those to start operating. And so these two systems<br>started operating about six months later, in June of 2010.<br>
And from those two systems, what we received, we received $9 million in prepaid rent, the day these start up, permanently operating. And, again,<br>they've been generating about $20 million in revenue a year for us. And, before the dilution -- or the Goldman Sachs transaction, we received about<br>$9 million in operating income. So, after the Goldman Sachs, we're expecting that to be about $7 million for us through the next 10 years.<br>
Well, at the end of last -- of 2010, an American Jobs Act that extended the Bush tax credits, Congress gave us one more year to put in additional<br>refined coal systems. So, during this past year, we installed and operated or met the placed-in-service requirements for 26 new refined coal facilities.<br>These new facilities will begin operation once we go through the process and we get the operating permits in place from the state; we get the<br>contracts negotiated between the monetizers and the power company; and in many cases, these contracts will have to be approved by the PUC.<br>
So the guidance we are providing on what these are going to do by the end of the year, we believe that we'll have sufficient units in place that<br>they will have generated about $70 million in prepaid rent for the joint venture and will have created -- be at a level that they are creating about<br>$100 million in revenue per year for ADA through 2021. And that will produce, once we pay out to our minority partners, $50 million per year in<br>EBIT for the next 21 years. So, pretty significant impact on our financials. And again, this is over 10 million shares.<br>
Well, let me move on to the emission control systems. Again, this is primarily the hardware. What you see on this slide is that the initial mercury<br>market came from individual states that passed rules. And so as part of that, we began selling into that from 2004 through 2010.We are the market<br>leader. We got a 35% market share of that competing with about 10 other companies. We got 55 systems in, as you can see on the map here.<br>
Well, with the new rule, we expect that this -- to create a much larger market that we've had. You see here on the graph, the bar charts; the red<br>bars represent the 180 systems that were sold as part of the state rules over that five-year period.The blue is what we expect to be generated from<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>477</i><br>
<hr>
<A name=478></a>JANUARY 05, 2012 / 12:35AM, ADES - ADA ES INC at Pritchard Capital Partners LLC "Energize` Conference<br>
this new match rule. So, about eight -- about 500 to 700 ACI systems will be needed. This is about a $600 million market. And we are hoping to<br>maintain our 35% market share on this.<br>
In addition to the activated carbon injection equipment, again, the MATS rule has other air toxicities that need to be controlled, including these<br>acid gases. So we provide the dry sorbent injection equipment to control those acid gases. These are a little bit larger than the ACI systems. They<br>run $2 million to $3 million. And the EPA expects this to be about a $600 million market.<br>
We're already in the process of bidding on fleet-wide sales with utilities. We expect some contracts to be awarded in the first couple quarters of<br>2012.<br>
On the technology side, I mentioned we had a third mercury control technology. This is a technology in which we've proven we can treat coal at<br>the mine so that when that coal is burned at the plant, it burns with reduced emissions.<br>
We've licensed this to Arch Coal. Arch will be applying it to their Powder River Basin coals. We think that the value of enhancing this coal with this<br>mercury control chemical will be worth about $1.00 to $4.00 per ton of coal. And so we expect that this can be priced at a premium.<br>
The relationship, the agreement with Arch, says that we share 50% of that premium of the coal up to $1.00 per ton and Arch moves 100 million to<br>150 million tons per year of coal out of that. So, the market on this will be created by this mercury control market. The initial market for this will be<br>in states that control mercury.<br>
Again, on the CO2 technology side, we also have CO2 developing technology. In this case, we're developing technologies through funding from<br>the Department of Energy and our customers.We are currently working on about a five-year program, about a year into it. It's a $19 million program,<br>developing our drive sorbent based regenerable CO2 capture technology.We think this has technical advantages over the solvent-based technologies<br>and we will be proving this out under this funded program over the next 2 to 3 years.<br>
Let me talk briefly about our finances.These are our third-quarter reported finances.You see that what you are seeing over the last year a significant<br>increase in revenues, even though it was a relatively down time because the new regulations have not come, but this reflects operations of our<br>first two refined coal units.You see very high gross margins and that's because our business is based around licensing technology. It's based around<br>this refined coal, which comes into the business primarily with most of the expenses taken out at the JV level.<br>
As we move -- as we increase our refined coal business, you'll see high margins on that. As we build up our equipment sales that's going to be<br>lower margins. So you're going to see quite a bit of fluctuation in that as the equipment comes in and out, but the higher gross margin technologies<br>like refined coal, like the enhanced coal, will be long-term for us.<br>
We had an operating profit in the first nine months, but you see on a net loss of $33 million primarily due to a one-time charge of an arbitration<br>ruling in the second quarter.<br>
Here is our balance sheet at the end of the third quarter. I won't spend a lot of time on this because we had so many significant events in the fourth<br>quarter. I would rather focus on giving you a little guidance on what the fourth quarter will look like.We did a capital raise in October, netted $28.4<br>million in the sales of 2 million shares with no warrants and another $4.3 million in exercise of the overallotment option on 300,000 shares.<br>
We also settled an indemnity claim with Energy Capital Partners related to our activated carbon manufacturing plant. What this did, it eliminated<br>$33 million in long-term liability from our balance sheet. As part of this transaction, in the fourth quarter, we will recognize a $19 million gain over<br>this transaction. We gave up our 21% ownership in the activated carbon plant. And what this means is because of the delays in the mercury rules,<br>this plant has been running at less than full capacity, and we've been recording our proportional share of those losses. So, by giving up the ownership<br>we will no longer be showing these losses that you've seen on our income statement over the last couple years.<br>
We did maintain rights to a 49% ownership of future activated carbon lines once the market develops and requires additional expansion. We will<br>also be -- expect to be recording $5 million in prepaid royalties for one of our refined coal technologies that was licensed to CCS in the third quarter.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>478</i><br>
<hr>
<A name=479></a>JANUARY 05, 2012 / 12:35AM, ADES - ADA ES INC at Pritchard Capital Partners LLC "Energize` Conference<br>
Current consolidated cash of about $40 million. So we are very excited about what we're able to accomplish in 2011.That has put us in a very strong<br>position with these 26 new refined coal facilities that we hope to get up and running this year and a new mercury control regulation that we feel<br>is going to be a significant revenue generator for us. So, with that, I thank you for your interest.<br>
<b>Unidentified Participant</b><br>
Thank you, Michael. We really appreciate your presentation. And Michael and Mark will be in the Commonwealth Room.<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
Well, do we need to move? We are the last presentation. If anybody has any questions, we'll be glad --<br>
<b>Unidentified Audience Member</b><br>
(multiple speakers) anybody has any questions for Michael, ask those, well they'd be happy to respond right now.<br>
<b>Unidentified Audience Member</b><br>
I was just kind of curious about the, wondering in Illinois if you have the ACI facilities installed. And what utilities? I'm from Illinois and I was just<br>kind of curious. It looked like one might have been in Peoria, and --<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
Well, those were primarily the Ameren plants. The Ameren, Illinois plants. So, I'm not so sure any particular city they are. They are kind of spread<br>around the state.<br>
<b>Unidentified Audience Member</b><br>
Sure. I was just kind of curious.<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
Yes, Kurt.<br>
<b>Unidentified Audience Member</b><br>
Options, fully diluted; where are you share-wise?<br>
<b>Mark McKinnies</b><i> - ADA-ES, Inc. - SVP &amp; CFO</i><br>
We are about 300,000 options outstanding, so we're right at that 10 million shares on a fully diluted bases.<br>
<b>Unidentified Audience Member</b><br>
Okay. And then on the deal that you guys cut on arbitration, (inaudible) 49% ability (inaudible) future lines for that (inaudible) facility?<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>479</i><br>
<hr>
<A name=480></a>JANUARY 05, 2012 / 12:35AM, ADES - ADA ES INC at Pritchard Capital Partners LLC "Energize` Conference<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
It's on any future lines that ADA Carbon Solutions builds, whether they are Red River, whether North Dakota or any other place. So as they expand<br>-- as this new market is created from this mass rule, if they build beyond the first unit at Red River, whether they build a second one there or<br>someplace else, we have the rights to participate up to the 49.9% ownership.<br>
<b>Unidentified Audience Member</b><br>
Okay. So (inaudible) is about two lines?<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
It's a single line with four furnaces. And so it has a permit for a second identical line that big there.<br>
<b>Unidentified Audience Member</b><br>
Okay. And the ability of one (inaudible) -- my recollection is there's a (inaudible) permit for the potential second facility in North Carolina.<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
North Dakota, yes.<br>
<b>Unidentified Audience Member</b><br>
Do you foresee that as something that may go forward, or is it still the way in which mercury should be able to (inaudible) still in the timing? Which<br>(inaudible)?<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
Well, the timing on new activated carbon production, this rule gives three years to comply. And what we have seen is, on this first line, it was built<br>in two years. So, you would want -- time it so that it's producing when the demand is there. So we will be looking at what kind of demand there is,<br>generated by this new rule and based on the ability to sign take or pay contracts to sell off that system. That's when we would make a decision to<br>participate in a future expansion.<br>
<b>Unidentified Audience Member</b><br>
Okay. (inaudible) what should be think about this year, next year, 2014, (inaudible) tax rates, lower tax rates, or (inaudible)?<br>
<b>Mark McKinnies</b><i> - ADA-ES, Inc. - SVP &amp; CFO</i><br>
Let me answer that.<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
Mark, this is webcast. So, if you want to come up here and answer that.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>480</i><br>
<hr>
<A name=481></a>JANUARY 05, 2012 / 12:35AM, ADES - ADA ES INC at Pritchard Capital Partners LLC "Energize` Conference<br>
<b>Mark McKinnies</b><i> - ADA-ES, Inc. - SVP &amp; CFO</i><br>
The question was about tax rates, which we should be looking forward to.<br>
One of our plans with the refined coal facilities is that we retain a few of those within the joint venture ourselves so that we're going to be generating<br>tax credits to offset taxable income that's generated there. So, for modeling purposes we have used a 35% rate kind of looking out, but as we look<br>forward past 2012 and we've got some NOLs in our balance sheet too of about $20 million after this extraordinary transaction in the fourth quarter<br>of 2011, we are expecting that we'll be able to offset the majority of the taxes generated from the refined coal activities with those credits. And so<br>for modeling purposes, we are expecting the federal rates to be in that 15% to 20%, if not lower than that.<br>
So, depending on what facilities we retain for our own purposes and operate and retain those tax credits. So it will be considerably less than the<br>35% kind of historical rate that we've looked at.<br>
<b>Unidentified Audience Member</b><br>
Okay. And then relative to Arch, my recollection is (inaudible).<br>
<b>Michael Durham</b><i> - ADA-ES, Inc. - President &amp; CEO</i><br>
Well, you're right. The enhanced coal was put on a back burner because it's the same groups of people that were putting in their refined coals and<br>testing it. So we have -- our plans -- multiple tests of the concept of the coal additive mercury control this year.<br>
The market for it will be, again, the states that are already regulating mercury. And that's going to be driven by, as those states started -- as the<br>plants in those states were controlling mercury, they signed long-term activated carbon contracts.<br>
So, as these long-term contracts are starting to come to the end of theirs, we will try to push into those as an alternative to additional contracts<br>there.<br>
Until -- other than that, the next market -- the biggest market is going to be -- wants compliance for the federal by all 1200 plants in 2015.<br>
All right, thank you.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4694811-2012-01-09T20:03:25.050</b><br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>481</i><br>
<hr>
<A name=482></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
INSP - INFOSPACE CONFERENCE<br>CALL TO DISCUSS ACQUISITION OF<br>TAXACT<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 1:30PM GMT<br>
OVERVIEW:<br>
INSP announced that it has entered into an agreement to acquire TaxACT, a leading<br>provider of online tax solutions. Under the terms of agreement, Co. is acquiring<br>TaxACT for $287.5m in cash.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>482</i><br>
<hr>
<A name=483></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Stacy Ybarra</b><i> InfoSpace - Senior Director, IR</i><br>
<b>Bill Ruckelshaus</b><i> InfoSpace - President and CEO</i><br>
<b>Eric Emans</b><i> InfoSpace - CFO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Clay Moran </b><i>The Benchmark Company - Analyst</i><br>
<b>Kartik Mehta</b><i> Northcoast Reasearch - Analyst</i><br>
<b>Eric Martinuzzi</b><i> Craig-Hallum - Analyst</i><br>
<b>Rich Tullo</b><i> Albert Fried &amp; Company - Analyst</i><br>
<b>Scott Kessler</b><i> Standard &amp; Poors - Analyst</i><br>
<b>Ned Davis </b><i>William Smith &amp; Co. - Analyst</i><br>
<b>OVERVIEW</b><br>
INSP announced that it has entered into an agreement to acquire TaxACT, a leading provider of online tax solutions. Under the terms<br>of agreement, Co. is acquiring TaxACT for $287.5m in cash.<br>
<b>FINANCIAL DATA</b><br>
<b>A. Transaction value = $287.5m in cash.</b><br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. ACQUISITION OVERVIEW (B.R.)</b><br>
<b>A. Highlights:</b><br>
<b>1. </b>Entered into an agreement to acquire TaxACT, a leading provider of online tax solutions.<br>
<b>a. </b>Significant milestone.<br>
<b>2. </b>Capital allocation has been a key focus of Co. for sometime.<br>
<b>a. </b>During 13 months of Bill Ruckelshaus as CEO, team has evaluated numerous acquisition opportunities.<br>
<b>i. </b>Found outstanding business in TaxACT with strong consumer brand in growing market run by a fantastic team with<br>
excellent track-record of execution and financial performance.<br>
<b>3. </b>Transaction aligns with capital deployment objectives and positions Co. well going forward.<br><b>4. </b>Enthusiastic about opportunity this combination will create for:<br>
<b>a. </b>Shareholders.<br><b>b. </b>TaxACT team.<br>
<b>c. </b>Co.'s employees.<br>
<b>5. </b>Under terms of agreement, Co. is acquiring TaxACT for $287.5m in cash.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>483</i><br>
<hr>
<A name=484></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>a. </b>Approx. 7.6 times trailing adjusted EBITDA.<br>
<b>6. </b>TaxACT has impressive financial profile.<br><b>7. </b>Transaction represents an attractive return on shareholder capital.<br>
<b>a. </b>Anticipates debt financing in connection with this acquisition.<br><b>b. </b>Following close, expects to have in excess of $90m in cash and equivalents on hand.<br>
<b>8. </b>Transaction should close in 1Q12 following satisfaction of customary closing conditions and regulatory approvals.<br>
<b>B. Benefits:</b><br>
<b>1. </b>Benefits of combination from business and financial perspective are compelling and clear.<br><b>2. </b>TaxACT operates in strong market in early stages of digital transition not unlike digital migrations underway in other<br>
consumer markets, travel, brokerage, banking, real estate and shopping to name a few.<br>
<b>a. </b>Travel industry was one of earliest to go online due to widespread adoption of e-tickets.<br>
<b>i. </b>Today, vast majority of airline tickets are sold online through agencies and supplier websites.<br>
<b>b. </b>Similar shifts are underway in tax preparation where government adoption and consumer behavior are driving online<br>
growth.<br>
<b>i. </b>Since 2000, US government has expanded access to electronic filing and faster refunds.<br>
<b>ii. </b>IRS e-file has grown at double-digit annual rates from tax year 2000 to tax year 2010.<br>
<b>iii. </b>On consumer side, filers are moving online as familiarity sets in, security concerns abate and enhance product offerings<br>
make it easier and quicker to do taxes online than alternative methods of preparation.<br>
<b>3. </b>Co. likes TaxACT's competitive position.<br>
<b>a. </b>They have an established brand and well-earned reputation for delivering value to consumers over years.<br>
<b>4. </b>TaxACT has successful track record of great execution, driven by top-flight management team with decades of experience<br>
providing consumer tax preparation solutions.<br>
<b>5. </b>Pro forma financial profile is compelling and offers strong and near-term return on shareholder capital.<br>
<b>C. Strategic Rationale:</b><br>
<b>1. </b>Tax preparation market is large and undergoing long-term, secular shift toward online do-it-yourself (DIY) preparation.<br>
<b>a. </b>Computer aided DIY tax preparation is supplementing paper and pencil and professional channels.<br><b>b. </b>Digital DIY market itself has grown at 12% compound annually since 2002.<br>
<b>i. </b>Estimated 30m filers completed their tax returns online in tax year 2010.<br>
<b>c. </b>Today only 20% of US tax payers using online solutions, suggesting Co. is early in trend.<br>
<b>i. </b>Expects this market to grow at 10% plus going forward driven by continued demographic shifts in base of taxpayers as<br>
mix of digitalized filers increases over time.<br>
<b>d. </b>From TaxACT perspective, this secular market growth can be complemented by growth in share and increasing paid<br>
offerings to consumers.<br>
<b>e. </b>Against this market backdrop, believes TaxACT is uniquely positioned.<br>
<b>i. </b>They have competitive market offering, leading brand and loyal and growing customer base.<br>
<b>D. Key Pillars of TaxACT's Favorable Positioning:</b><br>
<b>1. </b>Brand Acceptance:<br>
<b>a. </b>Co.'s research confirms that TaxACT has widespread acceptance among consumers.<br>
<b>i. </b>Its net promoter score is essentially net of promoters less detractors, speaks to its loyal following among consumers<br>
and its score compares with well-known trusted global brands.<br>
<b>b. </b>Feedback is exceptionally strong with 93% of customers surveyed indicating they would recommend TaxACT to others.<br>
<b>c. </b>YoverY retention rates on its various products are also quite high and speak to deep loyalty consumers developed for<br>
co.'s offerings.<br>
<b>2. </b>Superior Value:<br>
<b>a. </b>TaxACT is price and value leader in marketplace.<br><b>b. </b>Co.'s primary research confirms four key requirements among consumers in choosing their tax preparation solutions.<br>
<b>i. </b>Price.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>484</i><br>
<hr>
<A name=485></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>ii. </b>Ease of use.<br>
<b>iii. </b>Accuracy.<br>
<b>iv. </b>Accessibility/reliability.<br>
<b>c. </b>Among aforementioned, price is far and away most commonly referenced driver based on research.<br>
<b>i. </b>TaxACT is perceived as leading value-based provider.<br>
<b>3. </b>Financial Strength:<br>
<b>a. </b>TaxACT has developed its market position without sacrificing profitability or margin.<br>
<b>i. </b>This provides ample opportunity for further investment and pursued of market objectives.<br>
<b>b. </b>TaxACT has seen exceptional customer growth.<br>
<b>i. </b>Number of federal returns completed by TaxACT has been growing at 14% compound annual rates since 2005.<br>
<b>ii. </b>Over 5m individuals completed their returns with TaxACT in tax year 2010, of which vast majority did so using co.'s<br>
online offering.<br>
<b>E. TaxACT's Net Promoter Score (NPS):</b><br>
<b>1. </b>Ranks with other industry leading brands.<br><b>2. </b>From INSP's perspective, co.'s NPS clearly signifies high level of consumer satisfaction with its products across all important<br>
dimensions.<br>
<b>F. Product Leadership:</b><br>
<b>1. </b>TaxACT's solutions span Consumer Free, Consumer Paid and Professional segments.<br><b>2. </b>TaxACT monetizes through suite of premium features including:<br>
<b>a. </b>State tax preparation.<br><b>b. </b>Telephone support.<br>
<b>c. </b>Data archiving.<br>
<b>d. </b>Financial products like stored value cards and payment transfers.<br><b>e. </b>Deluxe bundling.<br>
<b>3. </b>Across range of offerings,TaxACT commands dramatic price advantage vs. equivalent competitive offerings in marketplace.<br>
<b>G. Sustained Execution:</b><br>
<b>1. </b>TaxACT team has an impressive record of execution over many years.<br>
<b>a. </b>Has years of experience in online direct response marketing and demonstrated effectiveness in retaining consumers.<br><b>b. </b>Has expanding presence social channels online and mobile offering.<br>
<b>2. </b>TaxACT's financial performance largely speaks for itself.<br>
<b>a. </b>They have accomplished so much while maintaining profit disciplines and preserving capacity for further investments.<br><b>b. </b>Co. looks forward to working with management team of TaxACT to evaluate for areas for future investment and opportunistic<br>
expansion.<br>
<b>3. </b>Co. believes transaction represents compelling ROC to shareholders.<br>
<b>II. FINANCIAL BENEFITS OF ACQUISITION (E.E.)</b><br>
<b>A. Return On Shareholder Capital:</b><br>
<b>1. </b>TaxACT's levered free cash flow for 12 months ending 09/30/11, $32.2m.<br>
<b>a. </b>Factoring $200m cash investment, ROE is approx. 16% for transaction.<br>
<b>i. </b>(indiscernible) transaction that contemplates modest leverage.<br>
<b>2. </b>Projects ROE will grow in 2012 and beyond.<br><b>3. </b>Cash tax savings from utilization of INSP's NOL significantly improves ROE by approx. 50% on a pro forma basis.<br>
<b>B. Pro Forma Financial Profile:</b><br>
<b>1. </b>Acquisition is immediately accretive to EPS.<br><b>2. </b>TaxACT financials for 12 months ending 09/30/11:<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>485</i><br>
<hr>
<A name=486></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>a. </b>Revenues $78.1m.<br><b>b. </b>Adjusted EBITDA $37.8m.<br>
<b>c. </b>On a pro forma basis, non-GAAP net income $31.8m or $0.85 per diluted INSP share, which includes reduction for imputed<br>
interest expense related to debt financing of [$4.5m] or $0.12 per diluted INSP share.<br>
<b>i. </b>Non-GAAP net income excludes non-cash income tax expense related to expected utilization of Co.'s NOLs, which<br>
provides enhanced value to INSP shareholders.<br>
<b>3. </b>Combined:<br>
<b>a. </b>For 12 months ending 09/30/11, combined entity would have generated:<br>
<b>i. </b>Pro forma revenue of $290m.<br>
<b>ii. </b>Pro forma adjusted EBITDA of $72.5m.<br>
<b>iii. </b>Pro forma non-GAAP net income of $45.6m or $1.21 per diluted share.<br>
<b>4. </b>TaxACT generates substantial free cash flow.<br>
<b>a. </b>Following completion of transaction, Co. will maintain strong balance sheet with cash in excess of $90m that will afford<br>
it opportunity to invest in future.<br>
<b>III. CLOSING REMARKS (B.R.)</b><br>
<b>A. Summary:</b><br>
<b>1. </b>Excited about next step in evaluation of Co.<br><b>2. </b>Search business is operating well and exits 2011 with lot of momentum.<br><b>3. </b>With TaxACT, has added a great business and team to mix, confronting growing market with leading product and strong<br>
following.<br>
<b>a. </b>Transaction represents attractive return for shareholders in combined co. as well-positioned for future growth, investment<br>
and value creation.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
(Operator Instructions). Clay Moran, Benchmark.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
Good morning. A couple of things. Could you talk a little bit about the competitive landscape where TaxACT fits in, what the barriers<br>to entry are? And seems like TaxSlayer may be somewhat new to the market, what do they represent in terms of a competitive threat?<br>
Secondly, just any change to management that is considered at this point -- TaxACT management, are they all staying on and what's<br>their incentive to stay?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, thanks, Clay. So the tax preparation market is -- consists of established providers, names you have heard of over time, H&amp;R Block,<br>and other off-line typically historically off-line paid professionals who prepare. The market is roughly 60% today on the side of<br>professionals and paid preparers and then about 40% what's called do-it-yourself, which historically has been pen and paper, more<br>recently has been desktop software and even more recently has been online.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>486</i><br>
<hr>
<A name=487></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
And the dynamics are not unlike dynamics, Clay, as I mentioned in my comments, that you see in other consumer segments where<br>just online is an easier way to do it. And there are some hurdles you've got to get over as it relates to the perceived complexities of<br>tax preparation and some of the consumer inhibitions around using an online service to do something like tax preparation.<br>
But nevertheless, that shift is underway. It's one that we recognize from other consumer verticals.<br>
The competitive landscape as it relates to the do-it-yourself includes Intuit, which is a large and respected player in the space; H&amp;R<br>Block is also online with an online solution; TaxACT is a leader as we have talked about. You mentioned TaxSlayer, there's a couple<br>of other players that would I think probably properly be put in the value segment within the online landscape.<br>
And I would say the barriers to entry principally, Clay, are really around the product and the domain expertise of providing consumers<br>with an easy way to do their taxes in an online format. That is -- as simple as that may seem to say, it's a very sophisticated offering<br>and capability that TaxACT has developed over a decade and prior to that at a different company.<br>
And the translation of what can be a rather complicated and confusing set of rules and procedures as they might apply to an individual<br>as they progress through life, translating that into an interview style product offering that gets people comfortable with doing such<br>an important thing online is actually a nontrivial thing and really deeply resides in product and understanding of the tax code and<br>translating that into something from a consumer interface standpoint that is intuitive and comfortable.<br>
So it really is just I think it has a lot to do with domain expertise, which is not uncommon for an industry like this.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
One follow up there before you move on to the management. Any plans at all to alter the strategy and/or just enhance the marketing<br>given that InfoSpace is traditionally an online marketing Company? Are there any tweaks to what they're doing that you feel you<br>can help the current situation?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Well, certainly we are optimistic that we can help and enable what the TaxACT team is doing.We really do like the strategy they have<br>been pursuing. I would say from a fit standpoint it lines up very well. We see a lot of cultural alignment between our two companies<br>at the core. We really do feel like there is the beginnings of a great relationship with the team in Cedar Rapids. So I would say that is<br>probably one of the best combination effects right off the bat.<br>
The second is we are both online companies and that's just through the DNA of both companies knowing what it means to own<br>and operate a website, the importance of keeping that website up to date, the importance of uptime and reliability, the importance<br>of security, all the aspects around being an online presence.<br>
And then the aspects with respect to product development and consumer marketing -- and I know you mentioned marketing in<br>particularly, those are two fundamental undertakings of the company of TaxACT that we think they're quite good at. We have been<br>impressed by them in both of those realms and to the extent that we can help, we're absolutely prepared to do that and do so in a<br>collaborative way.<br>
And as you can probably guess from the trended results of the company, the good news is that there's nothing broken at the moment<br>so they're humming along and we have lots of discussions under way as to how we can help them.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>487</i><br>
<hr>
<A name=488></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
I think, Clay, you had also asked a question about retention. And so the management team is sticking around, we have discussed<br>roles with the team there that are unaltered. As I had mentioned in my introductory remarks, the team was one of the real attractive<br>points for us in pursuing this combination.<br>
So we have as you might imagine, discussions and resolution as it relates to roles and responsibilities after this transaction.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
Okay, thank you, congratulations.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thanks a lot.<br>
<b>Operator</b><br>
Kartik Mehta, Northcoast Research.<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
Good morning. I was wondering, you gave some numbers as to what you thought the online market was growing and then you also<br>talked about how well TaxACT was growing. And I'm wondering for the upcoming tax season, would you expect to grow in line with<br>what you thought the online market was growing or is TaxACT in a position where you think you can grow faster?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Well, certainly it would be our expectation to grow in line with the market. It's early to speak to the 2011 tax year season as were<br>really just getting underway, as you know. But the company is excited about the plans it has in place.<br>
It has in the course of this year unlike -- not unlike prior years, learned a lot of things as it relates to the market and how it developed<br>in calendar year 2010, tax year 2010. Applied those learnings into its product, applied those learnings into its marketing, thoughts<br>around marketing budget and marketing mix and timing of its marketing spend. And so I think that they are very well positioned<br>to have a good year and certainly it's everybody's expectation that they will grow with the market.<br>
One thing I would say is that historically the growth formula is very logically a function of getting consumers to come to the site,<br>getting those that have worked with you in the past to revisit and reuse your product and then also making sure that they are making<br>it -- they have available to them a variety of offerings, some of which will be paid and that they make full use of those so that that<br>can go to conversion within the funnel. And all of those levers are being pursued.<br>
I think from a pricing standpoint, the company has not historically taken aggressive pricing year on year. Price and value and<br>affordability are fundamental to its core message to consumers. And so I think that is a lever that they'll use more judiciously than<br>it simply will be trying to drive year on year revenue growth through pricing action.<br>
But to your core question as it relates to the unit volumes, certainly they are expecting to grow with the market.<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>488</i><br>
<hr>
<A name=489></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
And so as I look at the numbers you presented in your presentation, obviously TaxACT grew revenue fairly well from FY '10 to FY '11.<br>Would that imply that the corresponding customers grew in the same manner concerning your statement that they have not used<br>pricing really?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Right. So for the most part, but not exactly. So the other determinant there as it relates to revenue growth is going to be mix. So<br>three to the extent that you had a constant mix from year to year, I think the answer to your question would be yes. But to the extent<br>that you have an evolved mix as it relates to paid versus nonpaid consumers and then on the paying consumers, what is the revenue<br>per consumer as i.e., the attach rate around paid offerings?<br>
So there are differences, as you know, from year to year as it relates to that.<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
I just want to make sure I understood the statement you said. So would it be fair to say that TaxACT will be more -- will be a little bit<br>more aggressive in how it prices its product, it has maybe more pricing power than the companies used in the past so now they'll<br>have more opportunity to use pricing as a way to grow?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Well I think I was speaking to their historical practice which historically that has not been -- that is a lever that many providers in the<br>marketplace and anybody naturally offering something that consumers might use.<br>
I think however that the deliberation that goes on within the TaxACT team as to how and when they take pricing, those types of<br>topics are given a lot of thought because fundamentally one of the reasons why the following is as strong as it is is that it has a<br>well-earned reputation for being a value provider, a provider of value, it's got a great product and it's also offered on great terms.<br>
And so care will be given as it relates to pricing decisions to make sure that they don't run awry of that relationship with their<br>consumers. So was less offering a view into the future.<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
And then just one final question. Any thoughts about further consolidating the industry as there are some other smaller players in<br>the market that do online?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes. So consolidation in the space has certainly been discussed. I think there -- in certain cases there would be advantages in<br>combining, in TaxACT's case and InfoSpace and TaxACT's case with another player in the market. I think we would want to give some<br>thought to what the expanded presence might be with consumers as it relates to the brands and what they signify. To the extent<br>those brands were entirely overlapping, I think the question would then go to more raw back-end economics and the advantages<br>of bringing two businesses together. But it is certainly something that is a possibility in the foreground.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>489</i><br>
<hr>
<A name=490></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
Thank you very much, I appreciate it.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
Eric Martinuzzi, Craig-Hallum.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
Thanks. Just going back to your description of the services, products and services that they currently offer, you talked about their --<br>it's do-it-yourself but there's a combination of desktop software as well as the online. What is the current revenue mix between the<br>two?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
Eric, it's Eric here. So right now, it's primarily driven by the online product, the desktop is declining over time as you would expect<br>those users to shift to online. So I would say about 70 -- over 70% of revenues coming from the online and desktop is at about 8%<br>for tax year 2010.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
I didn't follow that, you said online is primarily -- it is over 70 --.<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
So, online about 75% approximately.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
Okay, so online 75%<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
And desktop at about 8%.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
What makes up the balance?<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>490</i><br>
<hr>
<A name=491></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
You've got preparer -- we have a tax preparation offering and that is about 9%, and then we have some value-added services, bank<br>products and Stored Value Cards.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
As you -- the customer transformation, I imagine the first exposure for a consumer is the free federal online. What is the next thing<br>that consumers buy? Is it a state online or is it some kind of -- what's the upgrade past?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
That's right, Eric, this is Bill. So that is absolutely right. The company has over the years been steadfast in offering and really the first<br>in offering free federal filings, which as you can imagine is of great interest to a good swath of the market.Those consumers that are<br>residing in states where their state income tax, that is an upsell to provide that and the company has a product that addresses all<br>the states there.<br>
And there is another -- there are other upgrades as it relates to that rate card and the pricing sheet with respect to the types of<br>services that Eric had mentioned. There is a degree of stickiness as it relates to a consumer that enters in the first year whether they<br>are filing federal or federal and state as it relates to their information.<br>
And so the ability to access that information for retrieval purposes as it relates to future tax periods, for initiating your taxes in the<br>coming year is of great value and that is an example that is referred to as data archive service that the company offers, which would<br>be an example of a paid product above and beyond state.<br>
And then there are a variety of financial services including refund payment transfers, Stored Value Card solutions that offer consumers<br>flexibility as it relates to the receipt of refunds and what they do with those refunds and how they are processed.<br>
Support is another important -- another element of their service, Eric, and consumers that are looking for more hand holding and<br>walk-throughs, they perceive complexity of their filings as such that they want to get on the phone with somebody; that is offered<br>by the company as well.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
And then last question, just doing a quick search, I was not aware of this but apparently H&amp;R Block had made a play for TaxACT and<br>it was barred due to anti-competitive -- the Justice Department stepped in and said, no can do. At what point -- was this your first<br>go at this entity? Can you give any sort of background as to -- because it seems like only November that H&amp;R Block dropped their<br>efforts?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, that's right. It has been our first go at the company, as you say. And the company had announced an acquisition or a sale to H&amp;R<br>Block in October of 2010, which didn't come together and that became clear toward the back half of 2011.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
Thank you.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>491</i><br>
<hr>
<A name=492></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thanks.<br>
<b>Operator</b><br>
Rich Tullo, Albert Fried &amp; Company.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Congratulations on your deal, it's been a long time in coming.You said 40% of the market is electronic. What percent of that market<br>is TaxACT?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Good morning, Rich, this is Bill. I think and it is important from a market definition standpoint to walk through it a little bit. To be<br>more specific, 40% is what we call do-it-yourself and do-it-yourself historically has been pen and paper, people just don't want to<br>pay a storefront provider to do their taxes, their taxes are simple or they're at a level of comfort and sophistication where they are<br>happy doing it on their own.<br>
And that particular segment has been undergoing a pretty radical shift over the last 15 years, which is the initial alternative method<br>that was introduced was more of a CD-ROM desktop type offering where consumers could move away from pen and paper. And<br>then more recently which has now been going on for some time has been the online capability, which is replacing not only pen and<br>paper but also now desktop.<br>
But that 40%, which is the do-it-yourself, that is the segment that really refers to that subset of the filing population that is comfortable<br>whether it's just -- they just prefer to do it on their own, they have privacy concerns, they have a perfect level of sophistication and<br>comfort doing it on their own. But that's what we refer to as do-it-yourself.<br>
The subset of do-it-yourself, which is referred to as digital do-it-yourself is 33% of the market. The numbers are not super precise as<br>it relates to the sources but rough order of magnitude 140, 142 million filers in the US, 40% of which are in the do-it-yourself category<br>through whatever means and 33% of overall filers are in the digital do-it-yourself which includes both software and online. And then<br>the online portion is 20% which is where we came up with the 30 million filers out of the 140 million.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Okay. Second question is what are the regulatory and legal events which are likely to influence the business over the next six to 18<br>months? I guess this is an industry that's in some degree influenced by changes in the tax law. And how do you kind of look at that?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
It has historically been influenced by tax law. I think one of the real drivers of the opportunity we see in the digital online market is<br>the -- is really aided by the US government in terms of its initiatives around the Free File Alliance, which was in the early 2000s<br>teeming with industry participants to make it easy for individuals with incomes below $57,000 a year to file electronically which has<br>been a real catalyst. And also provides a lot of clarity with folks as to the dates of the filing and creates a rather regimented calendar<br>year in, year out.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>492</i><br>
<hr>
<A name=493></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
To the extent that there is simplification on the horizon, this is a difficult thing for anybody to crystal ball, but to the extent that the<br>tax code simplifies then you might imagine that consumers' perception of the complexity of their own filings will decrease which I<br>think as well would be a catalyst to the reception of online and the migration toward online.<br>
So we would certainly see that as being a tailwind to the extent it happens but that's a difficult thing to speak to.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
A couple of I guess kind of clean-up questions here. CapEx, what is the CapEx of this business? How is that going to integrate with<br>your own CapEx? And I guess we can ask the same question of non-cash executive compensation?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
So on the CapEx -- this is Eric -- historically it's about $500,000 a year. Yes, there is equity compensation involved. We're not going<br>to provide any forward-looking guidance on that at this time. But yes, we will have stock-based compensation.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, I would say philosophically welcoming the team into the fold is something that we want to do at all levels and allowing the<br>TaxACT management team to have prominent roles and responsibilities within our combined companies is absolutely something<br>we want to do and allowing them through stock-based compensation to take ownership in the value we create together is very<br>much in line with that.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Fair enough. Are there any key person provisions either in the debt agreement or in the M&amp;A deal plan?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
In regards to the debt agreement, we have a commitment at this time but we're not going to go into any further detail until we have<br>the definitive credit agreement in place. As far as key folks, the agreement contemplates what you'd expect provisions from the key<br>management as far as non-competes and in that regard. But outside of that, that's all we're looking at.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
I guess I know Intuit -- start again to the website development business with its tax folks, is that a business that you can kind of<br>leverage with the distributed search?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, we think there are opportunities to enhance the presence of TaxACT on our various web properties and use our search business<br>to TaxACT's advantage and we're looking into ways to do that even this tax season -- as soon as we close this transaction.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>493</i><br>
<hr>
<A name=494></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Do you have any idea what the closing costs are going to be facing us either in the fourth quarter or the first quarter this year?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
So in the deck, we had indicated transaction expenses would be about $5.5 million. I would say the lion's share of those will be in<br>the first quarter.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Thank you very much for taking my questions. It looks like a very interesting deal and good luck with it.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
Scott Kessler, S&amp;P Capital IQ.<br>
<b>Scott Kessler</b><i> - Standard &amp; Poors - Analyst</i><br>
My first question I think is one that seems obvious but I think is worth exploring. Bill, obviously since you've been leading the Company,<br>I think a lot of people have been anticipating a transaction like this. However -- and of course the fact that you have spoken to it in<br>generality would be one of the reasons why.<br>
I'm wondering if you could explain to us a little bit about how you decided on this company as opposed to one that might have<br>been within the construct of what you and we might have considered related adjacencies? I think one of the big questions about<br>this transaction as much as it seems appealing on some levels is it doesn't seem to have a lot to do with your core business right<br>now.<br>
And the second question I have is somewhat related, which is the prior proposed transaction between H&amp;R Block and TaxACT, not<br>coincidently seemed to be for about the same amount of money. So I'm wondering how you came to the sum and did your valuation<br>analysis? Thanks.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, sure, thanks, Scott. Yes, it's very, very reminiscent of that price so I will let let you arrive at your own conclusions as to how it is<br>we arrrived at that valuation. It was negotiated outcome as you might imagine as these things typically are. And there was a degree<br>of opportunism on our part as it relates to pursuing this opportunity.<br>
So one of the things that I think we have spoken about in prior calls has been as it relates to the successfulness of our acquisition<br>effort, making sure that we have the right resources in place, making sure that we have the right criteria established that best map<br>to our opportunity and where we think we can be successful and then also a degree of opportunism which is finding the right<br>situation and making sure that we act with urgency in pursuit of an opportunity.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>494</i><br>
<hr>
<A name=495></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
And this is I think straight down the fairway as it relates to those attributes that the idea of moving into an adjacent category that<br>would be more directly complementary of search was certainly something that was in the consideration set. And so by virtue of this<br>announcement, one should not assume that those types of opportunities weren't evaluated.<br>
This was one that was head and shoulders from our perspective more attractive, from a market opportunity perspective, from our<br>ability to influence the outcome of what the company is doing. And that may be through means of the catalyst of new ownership<br>and adopting a philosophy of investment and resourcing and things that we're all very much stand at the ready to do with this<br>business.<br>
But also in terms of cultural fit. We like the team, we think the team is doing really great things from their headquarters in Cedar<br>Rapids, Iowa and we look forward to enabling them.<br>
And so I think that's the -- that's really the way to answer that question. If you have any sort of more specific questions related to<br>that, I'm happy to answer them.<br>
<b>Scott Kessler</b><i> - Standard &amp; Poors - Analyst</i><br>
I guess one of the things that I know I'm thinking about is you look at the order of what transpired, clearly you guys have been looking<br>for a meaningful larger transaction for some time clearly in I guess -- what, the fall of last year, the deal with H&amp;R Block fell apart. So<br>it provided you guys with an opportunity. And I think that is something that you should be applauded for.<br>
But I guess what I'm wondering is, is it just that you didn't find what you wanted to find potentially in those adjacencies or was it a<br>valuation issue or is it just that this opportunity arose and it was so compelling you had to move forward with it?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Well, I think that's a good question, I think by definition because we didn't announce anything in an adjacent space, we didn't find<br>anything we liked. There were plenty of things that we've looked at. I mean I think we've gone into some detail on prior calls as it<br>relates to the exhaustiveness of our effort and I think price has been an issue, Scott. So we have turned over a lot of rocks and there<br>are a lot of great companies out there, there are a lot of great companies that think they are worth on a multiple basis 15 to 20 times<br>EBITDA and so it's difficult to reconcile in those conversations.<br>
And so I think the alignment that we feel as it relates to this company is kind of the points I had walked through the before as it<br>relates to it being an online company, the DNA is very similar to the DNA at this Company. TaxACT has what I would characterize as<br>a maniacal focus on the consumer, which is they have built relationships with over five million filers over the course of their 13-year<br>operating history that is really quite astounding and speaks to their attention to product detail and attention to maintaining<br>relationships beyond an initial tax season.<br>
And it's those types of attributes that as we think about the investment criteria and where we thought we would be most successful<br>allocating our capital, that was absolutely one of those attributes which probably falls under the broader heading of just a really<br>good company. And the fact that it's an online company and one that we think we're -- we understand and are positioned to help I<br>think only adds to the rationale.<br>
<b>Scott Kessler</b><i> - Standard &amp; Poors - Analyst</i><br>
Great. And the last question I had, just a really quick one if I may, any synergies you guys see on the revenue or on the cost side?<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>495</i><br>
<hr>
<A name=496></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
So I think that there likely will be synergies. My sense is that we're not coming at this from a cost rationalization standpoint in the<br>slightest. As I had mentioned, we may even on a more likely case see opportunities to invest together where we haven't before.<br>
And from a revenue standpoint, there are going to be opportunities for the InfoSpace search business to more prominently feature<br>TaxACT through the course of our search results pages and our display inventory and we're going to take advantage of those as you<br>might imagine and the next 3.5 months is a good time to do it.<br>
<b>Scott Kessler</b><i> - Standard &amp; Poors - Analyst</i><br>
Great, thank you.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thanks.<br>
<b>Operator</b><br>
Ned Davis, William Smith &amp; Co.<br>
<b>Ned Davis</b><i> - William Smith &amp; Co. - Analyst</i><br>
Thank you. Good morning, congratulations. I will only ask one question. Marketing expenses, the company has what looks to be<br>about a 45% operating margin.What are the marketing expenses in absolute terms maybe on a trailing 12? And how will you change<br>the marketing strategy at this business going forward?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Good morning, Ned, happy new year. So marketing expense as you might imagine is a significant piece of the company's SG&amp;A.The<br>spend is suffice it to say, well over $25 million a year. You could piece that together by looking at the results.<br>
The historical practice has been not unlike other consumer acquisition efforts where it's a multichannel marketing effort online and<br>off-line.There's a lot of experimentation and a lot of processing of learnings from one year to the next. Much of the buying that goes<br>on is bought ahead of time as you might imagine, there's quite a lot of messaging in the marketplace this time of year between now<br>and the end of tax season as it relates to tax preparation. It's a seasonal business and in further communications, we are going to<br>provide more detail as to the breakout of the business by quarter.<br>
But they have spent it in online and off-line channels and have had greater success in some areas than others, they spent a decent<br>amount of money in the search channel, which is an area where we spent a fair amount of time discussing and one we well understand.<br>
And so I think that I personally have been impressed by the company's direct marketing capabilities and the brand that they have<br>been able to build with the profit disciplines in place. So to the extent that we can work with the management team to continue<br>that tradition and accelerate that tradition, we see that as a real opportunity.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>496</i><br>
<hr>
<A name=497></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Ned Davis</b><i> - William Smith &amp; Co. - Analyst</i><br>
Thank you. Congratulations.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thank you.<br>
<b>Stacy Ybarra</b><i> - InfoSpace - Senior Director, IR</i><br>
Operator, we have time for one last question.<br>
<b>Operator</b><br>
Clay Moran, Benchmark.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
Just two more questions. First, just wondering if there's any change to the Board of Directors contemplated at this point specifically<br>is Andrew Snyder staying on in helping develop TaxACT?<br>
Secondly, do you have plans to pay down the debt and are there any terms that prevent you from paying it down quickly?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
No changes to the Board. Andy is absolutely staying on Board or certainly we hope he is. He's been a real contributor in the few short<br>months he's been on Board and certainly was helpful in this -- in getting to this point with this transaction. So, no nothing to<br>communicate to you on that front.<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
As far as the debt, we're not going to get into too many -- too much specifics. But I guess the way we look at it is we expect to pay<br>it off in about three years. And if we wanted to pay it off sooner, we could.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
Okay, thank you.<br>
<b>Operator</b><br>
This concludes the question-and-answer portion. I would like to turn the call back to Ms. Stacy Ybarra for closing remarks.<br>
<b>Stacy Ybarra</b><i> - InfoSpace - Senior Director, IR</i><br>
Thanks everyone for joining us today on such short notice. Have a good day.<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>497</i><br>
<hr>
<A name=498></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Operator</b><br>
And this concludes today's call. Thank you very much for your participation. You may now disconnect and have a great day.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4703246-5-2012-01-09T20:16:16.937</b><br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>498</i><br>
<hr>
<A name=499></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
INSP - INFOSPACE CONFERENCE CALL<br>TO DISCUSS ACQUISITION OF TAXACT<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 1:30PM GMT<br>
OVERVIEW:<br>
INSP announced that it has entered into an agreement to acquire TaxACT, a leading<br>provider of online tax solutions. Under the terms of agreement, Co. is acquiring<br>TaxACT for $287.5m in cash.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>499</i><br>
<hr>
<A name=500></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Stacy Ybarra</b><i> InfoSpace - Senior Director, IR</i><br>
<b>Bill Ruckelshaus</b><i> InfoSpace - President and CEO</i><br>
<b>Eric Emans</b><i> InfoSpace - CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Clay Moran </b><i>The Benchmark Company - Analyst</i><br>
<b>Kartik Mehta</b><i> Northcoast Reasearch - Analyst</i><br>
<b>Eric Martinuzzi</b><i> Craig-Hallum - Analyst</i><br>
<b>Rich Tullo</b><i> Albert Fried &amp; Company - Analyst</i><br>
<b>Scott Kessler</b><i> Standard &amp; Poors - Analyst</i><br>
<b>Ned Davis </b><i>William Smith &amp; Co. - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Good day, ladies and gentlemen, and welcome to the InfoSpace conference call. My name is Deana and I will be the operator for today. At this time<br>all participants are in a listen-only mode. After the presentation, we will open the lines to answer the questions that you may have. As a reminder<br>today, the conference is being recorded. (Operator Instructions).<br>
I would now like to turn the conference over to your host for today, Ms. Stacy Ybarra, Senior Investor Relations. Please proceed.<br>
<b>Stacy Ybarra</b><i> - InfoSpace - Senior Director, IR</i><br>
Good morning.Welcome to InfoSpace's investor conference call and thanks for joining us on such short notice to discuss the exciting announcement<br>our Company made this morning, the acquisition of TaxACT. A press release announcing the transaction was issued earlier today and can be<br>accessed to the investor relations section of our website. There's also a slide presentation with additional details regarding the transaction which<br>is available for download on our website.<br>
On the call today are a Bill Ruckelshaus, InfoSpace President and Chief Executive Officer, and Eric Emans, InfoSpace Chief Financial Officer.<br>
Before we begin, I would like to remind you that during the course of this call InfoSpace representatives will make forward-looking statements<br>including but not limited to statements regarding InfoSpace expectations about its products and services, outlooks for future of our business and<br>growth initiatives and acquisition strategy.<br>
Our statements that refer to our beliefs, plans, expectations or intentions which may be made in response to questions are also forward-looking<br>statements for purposes of the Safe Harbor provided by the Private Securities Ligitation Reform Act. Because these statements pertain to future<br>events, they are subject to various risks and uncertainties and actual results could differ materially from our current expectations and beliefs.<br>
Factors that could cause or contribute to such differences include but are not limited to the risks and factors discussed in InfoSpace's most recent<br>quarterly report on Form 10-Q on file with the Securities and Exchange Commission. InfoSpace assumes no obligation to update any forward-looking<br>statements which speak only as of the date the statement is made.<br>
After the prepared remarks, we will open up the call for questions. Now I will turn the call over to Bill.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>500</i><br>
<hr>
<A name=501></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thank you, Stacy, and good morning, everyone. I'm pleased to announce that we have entered into an agreement to acquire TaxACT, a leading<br>provider of online tax solutions.The purpose of today's call is to introduce TaxACT, briefly discuss their market opportunity and favorable positioning<br>and highlight why we believe this is an attractive opportunity for shareholders.<br>
I'll start by reviewing our summary messages regarding this transaction. Our CFO, Eric Emans, will then cover some of the key financial aspects of<br>the deal. I will provide a few closing remarks and then we will open the call for your questions. T<br>
he TaxACT leadership team is not on the call today given the demands of peak tax season but I look forward to introducing TaxACT President,<br>JoAnn Kintzel, at a later date to discuss her business in more detail.<br>
Before I get into any specifics, I want to underscore that this is a significant milestone for our Company. As many of you know, capital allocation<br>has been a key focus of ours for some time. During my 13 months as CEO, our team has evaluated numerous acquisition opportunities and we<br>found an outstanding business in TaxACT with a strong consumer brand and a growing market run by a fantastic team with an excellent track<br>record of execution and financial performance.<br>
This transaction aligns with our capital deployment objectives and positions us well going forward. I couldn't be more enthusiastic about the<br>opportunities this combination will create for our shareholders, for the TaxACT team, and for InfoSpace employees.<br>
Let me quickly review some of the key highlights. Under the terms of the agreement we are acquiring TaxACT for $287.5 million in cash. This<br>represents approximately 7.6 times trailing adjusted EBITDA.<br>
TaxACT has an impressive financial profile. As Eric will discuss in more detail, the transaction represents an attractive return on shareholder capital.<br>We are anticipating debt financing in connection with this acquisition and following close, we expect to have an excess of $90 million in cash and<br>equivalents on hand. The transaction should close in the first quarter following the satisfaction of customary closing conditions and regulatory<br>approvals.<br>
The benefits of this combination both from a business and financial perspective are compelling and clear. First,TaxACT operates in a strong market<br>in the early stages of a digital transition, not unlike digital migrations underway in other consumer markets, travel, brokerage, banking, real estate<br>and shopping, to name a few. The travel industry, for example, was one of the earliest to go online thanks to the widespread adoption of eTickets.<br>Today the vast majority of airline tickets are sold online through agencies and supplier websites.<br>
Similar shifts are underway in tax preparation where government adoption and consumer behavior are driving online growth. Since 2000, the US<br>government has expanded access to electronic filing and faster refunds. IRS e-File has grown at double-digit annual rates from tax year 2000 to<br>tax year 2010.<br>
On the consumer side, filers are moving online as familiarity sets in, security concerns abate, and enhanced product offerings make it easier and<br>quicker to do your taxes online than alternative methods of preparation.<br>
Second, we like the TaxACT competitive position. They have an established brand and a well-earned reputation for delivering value to consumers<br>over the years.<br>
Third, TaxACT has a successful track record of great execution driven by a top-flight management team with decades of experience providing<br>consumer tax preparation solutions. And finally, the pro forma financial profile is compelling and offers strong and near-term return on shareholder<br>capital.<br>
Now I'd like to spend a few minutes discussing the strategic rationale in more detail.The tax preparation market is large and undergoing a long-term<br>secular shift toward online, do-it-yourself preparation. Computer aided do-it-yourself tax preparation is supplementing paper and pencil as well<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>501</i><br>
<hr>
<A name=502></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
as professional channels.The digital DIY market itself has grown at 12% compounded annually since 2002, an estimated 30 million filers completed<br>their tax returns online in the tax year 2010.<br>
This shift has legs. Today only 20% of US taxpayers use an online solution, suggesting we are early in the trend. We expect this market to grow at<br>10% plus going forward driven by continued demographic shifts in the base of taxpayers as the mix of digital age filers increases over time.<br>
From the perspective of TaxACT, this secular market growth can be complemented by growth in share and increasing paid offerings to consumers.<br>
Against this market backdrop, we believe TaxACT is uniquely positioned. They have a competitive market offering, leading brand and a loyal and<br>growing customer base.<br>
The three key pillars combined to define TaxACT's favorable positioning. One, brand acceptance. Our research confirms that TaxACT has wide<br>spread acceptance among consumers. Its net provider -- net promoter score, essentially the net of promoters less detractors, speaks to its loyal<br>following among consumers and its score compares with well-known trusted global brands.<br>
Underneath this metric, feedback is exceptionally strong with 93% of customers surveyed indicating they would recommend TaxACT to others.<br>
Year-over-year retention rates on its various products are also quite high and speak to the deep loyalty consumers develop for the Company's<br>offerings.<br>
Number two, superior value.TaxACT is the price and value leader in the marketplace. Our primary research confirms four key requirements among<br>consumers in choosing their tax preparation solution, price, ease-of-use, accuracy and accessibility/reliability. Among these, price is far and away<br>the most commonly referenced driver based on our research and TaxACT is perceived as the leading value-based provider. Comparing pricing in<br>the marketplace underscores this point.<br>
And lastly, financial strength. It is important to note that TaxACT has developed its market position without sacrificing profitability or margin. This<br>provides ample opportunity for further investment in pursuit of market objectives.TaxACT has seen exceptional customer growth and the number<br>of federal returns completed by TaxACT has been growing at a 14% compound annual rate since 2005.<br>
Over 5 million individuals completed their returns with TaxACT in tax year 2010 of which the vast majority did so using the Company's online<br>offering.<br>
I wanted to take a minute to talk about the net promoter score which I mentioned and put it in a little context. TaxACT's net promoter score ranks<br>with other industry-leading brands. From our perspective, the company's NPS score clearly signifies the high level of consumer satisfaction with<br>its products across all important dimensions.<br>
TaxACT solutions span consumer free, consumer paid and professional segments. The company monetizes through a suite of premium features<br>including state tax preparation, telephone support, data archiving, financial products like stored value cards and payment transfers and deluxe<br>bundling. Across the range of offerings,TaxACT commands the dramatic price advantage versus equivalent competitive offerings in the marketplace.<br>
The TaxACT team has an impressive record of execution over many years. TaxACT has a great team that includes industry veterans who have led<br>the company for 13 years, President JoAnn Kintzel and the TaxACT leadership team have been in this business for a long time and together possess<br>decades of experience in consumer tax preparation solutions.<br>
More than anything else, the skills, expertise and relationships of this team constitute the competitive advantage of TaxACT. TaxACT also has years<br>of experience in online direct response marketing and demonstrated effectiveness in retaining consumers.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>502</i><br>
<hr>
<A name=503></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
The company has an expanding presence in social channels online and a mobile offering that now enables its consumers to extend their relationship<br>with the brand wherever they go. We have been impressed with the company's overall marketing capabilities and knowhow at TaxACT and look<br>forward to underwriting their team and investments in this area going forward.<br>
TaxACT financial performance largely speaks for itself. It is a testament to the team that they have accomplished so much while maintaining profit<br>disciplines and preserving capacity for further investment.We look forward to working with the management team at TaxACT to evaluate for areas<br>for future investment and opportunistic expansion.<br>
In addition to TaxACT being a great business, I also believe this transaction represents compelling return on capital to our shareholders.<br>
I would now like to turn the call over to Eric Emans to discuss the key financial benefits of the acquisition. Eric?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
Thanks, Bill. Let's start by taking a look at what this transaction represents in terms of return on shareholder capital. To illustrate, TaxACT levered<br>free cash flow for the 12 months ending September 30, 2011 was $32.2 million. Factoring the $200 million cash investment, the return on equity<br>is approximately 16% for the transaction, (technical difficulty) transaction that contemplates modest leverage.<br>
We project return on equity will grow in 2012 and beyond. It is worth noting the cash tax savings from the utilization of InfoSpace's NOL significantly<br>improves the return on equity by approximately 50% on a pro forma basis.<br>
Now let's take a look at the pro forma financial profile of the combined companies.<br>
As Bill mentioned, the acquisition is immediately accretive to earnings per share. For the 12 months ending September 30, 2011,TaxACT generated<br>revenues of $78.1 million and adjusted EBITDA of $37.8 million.<br>
On a pro forma basis,TaxACT's non-GAAP net income for the 12 months ending September 30, 2011 was $31.8 million, or $0.85 per diluted InfoSpace<br>share, which includes a reduction for imputed interest expense related to the debt financing, the $4.5 million or $0.12 per diluted InfoSpace share.<br>
As a reminder, non-GAAP net income excludes non-cash income tax expense related to our expected utilization of our NOL's which provides<br>enhanced value to InfoSpace shareholders.<br>
Shifting to the combined results, for the 12 months ending September 30, 2011, the combined entity would have generated pro forma revenue<br>of $290 million, pro forma adjusted EBITDA of $72.5 million and pro forma non-GAAP net income of $45.6 million or $1.21 per diluted share.<br>
Finally, TaxACT generates substantial free cash flow and following the completion of the transaction, we will maintain a strong balance sheet with<br>cash in excess of $90 million that will afford us the opportunity to invest in the future.<br>
Now I'll turn the call over to Bill for closing remarks.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thanks, Eric. So to sum it up, we are excited about this next step in the evolution of our Company. Our search business is operating well and exits<br>2011 with a lot of momentum. With TaxACT, we have added a great business and team to the mix confronting a growing market with a leading<br>product and a strong following.<br>
This transaction represents attractive return for our shareholders and the combined company is well positioned for future growth, investment and<br>value creation.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>503</i><br>
<hr>
<A name=504></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
Thanks for joining us this morning and we have a limited time set aside now to address any questions from the group. With that, I will open it up<br>to your questions.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
(Operator Instructions). Clay Moran, Benchmark.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
Good morning. A couple of things. Could you talk a little bit about the competitive landscape where TaxACT fits in, what the barriers to entry are?<br>And seems like TaxSlayer may be somewhat new to the market, what do they represent in terms of a competitive threat?<br>
Secondly, just any change to management that is considered at this point -- TaxACT management, are they all staying on and what's their incentive<br>to stay?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, thanks, Clay. So the tax preparation market is -- consists of established providers, names you have heard of over time, H&amp;R Block, and other<br>off-line typically historically off-line paid professionals who prepare.The market is roughly 60% today on the side of professionals and paid preparers<br>and then about 40% what's called do-it-yourself, which historically has been pen and paper, more recently has been desktop software and even<br>more recently has been online.<br>
And the dynamics are not unlike dynamics, Clay, as I mentioned in my comments, that you see in other consumer segments where just online is<br>an easier way to do it. And there are some hurdles you've got to get over as it relates to the perceived complexities of tax preparation and some<br>of the consumer inhibitions around using an online service to do something like tax preparation.<br>
But nevertheless, that shift is underway. It's one that we recognize from other consumer verticals.<br>
The competitive landscape as it relates to the do-it-yourself includes Intuit, which is a large and respected player in the space; H&amp;R Block is also<br>online with an online solution; TaxACT is a leader as we have talked about. You mentioned TaxSlayer, there's a couple of other players that would<br>I think probably properly be put in the value segment within the online landscape.<br>
And I would say the barriers to entry principally, Clay, are really around the product and the domain expertise of providing consumers with an easy<br>way to do their taxes in an online format. That is -- as simple as that may seem to say, it's a very sophisticated offering and capability that TaxACT<br>has developed over a decade and prior to that at a different company.<br>
And the translation of what can be a rather complicated and confusing set of rules and procedures as they might apply to an individual as they<br>progress through life, translating that into an interview style product offering that gets people comfortable with doing such an important thing<br>online is actually a nontrivial thing and really deeply resides in product and understanding of the tax code and translating that into something<br>from a consumer interface standpoint that is intuitive and comfortable.<br>
So it really is just I think it has a lot to do with domain expertise, which is not uncommon for an industry like this.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>504</i><br>
<hr>
<A name=505></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
One follow up there before you move on to the management. Any plans at all to alter the strategy and/or just enhance the marketing given that<br>InfoSpace is traditionally an online marketing Company? Are there any tweaks to what they're doing that you feel you can help the current situation?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Well, certainly we are optimistic that we can help and enable what the TaxACT team is doing.We really do like the strategy they have been pursuing.<br>I would say from a fit standpoint it lines up very well. We see a lot of cultural alignment between our two companies at the core. We really do feel<br>like there is the beginnings of a great relationship with the team in Cedar Rapids. So I would say that is probably one of the best combination effects<br>right off the bat.<br>
The second is we are both online companies and that's just through the DNA of both companies knowing what it means to own and operate a<br>website, the importance of keeping that website up to date, the importance of uptime and reliability, the importance of security, all the aspects<br>around being an online presence.<br>
And then the aspects with respect to product development and consumer marketing -- and I know you mentioned marketing in particularly, those<br>are two fundamental undertakings of the company of TaxACT that we think they're quite good at. We have been impressed by them in both of<br>those realms and to the extent that we can help, we're absolutely prepared to do that and do so in a collaborative way.<br>
And as you can probably guess from the trended results of the company, the good news is that there's nothing broken at the moment so they're<br>humming along and we have lots of discussions under way as to how we can help them.<br>
I think, Clay, you had also asked a question about retention. And so the management team is sticking around, we have discussed roles with the<br>team there that are unaltered. As I had mentioned in my introductory remarks, the team was one of the real attractive points for us in pursuing this<br>combination.<br>
So we have as you might imagine, discussions and resolution as it relates to roles and responsibilities after this transaction.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
Okay, thank you, congratulations.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thanks a lot.<br>
<b>Operator</b><br>
Kartik Mehta, Northcoast Research.<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
Good morning. I was wondering, you gave some numbers as to what you thought the online market was growing and then you also talked about<br>how well TaxACT was growing. And I'm wondering for the upcoming tax season, would you expect to grow in line with what you thought the<br>online market was growing or is TaxACT in a position where you think you can grow faster?<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>505</i><br>
<hr>
<A name=506></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Well, certainly it would be our expectation to grow in line with the market. It's early to speak to the 2011 tax year season as were really just getting<br>underway, as you know. But the company is excited about the plans it has in place.<br>
It has in the course of this year unlike -- not unlike prior years, learned a lot of things as it relates to the market and how it developed in calendar<br>year 2010, tax year 2010. Applied those learnings into its product, applied those learnings into its marketing, thoughts around marketing budget<br>and marketing mix and timing of its marketing spend. And so I think that they are very well positioned to have a good year and certainly it's<br>everybody's expectation that they will grow with the market.<br>
One thing I would say is that historically the growth formula is very logically a function of getting consumers to come to the site, getting those that<br>have worked with you in the past to revisit and reuse your product and then also making sure that they are making it -- they have available to them<br>a variety of offerings, some of which will be paid and that they make full use of those so that that can go to conversion within the funnel. And all<br>of those levers are being pursued.<br>
I think from a pricing standpoint, the company has not historically taken aggressive pricing year on year. Price and value and affordability are<br>fundamental to its core message to consumers. And so I think that is a lever that they'll use more judiciously than it simply will be trying to drive<br>year on year revenue growth through pricing action.<br>
But to your core question as it relates to the unit volumes, certainly they are expecting to grow with the market.<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
And so as I look at the numbers you presented in your presentation, obviously TaxACT grew revenue fairly well from FY '10 to FY '11. Would that<br>imply that the corresponding customers grew in the same manner concerning your statement that they have not used pricing really?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Right. So for the most part, but not exactly. So the other determinant there as it relates to revenue growth is going to be mix. So three to the extent<br>that you had a constant mix from year to year, I think the answer to your question would be yes. But to the extent that you have an evolved mix<br>as it relates to paid versus nonpaid consumers and then on the paying consumers, what is the revenue per consumer as i.e., the attach rate around<br>paid offerings?<br>
So there are differences, as you know, from year to year as it relates to that.<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
I just want to make sure I understood the statement you said. So would it be fair to say that TaxACT will be more -- will be a little bit more aggressive<br>in how it prices its product, it has maybe more pricing power than the companies used in the past so now they'll have more opportunity to use<br>pricing as a way to grow?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Well I think I was speaking to their historical practice which historically that has not been -- that is a lever that many providers in the marketplace<br>and anybody naturally offering something that consumers might use.<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>506</i><br>
<hr>
<A name=507></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
I think however that the deliberation that goes on within the TaxACT team as to how and when they take pricing, those types of topics are given<br>a lot of thought because fundamentally one of the reasons why the following is as strong as it is is that it has a well-earned reputation for being a<br>value provider, a provider of value, it's got a great product and it's also offered on great terms.<br>
And so care will be given as it relates to pricing decisions to make sure that they don't run awry of that relationship with their consumers. So was<br>less offering a view into the future.<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
And then just one final question. Any thoughts about further consolidating the industry as there are some other smaller players in the market that<br>do online?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes. So consolidation in the space has certainly been discussed. I think there -- in certain cases there would be advantages in combining, in TaxACT's<br>case and InfoSpace and TaxACT's case with another player in the market. I think we would want to give some thought to what the expanded<br>presence might be with consumers as it relates to the brands and what they signify. To the extent those brands were entirely overlapping, I think<br>the question would then go to more raw back-end economics and the advantages of bringing two businesses together. But it is certainly something<br>that is a possibility in the foreground.<br>
<b>Kartik Mehta</b><i> - Northcoast Reasearch - Analyst</i><br>
Thank you very much, I appreciate it.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
Eric Martinuzzi, Craig-Hallum.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
Thanks. Just going back to your description of the services, products and services that they currently offer, you talked about their -- it's do-it-yourself<br>but there's a combination of desktop software as well as the online. What is the current revenue mix between the two?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
Eric, it's Eric here. So right now, it's primarily driven by the online product, the desktop is declining over time as you would expect those users to<br>shift to online. So I would say about 70 -- over 70% of revenues coming from the online and desktop is at about 8% for tax year 2010.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
I didn't follow that, you said online is primarily -- it is over 70 --.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>507</i><br>
<hr>
<A name=508></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
So, online about 75% approximately.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
Okay, so online 75%<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
And desktop at about 8%.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
What makes up the balance?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
You've got preparer -- we have a tax preparation offering and that is about 9%, and then we have some value-added services, bank products and<br>Stored Value Cards.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
As you -- the customer transformation, I imagine the first exposure for a consumer is the free federal online. What is the next thing that consumers<br>buy? Is it a state online or is it some kind of -- what's the upgrade past?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
That's right, Eric, this is Bill. So that is absolutely right. The company has over the years been steadfast in offering and really the first in offering free<br>federal filings, which as you can imagine is of great interest to a good swath of the market.Those consumers that are residing in states where their<br>state income tax, that is an upsell to provide that and the company has a product that addresses all the states there.<br>
And there is another -- there are other upgrades as it relates to that rate card and the pricing sheet with respect to the types of services that Eric<br>had mentioned. There is a degree of stickiness as it relates to a consumer that enters in the first year whether they are filing federal or federal and<br>state as it relates to their information.<br>
And so the ability to access that information for retrieval purposes as it relates to future tax periods, for initiating your taxes in the coming year is<br>of great value and that is an example that is referred to as data archive service that the company offers, which would be an example of a paid<br>product above and beyond state.<br>
And then there are a variety of financial services including refund payment transfers, Stored Value Card solutions that offer consumers flexibility<br>as it relates to the receipt of refunds and what they do with those refunds and how they are processed.<br>
Support is another important -- another element of their service, Eric, and consumers that are looking for more hand holding and walk-throughs,<br>they perceive complexity of their filings as such that they want to get on the phone with somebody; that is offered by the company as well.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>508</i><br>
<hr>
<A name=509></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
And then last question, just doing a quick search, I was not aware of this but apparently H&amp;R Block had made a play for TaxACT and it was barred<br>due to anti-competitive -- the Justice Department stepped in and said, no can do. At what point -- was this your first go at this entity? Can you give<br>any sort of background as to -- because it seems like only November that H&amp;R Block dropped their efforts?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, that's right. It has been our first go at the company, as you say. And the company had announced an acquisition or a sale to H&amp;R Block in<br>October of 2010, which didn't come together and that became clear toward the back half of 2011.<br>
<b>Eric Martinuzzi</b><i> - Craig-Hallum - Analyst</i><br>
Thank you.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thanks.<br>
<b>Operator</b><br>
Rich Tullo, Albert Fried &amp; Company.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Congratulations on your deal, it's been a long time in coming. You said 40% of the market is electronic. What percent of that market is TaxACT?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Good morning, Rich, this is Bill. I think and it is important from a market definition standpoint to walk through it a little bit. To be more specific,<br>40% is what we call do-it-yourself and do-it-yourself historically has been pen and paper, people just don't want to pay a storefront provider to do<br>their taxes, their taxes are simple or they're at a level of comfort and sophistication where they are happy doing it on their own.<br>
And that particular segment has been undergoing a pretty radical shift over the last 15 years, which is the initial alternative method that was<br>introduced was more of a CD-ROM desktop type offering where consumers could move away from pen and paper. And then more recently which<br>has now been going on for some time has been the online capability, which is replacing not only pen and paper but also now desktop.<br>
But that 40%, which is the do-it-yourself, that is the segment that really refers to that subset of the filing population that is comfortable whether<br>it's just -- they just prefer to do it on their own, they have privacy concerns, they have a perfect level of sophistication and comfort doing it on their<br>own. But that's what we refer to as do-it-yourself.<br>
The subset of do-it-yourself, which is referred to as digital do-it-yourself is 33% of the market.The numbers are not super precise as it relates to the<br>sources but rough order of magnitude 140, 142 million filers in the US, 40% of which are in the do-it-yourself category through whatever means<br>and 33% of overall filers are in the digital do-it-yourself which includes both software and online. And then the online portion is 20% which is where<br>we came up with the 30 million filers out of the 140 million.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>509</i><br>
<hr>
<A name=510></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Okay. Second question is what are the regulatory and legal events which are likely to influence the business over the next six to 18 months? I guess<br>this is an industry that's in some degree influenced by changes in the tax law. And how do you kind of look at that?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
It has historically been influenced by tax law. I think one of the real drivers of the opportunity we see in the digital online market is the -- is really<br>aided by the US government in terms of its initiatives around the Free File Alliance, which was in the early 2000s teeming with industry participants<br>to make it easy for individuals with incomes below $57,000 a year to file electronically which has been a real catalyst. And also provides a lot of<br>clarity with folks as to the dates of the filing and creates a rather regimented calendar year in, year out.<br>
To the extent that there is simplification on the horizon, this is a difficult thing for anybody to crystal ball, but to the extent that the tax code<br>simplifies then you might imagine that consumers' perception of the complexity of their own filings will decrease which I think as well would be<br>a catalyst to the reception of online and the migration toward online.<br>
So we would certainly see that as being a tailwind to the extent it happens but that's a difficult thing to speak to.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
A couple of I guess kind of clean-up questions here. CapEx, what is the CapEx of this business? How is that going to integrate with your own CapEx?<br>And I guess we can ask the same question of non-cash executive compensation?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
So on the CapEx -- this is Eric -- historically it's about $500,000 a year. Yes, there is equity compensation involved. We're not going to provide any<br>forward-looking guidance on that at this time. But yes, we will have stock-based compensation.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, I would say philosophically welcoming the team into the fold is something that we want to do at all levels and allowing the TaxACT management<br>team to have prominent roles and responsibilities within our combined companies is absolutely something we want to do and allowing them<br>through stock-based compensation to take ownership in the value we create together is very much in line with that.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Fair enough. Are there any key person provisions either in the debt agreement or in the M&amp;A deal plan?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
In regards to the debt agreement, we have a commitment at this time but we're not going to go into any further detail until we have the definitive<br>credit agreement in place. As far as key folks, the agreement contemplates what you'd expect provisions from the key management as far as<br>non-competes and in that regard. But outside of that, that's all we're looking at.<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>510</i><br>
<hr>
<A name=511></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
I guess I know Intuit -- start again to the website development business with its tax folks, is that a business that you can kind of leverage with the<br>distributed search?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, we think there are opportunities to enhance the presence of TaxACT on our various web properties and use our search business to TaxACT's<br>advantage and we're looking into ways to do that even this tax season -- as soon as we close this transaction.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Do you have any idea what the closing costs are going to be facing us either in the fourth quarter or the first quarter this year?<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
So in the deck, we had indicated transaction expenses would be about $5.5 million. I would say the lion's share of those will be in the first quarter.<br>
<b>Rich Tullo</b><i> - Albert Fried &amp; Company - Analyst</i><br>
Thank you very much for taking my questions. It looks like a very interesting deal and good luck with it.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
Scott Kessler, S&amp;P Capital IQ.<br>
<b>Scott Kessler</b><i> - Standard &amp; Poors - Analyst</i><br>
My first question I think is one that seems obvious but I think is worth exploring. Bill, obviously since you've been leading the Company, I think a<br>lot of people have been anticipating a transaction like this. However -- and of course the fact that you have spoken to it in generality would be one<br>of the reasons why.<br>
I'm wondering if you could explain to us a little bit about how you decided on this company as opposed to one that might have been within the<br>construct of what you and we might have considered related adjacencies? I think one of the big questions about this transaction as much as it<br>seems appealing on some levels is it doesn't seem to have a lot to do with your core business right now.<br>
And the second question I have is somewhat related, which is the prior proposed transaction between H&amp;R Block and TaxACT, not coincidently<br>seemed to be for about the same amount of money. So I'm wondering how you came to the sum and did your valuation analysis? Thanks.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>511</i><br>
<hr>
<A name=512></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Yes, sure, thanks, Scott. Yes, it's very, very reminiscent of that price so I will let let you arrive at your own conclusions as to how it is we arrrived at<br>that valuation. It was negotiated outcome as you might imagine as these things typically are. And there was a degree of opportunism on our part<br>as it relates to pursuing this opportunity.<br>
So one of the things that I think we have spoken about in prior calls has been as it relates to the successfulness of our acquisition effort, making<br>sure that we have the right resources in place, making sure that we have the right criteria established that best map to our opportunity and where<br>we think we can be successful and then also a degree of opportunism which is finding the right situation and making sure that we act with urgency<br>in pursuit of an opportunity.<br>
And this is I think straight down the fairway as it relates to those attributes that the idea of moving into an adjacent category that would be more<br>directly complementary of search was certainly something that was in the consideration set. And so by virtue of this announcement, one should<br>not assume that those types of opportunities weren't evaluated.<br>
This was one that was head and shoulders from our perspective more attractive, from a market opportunity perspective, from our ability to influence<br>the outcome of what the company is doing. And that may be through means of the catalyst of new ownership and adopting a philosophy of<br>investment and resourcing and things that we're all very much stand at the ready to do with this business.<br>
But also in terms of cultural fit. We like the team, we think the team is doing really great things from their headquarters in Cedar Rapids, Iowa and<br>we look forward to enabling them.<br>
And so I think that's the -- that's really the way to answer that question. If you have any sort of more specific questions related to that, I'm happy<br>to answer them.<br>
<b>Scott Kessler</b><i> - Standard &amp; Poors - Analyst</i><br>
I guess one of the things that I know I'm thinking about is you look at the order of what transpired, clearly you guys have been looking for a<br>meaningful larger transaction for some time clearly in I guess -- what, the fall of last year, the deal with H&amp;R Block fell apart. So it provided you guys<br>with an opportunity. And I think that is something that you should be applauded for.<br>
But I guess what I'm wondering is, is it just that you didn't find what you wanted to find potentially in those adjacencies or was it a valuation issue<br>or is it just that this opportunity arose and it was so compelling you had to move forward with it?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Well, I think that's a good question, I think by definition because we didn't announce anything in an adjacent space, we didn't find anything we<br>liked. There were plenty of things that we've looked at. I mean I think we've gone into some detail on prior calls as it relates to the exhaustiveness<br>of our effort and I think price has been an issue, Scott. So we have turned over a lot of rocks and there are a lot of great companies out there, there<br>are a lot of great companies that think they are worth on a multiple basis 15 to 20 times EBITDA and so it's difficult to reconcile in those conversations.<br>
And so I think the alignment that we feel as it relates to this company is kind of the points I had walked through the before as it relates to it being<br>an online company, the DNA is very similar to the DNA at this Company.TaxACT has what I would characterize as a maniacal focus on the consumer,<br>which is they have built relationships with over five million filers over the course of their 13-year operating history that is really quite astounding<br>and speaks to their attention to product detail and attention to maintaining relationships beyond an initial tax season.<br>
And it's those types of attributes that as we think about the investment criteria and where we thought we would be most successful allocating our<br>capital, that was absolutely one of those attributes which probably falls under the broader heading of just a really good company. And the fact<br>that it's an online company and one that we think we're -- we understand and are positioned to help I think only adds to the rationale.<br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>512</i><br>
<hr>
<A name=513></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Scott Kessler</b><i> - Standard &amp; Poors - Analyst</i><br>
Great. And the last question I had, just a really quick one if I may, any synergies you guys see on the revenue or on the cost side?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
So I think that there likely will be synergies. My sense is that we're not coming at this from a cost rationalization standpoint in the slightest. As I had<br>mentioned, we may even on a more likely case see opportunities to invest together where we haven't before.<br>
And from a revenue standpoint, there are going to be opportunities for the InfoSpace search business to more prominently feature TaxACT through<br>the course of our search results pages and our display inventory and we're going to take advantage of those as you might imagine and the next<br>3.5 months is a good time to do it.<br>
<b>Scott Kessler</b><i> - Standard &amp; Poors - Analyst</i><br>
Great, thank you.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thanks.<br>
<b>Operator</b><br>
Ned Davis, William Smith &amp; Co.<br>
<b>Ned Davis</b><i> - William Smith &amp; Co. - Analyst</i><br>
Thank you. Good morning, congratulations. I will only ask one question. Marketing expenses, the company has what looks to be about a 45%<br>operating margin. What are the marketing expenses in absolute terms maybe on a trailing 12? And how will you change the marketing strategy<br>at this business going forward?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Good morning, Ned, happy new year. So marketing expense as you might imagine is a significant piece of the company's SG&amp;A.The spend is suffice<br>it to say, well over $25 million a year. You could piece that together by looking at the results.<br>
The historical practice has been not unlike other consumer acquisition efforts where it's a multichannel marketing effort online and off-line.There's<br>a lot of experimentation and a lot of processing of learnings from one year to the next. Much of the buying that goes on is bought ahead of time<br>as you might imagine, there's quite a lot of messaging in the marketplace this time of year between now and the end of tax season as it relates to<br>tax preparation. It's a seasonal business and in further communications, we are going to provide more detail as to the breakout of the business by<br>quarter.<br>
But they have spent it in online and off-line channels and have had greater success in some areas than others, they spent a decent amount of<br>money in the search channel, which is an area where we spent a fair amount of time discussing and one we well understand.<br>
14<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>513</i><br>
<hr>
<A name=514></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
And so I think that I personally have been impressed by the company's direct marketing capabilities and the brand that they have been able to<br>build with the profit disciplines in place. So to the extent that we can work with the management team to continue that tradition and accelerate<br>that tradition, we see that as a real opportunity.<br>
<b>Ned Davis</b><i> - William Smith &amp; Co. - Analyst</i><br>
Thank you. Congratulations.<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
Thank you.<br>
<b>Stacy Ybarra</b><i> - InfoSpace - Senior Director, IR</i><br>
Operator, we have time for one last question.<br>
<b>Operator</b><br>
Clay Moran, Benchmark.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
Just two more questions. First, just wondering if there's any change to the Board of Directors contemplated at this point specifically is Andrew<br>Snyder staying on in helping develop TaxACT?<br>
Secondly, do you have plans to pay down the debt and are there any terms that prevent you from paying it down quickly?<br>
<b>Bill Ruckelshaus</b><i> - InfoSpace - President and CEO</i><br>
No changes to the Board. Andy is absolutely staying on Board or certainly we hope he is. He's been a real contributor in the few short months he's<br>been on Board and certainly was helpful in this -- in getting to this point with this transaction. So, no nothing to communicate to you on that front.<br>
<b>Eric Emans</b><i> - InfoSpace - CFO</i><br>
As far as the debt, we're not going to get into too many -- too much specifics. But I guess the way we look at it is we expect to pay it off in about<br>three years. And if we wanted to pay it off sooner, we could.<br>
<b>Clay Moran</b><i> - The Benchmark Company - Analyst</i><br>
Okay, thank you.<br>
<b>Operator</b><br>
This concludes the question-and-answer portion. I would like to turn the call back to Ms. Stacy Ybarra for closing remarks.<br>
15<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>514</i><br>
<hr>
<A name=515></a>JANUARY 09, 2012 / 1:30PM, INSP - InfoSpace Conference Call to Discuss Acquisition of TaxACT<br>
<b>Stacy Ybarra</b><i> - InfoSpace - Senior Director, IR</i><br>
Thanks everyone for joining us today on such short notice. Have a good day.<br>
<b>Operator</b><br>
And this concludes today's call. Thank you very much for your participation. You may now disconnect and have a great day.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4703246-2012-01-09T20:16:16.937</b><br>
16<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>515</i><br>
<hr>
<A name=516></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
ONXX - ONYX PHARMACEUTICALS AT<br>JPMORGAN GLOBAL HEALTHCARE<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 5:30PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>516</i><br>
<hr>
<A name=517></a>JANUARY 09, 2012 / 5:30PM, ONXX - Onyx Pharmaceuticals at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Tony Coles</b><i> Onyx Pharmaceuticals, Inc. - President, CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Cory Kasimov</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Cory Kasimov</b><i> - JPMorgan - Analyst</i><br>
Good morning everybody. We will keep this moving. My name is Cory Kasimov, a senior biotech analyst at JPMorgan, and it is my pleasure to<br>introduce our next company, which is Onyx Pharmaceuticals. Onyx is coming off a very productive 2011, and we expect a lot of news flow from<br>this Company in 2012 revolving around their three oncology assets, Nexavar, regorafenib, and of course carfilzomib.<br>
Here to tell the Onyx story is the company's President and CEO, Tony Coles. And please note that following Tony's presentation there will be a<br>breakout session just across the hall in the Georgian Room. So with that I will turn it over to Tony.<br>
<b>Tony Coles</b><i> - Onyx Pharmaceuticals, Inc. - President, CEO</i><br>
Thanks, Cory; and good morning, everyone.Today's conversation is going to include forward-looking statements, and I will refer you to our various<br>SEC filings for additional details about the presentation.<br>
I actually want to tell you a story, and -- tell you a story, and unlike many stories that have a beginning, a middle, and an end, this is a story that has<br>a beginning, a middle, and a future. If I were going to use the method it would be -- once upon a time there was a tiny company that had one<br>product, maybe half a product, and that would describe Onyx 1.0. Nexavar just approved in liver and kidney cancers at the end of 2005 and 2007,<br>respectively, and it formed the basis for this tremendous engine for growth and opportunity that we now today call Onyx.<br>
In its current iteration, Onyx 2.0, Nexavar continues to grow globally. There are sales that are growing and advancing in liver cancer around the<br>world and importantly in the Asia-Pacific regions, where year over year we experienced approximately 27% growth in that critical region of the<br>market that represents the greatest demographic opportunity for liver cancer.<br>
And now, new to the story, new to Onyx 2.0 and its second iteration or its second chapter are a set of franchises that we are proud to call our own.<br>On the horizon, Onyx 3.0, the next evolution for the Company.<br>
And not very far away, because as you think about 2011 -- and we appreciate Cory's kind words -- 2011 really was a pivotal and a remarkable year<br>for the Company. The strength of news flow, the strength of significant strategic achievements have positioned the Company in several critical<br>areas. Importantly, advancing carfilzomib; expanding the portfolio; and as I have mentioned already, continuing to grow Nexavar, which now<br>entering its sixth year of commercialization continues to be the core for the growth for our Company.<br>
For carfilzomib we expanded the data set across treatment settings with something for everyone. In the frontline, the relapse setting, and importantly<br>in the relapsed and refractory setting, where critical treatments are needed and necessary for patients who today don't have any good alternatives.<br>
Starting the globalization of our efforts with clinical testing in Japan through our partners in Japan, Ono, as well as the expansion of our commercial<br>infrastructure and business infrastructure in Europe with headquarters now in Switzerland and regulatory headquarters in London marks the<br>globalization of Onyx as we enter this new phase or new chapter of our story. And then finally submitting the New Drug Application for review by<br>the FDA with an expected decision date in the middle of this year.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>517</i><br>
<hr>
<A name=518></a>JANUARY 09, 2012 / 5:30PM, ONXX - Onyx Pharmaceuticals at JPMorgan Global Healthcare Conference<br>
For the portfolio it has been our objective as we have started this journey to expand the portfolio to become something bigger than a one-product<br>company, and we have achieved that in several interesting and wonderful ways to expand the focus of the Company. The settlement and the<br>restructuring of our agreement with Bayer Pharmaceuticals for regorafenib gives us an additional entry in the kinase inhibitor space and now a<br>true franchise, an opportunity to grow and strategically position and leverage the power of two compounds in partnership with Bayer, with<br>significant economic interest; and then just two short weeks later, impressive data in the overall survival improvement for patients receiving<br>regorafenib, this new drug. And then Nexavar continues to be the workhorse, growing globally around the world.<br>
These two platforms for growth, which are enabling Onyx 3.0 in this next iteration for growth, critically in the kinase inhibitor space and in proteasome<br>inhibitor space recognize and bring to us unique opportunities.The power of the franchise opportunity in the kinase inhibitor space has everything<br>to do with strategic and complementary positioning of new indication opportunities to bring new therapies to multiple patient types who are in<br>desperate need. And the same on the proteasome inhibitor side.<br>
So if you think about Onyx in that once-upon-a-time day, moving from one product in two indications to potentially by the end of 2012 three<br>products with data or registration in up to seven indications in less than a year, a really miraculous transformation and evolution of the story. And<br>we will count the opportunities that we have. Important in all of this is the optionality we have built into the business to drive revenue and to help<br>patients importantly along the way.<br>
Let's start with the proteasome inhibitor franchise, carfilzomib and ONX 0912, the cornerstone of the new growth opportunities for the Company.<br>These are our proprietary compounds globally, and they are compounds that are advancing rapidly in the clinic as we seek answers to important<br>questions.<br>
The market itself is expected to be just under $9 billion in 2016 or so. And if you look at each of the colored segments of these cylinders, the relapsed<br>and refractory setting accounting for the smallest. And we recognize that as an entry point this is going to be critical -- critical for patients, critical<br>for myeloma, and critical for the evolution of this marketplace. Here, carfilzomib demonstrates a 1-in-4 response rate for patients, as I have said,<br>who have no treatment alternatives.<br>
And in the relapsed setting, which is also growing attractively, in combination with Revlimid and dexamethasone a nearly 78% response rate. But<br>perhaps most impressive is the complete response rate in the first-line or frontline setting, recent data there evidencing a nearly 80% complete<br>response with virtually no disease detected in these patients. Remarkable. Stunning and amazing.<br>
The proteasome inhibitor pipeline looks a little bit like this. It unfolds first in the relapsed and refractory setting. It is the subject of a New Drug<br>Application with the FDA. ASPIRE is our study for the relapsed population; and FOCUS of course to enable registration in the European Union.<br>
Then there are opportunities potentially for monotherapy, carfilzomib in solid tumors. A yet untapped opportunity for proteasome inhibitors, but<br>we think that we may be on to something in solid tumors in addition to liquid tumors. And if you add 0912, the oral proteasome inhibitor with an<br>opportunity for dosing in the maintenance setting, imagine the power of the franchise opportunity of these two compounds, therapies, together<br>in the marketplace.<br>
Today under review for the NDA is the relapsed and refractory population. Just to provide some context, with currently available therapies the<br>response rate for patients who have exhausted all therapies is about 11%. The pivotal data from our Phase 2b study suggests that this improves<br>to 24% in this same population, nearly doubling what available therapies provide. But you can see we have a very, very long way to go.<br>
Now impressively that is monotherapy, not combination.That is monotherapy carfilzomib. No dexamethasone, no Revlimid. Monotherapy carfilzomib.<br>So a powerful statement for the efficacy and the biological activity potential for this compound.<br>
Tomorrow as we think about this we add maintenance, we add relapse, we add the frontline as important opportunities in this strong Phase 2 data<br>in each of these settings -- relapsed and frontline in particular -- which point us towards a pathway for opportunity for patients.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>518</i><br>
<hr>
<A name=519></a>JANUARY 09, 2012 / 5:30PM, ONXX - Onyx Pharmaceuticals at JPMorgan Global Healthcare Conference<br>
The regulatory strategy complements this development program. In the first half of this year we expect to complete enrollment for the ASPIRE<br>study. It is our nearly 700-patient study, a global study looking at carfilzomib, Revlimid, and dexamethasone in patients who have received one to<br>three prior therapies. I have already told you that the Phase 2 results suggest an overall response rate of about 78% in this population, and we are<br>hoping to replicate that with this trial.<br>
To complement our efforts for the NDA filing in this country for relapsed and refractory we will begin -- we will expect completement of enrollment<br>in the FOCUS study in the fourth quarter of this year or early next year. So you can see very easily that each of these indications comes to bear in<br>an important way with pivotal data in the near term.<br>
This unlocking of the potential to build Onyx 3.0 comes with investment. Investment to unlock the potential, investment behind a compound that<br>we know has biological activity and has demonstrated improvement over standard therapies. And for that investment we expect clinical data in<br>the frontline setting to replicate those astounding findings I quoted just a moment ago of nearly 80% complete responses -- virtually no disease<br>detected in the newly diagnosed population.<br>
In the relapsed setting head-to-head possibilities against Velcade, the other proteasome inhibitor, and this is a strategy that we are studying very<br>carefully to design the appropriate trial to ensure we are bringing additional value to patients with carfilzomib. And then in the maintenance<br>setting, where there are long-term dosing opportunities, 0912 which has already begun its Phase 1b/2 program.<br>
So in summary for the proteasome inhibitor franchise -- what does it look like? What does it mean?<br>
Well, across carfilzomib and ONX 0912 the opportunity by the end of this year will begin the count. If you add to liver and kidney cancer, Nexavar;<br>relapsed and refractory myeloma for carfilzomib; 0912 earlier stage, but a great revenue opportunity and a great potential opportunity for patients<br>who desperately need oral therapies. Taken together these two compounds should amount to about $2.5 billion in franchise sales globally, with<br>an opportunity in Japan for our partner Ono and an opportunity for Onyx to expand its already existent US commercial infrastructure and, importantly,<br>plant a flag in Europe.<br>
Now, let's turn to the kinase inhibitor franchise, Nexavar and regorafenib; but I will start with Nexavar first. Let's continue our count. Beyond liver<br>and kidney cancer, now relapsed and refractory myeloma with carfilzomib, we add to that data in critical areas for lung cancer, for thyroid cancer;<br>and for regorafenib potentially colorectal cancer and GIST.<br>
We will talk about regorafenib in greater detail in just a moment, but I want to speak to the breadth of opportunity we have across solid tumors,<br>liquid tumors, and the opportunity to bring much-needed therapies where there is great need.<br>
Today as with the proteasome inhibitor franchise, this is where we start with liver and kidney cancer, the opportunity for adjuvant data. For<br>combination targeted, the data with Nexavar in combination with Tarceva. And for data critically in the setting of chemoembolization, the SPACE<br>study which will be reported on shortly, which is designed to indicate safety in coadministration of Nexavar with chemoembolization.<br>
Tomorrow we see the world potentially expanding to include thyroid cancer importantly, lung cancer. Gastrointestinal stromal tumor and colorectal<br>cancer for the franchise through regorafenib.<br>
In the near term, the key data points that we expect for the first half of this year come from MISSION the Phase 3 study of about 700 patients or so.<br>Its primary endpoint overall survival. Enrollment completed at the fourth quarter of 2010, and we are expecting data as quickly as the events accrue;<br>but we do expect it in the first half of this year.<br>
And for thyroid cancer, DECISION. 380 patients; progression-free survival is the primary endpoint; also coming in the first half of this year.<br>
Let's look at each of these important areas more carefully. $6.5 billion for the non-small cell lung cancer market, growing to just under $11 billion<br>by 2016. Nearly 2 million new cases diagnosed annually expected by 2016. And 94% of the market with significant unmet need in the advanced<br>metastatic setting. There are no good therapies for patients in the third- and fourth-line study, which is the subject of the MISSION trial.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>519</i><br>
<hr>
<A name=520></a>JANUARY 09, 2012 / 5:30PM, ONXX - Onyx Pharmaceuticals at JPMorgan Global Healthcare Conference<br>
For thyroid cancer, another area of significant clinical and treatment need.Thyroid cancer is not the largest cancer; it is 200,000 cases on an annual<br>basis. Prevalence of about 900,000, just under 1 million. But the interesting opportunity for thyroid cancer is for the chronic administration of oral<br>targeted therapy. In this we find an opportunity to drive the revenues for Nexavar and to help more patients who critically need help.<br>
Today the standard of care is cytotoxic chemotherapy, doxorubicin. 40 weeks in overall survival is about the best we have been able to demonstrate.<br>
The Phase 2 data for Nexavar in this population demonstrates 140 weeks, nearly two years and a half, in terms of overall survival improvement. So<br>this is a study that should work; and if it works -- and we will know by the first half of this year -- will give us an opportunity in the kind of thyroid<br>cancer that covers 95% of the cases of this deadly disease.<br>
Today, the kinase franchise is only Nexavar. But I would like you to imagine a world, a chapter, where regorafenib sales top this and the royalty that<br>we receive from regorafenib, where carfilzomib sales are additive to the sales that you see here. This year we are expecting somewhere between<br>$975 million and $1.25 billion in sales for Nexavar; through the third quarter of 2011, $730 million, nearly 11% in double-digit growth year over<br>year; and a cumulative nearly $4 billion in sales since launch. So a highly successful opportunity that has changed the lives of people around the<br>world.<br>
For regorafenib, the newest addition to the Onyx lineup, Phase 3 colorectal trial was stopped early by the DMC. We reported this in late October.<br>Regulatory filings are planned for this year, 2012, and notably data, top-line data and detailed data, to be delivered very shortly at an upcoming<br>medical meeting. This opportunity has a fast-track designation.<br>
And just behind that are data for GI stromal tumor, where we expect data very shortly, in this quarter for 2012. So think about the momentum,<br>think about the number of targeted therapy opportunities, think about the number of indication opportunities that we have for the kinase inhibitor<br>franchise and for the proteasome inhibitor franchise.<br>
Regorafenib is different than Nexavar. For those of you who recognize this particular mechanism, the proliferation of certain tumor cells is inhibited<br>by Nexavar; so that is the same. The inhibition of neo-angiogenesis is also part of the key mechanism for Nexavar.<br>
But what is quite interesting and unique is the inhibition of stromal signaling, the interaction between tumor cells and surrounding normal healthy<br>tissue cells, where regorafenib brings a unique perspective. It binds and inhibits different kinds of kinases than Nexavar.<br>
If you think back to the power of a franchise concept and the opportunity to strategically and with complement cover a number of solid tumors,<br>this gives us a great opportunity. Adding to the indication opportunities of Nexavar are colorectal and GIST and potentially other tumors as well.<br>
Let's take a look at the colorectal cancer market. Over 1 million cases on an incident basis.The five-year prevalence, 3.5 million cases.This is a tumor<br>that can be treated, but not cured.<br>
It is for those patients who develop metastatic disease, who have no other alternative, that regorafenib may provide an important benefit. 50% to<br>60% of patients will develop metastatic disease, which is astounding. And no standard of care, as is the case for lung cancer in the latest stages, for<br>this population.<br>
So we have made enormous strides in treating cancer, but we have that much more work to do, and that is part of Onyx 3.0.<br>
Let's talk about the trial design. 2-to-1 randomization. It is a Phase 3 study for this trial, and the primary endpoint was overall survival. 760 patients<br>randomizing, as I have mentioned. The DMC stopped this particular trial early and data results presented at an upcoming meeting.<br>
We have significant economic interest in regorafenib in a very P&amp;L-friendly structure, where we have no commitment to development or commercial<br>expenses and a 20% royalty worldwide on oncology sales for this particular compound. We have the option to co-promote in the United States,<br>which should complement what we do on the solid tumor space with Nexavar and add to what we do in the liquid tumor space with carfilzomib<br>and ONX 0912.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>520</i><br>
<hr>
<A name=521></a>JANUARY 09, 2012 / 5:30PM, ONXX - Onyx Pharmaceuticals at JPMorgan Global Healthcare Conference<br>
So how do we put all of this together? We started with a once-upon-a-time, a tiny company with half of a product. Our goal very simply and our<br>mission is to make a difference in the lives of patients. It is why I get up every morning, and it is the only expression of value that we know will bring<br>lasting shareholder value and lasting benefit to patients around the world.<br>
This year the critical news flow, the strength of our balance sheet with over $600 million in cash, the opportunities for a near-term registration for<br>carfilzomib, and then on the horizon new indication opportunities for Nexavar, for carfilzomib, for the rest of the proteasome inhibitor franchise<br>suggest that Onyx is well on its way to defining its next chapter. So if I were to close and invite you on the continuation of this great journey that<br>we have started, help us write the story for a Company that has all the potential to do a lot of good. Thank you very much.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4696501-2012-01-09T20:24:07.027</b><br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>521</i><br>
<hr>
<A name=522></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
TCK.B.TO - TECK RESOURCES LIMITED<br>TO ACQUIRE SILVERBIRCH -<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 2:00PM GMT<br>
OVERVIEW:<br>
Announced an agreement for TCK.B.TO to acquire SilverBirch Energy by way of<br>plan of arrangement and creation of SilverWillow Energy Corporation, a new<br>corporation focusing on in situ oil sands opportunities. SilverBirch shareholders<br>will receive CAD8.50 per share in cash plus one share of SilverWillow.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>522</i><br>
<hr>
<A name=523></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Michael Stevens</b><i> SilverBirch Energy Corporation - Manager- Finance, IR</i><br>
<b>Howard Lutley</b><i> SilverBirch Energy Corporation - President, CEO</i><br>
<b>Jina Abells Morissette</b><i> SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
<b>Wayne Bobye</b><i> SilverBirch Energy Corporation - VP, CFO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Sachin Shah </b><i>Tullett Prebon - Analyst</i><br>
<b>Mark Friesen</b><i> RBC Capital Markets - Analyst</i><br>
<b>Catharine Sterritt</b><i> Scotia Capital - Analyst</i><br>
<b>John Tumazos</b><i> John Tumazos Very Independent Research - Analyst</i><br>
<b>Mike Dunn</b><i> FirstEnergy Capital Corp. - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Operator</b><br>
Welcome to the SilverBirch Energy conference call. At this time, all participants are in a listen-only mode. Following the presentation, we will conduct<br>a question-and-answer session. Instructions will be provided at that time for you to queue up for questions. (Operator Instructions)<br>
The Company may make forward-looking statements during this call. These statements are based on SilverBirch's expectations and are subject to<br>a variety of risks and uncertainties and other factors which are inherent in a pre-development stage oil sands mining and extraction enterprise that<br>could materially affect SilverBirch's results. No representations can be, or is being made, with respect to the accuracy of projections or the ability<br>of SilverBirch to achieve the projected results. The Company assumes no obligation to update any forward-looking statements. I would like to<br>remind everyone that this conference call and webcast is being recorded on Monday, January 9, 2012, 7 AM Mountain Time and will be available<br>for playback on the Company's website.<br>
I will now turn the conference over to Mr. Michael Stevens, Head of Investor Relations. Please go ahead.<br>
<b>Michael Stevens</b><i> - SilverBirch Energy Corporation - Manager- Finance, IR</i><br>
Good morning, everyone, and thank you all for joining the call today. I am Michael Stevens, SilverBirch's Manager of Finance and Investor Relations.<br>Howard Lutley, President and Chief Executive Officer of SilverBirch Energy, will lead the call this morning and he will begin with some prepared<br>remarks. Also present in today's call is Wayne Bobye, Vice President and Chief Financial Officer, and Jina Abells Morissette, Vice President of Legal<br>and Administration. For today's conference call webcast, we will discuss the details of the announced agreement for Teck Resources Limited to<br>acquire SilverBirch Energy by way of a plan of arrangement and the creation of SilverWillow Energy Corporation, a new corporation focusing on<br>in situ oil sands opportunities. With that, I'll now turn the call over to Howard Lutley.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thanks, Mike.Welcome, everybody, and thank you for joining us this morning.We're very pleased to tell you about our transaction and the formation<br>of our new Company, SilverWillow Energy. Before I start, I want to acknowledge the tremendous efforts and work done by our team here in Calgary<br>and Teck's teams in Vancouver and Calgary as well as the numerous advisors that have assisted us in putting this deal together over the Christmas<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>523</i><br>
<hr>
<A name=524></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
and New Year's period, a difficult time for any of us with families, which is of course most of us. Anyway, this will be a fairly short call covering the<br>transaction and a description of the new Company and what assets will be in the new Company.<br>
So I turn your attention to the forward-looking statements on slides 2 and 3. And particularly, if you just would take a second to look at slide 4, as<br>for as the resource disclosure. When we're talking about SilverWillow and the Audet property, we will be talking about discovered bitumen<br>initially-in-place. In prior conference calls of course we've talked about contingent resources and I just wanted to draw your attention to this<br>distinction, the discovered bitumen initially-in-place.<br>
So now let's move on to slide 5, and we'll start discussing the proposed transaction. So SilverWillow, as Mike mentioned, is being created through<br>a plan of arrangement. And the construction of this transaction is quite similar to the one that we did 15 months ago between UTS and Total, so<br>it was familiar for us as we put this together. Teck Resources will acquire all of SilverBirch's common shares, and SilverWillow shareholders, and<br>SilverWillow being the spin out Company, will-- or sorry, SilverBirch shareholders will receive CAD8.50 per share in cash plus one share of SilverWillow.<br>
Now additionally,Teck will contribute CAD25 million in cash to SilverWillow and Teck will contribute it's 50% working interest in the Birch Mountain's<br>and Jordan properties which we held jointly to SilverWillow. All SilverBirch assets will be transferred to SilverWillow accept our working interest in<br>Frontier and Equinox projects and the Twin Lakes leases, which of course Teck will keep. So as a result, SilverWillow, which will be focused on in<br>situ rather than our former [career] in the mining site, will own 100% of the Audet properties, Birch Mountain's leases and the Jordan leases and<br>will be capitalized initially with CAD25 million.<br>
So let's go to slide 6. So to focus in a little bit on the details, so the cash component that each shareholder, SilverBirch shareholder, will receive is<br>CAD8.50 and for each share of SilverBirch they hold they will receive a share of SilverWillow, which will have approximately CAD0.50 of working<br>capital per share plus approximately 30 barrels of discovered resource per share in the Audet property. Of course at the moment we have no<br>knowledge of resources discovered or otherwise on the Audet, I'm sorry, on the Birch Mountains or the Jordan properties. In addition to the lands<br>described, we'll also have 117,000 acres of exploration. As far as the sort of the headline metrics, based just on the cash component alone, and<br>that's the cash that shareholders receive plus the cash going into SilverWillow, SilverBirch shareholders will be receiving a 25% premium to our<br>closing price on January 9 and a 38% premium to the 20-day volume weighted average price. As an important point here, is that SilverBirch's Board<br>of Management unanimously recommending the acceptance of this offer to SilverBirch's shareholders, and lock up agreements have been signed<br>including the two major shareholders, West Face and the Children's Investment Fund.<br>
So let's move to the slide 7 and we'll talk a bit about SilverWillow. Now as SilverBirch announced back in October, we have confirmed a significant<br>resource potential on the Audet property northeast of Fort McMurray. And we're in the field drilling as we speak, we basically got started a couple<br>of days ago with the rigs turning and so we'll have additional information, which by the end of this year should allow us to determine contingent<br>resources on this property. We also have the additional upside in the Birch Mountain's area, immediately west of Frontier, so this is the exploration<br>lands where the oil sands are a little deeper buried. And as you may have noticed in the past couple of years, this has been quite an active area for<br>exploration with a number of companies with programs going on in the Birch Mountains.<br>
We have taken across the complete Management team and the Board from the previous Company, from SilverBirch to SilverWillow, so you'll have<br>the same experienced leadership team with its proven exploration and development record working for you for the shareholders in SilverWillow.<br>We also have a work plan focused on doing what we do best, which is exploring these properties and then moving them forward along the regulatory<br>path and the engineering path and determining what the value is and whether it makes sense to keep advancing the project or looking for partners,<br>or looking for constructive deals once we know what we have and have derisked the projects for possible partners. And of course we'll have initial<br>working capital of approximately CAD25 million, and that will be subject to working capital corrections and adjustments following closing.<br>
So move on to slide 8. So there's a series of slides now which take us through the land position so that you can have a better appreciation of what<br>lands SilverWillow will own. So on slide 8, you can see the current situation in which this shows the lands that we have primarily 50/50 with Teck,<br>this will be prior to closing with the exception of Audet which currently SilverBirch owns 100%, and Audet is on the right side of the map there.<br>
Now if you go to slide 9, in bright blue it's highlighted the lands that Teck will now have 100% of. So that's the Frontier project, the Equinox project,<br>and the Twin Lakes leases just on the east of the Athabasca River. Now if you flip to slide 10, this highlights the lands that SilverWillow will own<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>524</i><br>
<hr>
<A name=525></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
100% of, that very large exploration block on the west side, the Birch Mountains, the Jordan lands on the middle of the map and then the Audet<br>leases on the east side of the map, which have the discovered resources that I mentioned earlier. And we're going to spend a little bit of time talking<br>about Audet, because that's the focus of our activity right now.<br>
So let's move on to slide 11. This is the summary of the discovered bitumen initially-in-place on the Audet lands. And this summary is from the<br>Sproule report that was released in October by SilverBirch, October 2011. As pointed out below that, we also have the Birch Mountains leases,<br>100% working interest in nine leases, 147 sections, very extensive land position, and then the Jordan leases 100% working interest in two leases<br>comprising 36 sections.<br>
We'll move on to slide 12. Again, the people that are familiar with SilverBirch, this will be a familiar drawing. We are moving Audet forward towards<br>development, but of course we have quite a way to go yet.The 2012 winter program as I mentioned is just underway, and in addition to additional<br>delineation drilling, we will be doing some 2-D seismic and a key part of the program will be a cap rock evaluation. One of the important things<br>about the Audet lease is that we know that the cap rock is intermittent across the lease. So our focus this year is to identify an area where there's<br>sufficient cap rock to allow us to proceed with a conventional SAGD project.<br>
Now we're quite confident that the resources there are based on last year's drilling program and we know that it is a very high-quality, quite thick<br>continuous bitumen resource. So the technical issue as far as production will be this presence of cap rock. However having said that, we also know<br>that there are new emerging technologies that may be applicable even if the cap rock is somewhat limited or intermittent. So we believe this whole<br>area has tremendous potential because of the size of the resource.<br>
The drilling will continue through the first six to eight weeks of this year, then of course the analysis cycle goes through the geotechnical testing<br>of the cap rock samples, the analysis of the many frac tests that we will be doing. And then once that data is all assembled, analyzed and evaluated<br>by our independent assessors, we should be able to report contingent resource either by the end of this year or early in 2013.The project schedule<br>below is notional because of course it assumes that we are successful in proving our technical project, but one could conjecture that it would be<br>viable to have production from these leases by 2016 or 2017 timeframe based on normal regulatory and development cycles.<br>
Let's move on to slide 13. So moving towards the summary here, Audet basically provides us a platform for growth, and as we mentioned that's<br>1.69 billion barrels of discovered resource in place, and we'll have our contingent resource by the end of this year. We'll also commence a desktop<br>assessment of the Birch Mountain's resources, which we-- back in the UTS days we had-- we put seven core holes into those leases on very preliminary<br>explorations. So in the balance of this year, we'll be doing some desktop work to identify best locations for seismic and perhaps drilling, and it'll<br>be later in the year before we can announce what we plan to do as far as an exploration program on those leases.<br>
Jordan, some-- an interesting little patch of land, it's quite close to some other major projects.The eight core holes that have been drilled in to date<br>have indicated there's bitumen, but it's not very extensive. However, we believe that this might be an interesting opportunity for some shallow<br>unconventional approaches to extraction, and so we will basically look at it in that light and see how that might be taken forward. As we do this<br>work, of course we're open-minded to consider joint venture prospects or other approaches and looking at the best way for Silver Willow shareholders<br>as to how to develop these resources.<br>
So let's move onto slide 14. So as far as financing, the initial CAD25 million will be used to finance our exploration work and analysis for the balance<br>of this year and of course G&amp;A and miscellaneous expenditures. As part of the transaction,Teck has provided an interim CAD20 million loan facility<br>and that expires in the middle of the year, but it helps tide us over any shortfalls in cash during the closing period and shortly thereafter. So we're<br>looking to once again be successful with the drill bit to drive the Company forward and create the financing flexibility and strategic opportunities.<br>We believe that with success in the field, it'll allow us to continue to fund our objectives and to meet our exploration and development objectives.<br>
So finally to close this part of the presentation, we believe we've completed a very successful transaction, obviously subject to closing, which should<br>be by the end of March. We believe we've provided a significant premium to our shareholders. Our shareholders, SilverBirch shareholders, will<br>receive a one for one share in the SilverWillow Company, and SilverBirch shareholders will retain the resource upside through its exposure to<br>SilverWillow. And your Management team is here to go to work on the SilverWillow resources. Finally, the Board of Directors has unanimously<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>525</i><br>
<hr>
<A name=526></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
approved this plan and recommend that SilverBirch shareholders vote in favor of it. So I'll finish my prepared comments at this point, and turn it<br>back to Mike and the Operator for the next step.<br>
<b>Michael Stevens</b><i> - SilverBirch Energy Corporation - Manager- Finance, IR</i><br>
Thank you, Howard. I would now like to open the floor for the question-and-answer session and ask the Operator to come back on to explain how<br>we will proceed.<br>
<b>Q U E S T I O N S   A N D   A N S W E R S</b><br>
<b>Operator</b><br>
Thank you, Mr. Stevens. Ladies and gentlemen, we will now conduct the question-and-answer session. (Operator Instructions) Sachin Shah with<br>Tullett Prebon.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Hi, good morning thanks for taking my question. I just wanted to go over the regulatory approvals. I did see that you're expecting this deal to close<br>kind of mid April, so just was wondering if you could go over that timeline? I did see here that you got some shareholders to support this transaction,<br>so maybe if you could just talk about the background and how you came to this transaction? I missed the first part of the call, so I apologize if you<br>discussed this already.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Okay. Yes, there's 39% of the shareholders, well that's basically Management's and the two major shareholders have already locked up to the deal.<br>As far as how the deal came together, I'm not quite sure on your question, but I'm assuming -- are you talking about timeline or --<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Yes, so when I say deal came together like were you talking to other parties, was this an auction process, did Teck approach you, I just want to<br>understand was this is solely one-off situation with Teck our did the Company solicit other offers and this was the kind of best situation for SilverBirch<br>shareholders as well as Teck shareholders kind of a situation?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Okay, I understand that. Actually no, we've been through a long strategic process almost, actually we are pretty well 12 months now. Once SilverBirch<br>was formed October 2010, we basically got up and running, got settled in. And then starting in January 2011, we formed an informal strategic<br>working group of some of the members of the Board with also our financial advisors joined the team as well. And we basically look at the strategic<br>options for the Company, understanding the assets that we had. Now of course at that time, we didn't have any results from our Audet drilling<br>program, so we didn't know the scale of the opportunity. So during the first sort of three or four months of that strategic process, we were assessing<br>our assets and then getting to understand what we had on the Audet property.<br>
So by sort of mid-year, we had some additional information.We had a pretty good understanding of the scale of the opportunity at Audet.We also<br>had completion of the design basis memorandum, we had the resource update from Frontier and Equinox. And probably the key factor was in end<br>of June, we had the revised capital cost estimates for the Frontier and Equinox projects. So again, with those bits of information, we were able to<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>526</i><br>
<hr>
<A name=527></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
get a pretty good handle on the potential economics of Frontier and Equinox as well as what the capital quantum that would be required from<br>SilverBirch to stay in the project at 50/50.<br>
Now of course all along we had always said at SilverBirch that at some point we would look at our options for how great our participation in the<br>project would be, in the Frontier and Equinox project, and that we'd be quite open to constructive ways to reduce our interest as long as it created<br>value for the shareholders. Now the financial advisors also conducted a confidential low-key process of contacting potential participants who might<br>be willing to either participate with us, buy our share, any number of the normal kind of things you would consider and that was quite extensive,<br>it was international, but it wasn't a public process.<br>
At the same time, commencing in about the mid-summer, we also started negotiations with Teck on our partnership agreement. And that had<br>been a long-standing commitment between both ourselves and Teck, was to form a partnership and properly paper it with a partnership agreement.<br>Through that process, we had to examine value, both parties examine value, and we are looking at ways to make a good agreement, having learned<br>a lot from our participation also with Teck in the Fort Hills agreement and recognizing that there were a few things in that agreement that hadn't<br>worked well for a junior partner, particularly during a financial crisis.<br>
So we wanted to come up with a similar partnership agreement but something that provided flexibility for the smaller Company, i.e. SilverBirch.<br>And we work hard with Teck to put that kind of agreement together, and actually had something that we could put in front of our Boards, and<br>ultimately then just two days before Christmas, Teck came back with the offer that we're looking at now rather than proceed with the partnership<br>approach. So really it was quite a long process, talked to either ourselves or our partners, talked to a lot of different parties over that intervening<br>period and finally came to what we believe now is the offer we have in front-- a good offer that we have in front of us now.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Okay, perfect. And then just as a kind of what regulatory approvals and then kind of a potential timeline between now and kind of mid-April, I think<br>that's when you're expecting the deal to close on or before mid-April?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes. I'll answer the one I know, Jina, our Legal Counsel, is here as well, so she can fill in. But there's competition acts, is that the --<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
That's the only one, yes.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
That's the only one.<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
And then it's a plan of arrangement, so we'll have to get the court order and take all of those steps. So I mean you know how it works once we mail<br>the circular the clock starts ticking, but because we are starting SilverWillow, the circular will have a lot of information in it about the new Company,<br>so that will take some time. So we're still aiming sort of for that end of March/early April closing timeframe.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>527</i><br>
<hr>
<A name=528></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Okay. And as far as regulatory approval on competition Canada, you're-- I mean this it seems pretty much not an issue, but is that the case, as a<br>confirmation?<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
We wouldn't be so presumptuous to speculate on that, however, we don't foresee any issue there.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Okay, all right. So it's no issue, you're going to go through the process, ultimately they'll make the decision?<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
Right.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Okay, fair enough. Thank you.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
Mark Friesen with RBC Capital Markets.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Thank you, good morning. I just have two questions for you Howard. First of all, is there any follow up lockup to shareholders post closing of this<br>transaction?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
I will ask Jina to answer that one.<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
Sorry Mark do you mean about additional shareholders locking up?<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
No, I mean following closing so once SilverWillow begins trading or--<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>528</i><br>
<hr>
<A name=529></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
No, it doesn't carry on into SilverWillow.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Okay, so-- all right. So second question, perhaps explain the context of why or how Twin Lakes became part of the 100% Teck lands?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, the-- it was really just a negotiation. We weren't-- we as SilverBirch didn't feel strongly about keeping Twin Lakes, our view on the geological<br>potential, is that it's probably limited but obviously that is SilverBirch's view and that's only subject to the limited drilling that has been done to<br>date. Teck was interested in keeping Twin Lakes, so it was easy for us to make that swap of those lands.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Sure. Is that a read through that that's possibly a mining opportunity?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
It's-- no I wouldn't say it is or and it isn't a mining opportunity, but it's certainly if there is going to be oil sand there, it would be at depths that would<br>be more likely a mineable prospect that an in situ prospect just because of the depth of the geology in that area.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Sure, okay. And finally if you could give a little more detail as to the terms of the interim loan facility, please?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
It's normal commercial terms. Wayne is sitting here, I will ask them to talk about that. There's not a whole lot about-- can be said about it I don't<br>think.<br>
<b>Wayne Bobye</b><i> - SilverBirch Energy Corporation - VP, CFO</i><br>
No Mark, it's just a regular loan. It's very similar to the one that we have in place now. It's put in place to provide flexibility. The rate on it is very<br>competitive with what we have now related to prime. And it's just put in place so that we have some flexibility going forward because we were--<br>if we hadn't done this transaction, we probably would've had to raise some equity, so this gives us some flexibility to move forward with our capital<br>spending program.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Sure, what's the duration of that facility?<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>529</i><br>
<hr>
<A name=530></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Wayne Bobye</b><i> - SilverBirch Energy Corporation - VP, CFO</i><br>
It would terminate in the middle of the year. I think August is the date on it.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Sure. Okay, great. Thanks very much.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thanks, Mark.<br>
<b>Operator</b><br>
[Andrew Wryneck] with Scotia Capital.<br>
<b>Catharine Sterritt</b><i> - Scotia Capital - Analyst</i><br>
Good morning it's Catharine Sterritt. Just two questions. Just to clarify the loan facility, so the intent is that when the transaction closes, you'll use<br>the CAD25 million working capital funding in part to repay that facility?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, but there is CAD24 million cash in SilverBirch right now. We'll also have proceeds from exercise of options, which we estimate up to now will<br>be about CAD22 million to SilverBirch. So that actually in the time period between now and closing, by our calculations, gives us sufficient cash to<br>meet current obligations and the first three months of drilling in 2012. So by closing, SilverBirch's working capital will be essentially zero. And the<br>CAD25 million that will be contributed by Teck will go into SilverWillow.<br>
Now as Wayne said, the CAD20 million loan provides us the flexibility because obviously the proceeds from the exercise of options will only come<br>in at closing, and so if there's a shortfall on cash just due to timing reasons, because drilling programs tend to be quite financially intense if you<br>spend a lot of money in a hurry and the bills come in very quickly. So we're just assuming that there may be a cash shortfall and that's really what<br>the loan will be used for so that in theory by closing, we should have most of the CAD25 million intact once we start at SilverWillow.<br>
<b>Catharine Sterritt</b><i> - Scotia Capital - Analyst</i><br>
Okay, that makes sense, thank you. And just a question on the timing. SilverWillow is being listed, do you expect that it'll-- that it's listing will be<br>coincident with the closing of the transaction? Or is it possible we might see the plan of arrangement close and then a few weeks later the SilverWillow<br>start to trade?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
I'll turn that one to Jina.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>530</i><br>
<hr>
<A name=531></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
Sure, we-- our hope is that we'll start listing a coincident with the closing, so we would close one day and start trading at SilverWillow the next,<br>that's what we're working towards.<br>
<b>Catharine Sterritt</b><i> - Scotia Capital - Analyst</i><br>
Okay, and that'll be on the venture exchange?<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
Yes, that's where we're applying to.<br>
<b>Catharine Sterritt</b><i> - Scotia Capital - Analyst</i><br>
Okay that's great. Congratulations on the transaction.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
(Operator Instructions) John Tumazos with John Tumazos Very Independent Research.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
I have three questions if you're so patient. Are the Twin Lakes areas an area that was contemplated potentially as a gift to the province for<br>environmental park or recreation area?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Well that's an interesting idea. There's been discussion of that kind of thing from time to time but nothing ever followed up on. I think there is<br>actually -- if you look at it John, all that SilverBirch and Teck had on there was the oil sands leases, we don't have any rights to the surface. But how<br>Teck will make use of this land obviously is a question for Teck.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
There was an area that I recall in the past that relatively close to the river that might have had such a potential use, maybe I'm confusing it with<br>another park.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, that-- we didn't have anything else close to the river that I can recall.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>531</i><br>
<hr>
<A name=532></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
Could you update us on the lease 421 area, I didn't seem to catch which of the two Companies it would go to. Lease was already sold to Imperial.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, our interest, or at least UTS' interest, was already sold to Imperial, Teck, again that would be an question for Teck, what's going on with their<br>interest in lease 421.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
The apparent price in terms of cash, I'm calculating is the 435 cash plus the CAD25 million working capital or 460 divided by 1.4 billion barrels, or<br>CAD0.33 a barrel. And that's less than the CAD2 apparent price at the time at a lower oil price for the 20% of Fort Hills sold to Total. Now admittedly<br>it's not exactly apples and oranges, because the degree of engineering and permitting and preliminary construction isn't the same, but could you<br>talk to the six-fold difference in valuation and why you're embracing selling Frontier Equinox at one-sixth of the terms or even if you made an<br>adjustment for the difference in phase one-third of the terms?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes. No, I think that one's one we could certainly respond to. If you look, we-- the number we use is about CAD0.34 a barrel, so agree with your<br>calculation, we come to the number slightly differently, but it's essentially CAD0.34 a barrel. This-- if you think of Frontier and Equinox, it's very<br>early stage, we don't have any regulatory approval at this pace, at this point. We've literally just submitted the application, or a least Teck had, at<br>the end of the year last year. And where as Fort Hills had had regulatory approval in place by the time we exited that project eight years, and CAD2.8<br>billion had been spent by the partners. In addition, UTS had an earn in right so there was additional value in Fort Hills from the earn in.<br>
So when you compare the metrics, it is quite a different transaction. Also keep in mind that Frontier and Equinox will not commence production<br>until about 2020 or 2021. And the issue that was facing SilverBirch that even prior to sanction, the partnership would have to spend CAD300 million<br>to CAD500 million just to get to sanction, so that's over the next three to four years. And we recognized that for us, that would be quite dilutive<br>with the equity we would raise, be quite dilutive for SilverBirch shareholders and that the offer finally made by Teck seemed to be quite fair and<br>quite reasonable and that was why we made that decision to proceed.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
If I could be so tedious with one more question.The calculation of CAD0.34 a barrel is only the cash consideration.There is the much more difficult<br>question of valuing the in situ assets or in situ potential assets that Teck is swapping with you in addition to the cash consideration. Did you assess<br>only the cash consideration in avoidance of dilution or did you assign value to the in situ assets were the documentation and the potential recovery<br>rates, the existence of the bitumen and recover ability of the bitumen require I guess a greater standard of documentation because they're deeper<br>et cetera?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Of course the potential value of the lands played into our consideration. Because obviously we are quite optimistic about the potential of both<br>Audet and Birch Mountains. As far as formally assigning value, we basically for our own the calculation purposes just use the book values which<br>provides quite a modest amount of value. I believe by closing our book value in those various properties will be about CAD90 million. So a little<br>over, what's that CAD1.80 a share roughly for the book value going into SilverWillow. Now obviously how the market values that we'll get to see<br>in the next few days, but so it was in our calculations from the point of view of establishing total value. But as far as the metrics we've referenced,<br>we've only referenced the cash component, John.<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>532</i><br>
<hr>
<A name=533></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
Thank you, Howard. It sounds like there were a lot of considerations that were hard to put an exact value upon.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, yes well thank you for your questions, John.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Mike Dunn with FirstEnergy Capital.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
Hi, good morning, everyone. I guess first question is just a follow up on your comments about the book value of the assets in SilverWillow, is that<br>CAD90 million, Howard, is that outside of the CAD25 million in working capital?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, that's right, that excludes the working capital.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
Great.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
And Mike, it's a bit approximate. We-- some of that working capital-- some of that book value is dependent on what we spend at Audet in the first<br>three months and then if you basically sort of notionally cut off at the end of March, what we've spent on Audet will count in that book value<br>calculation.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
I see. Okay, great. And then I just thought I'd ask, I'm not sure what you can comment on it on, but you mentioned potentially other recovery<br>techniques at Audet should the cap rock not prove sufficient, can you talk about what you're thinking there?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, what-- so the way we're looking at it right now and we've got a bit of modeling work going on with an engineering company that should be<br>completed sometime in the next two or three months, is we're looking at it as a conventional SAGD. And I think as we've mentioned in previous<br>calls, that we did have-- we did find some pretty extensive occurrences of what we believe will be a suitable cap rock material. But what we don't<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>533</i><br>
<hr>
<A name=534></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
know is how extensive. So our opening position is if we can prove up this cap rock materials existence in a big enough area and the modeling and<br>the testing and the many frac tests show that it's sufficient for conventional SAGD, and I wouldn't call it a low pressure, I'd call it sort of a moderate<br>pressure SAGD, then that's basically a conventional approach.<br>
So that if we find that that wouldn't necessarily be technically feasible, we would then look at other SAGD related approaches maybe with solvent<br>assist or low pressure SAGD as is being tried out in other places. And then a further fallback would be some of the new techniques that some of<br>the other companies have been talking about, perhaps with some of the electrical or other solvent assist type techniques. But certainly our focus<br>will for Audet be on conventional SAGD as the first case.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
Great. And have you been in touch with the regulator on what I guess their current thinking is about cap rock and I'm not sure if there is any -- if<br>they're getting any more stringent with regards to testing over the past couple of years on that, but just comment on that?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, certainly the engineering consultants that we've worked with have been involved with a number of the recent applications. And of course,<br>Sproule our other advisor, has been involved with a number of applications. So we are reasonably aware from the consultants of the regulatory<br>requirements. We recognize that there is a bit of a work in progress on how that will evolve over the next 12 to 24 months. But we're certainly<br>taking an approach that is relatively conservative as we consider what the operating pressures would be as we do in the current modeling. And of<br>course the current modeling is really just an early scoping study just to try and understand what the potential will be, there'll be further rounds of<br>engineering once we have the many frac tests, the rest of the data from the geotechnical program and of course more resource data.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
Okay, great. Thanks, Howard, thanks.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thanks, Mike.<br>
<b>Operator</b><br>
And Mr. Stevens, there no further questions at this time, please continue.<br>
<b>Michael Stevens</b><i> - SilverBirch Energy Corporation - Manager- Finance, IR</i><br>
Ladies and gentlemen, this concludes the conference call for today, thank you for participating. Please disconnect your lines.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>534</i><br>
<hr>
<A name=535></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4703356-2012-01-09T20:49:39.610</b><br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>535</i><br>
<hr>
<A name=536></a>THOMSON REUTERS STREETEVENTS<br>EDITED BRIEF<br>
TCK.B.TO - TECK RESOURCES LIMITED<br>TO ACQUIRE SILVERBIRCH -<br>CONFERENCE CALL<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 2:00PM GMT<br>
OVERVIEW:<br>
Announced an agreement for TCK.B.TO to acquire SilverBirch Energy by way of<br>plan of arrangement and creation of SilverWillow Energy Corporation, a new<br>corporation focusing on in situ oil sands opportunities. SilverBirch shareholders<br>will receive CAD8.50 per share in cash plus one share of SilverWillow.<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>536</i><br>
<hr>
<A name=537></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>CORPORATE PARTICIPANTS</b><br>
<b>Michael Stevens</b><i> SilverBirch Energy Corporation - Manager- Finance, IR</i><br>
<b>Howard Lutley</b><i> SilverBirch Energy Corporation - President, CEO</i><br>
<b>Jina Abells Morissette</b><i> SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
<b>Wayne Bobye</b><i> SilverBirch Energy Corporation - VP, CFO</i><br>
<b>CONFERENCE CALL PARTICIPANTS</b><br>
<b>Sachin Shah </b><i>Tullett Prebon - Analyst</i><br>
<b>Mark Friesen</b><i> RBC Capital Markets - Analyst</i><br>
<b>Catharine Sterritt</b><i> Scotia Capital - Analyst</i><br>
<b>John Tumazos</b><i> John Tumazos Very Independent Research - Analyst</i><br>
<b>Mike Dunn</b><i> FirstEnergy Capital Corp. - Analyst</i><br>
<b>OVERVIEW</b><br>
Announced an agreement for TCK.B.TO to acquire SilverBirch Energy by way of plan of arrangement and creation of SilverWillow<br>Energy Corporation, a new corporation focusing on in situ oil sands opportunities. SilverBirch shareholders will receive CAD8.50 per<br>share in cash plus one share of SilverWillow.<br>
<b>PRESENTATION SUMMARY</b><br>
<b>I. ANNOTATION (M.S.)</b><br>
<b>A. Note:</b><br>
<b>1. </b>Announced agreement for TCK.B.TO to acquire SilverBirch Energy by way of plan of arrangement and creation of SilverWillow<br>
Energy Corporation, a new corporation focusing on in situ oil sands opportunities.<br>
<b>II. ACQUISITION OVERVIEW (H.L.)</b><br>
<b>A. Resource Disclosure:</b><br>
<b>1. </b>When talking about SilverWillow and Audet property, will be talking about discovered bitumen initially-in-place.<br>
<b>B. SilverWillow Energy:</b><br>
<b>1. </b>SilverWillow being created through plan of arrangement.<br><b>2. </b>Construction of this transaction quite similar to the one that's done 15 months ago between UTS and Total.<br><b>3. </b>TCK.B.TO will:<br>
<b>a. </b>Acquire all of SilverBirch's common shares.<br>
<b>i. </b>SilverBirch shareholders will receive CAD8.50 per share in cash plus one share of SilverWillow.<br>
<b>b. </b>Contribute CAD25m in cash to SilverWillow.<br>
<b>c. </b>Contribute 50% working interest in Birch Mountains and Jordan Properties (held jointly to SilverWillow).<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>537</i><br>
<hr>
<A name=538></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>4. </b>All SilverBirch assets will be transferred to SilverWillow, except working interest in Frontier and Equinox projects and Twin<br>
Lakes leases, which Co. will keep.<br>
<b>a. </b>SilverWillow (will be focused on in situ rather than on mining) will own 100% of Audet properties, Birch Mountains leases<br>
and Jordan leases and will be capitalized initially with CAD25m.<br>
<b>5. </b>Cash component that each SilverBirch shareholder will receive is CAD8.50.<br>
<b>a. </b>For each share of SilverBirch they hold, they will receive a share of SilverWillow, which will have approx. CAD0.50 of working<br>
capital per share plus approx. 30 barrels of Discovered Resource per share in Audet property.<br>
<b>b. </b>At moment, has no knowledge of resources discovered or otherwise on Birch Mountains or Jordan Properties.<br>
<b>c. </b>In addition to lands described, will have 117,000 acres of exploration.<br>
<b>d. </b>Based on cash component alone (cash shareholders receive plus cash going into SilverWillow), SilverBirch shareholders<br>
will be receiving 25% premium to closing price on Jan 9 and 38% premium to 20-day volume weighted avg. price.<br>
<b>e. </b>SilverBirch's board and management unanimously recommending acceptance of this offer to SilverBirch's shareholders.<br>
<b>i. </b>Lock-up agreements signed including two major shareholders, West Face and The Children's Investment Fund.<br>
<b>C. SilverWillow:</b><br>
<b>1. </b>As SilverBirch announced in Oct., has confirmed significant resource potential on Audet property, northeast of Fort McMurray.<br>
<b>a. </b>In the field drilling.<br>
<b>i. </b>Basically got started a couple of days ago with rigs turning; has additional information which by this year-end should<br>
allow to determine contingent resources on this property.<br>
<b>2. </b>Additional upside in Birch Mountains area, immediately west of Frontier.<br>
<b>a. </b>Exploration lands where oil sands are little deep or buried.<br><b>b. </b>In past couple of years, has been quite active area for exploration with number of companies with programs going on in<br>
Birch Mountains.<br>
<b>3. </b>Taking across complete management team and board from previous co., SilverBirch to SilverWillow.<br><b>4. </b>Work plan focused on exploring these properties and then moving them forward along regulatory path and engineering<br>
path and determining what value is and whether it makes sense to keep bouncing projects or looking for partners or looking<br>for constructive deals once it knows what it has and de-risked projects for possible partners.<br>
<b>a. </b>Initial working capital approx. CAD25m, subject to working capital corrections and adjustments following closing.<br>
<b>D. Lands:</b><br>
<b>1. </b>Lands (indiscernible) of closing, with exception of Audet's which currently SilverBirch owns 100%.<br><b>2. </b>TCK.B.TO will have 100% of:<br>
<b>a. </b>Frontier project.<br><b>b. </b>Equinox project.<br>
<b>c. </b>Twin Lakes leases just on east of Athabasca River.<br>
<b>3. </b>SilverWillow will own 100% of:<br>
<b>a. </b>Large exploration block on west side of Birch Mountains.<br><b>b. </b>Jordan lands.<br>
<b>c. </b>Audet leases, which have discovered resources.<br>
<b>E. Discovered Bitumen Initially-In-Place Summary On Audet Lands:</b><br>
<b>1. </b>From Sproule report released by SilverBirch, Oct. 2011.<br><b>2. </b>Birch Mountains leases:<br>
<b>a. </b>100% working interest in nine leases, 147 sections, extensive land position.<br>
<b>3. </b>Jordan leases:<br>
<b>a. </b>100% working interest in two leases comprising 36 sections.<br>
<b>F. Audet Notional Development Plan:</b><br>
<b>1. </b>Moving Audet forward towards development.<br><b>2. </b>2012 winter program just underway.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>538</i><br>
<hr>
<A name=539></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>3. </b>In addition to additional delineation drilling, will be doing some 2D seismic and key part of program will be cap rock<br>
evaluation.<br>
<b>a. </b>Knows cap rock is intermittent across lease.<br><b>b. </b>Focus this year is to identify area where there is sufficient cap rock to allow to proceed with conventional (indiscernible)<br>
project.<br>
<b>c. </b>Quite confident that resources based on last year's drilling program.<br>
<b>d. </b>Knows it is high quality, quite thick continuous bitumen resource.<br><b>e. </b>Technical issue as far as production will be presence of cap rock.<br>
<b>f. </b>New emerging technologies may be applicable even if cap rock is somewhat limited or intermittent.<br>
<b>g. </b>Believes this whole area has tremendous potential because of resource size.<br>
<b>h. </b>Drilling will continue through first 6-8 weeks of this year.<br>
<b>i. </b>Analysis cycle goes through geotechnical testing of cap rock samples, analysis of mini-frac tests that will be done and<br>
once that date is all assembled, analyzed and evaluated by independent assessors, should report contingent resource,<br>either by this year-end or early 2013.<br>
<b>4. </b>Project schedule notional.<br><b>5. </b>Will be viable to have production from these leases by 2016 or 2017 timeframe, based on normal regulatory and development<br>
cycles.<br>
<b>6. </b>Audet basically provides platform for growth.<br>
<b>a. </b>1.69 billion barrels of discovered resource in place.<br><b>b. </b>Will have contingent resource by this year-end.<br>
<b>7. </b>Will commence desktop assessment of Birch Mountain resources, which back in UTS days, SBE.V put seven core holes into<br>
those leases on preliminary exploration.<br>
<b>a. </b>In balance of this year, will be doing some desktop work to identify best locations for seismic and perhaps drilling.<br><b>b. </b>Will be later in year before announcement of what it plans to do as far as exploration program on those leases.<br>
<b>8. </b>Jordan:<br>
<b>a. </b>Quite close to some other major projects.<br><b>b. </b>Eight core holes drilled to date indicated there's bitumen, but it's not extensive.<br>
<b>c. </b>Believes might be interesting opportunity for some shallow, unconventional approaches to extraction.<br>
<b>9. </b>Open minded to consider JV prospects or other approaches and looking at best way for SilverWillow shareholders as to<br>
how to develop these resources.<br>
<b>G. Financing:</b><br>
<b>1. </b>Initial CAD25m will be used to finance exploration work and analysis for balance of this year and G&amp;A and miscellaneous<br>
expenditures.<br>
<b>2. </b>As part of transaction, TCK.B.TO provided interim CAD20m loan facility, expiring in middle of year.<br>
<b>a. </b>Helps tied SBE.V over any shortfalls in cash, during closing period and shortly thereafter.<br>
<b>3. </b>Looking to once again be successful with drill bit to drive [co.] forward and create financing flexibility and strategic<br>
opportunities.<br>
<b>4. </b>Believes with success in field, will allow [SBE.V] to continue to fund objectives and meet exploration and development<br>
objectives.<br>
<b>H. Summary:</b><br>
<b>1. </b>Believes:<br>
<b>a. </b>Completed successful transaction, subject to closing, which should be by March-end.<br><b>b. </b>Provided significant premium to shareholders.<br>
<b>2. </b>SilverBirch shareholders will:<br>
<b>a. </b>Receive one-for-one share in SilverWillow co.<br><b>b. </b>Retain resource upside through exposure to SilverWillow.<br>
<b>3. </b>Management team to go to work on SilverWillow resources.<br><b>4. </b>Board of Directors unanimously approved this plan.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>539</i><br>
<hr>
<A name=540></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>a. </b>Recommends SilverBirch shareholders vote in favor of it.<br>
<b>QUESTIONS AND ANSWERS</b><br>
<b>Operator</b><br>
Thank you, Mr. Stevens. Ladies and gentlemen, we will now conduct the question-and-answer session. (Operator Instructions) Sachin<br>Shah with Tullett Prebon.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Hi, good morning thanks for taking my question. I just wanted to go over the regulatory approvals. I did see that you're expecting<br>this deal to close kind of mid April, so just was wondering if you could go over that timeline? I did see here that you got some<br>shareholders to support this transaction, so maybe if you could just talk about the background and how you came to this transaction?<br>I missed the first part of the call, so I apologize if you discussed this already.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Okay. Yes, there's 39% of the shareholders, well that's basically Management's and the two major shareholders have already locked<br>up to the deal. As far as how the deal came together, I'm not quite sure on your question, but I'm assuming -- are you talking about<br>timeline or --<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Yes, so when I say deal came together like were you talking to other parties, was this an auction process, did Teck approach you, I<br>just want to understand was this is solely one-off situation with Teck our did the Company solicit other offers and this was the kind<br>of best situation for SilverBirch shareholders as well as Teck shareholders kind of a situation?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Okay, I understand that. Actually no, we've been through a long strategic process almost, actually we are pretty well 12 months now.<br>Once SilverBirch was formed October 2010, we basically got up and running, got settled in. And then starting in January 2011, we<br>formed an informal strategic working group of some of the members of the Board with also our financial advisors joined the team<br>as well. And we basically look at the strategic options for the Company, understanding the assets that we had. Now of course at that<br>time, we didn't have any results from our Audet drilling program, so we didn't know the scale of the opportunity. So during the first<br>sort of three or four months of that strategic process, we were assessing our assets and then getting to understand what we had on<br>the Audet property.<br>
So by sort of mid-year, we had some additional information. We had a pretty good understanding of the scale of the opportunity at<br>Audet. We also had completion of the design basis memorandum, we had the resource update from Frontier and Equinox. And<br>probably the key factor was in end of June, we had the revised capital cost estimates for the Frontier and Equinox projects. So again,<br>with those bits of information, we were able to get a pretty good handle on the potential economics of Frontier and Equinox as well<br>as what the capital quantum that would be required from SilverBirch to stay in the project at 50/50.<br>
Now of course all along we had always said at SilverBirch that at some point we would look at our options for how great our<br>participation in the project would be, in the Frontier and Equinox project, and that we'd be quite open to constructive ways to reduce<br>our interest as long as it created value for the shareholders. Now the financial advisors also conducted a confidential low-key process<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>540</i><br>
<hr>
<A name=541></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
of contacting potential participants who might be willing to either participate with us, buy our share, any number of the normal<br>kind of things you would consider and that was quite extensive, it was international, but it wasn't a public process.<br>
At the same time, commencing in about the mid-summer, we also started negotiations with Teck on our partnership agreement.<br>And that had been a long-standing commitment between both ourselves and Teck, was to form a partnership and properly paper<br>it with a partnership agreement. Through that process, we had to examine value, both parties examine value, and we are looking<br>at ways to make a good agreement, having learned a lot from our participation also with Teck in the Fort Hills agreement and<br>recognizing that there were a few things in that agreement that hadn't worked well for a junior partner, particularly during a financial<br>crisis.<br>
So we wanted to come up with a similar partnership agreement but something that provided flexibility for the smaller Company,<br>i.e. SilverBirch. And we work hard with Teck to put that kind of agreement together, and actually had something that we could put<br>in front of our Boards, and ultimately then just two days before Christmas, Teck came back with the offer that we're looking at now<br>rather than proceed with the partnership approach. So really it was quite a long process, talked to either ourselves or our partners,<br>talked to a lot of different parties over that intervening period and finally came to what we believe now is the offer we have in front--<br>a good offer that we have in front of us now.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Okay, perfect. And then just as a kind of what regulatory approvals and then kind of a potential timeline between now and kind of<br>mid-April, I think that's when you're expecting the deal to close on or before mid-April?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes. I'll answer the one I know, Jina, our Legal Counsel, is here as well, so she can fill in. But there's competition acts, is that the --<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
That's the only one, yes.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
That's the only one.<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
And then it's a plan of arrangement, so we'll have to get the court order and take all of those steps. So I mean you know how it works<br>once we mail the circular the clock starts ticking, but because we are starting SilverWillow, the circular will have a lot of information<br>in it about the new Company, so that will take some time. So we're still aiming sort of for that end of March/early April closing<br>timeframe.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Okay. And as far as regulatory approval on competition Canada, you're-- I mean this it seems pretty much not an issue, but is that<br>the case, as a confirmation?<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>541</i><br>
<hr>
<A name=542></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
We wouldn't be so presumptuous to speculate on that, however, we don't foresee any issue there.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Okay, all right. So it's no issue, you're going to go through the process, ultimately they'll make the decision?<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
Right.<br>
<b>Sachin Shah</b><i> - Tullett Prebon - Analyst</i><br>
Okay, fair enough. Thank you.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
Mark Friesen with RBC Capital Markets.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Thank you, good morning. I just have two questions for you Howard. First of all, is there any follow up lockup to shareholders post<br>closing of this transaction?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
I will ask Jina to answer that one.<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
Sorry Mark do you mean about additional shareholders locking up?<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
No, I mean following closing so once SilverWillow begins trading or--<br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>542</i><br>
<hr>
<A name=543></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
No, it doesn't carry on into SilverWillow.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Okay, so-- all right. So second question, perhaps explain the context of why or how Twin Lakes became part of the 100% Teck lands?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, the-- it was really just a negotiation. We weren't-- we as SilverBirch didn't feel strongly about keeping Twin Lakes, our view on<br>the geological potential, is that it's probably limited but obviously that is SilverBirch's view and that's only subject to the limited<br>drilling that has been done to date.Teck was interested in keeping Twin Lakes, so it was easy for us to make that swap of those lands.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Sure. Is that a read through that that's possibly a mining opportunity?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
It's-- no I wouldn't say it is or and it isn't a mining opportunity, but it's certainly if there is going to be oil sand there, it would be at<br>depths that would be more likely a mineable prospect that an in situ prospect just because of the depth of the geology in that area.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Sure, okay. And finally if you could give a little more detail as to the terms of the interim loan facility, please?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
It's normal commercial terms. Wayne is sitting here, I will ask them to talk about that. There's not a whole lot about-- can be said<br>about it I don't think.<br>
<b>Wayne Bobye</b><i> - SilverBirch Energy Corporation - VP, CFO</i><br>
No Mark, it's just a regular loan. It's very similar to the one that we have in place now. It's put in place to provide flexibility. The rate<br>on it is very competitive with what we have now related to prime. And it's just put in place so that we have some flexibility going<br>forward because we were-- if we hadn't done this transaction, we probably would've had to raise some equity, so this gives us some<br>flexibility to move forward with our capital spending program.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Sure, what's the duration of that facility?<br>
7<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>543</i><br>
<hr>
<A name=544></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Wayne Bobye</b><i> - SilverBirch Energy Corporation - VP, CFO</i><br>
It would terminate in the middle of the year. I think August is the date on it.<br>
<b>Mark Friesen</b><i> - RBC Capital Markets - Analyst</i><br>
Sure. Okay, great. Thanks very much.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thanks, Mark.<br>
<b>Operator</b><br>
[Andrew Wryneck] with Scotia Capital.<br>
<b>Catharine Sterritt</b><i> - Scotia Capital - Analyst</i><br>
Good morning it's Catharine Sterritt. Just two questions. Just to clarify the loan facility, so the intent is that when the transaction<br>closes, you'll use the CAD25 million working capital funding in part to repay that facility?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, but there is CAD24 million cash in SilverBirch right now. We'll also have proceeds from exercise of options, which we estimate<br>up to now will be about CAD22 million to SilverBirch. So that actually in the time period between now and closing, by our calculations,<br>gives us sufficient cash to meet current obligations and the first three months of drilling in 2012. So by closing, SilverBirch's working<br>capital will be essentially zero. And the CAD25 million that will be contributed by Teck will go into SilverWillow.<br>
Now as Wayne said, the CAD20 million loan provides us the flexibility because obviously the proceeds from the exercise of options<br>will only come in at closing, and so if there's a shortfall on cash just due to timing reasons, because drilling programs tend to be<br>quite financially intense if you spend a lot of money in a hurry and the bills come in very quickly. So we're just assuming that there<br>may be a cash shortfall and that's really what the loan will be used for so that in theory by closing, we should have most of the CAD25<br>million intact once we start at SilverWillow.<br>
<b>Catharine Sterritt</b><i> - Scotia Capital - Analyst</i><br>
Okay, that makes sense, thank you. And just a question on the timing. SilverWillow is being listed, do you expect that it'll-- that it's<br>listing will be coincident with the closing of the transaction? Or is it possible we might see the plan of arrangement close and then<br>a few weeks later the SilverWillow start to trade?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
I'll turn that one to Jina.<br>
8<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>544</i><br>
<hr>
<A name=545></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
Sure, we-- our hope is that we'll start listing a coincident with the closing, so we would close one day and start trading at SilverWillow<br>the next, that's what we're working towards.<br>
<b>Catharine Sterritt</b><i> - Scotia Capital - Analyst</i><br>
Okay, and that'll be on the venture exchange?<br>
<b>Jina Abells Morissette</b><i> - SilverBirch Energy Corporation - VP - Legal and Administration</i><br>
Yes, that's where we're applying to.<br>
<b>Catharine Sterritt</b><i> - Scotia Capital - Analyst</i><br>
Okay that's great. Congratulations on the transaction.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thank you.<br>
<b>Operator</b><br>
(Operator Instructions) John Tumazos with John Tumazos Very Independent Research.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
I have three questions if you're so patient. Are the Twin Lakes areas an area that was contemplated potentially as a gift to the province<br>for environmental park or recreation area?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Well that's an interesting idea. There's been discussion of that kind of thing from time to time but nothing ever followed up on. I<br>think there is actually -- if you look at it John, all that SilverBirch and Teck had on there was the oil sands leases, we don't have any<br>rights to the surface. But how Teck will make use of this land obviously is a question for Teck.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
There was an area that I recall in the past that relatively close to the river that might have had such a potential use, maybe I'm<br>confusing it with another park.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, that-- we didn't have anything else close to the river that I can recall.<br>
9<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>545</i><br>
<hr>
<A name=546></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
Could you update us on the lease 421 area, I didn't seem to catch which of the two Companies it would go to. Lease was already<br>sold to Imperial.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, our interest, or at least UTS' interest, was already sold to Imperial, Teck, again that would be an question for Teck, what's going<br>on with their interest in lease 421.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
The apparent price in terms of cash, I'm calculating is the 435 cash plus the CAD25 million working capital or 460 divided by 1.4<br>billion barrels, or CAD0.33 a barrel. And that's less than the CAD2 apparent price at the time at a lower oil price for the 20% of Fort<br>Hills sold to Total. Now admittedly it's not exactly apples and oranges, because the degree of engineering and permitting and<br>preliminary construction isn't the same, but could you talk to the six-fold difference in valuation and why you're embracing selling<br>Frontier Equinox at one-sixth of the terms or even if you made an adjustment for the difference in phase one-third of the terms?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes. No, I think that one's one we could certainly respond to. If you look, we-- the number we use is about CAD0.34 a barrel, so agree<br>with your calculation, we come to the number slightly differently, but it's essentially CAD0.34 a barrel. This-- if you think of Frontier<br>and Equinox, it's very early stage, we don't have any regulatory approval at this pace, at this point. We've literally just submitted the<br>application, or a least Teck had, at the end of the year last year. And where as Fort Hills had had regulatory approval in place by the<br>time we exited that project eight years, and CAD2.8 billion had been spent by the partners. In addition, UTS had an earn in right so<br>there was additional value in Fort Hills from the earn in.<br>
So when you compare the metrics, it is quite a different transaction. Also keep in mind that Frontier and Equinox will not commence<br>production until about 2020 or 2021. And the issue that was facing SilverBirch that even prior to sanction, the partnership would<br>have to spend CAD300 million to CAD500 million just to get to sanction, so that's over the next three to four years. And we recognized<br>that for us, that would be quite dilutive with the equity we would raise, be quite dilutive for SilverBirch shareholders and that the<br>offer finally made by Teck seemed to be quite fair and quite reasonable and that was why we made that decision to proceed.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
If I could be so tedious with one more question.The calculation of CAD0.34 a barrel is only the cash consideration.There is the much<br>more difficult question of valuing the in situ assets or in situ potential assets that Teck is swapping with you in addition to the cash<br>consideration. Did you assess only the cash consideration in avoidance of dilution or did you assign value to the in situ assets were<br>the documentation and the potential recovery rates, the existence of the bitumen and recover ability of the bitumen require I guess<br>a greater standard of documentation because they're deeper et cetera?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Of course the potential value of the lands played into our consideration. Because obviously we are quite optimistic about the potential<br>of both Audet and Birch Mountains. As far as formally assigning value, we basically for our own the calculation purposes just use the<br>book values which provides quite a modest amount of value. I believe by closing our book value in those various properties will be<br>
10<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>546</i><br>
<hr>
<A name=547></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
about CAD90 million. So a little over, what's that CAD1.80 a share roughly for the book value going into SilverWillow. Now obviously<br>how the market values that we'll get to see in the next few days, but so it was in our calculations from the point of view of establishing<br>total value. But as far as the metrics we've referenced, we've only referenced the cash component, John.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
Thank you, Howard. It sounds like there were a lot of considerations that were hard to put an exact value upon.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, yes well thank you for your questions, John.<br>
<b>John Tumazos</b><i> - John Tumazos Very Independent Research - Analyst</i><br>
Thank you.<br>
<b>Operator</b><br>
Mike Dunn with FirstEnergy Capital.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
Hi, good morning, everyone. I guess first question is just a follow up on your comments about the book value of the assets in<br>SilverWillow, is that CAD90 million, Howard, is that outside of the CAD25 million in working capital?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, that's right, that excludes the working capital.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
Great.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
And Mike, it's a bit approximate. We-- some of that working capital-- some of that book value is dependent on what we spend at<br>Audet in the first three months and then if you basically sort of notionally cut off at the end of March, what we've spent on Audet<br>will count in that book value calculation.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
I see. Okay, great. And then I just thought I'd ask, I'm not sure what you can comment on it on, but you mentioned potentially other<br>recovery techniques at Audet should the cap rock not prove sufficient, can you talk about what you're thinking there?<br>
11<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>547</i><br>
<hr>
<A name=548></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, what-- so the way we're looking at it right now and we've got a bit of modeling work going on with an engineering company<br>that should be completed sometime in the next two or three months, is we're looking at it as a conventional SAGD. And I think as<br>we've mentioned in previous calls, that we did have-- we did find some pretty extensive occurrences of what we believe will be a<br>suitable cap rock material. But what we don't know is how extensive. So our opening position is if we can prove up this cap rock<br>materials existence in a big enough area and the modeling and the testing and the many frac tests show that it's sufficient for<br>conventional SAGD, and I wouldn't call it a low pressure, I'd call it sort of a moderate pressure SAGD, then that's basically a conventional<br>approach.<br>
So that if we find that that wouldn't necessarily be technically feasible, we would then look at other SAGD related approaches maybe<br>with solvent assist or low pressure SAGD as is being tried out in other places. And then a further fallback would be some of the new<br>techniques that some of the other companies have been talking about, perhaps with some of the electrical or other solvent assist<br>type techniques. But certainly our focus will for Audet be on conventional SAGD as the first case.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
Great. And have you been in touch with the regulator on what I guess their current thinking is about cap rock and I'm not sure if<br>there is any -- if they're getting any more stringent with regards to testing over the past couple of years on that, but just comment<br>on that?<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Yes, certainly the engineering consultants that we've worked with have been involved with a number of the recent applications.<br>And of course, Sproule our other advisor, has been involved with a number of applications. So we are reasonably aware from the<br>consultants of the regulatory requirements. We recognize that there is a bit of a work in progress on how that will evolve over the<br>next 12 to 24 months. But we're certainly taking an approach that is relatively conservative as we consider what the operating<br>pressures would be as we do in the current modeling. And of course the current modeling is really just an early scoping study just<br>to try and understand what the potential will be, there'll be further rounds of engineering once we have the many frac tests, the rest<br>of the data from the geotechnical program and of course more resource data.<br>
<b>Mike Dunn</b><i> - FirstEnergy Capital Corp. - Analyst</i><br>
Okay, great. Thanks, Howard, thanks.<br>
<b>Howard Lutley</b><i> - SilverBirch Energy Corporation - President, CEO</i><br>
Thanks, Mike.<br>
<b>Operator</b><br>
And Mr. Stevens, there no further questions at this time, please continue.<br>
12<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>548</i><br>
<hr>
<A name=549></a>JANUARY 09, 2012 / 2:00PM, TCK.B.TO - Teck Resources Limited to acquire SilverBirch - Conference Call<br>
<b>Michael Stevens</b><i> - SilverBirch Energy Corporation - Manager- Finance, IR</i><br>
Ladies and gentlemen, this concludes the conference call for today, thank you for participating. Please disconnect your lines.<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Briefs are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current<br>expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically<br>identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could<br>prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT BRIEFS REFLECTS THOMSON REUTERS'S SUBJECTIVE CONDENSED PARAPHRASE OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND THERE MAY BE MATERIAL ERRORS,<br>OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY<br>INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT BRIEF. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL<br>ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012 Thomson Reuters. All Rights Reserved. <b>4703356-4-2012-01-09T20:49:39.610</b><br>
13<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>549</i><br>
<hr>
<A name=550></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
EXXI - ENERGY XXI (BERMUDA) LTD AT<br>PRITCHARD CAPITAL PARTNERS LLC<br>"ENERGIZE` CONFERENCE<br>
EVENT DATE/TIME: JANUARY 05, 2012 / 10:05PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>550</i><br>
<hr>
<A name=551></a>JANUARY 05, 2012 / 10:05PM, EXXI - ENERGY XXI (BERMUDA) LTD at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>Stephen Berman</b><i> Pritchard Capital - Analyst</i><br>
<b>Stewart Lawrence</b><i> ENERGY XXI - VP IR &amp; Communications</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Stephen Berman</b><i> - Pritchard Capital - Analyst</i><br>
All right. Everyone quiet down. We're going to get started with our next presentation. We're pleased to have Energy XXI. Stewart Lawrence, he's<br>going to be up here representing the Company today. With that, I will turn it over.<br>
<b>Stewart Lawrence</b><i> - ENERGY XXI - VP IR &amp; Communications</i><br>
Short and sweet. Thanks, Stephen. Thanks, Pritchard, for this opportunity. It's always good.<br>
I'll walk you through Energy XXI, what we've got going on today real quick, just a quick snapshot of the Company. We're going right on sixth<br>anniversary actually as an operating company. In that short time, we have built it into an almost $3 billion market cap company. We're the third<br>largest producer in the Gulf of Mexico shelf, primarily producing oil; about two-thirds of that is oil. The latest quarter, the September quarter,<br>produced just shy of 41,000 BOE a day and we're on target to show some good growth in the December quarter as we've told people.<br>
Again, oil focused, producing oil that's getting a nice premium, not just WTI but actually premium to Brent. So today we're getting about $115 a<br>barrel for oil and spinning off cash flow at an amazing pace.<br>
A quick look at where those properties are. We set out to build the Company as an acquire and exploit model chasing after large, mature oilfields<br>with the thought being not so much that we were bullish oil, although we have all always have been, but as engineers we can get a lot more out<br>of an old, a big old oil field than you can get out of a natural gas field, particularly in smaller fields as well because the big fields give you an<br>opportunity to drain an undrained fault block that is meaningful whereas a small one obviously is not worth your time. So we've been very successful<br>with that.<br>
You can see the properties are all located on the Gulf of Mexico shelf, offshore, primarily all offshore Louisiana. It's not by chance that's where the<br>oil tends to be because the dump of the Mississippi River. So you can see the fields in green are oil and the few in red as well. Of course, we're<br>drilling some very highly prospective natural gas wells with the McMoRan partnership right now that could certainly make us more gassy in the<br>future but we're okay with the giant size of the targets you've got there in the economics involved.<br>
But bottom line, we operate six of the 11 largest oilfields in the Gulf of Mexico shelf and have an interest in a seventh. So you can see that the<br>original focus is paying off very well.<br>
On a proved reserves basis, we're just shy of 117 million barrels of oil equivalent with a present value run on recent strip in excess of our current<br>market cap alone, not to mention the value the probables and possibles that we have captured in addition.<br>
I would highlight the value of some of those probables particularly is extraordinary because more than a third of those are associated with currently<br>producing well bores, which means essentially you don't spend another dime to move those volumes from probable into proved. As you produce,<br>you are proved and the water contact hasn't been hit yet. Those probable volumes move into the proved category.<br>
You can see what we have been able to do over the time organically and of course through acquisitions, the most recently being December 17,<br>2010 just over a year ago then, the Exxon Mobil properties. I'll talk quite a bit about those core properties as we go through.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>551</i><br>
<hr>
<A name=552></a>JANUARY 05, 2012 / 10:05PM, EXXI - ENERGY XXI (BERMUDA) LTD at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
Looking to the drilling program then and what we're trying to deliver this year, you can see we've got a $450 million capital program underway,<br>the majority of which goes to the drill complete and to facilities, so call it $375 million of that, with a fairly even breakdown of the cash going to<br>the newly acquired Exxon properties, the ultradeep partnership that we've got going on with McMoRan and then our older legacy properties in<br>addition.Then look at it another way in terms of development versus exploration, you can see that less than a third of that is going to the higher-risk<br>exploration.<br>
Now, what does that capital program get you? We've taken a longer-term view of this, of the capital spending levels and what we expect it to<br>deliver. Again, as I said, fiscal year '12, I should've pointed that out, we're a June 30 year-end, so we just hit the halfway point of our fiscal year. That<br>program is $450 million. You can see the kind of volumes that it is expected to deliver. We said an average of 46,000 to 50,000 BOE a day is the<br>expectation for the current fiscal year.<br>
But importantly then you have to tie that into what it is expected to deliver on a free cash flow basis. This one typically needs some explanation<br>because it's kind of hard to get through your head that the more you spend on the capital program, the more free cash flow we actually generate<br>to pay down debt during that current year. That's -- not a lot of people have that opportunity to do it. That's a function of the projects that we're<br>chasing, some of which have two-month payouts, but on average we're getting about six to seven months on the overall program of when you<br>put the money in to when you get it all back and start generating free cash flow. So in other words, if we spend $10 million on a project, you get<br>that $10 million back within the next six months and then the rest of the year you are just free cash flow and able to pay down debt.<br>
Now, in that scenario, obviously I think the question that arises is, well, why don't you spend every single penny that you generate? The fact is then<br>you get organizationally limited. The number of teams that we have onboard and their ability to run rigs, we've gone through it and said really<br>right about now the $600 million is about the maximum we think we could put to work again with the teams we have in place today.We'll evaluate<br>going forward whether we want to grow the team and grow the capital program even bigger. But anyway, that's where we're focused right now,<br>about $450 million this year, should generate to just shy, or actually the way things are going with oil prices, at or more than $400 million of free<br>cash flow in the current fiscal year and levering that up to even more in the coming years.<br>
So, part of that then -- let's look at the rig activity, what we've got going on.We're getting very active right now.The ones at the top in the greenish<br>hue are the rigs that we operate. We've got going four rigs drilling right now, two of them at Grand Isle; one of them is a platform rig doing a<br>multi-well development program. Then we've just recently spud the Winters well and I will show you that in a little bit. And over at West Delta 73<br>we've just recently spud the Magnum well and that's coming on. Then we've got an exploration well we're 100% drilling Bullfrog. We're hoping to<br>have that one done by the end of this month maybe or early February.<br>
From there then, we've got some ultra-deep exploration wells that have been going on. I'll talk to those in more detail, but Davy Jones #1 we're in<br>the process of completing that well right now. That's the first big discovery and this will be the first one ever online. Then we also have the Lafitte<br>well drilling ultra-deep, and Blackbeard East, and we just put out some news on those as well. Then the Blackbeard West shallow -- that is the<br>Blackbeard West #2 well, targeting a shallower zone that we saw at Blackbeard East and have been able to trace over to the Blackbeard West block,<br>and so we're going after that. I will tell you a little bit more of that.<br>
then the last one going is actually Eugene Island 330.That is Apache operated. Again, that is one of the seven largest oilfields on the Gulf of Mexico<br>shelf.<br>
This gives a little more granularity to it in terms of when we're drilling what, but this is the entire drilling program that we have in place through<br>the end of June. You can see that, again, we're getting to be very busy part of the stage. In fact, the only well in here drilled so far in the entire<br>program in terms of a drill well, not recompletions, is Sunny. I will talk about that, but it came on way ahead of expectations. It would be a really<br>nice reserve add.<br>
Looked at another way, you can see the 2012 program on this inventory list. Again, maybe showing the ones I just showed you on the drill schedule,<br>but then looking out, you can see that we've got years of drilling opportunities already lined out. This only takes you through what preliminarily<br>we're looking through 2015, but we've got another almost 100 opportunities that -- and inventory that should give us organic growth opportunities<br>for years to come. That is something new for the Company.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>552</i><br>
<hr>
<A name=553></a>JANUARY 05, 2012 / 10:05PM, EXXI - ENERGY XXI (BERMUDA) LTD at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
You know, when we started, it was an acquire and exploit and, yes, you could grow reserves beyond what you bought, further developing it, but<br>it was tough to actually grow the Company outside of doing additional acquisitions.<br>
We're at a new place now. Those Exxon properties have given us drilling opportunities that should provide organic growth without acquisitions<br>for as far out as the eye can see. That doesn't mean we're out of the acquisition business, but we don't have a gun to our head to do it and we can<br>do things strategically if and when they come around.<br>
Okay, looking then specifically at some of the core properties, the Main Pass area is the largest complex within the portfolio. It's one of the oldest<br>fields out there, the largest fields, part of it discovered in '76 and the other part in 2000, produced almost 100 million barrels of oil in 338 billion<br>cubic feet with a lot of upside left to go. In fact, you can see from when we acquired the field initially in 2007 through the end of our last fiscal year,<br>we had grown the reserve 64% from what initially we said we acquired. So it's been a great success story with a lot of upside yet to go.<br>
Then looking at this year's capital program, what we have done there, the Ashton and Onyx wells were drilled using reprocessed seismic on the<br>sub salt, redefined the salt model entirely and it came in -- those lows came in great, producing a lot of oil. Particularly with Onyx, it has been just<br>amazing, came on 2200 barrels of a day of oil and it is just holding steady.<br>
Then the other big one then will be Bullfrog where we would expect some very good rates on that well. It is an offset to a discovery nearby.<br>
At South Pass 89, this is the 11th largest oilfield on the shelf. It has produced 192 million barrels of oil and almost 1 trillion cubic feet of gas with a<br>lot of upside yet to go. This shows our initial activity. This is where we focused right away when we acquired the Exxon properties because there<br>was a recompletion program ready to go that they had identified and we kind of fast-forwarded it all. But you can see the tremendous results here<br>in growing the volumes from where it was below 1000 barrels a day when we bought it, or at least when we acquired the operations, operational<br>control, to current, which is pushing above 5500 barrels a day. So tremendous growth here with an average payout for this program of under four<br>months.<br>
Looking now at Grand Isle 16 and 18, this is a big one. This is the fifth largest oilfield on the shelf with 380 million barrels of oil already produced<br>and almost 1 trillion cubic feet of gas. This is where we drilled the very first well on the Exxon property, Sunny -- and I'll show you that in a second<br>-- and where we're drilling Winters right now with Costello and Big Abbott yet to come.<br>
So looking at the activity already to date, you can see that we finished quite a few recompletions and workovers and have boosted those volumes<br>tremendously. The Sunny well again was a very nice success where we identified two additional big sands that we hadn't even seen going into it.<br>In fact, the sand that we went to drill forward we don't even have on production. It's completed and ready to come on when these lower zones<br>deplete. So it's been a great success and probably about a 1 million barrel add to proved reserves for about $10 million drilling complete.<br>
As you can see, we've got continued drilling going on that. Winters just started and then Costello yet to come in the January time frame. This is a<br>quick look then at the log that I was talking about at Sunny and some of the details there. Again, old established field. We're only talk about 8300<br>feet to total drill in shallow water, so very inexpensive to drill complete and the payout on this is pretty close to immediate.<br>
The Winters well, again, is the one we just spud and it's in offset to existing production in the K2 Sands. We would expect to get a pretty high IP<br>rate on this well given the type of sands that we're looking at. 3400 barrels a day, that would be a very nice addition. Costello again to come after<br>that with about 1000 barrels a day expected production just going updip, kind of amplitude supported here across the fault.<br>
The West Delta 73, the seventh largest oilfield on the shelf, and again, with a lot of activity planned. The very first drill prospect on that is Magnum.<br>That is in progress now and just spud. You can see we've got several additional wells that we'll be pursuing on this with expectations of adding<br>more than 5000 barrels a day from this work.<br>
Magnum I will point out real quick within West Delta 73, if this shows us what we think it's going to show us, particularly in the F-35 sand, which is<br>mapped here, you could open up additional opportunities, including horizontal drilling within this field. It's pretty amazing to think about. Actually<br>this is a 7000 acre structure just within this F-35 sand that has a total of 200 feet of relief from the top of the structure to the bottom. You have to<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>553</i><br>
<hr>
<A name=554></a>JANUARY 05, 2012 / 10:05PM, EXXI - ENERGY XXI (BERMUDA) LTD at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
be able to picture that standing within a 7000 acre field call it, so as far as the eye can see in either direction, and it would look as flat as this tabletop<br>over here to you. That's one big, flat, general structure. When you have something like that, you can run laterals, and instead of having 1000 barrels<br>a day production, then you can get it up to 4000, 5000 for not all that much additional cost. So we'll see. We'll drill two vertical wells first and then<br>take it from there to proceed potentially with the horizontal drilling, which all by the way speaks to significant additional recovery of original oil in<br>place that could be very meaningful to reserve adds.<br>
South Timbalier 54 is another big old oilfield, and we're getting going on that right now. We just completed the first recompletion. That came on<br>very nicely, planned IP on that net to us was 725 BOE.You can see it came in at 1100 BOE, so very good initial success.We've got another recompletion<br>scheduled for January and then we've got three development drill wells planned for that field, the first one being Camshaft, which is targeting<br>updip and fault separated production from known existing production. It should come on at pretty strong rates, 1700 BOE a day type target there,<br>drilling to 12,000 feet.<br>
So that covers the bread and butter. That covers the four properties that we're talking low risk kind of work to do that is delivering volume growth<br>and with opportunities continue to do so for years down the road and spinning off a tremendous amount of free cash flow. Part of that free cash<br>flow then we're redeploying back into the ultradeep partnership with McMoRan.<br>
This slide here is a depiction of the basic concept of what we're doing. We're chasing fields that were huge historic producers onshore and then<br>subsequently the same sands were found out in deepwater and have been very prolific discoveries out there. We've just brought that back onto<br>the Gulf of Mexico shallow-water shelf and in fact, as I will show you, we're starting to take it even onshore in the sort of transition zone that hadn't<br>been drilled to date. So it's a concept that is working so far phenomenally.We only have five wells into this area of the earth of that has never been<br>tested before, and everything is pointing in the right direction.<br>
The first part, Davy Jones, has been catching all the headlines because, again, this will be the Proof of Concept when we do flow. We'll get a lot of<br>data off this well that will be critical, particularly to the future development plans at Davy Jones, which we see as about a 6 trillion cubic feet base<br>case discovery, but also what it means going forward for the entire ultradeep program. So the completion is underway on this well. We've had a<br>couple of delays, nothing significant really, but everybody is anxious to get this on and see what it is going to do. The most recent delay was<br>announced this morning.We've lost a part of a motor.We're drilling this with a turbine bit that is powered by a mud pump.That mud pump decided<br>to fall apart, so there are pieces of the pump in the wellbore. We have to go down and fish it out. It's not a huge deal, but it is a little bit of a delay,<br>nothing significant. We're talking days or weeks, not months, on that.<br>
So, where we are on that is, once we get the junk out of the well, we've got about 5000 feet more of wellbore to clean out, the cement that we left<br>in behind when we came out of the well to prepare it for completion. We'll get that cleaned out, run the pack or the tubulars and install the<br>equipment, put the perf gun in there, seal it up and get ready to pop it and flow. So it's not far away; you've got to have some patience. There has<br>been no big issues in there that anybody needs to worry about.<br>
But a little bit of history then on what we have found there. Again, it's about a 20,000-acre structure and Davy Jones well #1 was drilled to just over<br>29,000 feet, found 20 feet of Wilcox pay. Again, that production is expected on very soon. We then stepped out and drilled an offset 2, 2.5 miles<br>away and found the same Wilcox Sands of 120 net feet, so proving the continuity of the sands across this major structure, but then we were able<br>to go deeper and through the Tuscaloosa Sands and the lower Cretaceous. So, those are additions to the original discovery. Yet to see just what<br>that means in terms of additional resource. The potential is huge. We will work to complete this well in the second half of this year, this calendar<br>year. We'll just see what we can get from those lower zones. We know we've got a nice well in terms of confirming the Wilcox but we'll see if we<br>can get anything out of the Cretaceous and the Tuscaloosa there.<br>
On Blackbeard, a summary. This is just a quick look at the whole area with Blackbeard East. As I'll talk about here in a second, Blackbeard West, the<br>initial well that we went into with McMoRan and then now the Blackbeard West shallow well. I'll talk a little bit about Blackbeard East, of what we<br>found in the upper and middle Miocene Sands that surprised us. Some very nice-looking pay there at Blackbeard East that we had not expected<br>at all. We had it modeled as salt and it turned out to be very high-quality Sands. So then with that knowledge, we could take it across the other<br>prospects and say where else might we be able to reach these shallow sands. We identified Blackbeard West, this shallow area, as a key potential<br>there. So that well is drilling below 11,700 feet right now with a proposed target depth of 26,000 feet.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>554</i><br>
<hr>
<A name=555></a>JANUARY 05, 2012 / 10:05PM, EXXI - ENERGY XXI (BERMUDA) LTD at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
Blackbeard East then, as I was mentioning, we've drilled and found a number of sands on there. We've announced 178 net feet of pay in the Upper<br>and the Middle Miocene. Again, the shallow parts that we're chasing elsewhere. And the importance -- one of the important parts there is you can<br>drill it with a much cheaper rig. It's not nearly as deep, so a lot quicker, easier to get to, and you can complete it with conventional off-the-shelf<br>equipment so you can get it online and cash flowing a lot sooner.<br>
Following that then, we logged Frio, some very nice clean pay sands, not all that thick but very, very good quality sands you can see on the log<br>there. Then we drilled down through the Sparta section at the top of the Eocene level, and we're in process right now of logging that well, so we<br>might have some results there to talk about in terms of what we've seen at Sparta.<br>
We've got 600 feet to go yet to the total depth of 34,000 feet in which we hope to see some Wilcox Sands here as well. So just stay tuned on that<br>one.<br>
Blackbeard West, again, this shows it in relation to the shallower well relative to the original Blackbeard well. That is proceeding.<br>
Then Lafitte I talked about a little bit. This well is drilling now just below 32,200 feet. We -- our proposed TD had been 32,000 feet on this well. We<br>got to that depth and just below it, and have logged it and have seen the same Frio sands here that we saw 80 miles away at Blackbeard East. So<br>that's very encouraging.<br>
The thing is we're still in the Lygocene section, whereas our model had said we would've been out of it by now. So we have extended the permitted<br>depth down to 33,000 feet to see if we can find any more sands within the Oligocene before stopping on that one. But we'd already logged a<br>significant amount of pay in the Lower Miocene, most important being the last 56 net feet over a 58-foot growth section, which is just one big<br>beautiful blocky sand. It's the kind of thing explorations dream of. So we feel pretty confident we have got something in this well already that we<br>will work to complete.<br>
Success there at Lafitte importantly opens -- it provides -- derisks, as it were, a couple of other key prospects that we have in the inventory which<br>is Barataria and Captain Blood. So in the overall regional scheme of things, Lafitte looks to be a very good success overall.<br>
That said then, just how much of this we have, we've got a lot of potential, a lot of prospects identified. We're learning more and more with every<br>single well. It's critical information that we have and nobody else but Chevron has in the entire industry. So, there is a lot farther to go.<br>
On that note then, we just got into a well that was announced this morning with Chevron. Chevron's operator with 50%.The McMoRan partnership<br>owns 50%, which means we end up with 9% working interest in that well, which is called Lineham Creek. So that one will be drilling here soon and<br>will be pretty exciting. It's an onshore well drilling to 29,000 feet, should be targeting the same exact sands that we saw at Davy Jones 2, which<br>would be the Wilcox, Tuscaloosa and Lower Cretaceous.<br>
That then just, again, sing the praises of this company. In six short years, we've come a long way and become the number three produced on the<br>Gulf of Mexico shelf, not just the third largest oil producer but third-largest producer overall. This shows our oil mix relative to the others. We're<br>just behind, well, third behind Chevron and Apache. It's delivering fantastic returns and free cash flow.<br>
We've got a large inventory, a low risk recompletions work-overs, a lot of PUD drilling and a wide range of exploration projects from lower risk to<br>obviously the high risk, the much higher potential ultra-deep. We are free cash flow like a machine you've never seen before and that's going to<br>pay down debt and build a big cash balance. What you have to understand is every dollar that you pay down in debt proves directly to the<br>shareholders. I'm not so sure that is being recognized right now, but it will be soon enough.<br>
So, with that, we'll end it. I believe we have a breakout session.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>555</i><br>
<hr>
<A name=556></a>JANUARY 05, 2012 / 10:05PM, EXXI - ENERGY XXI (BERMUDA) LTD at Pritchard Capital Partners LLC "Energize`<br>Conference<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4696294-2012-01-09T20:53:07.657</b><br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>556</i><br>
<hr>
<A name=557></a>THOMSON REUTERS STREETEVENTS<br>EDITED TRANSCRIPT<br>
GILD - GILEAD SCIENCES AT<br>JPMORGAN GLOBAL HEALTHCARE<br>CONFERENCE<br>
EVENT DATE/TIME: JANUARY 09, 2012 / 5:00PM GMT<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>557</i><br>
<hr>
<A name=558></a>JANUARY 09, 2012 / 5:00PM, GILD - Gilead Sciences at JPMorgan Global Healthcare Conference<br>
<b>C O R P O R A T E   P A R T I C I P A N T S</b><br>
<b>John Martin</b><i> Gilead Sciences, Inc. - Chairman and CEO</i><br>
<b>C O N F E R E N C E   C A L L   P A R T I C I P A N T S</b><br>
<b>Geoff Meacham</b><i> JPMorgan - Analyst</i><br>
<b>P R E S E N T A T I O N</b><br>
<b>Geoff Meacham</b><i> - JPMorgan - Analyst</i><br>
Okay, good morning, and welcome to the morning session of the 30th Annual JPMorgan Healthcare Conference. I'm Geoff Meacham, Senior Biotech<br>Analyst here at JPMorgan. It's my pleasure to have Gilead Sciences presenting. Gilead is one of the leaders in the antiviral space, particularly HIV<br>and hep C.<br>
And speaking on behalf of Gilead is its Chairman and CEO, John Martin. John?<br>
<b>John Martin</b><i> - Gilead Sciences, Inc. - Chairman and CEO</i><br>
Thanks, Geoff. It's always a pleasure to participate in this conference. We, at Gilead, had a very exciting year last year, that's for sure. We've<br>accomplished a lot and I'm proud to have the opportunity to tell you about that and tell you what we expect for the coming year.<br>
So, at first, I'll mention that there are forward-looking statements in this presentation and our GAAP reconciliation is available on our website. So,<br>the very significant accomplishments in 2011, these are a few. We received Complera approval, it's the second single-tablet regimen that contains<br>three drugs for treatment of AIDS and launched in U.S., Canada and the European Union.<br>
We presented topline results from two pivotal studies on Quad, which will be the third single-tablet regimen. We filed for approval in the [EU and<br>we] expect to launch it during this calendar year.<br>
We acquired additional assets in oncology and inflammation by acquiring two companies, Arresto and Calistoga. And then, finally, entered into<br>an agreement to acquire Pharmasset. It's a company that has a leading candidate for the treatment of hepatitis C. We have some additional<br>candidates in our portfolio. I'll tell you about this.<br>
A key attribute of this is the success we've had in HIV and hepatitis B, means we have the scientific, medical and commercial capabilities to do a<br>very good job commercializing hepatitis C products.<br>
This shows our portfolio of 14 products that are currently marketed [either] on our own or through partner promotion. On the left is HIV and the<br>second column is hepatitis B. So those are our virology franchises.<br>
Viread is the foundation of both of those. Viread is our first product for the treatment of HIV, approved just over 10 years ago. HIV disease or AIDS<br>needs to be treated with three oral antivirals simultaneously and in past, taking multiple pills multiple times a day, led to failure.<br>
What we intended to do at Gilead was to simplify therapy with really well-tolerated drugs. So Viread is once a day. Our second product, Emtriva, is<br>also once a day. We combined them together into two pills and one tablet and that's called Truvada. That was launched in 2004 and really started<br>to transform the treatment of HIV.<br>
We partnered with Bristol Myers and Merck, with their efavirenz to combine it with Truvada to have a single-tablet regimen, Atripla, and more<br>recently with Johnson &amp; Johnson and their rilpivirine to have Complera.<br>
1<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>558</i><br>
<hr>
<A name=559></a>JANUARY 09, 2012 / 5:00PM, GILD - Gilead Sciences at JPMorgan Global Healthcare Conference<br>
The Viread for hepatitis B is the leading product for the treatment of hepatitis B, now in the U.S. and again, very safe, very potent, well-tolerated.<br>We have a variety of other products that we're building out other franchises and I'll talk about that briefly at the end.<br>
First going to HIV, 1996 was -- just 16 years ago, it's the first time that a patient could take three different drugs and fully suppress the virus. Up<br>until 1996, the disease was fatal. But those patients who were treating their HIV, needed to take a handful of medications, taking pills multiple<br>times a day with and without food, with and without certain quantities of water. So it's just a very difficult regimen and no one could take all those<br>pills and that's why people would develop resistance and fail, you'd take a partial regimen.<br>
So we in our efforts were eventually able to come up with a single tablet, Atripla, that has all three drugs in one tablet. And, therefore, a patient<br>takes all or nothing. There is now this partial regimen stuff, which could give rise to resistance. And that took only 10 years from the beginning of<br>successful treatment of AIDS to have a single tablet. Now five years later, we have the second one, Complera, and you can see that Complera is<br>actually slightly smaller than Atripla, making it even more convenient.<br>
So, Truvada we think of as a backbone for the treatment of HIV, two nucleoside/nucleotide analogs, Viread and Emtriva. And Truvada is also part<br>of Atripla, where the efavirenz is added. You can see what percent of patients in the United States are on this Truvada backbone, whether it's<br>Truvada plus a third agent or Atripla directly. It's become the cornerstone of HIV therapy. The other two nucleoside combination [fix] those<br>combination products, Epzicom and Combivir, have a smaller market share.<br>
The dynamics of the HIV market, you can see that about 600,000 individuals with HIV are on treatment, that's the yellow bar and that's how the 1.2<br>million who are infected. As we've seen over the last few years with the evolvement of simple, well-tolerated regimens, the number of people being<br>treated has grown pretty dramatically. When we launched Viread, it was in the 340,000 range. And this is due to the better-tolerated treatments<br>and also with the better-tolerated treatments a recognition that if you treat people earlier in infection, they had better outcomes.<br>
When we launched Viread, patients were treated when their CD4 count fell from 800 to 200, that's the immune system being severely compromised<br>and, obviously, if you can treat when the immune system starts to compromise, the patient will do better.<br>
So we've seen a move to treating healthier and healthier people. It's also been more recently hypothesized that patients who are infected and<br>diagnosed or not diagnosed just in -- but not being treated, transmit the majority of the new infections. And as you'll see, that's become very well<br>established.<br>
The improvement of health is really characterized very nicely in this (inaudible) publication from September.This is a Johns Hopkins cohort, where<br>they follow the viral load in patients over time. The green bar is viral load below 200, which means the virus is suppressed in the body, it's not<br>causing any illness, it's not mutating and it's not infecting other people.You can see that green bar is up to about 80%. If you say below 500, which<br>is the old standard, we're really pushing 90% and this includes patients who are eligible for treatment, but not taking them for whatever reasons.<br>So the treatments have become highly efficacious and AIDS patients now can live a really quite normal life.<br>
Science Magazine just announced a couple weeks ago what they considered the breakthrough of the year and it was not published in Science,<br>they consider scientific contributions broadly. And Myron Cohen, the lead of HPTN 052 published the fact that if you take patients who are fairly<br>healthy and you roll them in therapy or defer that therapy, he was able to demonstrate that the people who have therapy have a 96% reduction<br>in transmission of virus.<br>
So, early treatment provides clearly better outcomes to patients, but now we can quantify the benefit it provides to society in terms of reduction<br>of new infections. It's, of course, highly cost effective. It also means when a physician diagnoses a patient with HIV, that physician will be cognizant<br>of the fact that if he puts that patient on drug, that patient will have the chance of infecting someone else reduced by 96%.<br>
Complera is the product we launched in the fall. It was approved in the U.S. in August, Canada in September, and the EU in November. As is typical<br>when a new drug is approved, there are a couple Phase III studies, but there is a lot more we'd like to know. And so, for instance, we're looking at<br>switching patients from a protease inhibitor containing regimens to Complera directly, so they can reduce their number of pills and see whether<br>or not we maintain good suppression, that's ongoing.<br>
2<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>559</i><br>
<hr>
<A name=560></a>JANUARY 09, 2012 / 5:00PM, GILD - Gilead Sciences at JPMorgan Global Healthcare Conference<br>
And then, of course, since Complera is the second single-tablet regimen on the market, it would be of interest and importance to know how<br>Complera compares head-to-head against our first single tablet, Atripla, and that's ongoing in a nearly 800 patient study.<br>
Our third single-tablet regimen, which is under review by regulatory bodies, takes what we've been talking about for a while,Truvada, the backbone<br>and combines it with an integrase inhibitor, elvitegravir, which is boosted with cobicistat.<br>
Cobicistat is a new boosting agent that we are developing in combination with a new integrase inhibitor, elvitegravir plus Truvada. And the FDA<br>and other regulatory bodies have accepted the review of this four drug in one pill with two new chemical entities without having yet approved<br>the individual components.<br>
This is a first, but it's what the FDA has committed to also for hepatitis C when we bring combination products forward, so that people will have<br>the benefit of fixed dose or single-tablet regimens and not take multiple pills, where resistance can occur. So it's a very exciting development<br>through regulatory bodies. The PDUFA date for the U.S. is August 27 of this year.<br>
We have some ongoing collaboration agreements in HIV and I think the theme you can see on this is, we've continued to innovate in HIV all these<br>years. So back to Tibotec or Johnson &amp; Johnson, they also have a protease inhibitor, which needs boostings, currently boosted with Abbott's<br>ritonavir.<br>
We're working with Tibotec to develop a fixed dose combination of cobicistat and their protease inhibitor, darunavir. And we're also working on<br>a new single-tablet regimen, which includes 7340. We have not advanced Viread with darunavir as a single tablet, because the mass of the pill<br>would be too big. You could not cut the size down to be one pill once a day.<br>
But we have a new form of the active ingredient Viread and this new form is called 7340. And we're developing that at only one-tenth of the dose<br>of Viread. We've used some targeting technology to target lymphocytes where the virus replicates, so we can give a much lower dose. And that<br>lower dose allows us to conceptualize the first single-tablet regimen containing a protease inhibitor.<br>
We also announced recently that Bristol Myers will be working to develop a fixed dose combination of cobicistat to boost their protease inhibitor,<br>atazanavir. And then in addition, we've taken over an intellectual property portfolio of integrase inhibitors from Boehringer Ingelheim. These<br>molecules target a different site, a non-catalytic site on integrase, but separate from elvitegravir and thus would be useful as an agent that would<br>have a different resistance profile.<br>
So we continue to innovate [in that] HIV. It's been a long process. Many of us at Gilead have spent big part of our careers on HIV. Viread was 2001,<br>as I mentioned, Truvada 2004, Atripla 2006, Complera last year, Quad this year, and then we have these additional ongoing projects. And 7340 is<br>not just being developed with Tibotec's darunavir, but, of course, the other products we have already on the market with Gilead.<br>
Moving now to hepatitis B, another foundation business for us. Hepatitis B's sales for the first nine-month or Viread sales for all indications were<br>$547 million for the first nine months. Pretty much U.S. and Europe have equal levels. We continue to expand that treatment and diagnosis of<br>hepatitis B through targeted programs and expand market share. This is much like we've done with HIV. But we also, over the last few years, have<br>worked very hard to build our global infrastructure. Hepatitis B is largely a disease of Asia. HIV is largely a global disease, as is hepatitis C, which<br>we'll get to.<br>
So, for instance, in HIV, we now treat over 900,000 people in our upper income markets, but we have about 2 million people on tenofovir therapy<br>in low middle income and low income markets, just broadly dispersed program that we do on our own and through many distributors.<br>
With hepatitis B, with the Asian focus, we've developed our commercial infrastructure and have approval now in Hong Kong, Korea, Taiwan and<br>Singapore. So we're building a broader, broader international foundation to our commercial and medical efforts.<br>
3<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>560</i><br>
<hr>
<A name=561></a>JANUARY 09, 2012 / 5:00PM, GILD - Gilead Sciences at JPMorgan Global Healthcare Conference<br>
We also, with hepatitis B, recognize that to [truly] get the hepatitis B problem globally, we need to find therapies of limited duration as is happening<br>now with hepatitis C. Right now, hepatitis B patient goes on Viread and maybe at five years, 10% of those people may clear the virus, but the vast<br>majority continue to replicate.<br>
We have seen the benefit of five years of therapy with Viread. Ishak's score going from left to right is increasing fibrosis of the liver 5 and 6 are called<br>cirrhosis, very significant damage to the liver. And what -- we knew with Viread we could stop viral replication and perhaps disease progression.<br>What we didn't know until just last fall, when we got the five-year data, is that we can dramatically improve the fibrosis of the liver and [you should<br>see as] the scores -- if the liver scores get worse at baseline, what we see after five years is a pretty significant improvement in terms of percentage<br>wise shown by those green bars on those -- especially on the right where there is the higher liver disease at baseline. So this is a pretty dramatic<br>improvement of liver scoring and something that does support therapy with Viread.<br>
Now moving to hepatitis C. The global prevalence of hepatitis C is about five times as much as HIV. This is a huge worldwide burden. Patients with<br>hepatitis C, as they get older, progress to liver failure and liver cancer. There are a variety of genotypes around the world, typically isolated by<br>different types of geographies. So what we need our products set work broadly against genotypes and can be given orally.<br>
There is, out of the 160 million, there is about 12 million hepatitis C patients that are in, what we would call, our more commercial markets and<br>only -- well, [fewer than] 200,000 are treated every year. Think about when you go back to the HIV, where half of the people are now being treated,<br>very few people are treated with hepatitis C, because of the toxicities and difficulties of existing therapy.<br>
So it's been probably one of the most competitive areas of pharmaceutical research over the last few years to come up with oral agents that can<br>cure hepatitis C with a limited duration of therapy. And really over the last few years, a lot of progress has been made by a lot of organizations.<br>
The current therapy involves interferon and it has a lot of challenges. The once-weekly, self-administered injection of interferon is difficult for<br>patients and has a lot of toxicities.There is very poor tolerability and a lot of safety issues. (inaudible) intensive and complexity of protease inhibitor<br>response guided therapy adds to the difficulty now that we're using protease inhibitors from two different companies on top of interferon and<br>ribavirin. The protease inhibitors have their own toxicities and it has not become easier to treat patients. A significant number of patients are in<br>fact completely not eligible for interferon therapy for a variety of reasons. So the current therapies are very limiting and that's why so few people<br>are taking current therapies.<br>
So as part of our ongoing work in hepatitis C, we recognize the progress made by Pharmasset and have a strategic rationale for that acquisition,<br>which we announced in November. [It accelerates] time to the first oral regimen, that will be PSI-7977 plus ribavirin for the treatment of hepatitis<br>C. This molecule is the most potent and advanced nucleotide in clinical development. And in fact, we have targeted as had Pharmasset before as<br>FDA approval during 2014.<br>
This provides for Gilead not only a product that can benefit a large number of patients, but for significant revenue growth and diversification in<br>2014 and beyond.The composition of pat matter for this product is into 2029. And as I've been trying to explain at least, the Pharmasset's strategic<br>fit with Gilead's scientific and commercial expertise is quite good with the work we've already done in HIV and in hepatitis B.<br>
Also we have a combined portfolio. Pharmasset's product is in Phase III. We have additional four molecules in Phase II. So we have a lot of ways to<br>confront how the research progresses into coming year to combine products into once-daily regimens for the treatment of hepatitis C.<br>
Pharmasset's data and genotype 2/3 are shown on this slide, it's the study, ELECTRON, and this was a study that advanced our understanding of<br>the treatment of hepatitis C.<br>
And the column on the left is the use of 7977 standard of care, ribavirin and peg interferon, but lowering the dose of interferon to only three months.<br>And you can see 100% of patients at week-12 are undetectable and that SVR12 is 12 weeks after stopping therapy, still 100% are undetectable.<br>
And incidentally, one of the reasons the timeline to approval can be quicker now as the FDA has realized that SVR12 is enough, we do not need<br>SVR24 for approval. So that shortens the timeline that these products for the treatment of hepatitis C will be available to patients.<br>
4<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>561</i><br>
<hr>
<A name=562></a>JANUARY 09, 2012 / 5:00PM, GILD - Gilead Sciences at JPMorgan Global Healthcare Conference<br>
The next question I ask was what about 12 weeks of therapy without the interferon component, just 7977 plus ribavirin? And you can see it's the<br>same result, SVR12 of 100%.<br>
Then the final question was, what about 7977 alone? And you can see there that monal therapy is not optimal that six -- four out of ten patients<br>failed or had rebound by four weeks and the 12 week data is not available yet.<br>
But this study gave clear guidance to a Phase III program of use in 7977 plus ribavirin and that is in the process of being initiated. The first study is<br>7977 plus ribavirin versus standard of care. And the second study is just the two arms, 7977 plus ribavirin, second arm being placebo, a head to<br>head comparison of placebo. And all arms will be analyzed at SVR12. We also have a Phase III program that will be initiating in other genotypes as<br>planned for this year.<br>
So this is the one slide I have on the other products that were shown on that earlier 14-product slide. And we have growing sales in this business<br>outside of antivirals. During the first nine months, AmBisome is still our leading product at $249 million. But you can see Ranexa's and Letairis are<br>having very good growth and catching up fairly rapidly. And Cayston's growth is quite good too for the treatment of cystic fibrosis.<br>
With Ranexa and Cayston, with Cayston, we have a number of additional studies ongoing for future indications.<br>
We also have expanded our effort in oncology. GS 1101 is a PI3K delta specific inhibitor that's in Phase III for CLL and in Phase II for indolent NHL.<br>So this is a product that's moving forward and that we're investing fairly significantly in.<br>
We also are developing a monoclonal antibody 6624 that's active against LOXL2, a fibrogen cross-linking enzyme.This is in Phase II in myelofibrosis<br>and also moving into Phase II for pancreatic and colorectal cancer, just in combination with standard of care for those two diseases and then we<br>also have initiated Phase I program in IPF.<br>
Financial highlights for the first nine months of 2011 are depicted here. We have product sales of $5.9 billion. That's up 9% year-over-year. Cash<br>flow, $2.7 billion. The non-GAAP operating margins 51%. And since 2010, we've purchased and retired 164 million shares of stock or 18% of the<br>total outstanding.<br>
Looking forward to this year, the significant milestones we anticipated one and very important to us is complete the Pharmasset acquisition. We<br>will be providing our financial results and guidance for 2012 on February 2 at our conference call. We'll be releasing hepatitis C tech data on<br>genotype 1 patients. Today I showed was genotype 2 and 3, but there's ongoing studies in genotype 1. And also some collaborated studies are<br>underway with other organizations.<br>
We'll be filing for approval of elvitegravir and cobicistat. Those are the individual components presenting Quad. We will receive or I should say, we<br>expect to receive Quad approval and to begin the launch of the product this year. And we have numerous pipeline programs that time does not<br>allow for talking about today, but are advancing in various stages of development.<br>
With that, I thank you very much. The time is up and look forward to talking to you in the breakout. Thank you.<br>
5<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>562</i><br>
<hr>
<A name=563></a>JANUARY 09, 2012 / 5:00PM, GILD - Gilead Sciences at JPMorgan Global Healthcare Conference<br>
<b>D I S C L A I M E R</b><br>
Thomson Reuters reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.<br>
In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon<br>current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more<br>specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the<br>assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.<br>
THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION,<br>THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES THOMSON REUTERS OR THE APPLICABLE COMPANY ASSUME<br>ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE<br>COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.<br>
©2012, Thomson Reuters. All Rights Reserved. <b>4699868-2012-01-09T20:58:07.780</b><br>
6<br>
THOMSON REUTERS STREETEVENTS | www.streetevents.com | Contact Us<br>
©2012 Thomson Reuters. All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without<br>the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated<br>companies.<br>
<i>563</i><br>
<hr>
<A name="outline"></a><h1>Document Outline</h1>
<ul><li>Table of Contents
<li>PERRIGO CO.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>ENDO PHARMACEUTICALS HOLDINGS INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>SILVERBIRCH ENERGY CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CONFERENCE CALL PARTICIPANTS
<li>TRANSCRIPT
<li>TRANSCRIPT
</ul><li>Page 3
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 4
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 5
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 6
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 7
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 8
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 9
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 10
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 11
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 12
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 13
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 14
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 15
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 16
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 17
<ul><li>TRANSCRIPT (CONT)
</ul><li>Page 18
<ul><li>TRANSCRIPT (CONT)
</ul></ul><li>WILLIAM MORRISON
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>WILLIAM MORRISON
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>PRESENTATION SUMMARY
<li>I. PRE-CLOSE TRADING UPDATE (D.P.)
</ul><li>Page 3
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>AUGME TECHNOLOGIES INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>PIEDMONT NATURAL GAS CO.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>RPM INTERNATIONAL INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 18
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 19
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>CONSTELLATION BRANDS INC.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 18
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 19
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 20
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 21
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>RPM INTERNATIONAL INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>FINANCIAL DATA
</ul><li>Page 3
<ul><li>PRESENTATION SUMMARY
<li>I. OPENING REMARKS (F.S.)
<li>II. 2Q12 FINANCIALS (B.M.)
</ul><li>Page 4
<ul><li>II. 2Q12 FINANCIALS (B.M.) (CONT)
</ul><li>Page 5
<ul><li>III.CLOSING COMMENTS (F.S.)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 18
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 19
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 20
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 21
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>CONSTELLATION BRANDS INC.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>FINANCIAL DATA
<li>PRESENTATION SUMMARY
<li>I. 3Q12 BUSINESS REVIEW (R.S.)
</ul><li>Page 3
<ul><li>I. 3Q12 BUSINESS REVIEW (R.S.) (CONT)
</ul><li>Page 4
<ul><li>I. 3Q12 BUSINESS REVIEW (R.S.) (CONT)
</ul><li>Page 5
<ul><li>II. 3Q12 FINANCIAL REVIEW (B.R.)
</ul><li>Page 6
<ul><li>II. 3Q12 FINANCIAL REVIEW (B.R.) (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 18
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 19
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 20
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 21
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 22
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>WORTHINGTON INDUSTRIES INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 18
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 19
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 20
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 21
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 22
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 23
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>WORTHINGTON INDUSTRIES INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>FINANCIAL DATA
<li>PRESENTATION SUMMARY
<li>I. 2Q12 BUSINESS REVIEW (J.M.)
</ul><li>Page 3
<ul><li>II. 2Q12 FINANCIALS (A.R.)
</ul><li>Page 4
<ul><li>II. 2Q12 FINANCIALS (A.R.) (CONT)
</ul><li>Page 5
<ul><li>III.2Q12 OPERATIONAL REVIEW (G.S.)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 18
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 19
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 20
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 21
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 22
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 23
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 24
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 25
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>ROSS STORES, INC.
<ul><li>Page 1
<li>Page 2
<ul><li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>MAGNUM HUNTER RESOURCES CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>DURECT CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>IHS INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>ALPHATEC HOLDINGS INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>INTEGRA LIFESCIENCES HOLDINGS CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>FINANCIAL DATA
</ul><li>Page 3
<ul><li>PRESENTATION SUMMARY
<li>I. OPENING REMARKS (P.A.)
<li>II. PRELIMINARY 4Q11 &AMP;AMP;AMP; FULL-YEAR 2011 FINANCIAL RESULTS (J.H.)
</ul><li>Page 4
<ul><li>III.ADDITIONAL METRICS (P.A.)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>INTEGRA LIFESCIENCES HOLDINGS CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>DURECT CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>PRESENTATION SUMMARY
<li>I. TRIAL RESULTS UPDATE (J.B.)
</ul><li>Page 3
<ul><li>I. TRIAL RESULTS UPDATE (J.B.) (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>IHS INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>FINANCIAL DATA
</ul><li>Page 3
<ul><li>PRESENTATION SUMMARY
<li>I. BUSINESS REVIEW (J.S.)
</ul><li>Page 4
<ul><li>II. 4Q11 OPERATIONAL REVIEW (S.K.)
</ul><li>Page 5
<ul><li>II. 4Q11 OPERATIONAL REVIEW (S.K.) (CONT)
</ul><li>Page 6
<ul><li>III.4Q11 FINANCIALS (R.W.)
</ul><li>Page 7
<ul><li>III.4Q11 FINANCIALS (R.W.) (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 18
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>THE ACTIVE NETWORK INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>HMV GROUP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>PENFORD CORP.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>NOVARTIS AG
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>MITCHAM INDUSTRIES INC.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>EVOLUTION PETROLEUM CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>ARTHROCARE CORP.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>THERAVANCE INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>AMERICAN STANDARD ENERGY CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>HEALTH NET, INC.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>INCYTE CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>COVIDIEN PLC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>BANKERS PETROLEUM LTD
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>UNION DRILLING INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>AMGEN INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>CAREFUSION CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>FINANCIAL DATA
<li>PRESENTATION SUMMARY
<li>I. PRELIMINARY 2Q12 RESULTS (K.G.)
</ul><li>Page 3
<ul><li>I. PRELIMINARY 2Q12 RESULTS (K.G.) (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>CAREFUSION CORP
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>CONTANGO OIL & GAS COMPANY
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>AGILENT TECHNOLOGIES INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 8
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>CELGENE CORP.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>ADA ES INC
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 8
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>INFOSPACE, INC.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>FINANCIAL DATA
<li>PRESENTATION SUMMARY
<li>I. ACQUISITION OVERVIEW (B.R.)
</ul><li>Page 3
<ul><li>I. ACQUISITION OVERVIEW (B.R.) (CONT)
</ul><li>Page 4
<ul><li>II. FINANCIAL BENEFITS OF ACQUISITION (E.E.)
</ul><li>Page 5
<ul><li>III.CLOSING REMARKS (B.R.)
<li>QUESTIONS AND ANSWERS
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>INFOSPACE, INC.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 15
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 16
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 17
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>ONYX PHARMACEUTICALS
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>TECK RESOURCES LTD
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>TECK RESOURCES LTD
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>OVERVIEW
<li>PRESENTATION SUMMARY
<li>I. ANNOTATION (M.S.)
<li>II. ACQUISITION OVERVIEW (H.L.)
</ul><li>Page 3
<ul><li>II. ACQUISITION OVERVIEW (H.L.) (CONT)
</ul><li>Page 4
<ul><li>II. ACQUISITION OVERVIEW (H.L.) (CONT)
</ul><li>Page 5
<ul><li>QUESTIONS AND ANSWERS
</ul><li>Page 6
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 7
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 8
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 9
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 10
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 11
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 12
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 13
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul><li>Page 14
<ul><li>QUESTIONS AND ANSWERS (CONT)
</ul></ul><li>ENERGY XXI BERMUDA LTD
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul><li>GILEAD SCIENCES INC.
<ul><li>Page 1
<li>Page 2
<ul><li>CORPORATE PARTICIPANTS
<li>CONFERENCE CALL PARTICIPANTS
<li>P R E S E N T A T I O N
</ul><li>Page 3
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 4
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 5
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 6
<ul><li>P R E S E N T A T I O N (CONT)
</ul><li>Page 7
<ul><li>P R E S E N T A T I O N (CONT)
</ul></ul></ul><hr>
</BODY>
</HTML>
